研究者基本情報

• 医学博士

• https://researchmap.jp/read0118235

• https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200901048889315599

• 200901048889315599

• 輸血学
• 移植片対宿主病
• 造血幹細胞移植
• 血液学
• Graft-versus-host disease
• Hematopoietic stem cell transplantation
• Hematology

• ライフサイエンス, 血液、腫瘍内科学

• 学士課程, 医学部（医学科）
• 修士課程, 医学院
• 博士課程, 医学院

研究活動情報

• 2023年07月, 国立研究開発法人科学技術振興機構, 第48回（令和5年度）井上春成賞
  新型コロナウイルス抗原定量試薬による唾液検査の開発と空港検疫への応用
• 2023年02月, 北海道総合政策部次世代社会戦略局科学技術振興課, 令和4年度北海道科学技術賞
  新型コロナウイルス感染症の唾液診断法の開発
• 2022年12月, 第一生命保険株式会社, 第74回 保健文化賞
• 2022年10月, 一般社団法人 日本血液学会, 第11回 日本血液学会学会賞
• 2021年10月, 北海道新聞社, 北海道新聞文化賞（学術部門）
• 2021年06月, 一般社団法人 減災サステナブル技術協会, 防災・減災×サステナブル大賞 サステナブル部門 グローバル賞
  唾液採取による新型コロナＰＣＲ検査
• 2021年02月, 国立大学法人北海道大学, 令和２年度北海道大学教育研究総長表彰
• 2020年10月, 公益財団法人伊藤医薬学術交流財団, 令和2年度 伊藤太郎特別賞
• 2019年03月, 一般社団法人日本造血細胞移植学会, 第1回日本造血細胞移植学会学会賞
  豊嶋 崇徳
• 2016年, 北海道大学大学院医学研究科・医学部医学科, 平成27年度北海道大学大学院医学研究科・医学部医学科 優秀研究賞
  豊嶋 崇徳
• 2012年10月, International Journal of Hematology 編集長賞
  豊嶋 崇徳
• 2005年, 武田科学振興財団, 一般研究奨励賞
  豊嶋 崇徳
• 1999年, Travel Award, 1999 Annual Meeting of American Society of Hematology
  豊嶋 崇徳
• 1999年, Best Abstract Award, 1999 American Society of Blood and Marrow Transplantation

• Adverse karyotype amplifies risk in secondary acute myeloid leukemia (AML) and AML with myelodysplasia-related changes.
  Toshihiro Matsukawa; Shota Yoshida; Masahiro Onozawa; Fumiaki Fujii; Jun Nagai; Tomoki Takahashi; Shuichi Ota; Junichi Hashiguchi; Akio Mori; Takuto Miyagishima; Makoto Ibata; Yasutaka Kakinoki; Tatsuo Oyake; Satoshi Yamamoto; Toshiaki Hayashi; Kentaro Wakasa; Tomoyuki Saga; Tetsuya Igarashi; Satoshi Iyama; Yutaka Tsutsumi; Katsuya Fujimoto; Masaaki Adachi; Masahiro Yoshida; Daigo Hashimoto; Takanori Teshima
  Hematology (Amsterdam, Netherlands), 31, 1, 2628479, 2628479, 2026年12月, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Secondary acute myeloid leukemia (sAML) and AML with myelodysplasia-related changes (AML-MRC) are associated with poor prognosis, but the impact relative to de novo AML remains controversial. We investigated clinical and genetic features in a multicenter Japanese cohort before CPX-351 approval. METHODS: We retrospectively analyzed 294 patients with newly diagnosed AML registered in the Hokkaido Leukemia Net between 2022 and 2023. Propensity score matching was used to adjust baseline variables. Genetic profiles were assessed in 160 matched patients. RESULTS: In the matched cohort, sAML/AML-MRC did not show inferior overall survival compared with non-sAML/non-AML-MRC (P = 0.90). Adverse karyotypes were the predominant determinant among sAML/AML-MRC. Among sAML/AML-MRC patients, adverse karyotypes were associated with poorer survival than those without adverse karyotypes (P = 0.0075). In contrast, non-sAML/non-AML-MRC groups did not affect survival regardless of adverse karyotypes (P = 0.51). Among 65 patients with ELN 2017 adverse-risk, those with TP53 mutations had markedly shorter survival than those with TP53 wild-type (P = 0.018). CONCLUSIONS: sAML/AML-MRC with an adverse karyotype had a dismal outcome. These findings provide a benchmark for risk stratification in the pre- CPX-351 era.
• Successful treatment with zanubrutinib for Bing-Neel syndrome progressing on ibrutinib: a case report and literature review.
  Shingo Nojima; Toru Miyajima; Reiki Ogasawara; Shota Yoshida; Hiroyuki Kimura; Rintaro Nozu; Fuka Horikita; Takahide Ara; Toshihiro Matsukawa; Souichi Shiratori; Masahiro Onozawa; Masao Nakagawa; Takanori Teshima
  Leukemia & lymphoma, 1, 4, 2026年04月08日, ［国際誌］
  英語, 研究論文（学術雑誌）
• Adenovirus-Associated Opsoclonus After Allogeneic Hematopoietic Stem Cell Transplantation.
  Toru Miyajima; Setsuaki Hoshino; Shingo Nojima; Souichi Shiratori; Taishi Iwanami; Takanori Teshima
  EJHaem, 7, 2, e70259, 2026年04月, ［国際誌］
  英語, 研究論文（学術雑誌）
• Real-world treatment patterns and clinical outcomes in patients with AML from 65 to 74 years unfit for first-line intensive chemotherapy in Japan.
  Fumiaki Fujii; Masahiro Onozawa; Shota Yoshida; Naoki Miyashita; Daisuke Hidaka; Reiki Ogasawara; Mutsumi Takahata; Junichi Hashiguchi; Shota Yokoyama; Masahiro Chiba; Tomoyuki Saga; Taku Shimizu; Ikumi Kasahara; Akio Shigematsu; Katsuya Fujimoto; Satoshi Iyama; Tetsuyuki Igarashi; Shinichi Ito; Yoshihito Haseyama; Mizuha Kosugi-Kanaya; Takeshi Kondo; Takanori Teshima
  International journal of hematology, 2026年03月19日, ［国内誌］
  英語, 研究論文（学術雑誌）, Venetoclax (VEN), a BCL-2 inhibitor, was approved in Japan in March 2021, for acute myeloid leukemia (AML). We retrospectively analyzed the impact of VEN approval on treatment patterns and outcomes in older AML patients aged 65-74 years unfit for intensive chemotherapy in Japan. Using the Hokkaido Leukemia Net database, we categorized 101 patients into pre-VEN (n = 46) and post-VEN (n = 55) cohorts, excluding those who had acute promyelocytic leukemia or received intensive chemotherapy. Following VEN approval, VEN + azacitidine (AZA) became the most frequently used initial regimen (56%). Despite higher rates of TP53 mutations and complex karyotypes (35.5%), VEN + AZA achieved comparable response rates (CR + CRi: 64.5%) and overall survival (OS, median 11.7 months) to r7 + 3 (CR + CRi: 64.5%, median OS: 13.1 months), and superior outcomes to cytarabine + aclarubicin + G-CSF (CAG, CR + CRi 37.5%, median OS 6.8 months) or AZA monotherapy (CR + CRi 12.5%, median OS 4.5 months). Early mortality at 60 days from diagnosis was lower with VEN + AZA (3.2%) than with reduced-dose cytarabine plus anthracycline (r7 + 3) (12.9%), CAG (26.7%), or AZA monotherapy (18.8%). Our findings demonstrate a substantial shift in real-world treatment practices following VEN approval and suggest that VEN + AZA is an effective option for older AML patients with adverse genetic features.
• Nonmyeloablative Allogeneic Stem Cell Transplantation With Postcyclophosphamide in a Case of Acute Lymphoblastic Leukemia Complicated by Ventricular Septal Defect.
  Yutaka Tsutsumi; Shinichi Ito; Toma Suzuki; Ryo Kikuchi; Hiroyuki Aoyagi; Hiroyuki Gibo; Takanori Teshima
  Transplantation proceedings, 58, 2, 385, 391, 2026年03月, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: We report a case of unrelated non-myeloablative allogeneic stem cell transplantation (allo-SCT) incorporating post-transplant cyclophosphamide (PTCy) in an adult patient with acute lymphoblastic leukemia (ALL) complicated by ventricular septal defect (VSD). CASE: A 62-year-old woman presented with pancytopenia and concurrent COVID-19 infection. Bone marrow examination revealed an increased number of CD19+, CD10+, CD34+, HLA-DR+ lymphoblasts, and she was diagnosed with ALL. She had a known membranous-type VSD from childhood, which was confirmed by echocardiography prior to chemotherapy. There were no signs of pulmonary hypertension or heart failure at that time. Given the concurrent infection, initial treatment prioritized managing the infection, followed by corticosteroid therapy with prednisolone and induction chemotherapy. She achieved first complete remission after induction therapy and subsequently underwent consolidation chemotherapy, followed by unrelated non-myeloablative allo-SCT with PTCy conditioning. Post-transplant, she developed stage 2, grade 1 acute graft-versus-host disease (aGVHD) of the skin, but otherwise experienced no major complications. However, the VSD hole diameter gradually increased from 2.6 mm at remission induction to a maximum of 4.7 mm at 6 months post-transplant. At that time, her brain natriuretic peptide (BNP) level rose sharply to 4577 pg/mL, with accompanying elevations in LDH and liver enzymes, indicative of right heart failure and congestive hepatopathy due to VSD enlargement. Treatment with pimobendan, tolvaptan, and spironolactone resulted in BNP reduction to <1000 pg/mL within 6 weeks, and normalization of LDH and liver function prior to the BNP peak. These medications were discontinued 4 months after the onset of right heart failure. By one year post-transplant, the VSD diameter had decreased to 3.5 mm and later stabilized at 3.9 mm. RESULTS: The patient with ALL complicated by VSD underwent induction chemotherapy followed by unrelated allogeneic nonmyeloablative SCT using a PTCy regimen. From the initiation of chemotherapy (including pre-transplant conditioning) up to 6 months post-transplant, the VSD hole progressively enlarged, leading to the development of right-sided heart failure. However, since post-transplant complications were mild, treatment with diuretics and other supportive measures led to improvement of heart failure. The VSD hole size decreased to some extent but did not return to its pre-treatment dimensions. CONCLUSION: In this case of ALL with VSD, the VSD hole diameter continued to enlarge during chemotherapy; however, after pre-transplant conditioning with PTCy, the diameter began to decrease around one year post-transplant, though it did not return to its original size. While careful monitoring is needed for right heart failure due to VSD enlargement, pre-transplant conditioning with PTCy was considered a feasible option for hematologic malignancies complicated by VSD.
• Evaluation of safety, efficacy, and guideline compliance in home-based red blood cell transfusions: An 8.5-year retrospective study in suburban Tokyo.
  Takeshi Hagino; Tomohiko Sato; Takenori Hayashi; Naoya Kaneko; Satoshi Noto; Daigo Hashimoto; Naoki Takezako; Takanori Teshima
  Transfusion medicine (Oxford, England), 2026年02月24日, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES: This study evaluated the safety, efficacy, and guideline adherence of home transfusions at a single institution over nearly a decade. BACKGROUND: In Japan, demand for home-based red blood cell (RBC) transfusions is increasing due to population aging and promotion of community-based care. Although national guidelines were issued by the Japanese Society of Transfusion Medicine and Cell Therapy (JSTMCT) in 2017, evidence regarding their real-world application and safety remains limited. METHODS/MATERIALS: We retrospectively reviewed 1007 planned RBC transfusion procedures in 181 patients (median age 81 years, range 37-97) between March 2016 and September 2024 in suburban Tokyo. Data included patient characteristics, transfusion details, haemoglobin (Hb) levels, adverse events, and JSTMCT guideline compliance. Paired Hb values were analysed using the Wilcoxon signed-rank test. RESULTS: Malignancy was the most common underlying condition (173/181 patients, 95.6%), with haematological disorders predominant (102/181, 56.4%). Of 1007 planned procedures, 48 (4.8%) were cancelled. The median number of procedures per patient was 7 (range 1-232). Among 410 procedures with paired Hb values within 15 days, Hb increased significantly (median 6.8 g/dL pre- vs. 7.4 g/dL post-transfusion, p < 0.05). Mild adverse reactions occurred in 0.31% (3/959), lower than the JSTMCT-reported hospital rate of 0.64%. Compliance with JSTMCT guidelines was highest for caregiver presence (100%) but lowest for initial hospital-based transfusion (74.6%). CONCLUSION: Home-based RBC transfusions demonstrated excellent safety and efficacy profiles with lower adverse reaction rates than hospital-based transfusions. This study suggests that the JSTMCT guideline revisions should consider real-world practices, particularly initial transfusion requirements and hospital-clinic collaboration.
• Both DLCO and KCO are vital indices in assessment of diffusing capacity for carbon monoxide by the single-breath method.
  Masafumi Yamamoto; Masaharu Nishimura; Kaoruko Shimizu; Naoki Yamashita; Hideki Goto; Hironi Makita; Ichiro Kuwahira; Takanori Teshima; Satoshi Konno
  Respiratory investigation, 64, 2, 101382, 101382, 2026年02月09日, ［国際誌］
  英語, 研究論文（学術雑誌）, The measurement of diffusing capacity of the lung for carbon monoxide (DLCO) is an invaluable pulmonary function test for assessing gas exchange in the lungs. Typically, the test is conducted via the single-breath method, wherein after maximum inhalation of carbon monoxide and helium simultaneously, the breath is held for 10 s. The test provides the single value of DLCO, and sometimes, the DLCO corrected by alveolar volume (VA) at the measurement. However, DLCO is the product of two independent components in reality-the transfer coefficient for carbon monoxide (KCO) and VA. Conventionally, KCO has often been expressed as DLCO/VA. In this report, we will demonstrate the change in relationship of DLCO with KCO uniquely and characteristically due to emphysema, fibrosis, and their combined disease. Therefore, the assessment of both indices is highly desirable in the precise interpretation of the test. The term "KCO" is preferable to DLCO/VA to avoid misleading.
• Subsequent Neoplasms After Umbilical Cord Blood Transplantation in the Japanese and European Populations.
  Junya Kanda; Fernanda Volt; Hanadi Rafii; Hideki Nakasone; Annalisa Ruggeri; Nobuharu Fujii; Chantal Kenzey; Naoyuki Uchida; Régis Peffault De La Tour; Hikaru Kobayashi; Graziana Maria Scigliuolo; Koji Kato; Barbara Cappelli; Fumihiko Ishimaru; Tatsuo Ichinohe; Satoshi Takahashi; Vanderson Rocha; Takanori Teshima; Yoshiko Atsuta; Eliane Gluckman
  Transplantation and cellular therapy, 2026年01月25日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Subsequent neoplasms (SN) are serious late complications after umbilical cord blood transplantation (UCBT). However, population-based comparisons of the incidence and outcomes of SN between Japan and Europe are lacking. OBJECTIVES: To compare the incidence, types, and outcomes of subsequent neoplasms after unrelated UCBT between Japan and Europe. METHODS: We conducted a retrospective registry-based study using data from the Japanese Society for Transplantation and Cellular Therapy/Japanese Data Center for Hematopoietic Cell Transplantation and Eurocord/European Society for Blood and Marrow Transplantation. Patients who underwent unrelated UCBT between 1998 and 2018 and later developed SN were included in this study. Patients with Fanconi anemia, Diamond-Blackfan anemia, solid tumors as the primary disease, or those who received combined grafts were excluded. Overall survival (OS) was assessed using the Kaplan-Meier method. RESULTS: Among 16,241 (Japan) and 10,358 (Europe) UCBT recipients, 527 (3.2%) and 232 (2.2%) developed SN. The incidence of donor-derived acute leukemia/myelodysplastic syndrome (AL/MDS) was higher in Japan (58%) than in Europe (13%). Solid tumor types differed, with upper gastrointestinal cancers being more frequently observed in Japan (20% versus 5%), while skin (14% versus 8%), thyroid (14% versus 4%), and soft tissue tumors (9% versus 1%) were more common in Europe. Five-year OS after post-transplant lymphoproliferative disorder was significantly higher in Japan than in Europe (48% versus 23%, P < .001), whereas after solid tumors and AL/MDS, it was comparable between the two groups. CONCLUSIONS: Marked regional differences exist in SN type and prognosis after UCBT. The observed variations in donor-derived leukemia and solid tumor types underscore the importance of tailored region-specific surveillance strategies for long-term post-transplant care.
• Long-term follow-up of belumosudil as second or subsequent line of therapy for steroid-dependent/resistant cGVHD: clinical outcomes from a Japanese study.
  Koji Kato; Yoshihiro Inamoto; Toshiro Kawakita; Yasushi Onishi; Ken-Ichi Matsuoka; Soichi Shiratori; Kazuhiro Ikegame; Nobuhiro Hiramoto; Masako Toyosaki; Yuta Katayama; Yuhki Koga; Shun Murayama; Yuji Sasagawa; Mami Shindo; Takanori Teshima; Kiyohiko Hatake; Yoshinobu Maeda
  Bone marrow transplantation, 2025年11月26日, ［国際誌］
  英語
• Effect of eltrombopag on biochemical assay parameters.
  Keiichi Nakano; Masanori Seimiya; Kazushige Kojima; Naoki Yamashita; Hideki Goto; Takanori Teshima
  Journal of pharmaceutical and biomedical analysis, 265, 117015, 117015, 2025年11月15日, ［国際誌］
  英語, 研究論文（学術雑誌）, Eltrombopag, which is used to treat thrombocytopenia, causes bilirubin-like yellowish-brown serum discoloration and interferes with biochemical parameter measurements. However, the extent of these interferences and the methods and reagents involved remain unclear. Although previous studies have examined the effects of eltrombopag on bilirubin measurements, its effect on enzymatic measuring of bilirubin levels, which is widely used in Japan, has been limited. Serum samples were collected from 17 eltrombopag-receiving patients. Eltrombopag was added to drug-free serum samples at concentrations ranging from 2.5 to 40.0 µg/mL. The light absorption spectra of the samples were recorded. The lipemia index and 21 biochemical parameters, including total bilirubin (TB) levels, measured by enzymatic, vanadate, and Doumas methods were analyzed. The addition of eltrombopag resulted in a concentration-dependent yellowish-brown discoloration of the serum samples and an increase in absorbance from 340 to 640 nm. The lipemia index significantly increased with increasing eltrombopag concentrations. Fourteen patients displayed triglyceride values below 2.60 mmol/L, one of whom exceeding the lipemia index threshold and exhibiting a yellowish-brown serum with an absorbance increase from 340 to 640 nm. The TB measurements showed a statistically significant positive bias across all three methods, with varying degrees of interference: enzymatic (280.2 %), vanadate (124.6 %), and Doumas (323.9 %) at 40.0 µg/mL eltrombopag. Moreover, uric acid levels showed a statistically significant, concentration-dependent negative bias. This study provides valuable insights into eltrombopag interference, offering well-defined methodological details to assist clinical laboratories in accurately interpreting the patient results.
• Correction: Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.
  Keito Suto; Norio Takei; Keito Yokoyama; Masahiro Chiba; Takashi Ishio; Michiyuki Maeda; Hideki Goto; Tomoyuki Endo; Takanori Teshima; Yibin Yang; Masao Nakagawa
  Leukemia, 2025年11月10日, ［国際誌］
  英語
• Safety and Efficacy of Graft-versus-Host Disease Prophylaxis with Mini-Dose Methotrexate in Umbilical Cord Blood Transplantation: An NJHSG-CBT18 Observational Study.
  Souichi Shiratori; Keito Suto; Yuta Hasegawa; Takahide Ara; Toshihiro Matsukawa; Hideki Goto; Masahiro Onozawa; Masao Nakagawa; Kaoru Kahata; Daisuke Hidaka; Reiki Ogasawara; Kohei Okada; Junichi Sugita; Yasutaka Kakinoki; Shuichi Ota; Daigo Hashimoto; Takanori Teshima
  Transplantation and cellular therapy, 2025年11月06日, ［国際誌］
  英語, 研究論文（学術雑誌）, Tacrolimus (Tac) and methotrexate (MTX) are standard graft-versus-host disease (GVHD) prophylaxis for umbilical cord blood transplantation (CBT); however, the optimal dose of MTX for CBT remains to be determined. We previously showed the safety and efficacy of reduced-dose MTX (mini-MTX; 5 mg/m2 on days 1, 3, and 6) combined with Tac as GVHD prophylaxis for CBT in a single-center retrospective study. Here we report a multicenter observational study in the North Japan Hematology Study Group (NJHSG; NJHSG-CBT18) conducted to evaluate transplantation outcomes according to GVHD prophylaxis in single-unit CBT, in which patients with hematologic malignancies scheduled for CBT were prospectively registered and followed for 2 years after CBT. A total of 112 patients were registered in NJHSG-CBT18, with a median age of 51 years. Eighty-nine patients received Tac + mini-MTX, 19 patients received Tac + mycophenolate mofetil (MMF), and 4 patients received Tac only as GVHD prophylaxis. Multivariate analysis identified GVHD prophylaxis other than Tac + mini-MTX as a significant risk factor for nonrelapse mortality (NRM) (hazard ratio [HR], 0.160; 95% confidence interval [CI], 0.065 to 0.391; P < .001), overall survival (OS) (HR, 2.971; 95% CI, 1.558 to 5.663; P < .001), progression-free survival (PFS) (HR, 2.383; 95% CI, 1.345 to 4.222; P = .003), and GVHD-free, relapse-free survival (GRFS) (HR, 3.075; 95% CI, 1.799 to 5.256; P < .001). In a comparison of clinical outcomes between the mini-MTX and MMF groups, the cumulative incidences of pre-engraftment immune reaction (5.7% versus 42.1%; P < .001), human herpesvirus 6 encephalitis (2.3% versus 15.8%, P = .011), grade II-IV acute GVHD (14.6% versus 47.4%, P < .001), and NRM (1.1% versus 52.6%, P < .001) were significantly lower and the cumulative incidence of immunosuppressant discontinuation was significantly higher (66.3% versus 18.4%, P = .004) in the mini-MTX group compared to the MMF group, while rates of chronic GVHD and relapse were comparable between the groups. The probabilities of OS (70.6% versus 31.6%, P < .001), PFS (58.1 versus 14.0%, P < .001), and GRFS (44.9% versus 5.1%, P < .001) were significantly higher in the mini-MTX group. Multivariate analysis of risk factors for OS in the mini-MTX group identified high-risk or very high-risk refined Disease Risk Index (rDRI) (HR, 3.896; 95% CI, 1.575 to 9.637; P = .003) and high HCT-CI (HR, 3.338; 95% CI, 1.301 to 8.569; P = .012) as significant risk factors for OS. Our data indicate that a combination of Tac + mini-MTX is safe and effective GVHD prophylaxis in CBT.
• Characterization of remdesivir resistance mutations in COVID-19 patients with various immunosuppressive diseases.
  Takaya Ichikawa; Tomokazu Tamura; Naganori Nao; Hikoyu Suzuki; Shuhei Maruyama; Daiki Wada; Shuhei Tsujino; Noriyoshi Yoshinaga; Kohsuke Asagoe; Mutsumi Takahata; Takashi Ishio; Makoto Ibata; Tanino Yoko; Yasutaka Kakinoki; Kazuhiro Okubo; Rigel Suzuki; Saori Suzuki; Yasushi Nakamori; Takanori Teshima; Takasuke Fukuhara
  Antiviral research, 242, 106264, 106264, 2025年10月, ［国際誌］
  英語, 研究論文（学術雑誌）, Immunocompromised patients (ICPs), such as those who receive certain immunosuppressive therapies, occasionally experience prolonged viral infections even after antiviral treatment. In some cases, antiviral-resistant viruses may eventually emerge. Remdesivir (RDV) is an adenosine nucleoside analog that inhibits the activity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA polymerase, which is composed of a catalytic subunit known as nsp12. Previous studies have reported that amino acid mutations around loci 790-810 in nsp12 are responsible for RDV resistance. However, the host immune status that promotes the emergence of resistant viruses and their virological features remain unclear. We therefore collected clinical samples from 15 coronavirus disease 2019 (COVID-19) patients with various immunosuppressive conditions who received RDV. Variant analysis identified a total of seven nsp12 mutations-V792I, M794I, E796D, E796K, C799F, C799Y, and T803I-in 80 % (12/15) of the participants, with M794I and V792I the most prevalent. The identified mutations were more frequently observed in severely ICPs (including patients with hematological malignancies or kidney transplantation) compared to non-severely ICPs (including patients with solid cancers or autoimmune diseases). In vitro analysis using recombinant viruses carrying each identified mutation demonstrated that all mutant viruses were less efficient in growth compared to wildtype but with a 1.8-fold (T803I) to 3.6-fold (V792I) increase in the half maximal effective concentration (EC50) of RDV. The present study highlights the importance of monitoring resistance mutations to anti-SARS-CoV-2 drugs in severely ICPs.
• A characteristic gene expression profile regulated by ACIN1::NUTM1 fusion in a newly identified infant leukaemic cell line and an ACIN1::NUTM1-inducible model.
  Minori Tamai; Chiaki Komatsu; Keiko Kagami; Shin Kasai; Atsushi Watanabe; Koshi Akahane; Kumiko Goi; Chihiro Tomoyasu; Toshihiko Imamura; Satoshi Oguri; Sumio Iwasaki; Takanori Teshima; Yasushi Yatabe; Takeshi Inukai
  British journal of haematology, 2025年08月29日, ［国際誌］
  英語, 研究論文（学術雑誌）, NUTM1-rearranged (NUTM1-R) infant acute lymphoblastic leukaemia (ALL) is a newly identified subgroup of non-KMT2A-R infant ALL, with ACIN1::NUTM1 the most frequent fusion. KMT2A-R and NUTM1-R infant ALL are characterized by fewer copy number alterations. Moreover, the gene expression profile in NUTM1-R infant ALL characteristically reveals upregulation of the genes that are involved in KMT2A-R infant ALL development, including HOXA9 and HOXA10. However, the direct association of NUTM1-fusion with this gene expression remains unexplored. Clinically, in sharp contrast to KMT2A-R infant ALL, the prognosis of NUTM1-R infant ALL is excellent, although its drug sensitivity profile remains unclear. Here, we newly identified an ACIN1::NUTM1-positive ALL cell line, KOPN32, which was previously established from a relapsed infant-ALL case, as the only cell line with NUTM1-fusion. KOPN32 had fewer copy number alterations, like KMT2A-R ALL cell lines. Both KOPN32 and an ACIN1::NUTM1-inducible ALL model, which was established using the ACIN1::NUTM1 fusion cDNA subcloned from KOPN32, revealed upregulation of HOXA9, HOXA10, SKIDA1 and BMI1, indicating direct involvement of ACIN1::NUTM1 fusion in the upregulation of these genes. In the drug sensitivity to eight standard agents, KOPN32 showed high sensitivity to both daunorubicin and vincristine; both are crucial agents in the induction therapy for infant ALL.
• Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study.
  Robert Zeiser; Domenico Russo; Ron Ram; Shahrukh K Hashmi; Ronjon Chakraverty; Jan Moritz Middeke; Maurizio Musso; Sebastian Giebel; Ant Uzay; Peter Langmuir; Nada Hamad; Karin Burock; Maanasa Gowda; Tommaso Stefanelli; Stephanie J Lee; Takanori Teshima; Franco Locatelli
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 43, 23, 2566, 2571, 2025年08月10日, ［国際誌］
  英語, 研究論文（学術雑誌）, In REACH3 (ClinicalTrials.gov identifier: NCT03112603), ruxolitinib was investigated versus best available therapy (BAT) for 3 years in patients with steroid-refractory/dependent chronic graft-versus-host-disease (SR/D-cGVHD). Patients received ruxolitinib (10 mg twice daily) or BAT for 24 weeks; thereafter (weeks 24-156), patients continued randomized treatment, entered long-term survival follow-up, or crossed over from BAT to ruxolitinib. In 329 randomly assigned patients (ruxolitinib: 165; BAT: 164), the median failure-free survival (FFS) was 38.4 months for ruxolitinib versus 5.7 months for BAT (hazard ratio, 0.36 [95% CI, 0.27 to 0.49]). Median duration of response (DOR) was not reached for ruxolitinib versus 6.4 months for BAT. Ruxolitinib-treated patients had a higher probability of FFS (ruxolitinib: 56.5%; BAT: 18.2%) and maintaining a response (ruxolitinib: 59.6%; BAT: 26.7%) at 36 months. Median overall survival was not reached. Nonrelapse mortality and malignancy relapse/recurrence events were low. In 70 patients who crossed over to ruxolitinib, the overall response rate (50.0%) at week 24 and best overall response (81.4%) during the crossover period were consistent with the primary analysis of randomly assigned patients. No new safety signals were observed. Ruxolitinib provided longer FFS and DOR than BAT, demonstrating sustained efficacy and manageable safety over 3 years of follow-up in patients with SR/D-cGVHD.
• Early cardiotoxicity in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis after HLA-haploidentical hematopoietic stem cell transplantation.
  Toshihiro Matsukawa; Junichi Sugita; Daigo Hashimoto; Masayuki Aiba; Kohei Okada; Takanori Teshima
  International journal of hematology, 122, 2, 247, 256, 2025年08月, ［国内誌］
  英語, 研究論文（学術雑誌）, INTRODUCTION: Post-transplant cyclophosphamide (PTCy)-based prophylaxis for graft-versus-host disease (GVHD) is widely used in HLA-haploidentical hematopoietic cell transplantation (haplo-HCT). One of the major drawbacks of PTCy is the risk of rare but potentially lethal cardiotoxicity, which prompted the development of regimens with reduced doses of PTCy. METHODS: We retrospectively compared the incidence of early cardiotoxicity with standard-dose of PTCy (cyclophosphamide 50 mg/kg/day for 2 days, PTCy100) versus reduced-dose (40 mg/kg/day for 2 days, PTCy80). In total, 179 patients underwent PTCy-based haplo-HCT, including PTCy100 (n = 111) and PTCy80 (n = 68). RESULTS: The PTCy80 group included significantly more elderly patients, patients who received reduced-intensity conditioning, and patients with a history of HCT than the PTCy100 group. Nine eligible patients (5.0%) experienced severe cardiotoxicity. The incidence of severe cardiotoxicity did not differ significant between PTCy80 and PTCy100 (4.4% vs. 5.4%; p = 1). The incidence of fatal cardiotoxicity was lower with PTCy80, but the small size may have prevented the difference from reaching statistical significance. CONCLUSION: Reducing the cyclophosphamide dose in PTCy-based GVHD prophylaxis may lower the risk of fatal cardiotoxicity without significantly altering the overall incidence of severe cardiotoxicity.
• Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net.
  Minoru Kanaya; Masahiro Onozawa; Toshihiro Matsukawa; Naoki Miyashita; Fumiaki Fujii; Shota Yoshida; Jun Nagai; Masayuki Aiba; Daisuke Hidaka; Junichi Hashiguchi; Hajime Senjo; Tetsuyuki Igarashi; Masahiro Chiba; Satoshi Yamamoto; Taku Shimizu; Takashi Ishio; Shota Yokoyama; Ko Ebata; Satoshi Iyama; Tatsuo Oyake; Takeshi Kondo; Takanori Teshima
  Blood cancer journal, 15, 1, 118, 118, 2025年07月03日, ［国際誌］
  英語
• The impact of the SARS-CoV-2 pandemic on umbilical cord blood transplantation in Japan: insights from an interrupted time series analysis.
  Nobuhiko Nakamura; Tetsuji Morishita; Hiromi Hayashi; Motohito Okabe; Hideki Nakasone; Naoyuki Uchida; Noriko Doki; Takahiro Fukuda; Satoshi Yoshihara; Masatsugu Tanaka; Tetsuya Nishida; Yuta Hasegawa; Ken-Ichi Matsuoka; Masashi Sawa; Tetsuya Eto; Makoto Onizuka; Yuta Katayama; Koji Kato; Fumihiko Ishimaru; Ken Tabuchi; Yoshiko Atsuta; Nobuhiro Kanemura; Takanori Teshima
  Bone marrow transplantation, 60, 7, 964, 970, 2025年07月, ［国際誌］
  英語, 研究論文（学術雑誌）, The SARS-CoV-2 pandemic disrupted healthcare systems worldwide, particularly affecting hematopoietic stem cell transplantation (HSCT) activities. Understanding the impact of the SARS-CoV-2 pandemic on transplant practices, especially in Japan, where cord blood transplantation (CBT) is prevalent, is crucial. A total of 40,444 allogeneic HSCT cases in Japan between 2011 and 2021 were examined using an interrupted time series analysis to assess the impact of COVID-19 on CBT utilization. Following the SARS-CoV-2 pandemic, CBT cases demonstrated a significant increase (11.06 [95% confidence interval (CI): 1.87 to 20.25] cases per month), whereas bone marrow transplantation cases decreased, by 10.74 cases per month (95% CI, -19.84 to -1.63 cases per month). Total HSCT cases remained stable with a level change of 5.47 cases per month (95% CI, -10.07 to 21.01 cases per month) and a trend change of -1.11 cases per month (95% CI, -2.22 to 0.004 cases per month). The interrupted time series analysis showed significantly increased CBT cases in Japan, highlighting its crucial role as an alternative transplant source during the pandemic. CBT offset the impact of the decrease in bone marrow transplantation and contributed to the maintenance of HSCT activity in Japan during the unprecedented crisis.
• TP53 and CDKN2A alterations define a poor prognostic subgroup in patients with nodal T follicular helper cell lymphoma.
  Yuta Ito; Joji Shimono; Keisuke Kawamoto; Kanako C Hatanaka; Yasunori Kogure; Mariko Tabata; Yuki Saito; Kota Mizuno; Sara Horie; Yosuke Mizukami; Junji Koya; Koichi Murakami; Takanori Teshima; Yutaka Hatanaka; Kenichi Chiba; Ai Okada; Yuichi Shiraishi; Hiroaki Miyoshi; Yoshihiro Matsuno; Koichi Ohshima; Keisuke Kataoka; Masao Nakagawa
  Leukemia, 39, 7, 1723, 1734, 2025年07月, ［国際誌］
  英語, Nodal T follicular helper cell lymphoma (nTFHL) exhibits unique immunophenotypes and somatic alterations, while the prognostic value of these alterations remains unclear. By analyzing 173 nTFHL cases, we identified 36 driver genes, including 4 novel ones (TET3, HLA-C, NRAS, and KLF2). Then, we classified nTFHL cases into four molecular subgroups by major driver alterations. TR-I (+) and TR-I (-) were characterized by TET2 and/or RHOA mutations with and without IDH2 mutations; AC53 by TP53 and/or CDKN2A alterations and aneuploidy; and NSD with no subgroup-defining alterations (namely without any of the above alterations). AC53 exhibited the worst survival, while NSD, particularly those lacking driver alterations, showed the best prognosis. nTFHL had a better prognosis than peripheral T-cell lymphoma, not otherwise specified, when TP53 and/or CDKN2A alterations were absent. Multivariable analyses showed that AC53, the presence of driver alterations, and international prognostic index high-risk were independently associated with worse survival. Finally, we developed a simple prognostic index (mTFHL-PI), which classified patients into three risk categories with a median OS of 181, 67, and 20 months, respectively. Our study identifies novel prognostic factors, namely TP53 and/or CDKN2A alterations and the presence of driver alterations, demonstrating the clinical relevance of molecular classification in nTFHL.
• Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC.
  Yu Akahoshi; Yoshihiro Inamoto; Nikolaos Spyrou; Hideki Nakasone; Marcio Diniz; Noboru Asada; Francis Ayuketang Ayuk; Hannah K Choe; Noriko Doki; Tetsuya Eto; Aaron M Etra; Elizabeth O Hexner; Nobuhiro Hiramoto; William J Hogan; Ernst Holler Prof. Dr. med; Keisuke Kataoka; Toshiro Kawakita; Masatsugu Tanaka; Takashi Tanaka; Naoyuki Uchida; Ingrid Vasova; Satoshi Yoshihara; Fumihiko Ishimaru; Takahiro Fukuda; Yi-Bin Chen; Junya Kanda; Ryotaro Nakamura; Yoshiko Atsuta; James L M Ferrara; Yoshinobu Kanda; John E Levine; Takanori Teshima
  Blood advances, 2025年07月01日, ［国際誌］
  英語, 研究論文（学術雑誌）, Overall response (OR) that combines complete (CR) and partial responses (PR) at day (D) 28 is the conventional endpoint for acute GVHD trials. Since PR includes heterogeneous clinical presentations, reclassifying PR could produce a better endpoint. Patients in the primary treatment cohort from JSTCT were randomly divided into training and validation sets. In the training set, a classification and regression tree algorithm generated D28 refined response (RR) criteria based on symptoms at treatment and D28. We then compared RR for primary and second-line treatments to conventional criteria, using the area under the receiver operating curve (AUC) and negative predictive value (NPV) for 6-month non-relapse mortality as performance measures. RR considered patients with grade 0/I at D28 without additional treatment as responders. RR for primary treatment produced higher AUCs than OR with small improvement of NPVs in both validation sets: JSTCT (AUC: 0.73 vs. 0.69, P<0.001; NPV: 92.0% vs. 89.6%, P<0.001) and MAGIC (AUC: 0.71 vs. 0.68, P=0.032; NPV: 90.9% vs. 89.8%, P=0.009). RR for second-line treatment produced similar AUCs but much higher NPVs than OR in both validation sets of JSTCT (AUC: 0.64 vs. 0.63, P=0.775; NPV: 74.5% vs. 66.0%, P<0.001) and MAGIC (AUC: 0.67 vs. 0.64, P=0.105; NPV: 86.8% vs. 76.1%, P=0.004). Classifying persistent, but mild skin symptoms as responses and residual lower GI GVHD as non-responses were major drivers in improving the prognostic performance of RR. Our externally validated D28 RR would serve as a better endpoint than conventional criteria in future first- and second-line treatment trials.
• A comparative study of GVHD prophylaxis using low dose ATG versus PTCy for PBSCT based on two independent prospective cohorts.
  Souichi Shiratori; Junichi Sugita; Jun Ishikawa; Takashi Kuroha; Yasuo Mori; Tetsuya Eto; Senji Kasahara; Kentaro Fukushima; Mine Harada; Takanori Teshima
  Scientific reports, 15, 1, 20677, 20677, 2025年07月01日, ［国際誌］
  英語, 研究論文（学術雑誌）, Both anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) have shown prophylactic effects on graft-versus-host disease (GVHD) in multiple phase III studies. We conducted a comparative study of for low dose ATG (thymoglobulin) versus PTCy for GVHD prophylaxis in peripheral blood stem cell transplantation (PBSCT). The ATG (n = 67) and PTCy (n = 40) groups included patients enrolled in multicenter phase II studies (JSCT-ATG15 and JSCT-PTCY19, respectively). The probability of GVHD-free and relapse-free survival at 2 years as the primary endpoint was not significantly different between these two groups (57.9% for ATG vs. 67.8% for PTCy, P = 0.49). Both neutrophil and platelet engraftments were both significantly shorter in the ATG group than in the PTCy group (neutrophils: median 13 days vs. 15 days, P = 0.007; platelets: median 20 days vs. 27 days, P = 0.007). The cumulative incidences of acute and chronic GVHD, relapse, non-relapse mortality, and off-immunosuppressant use were similar between these two groups. The probabilities of overall and progression-free survival were 83.4% and 70.0% in the ATG group and 76.5% and 75.2% in the PTCy group, respectively, with no significant differences. These data indicate that low dose ATG and PTCy are equivalent for GVHD prophylaxis for PBSCT.
• Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study.
  Tatsunori Goto; Hiroshi Okamura; Takashi Ikeda; Yasuo Mori; Souichi Shiratori; Shin-Ichiro Fujiwara; Noriko Doki; Ken-Ichi Matsuoka; Yuta Katayama; Yi-Bin Chen; Yngvar Fløisand; Guillermo Rossiter; Johan Jansson; Ryou Nakaya; Takanori Teshima
  International journal of hematology, 122, 1, 93, 105, 2025年07月, ［国内誌］
  英語, 研究論文（学術雑誌）, In the randomized, double-blind, phase 3 GRAPHITE study (NCT03657160), anti-α4β7 integrin antibody vedolizumab showed greater efficacy than placebo for prevention of lower-gastrointestinal (GI) acute graft-versus-host disease (aGVHD) after unrelated allogenic hematopoietic stem cell transplantation (allo-HSCT). This post hoc analysis assessed the efficacy and safety of vedolizumab versus placebo for lower-GI aGVHD prevention in Japanese and non-Japanese patients, when added to standard GVHD prophylaxis (calcineurin inhibitor + methotrexate/mycophenolate mofetil + / - anti-thymocyte globulin [ATG]). The analysis included 35 (18 vedolizumab-treated, 17 placebo-treated) Japanese and 298 (150 vedolizumab-treated, 148 placebo-treated) non-Japanese patients. Lower-GI aGVHD-free survival by day + 180 after allo-HSCT (primary endpoint) was 94% in vedolizumab-treated versus 81% in placebo-treated Japanese patients (HR 0.36; 95% CI 0.03-4.01; P = 0.2) and 84% in vedolizumab-treated versus 70% in placebo-treated non-Japanese patients (HR 0.47; 95% CI 0.28-0.78; P = 0.002). The number of events for the 5 key secondary endpoints (lower-GI aGVHD-free and relapse-free survival, Grade C-D aGVHD-free survival, non-relapse mortality, overall survival, and Grade B-D aGVHD-free survival) by day + 180 was lower in vedolizumab- versus placebo-treated Japanese patients. No safety concerns were identified for vedolizumab use as lower-GI aGVHD prophylaxis in Japanese patients.
• Is Age No Longer a Barrier to Allogeneic Hematopoietic Stem Cell Transplantation?
  Takanori Teshima
  Transplantation, 2025年06月17日, ［国際誌］
  英語, 研究論文（学術雑誌）
• Efficacy of Total-Body Irradiation-based Intensified Myeloablative Regimens for Acute Leukemia-An International Collaborative Study.
  Yasuyuki Arai; Ruta Brazauskas; Naya He; A Samer Al-Homsi; Saurabh Chhabra; Minoo Battiwalla; Masamitsu Yanada; Amir Steinberg; Miguel Angel Diaz Perez; Sanghee Hong; Junya Kanda; Asad Bashey; Haydar A Frangoul; Sherif M Badawy; Leo F Verdonck; Hillard M Lazarus; Jean A Yared; Hasan Hashem; Akshay Sharma; Mahmoud Aljurf; Ajoy L Dias; Muhammad Bilal Abid; Baldeep Wirk; César O Freytes; Amer M Zeidan; Usama Gergis; Amer Beitinjaneh; Medhat Askar; Jeffrey J Pu; Leslie E Lehmann; Hemalatha G Rangarajan; William A Wood; Shahrukh Hashmi; Shingo Yano; Shinichi Kako; Yukiyasu Ozawa; Noriko Doki; Yoshinobu Kanda; Takahiro Fukuda; Yuta Katayama; Tatsuo Ichinohe; Junji Tanaka; Takanori Teshima; Shinichiro Okamoto; Yoshiko Atsuta; Wael Saber
  EJHaem, 6, 3, e70061, 2025年06月, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: In this study, we compared outcomes of intensified myeloablative conditioning regimens using large registry data from Japan (Japanese Society for Transplantation and Cellular Therapy) and the United States (Center for International Blood and Marrow Transplant Research). METHODS: Adult patients who underwent their first myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia in remission between 2010 and 2018 using conditioning regimens of cyclophosphamide plus total-body irradiation (CY/TBI), CY/TBI+cytarabine (AraC), or CY/TBI+etoposide (VP16) were included. RESULTS: The acute myeloid leukemia (AML) cohort (N = 480, 38.8%) indicated that overall survival (OS) was poorer in CY/TBI+AraC (hazard ratio [HR] 1.46, p < 0.001) and CY/TBI+VP16 (HR 1.39, p = 0.059) compared to CY/TBI. Relapse was not suppressed, while treatment-related mortality (TRM) was significantly higher (HR 1.78 and 1.74, p < 0.001 and 0.018, respectively). In the acute lymphoblastic leukemia (ALL) cohort (N = 3901, 61.2%), OS was comparable among these regimens. With intensified regimens, relapse was significantly suppressed in CY/TBI+VP16 (HR 0.74, p = 0.005), while TRM was higher (HR 1.21, p = 0.077). No interactions were observed regarding the country. CONCLUSION: In AML adding AraC and VP16 to CY/TBI had an adverse effect on OS. Conversely, in ALL, adding VP16 or AraC to CY/TBI did not affect survival, but the addition of VP16 reduced the risk of relapse. CLINICAL TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.
• Peposertib suppresses generation of FLT3-internal tandem duplication formed by contralateral double nicks.
  Shota Yoshida; Masahiro Onozawa; Shota Yokoyama; Toshihiro Matsukawa; Hideki Goto; Shinsuke Hirabayashi; Takeshi Kondo; Daigo Hashimoto; Yasuhito Onodera; Takanori Teshima
  Experimental hematology, 149, 104819, 104819, 2025年05月31日, ［国際誌］
  英語, 研究論文（学術雑誌）, Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) is the most frequent gene mutation in acute myeloid leukemia. The consequences of FLT3-ITD have been analyzed in detail; however, the molecular mechanisms underlying the generation of FLT3-ITD remain to be elucidated. We analyzed FLT3-ITDs in clinical samples using deep sequencing and identified not only oligoclonal ITDs but also rare deletion clones clustered at the palindrome-like sequence at FLT3 exon 14. We hypothesized that FLT3 exon 14 is genetically unstable due to the palindrome-like sequence at the region and that genomic damage at the site initiates FLT3-ITD formation. We used clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 to induce DNA damage for creating artificial FLT3-ITDs in human and mouse cell lines. We found that double nicks on the adjacent contralateral strand most efficiently generate ITDs. The artificial ITDs resembled clinical ITDs in the length distribution and characteristics at the joint. We further compared the inhibitory effects of olaparib and peposertib, specific inhibitors of single-strand break (SSB) and double-strand break (DSB) repair, respectively. Peposertib remarkably reduced ITD formation, but olaparib did not affect the mutation pattern. The findings indicated that nonhomologous end joining has a crucial role in the generation of ITDs. Our data shed light to the new role of peposertib, which potentially suppresses the generation of de novo FLT3-ITDs caused by mis-repair events of the DNA damages in a clinical course.
• Asciminib in patients with newly diagnosed chronic myeloid leukemia: results from the Japanese subgroup of ASC4FIRST.
  Naoto Takahashi; Yoshikane Kikushige; Hirohisa Nakamae; Tatsunori Goto; Akihiro Tomita; Michiko Ichii; Satoshi Ito; Takanori Teshima; Keita Kirito; Takayuki Ikezoe; Kaoru Hatano; Hirokazu Tanaka; Nobuhiro Hiramoto; Ryohei Osako; Makoto Aoki; Kamel Malek; Yasunori Ueda
  International journal of hematology, 2025年05月26日, ［国内誌］
  英語, 研究論文（学術雑誌）, INTRODUCTION: The phase III ASC4FIRST study (NCT04971226) demonstrated superior efficacy and favorable safety and tolerability for asciminib against investigator-selected tyrosine kinase inhibitors (IS-TKI) in newly diagnosed chronic myeloid leukemia (CML). Results of a subgroup analysis in Japanese patients are presented here. METHODS: Adult patients were randomized 1:1 to asciminib or IS-TKI following stratification by European Treatment and Outcome Study long-term survival risk score and prerandomization-selected TKI (imatinib and second-generation [2G] TKI strata). At week 48, major molecular response (MMR) rate in all patients and imatinib stratum (primary endpoints) were assessed along with MR4.0, MR4.5, and safety (cutoff: November 28, 2023). RESULTS: In Japanese patients (asciminib, n = 21; IS-TKI, n = 17 [imatinib/2G TKI, n = 8/9]), the MMR rate was higher with asciminib (81.0%) than IS-TKI (47.1%), and versus imatinib (asciminib: 100%; imatinib: 25.0% [imatinib stratum]). More patients on asciminib than IS-TKI achieved MR4.0 (57.1% vs. 11.8%) and MR4.5 (28.6% vs. 5.9%). Fewer grade ≥ 3 adverse events (AEs; 42.9%, 50.0%, and 55.6%) and AEs leading to treatment discontinuation (0%, 37.5%, and 11.1%) occurred with asciminib than imatinib or 2G TKI. CONCLUSION: Outcomes in Japanese patients were consistent with the ASC4FIRST overall population. Asciminib may be a therapy of choice for Japanese patients with CML.
• Chronic graft-versus-host disease myelitis successfully treated with rituximab.
  Emi Yokoyama; Yuta Hasegawa; Kentaro Wakaki; Touma Suzuki; Sayaka Kajikawa; Minoru Kanaya; Koh Izumiyama; Makoto Saito; Masanobu Morioka; Jun Nagai; Tomoe Ichiki; Ryo Kikuchi; Satomi Okada; Hiroyuki Ohigashi; Hideki Goto; Masahiro Onozawa; Daigo Hashimoto; Akio Mori; Takanori Teshima; Takeshi Kondo
  International journal of hematology, 121, 5, 712, 717, 2025年05月, ［国内誌］
  英語, Chronic graft-versus-host disease (cGVHD) is a major serious complication after allogeneic stem-cell transplantation (allo-HSCT), and often mimics autoimmune diseases. Central nervous system (CNS) symptoms are rare manifestations of cGVHD, and are difficult to diagnose. CNS manifestations of cGVHD were discussed in the 2020 National Institutes of Health cGVHD Consensus Project as one of the "atypical cGVHD manifestations" with involvement of various organ systems other than classical cGVHD organs. We experienced a case of myelitis after allo-HSCT diagnosed as cGVHD of the CNS. The neurological symptoms progressed after corticosteroid pulse therapy, resulting in severe paralysis and paresthesia of the lower extremities. The clinical course and magnetic resonance imaging findings showed some similarities with multiple sclerosis. We decided to use rituximab after the patient became refractory to corticosteroids because rituximab has been reported to be effective in multiple sclerosis by suppressing B cells on both sides of the blood-brain barrier. Rituximab was effective for the neurologic symptoms in our case. In atypical cGVHD, treatments used in corresponding autoimmune diseases may be reasonable and effective.
• Ultrasonographic scoring system for SOS/VOD in pediatric hematopoietic stem cell transplant recipients.
  Mutsumi Nishida; Shinsuke Hirabayashi; Takahito Iwai; Megumi Sato; Yusuke Kudo; Satomi Omotehara; Tatsunori Horie; Ryosuke Sakano; Yukayo Terashita; Yuko Cho; Atsushi Manabe; Takanori Teshima
  International journal of hematology, 2025年04月26日, ［国内誌］
  英語, 研究論文（学術雑誌）, Sinusoidal obstruction syndrome (SOS)/veno-occlusive disease (VOD) is a serious complication following hematopoietic stem cell transplantation. It is more common in children, with an incidence of approximately 20% compared to 10% in adult patients. While the Hokkaido ultrasonography (US)-based scoring system (HokUS-10 and HokUS-6) has proven effective in diagnosing SOS/VOD in adults, its utility in children remains uncertain. This study evaluated the utility of the HokUS-10/6 scoring systems in diagnosing pediatric SOS/VOD (pSOS/VOD) in a cohort of 99 patients, including 13 diagnosed with pSOS/VOD. Hyperbilirubinemia (> 2 mg/dL) was observed in only three patients (23%), whereas transfusion-refractory thrombocytopenia, hepatomegaly, and ascites were observed in all 13 patients. When the cutoff values for HokUS-10 and HokUS-6 scores were set at 4 and 2, the respective areas under the curve were 0.977 and 0.957. The sensitivity and specificity were 100% and 80% for HokUS-10, and 77% and 97% for HokUS-6, respectively. The simplified HokUS-6 may be a practical tool for diagnosing pSOS/VOD when use of the HokUS-10 scoring system is not feasible. HokUS-10/6 is important for early detection of pSOS/VOD during regular examinations and plays a valuable role in the diagnosis of clinical pSOS/VOD.
• Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma.
  Hideki Goto; Masashi Sawa; Shin-Ichiro Fujiwara; Masaki Ri; Tadao Ishida; Masahiro Takeuchi; Kenji Ishitsuka; Masako Toyosaki; Kazutaka Sunami; Junichi Tsukada; Takashi Sonoki; Aiko Shimogomi; Yuki Ichihashi; Yoshiumi Ouchi; Toshihiro Miyamoto; Masayuki Hino; Yoshinobu Maeda; Takanori Teshima
  Scientific reports, 15, 1, 14523, 14523, 2025年04月25日, ［国際誌］
  英語, 研究論文（学術雑誌）, This phase 2 study evaluated the impact of pegfilgrastim, a single-dose, long-acting granulocyte colony-stimulating factor, on the steady-state mobilization of hematopoietic stem cells into peripheral blood in patients with multiple myeloma (MM) or malignant lymphoma (ML). Efficacy and safety, along with CD34-positive cell mobilization outcomes were assessed in patients with MM, who were randomly assigned to pegfilgrastim (n = 30) or daily filgrastim (n = 31), and ML (pegfilgrastim only, n = 13) cohorts. In the MM cohort, CD34-positive cell counts ≥ 2 × 106/kg were achieved in 100% of patients in the pegfilgrastim group and 96.7% in the filgrastim group (difference: 3.3%; 80% confidence interval: -0.9-7.5%), demonstrating the non-inferiority of pegfilgrastim to filgrastim. All patients in the ML cohort achieved ≥ 2 × 106/kg CD34-positive cell counts. The plerixafor administration rates in the MM cohort were 50.0% and 63.3% in the pegfilgrastim and filgrastim groups, respectively, and 91.7% in the ML cohort. There were no major differences in safety measures between the two groups. Although the sample size was small, particularly in the ML cohort, a single dose of pegfilgrastim demonstrated comparable efficacy and safety to daily doses of filgrastim, indicating its potential for clinical use while reducing patient burden.Trial Registration: jRCT2011210029, NCT05007652.
• Hitting the bullseye in GVHD.
  Takanori Teshima
  Blood, 145, 15, 1598, 1599, 2025年04月10日, ［国際誌］
  英語
• Utility of the Base Editing System for Introducing Drug-Resistant Gene Mutations Into Human Leukemia Cellular Models.
  Thao Nguyen; Minori Tamai; Shinichi Fujisawa; Akiko Nagamachi; Keiko Kagami; Chiaki Komatsu; Shotaro Iwamoto; Toshiya Inaba; Takanori Teshima; Takeshi Inukai
  Cureus, 17, 4, e81889, 2025年04月, ［国際誌］
  英語, 研究論文（学術雑誌）, Background Recent genomic analyses of poor prognostic and relapsed leukemia have revealed the involvement of diverse gene mutations in treatment resistance. These gene mutations are classified into two groups: mutations involving resistance to specific agents such as the BCR::ABL1 fusion gene mutations (typically T315I mutation) in tyrosine kinase inhibitor (TKI) resistance and those involving the resistance to diverse therapeutic modalities such as the TP53 gene mutations. In the latter type, although their associations with drug resistance have been clinically demonstrated, the direct association with resistance to each therapeutic modality remains to be fully elucidated. To overcome treatment resistance induced by these gene mutations, appropriate leukemic cellular models are urgently required. Using the cytidine base editing (CBE) system, we introduced two types of mutations through C-to-T transition into human leukemia cell lines and evaluated their significance in the drug sensitivities. Methods We applied the CBE system to introduce the T315I (ACT to ATT) mutation of the BCR::ABL1 fusion gene in a human Philadelphia chromosome-positive leukemia cell line and to introduce the T125M (ACG to ATG) mutation of the TP53 gene in a human B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cell line. Results We first confirmed an introduction of the T315I mutation in one of four BCR::ABL1 alleles as a result of base editing in the obtained TKI-resistant subline. We also identified the additional C-to-T transition at adjacent codon 314 (ATC), which resulted in a silent mutation, in the same allele. We next confirmed that the obtained subline acquired the T125M mutation of the TP53 gene without additional C-to-T transition. In the T125M subline, transcriptional activities of the p53 protein were disrupted and the sensitivities to diverse chemotherapeutic drugs and irradiation were reduced. Conclusion Our observations demonstrated the utility of the CBE system for introducing specific nucleotide transitions into human leukemia cell lines.
• CML With Mutant ASXL1 Showed Decreased Sensitivity to TKI Treatment via Upregulation of the ALOX5-BLTR Signaling Pathway.
  Naoki Miyashita; Masahiro Onozawa; Kohei Kasahara; Toshihiro Matsukawa; Yasuhito Onodera; Kohjin Suzuki; Tomoiku Takaku; Takanori Teshima; Takeshi Kondo
  Cancer science, 116, 4, 1115, 1125, 2025年04月, ［国際誌］
  英語, 研究論文（学術雑誌）, In this study, the mechanisms of tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia (CML) were investigated focusing additional sex combs-like 1 (ASXL1) gene mutations and their downstream effects. While TKIs have improved the prognosis of CML, some patients have shown resistant to therapy. Cases with mutations in epigenome-related genes such as ASXL1 are known to have a poor prognosis, but the underlying mechanisms of the poor prognosis are unclear. We showed that mutated ASXL1 reduces TKI sensitivity in CML cell lines, and RNA microarray analysis revealed that arachidonate 5-lipoxygenase (ALOX5) is a significantly upregulated gene under the conditional expression of mutated ASXL1. Enforced ALOX5 expression induced TKI resistance, while ALOX5 knockout increased TKI sensitivity. ALOX5 downstream signal inhibition by LY293111, a leukotriene B4 receptor (BLTR) antagonist, suppressed AKT phosphorylation and enhanced TKI sensitivity. This study revealed that TKI resistance in CML with ASXL1 mutation was induced via ALOX5 overexpression. ASXL1 mutations may confer a clonal advantage through activation of the AKT pathway following ALOX5 overexpression. While combined use of LY293111 with TKIs and asciminib showed synergistic effects against CML cells, the ALOX5-BLTR signaling pathway is novel therapeutic target for CML patients with mutated ASXL1.
• Temporal changes in corticosteroid dose during ibrutinib treatment in patients with cGVHD and pulmonary involvement.
  Masako Toyosaki; Shinichiro Machida; Daisuke Tomizawa; Masaya Okada; Masashi Sawa; Yasunori Ueda; Ai Omi; Yosuke Koroki; Takanori Teshima
  International journal of hematology, 121, 3, 388, 396, 2025年03月, ［国内誌］
  英語, 研究論文（学術雑誌）, The GVH3001 study assessed the efficacy and safety of ibrutinib in Japanese patients with steroid-dependent or -refractory chronic graft-versus-host disease (cGVHD). However, the effects of ibrutinib on lung function and reduction in corticosteroid dose, which is a measurable factor associated with improved quality of life, could not be adequately assessed in patients who initially presented with lung involvement. This post hoc analysis aimed to evaluate temporal changes in daily corticosteroid dose, as well as effectiveness outcomes based on lung function and symptom burden (percent predicted forced expiratory volume in 1 s [%FEV1] and Lee cGVHD Symptom Scale lung subscale score, respectively) in the subgroup of patients with cGVHD who had lung involvement at baseline. Seven of the 19 patients in the GVH3001 study had lung involvement at baseline. The daily corticosteroid dose for cGVHD decreased in five of these patients, and %FEV1 remained relatively stable in two patients but increased to > 80% in one patient. Lee cGVHD Symptom Scale scores were relatively stable throughout the study in patients with lung involvement. Ibrutinib may allow corticosteroid dose reduction without worsening lung function or increasing symptom burden in previously treated patients with cGVHD and associated lung involvement.
• Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1.
  Hideki Goto; Takahiro Kumode; Yuko Mishima; Keisuke Kataoka; Yoshiaki Ogawa; Nobuhiro Kanemura; Kazuyuki Shimada; Toshiki Uchida; Yukano Kuroe; Atsuko Kawasaki; Jotaro Sato; Takanori Teshima
  International journal of clinical oncology, 30, 2, 389, 396, 2025年02月, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: In a global phase I/II study (GO29781; NCT02500407), single-agent mosunetuzumab had a manageable safety profile and induced durable complete responses in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma, including in patients with R/R follicular lymphoma (FL). In this analysis, the efficacy and safety of mosunetuzumab monotherapy were evaluated in an expansion cohort, FLMOON-1, in Japanese patients with R/R FL who had received  ≥ 2 prior lines of therapy in a phase I study (JO40295, jRCT2080223801). METHODS: Mosunetuzumab was administered intravenously at the recommended phase II dose (with cycle 1 step-up dosing) for eight cycles or up to 17 cycles, or until disease progression or unacceptable toxicity. The pre-specified primary endpoint was Independent Review Facility (IRF)-assessed complete response rate (CRR; as best overall response). Secondary objectives included investigator (INV)-assessed CRR, INV- and IRF-assessed objective response rate (ORR), and safety. RESULTS: At the data cutoff (October 13, 2023), 19 patients (median age 72 years) were evaluated. The IRF-assessed CRR and ORR were 68.4% and 78.9%, respectively; the INV-assessed CRR and ORR were 63.2% and 84.2%, respectively. Grade 3-4 adverse events (AEs) were observed in 89.5% of patients, with a low incidence of AEs leading to mosunetuzumab discontinuation (10.5%) and one fatal AE unrelated to mosunetuzumab. Cytokine release syndrome occurred in 47.4% of patients and were mostly Grade 1 in severity. CONCLUSION: These findings indicate mosunetuzumab has a consistent efficacy and manageable safety profile in Japanese patients with R/R FL compared with previously reported data from the global phase I/II study.
• Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma.
  Keito Suto; Norio Takei; Keito Yokoyama; Masahiro Chiba; Takashi Ishio; Michiyuki Maeda; Hideki Goto; Tomoyuki Endo; Takanori Teshima; Yibin Yang; Masao Nakagawa
  Leukemia, 39, 1, 243, 247, 2025年01月, ［国際誌］
  英語, 研究論文（学術雑誌）
• ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies.
  Piyanuch Kongtim; Pongthep Vittayawacharin; Jun Zou; Samer Srour; Brian Shaffer; Roman M Shapiro; Ankur Varma; Joseph McGuirk; Bhagirathbhai R Dholaria; Shannon R McCurdy; Amy E DeZern; Nelli Bejanyan; Asad Bashey; Sabine Furst; Luca Castagna; Jacopo Mariotti; Annalisa Ruggeri; Rebeca Bailen; Takanori Teshima; Huang Xiao-Jun; Carmen Bonfim; Fleur Aung; Kai Cao; Paul A Carpenter; Mehdi Hamadani; Medhat Askar; Marcelo Fernandez-Vina; Alin Girnita; Stefan O Ciurea
  Transplantation and cellular therapy, 30, 12, 1139, 1154, 2024年12月, ［国際誌］
  英語, 研究論文（学術雑誌）, Donor-specific anti-HLA antibodies (DSA) are an important cause of engraftment failure and may negatively impact survival outcomes of patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) using an HLA-mismatched allograft. The incidence of DSA varies across studies, depending on individual factors, detection or identification methods and thresholds considered clinically relevant. Although DSA testing by multiplex bead arrays remains semiquantitative, it has been widely adopted as a standard test in most transplant centers. Additional testing to determine risk of allograft rejection may include assays with HLA antigens in natural conformation, such as flow cytometric crossmatch, and/or antibody binding assays, such as C1q testing. Patients with low level of DSA (<2,000 mean fluorescence intensity; MFI) may not require treatment, while others with very high level of DSA (>20,000 MFI) may be at very high-risk for engraftment failure despite current therapies. By contrast, in patients with moderate or high level of DSA, desensitization therapy can successfully mitigate DSA levels and improve donor cell engraftment rate, with comparable outcomes to patients without DSA. Treatment is largely empirical and multimodal, involving the removal, neutralization, and blocking of antibodies, as well as inhibition of antibody production to prevent activation of the complement cascade. Desensitization protocols are based on accumulated multicenter experience, while prospective multicenter studies remain lacking. Most patients require a full intensity protocol that includes plasma exchange, while protocols relying only on rituximab and intravenous immunoglobulin may be sufficient for patients with lower DSA levels and negative C1q and/or flow cytometric crossmatch. Monitoring DSA levels before and after HSCT could guide preemptive treatment when high levels persist after stem cell infusion. This paper aims to standardize current evidence-based practice and formulate future directions to improve upon current knowledge and advance treatment for this relatively rare, but potentially serious complication in allogeneic HSCT recipients.
• FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML.
  Toshihiro Matsukawa; Masahiro Onozawa; Takeshi Kondo; Minoru Kanaya; Daisuke Hidaka; Shuichi Ota; Akio Mori; Akio Shigematsu; Takuto Miyagishima; Yasutaka Kakinoki; Junichi Hashiguchi; Satoshi Yamamoto; Masayo Yamamoto; Kentaro Wakasa; Mutsumi Takahata; Toshimichi Ishihara; Yoshihito Haseyama; Akihito Fujimi; Tetsuya Igarashi; Takehiro Sarashina; Satoshi Iyama; Ryoji Kobayashi; Hajime Sakai; Katsuya Fujimoto; Junki Inamura; Yuji Kanisawa; Shinsuke Hirabayashi; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
  Annals of hematology, 103, 12, 5333, 5340, 2024年12月, ［国際誌］
  英語, 研究論文（学術雑誌）, Acute myeloid leukemia (AML) is an aggressive hematological malignancy with genetic alterations. The FMS-like tyrosine kinase 3 (FLT3) gene is frequently mutated in adult de novo AML, with two types of mutations: internal tandem duplication (ITD) and point mutations in the tyrosine kinase domain. This study aimed to investigate the impact of FLT3 inhibitors and hematopoietic cell transplantation (HCT) on survival outcomes in patients with FLT3-ITD AML in a real-world setting. We retrospectively analyzed 139 patients with FLT3-ITD-positive AML between 2012 and 2021. The median age was 63 years. In the propensity score-matched cohort, FLT3 inhibitors improved overall survival (OS) compared with patients treated without FLT3 inhibitors (3-year OS: 33.7% vs. 25.8%, p = 0.021). Patients who underwent HCT had superior outcomes to those without HCT (3-year OS: 45.3% vs. 2.2%, p < 0.0001). The combination of FLT3 inhibitors and HCT resulted in the highest OS and relapse-free survival (RFS) rates (3-year OS: 62.4%; 3-year RFS: 44.4%). Disease status before transplantation did not predict the prognosis, but use of FLT3 inhibitors increased survival in patients without complete remission before HCT. These results demonstrate the clinical impact of FLT3 inhibitors on survival outcomes in patients with FLT3-ITD-positive AML, particularly when combined with HCT. FLT3 inhibitors can improve the prognosis of AML with FLT3 mutations, especially in patients who undergo HCT.
• Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study.
  Souichi Shiratori; Kentaro Fukushima; Yasushi Onishi; Noriko Doki; Tatsunori Goto; Masaya Okada; Hirohisa Nakamae; Yoshinobu Maeda; Koji Kato; Takayuki Ishikawa; Tadakazu Kondo; Masako Toyosaki; Takashi Ikeda; Naoyuki Uchida; Akio Maki; Fumika Shimada; Takeshi Tajima; Tommaso Stefanelli; Takanori Teshima
  International journal of hematology, 120, 6, 705, 716, 2024年12月, ［国内誌］
  英語, 研究論文（学術雑誌）, Ruxolitinib, a Janus kinase (JAK1-JAK2) inhibitor, has demonstrated safety and efficacy in patients with graft-versus-host disease (GvHD). This phase 3 randomized trial (REACH3) evaluated the efficacy and the safety of ruxolitinib 10 mg twice daily compared with investigator-selected best available therapy (BAT) in a subgroup of Japanese patients (n = 37) with steroid-refractory or dependent (SR/D) chronic GvHD. At data cut-off, treatment was ongoing in 17 patients and discontinued in 20. The overall response rate (complete or partial) at week 24 was greater with ruxolitinib than BAT (50% vs. 20%; odds ratio, 4.13 [95% CI, 0.90-18.9]). The best overall response rate (complete or partial response at any time point up to week 24) was higher with ruxolitinib than BAT (68.2% vs. 46.7%; odds ratio, 2.69 [95% CI, 0.66-10.9]). Ruxolitinib led to longer median failure-free survival than BAT (18.6 months vs. 3.7 months; hazard ratio, 0.34; [95% CI, 0.14-0.85]). The most common grade ≥ 3 adverse events up to week 24 were anemia (ruxolitinib: 22.7%; BAT: 6.7%) and pneumonia (22.7% and 20.0%, respectively). Ruxolitinib showed a higher response rate and improvement in failure-free survival in Japanese patients with SR/D chronic GvHD, with a safety profile consistent with the overall study population.
• Safety and efficacy of acalabrutinib and obinutuzumab in treatment-naive chronic lymphocytic leukemia: a Japanese phase 1 study.
  Jun Takizawa; Takanori Teshima; Daisuke Ennishi; Satoshi Ichikawa; Ritsuro Suzuki; Akira Kojima; Yusuke Takahashi; Nobuya Hayashi; Hisashi Kawasumi; Kosho Murayama; Patricia Cheung; Toshio Kawata; Koji Izutsu
  Leukemia & lymphoma, 65, 11, 1586, 1594, 2024年11月, ［国際誌］
  英語, 研究論文（学術雑誌）, This report focuses on part 3 of a multicenter, open-label, phase 1 study (NCT03198650) assessing the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of acalabrutinib plus obinutuzumab in Japanese patients with treatment-naive (TN) chronic lymphocytic leukemia (CLL). Ten patients were included; median age was 68 years. With a median treatment duration of 27.2 months, treatment-emergent adverse events (AEs) occurred in all patients (grade ≥3, 70%), and the most common AEs were anemia and headache (40% each). One patient had a grade 4 AE of neutropenia (the only dose-limiting toxicity). PK results suggested no marked effects of concomitant obinutuzumab treatment on the exposure of acalabrutinib. PD assessment indicated that combination therapy provided >98% Bruton tyrosine kinase (BTK) occupancy. Overall response rate (ORR) was 100% with median duration of response (DoR) and median progression-free survival (PFS) not reached. Treatment with acalabrutinib plus obinutuzumab was generally safe and efficacious in adult Japanese patients with TN CLL.
• Validation of Left Ventricular Filling Pressure Evaluation by Order of Tricuspid and Mitral Valve Opening in Patients With Atrial Fibrillation.
  Hisao Nishino; Michito Murayama; Hiroyuki Iwano; Nobuyuki Kagiyama; Yutaka Nakamura; Yuka Akama; Misako Toki; Sachiko Takamatsu; Taiji Okada; Yasuyuki Chiba; Masahiro Nakabachi; Shinobu Yokoyama; Mana Goto; Yukino Suzuki; Suguru Ishizaka; Ko Motoi; Yoji Tamaki; Hiroyuki Aoyagi; Kosuke Nakamura; Sanae Kaga; Chiaki Watanabe; Kiwamu Kamiya; Toshiyuki Nagai; Takanori Teshima; Toshihisa Anzai
  Circulation. Cardiovascular imaging, 17, 11, e017134, 2024年11月, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Accurate assessment of left ventricular filling pressure in patients with atrial fibrillation or flutter (AF) remains difficult. A novel 2-dimensional scoring system, visually assessing time difference between mitral valve and tricuspid valve opening (VMT) score, based on temporal analysis of early diastolic valve opening, could be applied to these patients. We aimed to determine the usefulness of the VMT score in patients with AF. METHODS: We analyzed 119 consecutive patients with AF who underwent cardiac catheterization as a derivation cohort. The diagnostic performance of the VMT score was further evaluated in an external data set containing 189 patients with AF. Elevated left ventricular filling pressure was defined as a mean pulmonary arterial wedge pressure ≥15 mm Hg. The time sequence of atrioventricular valve opening was visually assessed and scored (0, tricuspid valve first; 1, simultaneous; 2, mitral valve first). When the inferior vena cava was dilated, 1 point was added, and the VMT score was finally graded as 0 to 3. Conventional Doppler parameters to estimate left ventricular filling pressure were also measured. RESULTS: Pulmonary arterial wedge pressure was elevated with an increase in the VMT score (0: 10±3, 1: 13±5, 2: 22±7, 3: 27±6 mm Hg; P<0.001), resulting in a significant rise in pulmonary arterial wedge pressure from VMT score 1 to 2. VMT≥2 predicted elevated pulmonary arterial wedge pressure with an accuracy of 87%, and the diagnostic accuracy of the VMT score was significantly higher than that of conventional Doppler parameters (C index, 0.88 versus 0.54-0.68; P<0.001). In addition, VMT ≥2 showed an incremental predictive value over plasma brain natriuretic peptide levels (C index, 0.79-0.93; P<0.001). In the external validation cohort, VMT≥2 demonstrated acceptable accuracy of 72%. CONCLUSIONS: VMT scoring was a useful echocardiographic marker of elevated left ventricular filling pressure and had an incremental benefit over practical biomarkers in patients with AF.
• Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group.
  Koh Izumiyama; Tasuku Inao; Hideki Goto; Shinpei Harada; Hajime Senjo; Keito Suto; Junichi Hashiguchi; Reiki Ogasawara; Tomoyuki Saga; Tetsuyuki Igarashi; Kentaro Wakasa; Ikumi Kasahara; Yukari Takeda; Keisuke Yamaguchi; Akio Shigematsu; Mutsumi Takahata; Katsuya Fujimoto; Yoshihito Haseyama; Takahiro Nagashima; Hajime Sakai; Yasutaka Kakinoki; Mitsutoshi Kurosawa; Isao Yokota; Takanori Teshima
  Haematologica, 109, 11, 3631, 3640, 2024年11月01日, ［国際誌］
  英語, 研究論文（学術雑誌）, Information regarding follow-up duration after treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL) is important. However, a clear endpoint has yet to be established. We totally enrolled 2182 patients newly diagnosed with DLBCL between 2008 and 2018. The median age of the patients was 71 years. All patients were treated with rituximab- and anthracycline-based chemotherapies. Each overall survival (OS) was compared with the age- and sex-matched Japanese general population (GP) data. At a median follow-up of 3.4 years, 985 patients experienced an event and 657 patients died. Patients who achieved an event-free survival (EFS) at 36 months (EFS36) had an OS equivalent to that of the matched GP (standard mortality ratio [SMR], 1.17; P=0.1324), whereas those who achieved an EFS24 did not have an OS comparable to that of the matched GP (SMR, 1.26; P=0.0095). Subgroup analysis revealed that relatively old patients (>60 years), male patients, those with limited-stage disease, those with a good performance status, and those with low levels of soluble interleukin 2 receptor already had a comparable life expectancy to the matched GP at an EFS24. In contrast, relatively young patients had a shorter life expectancy than matched GP, even with an EFS36. In conclusion, an EFS36 was shown to be a more suitable endpoint for newly diagnosed DLBCL patients than an EFS24. Of note, younger patients require a longer EFS period than older patients in order to obtain an equivalent life expectancy to the matched GP.
• Calcineurin inhibitor blocks tolerance by suppressing donor T cell terminal exhaustion after allogeneic hematopoietic cell transplantation.
  Hajime Senjo; Daigo Hashimoto; Takanori Teshima
  The Journal of clinical investigation, 134, 20, 2024年10月15日, ［国際誌］
  英語, 研究論文（学術雑誌）
• An open-label study of belumosudil, a selective ROCK2 inhibitor, as second or subsequent line of therapy for steroid-dependent/steroid-resistant chronic GVHD.
  Yoshihiro Inamoto; Koji Kato; Toshiro Kawakita; Yasushi Onishi; Ken-Ichi Matsuoka; Soichi Shiratori; Kazuhiro Ikegame; Nobuhiro Hiramoto; Masako Toyosaki; Yuta Katayama; Shun Murayama; Yuji Sasagawa; Yoshinobu Maeda; Kiyohiko Hatake; Takanori Teshima
  American journal of hematology, 99, 10, 1917, 1926, 2024年10月, ［国際誌］
  英語, 研究論文（学術雑誌）, Belumosudil mesylate is a selective Rho-associated coiled-coil kinase 2 inhibitor with immunomodulatory and antifibrosis effects. This multicenter, open-label, single-arm study evaluated belumosudil 200 mg once daily as second or subsequent line of therapy (LOT) in 21 Japanese patients ≥12 years of age with steroid-dependent/steroid-resistant chronic graft-versus-host disease (cGVHD). The primary endpoint of best overall response rate (ORR) at 24 weeks after enrollment of the last patient was 85.7% (95% confidence interval [CI]: 63.7-97.0), and the lower limit of the 95% CI exceeded the pre-defined threshold of 25%. The Kaplan-Meier estimate of duration of response rate at 24 weeks was 75% (95% CI: 46-90); 13/18 responders (72.2%) had a sustained response for ≥20 weeks. The median time to response was 4.1 weeks (range 3.90-8.10); ORR was 47.6% at 4 weeks and 75.0% at 24 weeks; best ORR was 80% for joints/fascia, 66.7% for the mouth, and 54.5% for skin. Overall, 57.1% of patients had clinically meaningful symptom improvement at least once; the median duration of symptom improvement was 22.2 weeks (range 4.0-51.3). Corticosteroid dose reductions were recorded for 57.1% of patients. Median failure-free and overall survival were not reached. Treatment-emergent adverse events occurred in 85.7% of patients (most commonly diarrhea, 19.0%), of which 38.1% were drug-related. There were no drug-related discontinuations or deaths. In summary, belumosudil 200 mg once daily as second or subsequent LOT in Japanese patients with steroid-dependent/steroid-resistant cGVHD was effective, with no new safety concerns.
• Real-World Outcomes of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Japan: Retrospective Analysis of the Transplant Registry Unified Management Program Registry.
  Junya Kanda; Takaya Mitsuyoshi; Masatoshi Sakurai; Hisakazu Nishimori; Makoto Murata; Naoyuki Uchida; Noriko Doki; Yoshihiro Inamoto; Tetsuya Nishida; Masatsugu Tanaka; Yuta Katayama; Tetsuya Eto; Ken-Ichi Matsuoka; Satoshi Yoshihara; Masashi Sawa; Toshiro Kawakita; Gyungjin Jun; Mio Kurata; Tatsuo Ichinohe; Takahiro Fukuda; Takanori Teshima; Yoshiko Atsuta; Seitaro Terakura
  Transplantation and cellular therapy, 30, 9, 907.e1-907.e16, 2024年09月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important therapeutic option for patients with hematological malignancies. However, the development of graft-versus-host disease (GVHD) after allo-HSCT remains a challenge. Although systemic steroid therapy is the established first-line therapy for acute GVHD (aGVHD) and chronic GVHD (cGVHD), many patients are unresponsive or resistant to corticosteroid therapy, and the response is insufficient. OBJECTIVE: To evaluate the clinical characteristics of patients who developed aGVHD and cGVHD after allo-HSCT. STUDY DESIGN: This noninterventional, retrospective study used large national registry data from the Transplant Registry Unified Management Program. The study included 29,690 patients with hematological diseases who underwent their first allo-HSCT between January 2010 and December 2019. The primary endpoints of this study were the cumulative incidence of aGVHD and cGVHD. The secondary endpoints were overall survival (OS) and non-relapse mortality (NRM) of patients with aGVHD and cGVHD and OS and NRM of patients who received second-line therapy for aGVHD. RESULTS: Of 29,690 patients who underwent allo-HSCT, 2,807, 6,167, 10,556, 774, and 9,339 patients received related bone marrow (RBM), related peripheral blood (RPB), unrelated bone marrow, unrelated peripheral blood (UPB), and unrelated cord blood, respectively. The cumulative incidence of aGVHD (grades II-IV) at 100 days was high after the related and unrelated mismatched transplantation. Furthermore, response rate for the first- and second-line therapy for aGVHD was low in the RBM/RPB-mismatched (59.6%/61.6%) and UPB-mismatched subgroup (45.5%), respectively. The 3-year NRM in patients with aGVHD was high in the RPB and UPB mismatched subgroups (37.9% and 31.2%, respectively). CONCLUSION: Developing a novel treatment for steroid-refractory aGVHD is necessary to improve transplant outcomes, particularly for patients undergoing HLA-mismatched transplantation.
• GVHD targets organoid-forming bile duct stem cells in a TGF-β-dependent manner.
  Yuta Hasegawa; Daigo Hashimoto; Zixuan Zhang; Toru Miyajima; Yumika Saito; Wenyu Li; Ryo Kikuchi; Hajime Senjo; Tomoko Sekiguchi; Takahiro Tateno; Xuanzhong Chen; Emi Yokoyama; Shuichiro Takahashi; Hiroyuki Ohigashi; Takahide Ara; Eiko Hayase; Isao Yokota; Takanori Teshima
  Blood, 144, 8, 904, 913, 2024年08月22日, ［国際誌］
  英語, 研究論文（学術雑誌）, Graft-versus-host disease (GVHD) is a major life-threatening complication that occurs after allogeneic hematopoietic cell transplantation (HCT). While adult tissue stem cells have been identified as targets of GVHD in the skin and gut, their role in hepatic GVHD is yet to be clarified. In the current study, we explored the fate of bile duct stem cells (BDSCs), capable of generating liver organoids in vitro, during hepatic GVHD after allogeneic HCT. We observed a significant expansion of biliary epithelial cells (BECs) upon injury early after allogeneic HCT. Organoid-forming efficiency from the bile duct was also significantly increased early after allogeneic HCT. Subsequently, the organoid-forming efficiency from bile ducts was markedly decreased in association with the reduction of BECs and the elevation of plasma concentrations of bilirubin, suggesting that GVHD targets BDSCs and impairs the resilience of BECs. The growth of liver organoids in the presence of liver-infiltrating mononuclear cells from allogeneic recipients, but not from syngeneic recipients, significantly reduced in a TGF--dependent manner. Administration of SB-431542, an inhibitor of TGF-β signaling, from day 14 to day 28 protected organoid-forming BDSCs against GVHD and mitigated biliary dysfunction after allogeneic HCT, suggesting that BDSCs are a promising therapeutic target for hepatic GVHD.
• Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.
  Yi-Bin Chen; Mohamad Mohty; Robert Zeiser; Takanori Teshima; Omer Jamy; Johan Maertens; Duncan Purtill; Jingjing Chen; Hong Cao; Guillermo Rossiter; Johan Jansson; Yngvar Fløisand
  Nature medicine, 30, 8, 2277, 2287, 2024年08月, ［国際誌］
  英語, 研究論文（学術雑誌）, Acute graft-versus-host disease (aGVHD) of the lower gastrointestinal (GI) tract is a major cause of morbidity and mortality in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). Vedolizumab is a gut-selective anti-α4β7 integrin monoclonal antibody that reduces gut inflammation by inhibiting migration of GI-homing T lymphocytes. The efficacy and safety of vedolizumab added to standard GVHD prophylaxis (calcineurin inhibitor plus methotrexate/mycophenolate mofetil) was evaluated for prevention of lower-GI aGVHD after unrelated donor allo-HSCT in a randomized, double-blind, placebo-controlled phase 3 trial. Enrollment closed early during the COVID-19 pandemic with 343 patients randomized (n = 174 vedolizumab, n = 169 placebo), and 333 received ≥1 intravenous dose of 300 mg vedolizumab (n = 168) or placebo (n = 165) and underwent allo-HSCT. The primary end point was met; Kaplan-Meier (95% confidence interval) estimated rates of lower-GI aGVHD-free survival by day +180 after allo-HSCT were 85.5% (79.2-90.1) with vedolizumab versus 70.9% (63.2-77.2) with placebo (hazard ratio, 0.45; 95% confidence interval, 0.27-0.73; P < 0.001). For the 5 key secondary efficacy end points analyzed by day +180 after allo-HSCT, rates of lower-GI aGVHD-free and relapse-free survival and grade C-D aGVHD-free survival were significantly higher with vedolizumab versus placebo. No significant treatment differences were found for the other key secondary end points of non-relapse mortality, overall survival and grade B-D aGVHD-free survival, respectively. Incidence of treatment-related serious adverse events analyzed in patients receiving ≥1 dose of study treatment (n = 334) was 6.5% (n = 11 of 169) vedolizumab versus 8.5% (n = 14 of 165) placebo. When added to standard calcineurin inhibitor-based GVHD prevention, lower-GI aGVHD-free survival was significantly higher with vedolizumab versus placebo. ClinicalTrials.gov identifier: NCT03657160 .
• Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial.
  Takanori Teshima; Yasushi Onishi; Koji Kato; Shuichi Taniguchi; Koichi Miyamura; Kentaro Fukushima; Jun Kato; Takayuki Ishikawa; Noriko Doki; Hirohisa Nakamae; Yoshinobu Maeda; Yoshihiro Inamoto; Masaya Okada; Akio Maki; Fumika Shimada; Takeshi Tajima; Monika Wroclawska; Robert Zeiser; Makoto Onizuka
  International journal of hematology, 120, 1, 106, 116, 2024年07月, ［国内誌］
  英語, 研究論文（学術雑誌）, Acute graft-versus-host disease (aGvHD) is a major complication after allogeneic hematopoietic stem cell transplantation in Japan and other countries. Nearly one-third of patients do not respond to standard systemic steroid therapy and no standard second-line treatment has been established in Japan. We report efficacy and safety findings of ruxolitinib versus best available therapy (BAT) from a subgroup analysis of the international, phase 3 REACH2 study in Japanese patients with steroid-refractory aGvHD. The primary endpoint was overall response rate (ORR) at day 28. Overall, 9 patients received ruxolitinib and 21 received BAT. The ORR at day 28 (88.9% vs 52.4%) and durable ORR at day 56 (66.7% vs 28.6%) were higher with ruxolitinib versus BAT. The estimated cumulative incidence of loss of response at 6 months was 12.5% with ruxolitinib and 18.2% with BAT. The median failure-free survival was longer with ruxolitinib versus BAT (2.73 vs 1.25 months). The most common adverse events up to day 28 in the ruxolitinib and BAT groups were anemia (55.6% vs 19.0%) and thrombocytopenia (44.4% vs 4.8%, respectively). Ruxolitinib showed better efficacy outcomes and a consistent safety profile compared with BAT in the Japanese subgroup, and the findings were consistent with overall study results.
• Novel CAR T cell therapies for patients with large B cell lymphoma.
  Hideki Goto; Masahiro Onozawa; Takanori Teshima
  International journal of hematology, 2024年05月25日, ［国内誌］
  英語, 研究論文（学術雑誌）, Approximately 60-70% of patients with large B cell lymphoma (LBCL) achieve long-term remission or a cure after initial treatment. However, patients who relapse or are refractory to initial treatment have a poor prognosis. Chimeric antigen receptor (CAR) T cell therapy has recently attracted attention for its potential to provide a cure or long-term remission even for LBCL that has relapsed or is refractory to conventional chemotherapy. Currently, three CAR T cell products are clinically available for LBCL: tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel). These CAR T cell products were initially approved as third- or later-line therapies worldwide. Recently, axi-cel and liso-cel have become feasible as second-line therapies for patients with early relapsed or refractory disease after first-line chemotherapy. Although a large body of data on CAR T cell therapy has been accumulated, the clinical question of how to choose between these three available CAR T cell products has yet to be resolved. The appropriate approach to treatment selection for patients who relapse after CAR T cell therapy also remains unclear. This review discusses treatment strategies to maximize the benefits of CAR T cell therapy.
• American Society for Transplantation and Cellular Therapy International Affairs Committee: Report of the 4th Workshop on Quality as a Development Tool for Hematopoietic Cell Transplantation Programs at the 2023 Tandem BMT Meetings.
  Pablo Ramirez; Yoshiko Atsuta; Amal Alseraihy; Shinichiro Okamoto; Takanori Teshima; Mahmoud Aljurf; Navneet S Majhail; Damiano Rondelli; Nelson Chao; Mary E Flowers
  Transplantation and cellular therapy, 30, 5, 468, 474, 2024年05月, ［国際誌］
  英語, We provide a summary of the 4th ASTCT International Workshop with presentations from experts from Chile ("Setting Up a Transplantation Program in Chile," by Dr Pablo Ramirez), Saudi Arabia ("Developing Quality Programs in North Africa," by Dr Amal Alseraihy), and Japan ("The Japanese Transplant Registry Unified Management Program [TRUMP]: Current Issues and the Future," by Dr Yoshiko Atsuta). Workshop objectives included: (1) recognizing the benefits and importance for low- and middle-income countries of developing quality criteria and programs beyond existing accreditation programs, such as the Foundation for the Accreditation of Cellular Therapy (FACT) and the Joint Accreditation Committee ISCT-Europe and EBMT (JACIE); (2) describing the relationships among monitoring outcomes, including mortality, improvement of care, data reporting, and associated costs; and (3) reviewing how quality structures have been implemented and are improving care worldwide.
• Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
  Martin Dreyling; Nathan Hale Fowler; Michael Dickinson; Joaquin Martinez-Lopez; Arne Kolstad; Jason Butler; Monalisa Ghosh; Leslie Popplewell; Julio C Chavez; Emmanuel Bachy; Koji Kato; Hideo Harigae; Marie José Kersten; Charalambos Andreadis; Peter A Riedell; P Joy Ho; José Antonio Pérez-Simón; Andy I Chen; Loretta J Nastoupil; Bastian von Tresckow; Andrés José María Ferreri; Takanori Teshima; Piers E M Patten; Joseph P McGuirk; Andreas L Petzer; Fritz Offner; Andreas Viardot; Pier Luigi Zinzani; Ram Malladi; Ines Paule; Aiesha Zia; Rakesh Awasthi; Xia Han; Davide Germano; Darragh O'Donovan; Roberto Ramos; Harald J Maier; Aisha Masood; Catherine Thieblemont; Stephen J Schuster
  Blood, 143, 17, 1713, 1725, 2024年04月25日, ［国際誌］
  英語, 研究論文（学術雑誌）, Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL) in the third- or later-line setting. The primary analysis (median follow-up, 17 months) of the phase 2 ELARA trial reported high response rates and excellent safety profile in patients with extensively pretreated r/r FL. Here, we report longer-term efficacy, safety, pharmacokinetic, and exploratory biomarker analyses after median follow-up of 29 months (interquartile range, 22.2-37.7). As of 29 March 2022, 97 patients with r/r FL (grades 1-3A) received tisagenlecleucel infusion (0.6 × 108-6 × 108 chimeric antigen receptor-positive viable T cells). Bridging chemotherapy was allowed. Baseline clinical factors, tumor microenvironment, blood soluble factors, and circulating blood cells were correlated with clinical response. Cellular kinetics were assessed by quantitative polymerase chain reaction. Median progression-free survival (PFS), duration of response (DOR), and overall survival (OS) were not reached. Estimated 24-month PFS, DOR, and OS rates in all patients were 57.4% (95% confidence interval [CI], 46.2-67), 66.4% (95% CI, 54.3-76), and 87.7% (95% CI, 78.3-93.2), respectively. Complete response rate and overall response rate were 68.1% (95% CI, 57.7-77.3) and 86.2% (95% CI, 77.5-92.4), respectively. No new safety signals or treatment-related deaths were reported. Low levels of tumor-infiltrating LAG3+CD3+ exhausted T cells and higher baseline levels of naïve CD8+ T cells were associated with improved outcomes. Tisagenlecleucel continued to demonstrate highly durable efficacy and a favorable safety profile in this extended follow-up of 29 months in patients with r/r FL enrolled in ELARA. This trial was registered at www.clinicaltrials.gov as #NCT03568461.
• Acute onset of constrictive pericarditis due to acute myelomonocytic leukemia: A case and literature review.
  Naoki Kosaka; Takanori Uchiyama; Masahiro Onozawa; Jun Nagai; Jiro Koya; Suguru Ishizaka; Toshiyuki Nagai; Yohei Ikebe; Kenjiro Kato; Zen-Ichi Tanei; Jun Sakakibara-Konishi; Yuta Hasegawa; Hiroyuki Ohigashi; Hideki Goto; Daigo Hashimoto; Hideki Ujiie; Satoshi Hirano; Satoshi Konno; Toshihisa Anzai; Koji Taniguchi; Shinya Tanaka; Takanori Teshima
  Internal medicine (Tokyo, Japan), 2024年04月16日, ［国内誌］
  英語, 研究論文（学術雑誌）, We herein present a fatal case of constrictive pericarditis (CP) due to acute myelomonocytic leukemia (AMML) in a patient who initially complained of an acute onset of chest pain two days after COVID-19 vaccination. An autopsy revealed pericardial infiltration of leukemic cells. CP is rarely associated with leukemia and only 14 cases have been reported in the literature. The etiology of CP in previous reports included leukemic infiltration, graft-versus-host disease, drug-induced, post-radiation, autoimmune, and otherwise unidentified. This case indicates that leukemic infiltration can cause CP and that clinicians should include leukemia in the differential diagnosis of CP.
• Patent blue interferes with the measurement of lipemia index in a patient with sentinel lymph node.
  Keiichi Nakano; Masanori Seimiya; Kojiro Yamazaki; Keiko Yasuda; Naoki Yamashita; Hideki Goto; Takanori Teshima
  Laboratory medicine, 2024年04月15日, ［国際誌］
  英語, 研究論文（学術雑誌）, Lipids interfere with absorbance measurements conducted using colorimetric methods. To monitor lipemia, some systems measure absorbance using an analyzer. This report describes a novel case of interference with the lipemia index without lipemia. A 64-year-old woman with giant basal cell carcinoma underwent resection and sentinel lymph node biopsy. The patient had been subcutaneously injected with patent blue during sentinel lymph node resection. After surgery, her serum and urine were yellow-green, and the lipemia index, calculated by measuring absorbance at 658 nm (main wavelength) and 694 nm (secondary wavelength) using a JCA-BM8040 chemistry analyzer, was high. The absorbance spectrum of the patient's serum and patent blue solution were compared to determine the cause of the high lipemia index. The patient's serum and the patent blue solution showed absorption at wavelengths between 540 and 698 nm. Moreover, the absorbance was concentration-dependent for patent blue. These results thus indicated that the patient's serum contained patent blue. Here, we report a case wherein patent blue affected the lipemia index. Thus, it must be noted that patent blue injection may yield inaccurate results when evaluating lipemia index.
• Relative impact of THPO mutation causing hereditary thrombocythemia.
  Hiroyuki Kimura; Masahiro Onozawa; Toshihiro Matsukawa; Hideki Goto; Takeshi Kondo; Takanori Teshima
  Experimental hematology, 104208, 104208, 2024年03月26日, ［国際誌］
  英語, 研究論文（学術雑誌）, Germline mutations of THPO were reported as causes of hereditary thrombocythemia. Six previously reported distinct sites of the mutation were clustered at the 5'-untranslated region or the exon 3 splicing donor site of the THPO gene. Each mutation was identified in an independent pedigree and the difference in the mutations were not compared. We cloned 6 distinct THPO mutations (THPO c.-47delG, THPO c.-31G>T, THPO c.13G>A, THPO c.13+1G>A, THPO c.13+2T>C, and THPO c.13+5G>A) and compared the molecular mechanisms that underlie the increased production of THPO protein. At the transcript level, all of the mutations except THPO c.-47delG showed an exon 3 skipping transcript including 2 mutations (THPO c.-31G>T and THPO c.13+5G>A) that were distant from the splicing donor site. THPO c.-47delG showed the same full-length transcript as that of the wild-type transcript. At the protein level, all mutations resulted in a higher level of production of THPO protein compared to wild-type THPO. There are only two distinct patterns of mechanisms for increased production of THPO: 1) exon 3 skipping that deleted upstream suppressive open reading frame (ORF) 7 and 2) one base deletion that shifted ORF7 to connect to the initial codon of THPO in-frame. The common mechanisms of hereditary thrombocytosis due to THPO mutation are unleashed THPO translation that is usually suppressed by upstream out-of-frame ORF7.
• R-Spondin1 protects gastric stem cells and mitigates gastric GVHD in allogeneic hematopoietic stem cell transplantation.
  Eiko Hayase; Takahide Ara; Yumika Saito; Shuichiro Takahashi; Kosuke Yoshioka; Hiroyuki Ohigashi; Reiki Ogasawara; Emi Yokoyama; Tomohiro Yamakawa; Ko Ebata; Yuta Hasegawa; Kazuma Tomizuka; Takanori Teshima
  Blood advances, 8, 3, 725, 731, 2024年02月13日, ［国際誌］
  英語, 研究論文（学術雑誌）, Graft-versus-host disease (GVHD) is the major obstacle to performing allogeneic hematopoietic cell transplantation (allo-HCT). We and others have shown that intestinal stem cells are targeted in lower gastrointestinal GVHD. A leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5)-expressing gastric stem cells (GSCs) reside at the base of the gastric glands in mice. After experimental allo-HCT, Lgr5+ GSCs significantly decreased. Parietal cells, which underwent continuous renewal by GSCs, were injured in gastric GVHD, leading to failure of gastric acidification and aerobic bacterial overgrowth in the duodenum. Fate-mapping analysis demonstrated that administration of R-Spondin1 (R-Spo1) that binds to Lgr5 for 6 days in naïve mice significantly increased proliferating epithelial cells derived from Lgr5+ GSCs. R-Spo1 administered on days -3 to -1 and from days +1 to +3 of allo-HCT protected GSCs, leading to amelioration of gastric GVHD and restoration of gastric acidification, and suppression of aerobic bacterial overgrowth in the duodenum. In conclusion, Lgr5+ GSCs were targeted by gastric GVHD, resulting in disruption of the gastric homeostasis, whereas R-Spo1 protected Lgr5+ GSCs from GVHD and maintained homeostasis in the stomach.
• Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study.
  Naoki Miyashita; Masahiro Onozawa; Toshihiro Matsukawa; Akio Mori; Daisuke Hidaka; Koichiro Minauchi; Akio Shigematsu; Junichi Hashiguchi; Tetsuyuki Igarashi; Yasutaka Kakinoki; Yutaka Tsutsumi; Makoto Ibata; Kentaro Wakasa; Katsuya Fujimoto; Toshimichi Ishihara; Hajime Sakai; Satoshi Iyama; Tatsuo Oyake; Takeshi Kondo; Takanori Teshima
  British journal of haematology, 2024年01月18日, ［国際誌］
  英語, 研究論文（学術雑誌）
• Evaluation of the Loopamp SARS-CoV-2 detection kit using saliva for the detection of SARS-CoV-2 Omicron
  Oguri Satoshi; Iwasaki Sumio; Inao Tasuku; Yokota Isao; Murakami Kaoru; Tanaka Kumiko; Hayasaka Kasumi; Fujisawa Shinichi; Watanabe Chiaki; Konno Satoshi; Murakami Masaaki; Teshima Takanori
  Laboratory Medicine International, 3, 3, 70, 73, Japanese Society of Laboratory Medicine, 2024年
  英語, Aims: The Omicron variant of SARS-CoV-2 spreads more rapidly than ancestral lineages. Reverse-transcription loop-mediated isothermal amplification (RT-LAMP) provides results more rapidly than reverse-transcription
  polymerase chain reaction (RT-PCR). However, the reliability in detecting omicrons variant is still unclear due
  to possible differences in target sequences.
  
  Methods: Fifty-one saliva specimens, which were positive for the Omicron variant SARS-CoV-2 by real-time RT-PCR and sequencing of the S region, were subjects for this study. The RT-LAMP assay was performed using
  the Loopamp SARS-CoV-2 detection kit with (n=51) or without it (n=50).
  
  Results: The RT-LAMP assay following RNA extraction from saliva specimens had a sensitivity of 100% (95%CI: 93.0–100.0%) with 0.969 Kendall’s coefficient of concordance between LAMP threshold time and PCR cycle
  threshold value. Forty-five of fifty (90.0%, 95%CI: 78.2–96.7%) specimens positive were also positive by RTLAMP
  without RNA extraction.
  
  Conclusions: The Omicron variant was effectively detected in saliva by RT-LAMP using saliva specimens and RNA extraction could improve its efficacy.
• Hereditary thrombocythemia due to splicing donor site mutation of THPO in a Japanese family.
  Hiroyuki Kimura; Masahiro Onozawa; Junichi Hashiguchi; Daisuke Hidaka; Minoru Kanaya; Toshihiro Matsukawa; Hiromi Okada; Takeshi Kondo; Yoshihiro Matsuno; Takanori Teshima
  Annals of hematology, 103, 1, 89, 96, 2024年01月, ［国際誌］
  英語, 研究論文（学術雑誌）, Thrombopoietin (THPO) is an essential factor for platelet production. Hereditary thrombocythemia (HT) is caused by a germline mutation of THPO, MPL, or JAK2 and is inherited in an autosomal-dominant manner. We identified a Japanese family with HT due to a point mutation of the splicing donor site of the THPO gene (THPO c.13 + 1G > A). Bone marrow biopsy showed increased megakaryocytes mimicking essential thrombocythemia. One affected family member developed chronic myeloid leukemia. We cloned the mutation and developed mutated and wild type THPO expression vectors. Molecular analysis showed that the mutation causes an exon 3 skipping transcript of THPO that abrogates a suppressive untranslated upstream open reading frame. Although the transcript levels of THPO mRNA were comparable, mutated transcripts were more efficiently translated and THPO protein expression was significantly higher than that of the wild type.
• Whole genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in Adult T-cell leukemia/lymphoma.
  Masahiro Chiba; Joji Shimono; Keito Suto; Takashi Ishio; Tomoyuki Endo; Hideki Goto; Hiroo Hasegawa; Michiyuki Maeda; Takanori Teshima; Yibin Yang; Masao Nakagawa
  Blood, 2023年12月24日, ［国際誌］
  英語, 研究論文（学術雑誌）, Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell malignancy with a poor prognosis and limited treatment options. Programmed cell death ligand 1(PD-L1) is recognized to be involved in the pathobiology of ATLL. However, what molecules control PD-L1 expression and whether genetic or pharmacological intervention might modify PD-L1 expression in ATLL cells is still unknown. In order to comprehend the regulatory mechanisms of PD-L1 expression in ATLL cells, we performed unbiased genome-wide clustered regularly interspaced short palindromic repeat (CRISPR) screening in this work. In ATLL cells, we discovered that the neddylation-associated genes NEDD8, NAE1, UBA3, and CUL3 negatively regulated PD-L1 expression while STAT3 positively did so in ATLL cells. We verified, in line with the genetic results, that treatment with the JAK1/2 inhibitor ruxolitinib or the neddylation pathway inhibitor pevonedistat resulted in a decrease in PD-L1 expression in ATLL cells or an increase in it. It is significant that these results held true regardless of whether ATLL cells had the PD-L1 3' structural variant, a known genetic anomaly that promotes PD-L1 overexpression in certain primary ATLL patients. Pevonedistat alone showed cytotoxicity for ATLL cells, but compared to each single modality, pevonedistat improved the cytotoxic effects of the anti-PD-L1 monoclonal antibody Avelumab and chimeric antigen receptor T-cells targeting PD-L1 in vitro. As a result, our work provided insight into a portion of the complex regulatory mechanisms governing PD-L1 expression in ATLL cells and demonstrated the in vitro preliminary preclinical efficacy of PD-L1-directed immunotherapies by using pevonedistat to upregulate PD-L1 in ATLL cells.
• Posttransplant cyclophosphamide in unrelated and related peripheral blood stem cell transplantation from HLA-matched and 1 allele mismatched donor.
  Junichi Sugita; Takashi Kuroha; Jun Ishikawa; Tetsuya Eto; Kentaro Fukushima; Isao Yokota; Koichi Akashi; Shuichi Taniguchi; Mine Harada; Takanori Teshima
  Bone marrow transplantation, 2023年12月19日, ［国際誌］
  英語, 研究論文（学術雑誌）, Posttransplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis has been increasingly used in HLA-haploidentical transplantation and recent studies also demonstrated the efficacy of PTCy in HLA-matched transplantation. We conducted a prospective multicenter phase II study to evaluate the safety and efficacy of PTCy with tacrolimus and mycophenolate mofetil in 43 patients who underwent HLA-matched (n = 21), 1 allele mismatched (n = 20), or 2 allele mismatched (n = 2) peripheral blood stem cell transplantation (PBSCT) following myeloablative (n = 28) or reduced-intensity (n = 15) conditioning. The incidence of grade III-IV acute GVHD at 100 days was 2.3%. The incidences of grades II-IV acute GVHD, all grade chronic GVHD, and moderate to severe chronic GVHD at 2 years were 16.3%, 14.0%, and 4.7%, respectively. Overall survival, disease-free survival, and non-relapse mortality at 2 years were 75.3%, 74.0%, and 7.0%, respectively. GVHD-free, relapse-free survival at 2 years was 67.0%. The rate of off-immunosuppressants in patients who survived without relapse at 2 years was 85.4%. These results indicate that PTCy is a valid option for GVHD prophylaxis in both HLA-matched and HLA 1-2 allele mismatched PBSCT.
• COVID‑19 antibody production by vaccination in chemotherapy with CD20 antibody for B‑cell lymphoma.
  Yutaka Tsutsumi; Shinichi Ito; Fuka Horikita; Asako Moriki; Takanori Teshima
  Molecular and clinical oncology, 19, 6, 96, 96, 2023年12月, ［国際誌］
  英語, 研究論文（学術雑誌）, Most hematologic diseases are immunosuppressed, either by the disease itself or by treatment. As such, the implementation of vaccination is largely at the discretion of the attending physician. In this context, an objective measure is needed, therefore the index of vaccination against coronavirus disease 2019 (COVID-19) in B-cell lymphomas treated with antibody therapy against CD20 (including after the completion of therapy) was examined. A total of 40 patients with B-cell lymphoma during or after antibody therapy against CD20 were vaccinated twice with the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine (Pfizer, Inc. and BioNTech SE.) at 3-week intervals and then again six months later with the same vaccine or mRNA-1273 (Moderna, Inc.). Antibody testing was conducted ~1 month after the third vaccination. Analysis was performed using the antibody titers to the anti-spike immunoglobulin assay, with a titer of 0.8 U/ml or higher (considered positive) and a titer of 264 U/ml or higher (considered the value at which the efficacy of the vaccine can be fully expected). Significant factors of antibody acquisition were identified when i) antibody titers were 0.8 U/ml or higher (CD4 ≥400/µl), ii) no anti-CD20 antibody maintenance therapy was undertaken (CD19 ≥100/µl), iii) patients were not on treatment (CD4 ≥400/µl), or 4) at least six months had passed since treatment ended (CD19 ≥100/µl). When antibody titers were 264 U/ml or higher, the treatment method, the stage of the primary disease and other factors related to the condition treatment method of the patient were relevant. When these were analyzed by multivariate analysis, the significant factor when antibody titers were set to 0.8 U/ml was CD19 ≥100/µl. In contrast, when setting them to 264 U/ml or higher, CD4 ≥400/µl was not significant, but there was a tendency for it to be related. The findings of the present study on vaccine-induced antibody acquisition in patients with B-cell lymphoma indicated that it is desirable to have a CD19 titer of at least 100/µl and a CD4 titer of at least 400/µl (both conditions should be met), and that no maintenance therapy with anti-CD20 antibody should be administered for at least six months after the last treatment or completion of the treatment. Interestingly, when the criteria for antibody titers were compared between 0.8 U/ml, where antibody titer is detected, and 264 U/ml, where vaccine efficacy is expected, several key factors were different. It is possible that these key factors may change depending on the antibody titer used as a criterion.
• Genetic background of thrombocytosis in mice mimicking hereditary thrombocytosis in humans.
  Hiroyuki Kimura; Masahiro Onozawa; Takanori Teshima
  Platelets, 34, 1, 2276697, 2276697, 2023年12月, ［国際誌］
  英語, 研究論文（学術雑誌）
• A Longitudinal Study of the Physical Characteristics, Muscle-Tendon Structure Properties, and Skeletal Age in Preadolescent Boys.
  Keitaro Kubo; Takanori Teshima; Norikazu Hirose; Naoya Tsunoda
  Journal of musculoskeletal & neuronal interactions, 23, 4, 407, 416, 2023年12月01日, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES: The purpose of this study was to examine longitudinal growth changes in physical characteristics, muscle-tendon structure properties, and skeletal age in preadolescent boys and to compare the relationship between the changes in physical characteristics and muscle-tendon properties and the changes in chronological and skeletal ages. METHODS: Fourteen prepubescent boys (10.9 ± 1.1 years old at the onset of the study) participated in this study over two years (yearly). Maximal muscle strength and maximal strain of tendon structure during ramp isometric contraction and muscle and tendon thickness for knee extensors and plantar flexors were measured. In addition, skeletal age was assessed using Tanner-Whitehouse three method. RESULTS: Changes in height, thigh length, and lower leg length were highly correlated with changes in skeletal age but not chronological age. However, changes in the morphological and mechanical properties of muscle and tendon structure were not significantly associated with changes in chronological and skeletal ages. CONCLUSION: The present preliminary results suggest that longitudinal growth changes in the long-axis of the body are highly correlated with skeletal age change, whereas those in the muscle-tendon structure properties were not.
• Association of wastewater SARS-CoV-2 load with confirmed COVID-19 cases at a university hospital in Sapporo, Japan during the period from February 2021 to February 2023.
  Keisuke Kagami; Masaaki Kitajima; Hisashi Takahashi; Takanori Teshima; Nobuhisa Ishiguro
  The Science of the total environment, 899, 165457, 165457, 2023年11月15日, ［国際誌］
  英語, 研究論文（学術雑誌）, Wastewater surveillance for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been used to monitor trends in SARS-CoV-2 prevalence in a community without being influenced by clinical testing resources or healthcare-seeking behaviors. Since the rate of mortality from COVID-19 is higher in elderly patients with comorbidities, it is important to protect hospitalized patients from nosocomial infections caused by SARS-CoV-2. SARS-CoV-2 dissemination within a hospital ward was mostly mediated by healthcare workers (HCWs) and patients. HCWs need to understand the occurrence of COVID-19 and reflect this in their infection control measures. The aim of the present study was to determine the potential of SARS-CoV-2 RNA in wastewater as a leading indicator of confirmed COVID-19 cases at a university hospital. The trend of the geometric mean RNA concentrations in wastewater collected in Sapporo corresponded well with that of the number of newly confirmed COVID-19 cases at Hokkaido University Hospital between February 15, 2021 and February 26, 2023 (Pearson's r = 0.8823, p < 0.0001). Our results showed that monitoring SARS-CoV-2 RNA in municipal wastewater was useful for estimating the number of COVID-19 patients in healthcare facilities in the city.
• High-precision rapid testing of omicron SARS-CoV-2 variants in clinical samples using AI-nanopore.
  Kaoru Murakami; Shimpei I Kubota; Kumiko Tanaka; Hiroki Tanaka; Keiichiroh Akabane; Rigel Suzuki; Yuta Shinohara; Hiroyasu Takei; Shigeru Hashimoto; Yuki Tanaka; Shintaro Hojyo; Osamu Sakamoto; Norihiko Naono; Takayui Takaai; Kazuki Sato; Yuichi Kojima; Toshiyuki Harada; Takeshi Hattori; Satoshi Fuke; Isao Yokota; Satoshi Konno; Takashi Washio; Takasuke Fukuhara; Takanori Teshima; Masateru Taniguchi; Masaaki Murakami
  Lab on a chip, 23, 22, 4909, 4918, 2023年11月07日, ［国際誌］
  英語, 研究論文（学術雑誌）, A digital platform that can rapidly and accurately diagnose pathogenic viral variants, including SARS-CoV-2, will minimize pandemics, public anxiety, and economic losses. We recently reported an artificial intelligence (AI)-nanopore platform that enables testing for Wuhan SARS-CoV-2 with high sensitivity and specificity within five minutes. However, which parts of the virus are recognized by the platform are unknown. Similarly, whether the platform can detect SARS-CoV-2 variants or the presence of the virus in clinical samples needs further study. Here, we demonstrated the platform can distinguish SARS-CoV-2 variants. Further, it identified mutated Wuhan SARS-CoV-2 expressing spike proteins of the delta and omicron variants, indicating it discriminates spike proteins. Finally, we used the platform to identify omicron variants with a sensitivity and specificity of 100% and 94%, respectively, in saliva specimens from COVID-19 patients. Thus, our results demonstrate the AI-nanopore platform is an effective diagnostic tool for SARS-CoV-2 variants.
• Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study
  Shunsuke Uno; Hiroyuki Gatanaga; Tsunefusa Hayashida; Mayumi Imahashi; Rumi Minami; Michiko Koga; Sei Samukawa; Dai Watanabe; Teruhisa Fujii; Masao Tateyama; Hideta Nakamura; Shuzo Matsushita; Yusuke Yoshino; Tomoyuki Endo; Masahide Horiba; Toshibumi Taniguchi; Hiroshi Moro; Hidetoshi Igari; Shigeru Yoshida; Takanori Teshima; Hideaki Nakajima; Masako Nishizawa; Yoshiyuki Yokomaku; Yasumasa Iwatani; Atsuko Hachiya; Shingo Kato; Naoki Hasegawa; Kazuhisa Yoshimura; Wataru Sugiura; Tadashi Kikuchi
  Journal of Antimicrobial Chemotherapy, Oxford University Press (OUP), 2023年10月19日, ［査読有り］
  研究論文（学術雑誌）, Abstract
  
  Background
  
  Integrase strand transfer inhibitors (INSTIs) are recommended as first-line ART for people living with HIV (PLWH) in most guidelines. The INSTI-resistance-associated mutation E157Q, a highly prevalent (2%–5%) polymorphism of the HIV-1 (human immunodeficiency virus type 1) integrase gene, has limited data on optimal first-line ART regimens. We assessed the virological outcomes of various first-line ART regimens in PLWH with E157Q in real-world settings.
  
  Methods
  
  A multicentre retrospective observational study was conducted on PLWH who underwent integrase genotypic drug-resistance testing before ART initiation between 2008 and 2019 and were found to have E157Q. Viral suppression (&lt;50 copies/mL) rate at 24 and 48 weeks, time to viral suppression and time to viral rebound (≥100 copies/mL) were compared among the first-line ART regimens.
  
  Results
  
  E157Q was detected in 167 (4.1%) of 4043 ART-naïve PLWH. Among them, 144 had available clinical data after ART initiation with a median follow-up of 1888 days. Forty-five started protease inhibitors + 2 NRTIs (PI group), 33 started first-generation INSTI (raltegravir or elvitegravir/cobicistat) + 2 NRTIs (INSTI-1 group), 58 started once-daily second-generation INSTI (dolutegravir or bictegravir) + 2 NRTIs (INSTI-2 group) and eight started other regimens. In the multivariate analysis, the INSTI-2 group showed similar or favourable outcomes compared with the PI group for viral suppression rates, time to viral suppression and time to viral rebound. Two cases in the INSTI-1 group experienced virological failure.
  
  Conclusions
  
  The general guideline recommendation of second-generation INSTI-based first-line ART for most PLWH is also applicable to PLWH harbouring E157Q.
• HokUS-10 scoring system predicts the treatment outcome for sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation.
  Souichi Shiratori; Kohei Okada; Junichi Sugita; Mutsumi Nishida; Takahito Iwai; Shuichi Ota; Daigo Hashimoto; Takanori Teshima
  Scientific reports, 13, 1, 17374, 17374, 2023年10月13日, ［国際誌］
  英語, 研究論文（学術雑誌）, Hepatic sinusoidal obstruction syndrome (SOS) is a severe and life-threatening complication after allogeneic hematopoietic stem cell transplantation (HSCT). We conducted a multi-center retrospective study to evaluate the utility of our ultrasonographic scoring system for the diagnosis of SOS (HokUS-10) in predicting SOS-related mortality (SOS-RM). We analyzed a total of 42 patients who developed SOS after HSCT. The cumulative incidences of SOS-RM, non-relapse mortality (NRM), and overall survival at day 180 after the diagnosis of SOS were 26.4%, 28.8% and 54.5%, respectively. The area under the receiver operating characteristic curve analysis showed that the optimal cut-off value of HokUS-10 total score to predict SOS-RM was 8 points after the treatment of SOS. In the individual HokUS-10 score, ascites and portal vein flow-related scores (PV mean velocity and PV flow direction) after the treatment of SOS were shown as significant risk factors for SOS-RM. Our study suggested that US findings after the treatment can predict the treatment outcomes for SOS.
• Prolonged shedding of viable SARS‐CoV‐2 in immunocompromised patients with haematological malignancies: A prospective study
  Takaya Ichikawa; Tomokazu Tamura; Mutsumi Takahata; Takashi Ishio; Makoto Ibata; Ikumi Kasahara; Koichiro Minauchi; Satoshi Yamamoto; Takanori Teshima; Takasuke Fukuhara
  British Journal of Haematology, 204, 3, 815, 820, Wiley, 2023年10月05日
  研究論文（学術雑誌）, Summary
  
  Prolonged SARS‐CoV‐2 infection in immunocompromised individuals has been scattered, but the details remain unclear. We conducted a prospective study with 26 COVID‐19 patients with haematological malignancies to determine viral shedding kinetics and characteristics. We obtained nasopharyngeal swabs from the patients 21–28 days post‐onset for a PCR test and performed virus isolation from the PCR‐positive samples. A viable virus was detected in five patients (19.2%), all of whom had malignant lymphoma. Those patients had significantly lower CD4⁺ T‐cell counts than the PCR‐negative patients. A comparison of previous chemotherapy showed that anti‐CD20 antibodies and bendamustine may be risk factors for prolonged viral shedding.
• Ultrasonographic diagnosis of cystitis glandularis with severe intestinal metaplasia.
  Satomi Omotehara; Mutsumi Nishida; Momoka Kikuchi; Yusuke Kudo; Aya Matsui; Soshu Sato; Shin-Ichi Murata; Hiroko Gotoda; Takanori Teshima
  Journal of clinical ultrasound : JCU, 51, 8, 1397, 1400, 2023年10月, ［国際誌］
  英語, 研究論文（学術雑誌）, This study presents the case of man who underwent ultrasonography (US) for the diagnosis and follow-up of cystitis glandularis with severe intestinal metaplasia. We believe that our study makes a significant contribution to the literature because the findings of cystitis glandularis that forms a mass is relatively rare.
• Prognostic Value of Hematogones in Patients With Hematopoietic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
  Hirotaka Mori; Daisuke Koyama; Yuki Sato; Yuki Kataoka; Shunsuke Taito; Takashi Ishio; Takanori Teshima; Isao Yokota
  Cureus, 15, 10, e47184, 2023年10月, ［国際誌］
  英語, 研究論文（学術雑誌）, This systematic review and meta-analysis aimed to determine whether hematogones in patients with hematopoietic disorders after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are associated with clinical outcomes. We searched the MEDLINE, Embase, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and World Health Organization International Clinical Trials Registry Platform databases from their inception to March 2023. The primary outcome in the summary of findings was three-year relapse-free survival (RFS), and secondary outcomes in the summary of findings included three-year relapse, non-relapse mortality (NRM), overall survival (OS), acute and chronic graft-versus-host disease (GVHD), and infection. The certainty of evidence was determined using the grading of recommendation assessment, development, and evaluation approaches. A systematic review and meta-analysis of outcome measures were conducted using a random-effects model. This study protocol was registered in the Open Science Framework. A total of six studies (including 888 patients) were included in the meta-analysis. Hematogones were related to favorable three-year RFS (risk ratio (RR) = 1.84; 95% confidence interval (CI) = 1.01 to 3.34) and favorable NRM (RR = 0.14; 95% CI = 0.04 to 0.51), OS (RR = 1.51; 95% CI = 1.13 to 2.02), and acute GVHD (RR = 0.44; 95% CI = 0.33 to 0.59). The certainty of the evidence was low for RFS, NRM, OS, and acute GVHD. Evidence regarding the association between hematogones, relapse, and infections is uncertain. Hematogones may be a prognostic factor for long-term prognosis and acute adverse events in patients with hematopoietic disorders after allo-HSCT. Further studies are required to address the long-term life-threatening events.
• Chronic GvHD NIH Consensus Project Biology Task Force: evolving path to personalized treatment of chronic GvHD.
  Nataliya P Buxbaum; Gerard Socié; Geoffrey R Hill; Kelli P A MacDonald; Victor Tkachev; Takanori Teshima; Stephanie J Lee; Jerome Ritz; Stefanie Sarantopoulos; Leo Luznik; Defu Zeng; Sophie Paczesny; Paul J Martin; Steven Z Pavletic; Kirk R Schultz; Bruce R Blazar
  Blood advances, 7, 17, 4886, 4902, 2023年09月12日, ［国際誌］
  英語, 研究論文（学術雑誌）, Chronic graft-versus-host disease (cGvHD) remains a prominent barrier to allogeneic hematopoietic stem cell transplantion as the leading cause of nonrelapse mortality and significant morbidity. Tremendous progress has been achieved in both the understanding of pathophysiology and the development of new therapies for cGvHD. Although our field has historically approached treatment from an empiric position, research performed at the bedside and bench has elucidated some of the complex pathophysiology of cGvHD. From the clinical perspective, there is significant variability of disease manifestations between individual patients, pointing to diverse biological underpinnings. Capitalizing on progress made to date, the field is now focused on establishing personalized approaches to treatment. The intent of this article is to concisely review recent knowledge gained and formulate a path toward patient-specific cGvHD therapy.
• Incidence and course of Epstein-Barr virus viremia after allogeneic hematopoietic stem cell transplant for adult-onset systemic chronic active Epstein-Barr virus disease.
  Preeti Prerna M Vaswani; Masahiro Onozawa; Yuta Hasegawa; Hiroyuki Ohigashi; Takahide Ara; Toshihiro Matsukawa; Atsushi Yasumoto; Souichi Shiratori; Hideki Goto; Masao Nakagawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
  Bone marrow transplantation, 2023年09月05日, ［国際誌］
  英語
• Factors associated with household transmission of SARS-CoV-2 omicron variant to health care workers: A retrospective cohort study.
  Keisuke Kagami; Reiko Oyamada; Tsubasa Watanabe; Sho Nakakubo; Takahiro Hayashi; Sumio Iwasaki; Tatsuya Fukumoto; Takayuki Usami; Kasumi Hayasaka; Shinichi Fujisawa; Chiaki Watanabe; Mutsumi Nishida; Takanori Teshima; Yusuke Niinuma; Isao Yokota; Yoh Takekuma; Mitsuru Sugawara; Nobuhisa Ishiguro
  International journal of nursing practice, 29, 5, e13195, 2023年08月24日, ［国際誌］
  英語, 研究論文（学術雑誌）, AIM: The aim of this study was to determine the risk factors for household transmission of the omicron variant of SARS-CoV-2. BACKGROUND: The household infection rate has been reported to be higher for the omicron variant than for non-omicron variants of SARS-CoV-2. Determination of the risk factors for household transmission of the omicron variant is therefore important. DESIGN: A Retrospective Cohort Study was conducted. METHODS: When family members of health care workers (HCWs) were found to be infected with SARS-CoV-2, the HCWs had to receive two nucleic acid amplification tests for SARS-CoV-2: immediately after and 5 to 10 days after the onset of COVID-19 in the family members. Risk factors of household transmission were analysed by comparing cases (HCWs infected with SARS-CoV-2) and controls (HCWs not infected with SARS-CoV-2) using multivariable analysis. RESULTS: Unvaccinated status (OR: 3.97), age of index cases (≤6 years) (OR: 1.94) and staying at home with index cases (OR: 10.18) were risk factors for household transmission. CONCLUSION: If there is a strong desire to avoid household infection, family members infected with SARS-CoV-2 should live separately during the period of viral shedding.
• Dominant-negative type of IKZF1 deletion showed a favorable prognosis in adult B-cell acute lymphoblastic leukemia.
  Hiroyuki Kimura; Masahiro Onozawa; Shota Yoshida; Naoki Miyashita; Shota Yokoyama; Toshihiro Matsukawa; Shinsuke Hirabayashi; Hideki Goto; Tomoyuki Endo; Satoshi Oguri; Shinichi Fujisawa; Akio Mori; Takeshi Kondo; Daisuke Hidaka; Kohei Okada; Shuichi Ota; Yasutaka Kakinoki; Yutaka Tsutsumi; Satoshi Yamamoto; Takuto Miyagishima; Junichi Hashiguchi; Takahiro Nagashima; Makoto Ibata; Kentaro Wakasa; Yoshihito Haseyama; Katsuya Fujimoto; Toshimichi Ishihara; Hajime Sakai; Takanori Teshima
  Annals of hematology, 2023年08月19日, ［国際誌］
  英語, 研究論文（学術雑誌）, IKZF1 deletion is a recurrent genomic alteration in B-cell acute lymphoblastic leukemia (B-ALL) and is divided into dominant-negative (DN) and loss of function (LOF) deletions. The prognostic impact of each deletion has not been fully elucidated. We retrospectively analyzed 117 patients with adult B-ALL including 60 patients with BCR::ABL1-positive B-ALL and 57 patients with BCR::ABL1-negative B-ALL by the fluorescence in situ hybridization (FISH) method for IKZF1 deletion and multiplex PCR for the 4 most common IKZF1 deletions (∆4-7, ∆2-7, ∆2-8, and ∆4-8). Samples, in which IKZF1 deletion was detected by FISH but a specific type of deletion was not identified by the PCR, were categorized as "other." Patients were classified into a DN group that had at least 1 allele of ∆4-7 (n = 23), LOF and other group (n = 40), and wildtype group (n = 54). DN type IKZF1 deletions were found in 33.3% of BCR::ABL1-positive cases and 5.2% of BCR::ABL1-negative cases. LOF and other type IKZF1 deletions were found in 43.4% of BCR::ABL1-positive cases and 24.6% of BCR::ABL1-negative cases. Patients with the DN group showed significantly higher overall survival (OS) than that of the LOF and other and WT groups (P = 0.011). Multivariate analysis including age, WBC counts, complex karyotype, and DN type IKZF1 deletion showed that the DN type of IKZF1 deletion (HR = 0.22, P = 0.013) had a positive impact and age ≥ 65 (HR = 1.92, P = 0.029) had a negative impact on OS. The prognostic impact of IKZF1 deletion depends on the type of deletion and DN type of IKZF1 deletion showed better prognosis in adult B-ALL patients.Clinical trial registration This study was part of a prospective observational study (Hokkaido Leukemia Net, UMIN000048611). It was conducted in compliance with ethical principles based on the Helsinki Declaration and was approved by the institutional review board of Hokkaido University Hospital (#015-0344).
• Booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies.
  Akio Mori; Masahiro Onozawa; Mirei Kobayashi; Shihori Tsukamoto; Hajime Senjo; Takashi Ishio; Emi Yokoyama; Minoru Kanaya; Koh Izumiyama; Makoto Saito; Haruna Muraki; Masanobu Morioka; Takanori Teshima; Takeshi Kondo
  Cancer medicine, 12, 16, 16881, 16888, 2023年08月, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: We have reported that seroconversion rates after the second dose of mRNA-based COVID-19 vaccines for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) were 100% and 95% respectively, with no significant difference from healthy controls (HCs).However, there are very limited data for the response to a third vaccine dose in those patients. AIMS: In this complementary study, we investigated the booster effect of a third mRNA-based COVID-19 vaccine dose in patients with myeloid malignancies. MATERIALS & METHODS: A total 58 patients including 20 patients with MDS and 38 patients with AML were enrolled. Anti-SARS-CoV-2S immunoassays were performed at 3, 6, and 9 months after the second vaccine dose. RESULTS: Seventy-five percent of the MDS patients and 37% of the AML patients were receiving active treatment at the time of the third vaccination. Both the initial and third vaccine response in AML patients were comparable to those in HCs. In MDS patients, although the initial vaccine immunogenicity was inferior to that in HCs and AML patients, the third vaccine improved the response to a level not inferior to those in HCs and AML patients. Of note, the third vaccine resulted in a significant increase of antibodies in actively treated MDS patients who had shown a response inferior to that in untreated patients after two doses of vaccination. DISCUSSION: In patients with myeloid malignancies, the third vaccine dose showed a booster effect, and disease- and therapy-related factors associated with the booster response have been identified. CONCLUSION: The third dose of an mRNA-based COVID-19 vaccine showed a booster effect in patients with myeloid malignancies. Such a good booster response has not been reported in other haematological malignancies.
• Clinical implications of NUP98::NSD1 fusion at diagnosis in adult FLT3-ITD positive AML.
  Toru Miyajima; Masahiro Onozawa; Shota Yoshida; Naoki Miyashita; Hiroyuki Kimura; Shogo Takahashi; Shota Yokoyama; Toshihiro Matsukawa; Hideki Goto; Junichi Sugita; Shinichi Fujisawa; Daisuke Hidaka; Reiki Ogasawara; Akio Mori; Satomi Matsuoka; Akio Shigematsu; Kentaro Wakasa; Ikumi Kasahara; Tomoyuki Saga; Junichi Hashiguchi; Yukari Takeda; Makoto Ibata; Tsutsumi Yutaka; Katsuya Fujimoto; Takeshi Kondo; Takanori Teshima
  European journal of haematology, 2023年07月19日, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES: The cryptic fusion oncogene NUP98::NSD1 is known to be associated with FLT3-ITD mutation in acute myeloid leukemia (AML), and an independent poor prognostic factor in pediatric AML. However, there are little data regarding the clinical significance of NUP98::NSD1 in adult cohort. METHODS: We conducted a multicenter retrospective study to investigate the prevalence, clinical characteristics, and prognostic impact of NUP98::NSD1 in adult FLT3-ITD-positive AML patients. RESULTS: In a total of 97 FLT3-ITD-positive AML patients, six cases (6.2%) were found to harbor the NUP98::NSD1 fusion transcript. NUP98::NSD1 positive cases had significantly higher platelet counts and a higher frequency of FAB-M4 morphology than NUP98::NSD1 negative cases. NUP98::NSD1 was found to be mutually exclusive with NPM1 mutation, and was accompanied by the WT1 mutation in three of the six cases. The presence of NUP98::NSD1 fusion at the time of diagnosis predicted poor response to cytarabine-anthracycline-based intensive induction chemotherapy (induction failure rate: 83% vs. 36%, p = .038). Five of the six cases with NUP98::NSD1 underwent allogeneic hematopoietic stem cell transplantation (HSCT). Two of the five cases have successfully maintained remission, with one of them being rescued through a second HSCT. CONCLUSIONS: Detecting NUP98::NSD1 in adult FLT3-ITD-positive AML is crucial to recognizing chemotherapy-resistant group.
• Assessment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome using different scanning approaches for the ultrasonographic evaluation of portal vein blood flow and hepatic artery resistive index in hematopoietic stem cell transplant recipients.
  Momoka Kikuchi; Takahito Iwai; Mutsumi Nishida; Yusuke Kudo; Satomi Omotehara; Megumi Sato; Junichi Sugita; Hideki Goto; Isao Yokota; Takanori Teshima
  Journal of medical ultrasonics (2001), 2023年07月04日, ［国内誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Sinusoidal obstruction syndrome (SOS) is a fatal complication of hematopoietic stem cell transplantation (HSCT). Previously, we established a scoring system (Hokkaido ultrasound-based scoring system-10; HokUS-10) comprising 10 ultrasound parameters for SOS diagnosis. In HokUS-10, the portal vein time-averaged flow velocity (PV TAV) and hepatic artery resistive index (HA RI) are measured using subcostal scanning. However, measurement errors and delineation difficulties occur. Therefore, we aimed to prospectively evaluate PV TAV and HA RI measurements obtained via intercostal scanning as an alternative method to subcostal scanning and determine their cutoff values. METHODS: HokUS-10 was administered before and after HSCT. PV TAV and HA RI were measured on subcostal and right intercostal scans. RESULTS: We performed 366 scans on 74 patients. The median value (range) of PV TAV in the main and right portal veins was 15.0 cm/s (2.2-49.6 cm/s) and 10.5 cm/s (1.6-22.0 cm/s), respectively. A low correlation was observed between the two values (r = 0.39, p < 0.01). The highest diagnostic value of the right portal vein was less than 8.0 cm/s. The median value (range) of HA RI in the proper and right hepatic arteries was 0.72 (0.52-1.00) and 0.70 (0.51-1.00), respectively. A strong correlation was observed between the two values (r = 0.65, p < 0.01). The highest diagnostic value of the right HA RI was 0.72 or higher. CONCLUSION: Quantitative measurement of PV TAV and HA RI using intercostal scanning can be appropriately performed as an alternative method to using subcostal scanning.
• Corrigendum to "IgG4-IgE complex in patients with IgG4-related disease" [Clin. Chim. Acta 531 (2022) 261-264].
  Keiichi Nakano; Junichi Sugita; Masanori Seimiya; Keiko Yasuda; Chiaki Watanabe; Takanori Teshima
  Clinica chimica acta; international journal of clinical chemistry, 547, 117454, 117454, 2023年07月01日, ［国際誌］
  英語
• Type 1 Cryoglobulinemic Vasculitis Due to Monoclonal Gammopathy of Undetermined Significance Successfully Treated by Bortezomib Plus Dexamethasone.
  Ryo Kikuchi; Masahiro Onozawa; Jun Nagai; Satomi Okada; Yuta Hasegawa; Hiroyuki Ohigashi; Shintaro Mitamura; Taku Maeda; Emi Takakuwa; Yuichiro Fujieda; Hideki Goto; Daigo Hashimoto; Yoshihiro Matsuno; Takanori Teshima
  Internal medicine (Tokyo, Japan), 2023年06月14日, ［国内誌］
  英語, 研究論文（学術雑誌）, Cryoglobulins are immunoglobulins that precipitate in cold conditions. Type I cryoglobulinemic vasculitis is associated with hematological malignancies. We herein report a case of steroid-resistant type 1 cryoglobulinemic vasculitis associated with monoclonal gammopathy of undetermined significance (MGUS) in a 47-year-old woman. By immunofixation of cryoglobulin, we found that the main component of cryoglobulin was the M protein due to MGUS, so treatment of MGUS was needed. Bortezomib+dexamethasone therapy resulted in a rapid decrease in cryoglobulin and improvement in the symptoms of cryoglobulinemic vasculitis. In refractory type I cryoglobulinemic vasculitis, treatment of the underlying gammaglobulinopathy should be considered.
• Novel insights into GVHD and immune reconstitution after allogeneic hematopoietic cell transplantation.
  Takanori Teshima; Jaap Jan Boelens; Ken-Ichi Matsuoka
  Blood cell therapy, 6, 2, 42, 48, 2023年05月25日, ［国内誌］
  英語, 研究論文（学術雑誌）, Effective control of the graft-versus-host disease (GVHD) and immune reconstitution are crucial in improving the outcome of allogeneic hematopoietic stem cell transplantation (HSCT) as well as the quality of life of the transplant survivors. Recent basic and clinical studies have deepened our understanding of the mechanisms of the immunological sequelae of HSCT, GVHD, and compromised immune systems. Based on the findings, various novel approaches have also been developed and tested clinically. However, further studies are necessary to develop therapeutic strategies with significant clinical benefits.
• Association of demographics, HCV co‐infection, HIV‐1 subtypes and genetic clustering with late HIV diagnosis: a retrospective analysis from the Japanese Drug Resistance HIV‐1 Surveillance Network
  Machiko Otani; Teiichiro Shiino; Atsuko Hachiya; Hiroyuki Gatanaga; Dai Watanabe; Rumi Minami; Masako Nishizawa; Takanori Teshima; Shigeru Yoshida; Toshihiro Ito; Tsunefusa Hayashida; Michiko Koga; Mami Nagashima; Kenji Sadamasu; Makiko Kondo; Shingo Kato; Shunsuke Uno; Toshibumi Taniguchi; Hidetoshi Igari; Sei Samukawa; Hideaki Nakajima; Yusuke Yoshino; Masahide Horiba; Hiroshi Moro; Tamayo Watanabe; Mayumi Imahashi; Yoshiyuki Yokomaku; Haruyo Mori; Teruhisa Fujii; Kiyonori Takada; Asako Nakamura; Hideta Nakamura; Masao Tateyama; Shuzo Matsushita; Kazuhisa Yoshimura; Wataru Sugiura; Tetsuro Matano; Tadashi Kikuchi
  Journal of the International AIDS Society, 26, 5, Wiley, 2023年05月23日, ［査読有り］
  研究論文（学術雑誌）
• Calcineurin inhibitor inhibits tolerance induction by suppressing terminal exhaustion of donor T cells after allo-HCT
  Hajime Senjo; Shinpei Harada; Shimpei I Kubota; Yuki Tanaka; Takahiro Tateno; Zixuan Zhang; Satomi Okada; Xuanzhong Chen; Ryo Kikuchi; Naoki Miyashita; Masahiro Onozawa; Hideki Goto; Tomoyuki Endo; Yuta Hasegawa; Hiroyuki Ohigashi; Takahide Ara; Yoshinori Hasegawa; Masaaki Murakami; Takanori Teshima; Daigo Hashimoto
  Blood Journal, American Society of Hematology, 2023年05月22日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis is standard in allogeneic hematopoietic stem cell transplantation (HCT) but fails to induce long-term tolerance without chronic GVHD in a considerable number of patients. In this study, we addressed this long-standing question in mouse models of HCT. After HCT, alloreactive donor T cells rapidly differentiated into PD-1+ TIGIT+ terminally exhausted T cells (terminal-Tex). GVHD prophylaxis with cyclosporine (CSP) suppressed donor T-cell expression of TOX, a master regulator to promote differentiation of transitory exhausted T cells (transitory-Tex), expressing both inhibitory receptors and effector molecules, into terminal-Tex, and inhibited tolerance induction. Adoptive transfer of transitory-Tex, but not terminal-Tex, into secondary recipients developed chronic GVHD. Transitory-Tex maintained alloreactivity and thus PD-1 blockade restored graft-versus-leukemia (GVL) activity of transitory-Tex, not terminal-Tex. In conclusion, CSP inhibits tolerance induction by suppressing the terminal exhaustion of donor T cells, while maintaining GVL effects to suppress leukemia relapse.
• Hepatitis C Virus (HCV)-Ribonucleic Acid (RNA) As a Biomarker for Lymphoid Malignancy with HCV Infection
  Yutaka Tsutsumi; Shinichi Ito; Souichi Shiratori; Takanori Teshima
  Cancers, 15, 10, 2852, 2852, MDPI AG, 2023年05月21日, ［査読有り］, ［最終著者］
  研究論文（学術雑誌）, The hepatitis C virus (HCV) is potentially associated with liver cancer, and advances in various drugs have led to progress in the treatment of hepatitis C and attempts to prevent its transition to liver cancer. Furthermore, reactivation of HCV has been observed in the treatment of lymphoma, during which the immortalization and proliferation of lymphocytes occur, which leads to the possibility of further stimulating cytokines and the like and possibly to the development of lymphoid malignancy. There are also cases in which the disappearance of lymphoid malignancy has been observed by treating HCV and suppressing HCV-Ribonucleic acid (RNA), as well as cases of recurrence with an increase in HCV-RNA. While HCV-associated lymphoma has a poor prognosis, improving the prognosis with Direct Acting Antivirals (DAA) has recently been reported. The reduction and eradication of HCV-RNA by means of DAA is thus important for the treatment of lymphoid malignancy associated with HCV infection, and HCV-RNA can presumably play a role as a biomarker. This review provides an overview of what is currently known about HCV-associated lymphoma, its epidemiology, the mechanisms underlying the progression to lymphoma, its treatment, the potential and limits of HCV-RNA as a therapeutic biomarker, and biomarkers that are expected now that DAA therapy has been developed.
• Pseudotumor of the skin due to Mycobacterium genavense.
  Suguru Kurosawa; Keisuke Imafuku; Sho Nakakubo; Sumio Iwasaki; Takanori Teshima; Hideki Goto; Hideyuki Ujiie
  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2023年05月15日, ［国際誌］
  英語, Mycobacterium genavense is a rare type of non-tuberculous mycobacterium (NTM) that has been reported to cause disseminated infections in immunocompromised patients. Because M. genavense is slow-growing and poorly able to form colonies on Ogawa's medium, genetic and molecular analyses are necessary to identify this pathogen. NTM infections present with various cutaneous manifestations. Of these, rare cases have been reported to present with mycobacterial pseudotumors. However, there are no reports of M. genavense with cutaneous pseudotumors. In this paper, we report a case of a pseudotumor due to M. genavense infection that was observed only in a cutaneous lesion. The patient was taking 5 mg of prednisolone and was aware of a tumor on the right lower leg. Biopsy samples showed diffuse spindle-shaped histiocytes and various other inflammatory cell infiltrates, and Ziehl-Neelsen staining detected mycobacterium. Since no colonies formed on Ogawa medium, genetic testing was performed, and M. genavense was identified by DNA sequence analysis. There were no other disseminated lesions beyond the skin, including in the lungs and liver. Since the patient was immunosuppressed, in accordance with previous literature, a combination therapy of clarithromycin, ethambutol, and rifampicin for 4 months was recommended. When no growth is observed on Ogawa's medium in cases of infection, it is essential to identify the infectious pathogen by genetic analysis.
• Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial
  Stephan A Grupp; Selim Corbacioglu; Hyoung Jin Kang; Takanori Teshima; Seong Lin Khaw; Franco Locatelli; Johan Maertens; Matthias Stelljes; Polina Stepensky; Paty Lopez; Vian Amber; Antonio Pagliuca; Paul G Richardson; Mohamad Mohty
  The Lancet Haematology, 10, 5, e333, e345, Elsevier BV, 2023年05月, ［査読有り］
  研究論文（学術雑誌）
• Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan
  Hideki Goto; Toshio Kitawaki; Nobuharu Fujii; Koji Kato; Yasushi Onishi; Noriko Fukuhara; Takuji Yamauchi; Kazunori Toratani; Hiroki Kobayashi; Shota Yoshida; Masatoshi Shimo; Koichi Onodera; Hajime Senjo; Masahiro Onozawa; Kenji Hirata; Isao Yokota; Takanori Teshima
  International Journal of Clinical Oncology, 28, 6, 816, 826, Springer Science and Business Media LLC, 2023年04月18日, ［査読有り］, ［最終著者］, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Tisagenlecleucel, an autologous CD19-directed T-cell immunotherapy, can induce a durable response in adult patients with relapsed/refractory (r/r) B-cell lymphoma. METHODS: To elucidate the outcome of chimeric antigen receptor (CAR) T-cell therapy in Japanese, we retrospectively analyzed the outcomes of 89 patients who received tisagenlecleucel for r/r diffuse large B-cell lymphoma (n = 71) or transformed follicular lymphoma (n = 18). RESULTS: With a median follow-up of 6.6-months, 65 (73.0%) patients achieved a clinical response. The overall survival (OS) and event-free survival (EFS) rates at 12 months were 67.0% and 46.3%, respectively. Overall, 80 patients (89.9%) had cytokine release syndrome (CRS), and 6 patients (6.7%) had a grade ≥ 3 event. ICANS occurred in 5 patients (5.6%); only 1 patient had grade 4 ICANS. Representative infectious events of any grade were cytomegalovirus viremia, bacteremia and sepsis. The most common other adverse events were ALT elevation, AST elevation, diarrhea, edema, and creatinine elevation. No treatment-related mortality was observed. A Sub-analysis showed that a high metabolic tumor volume (MTV; ≥ 80 ml) and stable disease /progressive disease before tisagenlecleucel infusion were both significantly associated with a poor EFS and OS in a multivariate analysis (P < 0.05). Notably, the combination of these 2 factors efficiently stratified the prognosis of these patients (HR 6.87 [95% CI 2.4-19.65; P < 0.05] into a high-risk group). CONCLUSION: We report the first real-world data on tisagenlecleucel for r/r B-cell lymphoma in Japan. Tisagenlecleucel is feasible and effective, even in late line treatment. In addition, our results support a new algorithm for predicting the outcomes of tisagenlecleucel.
• Subclinical minute FLT3-ITD clone can be detected in clinically FLT3-ITD-negative acute myeloid leukaemia at diagnosis
  Shota Yokoyama; Masahiro Onozawa; Shota Yoshida; Naoki Miyashita; Hiroyuki Kimura; Shogo Takahashi; Toshihiro Matsukawa; Hideki Goto; Shinichi Fujisawa; Kosuke Miki; Daisuke Hidaka; Junichi Hashiguchi; Kentaro Wakasa; Makoto Ibata; Yukari Takeda; Akio Shigematsu; Katsuya Fujimoto; Yutaka Tsutsumi; Akio Mori; Toshimichi Ishihara; Yasutaka Kakinoki; Takeshi Kondo; Daigo Hashimoto; Takanori Teshima
  British Journal of Haematology, 201, 6, 1144, 1152, Wiley, 2023年04月17日, ［査読有り］, ［最終著者］, ［国際誌］
  英語, 研究論文（学術雑誌）, Recent advances in next-generation sequencing (NGS) have enabled the detection of subclinical minute FLT3-ITD. We selected 74 newly diagnosed, cytogenetically normal acute myeloid leukaemia (AML) samples in which FLT3-ITD was not detected by gel electrophoresis. We sequenced them using NGS and found minute FLT3-ITDs in 19 cases. We compared cases with clinically relevant FLT3-ITD (n = 37), cases with minute FLT3-ITD (n = 19) and cases without detectable FLT3-ITD (n = 55). Molecular characteristics (location and length) of minute FLT3-ITD were similar to those of clinically relevant FLT3-ITD. Survival of cases with minute FLT3-ITD was similar to that of cases without detectable FLT3-ITD, whereas the relapse rate within 1 year after onset was significantly higher in cases with minute FLT3-ITD. We followed 18 relapsed samples of cases with clinically FLT3-ITD-negative at diagnosis. Two of 3 cases with minute FLT3-ITD relapsed with progression to clinically relevant FLT3-ITD. Two of 15 cases in which FLT3-ITD was not detected by NGS relapsed with the emergence of minute FLT3-ITD, and one of them showed progression to clinically relevant FLT3-ITD at the second relapse. We revealed the clonal dynamics of subclinical minute FLT3-ITD in clinically FLT3-ITD-negative AML. Minute FLT3-ITD at the initial AML can expand to become a dominant clone at relapse.
• Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study
  David Bernard Miklos; Mohammad Abu Zaid; Julian P. Cooney; Jörn C. Albring; Mary Flowers; Alan P. Skarbnik; Ibrahim Yakoub-Agha; Bor-Sheng Ko; Benedetto Bruno; Edmund K. Waller; Jean Yared; Sang Kyun Sohn; Claude-Eric Bulabois; Takanori Teshima; David Jacobsohn; Hildegard Greinix; Ahmad Mokatrin; Yihua Lee; Justin T. Wahlstrom; Lori Styles; Gerard Socie
  Journal of Clinical Oncology, 41, 10, 1876, 1887, American Society of Clinical Oncology (ASCO), 2023年04月01日, ［査読有り］
  研究論文（学術雑誌）, PURPOSE
  
  To present primary and final analyses from the randomized, double-blind, placebo-controlled, phase III iNTEGRATE study, which evaluated the safety and efficacy of ibrutinib with prednisone in previously untreated patients with chronic graft-versus-host disease (cGVHD).
  
  METHODS
  
  Patients (age ≥ 12 years) with newly diagnosed moderate or severe cGVHD, requiring systemic corticosteroid therapy, and with no prior systemic treatment for cGVHD were randomly assigned 1:1 to receive ibrutinib 420 mg once daily plus prednisone, starting at 1 mg/kg once daily or placebo plus prednisone. The primary end point was response rate at 48 weeks according to 2014 National Institutes of Health Consensus Development Project Criteria. Other end points included event-free survival, duration of response, time to withdrawal of immunosuppressants, improvement in Lee cGVHD Symptom Scale score, overall survival (OS), and safety.
  
  RESULTS
  
  Ninety-five and 98 patients enrolled in the ibrutinib-prednisone and placebo-prednisone arms, respectively. At 48 weeks, response rates were 41% (ibrutinib-prednisone) and 37% (placebo-prednisone; P = .54). At 33 months of follow-up, median duration of response was 19 months (ibrutinib-prednisone) and 10 months (placebo-prednisone; P = .10). Median event-free survival was 15 months (ibrutinib-prednisone) and 8 months (placebo-prednisone; hazard ratio, 0.76; 95% CI, 0.54 to 1.1; P = .11). Improvement in overall Lee cGVHD Symptom Scale was 43% (ibrutinib-prednisone) and 31% (placebo-ibrutinib; P = .07). Median OS was not reached in either arm. The 24-month Kaplan-Meier OS estimates were 80% for both arms (hazard ratio, 1.06; 95% CI, 0.59 to 1.90). Grade ≥ 3 serious adverse events occurred in 49% (ibrutinib-prednisone) and 47% (placebo-prednisone) of patients.
  
  CONCLUSION
  
  There was no statistical difference observed in the primary and secondary end points with ibrutinib-prednisone treatment. No new safety signals were observed with ibrutinib treatment in previously untreated patients with cGVHD. The primary end point of iNTEGRATE was not met.
• Subcutaneous Panniculitis-like T-cell Lymphoma Lacking Subcutaneous Tumor Mimicking Adult-onset Still's Disease.
  Maria Tada; Shion Kachi; Masahiro Onozawa; Yuichiro Fujieda; Shota Yoshida; Yotaro Oki; Kazuro Kamada; Jun Nagai; Satomi Okada; Ryo Kikuchi; Ryo Hisada; Yuta Hasegawa; Hiroyuki Ohigashi; Hideki Goto; Daigo Hashimoto; Shinichi Nakazato; Yoshihiro Matsuno; Takanori Teshima; Tatsuya Atsumi
  Internal medicine (Tokyo, Japan), 2023年03月15日, ［国内誌］
  英語, 研究論文（学術雑誌）, We herein report a case of subcutaneous panniculitis-like T-cell lymphoma (SPTCL) resembling adult-onset Still's disease (AOSD). A 40-year-old woman presented with a fever, erythema, and painful subcutaneous nodules on the trunk. Laboratory data and a bone marrow analysis showed hemophagocytic syndrome. Although AOSD was suspected, based on a histopathological evaluation of the erythema, she was diagnosed with SPTCL. She was refractory to combination chemotherapy but achieved durable remission with cyclosporine monotherapy. Genetic testing revealed a homozygous HAVCR2 c.245A>G variant (rs184868814) that had caused NLRP3 inflammasome activation. SPTCL and AOSD share a pathogenesis in terms of NLRP3 inflammasome activation, so the clinical phenotype of SPTCL reasonably mimics AOSD.
• Decreased Paneth cell α-defensins promote fibrosis in a choline-deficient L-amino acid-defined high-fat diet-induced mouse model of nonalcoholic steatohepatitis via disrupting intestinal microbiota
  Shunta Nakamura; Kiminori Nakamura; Yuki Yokoi; Yu Shimizu; Shuya Ohira; Mizu Hagiwara; Zihao Song; Li Gan; Tomoyasu Aizawa; Daigo Hashimoto; Takanori Teshima; Andre J. Ouellette; Tokiyoshi Ayabe
  Scientific Reports, 13, 1, Springer Science and Business Media LLC, 2023年03月09日, ［査読有り］
  研究論文（学術雑誌）, Abstract
  
  Nonalcoholic steatohepatitis (NASH) is a chronic liver disease characterized by fibrosis that develops from fatty liver. Disruption of intestinal microbiota homeostasis, dysbiosis, is associated with fibrosis development in NASH. An antimicrobial peptide α-defensin secreted by Paneth cells in the small intestine is known to regulate composition of the intestinal microbiota. However, involvement of α-defensin in NASH remains unknown. Here, we show that in diet-induced NASH model mice, decrease of fecal α-defensin along with dysbiosis occurs before NASH onset. When α-defensin levels in the intestinal lumen are restored by intravenous administration of R-Spondin1 to induce Paneth cell regeneration or by oral administration of α-defensins, liver fibrosis is ameliorated with dissolving dysbiosis. Furthermore, R-Spondin1 and α-defensin improved liver pathologies together with different features in the intestinal microbiota. These results indicate that decreased α-defensin secretion induces liver fibrosis through dysbiosis, further suggesting Paneth cell α-defensin as a potential therapeutic target for NASH.
• Humoral response to mRNA-based COVID-19 vaccine and booster effect of a third dose in patients with mature T cell and NK-cell neoplasms
  Mirei Kobayashi; Akio Mori; Masahiro Onozawa; Shihori Tsukamoto; Hajime Senjo; Takashi Ishio; Emi Yokoyama; Minoru Kanaya; Koh Izumiyama; Makoto Saito; Haruna Muraki; Masanobu Morioka; Takanori Teshima; Takeshi Kondo
  Annals of Hematology, 102, 4, 819, 827, Springer Science and Business Media LLC, 2023年03月02日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Abstract
  
  Patients with lymphoid malignancies have impaired humoral immunity caused by the disease itself and its treatment, placing them at risk for severe coronavirus disease-19 (COVID-19) and reduced response to vaccination. However, data for COVID-19 vaccine responses in patients with mature T cell and NK-cell neoplasms are very limited. In this study of 19 patients with mature T/NK-cell neoplasms, anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike antibodies were measured at 3 months, 6 months, and 9 months after the second mRNA-based vaccination. At the time of the second and third vaccinations, 31.6% and 15.4% of the patients were receiving active treatment. All patients received the primary vaccine dose and the third vaccination rate was 68.4%. In patients with mature T/NK-cell neoplasms, both seroconversion rate (p < 0.01) and antibody titers (p < 0.01) after the second vaccination were significantly lower than those in healthy controls (HC). In individuals who received the booster dose, patients had significantly lower antibody titers than those in HC (p < 0.01); however, the seroconversion rate in patients was 100%, which was the same as that in HC. The booster vaccine resulted in a significant increase of antibodies in elderly patients who had shown a response that was inferior to that in younger patients after two doses of vaccination. Since higher antibody titers and higher seroconversion rate reduced the incidence of infection and mortality, vaccination more than three times may have the advantage for patients with mature T/NK-cell neoplasms, especially in elderly patients. Clinical trial registration number: UMIN 000,045,267 (August 26th, 2021), 000,048,764 (August 26th, 2022).
• Correction to: Refined ultrasonographic criteria for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation.
  Mutsumi Nishida; Junichi Sugita; Shuichiro Takahashi; Takahito Iwai; Megumi Sato; Yusuke Kudo; Satomi Omotehara; Tatsunori Horie; Ryosuke Sakano; Hitoshi Shibuya; Isao Yokota; Akihiro Iguchi; Takanori Teshima
  International journal of hematology, 117, 3, 468, 468, 2023年03月, ［国内誌］
  英語
• Prognostic impact of FLT3-ITD, NPM1 mutation and CEBPA bZIP domain mutation in cytogenetically normal acute myeloid leukemia: a Hokkaido Leukemia Net study
  Naoki Miyashita; Masahiro Onozawa; Shota Yoshida; Hiroyuki Kimura; Shogo Takahashi; Shota Yokoyama; Toshihiro Matsukawa; Shinsuke Hirabayashi; Shinichi Fujisawa; Akio Mori; Shuichi Ota; Yasutaka Kakinoki; Yutaka Tsutsumi; Satoshi Yamamoto; Takuto Miyagishima; Takahiro Nagashima; Makoto Ibata; Kentaro Wakasa; Yoshihito Haseyama; Katsuya Fujimoto; Toshimichi Ishihara; Hajime Sakai; Takeshi Kondo; Takanori Teshima
  International Journal of Hematology, 118, 1, 36, 46, Springer Science and Business Media LLC, 2023年02月28日, ［査読有り］, ［最終著者］, ［国内誌］
  英語, 研究論文（学術雑誌）, Mutation status of FLT3, NPM1, and CEBPA is used to classify the prognosis of acute myeloid leukemia, but its significance in patients with cytogenetically normal (CN) AML is unclear. We prospectively analyzed these genes in 295 patients with CN-AML and identified 76 (25.8%) FLT3-ITD, 113 (38.3%) NPM1 mutations, and 30 (10.2%) CEBPA biallelic mutations. We found that patients with FLT3-ITD had a poor prognosis at any age, while patients with CEBPA biallelic mutation were younger and had a better prognosis. FLT3-ITD and NPM1 mutations were correlated, and the favorable prognostic impact of being FLT3-ITD negative and NPM1 mutation positive was evident only in patients aged 65 years or more. For CEBPA, 86.7% of the patients with biallelic mutation and 9.1% of patients with the single allele mutation had in-frame mutations in the bZIP domain, which were strongly associated with a favorable prognosis. Multivariate analysis showed that age < 65 years, FLT3-ITD and CEBPA bZIP in-frame mutation were independent prognostic factors. The results suggest that analyzing these gene mutations at diagnosis can inform selection of the optimal intensity of therapy for patients with CN-AML.
• IgG4-IgE complex interferes with measurement of IgE concentration
  Keiichi Nakano; Junichi Sugita; Masanori Seimiya; Keiko Yasuda; Chiaki Watanabe; Hideki Goto; Takanori Teshima
  Clinical Biochemistry, 112, 11, 16, Elsevier BV, 2023年02月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND AND AIMS: Patients with immunoglobulin G4 (IgG4)-related disease (IgG4-RD) have elevated immunoglobulin E (IgE) concentration compared to that in healthy individuals, which suggests the occurrence of IgE-mediated allergic reactions. We have previously shown that IgG4 and IgE form a complex in some patients with IgG4-RD. However, it is currently unknown whether and how the presence of the IgG4-IgE complex affects IgE concentration measurements by different assays. MATERIALS AND METHODS: Twenty patients with confirmed presence or absence of IgG4-IgE complex were evaluated. We compared IgE concentrations measured by ST AIA-PACK IgE II (AIA-PACK), Elecsys IgE II Immunoassay (Elecsys), and Iatroace IgE (Iatroace) and evaluated to what extent the IgG4-IgE complex interfered with these measurements. RESULTS: In patients with the IgG4-IgE complex, IgE concentrations measured using Iatroace were significantly lower than those measured using Elecsys and tended to be lower than those measured using AIA-PACK. IgE concentrations determined by Iatroace were significantly different in patients with and without the IgG4-IgE complex, whereas no significant differences between these groups were detected when IgE concentrations were measured by AIA-PACK or Elecsys. CONCLUSION: The formation of the IgG4-IgE complex underestimates measured IgE concentrations depending on the method used. Therefore, caution should be exercised when selecting a specific IgE assay for patients with IgG4-RD.
• Conditioning Regimens are Associated with Distinct Patterns of Microbiota Injury in Allogeneic Hematopoietic Cell Transplantation.
  Roni Shouval; Nicholas R Waters; Antonio L C Gomes; Corrado Zuanelli Brambilla; Teng Fei; Sean M Devlin; Chi L Nguyen; Kate A Markey; Anqi Dai; John B Slingerland; Annelie G Clurman; Emily Fontana; Luigi A Amoretti; Roberta J Wright; Tobias M Hohl; Ying Taur; Anthony D Sung; Daniela Weber; Daigo Hashimoto; Takanori Teshima; Nelson J Chao; Ernst Holler; Michael Scordo; Sergio A Giralt; Miguel-Angel Perales; Jonathan U Peled; Marcel R M van den Brink
  Clinical cancer research : an official journal of the American Association for Cancer Research, 29, 1, 165, 173, 2023年01月04日, ［国際誌］
  英語, 研究論文（学術雑誌）, PURPOSE: The gut microbiota is subject to multiple insults in allogeneic hematopoietic cell transplantation (allo-HCT) recipients. We hypothesized that preparative conditioning regimens contribute to microbiota perturbation in allo-HCT. EXPERIMENTAL DESIGN: This was a retrospective study that evaluated the relationship between conditioning regimens exposure in 1,188 allo-HCT recipients and the gut microbiome. Stool samples collected from 20 days before transplantation up to 30 days after were profiled using 16S rRNA sequencing. Microbiota injury was quantified by changes in α-diversity. RESULTS: We identified distinct patterns of microbiota injury that varied by conditioning regimen. Diversity loss was graded into three levels of conditioning-associated microbiota injury (CMBI) in a multivariable model that included antibiotic exposures. High-intensity regimens, such as total body irradiation (TBI)-thiotepa-cyclophosphamide, were associated with the greatest injury (CMBI III). In contrast, the nonmyeloablative regimen fludarabine-cyclophosphamide with low-dose TBI (Flu/Cy/TBI200) had a low-grade injury (CMBI I). The risk of acute GVHD correlated with CMBI degree. Pretransplant microbial compositions were best preserved with Flu/Cy/TBI200, whereas other regimens were associated with loss of commensal bacteria and expansion of Enterococcus. CONCLUSIONS: Our findings support an interaction between conditioning at the regimen level and the extent of microbiota injury.
• Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy.
  Simone Dertschnig; Peter Gergely; Jürgen Finke; Urs Schanz; Ernst Holler; Udo Holtick; Gérard Socié; Michael Medinger; Jakob Passweg; Takanori Teshima; Christos Stylianou; Stephan Oehen; Dominik Heim; Christoph Bucher
  Transplantation and cellular therapy, 29, 1, 41.e1-41.e9, 2023年01月, ［国際誌］
  英語, 研究論文（学術雑誌）, Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the sole curative option for patients with acute myelogenous leukemia. Outcomes are limited by leukemia relapse, graft-versus-host disease (GVHD), and abnormal immune reconstitution. Mocravimod (KRP203) is an oral sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod retains T cell effector function, a main differentiator to immunosuppressants. In preclinical models, mocravimod improves survival by maintaining graft-versus-leukemia (GVL) activity while reducing GVHD. In patients undergoing allo-HSCT for hematological malignancies, mocravimod is postulated to prevent GVHD by redistributing allogeneic donor T cells to lymphoid tissues while allowing a sufficient GVL effect in the lymphoid, where malignant cells usually reside. The primary objective of this study was to assess the safety and tolerability of mocravimod in patients undergoing allo-HSCT for hematologic malignancies. Secondary objectives were to determine the pharmacokinetic profiles of mocravimod and its active metabolite mocravimod-phosphate in this patient group, as well as to assess GVHD-free, relapse free survival at 6 months after the last treatment. In this 2-part, single- and 2-arm randomized, open-label trial, we evaluated the safety, tolerability, and pharmacokinetics of mocravimod in allo-HSCT recipients (ClinicalTrials.gov identifier NCT01830010). Patients received either 1 mg or 3 mg mocravimod per day on top of standard of care GVHD prophylaxis with either cyclosporine A/methotrexate or tacrolimus/methotrexate. We found that mocravimod can be safely added to standard treatment regimens in patients with hematologic malignancies requiring allo-HSCT. Mocravimod resulted in a significant reduction of circulating lymphocyte numbers and had no negative impact on engraftment and transplantation outcomes. Our results indicate that mocravimod is safe and support a larger study to investigate its efficacy in a homogeneous acute myelogenous leukemia patient population undergoing allo-HSCT.
• A case of breast angiosarcoma clearly delineated by contrast-enhanced ultrasonography.
  Takahito Iwai; Mutsumi Nishida; Yusuke Kudo; Satomi Omotehara; Kenjiro Kato; Emi Takakuwa; Ai Shimizu; Fumi Kato; Mitsuchika Hosoda; Masato Takahashi; Takanori Teshima
  Journal of clinical ultrasound : JCU, 51, 6, 1048, 1050, 2023年, ［国際誌］
  英語, 研究論文（学術雑誌）, We present a case of breast angiosarcoma. Although B-mode ultrasonography did not indicate a tumor, contrast-enhanced ultrasonography (CEUS) was successfully delineated it. CEUS helped identify the tumor and its extent.
• Separation of GVL from GVHD -location, location, location.
  Takanori Teshima; Daigo Hashimoto
  Frontiers in immunology, 14, 1296663, 1296663, 2023年, ［国際誌］
  英語, 研究論文（学術雑誌）, Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for various hematologic malignancies. However, alloimmune response is a double-edged sword that mediates both beneficial graft-versus-leukemia (GVL) effects and harmful graft-versus-host disease (GVHD). Separation of GVL effects from GVHD has been a topic of intense research to improve transplant outcomes, but reliable clinical strategies have not yet been established. Target tissues of acute GVHD are the skin, liver, and intestine, while leukemic stem cells reside in the bone marrow. Tissue specific effector T-cell migration is determined by a combination of inflammatory and chemotactic signals that interact with specific receptors on T cells. Specific inhibition of donor T cell migration to GVHD target tissues while preserving migration to the bone marrow may represent a novel strategy to separate GVL from GVHD. Furthermore, tissue specific GVHD therapy, promoting tissue tolerance, and targeting of the tumor immune microenvironment may also help to separate GVHD and GVL.
• Breaking away from an endemic state of multidrug-resistant Pseudomonas aeruginosa by daily sink disinfection.
  Sumio Iwasaki; Rikako Sato; Keisuke Kagami; Kouji Akizawa; Kasumi Hayasaka; Tatsuya Fukumoto; Keisuke Taki; Yusuke Niinuma; Takehiro Yamada; Reiko Oyamada; Tsubasa Watanabe; Sho Nakakubo; Chiaki Watanabe; Takanori Teshima; Nobuhisa Ishiguro
  Antimicrobial stewardship & healthcare epidemiology : ASHE, 3, 1, e209, 2023年, ［国際誌］
  英語, 研究論文（学術雑誌）, The detection rate of multidrug-resistant Pseudomonas aeruginosa in patients admitted to 2 wards and the intensive care unit decreased from 20.3% (129 of 636 isolates) to 4.2% (37 of 889 isolates) after the start of disinfection of hand washing sinks using alkyl diaminoethylglycine hydrochloride.
• Clinical features of complex karyotype in newly diagnosed acute myeloid leukemia
  Shota Yoshida; Masahiro Onozawa; Naoki Miyashita; Hiroyuki Kimura; Shogo Takahashi; Shota Yokoyama; Toshihiro Matsukawa; Shinsuke Hirabayashi; Akio Mori; Daisuke Hidaka; Koichiro Minauchi; Akio Shigematsu; Junichi Hashiguchi; Tetsuyuki Igarashi; Yasutaka Kakinoki; Yutaka Tsutsumi; Makoto Ibata; Hajime Kobayashi; Yoshihito Haseyama; Katsuya Fujimoto; Toshimichi Ishihara; Hajime Sakai; Shuichi Ota; Takeshi Kondo; Takanori Teshima
  International Journal of Hematology, 117, 4, 544, 552, Springer Science and Business Media LLC, 2022年12月26日, ［査読有り］, ［最終著者］, ［国内誌］
  英語, 研究論文（学術雑誌）, Complex karyotype acute myeloid leukemia (CK-AML) has been classified as an adverse-risk subtype. Although a few reports have further classified CK-AML as typical (including monosomy of chromosomes 5, 7 and 17 or deletion of 5q, 7q and/or 17p) or atypical, the clinical features of these subtypes in Japanese patients remain unclear. We retrospectively analyzed a total of 115 patients with CK-AML, including 77 with typical CK-AML and 38 with atypical CK-AML. Median overall survival (OS) was significantly shorter in patients with typical CK-AML than atypical CK-AML (143 days vs. 369 days, P = 0.009). Among patients with typical CK-AML, those with monosomy 17 or deletion of 17p had significantly shorter OS than patients without such abnormalities (105 days vs. 165 days, P = 0.033). TP53 mutations were more predominant in patients with typical CK-AML than in patients with atypical CK-AML (69.7% vs. 32.4%, P < 0.001). Patients with typical CK-AML had a poor prognosis regardless of TP53 mutation status. Among patients with atypical CK-AML, however, prognosis was worse for those with the TP53 mutation than those without the mutation. In conclusion, prognosis is extremely poor for both typical CK-AML and atypical CK-AML with TP53 mutation.
• Effect of the COVID-19 pandemic on allogeneic stem cell transplantation in Japan
  Yoshimitsu Shimomura; Tetsuhisa Kitamura; Masashi Nishikubo; Tomotaka Sobue; Naoyuki Uchida; Noriko Doki; Masatsugu Tanaka; Ayumu Ito; Jun Ishikawa; Takahide Ara; Shuichi Ota; Makoto Onizuka; Masashi Sawa; Yukiyasu Ozawa; Yumiko Maruyama; Kazuhiro Ikegame; Yoshinobu Kanda; Tatsuo Ichinohe; Takahiro Fukuda; Shinichiro Okamoto; Takanori Teshima; Yoshiko Atsuta
  International Journal of Hematology, 117, 4, 590, 597, Springer Science and Business Media LLC, 2022年12月14日, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, The coronavirus disease 2019 (COVID-19) pandemic affected healthcare quality and access worldwide and may also have negatively affected the frequency and outcomes of allogeneic hematopoietic stem cell transplantation (HSCT). We evaluated the effect of the pandemic on allogeneic HSCT in Japan. Our subjects were patients who received allogeneic HSCT during January 2018-December 2020 in Japan. We assessed differences in yearly number of allogeneic HSCTs and 1-year outcomes in 2020 versus both 2019 and 2018. The total number of patients who received allogeneic HSCT increased from 3621 patients in 2018 and 3708 patients in 2019 to 3865 patients in 2020. Some following changes in allogeneic HSCT methods were observed: patients were older, fewer patients received bone marrow transplantation, fewer patients received transplants from unrelated donors, fewer patients received transplants from matched donors, more patients received reduced-intensity conditioning, and fewer patients received anti-thymocyte globulin in 2020 compared with previous years. HSCT outcomes were not affected, as 1-year overall survival was not significantly different (65.8% in 2020, vs. 66.5% in 2019 and 66.4% in 2018). Our results suggest that we can maintain transplant care during the pandemic by controlling the spread of COVID-19 and modifying HSCT methods.
• Antibody feedback contributes to facilitating the development of Omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees
  Takeshi Inoue; Ryo Shinnakasu; Chie Kawai; Hiromi Yamamoto; Shuhei Sakakibara; Chikako Ono; Yumi Itoh; Tommy Terooatea; Kazuo Yamashita; Toru Okamoto; Noritaka Hashii; Akiko Ishii-Watabe; Noah S. Butler; Yoshiharu Matsuura; Hisatake Matsumoto; Shinya Otsuka; Kei Hiraoka; Takanori Teshima; Masaaki Murakami; Tomohiro Kurosaki
  Journal of Experimental Medicine, 220, 2, Rockefeller University Press, 2022年12月13日, ［査読有り］
  研究論文（学術雑誌）, In contrast to a second dose of the SARS-CoV-2 mRNA vaccine, a third dose elicits potent neutralizing activity against the Omicron variant. To address the underlying mechanism for this differential antibody response, we examined spike receptor-binding domain (RBD)–specific memory B cells in vaccinated individuals. Frequency of Omicron-reactive memory B cells increased ∼9 mo after the second vaccine dose. These memory B cells show an altered distribution of epitopes from pre-second memory B cells, presumably due to an antibody feedback mechanism. This hypothesis was tested using mouse models, showing that an addition or a depletion of RBD-induced serum antibodies results in a concomitant increase or decrease, respectively, of Omicron-reactive germinal center (GC) and memory B cells. Our data suggest that pre-generated antibodies modulate the selection of GC and subsequent memory B cells after the second vaccine dose, accumulating more Omicron-reactive memory B cells over time, which contributes to the generation of Omicron-neutralizing antibodies elicited by the third vaccine dose.
• Ultrasonographic monitoring of sinusoidal obstruction syndrome in patients treated with inotuzumab ozogamicin.
  Takahito Iwai; Mutsumi Nishida; Junichi Sugita; Atsushi Yasumoto; Yuta Hasegawa; Tomoko Morimoto; Daishi Nakayama; Kohei Okada; Akio Mori; Takanori Teshima
  International journal of hematology, 116, 6, 973, 975, 2022年12月, ［国内誌］
  英語
• Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
  Sandra Dupouy; Ibtissam Marchiq; Thibaud Derippe; Maria Almena-Carrasco; Agnieszka Jozwik; Sylvain Fouliard; Yasmina Adimy; Julia Geronimi; Charlotte Graham; Nitin Jain; Marcela V. Maus; Mohamad Mohty; Nicolas Boissel; Takanori Teshima; Koji Kato; Reuben Benjamin; Svetlana Balandraud
  Cancer Research Communications, 2, 11, 1520, 1531, American Association for Cancer Research (AACR), 2022年11月30日, ［査読有り］
  研究論文（学術雑誌）, Background:
  
  UCART191 is an “off-the-shelf” genome-edited anti-CD19 chimeric antigen receptor (CAR)-T cell product, manufactured from unrelated healthy donor cells.
  
  Methods:
  
  UCART19 was administered to 25 adult patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) in the CALM trial. All patients underwent lymphodepletion with fludarabine and cyclophosphamide ± alemtuzumab and received one of three ascending doses of UCART19. Given the allogeneic nature of UCART19, we analyzed the impact of lymphodepletion, HLA disparities, and host immune system reconstitution on its kinetics, along with other factors known to affect autologous CAR-T cell clinical pharmacology.
  
  Results:
  
  Responder patients (12/25) had higher UCART19 expansion (Cmax) and exposure (AUCTlast) than nonresponders (13/25), as measured by transgene levels in peripheral blood. The persistence of CAR+ T cells did not exceed 28 days in 10/25 patients and lasted beyond 42 days in 4/25. No significant correlation was found between UCART19 kinetics and administered cell dose, patient and product characteristics or HLA disparities. However, the number of prior lines of therapy and absence of alemtuzumab negatively impacted UCART19 expansion and persistence. Alemtuzumab exposure positively affected IL7 and UCART19 kinetics, while negatively correlating with host T lymphocyte AUC0-28.
  
  Conclusions:
  
  UCART19 expansion is a driver of response in adult patients with R/R B-ALL. These results shed light on the factors associated with UCART19 kinetics, which remain highly affected by the impact of alemtuzumab on IL7 and host-versus-graft rejection.
  
  Significance:
  
  First description of the clinical pharmacology of a genome-edited allogeneic anti-CD19 CAR-T cell product showing the crucial role of an alemtuzumab-based regimen in sustaining UCART19 expansion and persistence through increased IL7 availability and decreased host T lymphocyte population.
• Reactive granulopoiesis depends on T-cell production of IL-17A and neutropenia-associated alteration of gut microbiota.
  Xuanzhong Chen; Daigo Hashimoto; Ko Ebata; Shuichiro Takahashi; Yu Shimizu; Ryuga Shinozaki; Yuta Hasegawa; Ryo Kikuchi; Hajime Senjo; Kazuki Yoneda; Zixuan Zhang; Shinpei Harada; Eiko Hayase; Takahide Ara; Hiroyuki Ohigashi; Yoichiro Iwakura; Kiminori Nakamura; Tokiyoshi Ayabe; Takanori Teshima
  Proceedings of the National Academy of Sciences of the United States of America, 119, 48, e2211230119, 2022年11月29日, ［国際誌］
  英語, 研究論文（学術雑誌）, Granulopoiesis in the bone marrow adjusts cellular output as demand for neutrophils changes. Reactive granulopoiesis is induced by profound neutropenia, but its mechanism remains to be clarified. We herein explored its mechanisms using mouse models of syngeneic hematopoietic stem cell transplantation (SCT) and 5-fluorouracil-induced neutropenia. After SCT, T cell production of IL-17A was up-regulated. Neutrophil recovery was significantly delayed in IL-17A-deficient or T cell-deficient RAG1-/- mice, and adoptive transfer of wild-type (WT) T cells facilitated neutrophil engraftment. Gut decontamination with oral antibiotics suppressed T cell production of IL-17A and impaired neutrophil recovery. Transplantation of fecal microbiota collected from neutropenic, not naive, mice promoted neutrophil recovery in these mice, suggesting that neutropenia-associated microbiota had a potential to stimulate reactive granulopoiesis. Our study uncovered a cross talk between gut microbiota and neutropenia after SCT and chemotherapy.
• Humoral response to mRNA-based COVID-19 vaccine in patients with immune thrombocytopenia
  Akio Mori; Masahiro Onozawa; Mirei Kobayashi; Shihori Tsukamoto; Hajime Senjo; Takashi Ishio; Emi Yokoyama; Koh Izumiyama; Makoto Saito; Haruna Muraki; Masanobu Morioka; Takanori Teshima; Takeshi Kondo
  British Journal of Haematology, 200, 6, 717, 721, Wiley, 2022年11月28日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Data for COVID-19 vaccine response in patients with immune thrombocytopenia (ITP) are very limited. In a study of 28 patients with ITP, anti-severe acute respiratory syndrome coronavirus 2 spike antibody titres were measured after vaccination. The seroconversion rate for ITP patients was 91.3%, comparable to that in healthy controls (HCs). However, the antibody titre in ITP patients was significantly lower than that in HCs and declined with ageing. Furthermore, the antibody titre in ITP patients who received a minimum prednisolone dose of at least 5 mg/day at any time-point at or after initial vaccination was lower than that in other patients.
• Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial.
  Noriko Fukuhara; Koji Kato; Hideki Goto; Tajima Takeshi; Mayu Kawaguchi; Kota Tokushige; Koichi Akashi; Takanori Teshima; Hideo Harigae; Stephen J Schuster; Catherine Thieblemont; Martin Dreyling; Nathan Fowler
  International journal of hematology, 117, 2, 251, 259, 2022年11月21日, ［国内誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Tisagenlecleucel yielded a high durable response rate in patients with relapsed/refractory (r/r) follicular lymphoma (FL) in the global phase 2 ELARA trial. Here, we report the efficacy, safety, and cellular kinetics of tisagenlecleucel in a subgroup of Japanese patients with r/r FL from ELARA. METHODS: ELARA (NCT03568461) is a global single-arm trial of tisagenlecleucel in patients with r/r FL who received ≥ 2 prior lines of therapy. The primary endpoint was the complete response rate (CRR), and the secondary endpoints were the overall response rate, duration of response, progression-free survival, overall survival, safety, and cellular kinetics. RESULTS: As of March 29, 2021, nine Japanese patients were enrolled and received tisagenlecleucel with a median follow-up of 13.6 months (range, 10.5‒19.3). Per independent review committee, CRR was 100% (95% CI 63.1‒100). Within 8 weeks of infusion, cytokine release syndrome (CRS) of any grade was reported in 6 patients (66.7%); however, no grade ≥ 3 CRS or any grade serious neurological events or treatment-related deaths were observed. CONCLUSION: Tisagenlecleucel showed high efficacy and manageable safety in adult Japanese patients with r/r FL. Moreover, the clinical outcomes were similar to the global population, which supports the potential of tisagenlecleucel in Japanese patients with r/r FL.
• A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.
  Koji Kato; Nobuharu Fujii; Shinichi Makita; Hideki Goto; Junya Kanda; Kazuyuki Shimada; Koichi Akashi; Koji Izutsu; Takanori Teshima; Natsuko Fukuda; Tokuhito Sumitani; Shota Nakamura; Hiroyuki Sumi; Shinji Shimizu; Yasuyuki Kakurai; Kenji Yoshikawa; Kensei Tobinai; Noriko Usui; Kiyohiko Hatake
  International journal of hematology, 2022年11月18日, ［国内誌］
  英語, 研究論文（学術雑誌）, Axicabtagene ciloleucel (axi-cel) is an autologous, CD19-targeting chimeric antigen receptor T‑cell therapy. We recently reported the 3-month follow-up results of a phase 2, multicenter, open‑label, single-arm study of axi-cel in Japanese patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) (JapicCTI-183914). Here, we present 1-year efficacy and safety data and biomarker analysis data regarding mechanisms of resistance to axi-cel. Primary and secondary endpoints included investigator-assessed objective response rate (ORR), serious adverse events, and treatment-emergent adverse events. Axi-cel pharmacokinetics were also examined. Biomarker analysis was performed by cytokine measurement, immunohistochemistry, RNA sequencing, and whole-exome sequencing. At a median follow-up of 13.4 months, ORR was 86.7% (13/15 patients), and the complete response (CR) rate improved to 53.3% (8/15 patients) due to response conversion. Seven patients experienced disease progression, and one achieved CR after re-treatment with axi-cel. No new safety concerns were detected. Plausible resistance mechanisms to axi-cel varied among patients but included CD19 downregulation, programmed death-ligand 1 upregulation, and increased macrophage and angiogenesis signatures. The 1-year efficacy and safety of axi-cel were confirmed in Japanese patients with R/R LBCL. Resistance to treatment may involve multiple factors, including target antigen loss and an unfavorable tumor environment.Clinical trial registration: Japan Clinical Trials Information; JapicCTI-183914.
• Frequencies of Anti-Troponin I vs Anti-Troponin T Autoantibodies and Degrees of Interference on Troponin Assays.
  Keiichi Nakano; Satoshi Sugawa; Masanori Seimiya; Satoshi Murakami; Keiko Yasuda; Chiaki Watanabe; Hideki Goto; Takanori Teshima
  Laboratory medicine, 2022年11月02日, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVE: Presence of autoantibodies against troponin I (cTnI) or T (cTnT) has been reported to interfere with troponin assays. However, the extent of the interference with the measurement has not been explored sufficiently. The aims of this study were to examine the frequencies of autoantibodies against troponin I and troponin T and how much these antibodies would affect the measurement. METHODS: The study comprised 52 subjects who visited Hokkaido University Hospital with suspected ischemic heart diseases. To evaluate the presence of autoantibodies, we calculated the recoveries of cTnI or cTnT after immunoglobulin G depletion, and the distributions of peaks reactive with cTnI or cTnT by high-performance liquid chromatography were examined. RESULTS: Autoantibodies against cTnI and cTnT were identified in 8 subjects (15.4%) and 1 subject (1.9%), respectively. Although the greatest difference between cTnI and cTnT was 32-fold, the distributions of cTnI-to-cTnT ratios in groups with and without anti-cTnI were not statistically different. CONCLUSION: Autoantibodies against cTnI were more frequent by several fold than those against cTnT. Their presence did not significantly expand the discrepancy between cTnI and cTnT assays.
• SARS-CoV-2 Omicron detection by antigen tests using saliva.
  Kaoru Murakami; Sumio Iwasaki; Satoshi Oguri; Kumiko Tanaka; Rigel Suzuki; Kasumi Hayasaka; Shinichi Fujisawa; Chiaki Watanabe; Satoshi Konno; Isao Yokota; Takasuke Fukuhara; Masaaki Murakami; Takanori Teshima
  Journal of clinical virology plus, 2, 4, 100109, 100109, 2022年11月, ［国際誌］
  英語, 研究論文（学術雑誌）, The Omicron emerged in November 2021 and became the predominant SARS-CoV-2 variant globally. It spreads more rapidly than ancestral lineages and its rapid detection is critical for the prevention of disease outbreaks. Antigen tests such as immunochromatographic assay (ICA) and chemiluminescent enzyme immunoassay (CLEIA) yield results more quickly than standard polymerase chain reaction (PCR). However, their utility for the detection of the Omicron variant remains unclear. We herein evaluated the performance of ICA and CLEIA in saliva from 51 patients with Omicron and 60 PCR negative individuals. The sensitivity and specificity of CLEIA were 98.0% (95%CI: 89.6-100.0%) and 100.0% (95%CI: 94.0-100.0%), respectively, with fine correlation with cycle threshold (Ct) values. The sensitivity and specificity of ICA were 58.8% (95%CI: 44.2-72.4%) and 100.0% (95%CI: 94.0-100.0%), respectively. The sensitivity of ICA was 100.0% (95%CI: 80.5-100.0%) when PCR Ct was less than 25. The Omicron can be efficiently detected in saliva by CLEIA. ICA also detects high viral load Omicron using saliva.
• The preceding hyponatremia is a useful hallmark for the diagnosis of HHV-6 encephalitis after allogeneic hematopoietic stem cell transplantation.
  Shota Yoshida; Takahide Ara; Kohei Okada; Yuto Mori; Shihori Tsukamoto; Naoki Miyashita; Kohei Kasahara; Ko Ebata; Junko Iwasaki; Shojiro Takahashi; Akio Shigematsu; Koichiro Minauchi; Naoki Kobayashi; Masahiro Ogasawara; Masahiro Imamura; Takanori Teshima; Shuichi Ota
  Bone marrow transplantation, 58, 1, 97, 99, 2022年10月15日, ［国際誌］
  英語
• UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
  Reuben Benjamin; Nitin Jain; Marcela V Maus; Nicolas Boissel; Charlotte Graham; Agnieszka Jozwik; Deborah Yallop; Marina Konopleva; Matthew J Frigault; Takanori Teshima; Koji Kato; Floriane Boucaud; Svetlana Balandraud; Athos Gianella-Borradori; Florence Binlich; Ibtissam Marchiq; Sandra Dupouy; Maria Almena-Carrasco; Matthieu Pannaux; Sylvain Fouliard; Eolia Brissot; Mohamad Mohty
  The Lancet. Haematology, 2022年10月10日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia remains poor. UCART19, an allogeneic genome-edited anti-CD19 chimeric antigen receptor (CAR) T-cell product derived from healthy donors and available for immediate clinical use, offers a potential therapeutic option for such patients. The CALM trial is a first-in-human study evaluating the safety and antileukaemic activity of UCART19 in adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia. METHODS: This phase 1, open-label study was conducted at eight centres across France, the UK, the USA, and Japan. Adult patients aged 16-70 years with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukaemia who had morphological relapse or a minimal residual disease level of at least 1 × 10-3 and had exhausted standard treatment options were enrolled in the study, which comprised a dose-escalation phase of up to three UCART19 doses followed by a safety expansion phase. Patients underwent lymphodepletion with fludarabine (30 mg/m2 per day intravenously for 3 days) and cyclophosphamide (500 mg/m2 per day intravenously for 3 days) with or without alemtuzumab (1 mg/kg or 40 mg or 60 mg over 5 days) and received UCART19 doses of 6 × 106, 6-8 × 107, or 1·8-2·4 × 108 total CAR T cells intravenously, followed by safety evaluation and disease response assessments. The primary endpoint was incidence and severity of adverse events. Secondary endpoints were the overall response rate, duration of response, relapse-free survival, progression-free survival, and overall survival. This trial is registered with ClinicalTrials.gov (NCT02746952) and is complete. FINDINGS: Between Aug 1, 2016, and June 30, 2020, 25 patients were enrolled in the study and treated with UCART19. Median duration of follow-up was 12·8 months (IQR 2·8-24·8). Median age was 37 years (IQR 28-45). 14 (56%) patients were male and 11 (44%) female. 17 (68%) patients were White, two (8%) Black, two (8%) Asian, and four (16%) from other racial or ethnic groups. Three patients developed dose-limiting toxicities (one at each dose level); one had grade 4 cytokine release syndrome and two had grade 4 prolonged cytopenias. Grade 3 or higher cytokine release syndrome was reported in six (24%) patients and grade 3 or higher neurological toxicity in one (4%) patient. Grade 3 or higher infections occurred in seven (28%) patients, and grade 4 prolonged cytopenia in four (16%) patients. Two (8%) patients developed grade 1 acute cutaneous graft-versus-host disease. 14 patients died, nine from progressive disease and five from infections or other complications, of which four were considered to be related to UCART19 or lymphodepletion, or both. After a median of follow-up of 12·8 months (IQR 2·8-24·8), overall response rate was 48% (95% CI 28-69; 12 of 25 patients), duration of response and median relapse-free survival were 7·4 months (95% CI 1·8 to not calculable), progression-free survival was 2·1 months (95% CI 1·2-2·8), and overall survival was 13·4 months (95% CI 4·8-23·0). INTERPRETATION: UCART19 had a manageable safety profile, and showed evidence of antileukaemic activity in heavily pretreated adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia. This study shows that allogeneic off-the-shelf CAR T cells can be used safely to treat patients with relapsed B-cell acute lymphoblastic leukaemia. FUNDING: Servier.
• Neurolymphomatosis in Intravascular Large B-cell Lymphoma.
  Toru Miyajima; Hiroyuki Ohigashi; Hiroaki Yaguchi; Takanori Teshima
  Internal medicine (Tokyo, Japan), 2022年10月05日, ［国内誌］
  英語, 研究論文（学術雑誌）
• Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.
  Rima M Saliba; Amin M Alousi; Joseph Pidala; Mukta Arora; Stephen R Spellman; Michael T Hemmer; Tao Wang; Camille Abboud; Sairah Ahmed; Joseph H Antin; Amer Beitinjaneh; David Buchbinder; Michael Byrne; Jean-Yves Cahn; Hannah Choe; Rabi Hanna; Peiman Hematti; Rammurti T Kamble; Carrie L Kitko; Mary Laughlin; Lazaros Lekakis; Margaret L MacMillan; Rodrigo Martino; Parinda A Mehta; Taiga Nishihori; Sagar S Patel; Miguel-Angel Perales; Hemalatha G Rangarajan; Olov Ringdén; Joseph Rosenthal; Bipin N Savani; Kirk R Schultz; Sachiko Seo; Takanori Teshima; Marjolein van der Poel; Leo F Verdonck; Daniel Weisdorf; Baldeep Wirk; Jean A Yared; Jeffrey Schriber; Richard E Champlin; Stefan O Ciurea
  Transplantation and cellular therapy, 28, 10, 681, 693, 2022年10月, ［国際誌］
  英語, 研究論文（学術雑誌）, Post-transplantation cyclophosphamide (PTCy) has been shown to effectively control graft-versus-host disease (GvHD) in haploidentical (Haplo) transplantations. In this retrospective registry study, we compared GvHD organ distribution, severity, and outcomes in patients with GvHD occurring after Haplo transplantation with PTCy GvHD prophylaxis (Haplo/PTCy) versus HLA-matched unrelated donor transplantation with conventional prophylaxis (MUD/conventional). We evaluated 2 cohorts: patients with grade 2 to 4 acute GvHD (aGvHD) including 264 and 1163 recipients of Haplo and MUD transplants; and patients with any chronic GvHD (cGvHD) including 206 and 1018 recipients of Haplo and MUD transplants, respectively. In comparison with MUD/conventional transplantation ± antithymocyte globulin (ATG), grade 3-4 aGvHD (28% versus 39%, P = .001), stage 3-4 lower gastrointestinal (GI) tract aGvHD (14% versus 21%, P = .01), and chronic GI GvHD (21% versus 31%, P = .006) were less common after Haplo/PTCy transplantation. In patients with grade 2-4 aGvHD, cGvHD rate after Haplo/PTCY was also lower (hazard ratio [HR] = .4, P < .001) in comparison with MUD/conventional transplantation without ATG in the nonmyeloablative conditioning setting. Irrespective of the use of ATG, non-relapse mortality rate was lower (HR = .6, P = .01) after Haplo/PTCy transplantation, except for transplants that were from a female donor into a male recipient. In patients with cGvHD, irrespective of ATG use, Haplo/PTCy transplantation had lower non-relapse mortality rates (HR = .6, P = .04). Mortality rate was higher (HR = 1.6, P = .03) during, but not after (HR = .9, P = .6) the first 6 months after cGvHD diagnosis. Our results suggest that PTCy-based GvHD prophylaxis mitigates the development of GI GvHD and may translate into lower GvHD-related non-relapse mortality rate.
• Antiretroviral therapy achieved metabolic complete remission of hepatic AIDS related Epstein-Barr virus-associated smooth muscle tumor.
  Takahide Ara; Tomoyuki Endo; Hideki Goto; Kohei Kasahara; Yuta Hasegawa; Shota Yokoyama; Souichi Shiratori; Masao Nakagawa; Ken Kuwahara; Emi Takakuwa; Satoshi Hashino; Takanori Teshima
  Antiviral therapy, 27, 5, 13596535221126828, 13596535221126828, 2022年10月, ［国際誌］
  英語, 研究論文（学術雑誌）, Epstein-Barr virus-associated smooth muscle tumor (EBV-SMT) is a rare mesenchymal tumor which occurs in immunocompromised patients. The immune status is an important factor in the treatment of EBV-SMTs, but the efficacy of antiretroviral therapy (ART) is not elucidated in acquired immune deficiency syndrome (AIDS) related EBV-SMTs. Here, we report the first successful case of a 29-year-old man with hepatic AIDS related EBV-SMT treated with ART solely. Positron emission tomography scan was useful for the evaluation of disease status. Recent advances in ART that enables to restore patient's immune status rapidly may change the treatment strategy in AIDS related EBV-SMT.
• Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study.
  Hideki Goto; Koji Izutsu; Daisuke Ennishi; Yuko Mishima; Shinichi Makita; Koji Kato; Miyoko Hanaya; Satoshi Hirano; Kazuya Narushima; Takanori Teshima; Hirokazu Nagai; Kenichi Ishizawa
  International journal of hematology, 116, 6, 911, 921, 2022年09月15日, ［国内誌］
  英語, 研究論文（学術雑誌）, The selective phosphatidylinositol 3-kinase δ inhibitor zandelisib demonstrated favorable safety and efficacy [objective response rate (ORR) 79%] in patients with B-cell malignancies in a phase 1b study in the US and Switzerland. In this phase 1 dose-escalation study (NCT03985189), 9 Japanese patients with relapsed/refractory indolent non-Hodgkin's lymphoma (R/R iNHL) received zandelisib on a continuous daily schedule (45 or 60 mg) until progressive disease/unacceptable toxicity. No dose-limiting toxicities were observed. The maximum tolerated dose was not reached. At a median follow-up of 17.5 months, Grade ≥ 3 treatment-emergent adverse events that occurred in 2 or more patients were neutrophil count decreased (55.6%; 5/9) and diarrhea (33.3%; 3/9). Immune-related toxicities, including hepatobiliary disorder, aspartate/alanine aminotransferase increased, diarrhea/colitis, organizing pneumonia, stomatitis, and rash, led to zandelisib discontinuation in 4 patients. The investigator-assessed ORR, based on modified Lugano criteria, was 100%, including 2 complete responses (22.2%; in follicular lymphoma patients receiving 60 mg/day). Median duration of response, progression-free survival, and time to response were 7.9, 11.1, and 1.9 months, respectively. Zandelisib demonstrated a manageable safety profile at 60 mg, the recommended phase 2 dose (RP2D) in Japanese patients. The RP2D resulted in favorable pharmacokinetics and anti-tumor efficacy in Japanese patients with R/R iNHL.Trial registration. NCT03985189 (ClinicalTrials.gov).
• Humoral response to mRNA-based COVID-19 vaccine in patients with de novo and pre-existing immune thrombocytopenia with exacerbation of thrombocytopenia after vaccination.
  Akio Mori; Masahiro Onozawa; Mirei Kobayashi; Shihori Tsukamoto; Takashi Ishio; Emi Yokoyama; Koh Izumiyama; Makoto Saito; Haruna Muraki; Masanobu Morioka; Takanori Teshima; Takeshi Kondo
  British journal of haematology, 2022年09月12日, ［国際誌］
  英語
• Comparable survival outcomes with haploidentical stem cell transplantation and unrelated bone marrow transplantation.
  Yoshiko Atsuta; Junichi Sugita; Hirohisa Nakamae; Yumiko Maruyama; Ken Ishiyama; Souichi Shiratori; Takahiro Fukuda; Mio Kurata; Naoki Shingai; Yukiyasu Ozawa; Masayoshi Masuko; Koji Nagafuji; Satoru Takada; Shinichi Kako; Yoshinobu Kanda; Junya Kanda; Tatsuo Ichinohe; Takanori Teshima
  Bone marrow transplantation, 57, 12, 1781, 1787, 2022年09月12日, ［国際誌］
  英語, 研究論文（学術雑誌）, We retrospectively compared outcomes of unrelated donor bone marrow transplant (UBMT) and HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide (PTCy-haploPBSCT) using the Japanese registry data. Recipients of first HCT for acute leukemia and myelodysplastic syndromes between 2012 and 2015 were included. The analyzed subjects comprised UBMT recipients with 8/8 matched HLA alleles (n = 1470), 7/8 matched alleles (n = 859), 6/8 matched alleles (n = 186), and recipients of PTCy-haploPBSCT (n = 133). In multivariate analyses with 8/8 matched UBMT as the reference, PTCy-haploPBSCT showed similar overall mortality, decreased risk of non-relapse mortality (NRM), increased risk of relapse, and decreased risk of grade II-IV acute graft-versus-host disease (GVHD) and chronic GVHD. Adjusted probabilities for 8/8 matched UBMT, PTCy-haploPBSCT, and 7/8 and 6/8 matched UBMT groups at 2 years post-transplant were 61%, 60%, 58%, and 52% for overall survival, 23%, 28%, 21%, and 19% for relapse, and 20%, 7%, 24%, and 33% for NRM. PTCy-haploPBSCT was associated with remarkably low NRM, contributing to survival outcomes that were comparable to 8/8 matched UBMT. The higher relapse rate in the PTCy-haploPBSCT group might be associated with the higher proportion of high-risk patients. PTCy-haploPBSCT may be a viable alternative when HLA-matched related donors are not available.
• Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohort.
  Masaki Ri; Kenshi Suzuki; Tadao Ishida; Junya Kuroda; Taku Tsukamoto; Takanori Teshima; Hideki Goto; Carolyn C Jackson; Huabin Sun; Lida Pacaud; Ei Fujikawa; Tzu-Min Yeh; Tomoyoshi Hatayama; Kensuke Aida; Yoshihiro Sunagawa; Shinsuke Iida
  Cancer science, 2022年09月02日, ［国際誌］
  英語, 研究論文（学術雑誌）, Chimeric antigen receptor (CAR) T cells targeting B-cell maturation antigen have shown positive responses in patients with multiple myeloma (MM). The phase 2 portion of the CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) included a cohort of Japanese patients with relapsed/refractory MM. Following a conditioning regimen of cyclophosphamide (300 mg/m2 ) and fludarabine (30 mg/m2 ), patients received a single cilta-cel infusion at a target dose of 0.75 × 106 (range, 0.5-1.0 × 106 ) CAR-positive viable T cells/kg. The primary endpoint was overall response rate (ORR; defined as partial response or better) by International Myeloma Working Group criteria. A key secondary endpoint was the rate of very good partial response (VGPR) or better (defined as VGPR, complete response, stringent complete response). This first analysis was performed at 6 months after the last patient received cilta-cel. Thirteen patients underwent apheresis, nine of whom received cilta-cel infusion. Eight patients who received cilta-cel at the target dose responded, yielding an ORR of 100%. Seven of eight (87.5%) patients achieved a VGPR or better. One additional patient who received a below-target dose of cilta-cel also achieved a best response of VGPR. MRD negativity (10-5 threshold) was achieved in all six evaluable patients. Eight of nine (88.9%) patients who received cilta-cel infusion experienced a grade 3 or 4 adverse event, and eight (88.9%) patients experienced cytokine release syndrome (all grade 1 or 2). No CAR-T cell neurotoxicity was reported. A positive benefit/risk profile for cilta-cel was established for heavily pretreated Japanese patients with relapsed or refractory MM.
• Serum levels of albumin and creatinine predict the outcome of sinusoidal obstruction syndrome after allogeneic HSCT.
  Souichi Shiratori; Kohei Okada; Satomi Matsuoka; Shinichi Ito; Junichi Sugita; Takanori Teshima
  Annals of hematology, 101, 9, 2117, 2118, 2022年09月, ［国際誌］
  英語
• Creation of Philadelphia chromosome by CRISPR/Cas9-mediated double cleavages on BCR and ABL1 genes as a model for initial event in leukemogenesis.
  Minori Tamai; Shinichi Fujisawa; Thao T T Nguyen; Chiaki Komatsu; Keiko Kagami; Kenji Kamimoto; Kohei Omachi; Shin Kasai; Daisuke Harama; Atsushi Watanabe; Koshi Akahane; Kumiko Goi; Kazuhito Naka; Tadashi Kaname; Takanori Teshima; Takeshi Inukai
  Cancer gene therapy, 2022年08月23日, ［国際誌］
  英語, 研究論文（学術雑誌）, The Philadelphia (Ph) chromosome was the first translocation identified in leukemia. It is supposed to be generated by aberrant ligation between two DNA double-strand breaks (DSBs) at the BCR gene located on chromosome 9q34 and the ABL1 gene located on chromosome 22q11. Thus, mimicking the initiation process of translocation, we induced CRISPR/Cas9-mediated DSBs simultaneously at the breakpoints of the BCR and ABL1 genes in a granulocyte-macrophage colony-stimulating factor (GM-CSF) dependent human leukemia cell line. After transfection of two single guide RNAs (sgRNAs) targeting intron 13 of the BCR gene and intron 1 of the ABL1 gene, a factor-independent subline was obtained. In the subline, p210 BCR::ABL1 and its reciprocal ABL1::BCR fusions were generated as a result of balanced translocation corresponding to the Ph chromosome. Another set of sgRNAs targeting intron 1 of the BCR gene and intron 1 of the ABL1 gene induced a factor-independent subline expressing p190 BCR::ABL1. Both p210 and p190 BCR::ABL1 induced factor-independent growth by constitutively activating intracellular signaling pathways for transcriptional regulation of cell cycle progression and cell survival that are usually regulated by GM-CSF. These observations suggested that simultaneous DSBs at the BCR and ABL1 gene breakpoints are initiation events for oncogenesis in Ph+ leukemia. (200/200 words).
• Comparable survival outcomes with haploidentical stem cell transplantation and cord blood transplantation.
  Junichi Sugita; Yoshiko Atsuta; Hirohisa Nakamae; Yumiko Maruyama; Ken Ishiyama; Souichi Shiratori; Takahiro Fukuda; Mio Kurata; Naoki Shingai; Yukiyasu Ozawa; Masayoshi Masuko; Koji Nagafuji; Naoyuki Uchida; Masatsugu Tanaka; Makoto Onizuka; Junya Kanda; Takafumi Kimura; Tatsuo Ichinohe; Takanori Teshima
  Bone marrow transplantation, 57, 11, 1681, 1688, 2022年08月20日, ［国際誌］
  英語, 研究論文（学術雑誌）, HLA-haploidentical stem cell transplantation using post-transplant cyclophosphamide (PTCy-haplo) and umbilical cord blood transplantation (UCBT) are alternative to HLA-matched stem cell transplantation. We conducted a matched-pair analysis of PTCy-haplo and UCBT using the Japanese registry data. We identified 136 patients aged between 16 and 69 years who received PTCy-haplo as their first transplantation for acute leukemia or myelodysplastic syndromes. Control group included 408 UCBT recipients selected to match the PTCy-haplo group. Overall and relapse-free survival probabilities at 2 years were comparable between the PTCy-haplo and UCBT groups: 55% vs. 53% for overall survival (p = 0.46), and 47% vs. 48% for relapse-free survival (p = 0.79), respectively. The cumulative incidence of relapse was significantly higher (43% vs. 29%, respectively, p = 0.006), while the cumulative incidence of non-relapse mortality (NRM) was significantly lower (9% vs. 23%, respectively, p < 0.001) in the PTCy-haplo group. The cumulative incidence of grade II-IV acute graft-versus-host disease (GVHD) was lower in the PTCy-haplo group compared to the UCBT group (29% vs. 41%, respectively, p = 0.016), while those of grade III-IV acute GVHD and chronic GVHD were not statistically different between the two groups. Our results suggest that both PTCy-haplo and UCBT are viable alternatives to HLA-matched stem cell transplantation.
• Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas.
  Masahiro Chiba; Joji Shimono; Takashi Ishio; Norio Takei; Kohei Kasahara; Reiki Ogasawara; Takahide Ara; Hideki Goto; Koh Izumiyama; Satoko Otsuguro; Liyanage P Perera; Hiroo Hasegawa; Michiyuki Maeda; Satoshi Hashino; Katsumi Maenaka; Takanori Teshima; Thomas A Waldmann; Yibin Yang; Masao Nakagawa
  Blood, 140, 18, 1951, 1963, 2022年08月03日, ［国際誌］
  英語, 研究論文（学術雑誌）, Adult T-cell leukemia/lymphoma (ATLL) is one of the aggressive peripheral T-cell neoplasms with a poor prognosis. Accumulating evidence demonstrates that escape from adaptive immunity is a hallmark for ATLL pathogenesis. However, the mechanisms by which ATLL cells evade NK-cell-mediated immunity have been poorly understood. Here we show that CD48 expression in ATLL cells determines the sensitivity for NK-cell-mediated cytotoxicity against ATLL cells. We performed unbiased genome-wide clustered regularly interspaced short palindromic repeat (CRISPR) screening using two ATLL derived cell lines and discovered CD48 as one of the best enriched genes whose knockout conferred resistance to YT-1 NK cell line mediated cytotoxicity. The ability of CD48-knockout ATLL cells to evade NK cell effector function was confirmed using human primary NK cells with reduced IFNg induction and degranulation. We found that primary ATLL cells had reduced CD48 expression along with disease progression. Furthermore, other subgroups among aggressive peripheral T-cell lymphomas (PTCL) also expressed lower levels of CD48 than normal T-cells, suggesting that CD48 is a key molecule in malignant T-cell evasion of NK cell surveillance. Thus, this study demonstrates that CD48 expression is likely critical for malignant T-cell lymphoma cell regulation of NK cell mediated immunity and provides a rationale for future evaluation of CD48 as a molecular biomarker in NK cell-associated immunotherapies.
• Ultrasonographic scoring system of late-onset sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic stem cell transplantation.
  Mutsumi Nishida; Junichi Sugita; Takahito Iwai; Megumi Sato; Yusuke Kudo; Satomi Omotehara; Tatsunori Horie; Ryosuke Sakano; Yuta Hasegawa; Atsushi Yasumoto; Yuko Cho; Takanori Teshima
  Bone marrow transplantation, 57, 8, 1338, 1340, 2022年08月, ［国際誌］
  英語
• Unilateral recurrent laryngeal nerve palsy detected by PET/CT in a patient with mediastinal T-cell lymphoblastic lymphoma.
  Toru Miyajima; Yuta Hasegawa; Daigo Hashimoto; Takanori Teshima
  International journal of hematology, 116, 1, 3, 4, 2022年07月, ［国内誌］
  英語
• Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma.
  Ulrich Jaeger; Constantine S Tam; Peter Borchmann; Joseph P McGuirk; Marianne Johansen; Edmund K Waller; Samantha M Jaglowski; Charalambos Andreadis; Ronan Ronan Foley; Jason R Westin; Isabelle Fleury; P Joy Ho; Stephan Mielke; Takanori Teshima; Gilles Andre Salles; Stephen J Schuster; Fiona C He; Richard T Maziarz; Sebastian A Mayer; Shinichi Makita; Marie José Kersten; Monalisa Ghosh; Nina D Wagner-Johnston; Koji Kato; Paolo Corradini; Hideki Goto; Silvia Colicino; Abhijit Agarwal; Chiari Lobetti Lobetti-Bodoni; Michael R Bishop
  Blood advances, 6, 16, 4816, 4820, 2022年06月10日, ［国際誌］
  英語, 研究論文（学術雑誌）
• IgG4-IgE complex in patients with IgG4-related disease.
  Keiichi Nakano; Junichi Sugita; Masanori Seimiya; Keiko Yasuda; Chiaki Watanabe; Takanori Teshima
  Clinica chimica acta; international journal of clinical chemistry, 531, 261, 264, 2022年06月01日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: IgG4-related disease (IgG4-RD) is an immune-mediated fibroinflammatory disease characterized by high IgE levels; however, the physiological significance of elevated IgE levels in patients with IgG4-RD is unclear. Previously, we reported the formation of IgG4-IgE complex in IgG4-RD patients with elevated IgE levels. In this study, we examined the frequency of this complex formation and its relationship with the clinical features in IgG4-RD patients. METHODS: The IgG4-IgE complex was evaluated in 33 and 17 patients with and without IgG4-RD, respectively. The IgG4-IgE complex was evaluated by performing the immunoadsorption of IgG4 using anti-IgG4 antibody-conjugated matrices. RESULTS: The frequency of IgG4-IgE complex formation in patients with IgG4-RD was significantly higher than that in those without IgG4-RD (21.2% vs. 0%). No significant differences were observed between the groups in terms of clinical characteristics and laboratory data. However, the IgG4-IgE complex-positive group had a significantly higher frequency of pancreatic lesions (85.7% vs. 42.3%) and a significantly lower rate of retroperitoneal fiber/periarterial lesions (0% vs. 38.5%) than the IgG4-IgE complex-negative group. CONCLUSION: The IgG4-IgE complex was found only in patients with IgG4-RD which may provide some clues to the pathogenesis and etiology of IgG4-RD.
• Humoral response to mRNA-based COVID-19 vaccine in patients with myeloid malignancies.
  Akio Mori; Masahiro Onozawa; Shihori Tsukamoto; Takashi Ishio; Emi Yokoyama; Koh Izumiyama; Makoto Saito; Haruna Muraki; Masanobu Morioka; Takanori Teshima; Takeshi Kondo
  British journal of haematology, 197, 6, 691, 696, 2022年06月, ［国際誌］
  英語, 研究論文（学術雑誌）, Data on the response to the COVID-19 vaccine in patients with myeloid malignancy, who are at severe risk in case of infection, have not emerged. In a study of 69 patients with myeloid malignancies, including 46 patients with acute myeloid leukaemia (AML) and 23 patients with myelodysplastic syndrome (MDS), anti-spike SARS-CoV-2 antibody titres were measured 3 months after the second mRNA-based vaccination. Seroconversion rates for AML and MDS were 94.7% and 100% respectively, with no significant difference from healthy controls (HCs). Patients with MDS showed a significantly lower antibody titre than that in HCs or AML patients. In AML patients, the antibody titres were comparable to those in HCs when treatment was completed, but lower in patients under maintenance therapy. The response to COVID-19 vaccine appears to be related to disease and treatment status. Patients with myeloid malignancies may be more responsive to vaccines than patients with lymphoid malignancies.
• Dynamic change in peripheral blood WT1 mRNA levels within three cycles of azacitidine predict treatment response in patients with high-risk myelodysplastic syndromes.
  Shinpei Harada; Masahiro Onozawa; Daisuke Hidaka; Shota Yokoyama; Hajime Senjo; Shogo Takahashi; Reiki Ogasawara; Minoru Kanaya; Akio Mori; Shuichi Ota; Takeshi Kondo; Takanori Teshima
  Annals of hematology, 101, 6, 1239, 1250, 2022年06月, ［国際誌］
  英語, 研究論文（学術雑誌）, Azacitidine (AZA) improves overall survival (OS) in patients with high-risk myelodysplastic syndromes (MDS). However, predictive factors for response to AZA remain largely unknown. To elucidate whether dynamic change in peripheral blood (PB) Wilms' Tumor 1 (WT1) mRNA levels could predict response to AZA, we retrospectively identified 75 treatment-naïve patients with high-risk MDS who received at least 3 cycles of AZA. We classified patients into 4 groups, low-increase (LI), low-stable (LS), high-decrease (HD), and high-stable (HS) based on the dynamic change in PB WT1 mRNA levels within 3 cycles of AZA. Cumulative incidence of overall response after 10 cycles of AZA was significantly higher in LS/HD than in HS/LI (75.5% vs 4.5%, P < 0.001). The median OS for LS/HD was 18.2 months (95% CI, 12.8-28.1 months), whereas it was 11.6 months for HS/LI (95% CI, 6.6-14.1 months; P < 0.001). Multivariate analysis demonstrated that poor-/very poor-IPSS-R cytogenetic risk and HS/LI were independently associated with poor OS (poor-/very poor-IPSS-R cytogenetic risk: HR, 2.26; 95% CI, 1.10-4.68, P = 0.03, HS/LI: HR, 2.32; 95% CI, 1.21-4.46, P = 0.01). Patients with HS/LI did not show any further response to continuous AZA, and they should be considered for alternative therapy from earlier cycles.
• High CRP-albumin ratio predicts poor prognosis in transplant ineligible elderly patients with newly diagnosed acute myeloid leukemia.
  Hajime Senjo; Masahiro Onozawa; Daisuke Hidaka; Shota Yokoyama; Satoshi Yamamoto; Yutaka Tsutsumi; Yoshihito Haseyama; Takahiro Nagashima; Akio Mori; Shuichi Ota; Hajime Sakai; Toshimichi Ishihara; Takuto Miyagishima; Yasutaka Kakinoki; Mitsutoshi Kurosawa; Hajime Kobayashi; Hiroshi Iwasaki; Daigo Hashimoto; Takeshi Kondo; Takanori Teshima
  Scientific reports, 12, 1, 8885, 8885, 2022年05月25日, ［国際誌］
  英語, 研究論文（学術雑誌）, Acute myeloid leukemia (AML) patients older than 65 years have a poor prognosis. Recently, CAR (C-reactive-protein/albumin ratio) has been actively reported as a prognostic index reflecting the nutritional and inflammatory status of elderly patients with solid tumors, but the usefulness of this index as a prognostic indicator in transplant-ineligible elderly AML patients has not been investigated. We studied genetic alterations and CARs in 188 newly diagnosed AML patients aged 65 years or older who were treated in a multicenter setting and had treated without HSCT. Both NCCN 2017 risk group, reflecting the genetic component of the tumor, and CAR, reflecting the inflammatory and nutritional status of the patient, successfully stratified the overall survival (OS) of the patients (2-year OS; CAR low vs high, 42.3% vs 17.8%, P < 0.001). Furthermore, in multivariate analysis, NCCN 2017 poor group and high CAR were extracted as independent poor prognostic factors predicting 2-year OS in the current study. We found, for the first time, that CAR at diagnosis predicted the prognosis of elderly patients with newly diagnosed AML treated without HSCT.
• MEdical Database AnaLysIS of Japanese multiple myeloma patienTs with apheresis #2 (MEDALIST-2): the impact of plerixafor use on costs and healthcare resources during mobilization and stem cell transplantation.
  Shinsuke Iida; Tadao Ishida; Toshihiro Miyamoto; Satoshi Teramukai; Heigoroh Shirai; Rie Kanamori; Yuki Tajima; Bruce Crawford; Jingbo Yi; Takanori Teshima
  International journal of hematology, 116, 3, 411, 422, 2022年05月13日, ［国内誌］
  英語, 研究論文（学術雑誌）, Treatment for multiple myeloma (MM) can involve apheresis to mobilize hematopoietic stem cells for later autologous stem cell transplantation (ASCT), which can become costly over time. This retrospective claims database study examined healthcare resource use and medical costs associated with plerixafor, a selective CXCR4 inhibitor that mobilizes hematopoietic stem cells and minimizes apheresis times. Medical data were sampled from Japanese MM patients between April 2017 and September 2019, after the Japanese launch of plerixafor. The study population (190 plerixafor users and 180 non-users) was identified from the Medical Data Vision database, and further stratified into those using granulocyte-colony stimulating factor in monotherapy or in combination with cyclophosphamide to trigger apheresis. A descriptive comparison of patient characteristics, healthcare resource use, and medical costs across the mobilization and ASCT phases indicated plerixafor is associated with higher average total medical costs. However, plerixafor-treated patients received fewer concomitant medications and spent less time in apheresis than non-users. A comparison of non-users with a similar analysis conducted pre-plerixafor launch (2013-2017) showed general improvements to treatment independent of plerixafor. The results of this research can inform guidelines for the role of plerixafor in balancing cost-effectiveness and drug efficacy in MM treatment.
• Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation.
  Zixuan Zhang; Yuta Hasegawa; Daigo Hashimoto; Hajime Senjo; Ryo Kikuchi; Xuanzhong Chen; Kazuki Yoneda; Tomoko Sekiguchi; Tatsuya Kawase; Hirofumi Tsuzuki; Takashi Ishio; Takahide Ara; Hiroyuki Ohigashi; Masao Nakagawa; Takanori Teshima
  Bone marrow transplantation, 57, 5, 775, 780, 2022年05月, ［国際誌］
  英語, 研究論文（学術雑誌）, Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative therapy for FLT3 internal tandem duplication mutant (FLT3-ITD+) acute myeloid leukemia, but relapse rate is high. A recent study showed that sorafenib, a first generation FLT3 and multikinase inhibitor, enhanced graft-versus-leukemia (GVL) effects against FLT3-ITD+ leukemia via interleukin-15 (IL-15) production. However, it remains to be clarified whether this effect could be mediated by selective FLT3 inhibition. We investigated whether gilteritinib, a selective FLT3 inhibitor, could enhance GVL effects against FLT3-ITD transfected Ba/F3 leukemia (Ba/F3-FLT3-ITD) in mice. Oral administration of gilteritinib from day +5 to +14 after allo-SCT reduced expression of the co-inhibitory receptors PD-1 and TIGIT on donor CD8+ T cells and enhanced IL-15 expression in Ba/F3-FLT3-ITD. Bioluminescent imaging using luciferase-transfected Ba/F3-FLT3-ITD demonstrated that gilteritinib significantly suppressed leukemia expansion after allo-SCT, whereas it did not impact the morbidity or mortality of graft-versus-host disease (GVHD), resulting in significant improvement of overall survival. In conclusion, short-term administration of gilteritinib after allo-SCT enhanced GVL effects against FLT3-ITD+ leukemia without exacerbating GVHD.
• IgG4-IgE complex in a patient with IgG4-related disease.
  Keiichi Nakano; Junichi Sugita; Naoki Mafune; Masanori Seimiya; Keiko Yasuda; Chiaki Watanabe; Takanori Teshima
  Clinica chimica acta; international journal of clinical chemistry, 528, 52, 55, 2022年03月01日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: IgE concentrations are occasionally elevated in patients with IgG4-related disease (IgG4-RD). In this report, we describe a novel case of IgG4-RD in which IgE concentrations were discordant between measuring reagents. CASE: An 81-year-old man was diagnosed with IgG4-RD and histological autoimmune pancreatitis, which ensued without treatment. The IgE concentrations measured using Elecsys IgE II Immunoassay and Iatroace IgE were 1287.0 IU/mL and 60.9 IU/mL, respectively. IgG4 concentration was 675 mg/dL. METHODS: To identify IgG and IgG4 directly bound to IgE, purification using protein G and anti-IgG4 antibody-conjugated matrixes and size-exclusion high-performance liquid chromatography (HPLC) were performed. RESULTS: In purification analysis, the IgE concentration of the flow-through and bound fractions were 6.8 IU/mL (10.8%) and 56.2 IU/mL (89.2%) for IgG purification and 6.8 IU/mL (12.2%) and 49.0 IU/mL (87.8%) for IgG4 purification. IgE was eluted as a single peak (640 kDa) using size-exclusion HPLC. In the elution pattern of IgG4, a minor peak (640 kDa) and a major peak (170 kDa) were observed. These results indicate that IgG4 binds to IgE and forms a complex, resulting in a discrepancy between reagents. CONCLUSIONS: In this report, we present an IgG4-IgE complex in a patient with IgG4-RD, which affected the discrepancy in IgE concentrations between IgE reagents. This report points to the significance of increased IgE production in IgG4-RD.
• Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation.
  Kotaro Miyao; Yachiyo Kuwatsuka; Makoto Murata; Koji Nagafuji; Takanori Teshima; Yuki Takeuchi; Souichi Shiratori; Yuho Najima; Naoyuki Uchida; Masatsugu Tanaka; Masashi Sawa; Shuichi Ota; Takahiro Fukuda; Yukiyasu Ozawa; Shinichi Kako; Toshiro Kawakita; Takahide Ara; Junji Tanaka; Yoshinobu Kanda; Yoshiko Atsuta; Junya Kanda; Seitaro Terakura
  Transplantation and cellular therapy, 28, 3, 153.e1-153.e11, 2022年03月, ［国際誌］
  英語, 研究論文（学術雑誌）, Previous Japanese studies have shown that bone marrow transplantation (BMT) is associated with better survival compared with peripheral blood stem cell transplantation (PBSCT) from a matched related donor (MRD). PBSCT recipients have shown higher incidences of severe graft-versus-host disease (GVHD) and nonrelapse mortality (NRM) compared with BMT recipients. In recent years, the efficacy and safety of antithymocyte globulin (ATG) for PBSCT recipients has been evaluated worldwide. In the present study, we aimed to compare BMT and PBSCT recipients to identify current improvements and unmet needs among MRD PBSCT recipients. In addition, we evaluated the impact of ATG administration on the outcomes of PBSCT recipients. We retrospectively analyzed patients age ≥16 years with acute leukemia, myelodysplastic syndrome, or chronic myelogenous leukemia who underwent their first BMT or PBSCT from an MRD between 2009 and 2018 in Japan. A total of 3599 transplantations were performed (BMT, n = 1218; PBSCT without ATG [PBSCT-ATG(-)], n = 2288; PBSCT with ATG [PBSCT-ATG(+)], n = 93). The PBSCT-ATG(-) group had a higher NRM (hazard ratio [HR], 1.30; 95% confidence interval [CI], 1.08 to 1.57; P = .005) and lower overall survival (OS) (HR, 1.16; 95% CI, 1.04 to 1.30; P = .011) compared with the BMT group. Furthermore, the PBSCT-ATG(-) group had higher incidences of grade III-IV, stage 2-4 gut, high-risk, and steroid-refractory acute GVHD compared with the BMT group. Acute GVHD had a negative impact on NRM and OS. The PBSCT-ATG(-) group also was associated with an elevated risk of chronic GVHD (HR, 1.89; 95% CI, 1.24 to 2.57; P < .001) and extensive chronic GVHD (HR, 1.44; 95% CI, 1.23 to 1.68; P < .001). The incidences of acute GVHD, chronic GVHD, and NRM and chronic GVHD-free relapse-free survival rates were comparable between the PBSCT-ATG(+) and BMT groups. The OS of patients with acute GVHD was similar in the 3 donor groups. Patients treated with reduced-intensity conditioning in the PBSCT-ATG(+) group had a higher relapse rate and lower OS rate compared with those in the BMT group. In this Japanese cohort, standard calcineurin inhibitor-based GVHD prophylaxis was not sufficient for recipients of MRD PBSCT because of the high incidence of severe acute GVHD. Prophylactic ATG was found to be a promising strategy against GVHD.
• Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
  Nathan Hale Fowler; Michael Dickinson; Martin Dreyling; Joaquin Martinez-Lopez; Arne Kolstad; Jason Butler; Monalisa Ghosh; Leslie Popplewell; Julio C Chavez; Emmanuel Bachy; Koji Kato; Hideo Harigae; Marie José Kersten; Charalambos Andreadis; Peter A Riedell; P Joy Ho; José Antonio Pérez-Simón; Andy I Chen; Loretta J Nastoupil; Bastian von Tresckow; Andrés José María Ferreri; Takanori Teshima; Piers E M Patten; Joseph P McGuirk; Andreas L Petzer; Fritz Offner; Andreas Viardot; Pier Luigi Zinzani; Ram Malladi; Aiesha Zia; Rakesh Awasthi; Aisha Masood; Oezlem Anak; Stephen J Schuster; Catherine Thieblemont
  Nature medicine, 28, 2, 325, 332, 2022年02月, ［国際誌］
  英語, 研究論文（学術雑誌）, Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell lymphoma. In a previous pilot study of tisagenlecleucel in r/r follicular lymphoma (FL), 71% of patients achieved a complete response (CR). Here we report the primary, prespecified interim analysis of the ELARA phase 2 multinational trial of tisagenlecleucel in adults with r/r FL after two or more treatment lines or who relapsed after autologous stem cell transplant (no. NCT03568461). The primary endpoint was CR rate (CRR). Secondary endpoints included overall response rate (ORR), duration of response, progression-free survival, overall survival, pharmacokinetics and safety. As of 29 March 2021, 97/98 enrolled patients received tisagenlecleucel (median follow-up, 16.59 months; interquartile range, 13.8-20.21). The primary endpoint was met. In the efficacy set (n = 94), CRR was 69.1% (95% confidence interval, 58.8-78.3) and ORR 86.2% (95% confidence interval, 77.5-92.4). Within 8 weeks of infusion, rates of cytokine release syndrome were 48.5% (grade ≥3, 0%), neurological events 37.1% (grade ≥3, 3%) and immune effector cell-associated neurotoxicity syndrome (ICANS) 4.1% (grade ≥3, 1%) in the safety set (n = 97), with no treatment-related deaths. Tisagenlecleucel is safe and effective in extensively pretreated r/r FL, including in high-risk patients.
• Non-age-related neoplastic loss of sex chromosome correlated with prolonged survival in real-world CBF-AML patients.
  Akio Mori; Masahiro Onozawa; Daisuke Hidaka; Shota Yokoyama; Toru Miyajima; Emi Yokoyama; Reiki Ogasawara; Koh Izumiyama; Makoto Saito; Shinichi Fujisawa; Shuichi Ota; Yasutaka Kakinoki; Yutaka Tsutsumi; Satoshi Yamamoto; Takuto Miyagishima; Takahiro Nagashima; Hiroshi Iwasaki; Hajime Kobayashi; Yoshihito Haseyama; Mitsutoshi Kurosawa; Masanobu Morioka; Takanori Teshima; Takeshi Kondo
  International journal of hematology, 115, 2, 188, 197, 2022年02月, ［国内誌］
  英語, 研究論文（学術雑誌）, In this real-world clinical study, in which we determined eligibility for allogenic hematopoietic stem cell transplantation by prognostic factors and minimal residual disease status, we retrospectively evaluated cytogenetic, genetic, and clinical features in 96 patients with core-binding factor acute myeloid leukemia (CBF-AML) including 62 patients with RUNX1/RUNX1T1 and 34 patients with CBFβ/MYH11. Multivariate analyses for 5-year overall survival (OS) in CBF-AML patients revealed that age of 50 years or older (HR: 3.46, 95% CI 1.47-8.11, P = 0.004) and receiving 2 or more induction cycles (HR: 3.55, 95% CI 1.57-8.05, P = 0.002) were independently associated with worse OS and that loss of sex chromosome (LOS) was independently associated with better OS (HR: 0.09, 95% CI 0.01-0.71, P = 0.022). At the time of complete remission, all 21 karyotyped patients with LOS had a normal karyotype. Furthermore, in all 9 patients with LOS who had a mosaic of metaphase cells with and without t(8;21) or inv(16), the metaphase cells without t(8;21)/inv(16) showed a normal karyotype. These results proved that LOS was not age-related and physiological, but rather a neoplastic chromosomal abnormality.
• A Rare Case of BCL2-Positive Multiple Myeloma Complicated with Follicular Lymphoma.
  Yutaka Tsutsumi; Shinich Ito; Mirei Kobayashi; Takanori Teshima
  Case reports in hematology, 2022, 3076968, 3076968, 2022年, ［国際誌］
  英語, A 68-year-old woman presented with follicular lymphoma complicated by IgG kappa-positive multiple myeloma. In this case, both follicular lymphoma and plasma cells were positive for BCL2 by immunostaining. T-cell association in the FL and MM was also analyzed in this case. Some CD3-positive T-cells were found around the plasma cells. These cells were mainly CD8-positive T-cells and not CD4-positive T-cells. These results suggest that CD4-positive T-cells were not associated with the proliferation of the plasma cells in this case. Although the FL that developed was initially positive for BCL2 protein, this does not indicate that plasma cells were derived from FL cells because of the eventual complication that occurred in this case. Furthermore, in this case, rituximab and bendamustine were effective for FL. They were not effective for MM, however, demonstrating that additional treatment options are necessary for the simultaneous treatment of BCL2-positive MM with FL.
• Aleukemic Extramedullary Blast Crisis as an initial presentation of Chronic Myeloid Leukemia with E1A3 BCR-ABL1 Fusion Transcript
  Naoki Miyashita; Masahiro Onozawa; Keito Suto; Shinichi Fujisawa; Nanase Okazaki; Daisuke Hidaka; Hiroyuki Ohigashi; Atsushi Yasumoto; Junichi Sugita; Daigo Hashimoto; Yoshihiro Matsuno; Takanori Teshima
  Internal Medicine, Japanese Society of Internal Medicine, 2022年, ［査読有り］
  研究論文（学術雑誌）
• Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of FLT3-ITD-positive AML treated with gilteritinib.
  Takeshi Kondo; Masahiro Onozawa; Shinichi Fujisawa; Shinpei Harada; Reiki Ogasawara; Koh Izumiyama; Makoto Saito; Masanobu Morioka; Akio Mori; Takanori Teshima
  Hematology (Amsterdam, Netherlands), 26, 1, 256, 260, 2021年12月, ［国際誌］
  英語, 研究論文（学術雑誌）, Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in acute myelogenous leukemia (AML) and the mutation is associated with poor prognosis of patients. Two distinct types of activating mutations have been identified in AML samples. One is internal tandem duplications in the juxtamembrane domain (FLT3-ITD) and the other is point mutations in the tyrosine kinase domain (FLT3-TKD). Gilteritinib is a FLT3 inhibitor that inhibits both FLT3-ITD and FLT3-TKD. It was reported that differentiation of leukemic blasts accompanied by differentiation syndrome occurs in some patients treated with gilteritinib. However, information about the precise clinical course is limited, and appropriate management of differentiation syndrome has not been established. We report a case of relapsed AML with FLT3-ITD that was treated with gilteritinib. Analysis of the FLT3-ITD variant allele frequency (VAF) revealed that FLT3-ITD VAF was not decreased despite achievement of complete remission with incomplete hematologic recovery. Remarkable increases of monocytes and granulocytes accompanied by differentiation syndrome were observed at 6 months after the initiation of gilteritinib treatment. Intermittent chemotherapy with low-dose cytarabine and mitoxantrone was effective for reducing myelomonocytosis and resolving differentiation syndrome.
• Equivalent SARS-CoV-2 viral loads by PCR between nasopharyngeal swab and saliva in symptomatic patients
  Isao Yokota; Takeshi Hattori; Peter Y. Shane; Satoshi Konno; Atsushi Nagasaka; Kimihiro Takeyabu; Shinichi Fujisawa; Mutsumi Nishida; Takanori Teshima
  Scientific Reports, 11, 1, 4500, 4500, Springer Science and Business Media LLC, 2021年12月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Emerging evidences have shown the utility of saliva for the detection of SARS-CoV-2 by PCR as alternative to nasopharyngeal swab (NPS). However, conflicting results have been reported regarding viral loads between NPS and saliva. We conducted a study to compare the viral loads between NPS and saliva in 42 COVID-19 patients. Viral loads were estimated by the cycle threshold (Ct) values. SARS-CoV-2 was detected in 34 (81%) using NPS with median Ct value of 27.4, and 38 (90%) using saliva with median Ct value of 28.9 (P = 0.79). Kendall’s W was 0.82, showing a high degree of agreement, indicating equivalent viral loads in NPS and saliva. After symptom onset, the Ct values of both NPS and saliva continued to increase over time, with no substantial difference. Self-collected saliva has a detection sensitivity comparable to that of NPS and is a useful diagnostic tool with mitigating uncomfortable process and the risk of aerosol transmission to healthcare workers.
• Genome-wide CRISPR screen identifies CDK6 as a therapeutic target in Adult T-cell leukemia/lymphoma.
  Takashi Ishio; Sarvesh Kumar; Joji Shimono; Anusara Daenthanasanmak; Sigrid Dubois; Yuquan Lin; Bonita R Bryant; Michael N Petrus; Emmanuel Bachy; Da Wei Huang; Yandan Yang; Patrick L Green; Hiroo Hasegawa; Michiyuki Maeda; Hideki Goto; Tomoyuki Endo; Takashi Yokota; Kanako C Hatanaka; Yutaka Hatanaka; Shinya Tanaka; Yoshihiro Matsuno; Yibin Yang; Satoshi Hashino; Takanori Teshima; Thomas A Waldmann; Louis M Staudt; Masao Nakagawa
  Blood, 139, 10, 1541, 1556, 2021年11月24日, ［国際誌］
  英語, 研究論文（学術雑誌）, Adult T-cell leukemia/lymphoma (ATLL) is an aggressive T-cell malignancy with a poor prognosis with current therapy. Here we report genome-wide CRISPR-Cas9 screening of ATLL models, which identified CDK6, CCND2, BATF3, JUNB, STAT3, and IL10RB as genes that are essential for the proliferation and/or survival of ATLL cells. As a single agent, the CDK6 inhibitor palbociclib induced cell cycle arrest and apoptosis in ATLL models with wild type TP53. ATLL models that had inactivated TP53 genetically were relatively resistant to palbociclib owing to compensatory CDK2 activity, and this resistance could be reversed by APR-246, a small molecule activator of mutant TP53. The CRISPR-Cas9 screen further highlighted the dependence of ATLL cells on mTORC1 signaling. Treatment of ATLL cells with palbociclib in combination with mTORC1 inhibitors was synergistically toxic irrespective of the TP53 status. This work defines CDK6 as a novel therapeutic target for ATLL and supports the clinical evaluation of palbociclib in combination with mTORC1 inhibitors in this recalcitrant malignancy.
• Multiple introductions of SARS-CoV-2 B.1.1.214 lineages from mainland Japan preceded the third wave of the COVID-19 epidemic in Hokkaido.
  Takako Shimura; Kodai Abe; Toshiki Takenouchi; Mamiko Yamada; Hisato Suzuki; Makoto Suematsu; Sho Nakakubo; Keisuke Kamada; Satoshi Konno; Takanori Teshima; Kenjiro Kosaki
  Travel medicine and infectious disease, 44, 102210, 102210, 2021年11月22日, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: The third wave of the COVID-19 epidemic in the island of Hokkaido, the second largest island in Japan, began abruptly in October 2020. METHODS: We conducted a phylodynamic analysis of the SARS-CoV-2 genome sequences obtained from tertiary medical centers in the Greater Tokyo Area and Sapporo, the largest city in the island of Hokkaido, and genome sequences published by GISAID, an international SARS-CoV-2 genome database. We also analyzed the statistics on the person-nights of travelers in the island of Hokkaido from the Greater Tokyo Area in 2019 versus 2020. RESULTS: At least eight sub-lineages belonging to the B.1.1.214 lineage were introduced to the island of Hokkaido from the island of Honshu, the mainland of Japan from late July to November 2020, during the governmental travel promotion program. Five of the eight sub-lineages originated from the Greater Tokyo Area. Comparison of the monthly ratios of the person-nights of travelers in the island of Hokkaido from the Greater Tokyo Area in 2019 and 2020 revealed that the highest value occurred in October 2020. CONCLUSION: We contend that the Japanese governmental travel promotion program contributed to the introduction of the B.1.1.214 sub-lineages from the main island of Honshu to the island of Hokkaido, and drove the third wave in Hokkaido, even if we are unable to establish the causality.
• Ruxolitinib for Chronic Graft-versus-Host Disease. Reply.
  Robert Zeiser; Takanori Teshima; Franco Locatelli
  The New England journal of medicine, 385, 17, 1631, 1632, 2021年10月21日, ［国際誌］
  英語
• Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
  Stephen J Schuster; Constantine S Tam; Peter Borchmann; Nina Worel; Joseph P McGuirk; Harald Holte; Edmund K Waller; Samantha Jaglowski; Michael R Bishop; Lloyd E Damon; Stephen Ronan Foley; Jason R Westin; Isabelle Fleury; P Joy Ho; Stephan Mielke; Takanori Teshima; Murali Janakiram; Jing-Mei Hsu; Koji Izutsu; Marie José Kersten; Monalisa Ghosh; Nina Wagner-Johnston; Koji Kato; Paolo Corradini; Marcela Martinez-Prieto; Xia Han; Ranjan Tiwari; Gilles Salles; Richard T Maziarz
  The Lancet Oncology, 22, 10, 1403, 1415, Elsevier BV, 2021年10月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall response rate was 52% and the complete response rate was 40% in 93 evaluable adult patients with relapsed or refractory aggressive B-cell lymphomas. We aimed to do a long-term follow-up analysis of the clinical outcomes and correlative analyses of activity and safety in the full adult cohort. METHODS: In this multicentre, open-label, single-arm, phase 2 trial (JULIET) done at 27 treatment sites in ten countries (Australia, Austria, Canada, France, Germany, Italy, Japan, the Netherlands, Norway, and the USA), adult patients (≥18 years) with histologically confirmed relapsed or refractory large B-cell lymphomas who were ineligible for, did not consent to, or had disease progression after autologous haematopoietic stem-cell transplantation, with an Eastern Cooperative Oncology Group performance status of 0-1 at screening, were enrolled. Patients received a single intravenous infusion of tisagenlecleucel (target dose 5 × 108 viable transduced CAR T cells). The primary endpoint was overall response rate (ie, the proportion of patients with a best overall disease response of a complete response or partial response using the Lugano classification, as assessed by an independent review committee) at any time post-infusion and was analysed in all patients who received tisagenlecleucel (the full analysis set). Safety was analysed in all patients who received tisagenlecleucel. JULIET is registered with ClinialTrials.gov, NCT02445248, and is ongoing. FINDINGS: Between July 29, 2015, and Nov 2, 2017, 167 patients were enrolled. As of Feb 20, 2020, 115 patients had received tisagenlecleucel infusion and were included in the full analysis set. At a median follow-up of 40·3 months (IQR 37·8-43·8), the overall response rate was 53·0% (95% CI 43·5-62·4; 61 of 115 patients), with 45 (39%) patients having a complete response as their best overall response. The most common grade 3-4 adverse events were anaemia (45 [39%]), decreased neutrophil count (39 [34%]), decreased white blood cell count (37 [32%]), decreased platelet count (32 [28%]), cytokine release syndrome (26 [23%]), neutropenia (23 [20%]), febrile neutropenia (19 [17%]), hypophosphataemia (15 [13%]), and thrombocytopenia (14 [12%]). The most common treatment-related serious adverse events were cytokine release syndrome (31 [27%]), febrile neutropenia (seven [6%]), pyrexia (six [5%]), pancytopenia (three [3%]), and pneumonia (three [3%]). No treatment-related deaths were reported. INTERPRETATION: Tisagenlecleucel shows durable activity and manageable safety profiles in adult patients with relapsed or refractory aggressive B-cell lymphomas. For patients with large B-cell lymphomas that are refractory to chemoimmunotherapy or relapsing after second-line therapies, tisagenlecleucel compares favourably with respect to risk-benefit relative to conventional therapeutic approaches (eg, salvage chemotherapy). FUNDING: Novartis Pharmaceuticals.
• Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
  Koji Kato; Shinichi Makita; Hideki Goto; Junya Kanda; Nobuharu Fujii; Kazuyuki Shimada; Koichi Akashi; Koji Izutsu; Takanori Teshima; Natsuko Fukuda; Tokuhito Sumitani; Hiroyuki Sumi; Shinji Shimizu; Yasuyuki Kakurai; Kenji Yoshikawa; Kensei Tobinai; Noriko Usui; Kiyohiko Hatake
  International Journal of Clinical Oncology, 27, 1, 213, 223, Springer Science and Business Media LLC, 2021年10月01日, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）,
  
  Axicabtagene ciloleucel (axi-cel) is an autologous chimeric antigen receptor T-cell based anti-CD19 therapy. The ZUMA-1 study, multicenter, single-arm, registrational Phase 1/2 study of axi-cel demonstrated high objective response rate in patients with relapsed/refractory large B-cell lymphoma. Here, we present the results of the bridging study to evaluate the efficacy and safety of axi-cel in Japanese patients (JapicCTI-183914).
  
  
  
  
  This study was the phase 2, multicenter, open-label, single-arm trial. Following leukapheresis, axi-cel manufacturing and lymphodepleting chemotherapy, patients received a single infusion of axi-cel (2.0 × 10⁶ cells/kg). Bridging therapy between leukapheresis and conditioning chemotherapy was not allowed. The primary endpoint was objective response rate.
  
  
  
  
  Among 17 enrolled patients, 16 received axi-cel infusion. In the 15 efficacy evaluable patients, objective response rate was 86.7% (95% confidence interval: 59.5–98.3%); complete response/partial response were observed in 4 (26.7%)/9 (60.0%) patients, respectively. No dose-limiting toxicities were observed. Grade ≥ 3 treatment-emergent adverse events occurred in 16 (100%) patients—most commonly neutropenia (81.3%), lymphopenia (81.3%) and thrombocytopenia (62.5%). Cytokine release syndrome occurred in 13 (81.3%) patients (12 cases of grade 1 or 2 and 1 case of grade 4). No neurologic events occurred. Two patients died due to disease progression, but no treatment-related death was observed by the data-cutoff date (October 23, 2019).
  
  
  
  
  The efficacy and safety of axi-cel was confirmed in Japanese patients with relapsed/refractory large B-cell lymphoma who have otherwise limited treatment options.
  
  
  
  
  JapicCTI-183914.
  
  
  
• National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report
  Daniel Wolff; Vedran Radojcic; Robert Lafyatis; Resat Cinar; Rachel K. Rosenstein; Edward W. Cowen; Guang-Shing Cheng; Ajay Sheshadri; Anne Bergeron; Kirsten M. Williams; Jamie L. Todd; Takanori Teshima; Geoffrey D.E. Cuvelier; Ernst Holler; Shannon R. McCurdy; Robert R. Jenq; Alan M. Hanash; David Jacobsohn; Bianca D. Santomasso; Sandeep Jain; Yoko Ogawa; Philipp Steven; Zhonghui Katie Luo; Tina Dietrich-Ntoukas; Daniel Saban; Ervina Bilic; Olaf Penack; Linda M. Griffith; Meredith Cowden; Paul J. Martin; Hildegard T. Greinix; Stefanie Sarantopoulos; Gerard Socie; Bruce R. Blazar; Joseph Pidala; Carrie L. Kitko; Daniel R. Couriel; Corey Cutler; Kirk R. Schultz; Steven Z. Pavletic; Stephanie J. Lee; Sophie Paczesny
  Transplantation and Cellular Therapy, 27, 10, 817, 835, Elsevier BV, 2021年10月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Chronic graft-versus-host disease (GVHD) can be associated with significant morbidity, in part because of nonreversible fibrosis, which impacts physical functioning (eye, skin, lung manifestations) and mortality (lung, gastrointestinal manifestations). Progress in preventing severe morbidity and mortality associated with chronic GVHD is limited by a complex and incompletely understood disease biology and a lack of prognostic biomarkers. Likewise, treatment advances for highly morbid manifestations remain hindered by the absence of effective organ-specific approaches targeting "irreversible" fibrotic sequelae and difficulties in conducting clinical trials in a heterogeneous disease with small patient numbers. The purpose of this document is to identify current gaps, to outline a roadmap of research goals for highly morbid forms of chronic GVHD including advanced skin sclerosis, fasciitis, lung, ocular and gastrointestinal involvement, and to propose strategies for effective trial design. The working group made the following recommendations: (1) Phenotype chronic GVHD clinically and biologically in future cohorts, to describe the incidence, prognostic factors, mechanisms of organ damage, and clinical evolution of highly morbid conditions including long-term effects in children; (2) Conduct longitudinal multicenter studies with common definitions and research sample collections; (3) Develop new approaches for early identification and treatment of highly morbid forms of chronic GVHD, especially biologically targeted treatments, with a special focus on fibrotic changes; and (4) Establish primary endpoints for clinical trials addressing each highly morbid manifestation in relationship to the time point of intervention (early versus late). Alternative endpoints, such as lack of progression and improvement in physical functioning or quality of life, may be suitable for clinical trials in patients with highly morbid manifestations. Finally, new approaches for objective response assessment and exploration of novel trial designs for small populations are required.
• Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence
  Makoto Murata; Seitaro Terakura; Atsushi Wake; Kotaro Miyao; Kazuhiro Ikegame; Naoyuki Uchida; Keisuke Kataoka; Toshihiro Miyamoto; Makoto Onizuka; Tetsuya Eto; Noriko Doki; Shuichi Ota; Maho Sato; Yoshiko Hashii; Tatsuo Ichinohe; Takahiro Fukuda; Yoshiko Atsuta; Shinichiro Okamoto; Takanori Teshima
  Bone Marrow Transplantation, 56, 10, 2355, 2366, Springer Science and Business Media LLC, 2021年10月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Temcell is a cryopreserved, human bone marrow-derived mesenchymal stem cell (MSC) product approved for the treatment of patients of all ages with acute graft-versus-host disease (GVHD). Initial experience with Temcell in a real-world setting from a cellular therapy registry in Japan is presented. A total of 381 consecutive patients were enrolled since its approval in 2016. The median cell number infused was 2.00 × 106/kg. The most common number of infusions was 8 in 100 patients. Of the 306 evaluable patients, the overall response rate (ORR) on day 28 after the start of MSC therapy was 56%. Of the 151 evaluable patients who received it as second-line therapy following first-line steroid therapy for classic acute GVHD, the ORR was 61%. Liver involvement of GVHD and ≥14 days from first-line steroid therapy to second-line MSC therapy was associated with a lower ORR. Day 28 ORR, patient age, GVHD grade, GVHD organ involvement, and a number of GVHD therapies before MSC therapy were associated with nonrelapse mortality. Overall survival at 6 months in 381 patients was 40%. This study suggests that Temcell is one of the treatment options for steroid-refractory acute GVHD until a new treatment with survival benefit is developed.
• Application of the proximal isovelocity surface area method for estimation of the effective orifice area in aortic stenosis
  Masahiro Nakabachi; Hiroyuki Iwano; Michito Murayama; Hisao Nishino; Shinobu Yokoyama; Shingo Tsujinaga; Yasuyuki Chiba; Suguru Ishizaka; Ko Motoi; Kazunori Okada; Sanae Kaga; Mutsumi Nishida; Takanori Teshima; Toshihisa Anzai
  Heart and Vessels, 37, 4, 638, 646, Springer Science and Business Media LLC, 2021年09月25日, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, Although the echocardiographic effective orifice area (EOA) calculated using the continuity equation is widely used for the assessment of severity in aortic stenosis (AS), the existence of high flow velocity at the left ventricular outflow tract (LVOT) potentially causes its overestimation. The proximal isovelocity surface area (PISA) method could be an alternative tool for the estimation of EOA that limits the influence of upstream flow velocity. EOA was calculated using the continuity equation (EOACont) and PISA method (EOAPISA), respectively, in 114 patients with at least moderate AS. The geometric orifice area (GOA) was also measured using the planimetry method in 51 patients who also underwent three-dimensional transesophageal echocardiography. Patients were divided into two groups according to the median LVOT flow velocity. EOAPISA could be obtained in 108 of the 114 patients (95%). Although there was a strong correlation between EOACont and EOAPISA (r = 0.78, P < 0.001), EOACont was statistically significantly larger than EOAPISA (0.86 ± 0.33 vs 0.75 ± 0.29 cm2, P < 0.001). Both EOACont and EOAPISA similarly correlated with GOA (r = 0.70, P < 0.001 and r = 0.77, P < 0.001, respectively). However, a fixed bias, which is hydrodynamically supposed to exist between EOA and GOA, was not observed between EOACont and GOA. In contrast, there was a negative fixed bias between EOAPISA and GOA with smaller EOAPISA than GOA. The difference between EOACont and GOA was significantly greater with a larger EOACont relative to GOA in patients with high LVOT flow velocity than in those without (0.16 ± 0.25 vs - 0.07 ± 0.10 cm2, P < 0.001). In contrast, the difference between EOAPISA and GOA was consistent regardless of the LVOT flow velocity (- 0.07 ± 0.12 vs - 0.07 ± 0.15 cm2, P = 0.936). The PISA method was applied to estimate EOA in patients with AS. EOAPISA could be an alternative parameter for AS severity grading in patients with high LVOT flow velocity in whom EOACont would potentially overestimate the orifice area.
• Non-classical manifestations of acute GVHD
  Robert Zeiser; Takanori Teshima
  Blood, 138, 22, 2165, 2172, American Society of Hematology, 2021年09月05日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Acute graft-versus-host disease (GVHD) is a major life-threatening complication after allogeneic hematopoietic cell transplantation (allo-HCT). The classical target organs of acute GVHD include the intestines, liver, and skin. The damage of these organs is relatively easy to detect for the clinician as diarrhea, increased bilirubin, and rash. However, there is increasing evidence that also other organs, where the acute damage is less apparent or more difficult to distinguish from drug toxicity, such as the central nervous system, the lungs, the ovaries and testis, the thymus, the bone marrow and the kidney, can be target organs of acute GVHD. Here, we review current evidence for non-classical manifestations of acute GVHD in rodent models and in patients and discuss them in the context of novel emerging therapies for GVHD. A better understanding of the involvement of the non-classical GVHD target organs may help to improve patient outcomes after allo-HCT.
• Graft-Versus-Host Disease Prophylaxis Using Low-Dose Antithymocyte Globulin in Peripheral Blood Stem Cell Transplantation—A Matched-Pair Analysis
  Souichi Shiratori; Mio Kurata; Junichi Sugita; Shuichi Ota; Senji Kasahara; Jun Ishikawa; Kazunori Imada; Yasushi Onishi; Ken Ishiyama; Takashi Ashida; Yoshinobu Kanda; Tatsuo Ichinohe; Takahiro Fukuda; Yoshiko Atsuta; Takanori Teshima
  Transplantation and Cellular Therapy, 27, 12, 995.e1-995.e6, Elsevier BV, 2021年09月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Antithymocyte globulin (ATG) decreases chronic graft-versus-host disease (cGVHD) in peripheral blood stem cell transplantation (PBSCT); however, the optimal ATG dose has not been elucidated. We conducted a matched-pair analysis to evaluate whether low-dose ATG could inhibit cGVHD in HLA-matched PBSCT after myeloablative conditioning. A total of 70 patients who were enrolled in the JSCT-ATG15 study, a multicenter phase II clinical trial of 2 mg/kg of ATG (thymoglobulin) given on days -2 and -1, were compared with 210 patients not receiving ATG, who were matched for age, sex, disease, and calcineurin inhibitor selected from the database in Japan. The primary endpoint, cumulative incidence of extensive cGVHD at 2 years was significantly less in the ATG group than that in the non-ATG group (8.7% [95% CI, 3.5%-16.8%] versus 26.2% [95% CI, 20.3%-32.5%], P = .002). ATG significantly reduced the incidence of overall cGVHD and inhibited multiple organ involvement. The ATG group had favorable outcome compared to the non-ATG group in GVHD-free, and relapse-free survival at 2 years. In conclusion, low-dose ATG effectively inhibits chronic GVHD in PBSCT.
• Phase II study of tazemetostat for relapsed or refractory B‐cell non‐Hodgkin lymphoma with EZH2 mutation in Japan
  Koji Izutsu; Kiyoshi Ando; Momoko Nishikori; Hirohiko Shibayama; Takanori Teshima; Junya Kuroda; Koji Kato; Yoshitaka Imaizumi; Kisato Nosaka; Rika Sakai; Seiichiro Hojo; Tadashi Nakanishi; Shinya Rai
  Cancer Science, 112, 9, 3627, 3635, Wiley, 2021年09月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Tazemetostat is a selective, reversible, small-molecule inhibitor of the histone methyltransferase enzyme, enhancer of zest homolog 2 (EZH2). In this multicenter, open-label, phase II study, we assessed the efficacy and safety of tazemetostat in Japanese patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma harboring the EZH2 mutation. Tazemetostat (800 mg twice daily) was given orally (28-day cycle) until disease progression or unacceptable toxicity. Among the 20 eligible patients, 17 were enrolled in cohort 1 (follicular lymphoma [FL]), and three were enrolled in cohort 2 (diffuse large B-cell lymphoma). At data cut-off, the objective response rate in cohort 1 was 76.5%, including six patients (35.3%) with complete response and seven patients (41.2%) with partial response (PR). All three patients in cohort 2 achieved PR. In cohort 1, median progression-free survival (PFS) was not reached at the median follow-up of 12.9 months. The estimated PFS rate at 12 and 15 months was 94.1% and 73.2%, respectively. The most common grade 3 treatment-emergent adverse event (TEAE) was lymphopenia (n = 2). Grade 4 TEAEs included hypertriglyceridemia and pneumonia aspiration (n = 1 each), which were not related to tazemetostat. Treatment-emergent adverse events leading to study drug discontinuation were reported in four of the 20 patients, indicating that the safety profile of tazemetostat was acceptable and manageable. Tazemetostat 800 mg twice daily showed encouraging efficacy in patients with R/R EZH2 mutation-positive FL with a manageable safety profile in the overall population. Thus, tazemetostat could be a potential treatment for R/R EZH2 mutation-positive FL.
• Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors
  Souichi Shiratori; Junichi Sugita; Shigeo Fuji; Jun Aoki; Masashi Sawa; Yukiyasu Ozawa; Daigo Hashimoto; Ken-ichi Matsuoka; Kazunori Imada; Noriko Doki; Takashi Ashida; Yasunori Ueda; Masatsugu Tanaka; Yasushi Sawayama; Tatsuo Ichinohe; Seitaro Terakura; Satoko Morishima; Yoshiko Atsuta; Takahiro Fukuda; Takanori Teshima
  Bone Marrow Transplantation, 56, 9, 2231, 2240, Springer Science and Business Media LLC, 2021年09月, ［査読有り］
  研究論文（学術雑誌）
• Logistic advantage of two-step screening strategy for SARS-CoV-2 at airport quarantine
  Isao Yokota; Peter Y. Shane; Takanori Teshima
  Travel Medicine and Infectious Disease, 43, 102127, 102127, Elsevier BV, 2021年09月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Airport quarantine is required to reduce the risk of entry of travelers infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, it is challenging for both high accuracy and rapid turn-around time to coexist in testing; polymerase chain reaction (PCR) is time-consuming with high accuracy, while antigen testing is rapid with less accuracy. However, there are few data on the concordance between PCR and antigen testing. METHODS: Arrivals at three international airports in Japan between July 29 and September 30, 2020 were tested for SARS-CoV-2 using self-collected saliva by a screening strategy with initial chemiluminescent enzyme immunoassay (CLEIA) followed by confirmatory nucleic acid amplification tests (NAAT) only for intermediate range antigen concentrations. RESULTS: Among the 95,457 persons entering Japan during the period, 88,924 (93.2%) were tested by CLEIA, and 0.29% (254/88,924) were found to be SARS-CoV-2 antigen positive (≥4.0 pg/mL). NAAT was required for confirmatory testing in 0.58% (513/88,924) with intermediate antigen concentrations (0.67-4.0 pg/mL) whereby the virus was detected in 6.6% (34/513). This two-step strategy reduced the utilization of NAAT to one out of every 173 test subjects. The estimated performance of this strategy did not show significant increase in false negatives as compared to performing NAAT in all subjects. CONCLUSIONS: Point of care testing by quantitative CLEIA using self-collected saliva is less labor-intensive and yields results rapidly, thus suitable as an initial screening test. Reserving NAAT for CLEIA indeterminate cases may prevent compromising accuracy while significantly improving the logistics of administering mass-screening at large venues.
• Relevance of early-diastolic mitral regurgitation in dilated heart
  Asuka Tanemura; Michito Murayama; Hiroyuki Iwano; Yasuyuki Chiba; Mutsumi Nishida; Takanori Teshima; Toshihisa Anzai
  Journal of Echocardiography, 21, 1, 50, 52, Springer Science and Business Media LLC, 2021年08月30日, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Performance of Qualitative and Quantitative Antigen Tests for SARS-CoV-2 Using Saliva
  Isao Yokota; Takayo Sakurazawa; Junichi Sugita; Sumio Iwasaki; Keiko Yasuda; Naoki Yamashita; Shinichi Fujisawa; Mutsumi Nishida; Satoshi Konno; Takanori Teshima
  Infectious Disease Reports, 13, 3, 742, 747, MDPI AG, 2021年08月24日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, The rapid detection of SARS-CoV-2 is critical for the prevention of disease outbreaks. Antigen tests such as immunochromatographic assay (ICA) and chemiluminescent enzyme immunoassay (CLEIA) can yield results more quickly than PCR. We evaluated the performance of ICA and CLEIA using 34 frozen PCR-positive (17 saliva samples and 17 nasopharyngeal swabs [NPS]) and 309 PCR-negative samples. ICA detected SARS-CoV-2 in only 14 (41%) samples, with positivity rates of 24% in saliva and 59% in NPS. Notably, ICA detected SARS-CoV-2 in 5 of 6 samples collected within 4 days after symptom onset. CLEIA detected SARS-CoV-2 in 31 (91%) samples, with a positivity of 82% in saliva and 100% in NPS. These results suggest that the use of ICA should be limited to an earlier time after symptom onset and CLEIA is more sensitive and can be used in situations where quick results are required.
• The Pathophysiology and Treatment of Graft-Versus-Host Disease: Lessons Learnt From Animal Models
  Takanori Teshima; Geoffrey R. Hill
  Frontiers in Immunology, 12, 715424, 715424, Frontiers Media SA, 2021年08月19日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Allogeneic hematopoietic cell transplantation (HCT) is a curative treatment for hematologic malignancies, bone marrow failure syndromes, and inherited immunodeficiencies and metabolic diseases. Graft-versus-host disease (GVHD) is the major life-threatening complication after allogeneic HCT. New insights into the pathophysiology of GVHD garnered from our understanding of the immunological pathways within animal models have been pivotal in driving new therapeutic paradigms in the clinic. Successful clinical translations include histocompatibility matching, GVHD prophylaxis using cyclosporine and methotrexate, posttransplant cyclophosphamide, and the use of broad kinase inhibitors that inhibit cytokine signaling (e.g. ruxolitinib). New approaches focus on naïve T cell depletion, targeted cytokine modulation and the inhibition of co-stimulation. This review highlights the use of animal transplantation models to guide new therapeutic principles.
• Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease Using Commercial Mesenchymal Stem Cell Products
  Makoto Murata; Takanori Teshima
  Frontiers in Immunology, 12, 724380, 724380, Frontiers Media SA, 2021年08月19日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Acute graft-versus-host disease (GVHD) is a life-threatening complication that can develop after allogeneic hematopoietic stem cell transplantation. In particular, the prognosis of patients with steroid-refractory acute GVHD is extremely poor. Ryoncil™ (remestemcel-L), a human bone marrow-derived mesenchymal stem cell (MSC) product, failed to show superiority over placebo in patients with steroid-refractory acute GVHD, but it was approved for use in pediatric patients in Canada and New Zealand based on the results of a subgroup analysis. Temcell^®, an equivalent manufactured MSC product to remestemcel-L, was approved in Japan based on small single-arm studies by using a regulation for regenerative medicine in 2016. The efficacy of Temcell was evaluated in 381 consecutive patients treated with Temcell during the initial 3 years after its approval. Interestingly, its real-world efficacy was found to be equivalent to that observed in a prospective study of remestemcel-L with strict eligibility criteria. In this article, the potential of MSC therapy in the treatment of acute GVHD is discussed. A meticulous comparison of studies of remestemcel-L and Temcell, remestemcel-L/Temcell and ruxolitinib, and remestemcel-L/Temcell and thymoglobulin showed that the precise position of remestemcel-L/Temcell therapy in the treatment of acute GVHD remains to be determined.
• Graft-versus-host disease: a disorder of tissue regeneration and repair
  Ronjon Chakraverty; Takanori Teshima
  Blood, 138, 18, 1657, 1665, American Society of Hematology, 2021年08月09日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Regenerative failure at barrier surfaces and maladaptive repair leading to fibrosis are hallmarks of graft-versus-host disease (GVHD). Although immunosuppressive treatment can control inflammation, impaired tissue homeostasis leads to prolonged organ damage and impaired quality of life. In this Spotlight article, we review recent research that addresses the critical failures in tissue regeneration and repair that underpin treatment-resistant GVHD. We highlight current interventions designed to overcome these defects and provide our assessment of the future therapeutic landscape.
• Patients with marginal zone dural lymphoma successfully treated with rituximab and bendamustine: A report of two cases
  Yutaka Tsutsumi; Shinichi Ito; Jun Nagai; Takahiro Tateno; Takanori Teshima
  Molecular and Clinical Oncology, 15, 4, 208, 208, Spandidos Publications, 2021年08月09日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Primary dural low-grade marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) is a rare disease whose main treatment has been local surgery or radiotherapy. Until now, there have been no cases of dural MALT lymphoma treatment of a patient with several relapses or systemic disease. The present study included two patients with dural MALT lymphoma who had several relapses or systemic disease. Since local therapy was not enough to control the disease for these patients, they were treated with systemic chemotherapy. The patients were administered rituximab (375 mg/m2) and two days of bendamustine (90 mg/m2). Both patients recovered from their clinical symptoms immediately, and their tumors were reduced. During and after rituximab and bendamustine therapy, no central nervous system (CNS) metastasis or cerebrospinal fluid invasion of MALT were observed. The current approach using rituximab and bendamustine treatment was effective against dural MALT lymphoma and may prevent its invasion of the CNS.
• Mass Screening of Asymptomatic Persons for Severe Acute Respiratory Syndrome Coronavirus 2 Using Saliva
  Isao Yokota; Peter Y Shane; Kazufumi Okada; Yoko Unoki; Yichi Yang; Tasuku Inao; Kentaro Sakamaki; Sumio Iwasaki; Kasumi Hayasaka; Junichi Sugita; Mutsumi Nishida; Shinichi Fujisawa; Takanori Teshima
  Clinical Infectious Diseases, 73, 3, e559, e565, Oxford University Press (OUP), 2021年08月02日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）,
  
  
  Coronavirus disease 2019 (COVID-19) has rapidly evolved to become a global pandemic, largely owing to the transmission of its causative virus through asymptomatic carriers. Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in asymptomatic people is an urgent priority for the prevention and containment of disease outbreaks in communities. However, few data are available in asymptomatic persons regarding the accuracy of polymerase chain reaction testing. In addition, although self-collected saliva samples have significant logistical advantages in mass screening, their utility as an alternative specimen in asymptomatic persons is yet to be determined.
  
  
  
  
  
  We conducted a mass screening study to compare the utility of nucleic acid amplification, such as reverse-transcription polymerase chain reaction testing, using nasopharyngeal swab (NPS) and saliva samples from each individual in 2 cohorts of asymptomatic persons: the contact-tracing cohort and the airport quarantine cohort.
  
  
  
  
  
  In this mass screening study including 1924 individuals, the sensitivities of nucleic acid amplification testing with NPS and saliva specimens were 86% (90% credible interval, 77%–93%) and 92% (83%–97%), respectively, with specificities &gt;99.9%. The true concordance probability between the NPS and saliva tests was estimated at 0.998 (90% credible interval, .996–.999) given the recent airport prevalence of 0.3%. In individuals testing positive, viral load was highly correlated between NPS and saliva specimens.
  
  
  
  
  
  Both NPS and saliva specimens had high sensitivity and specificity. Self-collected saliva specimens are valuable for detecting SARS-CoV-2 in mass screening of asymptomatic persons.
  
  
  
• Clinical outcomes of intervention for carbapenems and anti-methicillin-resistant Staphylococcus aureus antibiotics by an antimicrobial stewardship team
  Keisuke Kagami; Nobuhisa Ishiguro; Takehiro Yamada; Yusuke Niinuma; Sumio Iwasaki; Keisuke Taki; Tatsuya Fukumoto; Kasumi Hayasaka; Mutsumi Nishida; Junichi Sugita; Takanori Teshima; Mitsuru Sugawara; Yoh Takekuma
  American Journal of Infection Control, 49, 12, 1493, 1498, Elsevier BV, 2021年08月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: There are no reports on the effects of interventions, such as discontinuation and change and/or de-escalation of carbapenems and anti-methicillin-resistant Staphylococcus aureus (MRSA) antibiotics by an antimicrobial stewardship team focusing on detailed patient outcomes. This study aimed to evaluate these effects. METHODS: This retrospective cohort study was conducted at a tertiary care hospital from December 2018 to November 2019. RESULTS: Favorable clinical responses were obtained in 165 of 184 cases (89.7%) in the intervention-accepted group, higher than those in the not accepted group (14/19 cases, 73.7%; P = .056). All-cause 30 day mortality was lower in the accepted group than in the not accepted group (1.1% and 10.5%, respectively; P = .045). The microbiological outcomes were similar between the two groups. Duration of carbapenem and anti-MRSA antibiotic use in the accepted group was significantly lower than that in the not accepted group (median [interquartile range]: 8 days [5-13] versus 14 days [8-15], respectively, P = .026 for carbapenem; 10 days [5.3-15] vs 15.5 days [13.8-45.3], respectively, P = .014 for anti-MRSA antibiotic). CONCLUSIONS: This is the first study to investigate the effects of interventions such as discontinuation and change and/ or de-escalation of antibiotics on detailed outcomes. Our intervention could reduce the duration of carbapenem and anti-MRSA antibiotic use without worsening clinical and microbiological outcomes.
• A novel strategy for SARS-CoV-2 mass screening with quantitative antigen testing of saliva: a diagnostic accuracy study
  Isao Yokota; Peter Y Shane; Kazufumi Okada; Yoko Unoki; Yichi Yang; Sumio Iwasaki; Shinichi Fujisawa; Mutsumi Nishida; Takanori Teshima
  The Lancet Microbe, 2, 8, e397, e404, Elsevier BV, 2021年08月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Background: Quantitative RT-PCR (RT-qPCR) of nasopharyngeal swab (NPS) samples for SARS-CoV-2 detection requires medical personnel and is time consuming, and thus is poorly suited to mass screening. In June, 2020, a chemiluminescent enzyme immunoassay (CLEIA; Lumipulse G SARS-CoV-2 Ag kit, Fujirebio, Tokyo, Japan) was developed that can detect SARS-CoV-2 nucleoproteins in NPS or saliva samples within 35 min. In this study, we assessed the utility of CLEIA in mass SARS-CoV-2 screening. Methods: We did a diagnostic accuracy study to develop a mass-screening strategy for salivary detection of SARS-CoV-2 by CLEIA, enrolling hospitalised patients with clinically confirmed COVID-19, close contacts identified at community health centres, and asymptomatic international arrivals at two airports, all based in Japan. All test participants were enrolled consecutively. We assessed the diagnostic accuracy of CLEIA compared with RT-qPCR, estimated according to concordance (Kendall's coefficient of concordance, W), and sensitivity (probability of CLEIA positivity given RT-qPCR positivity) and specificity (probability of CLEIA negativity given RT-qPCR negativity) for different antigen concentration cutoffs (0·19 pg/mL, 0·67 pg/mL, and 4·00 pg/mL; with samples considered positive if the antigen concentration was equal to or more than the cutoff and negative if it was less than the cutoff). We also assessed a two-step testing strategy post hoc with CLEIA as an initial test, using separate antigen cutoff values for test negativity and positivity from the predefined cutoff values. The proportion of intermediate results requiring secondary RT-qPCR was then quantified assuming prevalence values of RT-qPCR positivity in the overall tested population of 10%, 30%, and 50%. Findings: Self-collected saliva was obtained from 2056 participants between June 12 and Aug 6, 2020. Results of CLEIA and RT-qPCR were concordant in 2020 (98·2%) samples (Kendall's W=0·99). Test sensitivity was 85·4% (76 of 89 positive samples; 90% credible interval [CrI] 78·0-90·3) at the cutoff of 0·19 pg/mL; 76·4% (68 of 89; 68·2-82·8) at the cutoff of 0·67 pg/mL; and 52·8% (47 of 89; 44·1-61·3) at the cutoff of 4·0 pg/mL. Test specificity was 91·3% (1796 of 1967 negative samples; 90% CrI 90·2-92·3) at the cutoff of 0·19 pg/mL, 99·2% (1952 of 1967; 98·8-99·5) at the cutoff of 0·67 pg/mL, and 100·0% (1967 of 1967; 99·8-100·0) at the cutoff of 4·00 pg/mL. Using a two-step testing strategy with a CLEIA negativity cutoff of 0·19 pg/mL (to maximise sensitivity) and a CLEIA positivity cutoff of 4·00 pg/mL (to maximise specificity), the proportions of indeterminate results (ie, samples requiring secondary RT-qPCR) would be approximately 11% assuming a prevalence of RT-qPCR positivity of 10%, 16% assuming a prevalence of RT-qPCR positivity of 30%, and 21% assuming a prevalence of RT-qPCR positivity of 50%. Interpretation: CLEIA testing of self-collected saliva is simple and provides results quickly, and is thus suitable for mass testing. To improve accuracy, we propose a two-step screening strategy with an initial CLEIA test followed by confirmatory RT-qPCR for intermediate concentrations, varying positive and negative thresholds depending on local prevalence. Implementation of this strategy has expedited sample processing at Japanese airports since July, 2020, and might apply to other large-scale mass screening initiatives. Funding: Ministry of Health, Labour and Welfare, Japan.
• Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
  Robert Zeiser; Nicola Polverelli; Ron Ram; Shahrukh K. Hashmi; Ronjon Chakraverty; Jan Moritz Middeke; Maurizio Musso; Sebastian Giebel; Ant Uzay; Peter Langmuir; Norbert Hollaender; Maanasa Gowda; Tommaso Stefanelli; Stephanie J. Lee; Takanori Teshima; Franco Locatelli
  New England Journal of Medicine, 385, 3, 228, 238, Massachusetts Medical Society, 2021年07月15日, ［査読有り］
  研究論文（学術雑誌）
• A case of immune checkpoint inhibitor-associated gastroenteritis detected by ultrasonography.
  Satomi Omotehara; Mutsumi Nishida; Kana Yamanashi; Kensuke Sakurai; Takehiko Katsurada; Yoshito Komatsu; Ai Shimizu; Hitoshi Shibuya; Naofumi Shinagawa; Junichi Sugita; Takanori Teshima
  Journal of clinical ultrasound : JCU, 49, 6, 605, 609, 2021年07月, ［国際誌］
  英語, While immune checkpoint inhibitors (ICIs) have antitumor effects, they also have characteristic side effects, including colitis. However, gastritis has rarely been reported. We report a case of a patient with lung adenocarcinoma who presented with epigastric pain and diarrhea following pembrolizumab administration. Sonography of the abdomen demonstrated diffuse, although mild, gastric wall thickening (mainly in the submucosa), as well as a slight decrease in echogenicity throughout the gastric wall. While the mucosal surface was relatively smooth, color Doppler examination showed increased vascularity. Esophagogastroduodenoscopy and pathological examination confirmed the diagnosis of ICI-related gastroenteritis.
• Effect of varying storage conditions on diagnostic test outcomes of SARS-CoV-2
  Satoshi Oguri; Shinichi Fujisawa; Keisuke Kamada; Sho Nakakubo; Yu Yamashita; Junichi Nakamura; Hiroshi Horii; Kazuki Sato; Mutsumi Nishida; Takanori Teshima; Yoichi Ohiro; Ayato Takada; Satoshi Konno
  Journal of Infection, 83, 1, 119, 145, Elsevier BV, 2021年07月, ［査読有り］
  研究論文（学術雑誌）
• Refined ultrasonographic criteria for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation
  Mutsumi Nishida; Junichi Sugita; Shuichiro Takahashi; Takahito Iwai; Megumi Sato; Yusuke Kudo; Satomi Omotehara; Tatsunori Horie; Ryosuke Sakano; Hitoshi Shibuya; Isao Yokota; Akihiro Iguchi; Takanori Teshima
  International Journal of Hematology, 114, 1, 94, 101, Springer Science and Business Media LLC, 2021年07月, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, Hepatic sinusoidal obstruction syndrome (SOS)/veno-occlusive disease is a life-threatening complication after hematopoietic stem cell transplantation (HSCT). We previously reported the efficacy of the Hokkaido Ultrasonography (US)-based scoring system (HokUS-10) for US findings. To establish easier-to-use criteria, we retrospectively evaluated US findings from 441 patients, including 30 patients with SOS using the HokUS-10 scoring system. Using logistic regression analysis, we established the novel diagnostic criteria HokUS-6. In the presence of ascites, US diagnosis was made in the presence of two of the following 6 parameters: moderate amount of ascites, the appearance of a paraumbilical vein blood flow signal, gallbladder wall thickening, portal vein dilatation, portal vein velocity decrease, and hepatic artery resistive index increase. The AUC, sensitivity, and specificity of HokUS-6 were 0.974 (95% confidence interval 0.962-0.990), 95.2%, and 96.9%, respectively. The scores were significantly higher in patients with severe SOS than in those with non-severe SOS (p = 0.013). Furthermore, the scores before HSCT were significantly higher in patients who developed SOS than in controls (p = 0.001). The HokUS-6 is an easy and useful way to diagnose and identify the risk of SOS.
• Platelet decrease and efficacy of platelet‐rich plasma return following peripheral blood stem cell apheresis
  Takahiro Shima; Teppei Sakoda; Tomoko Henzan; Yuya Kunisaki; Takeshi Sugio; Kenjiro Kamezaki; Hiromi Iwasaki; Takanori Teshima; Takahiro Maeda; Koichi Akashi; Toshihiro Miyamoto
  Journal of Clinical Apheresis, 36, 5, 687, 696, Wiley, 2021年06月16日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Peripheral blood stem cell (PBSC) transplantation is a key treatment option for hematological diseases and is widely performed in clinical practice. Platelet loss is one of the major complications of PBSC apheresis, and platelet-rich plasma (PRP) return is considered in case of platelet decrease following apheresis; however, little is known about the frequency and severity of platelet loss and the efficacy of PRP return postapheresis. METHODS: We assessed changes in platelet counts following PBSC-related apheresis in 270 allogeneic (allo)- and 105 autologous (auto)-PBSC settings. We also evaluated the efficacy of PRP transfusion on platelet recovery postapheresis. RESULTS: In both allo- and auto-PBSC settings, the preapheresis platelet count (range, 84-385 and 33-558 × 109 /L, respectively) decreased postapheresis (range, 57-292 and 20-429 × 109 /L, respectively), whereas severe platelet decrease (<50 × 109 /L) was only observed in auto-PBSC patients (n = 9). We confirmed that platelet count before apheresis was a risk factor for severe platelet decrease (<50 × 109 /L) following auto-PBSC apheresis (odds ratio 0.749, P < .049). PRP return postapheresis facilitated platelet recovery in more than 80% of cases in both allo and auto settings. CONCLUSION: Lower platelet count preapheresis is a useful predictor of severe platelet decrease following auto-PBSC apheresis and PRP return is an effective process to facilitate platelet recovery postapheresis.
• Cost Effectiveness Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma in Japan
  Shiho Wakase; Takanori Teshima; Jie Zhang; Qiufei Ma; Taizo Fujita; Hongbo Yang; Xinglei Chai; Cynthia Z. Qi; Qing Liu; Eric Q. Wu; Ataru Igarashi
  Transplantation and Cellular Therapy, 27, 6, 506.e1, 506.e10, Elsevier BV, 2021年06月, ［査読有り］
  英語, 研究論文（学術雑誌）, There are limited treatment options and substantial unmet needs for adult patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL) in Japan. In 2019, tisagenlecleucel, a CD19-directed chimeric antigen receptor T cell therapy, was approved for r/r DLBCL in Japan. The efficacy and safety of tisagenlecleucel were demonstrated in the pivotal phase II single-arm JULIET trial. The objective of the current study was to assess the cost-effectiveness of tisagenlecleucel treatment strategy versus current standard of care (salvage chemotherapy treatment strategy) for the treatment of patients with r/r DLBCL in Japan. A three-state partitioned survival model was constructed from a Japanese public healthcare payer's perspective, with the following three health states: progression-free survival, progressive/relapsed disease, and death. Because the tisagenlecleucel arm included patients who did or did not receive the infusion, a decision-tree structure was used to partition patients based on their infusion status. Treatment efficacy and costs were based on tisagenlecleucel-infused patients for those who received the infusion; for non-infused patients, they were based on standard salvage chemotherapy. The efficacy inputs for tisagenlecleucel-infused patients and salvage chemotherapy were based on observed data in the JULIET trial and the international SCHOLAR-1 meta-analysis, respectively, before year 3. Afterward, all patients were assumed to have no further progression and to incur the mortality risk of long-term DLBCL survivors. The base case analysis explored a lifetime horizon (44 years), with costs and effectiveness discounted 2.0% annually, and it used a monthly model cycle. Direct costs were considered in the base case, composed of pretreatment costs, treatment costs, adverse events management costs, follow-up costs before progression, subsequent SCT costs, post-progression costs, and terminal care costs. Total incremental costs, life years (LYs), and quality-adjusted life years (QALYs) were compared for tisagenlecleucel versus salvage chemotherapy. The incremental cost-effectiveness ratio (ICER) was estimated as the costs per QALY gained, and a threshold of \7.5 million was used to assess whether tisagenlecleucel is cost effective. Deterministic and probabilistic sensitivity analyses were performed. The total LYs (discounted) for tisagenlecleucel and salvage chemotherapy were 7.24 and 4.35 years, respectively; the corresponding QALYs were 5.42 and 2.57 years, respectively. The discounted incremental LYs and QALYs comparing tisagenlecleucel to salvage chemotherapy were estimated as 2.89 and 2.85 years, respectively. Over a lifetime horizon, the model estimated that tisagenlecleucel had a total incremental cost of \15,590,335 (discounted) versus salvage chemotherapy. Tisagenlecleucel was associated with an ICER of \5,476,496 per QALY gained compared to salvage chemotherapy. Extensive sensitivity analyses supported the base-case findings. Tisagenlecleucel is a cost-effective treatment strategy for r/r DLBCL compared to salvage chemotherapy treatment strategy from a Japanese public healthcare payer's perspective.
• High lymphocyte counts before antithymocyte globulin administration predict acute graft-versus-host disease
  Souichi Shiratori; Hiroyuki Ohigashi; Takahide Ara; Atsushi Yasumoto; Hideki Goto; Masao Nakagawa; Junichi Sugita; Masahiro Onozawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
  Annals of Hematology, 100, 5, 1321, 1328, Springer Science and Business Media LLC, 2021年05月, ［査読有り］
  研究論文（学術雑誌）
• Learning to mellow out GVHD.
  Takanori Teshima
  Blood, 137, 9, 1142, 1143, 2021年03月04日, ［国際誌］
  英語, 研究論文（学術雑誌）
• Extramedullary hematopoiesis of the cranial dura.
  Keito Suto; Junichi Sugita; Daigo Hashimoto; Hiroyuki Kameda; Tomoko Mitsuhashi; Takanori Teshima
  International journal of hematology, 113, 3, 315, 317, 2021年03月, ［国内誌］
  英語
• Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan
  Shiho Wakase; Takanori Teshima; Jie Zhang; Qiufei Ma; Yoko Watanabe; Hongbo Yang; Cynthia Z. Qi; Xinglei Chai; Yanwen Xie; Eric Q. Wu; Ataru Igarashi
  Transplantation and Cellular Therapy, 27, 3, 241.e1, 241.e11, Elsevier BV, 2021年03月, ［査読有り］
  英語, 研究論文（学術雑誌）, Until recently, treatment options were relatively limited for children and young adults with relapsed or refractory (r/r) acute lymphoblastic leukemia (ALL). Tisagenlecleucel is a chimeric antigen receptor T cell (CAR-T) immunotherapy with promising efficacy and manageable safety that was approved in Japan in 2019 for the treatment of CD19-positive r/r B cell ALL (B-ALL). However, there is no publication assessing the cost-effectiveness of CAR-T in Japan. The objective of this study was to assess the cost-effectiveness of a tisagenlecleucel treatment strategy compared to a blinatumomab treatment strategy and a clofarabine combination treatment strategy (i.e., clofarabine + cyclophosphamide + etoposide) in Japan for pediatric and young adult patients up to 25 years of age with r/r B-ALL. A partitioned survival model with a lifetime horizon and monthly cycle was constructed from a Japanese public healthcare payer's perspective. Patients were distributed across the following partitioned health states: event-free survival (EFS), progressive disease, and death, which were informed by the EFS and overall survival (OS) data of respective clinical trials before year 5. For the tisagenlecleucel arm, a decision-tree structure was used to partition patients based on the infusion status; those who discontinued prior to receiving infusion were assigned efficacy and cost inputs of blinatumomab and those who received infusion were assigned efficacy and costs inputs based on tisagenlecleucel-infused patients. As trial data for blinatumomab and clofarabine ended before year 5, matching-adjusted indirect comparisons were used to extrapolate OS between the end of trial observation and up to year 5. All surviving patients followed the mortality risk of long-term ALL survivors without additional risk of disease relapse after year 5, regardless of initial treatment strategies. The model accounted for pretreatment costs, treatment costs, adverse event costs, follow-up costs, subsequent allogeneic hematopoietic stem cell transplantation costs, and terminal care costs. Incremental cost-effectiveness ratios (ICERs) per life-years (LYs) gained and ICERs per quality-adjusted life-years (QALYs) gained were evaluated using a 2% discount rate, and a threshold of \7.5 million was used to assess cost-effectiveness. Deterministic and probabilistic sensitivity analyses were performed. The total LYs (discounted) for tisagenlecleucel, blinatumomab, and clofarabine combination treatment strategies were 13.3, 4.0, and 2.7 years, respectively; the corresponding QALYs were 11.6, 3.1, and 2.1 years, respectively. The ICERs per QALY gained for tisagenlecleucel were \2,035,071 versus blinatumomab and \2,644,702 versus clofarabine combination therapy. Extensive sensitivity analyses supported the findings. Tisagenlecleucel is a cost-effective treatment strategy for pediatric and young adult patients with r/r B-ALL from a Japanese public healthcare payer's perspective.
• A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin
  Tetsuya Nishida; Takeshi Kobayashi; Masashi Sawa; Shinichi Masuda; Yasuhiko Shibasaki; Tatsunori Goto; Noriko Fukuhara; Nobuharu Fujii; Kazuhiro Ikegame; Junichi Sugita; Takashi Ikeda; Yachiyo Kuwatsuka; Ritsuro Suzuki; Yuho Najima; Noriko Doki; Tomonori Kato; Yuichiro Inagaki; Yoshikazu Utsu; Nobuyuki Aotsuka; Masayoshi Masuko; Seitaro Terakura; Yasushi Onishi; Yoshinobu Maeda; Masaya Okada; Takanori Teshima; Makoto Murata
  Annals of Hematology, 100, 3, 743, 752, Springer Science and Business Media LLC, 2021年03月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, To overcome the delayed or failed engraftment after unrelated cord blood transplantation (CBT), we conducted a multicenter phase II study of intrabone single-unit CBT without antithymocyte globulin (ATG) for adult patients with hematological malignancies (UMIN-CTR, UMIN000020997). Sixty-four patients received an intrabone injection of unwashed (n = 61) or washed (n = 3) cord blood after local anesthesia. All injection-related adverse events were mild and resolved spontaneously. Sixty-two patients were evaluable for the efficacy of intrabone CBT of serological HLA-A, -B, and -DR ≥ 4/6 matched cord blood with a median number of 2.57 × 107/kg cryopreserved total nucleated cells. The probability of survival with neutrophil engraftment on day 28 was 77.4% (95% confidence interval, 67.0-85.8%), which exceeded the threshold value. The cumulative incidences of neutrophils ≥ 0.5 × 109/L on day 60 was 80.6% (68.2-88.6%), with a median time to recovery of 21 days after transplantation. The cumulative incidences of platelets ≥ 20 × 109/L and platelets ≥ 50 × 109/L on day 100 were 75.8% (62.6-84.9%) and 72.6% (59.4-82.1%), respectively, with median time to platelets ≥ 20 × 109/L and platelets ≥ 50 × 109/L of 38 and 45 days after transplantation, respectively. The cumulative incidences of grade II-IV and III-IV acute graft-versus-host disease were 29.0% and 6.5%, respectively. All responded to steroid therapy, and secondary treatments were not required. The present study suggests the efficacy of intrabone single-unit CBT without ATG in terms of early engraftment and controllable acute graft-versus-host disease.
• Efficacy and safety of colistin for the treatment of infections caused by multidrug-resistant gram-negative bacilli
  Keisuke Kagami; Nobuhisa Ishiguro; Takehiro Yamada; Yusuke Niinuma; Sumio Iwasaki; Keisuke Taki; Tatsuya Fukumoto; Kasumi Hayasaka; Reiko Oyamada; Tsubasa Watanabe; Mutsumi Nishida; Junichi Sugita; Takanori Teshima; Mitsuru Sugawara; Yoh Takekuma
  Journal of Infection and Chemotherapy, 27, 3, 473, 479, Elsevier BV, 2021年03月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: The efficacy and safety of colistin for the treatment of infections caused by multidrug-resistant gram-negative bacilli have been poorly investigated in Japanese patients. This study was performed to investigate the efficacy and safety of colistin in Japanese patients by analyzing a considerable number of cases. Furthermore, we evaluated the relationship between the plasma concentration and efficacy and safety of colistin in some cases. METHODS: A retrospective cohort study was conducted at Hokkaido University Hospital, analyzing patients treated with colistin (colistimethate sodium) during the period from January 2007 to December 2019. RESULTS: Overall, 42 cases were enrolled. Favorable clinical response was observed in 25 cases (59.5%), with an all-cause 30-day mortality of 33.3% (14/42 cases). Microbiological eradication was achieved in 18 cases (42.9%). Nephrotoxicity was observed in 20 cases (47.6%) and was mild and reversible in all cases. Plasma trough concentrations of colistin determined in nine patients correlated with changes in serum creatinine concentration (⊿) and creatinine clearance (%). The cutoff value of colistin trough concentration for nephrotoxicity was 2.02 μg/mL. CONCLUSION: Our results showed approximately 60% clinical efficacy of colistin therapy against infections caused by multidrug-resistant gram-negative bacilli in the patients. Further studies with larger populations are needed to elucidate the efficacy and safety of colistin in Japanese patients.
• Reduced dose of posttransplant cyclophosphamide in HLA-haploidentical peripheral blood stem cell transplantation
  Junichi Sugita; Tomohiko Kamimura; Takayuki Ishikawa; Shuichi Ota; Tetsuya Eto; Takashi Kuroha; Yasuhiko Miyazaki; Hiroaki Kumagai; Keitaro Matsuo; Koichi Akashi; Shuichi Taniguchi; Mine Harada; Takanori Teshima
  Bone Marrow Transplantation, 56, 3, 596, 604, Springer Science and Business Media LLC, 2021年03月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Posttransplant cyclophosphamide (PTCy:100 mg/kg) has been increasingly used in allogeneic hematopoietic stem cell transplantation, however, few studies compared different doses of PTCy. We conducted two consecutive prospective multicenter phase II studies to evaluate the safety and efficacy of 80 mg/kg of PTCy in 137 patients who underwent HLA-haploidentical peripheral blood stem cell transplantation (haploPBSCT) following reduced-intensity conditioning (RIC). GVHD prophylaxis consisted of PTCy at a dose of 40 mg/kg/day on days 3 and 4, tacrolimus, and mycophenolate mofetil. Neutrophil engraftment was achieved in 97% and 96% in the first and second studies, respectively. The incidences of grades II-IV acute GVHD, III-IV acute GVHD, all grade chronic GVHD, and moderate to severe chronic GVHD at 2 years were 26%, 5%, 35%, and 18% in the first study, and 23%, 1%, 28%, and 15% in the second study, respectively. Overall survival (OS), disease-free survival (DFS), and non-relapse mortality (NRM) at 2 years were 51%, 42%, and 18% in the first study, and 58%, 48%, and 16% in the second study, respectively. The rates of off-immunosuppressants in patients who survived without relapse at 2 years were 83 and 76%. Our results suggest that 80 mg/kg of PTCy is a valid option in haploPBSCT following RIC.
• Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia
  Seitaro Terakura; Yachiyo Kuwatsuka; Junichi Sugita; Satoshi Takahashi; Yukiyasu Ozawa; Kazutaka Ozeki; Satoshi Yoshioka; Hirohisa Nakamae; Toshiro Kawakita; Masashi Sawa; Satoshi Morishige; Yuho Najima; Yuna Katsuoka; Emiko Sakaida; Yasuji Kouzai; Takafumi Kimura; Tatsuo Ichinohe; Takahiro Fukuda; Yoshiko Atsuta; Makoto Murata; Takanori Teshima
  International Journal of Hematology, 113, 6, 840, 850, Springer Science and Business Media LLC, 2021年02月21日, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, To investigate the association between methotrexate (MTX) dosage and engraftment, graft-versus-host disease (GVHD) incidence, and survival in umbilical cord blood transplantation (UCBT), we compared transplant outcomes after UCBT with various GVHD prophylaxis regimens, using registry data with additional data collection. Patients transplanted for acute myeloid leukemia with a calcineurin inhibitor (CNI) and either MTX or mycophenolate mofetil (MMF) combination were selected. In total, 888 single-unit UCBTs (MTX15-10-10, 415; MTX10-7-7, 294; MTX5-5-5, 71; MMF, 108) were included. In multivariate analyses with MTX15-10-10 as the reference, the likelihood of neutrophil and platelet engraftment was significantly worse in the MTX10-7-7 group, and similarly better in MMF group compared with MTX15-10-10. All variables including CyA vs Tac and 4-group GVHD prophylaxis became significant for the risk of grade II-IV acute GVHD in the final multivariate model. We observed significant additional effects of combined MTX dose in the Tac group, which were larger with lower MTX dose and MMF. No significant difference was observed in survival risk among GVHD prophylaxis groups. Despite the potential background differences in the combined CNI and conditioning regimen, we conclude that the recommended GVHD prophylaxis is a combination of CyA plus MTX15-10-10 or Tac plus MMF.
• Factors for the Variability of Three Acceptable Maximal Expiratory Flow–Volume Curves in Chronic Obstructive Pulmonary Disease
  Masafumi Yamamoto; Satoshi Konno; Hironi Makita; Katsuaki Nitta; Kaoruko Shimizu; Masaru Suzuki; Mutsumi Nishida; Junichi Sugita; Takanori Teshima; Masaharu Nishimura
  International Journal of Chronic Obstructive Pulmonary Disease, Volume 16, 415, 422, Informa UK Limited, 2021年02月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Background: Generally, the maximal expiratory flow-volume (MEFV) curve must be measured for the diagnosis and staging of chronic obstructive pulmonary disease (COPD). As this test is effort dependent, international guidelines recommend that three acceptable trials are required for each test. However, no study has examined the magnitude and factors for the variability in parameters among three acceptable trials. Methods: We evaluated the intra-individual variations in several parameters among three acceptable MEFV curves obtained at one-time point in patients with COPD (n = 28, stage 1; n = 36, stage 2; n = 21, stages 3-4). Next, the factors for such variations were examined using forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC). Results: The averages of coefficient of variation (CV) for FEV1 and FVC were 2.0% (range: 1.0-3.0%) and 1.6% (0.9-2.2%), respectively. Both parameters were significantly better than peak expiratory flow rate, forced expiratory flow at 50% of expired FVC, and forced expiratory flow at 75% of expired FVC (CVs: 5.0-6.9%). A higher spirometric stage was significantly associated with higher CVs for FVC and FEV1, and older age was significantly correlated with a higher variation in FEV1 alone. Furthermore, a significantly inverse association was observed between emphysema severity, and the CVs for FEV1, but not that for FVC, regardless of spirometric stage. Conclusion: Both FVC and FEV1 are highly reproducible; nevertheless, older age, lower FEV1 at baseline, and non-emphysema phenotype are factors for a higher variability in FEV1 in patients with COPD.
• SARS-CoV-2 detection by fluorescence loop-mediated isothermal amplification with and without RNA extraction
  Keisuke Taki; Isao Yokota; Tatsuya Fukumoto; Sumio Iwasaki; Shinichi Fujisawa; Masayoshi Takahashi; Saeki Negishi; Kasumi Hayasaka; Kaori Sato; Satoshi Oguri; Mutsumi Nishida; Junichi Sugita; Satoshi Konno; Tomoya Saito; Takanori Teshima
  Journal of Infection and Chemotherapy, 27, 2, 410, 412, Elsevier BV, 2021年02月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Rapid and simple point-of-care detection of SARS-CoV-2 is an urgent need to prevent pandemic. Reverse transcription loop-mediated isothermal amplification (RT-LAMP) can detect SARS-CoV-2 more rapidly than RT-PCR. Saliva is non-invasive specimen suitable for mass-screening, but data comparing utility of nasopharyngeal swab (NPS) and saliva in RT-LAMP test are lacking and it remains unclear whether SARS-CoV-2 could be detected by direct processing of samples without the need for prior RNA extraction saliva. In this study, we compared utility of saliva and NPS samples for the detection of SARS-CoV-2 by a novel RT-fluorescence LAMP (RT-fLAMP). The sensitivity and specificity of the RT-fLAMP with RNA extraction were 97% and 100%, respectively, with equivalent utility of NPS and saliva. However, sensitivity was decreased to 71% and 47% in NPS and saliva samples without RNA extraction, respectively, suggesting that RNA extraction process may be critical for the virus detection by RT-fLAMP.
• Medical database analysis of japanese multiple myeloma patients with planned stem cell transplantation (MEDALIST) – a focus on healthcare resource utilization and cost
  Shinsuke Iida; Tadao Ishida; Katsuhisa Horimoto; Hirotaka Kazama; Hyunchung Kim; Bruce Crawford; Takanori Teshima
  International Journal of Hematology, 113, 2, 271, 278, Springer Science and Business Media LLC, 2021年02月, ［査読有り］
  研究論文（学術雑誌）
• Two cases of chronic obstructive pulmonary disease with undetectable diffusing capacity for carbon monoxide.
  Ayumi Ohara; Satoshi Konno; Kaoruko Shimizu; Masaru Suzuki; Masafumi Yamamoto; Asako Mitani; Mutsumi Nishida; Takanori Teshima; Masaharu Nishimura
  Respiratory investigation, 59, 1, 145, 148, 2021年01月, ［国際誌］
  英語, 研究論文（学術雑誌）, Pulmonary diffusing capacity for carbon monoxide (DLCO) is a valuable pulmonary function test to evaluate the gas exchange capacity of the lungs. Generally, DLCO values are significantly lower in patients with chronic obstructive pulmonary disease (COPD), particularly in those with a predominantly emphysema phenotype. However, it is extremely rare that DLCO values cannot be obtained for reasons other than technical errors. Herein, we report two patients with COPD in whom DLCO values were undetectable without prolonging the breath-holding time for the test. We discuss possible mechanisms for these peculiar findings.
• The Combined Usage of the Global Leadership Initiative on Malnutrition Criteria and Controlling Nutrition Status Score in Acute Care Hospitals
  Asako Mitani; Takahito Iwai; Toshiaki Shichinohe; Hiroshi Takeda; Satomi Kumagai; Mutsumi Nishida; Junichi Sugita; Takanori Teshima
  Annals of Nutrition and Metabolism, 77, 3, 178, 184, S. Karger AG, 2021年, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, <b><i>Introduction:</i></b> The Global Leadership Initiative on Malnutrition (GLIM) lacks reliable blood tests for evaluating the nutrition status. We retrospectively compared the GLIM criteria, Controlling Nutrition Status (CONUT) score, and Subjective Global Assessment (SGA) to establish effective malnutrition screening and provide appropriate nutritional interventions according to severity. <b><i>Methods:</i></b> We classified 177 patients into 3 malnutrition categories (normal/mild, moderate, and severe) according to the GLIM criteria, CONUT score, and SGA. We investigated the malnutrition prevalence, concordance of malnutrition severity, predictability of clinical outcome, concordance by etiology, and clinical outcome by inflammation. <b><i>Results:</i></b> The highest prevalence of malnutrition was found using the GLIM criteria (87.6%). Concordance of malnutrition severity was low between the GLIM criteria and CONUT score. Concordance by etiology was low in all groups but was the highest in the “acute disease” group. The area under the curve of clinical outcome and that of the “with inflammation group” were significantly higher when using the CONUT score versus using the other tools (0.679 and 0.683, respectively). <b><i>Conclusion:</i></b> The GLIM criteria have high sensitivity, while the CONUT score can effectively predict the clinical outcome of malnutrition. Their combined use can efficiently screen for malnutrition and patient severity in acute care hospitals.
• Reliability of an ultrasonographical scoring system for diagnosis of sinusoidal obstruction syndrome/veno-occlusive disease in patients with hematopoietic stem cell transplantation
  Takahito Iwai; Mutsumi Nishida; Junichi Sugita; Yusuke Kudo; Rika Takasugi; Isao Yokota; Ryo Takagi; Hitoshi Shibuya; Shuichiro Takahashi; Takanori Teshima
  Journal of Medical Ultrasonics, 48, 1, 45, 52, Springer Science and Business Media LLC, 2021年01月, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, PURPOSE: Sinusoidal obstruction syndrome (SOS)/hepatic veno-occlusive disease (VOD) is a fatal complication after hematopoietic stem cell transplantation. We previously reported the usefulness of an ultrasonographical (US) scoring system, the Hokkaido US-based scoring system consisting of ten parameters (HokUS-10): (1) hepatomegaly in the left lobe and (2) right lobe, (3) dilatation of the main portal vein (PV), (4) hepatofugal flow in the main PV, (5) decreased velocity of the PV, (6) dilatation of the para-umbilical vein (PUV), (7) appearance of blood flow signal in the PUV, (8) gallbladder (GB) wall thickening, (9) ascites, and (10) increased resistive index of the hepatic artery, for the diagnosis of SOS/VOD. However, the reliability of this system among operators remains elusive. Therefore, we prospectively evaluated the reliability of HokUS-10. METHODS: Twenty-four healthy volunteers and 40 patients with liver dysfunction were enrolled. Inter- and intra-operator reliabilities were analyzed using three sonographers. RESULTS: The median concordance rate of HokUS-10 among three sonographers and intra-operator in 24 volunteers was 92% (95% CI: 73-98%) and 98% (95% CI: 92-100%), respectively. In all 64 cases, in terms of the reliability between two sonographers for three representative US parameters (amount of ascites, GB wall thickening, and appearance of PUV blood flow signal), the median concordance rate was more than 98% (95% CI: 86-106%). CONCLUSION: The inter- and intra-reliabilities of HokUS-10 were excellent. Thus, US might be a reliable tool for SOS/VOD diagnosis.
• Older age is associated with sustained detection of SARS-CoV-2 in nasopharyngeal swab samples
  Takeshi Hattori; Masaru Amishima; Daisuke Morinaga; Keisuke Kamada; Sho Nakakubo; Yu Yamashita; Yasuo Shichinohe; Shinichi Fujisawa; Mutsumi Nishida; Yasuyuki Nasuhara; Takanori Teshima; Satoshi Konno
  Journal of Infection, 82, 1, 159, 198, Elsevier BV, 2021年01月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Low-dose anti-thymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation
  Souichi Shiratori; Junichi Sugita; Shuichi Ota; Senji Kasahara; Jun Ishikawa; Takayoshi Tachibana; Yoshiki Hayashi; Goichi Yoshimoto; Tetsuya Eto; Hiromi Iwasaki; Mine Harada; Keitaro Matsuo; Takanori Teshima
  Bone Marrow Transplantation, 56, 1, 129, 136, Springer Science and Business Media LLC, 2021年01月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Allogeneic peripheral blood stem cell transplantation (PBSCT) is associated with an increased risk of severe acute and chronic graft-versus-host disease (GVHD) compared to bone marrow transplantation. Anti-thymocyte globulin (ATG) can reduce severe acute and chronic GVHD in PBSCT; however, an optimal dose of ATG remains undefined. We conducted a multicenter phase II study to investigate safety and efficacy of low-dose ATG (a total of 2 mg/kg Thymoglobulin) in patients undergoing HLA-matched PBSCT after myeloablative conditioning. The primary endpoint was grades III-IV GVHD at 100 days. Seventy-seven patients were enrolled and 72 patients with a median age of 46.5 years were eligible for analysis. The primary endpoint, cumulative incidence of grades III-IV acute GVHD at 100 days was 1.4% (95% CI, 0.1-6.7%), which was greatly less than our pre-defined statistical threshold value (18.0%). The incidence of chronic GVHD at 1 year was also low (all-grade; 15.3%, moderate to severe; 5.6%). Non-relapse mortality, relapse, overall survival, disease-free survival, and GVHD-free, relapse-free survival at 1 year were 4.2%, 20.8%, 84.7%, 75.0%, and 69.4%, respectively. Low dose thymoglobulin is promising to reduce severe acute and chronic GVHD in HLA-matched PBSCT following myeloablative conditioning.
• Pharmacokinetics of mycophenolic acid after haplo-hematopoietic stem cell transplantation in Japanese recipients
  Kazuki Uchiyama; Yoshitaka Saito; Yoh Takekuma; Junichi Sugita; Takanori Teshima; Mitsuru Sugawara
  Journal of Oncology Pharmacy Practice, 28, 1, 107815522098081, 107815522098081, SAGE Publications, 2020年12月22日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Mycophenolate mofetil (MMF), a mycophenolic acid (MPA) prodrug, is used to prevent graft-versus-host disease (GVHD) in hematopoietic stem cell transplantation (HSCT). Although previous studies have reported that enterohepatic circulation (EHC) of MPA, which is usually observed in MMF-treated patients, does not occur in HSCT patients, it is unclear what happens in haploidentical–HSCT (haplo-HSCT) patients, who are using post-transplant cyclophosphamide. This study was conducted to investigate MPA pharmacokinetics in haplo-HSCT patients.
  
  Seventeen haplo-HSCT patients, who received MMF for GVHD prophylaxis, were enrolled in this study. We collected blood samples on days 14 and 28, and plasma MPA concentrations were measured by high-performance liquid chromatography; pharmacokinetic parameters such as area under the curve (AUC), mean residence time (MRT), and apparent oral clearance (CL/F) were measured with moment analysis. We also evaluated EHC as AUC_6-12h/AUC_0-12h.
  
  There was no significant difference in MPA pharmacokinetic parameters between days 14 and 28. There was also no difference between the pharmacokinetic parameter changes and diarrhea. Additionally, varying plasma MPA concentrations suggested that MPA EHC did not occur.
  
  In this study, we revealed the pharmacokinetics of MMF in Japanese haplo-HSCT recipients. Additionally, our study demonstrated that MPA EHC might not occur in Japanese haplo-HSCT recipients.
  
  
• A novel nutritional index “simplified CONUT” and the disease risk index independently stratify prognosis of elderly patients with acute myeloid leukemia
  Hajime Senjo; Masahiro Onozawa; Daisuke Hidaka; Shota Yokoyama; Satoshi Yamamoto; Yutaka Tsutsumi; Yoshihito Haseyama; Takahiro Nagashima; Akio Mori; Shuichi Ota; Hajime Sakai; Toshimichi Ishihara; Takuto Miyagishima; Yasutaka Kakinoki; Mitsutoshi Kurosawa; Hajime Kobayashi; Hiroshi Iwasaki; Daigo Hashimoto; Takeshi Kondo; Takanori Teshima
  Scientific Reports, 10, 1, Springer Science and Business Media LLC, 2020年12月, ［査読有り］
  研究論文（学術雑誌）,
  Elderly patients aged 65 or older with acute myeloid leukemia (AML) have poor prognosis. The risk stratification based on genetic alteration has been proposed in national comprehensive cancer network (NCCN) guideline but its efficacy was not well verified especially in real world elderly patients. The nutritional status assessment using controlling nutritional status (CONUT) score is a prognostic biomarker in elderly patients with solid tumors but was not examined in elderly AML patients. We performed prospective analysis of genetic alterations of 174 patients aged 65 or older with newly diagnosed AML treated without hematopoietic stem cell transplantation (HSCT) and developed simplified CONUT (sCONUT) score by eliminating total lymphocyte count from the items to adapt AML patients. In this cohort, both the NCCN 2017 risk group and sCONUT score successfully stratified the overall survival (OS) of the elderly patients. A multivariable analysis demonstrated that adverse group in NCCN 2017 and high sCONUT score were independently associated with poor 2-year OS. Both risk stratification based on NCCN 2017 and sCONUT score predict prognosis in the elderly patients with newly diagnosed AML.
• Association of Epstein–Barr virus with regression after withdrawal of immunosuppressive drugs and subsequent progression of iatrogenic immunodeficiency‐associated lymphoproliferative disorders in patients with autoimmune diseases
  Katsuya Fujimoto; Kanako C. Hatanaka; Yutaka Hatanaka; Ikumi Kasahara; Satoshi Yamamoto; Takahiro Tsuji; Masanobu Nakata; Yasunari Takakuwa; Yoshihito Haseyama; Yumiko Oyamada; Masakatsu Yonezumi; Hiroaki Suzuki; Hajime Sakai; Hiroko Noguchi; Akio Mori; Hiroshi Nishihara; Takanori Teshima; Yoshihiro Matsuno
  Hematological Oncology, 38, 5, 799, 807, Wiley, 2020年12月, ［査読有り］
  研究論文（学術雑誌）
• Validation and comparison of prognostic values of GNRI, PNI, and CONUT in newly diagnosed diffuse large B cell lymphoma
  Toshihiro Matsukawa; Keito Suto; Minoru Kanaya; Koh Izumiyama; Koichiro Minauchi; Shota Yoshida; Hisashi Oda; Takuto Miyagishima; Akio Mori; Shuichi Ota; Daigo Hashimoto; Takanori Teshima
  Annals of Hematology, 99, 12, 2859, 2868, Springer Science and Business Media LLC, 2020年12月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Diffuse large B cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma. Emerging evidence indicates that poor nutritional status determined with nutritional indices such as geriatric nutritional risk index (GNRI), prognostic nutritional index (PNI), and controlling nutritional status score (CONUT) was associated with poor prognosis of DLBCL. We conducted this multicenter retrospective study to validate and compare prognostic values of the three indices in 615 newly diagnosed DLBCL patients. The overall survival (OS) in patients with poor nutritional status determined with each of these nutritional indices were significantly inferior compared with that in those without nutritional risks (5-year OS in patients with GNRI < 95.7 and GNRI ≥ 95.7 were 56.4% and 83.5%, P < 0.001; PNI < 42.4 and PNI ≥ 42.4 were 56.1% and 81.0%, P < 0.001; CONUT > 4 and CONUT ≤ 4 were 53.1% and 77.1%, P < 0.001). GNRI and CONUT were independent prognostic predictors for OS (GNRI < 95.7, hazard ratio [HR] 1.83, 95% confidence interval [CI] 1.22-2.74, P = 0.0032; CONUT > 4, HR 1.53, 95% CI 1.05-2.23, P = 0.028) after multivariate analyses. Nutritional status determined with GNRI affected OS more strongly in the patients with nongerminal center B cell-like (nonGCB) DLBCL compared with that in those with GCB-type DLBCL. In conclusion, baseline poor nutritional status determined based on GNRI or CONUT was an independent risk factor of newly diagnosed DLBCL, and GNRI was also useful as an independent prognostic factor for patients with nonGCB-type DLBCL.
• Pembrolizumab plus lenalidomide and dexamethasone in treatment-naive multiple myeloma (KEYNOTE-185): subgroup analysis in Japanese patients
  Naoki Takezako; Hiroshi Kosugi; Morio Matsumoto; Shinsuke Iida; Takayuki Ishikawa; Yukio Kondo; Kiyoshi Ando; Hirokazu Miki; Itaru Matsumura; Kazutaka Sunami; Takanori Teshima; Hiromi Iwasaki; Yasushi Onishi; Masahiro Kizaki; Koji Izutsu; Dai Maruyama; Kensei Tobinai; Razi Ghori; Mohammed Farooqui; Jason Liao; Patricia Marinello; Kenji Matsuda; Yasuhiro Koh; Takashi Shimamoto; Kenshi Suzuki
  International Journal of Hematology, 112, 5, 640, 649, Springer Science and Business Media LLC, 2020年11月, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, The global, randomized, open-label KEYNOTE-185 study closed early after an interim analysis showed an unfavorable benefit-risk profile with pembrolizumab plus lenalidomide and low-dose dexamethasone (Rd) versus Rd alone in treatment-naive, transplant-ineligible multiple myeloma. This subgroup analysis reported outcomes in the Japanese population. Patients were randomly assigned (1:1) to pembrolizumab plus Rd or Rd alone, stratified by age and International Staging System. The primary end point was progression-free survival (PFS). Fifty-two Japanese patients were randomly assigned to pembrolizumab plus Rd (n = 27) or Rd (n = 25). The median follow-up was 7.2 months (range, 0.4-13.8). The median PFS was not reached (NR); 6-month PFS was 91.2% versus 86.2% with pembrolizumab plus Rd versus Rd [hazard ratio (HR), 0.31; 95% CI, 0.06-1.63]. The median overall survival (OS) was NR; 6-month OS was 96.2% versus 95.7% with pembrolizumab plus Rd versus Rd (HR, 0.33; 95% CI, 0.03-3.72). With pembrolizumab plus Rd versus Rd, grade 3-5 adverse events occurred in 70.4% versus 69.6% of patients; serious adverse events occurred in 40.7% versus 52.5%. Although in the Japanese subgroup of KEYNOTE-185 adding pembrolizumab to Rd did not show an unfavorable risk-benefit, the analysis is limited by short follow-up and small sample size, affecting generalizability of the results.
• Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study
  Ayumu Ito; Sung-Won Kim; Ken-ichi Matsuoka; Toshiro Kawakita; Takashi Tanaka; Yoshihiro Inamoto; Tomomi Toubai; Shin-ichiro Fujiwara; Masafumi Fukaya; Tadakazu Kondo; Junichi Sugita; Miho Nara; Yuna Katsuoka; Yosuke Imai; Hideyuki Nakazawa; Ichiro Kawashima; Rika Sakai; Arata Ishii; Makoto Onizuka; Tomonari Takemura; Seitaro Terakura; Hiroatsu Iida; Mika Nakamae; Kohei Higuchi; Shinobu Tamura; Satoshi Yoshioka; Kazuto Togitani; Noriaki Kawano; Ritsuro Suzuki; Junji Suzumiya; Koji Izutsu; Takanori Teshima; Takahiro Fukuda
  International Journal of Hematology, 112, 5, 674, 689, Springer Science and Business Media LLC, 2020年11月, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, We conducted a multicenter study on anti-programmed cell death-1 monoclonal antibodies (anti-PD-1 mAbs) before/after allogeneic hematopoietic cell transplantation (allo-HCT) for Hodgkin lymphoma. Anti-PD-1 mAbs were administered to 25 patients before allo-HCT and to 20 after allo-HCT. In pre-allo-HCT setting, the median interval from the last administration to allo-HCT was 59 days. After allo-HCT, 12 patients developed non-infectious febrile syndrome requiring high-dose corticosteroid. The cumulative incidences of grade II-IV acute graft-versus-host disease (aGvHD) were 47.1%. Eight patients who had GvHD prophylaxis with post-transplant cyclophosphamide (PTCy) had less frequent aGvHD (grade II-IV, 14.6% versus 58.8%; P = 0.086). The 1 year overall survival (OS), relapse/progression, and non-relapse mortality rates were 81.3%, 27.9%, and 8.4%. In post-allo-HCT setting, the median interval from allo-HCT to the first administration was 589 days. The overall and complete response rates were 75% and 40%. At 100 days after anti-PD-1 therapy, the cumulative incidences of grade II-IV aGvHD, moderate-to-severe chronic GvHD, and grade 3-4 immune-related toxicity were 15.0%, 30.0%, and 30.0%. While the 1 year relapse/progression rate was 47.4%, the 1 year OS probability was 89.7%. In conclusion, immune-related complications were frequent despite modifications of GvHD prophylaxis or anti-PD-1 mAb dosing. In anti-PD-1-mAb-pretreated patients, PTCy-based GvHD prophylaxis may be effective.
• Reply to authors.
  Isao Yokota; Kentaro Sakamaki; Peter Y Shane; Takanori Teshima
  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 73, 11, e3986-e3987, 2020年10月26日, ［国際誌］
  英語, 研究論文（学術雑誌）
• Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies
  Naoyuki Uchida; Kana Matsumoto; Toru Sakura; Michihiro Hidaka; Toshihiro Miyamoto; Tetsuya Eto; Yoshinobu Maeda; Tohru Murayama; Naohito Fujishima; Goichi Yoshimoto; Kunihiko Morita; Junji Kishimoto; Takanori Teshima; Shuichi Taniguchi; Takuya Yamashita; Shin-ichiro Mori; Koichi Akashi; Mine Harada
  International Journal of Hematology, 112, 4, 510, 523, Springer Science and Business Media LLC, 2020年10月, ［査読有り］
  研究論文（学術雑誌）
• Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy‐associated hepatitis in Japan
  Takashi Kitagataya; Goki Suda; Kazunori Nagashima; Takehiko Katsurada; Koji Yamamoto; Megumi Kimura; Osamu Maehara; Ren Yamada; Taku Shigesawa; Kazuharu Suzuki; Akihisa Nakamura; Masatsugu Ohara; Machiko Umemura; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Yoshito Komatsu; Hiroo Hata; Satoshi Takeuchi; Takashige Abe; Jun Sakakibara‐Konishi; Takanori Teshima; Akihiro Homma; Naoya Sakamoto
  Journal of Gastroenterology and Hepatology, 35, 10, 1782, 1788, Wiley, 2020年10月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND AND AIM: Immune checkpoint inhibitors (ICI) have revolutionized anti-malignancy therapy and thus have been increasingly used. Although ICI may cause immune-related adverse events (irAE) in various organs, including the liver, the prevalence and predictive factors of irAE have not been clarified. METHODS: In this retrospective study, consecutive patients who had malignancies and were treated with ICI without other chemotherapeutic agents at Hokkaido University Hospital between 2014 and 2019 were screened. Patients were excluded if they were < 20 years old and had insufficient clinical data. RESULTS: Of the 233 patients screened, 202 patients met the inclusion criteria and were included in the analysis. The patients were aged 25-92 years, and 60.9% were male. The patients received nivolumab (n = 137), pembrolizumab (n = 45), ipilimumab (n = 17), atezolizumab (n = 2), and avelumab (n = 1). The prevalence of any grade and grade ≥ 3 irAE hepatitis was 8.4% (17/202) and 4.0% (8/202), respectively. irAE hepatitis occurred at a median duration of 42 days in any grade and 36 days in grade ≥ 3 after ICI initiation. The clinical course of grade ≥ 3 irAE hepatitis was generally favorable; however, 50% required corticosteroid treatment and two patients required additional mycophenolate mofetil. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis. CONCLUSIONS: Grade ≥ 3 irAE hepatitis was observed in 4.0% of the patients who were treated with ICI. Female sex and history of ICI treatment were significantly associated with the incidence of grade ≥ 3 irAE hepatitis.
• Short-term treatment with imetelstat sensitizes hematopoietic malignant cells to a genotoxic agent via suppression of the telomerase-mediated DNA repair process
  Daisuke Hidaka; Masahiro Onozawa; Naohiro Miyashita; Shota Yokoyama; Masao Nakagawa; Daigo Hashimoto; Takanori Teshima
  Leukemia & Lymphoma, 61, 11, 2722, 2732, Informa UK Limited, 2020年09月18日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Imetelstat is a specific and competitive inhibitor of telomerase enzymatic activity. We demonstrated that imetelstat could interfere with the DNA repair process and enhance the effect of DNA damaging agents using hematological tumor cell lines. Short-term administration of imetelstat enhanced growth suppression by anticancer agents and radiation. It also upregulated γH2AX expression induced by irradiation. Immunofluorescence staining showed that both human telomerase reverse transcriptase (hTERT) and γH2AX were upregulated and co-localized in the nucleus of peripheral blood mononuclear cells after irradiation, suggesting that hTERT was involved in the DNA-DSB repair process. Imetelstat enhanced growth inhibitory effect of cytotoxic agents in short-term culture without shortening of telomeres, indicating that this effect was attributed by telomere length independent mechanism. Our results suggest that the combination of short-term treatment with imetelstat and cytotoxic agent is a promising strategy to treat a wide variety of hematopoietic malignancies.
• Feasibility and efficacy of low‐dose pegfilgrastim for CD34 + cell mobilization in lymphoma
  Hideki Goto; Daisuke Hidaka; Satoshi Yamamoto; Koji Hayasaka; Rie Michimata; Ikuko Kagawa; Kana Sunagoya; Hiroaki Iijima; Eiko Hayase; Souichi Shiratori; Kohei Okada; Junichi Sugita; Masahiro Onozawa; Daigo Hashimoto; Kaoru Kahata; Katsuya Fujimoto; Tomoyuki Endo; Chikara Shimizu; Takanori Teshima
  Journal of Clinical Apheresis, 35, 5, 413, 419, Wiley, 2020年09月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Pegfilgrastim has equivalent efficacy to daily granulocyte colony-stimulating factor (G-CSF) in enhancing neutrophil recovery after chemotherapy, but data on its use for peripheral blood stem cell (PBSC) mobilization are limited. We evaluated the safety and efficacy of CD34+ PBSC mobilization by low-dose (3.6 mg) pegfilgrastim after chemotherapy in patients with malignant lymphoma. STUDY DESIGN AND METHODS: Twenty patients with malignant lymphoma were enrolled in this study. Cytotoxic chemotherapy was started on day 1, and 3.6 mg of pegfilgrastim was subcutaneously administered on day 7. CD34+ cells were counted in the peripheral blood daily from days 11 to 14 using a flow cytometric analysis. RESULTS: In 19 of the 20 patients (95%), the CD34+ cell counts in the peripheral blood exceeded 10 × 106/L, with a mean value of 20.3 on day 11, 38.0 on day 12, 40.3 on day 13, and 40.1 on day 14. Older age was associated with lower maximum CD34+ cell mobilization. The most frequent adverse events associated with pegfilgrastim were back pain, nausea, appetite loss, and lactate dehydrogenase elevation. CONCLUSION: Our data indicated that a single dose of 3.6 mg pegfilgrastim on day 7 after chemotherapy safely and effectively mobilized CD34+ cells.
• Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma
  Hideki Goto; Shinichi Makita; Koji Kato; Kota Tokushige; Taizo Fujita; Koichi Akashi; Koji Izutsu; Takanori Teshima
  International Journal of Clinical Oncology, 25, 9, 1736, 1743, Springer Science and Business Media LLC, 2020年09月, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）,
  
  Tisagenlecleucel demonstrated a high rate of durable response in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) in the pivotal global phase 2 JULIET study. Here, we report the efficacy and safety of tisagenlecleucel in the Japanese subgroup.
  
  
  
  
  JULIET (NCT02445248) is a single-arm, open-label, multicenter, phase 2 study involving adult patients with r/r DLBCL who either relapsed after or were ineligible for autologous stem cell transplant. Primary endpoint was best overall response rate (ORR; complete response [CR] + partial response [PR]) as judged by an independent review committee.
  
  
  
  
  In Japan, of 17 patients enrolled, 9 were infused with tisagenlecleucel and completed ≥ 3 months of follow-up. Best ORR was 77.8% (7/9; 95% confidence interval, 40.0–97.2), with 5 patients (55.6%) in CR and 2 (22.2%) in PR. Cytokine release syndrome (CRS) occurred in 6 patients (66.7%), with grade 3 CRS in 2 patients (Penn grading scale). Two patients received tocilizumab. Two deaths (22.2%) occurred more than 30 days after tisagenlecleucel infusion due to disease progression, neither of which were related to tisagenlecleucel.
  
  
  
  
  Tisagenlecleucel showed a high best ORR with a manageable safety profile, thus offering a new treatment option in selected Japanese patients with r/r DLBCL.
  
  
  
• Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva
  Sumio Iwasaki; Shinichi Fujisawa; Sho Nakakubo; Keisuke Kamada; Yu Yamashita; Tatsuya Fukumoto; Kaori Sato; Satoshi Oguri; Keisuke Taki; Hajime Senjo; Junichi Sugita; Kasumi Hayasaka; Satoshi Konno; Mutsumi Nishida; Takanori Teshima
  Journal of Infection, 81, 2, e145, e147, Elsevier BV, 2020年08月, ［査読有り］
  研究論文（学術雑誌）
• Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide
  Annie Im; Armin Rashidi; Tao Wang; Michael Hemmer; Margaret L. MacMillan; Joseph Pidala; Madan Jagasia; Steven Pavletic; Navneet S. Majhail; Daniel Weisdorf; Hisham Abdel-Azim; Vaibhav Agrawal; A. Samer Al-Homsi; Mahmoud Aljurf; Medhat Askar; Jeffery J. Auletta; Asad Bashey; Amer Beitinjaneh; Vijaya Raj Bhatt; Michael Byrne; Jean-Yves Cahn; Mitchell Cairo; Paul Castillo; Jan Cerny; Saurabh Chhabra; Hannah Choe; Stefan Ciurea; Andrew Daly; Miguel Angel Diaz Perez; Nosha Farhadfar; Shahinaz M. Gadalla; Robert Gale; Siddhartha Ganguly; Usama Gergis; Rabi Hanna; Peiman Hematti; Roger Herzig; Gerhard C. Hildebrandt; Deepesh P. Lad; Catherine Lee; Leslie Lehmann; Lazaros Lekakis; Rammurti T. Kamble; Mohamed A. Kharfan-Dabaja; Pooja Khandelwal; Rodrigo Martino; Hemant S. Murthy; Taiga Nishihori; Tracey A. O'Brien; Richard F. Olsson; Sagar S. Patel; Miguel-Angel Perales; Tim Prestidge; Muna Qayed; Rizwan Romee; Hélène Schoemans; Sachiko Seo; Akshay Sharma; Melhem Solh; Roger Strair; Takanori Teshima; Alvaro Urbano-Ispizua; Marjolein Van der Poel; Ravi Vij; John L. Wagner; Basem William; Baldeep Wirk; Jean A. Yared; Steve R. Spellman; Mukta Arora; Betty K. Hamilton
  Biology of Blood and Marrow Transplantation, 26, 8, 1459, 1468, Elsevier BV, 2020年08月, ［査読有り］
  研究論文（学術雑誌）
• Lymphocyte‐monocyte ratio (LMR) can predict bendamustine therapeutic efficacy in low‐grade B‐cell lymphoma
  Joji Shimono; Koh Izumiyama; Shinichi Ito; Yutaka Tsutsmi; Takeshi Kondo; Yasutaka Kakinoki; Takanori Teshima
  International Journal of Laboratory Hematology, 42, 4, 431, 438, Wiley, 2020年08月, ［査読有り］
  研究論文（学術雑誌）
• Create a healthy diet after transplant!
  Takanori Teshima
  Blood, 136, 1, 8, 9, 2020年07月02日, ［国際誌］
  英語, 研究論文（学術雑誌）
• Effect of graft-versus-host disease on outcomes after pediatric single cord blood transplantation
  Junya Kanda; Katsutsugu Umeda; Koji Kato; Makoto Murata; Junichi Sugita; Souichi Adachi; Katsuyoshi Koh; Maiko Noguchi; Hiroaki Goto; Nao Yoshida; Maho Sato; Yuhki Koga; Tsukasa Hori; Yuko Cho; Atsushi Ogawa; Masami Inoue; Yoshiko Hashii; Yoshiko Atsuta; Takanori Teshima
  Bone Marrow Transplantation, 55, 7, 1430, 1437, Springer Science and Business Media LLC, 2020年07月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, The effect of GVHD on transplant outcomes after unrelated cord blood transplantation (UCBT) is not yet fully understood. Pediatric patients aged 0-15 years with acute leukemia or myelodysplastic syndrome who underwent their first UCBT (n = 740) were selected from the Japanese registry. Fifty percent of the patients received a UCB unit containing more than 5.0 × 107/kg total nucleated cells. The occurrence of grade III-IV acute GVHD was associated with a higher risk of non-relapse mortality (NRM, hazard ratio [HR] 4.07, P < 0.001) compared with no acute GVHD. Grade I-II acute GVHD was not associated with NRM. The occurrence of grade I-II or grade III-IV acute GVHD was not associated with a relapse risk. These findings showed that grade I-II acute GVHD carried no survival benefit and grade III-IV acute GVHD had an adverse effect (HR 1.68, P = 0.007). The occurrence of limited chronic GVHD was associated with a low risk of overall mortality (HR 0.60, P = 0.045). Severe acute GVHD should be prevented because of its association with high overall mortality and NRM in pediatric single UCBT. Mild acute GVHD provides no overall benefit. Mild chronic GVHD may be beneficial for survival.
• Intestinal goblet cells protect against GVHD after allogeneic stem cell transplantation via Lypd8
  Takahide Ara; Daigo Hashimoto; Eiko Hayase; Clara Noizat; Ryo Kikuchi; Yuta Hasegawa; Kana Matsuda; Shoko Ono; Yoshihiro Matsuno; Ko Ebata; Reiki Ogasawara; Shuichiro Takahashi; Hiroyuki Ohigashi; Emi Yokoyama; Keitaro Matsuo; Junichi Sugita; Masahiro Onozawa; Ryu Okumura; Kiyoshi Takeda; Takanori Teshima
  Science Translational Medicine, 12, 550, eaaw0720, eaaw0720, American Association for the Advancement of Science (AAAS), 2020年07月01日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Graft-versus-host disease (GVHD) and infection are major obstacles to successful allogeneic hematopoietic stem cell transplantation (HSCT). Intestinal goblet cells form the mucus layers, which spatially segregate gut microbiota from host tissues. Although it is well known that goblet cell loss is one of the histologic features of GVHD, effects of their loss in pathophysiology of GVHD remain to be elucidated. In mouse models of allogeneic HSCT, goblet cells in the colon were significantly reduced, resulting in disruption of the inner mucus layer of the colon and increased bacterial translocation into colonic mucosa. Pretransplant administration of interleukin-25 (IL-25), a growth factor for goblet cells, protected goblet cells against GVHD, prevented bacterial translocation, reduced plasma concentrations of interferon-γ (IFN-γ) and IL-6, and ameliorated GVHD. The protective role of IL-25 was dependent on Lypd8, an antimicrobial molecule produced by enterocytes in the colon that suppresses motility of flagellated bacteria. In clinical colon biopsies, low numbers of goblet cells were significantly associated with severe intestinal GVHD, increased transplant-related mortality, and poor survival after HSCT. Goblet cell loss is associated with poor transplant outcome, and administration of IL-25 represents an adjunct therapeutic strategy for GVHD by protecting goblet cells.
• Efficacy of a novel SARS-CoV-2 detection kit without RNA extraction and purification.
  Tatsuya Fukumoto; Sumio Iwasaki; Shinichi Fujisawa; Kasumi Hayasaka; Kaori Sato; Satoshi Oguri; Keisuke Taki; Sho Nakakubo; Keisuke Kamada; Yu Yamashita; Satoshi Konno; Mutsumi Nishida; Junichi Sugita; Takanori Teshima
  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 98, 16, 17, Elsevier BV, 2020年06月26日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Rapid detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is critical for the diagnosis of coronavirus disease 2019 (COVID-19) and preventing the spread of the virus. A novel detection kit - the 2019 Novel Coronavirus Detection Kit (nCoV-DK) - halves the detection time by eliminating the steps of RNA extraction and purification. We evaluated the concordance between the nCoV-DK and direct PCR. The virus was detected in 53/71 specimens (74.6%) by direct PCR and in 55/71 specimens (77.5%) by nCoV-DK; the overall concordance rate was 94.4%: 95.2% for nasopharyngeal swab, 95.5% for saliva, and 85.7% for sputum. The nCoV-DK test effectively detects SARS-CoV-2 in all types of sample including saliva, while reducing the time required for detection, labor, and the risk of human error.
• Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT
  Rohtesh S. Mehta; Shernan G. Holtan; Tao Wang; Michael T. Hemmer; Stephen R. Spellman; Mukta Arora; Daniel R. Couriel; Amin M. Alousi; Joseph Pidala; Hisham Abdel-Azim; Vaibhav Agrawal; Ibrahim Ahmed; A. Samer Al-Homsi; Mahmoud Aljurf; Joseph H. Antin; Medhat Askar; Jeffery J. Auletta; Vijaya Raj Bhatt; Lynette Chee; Saurabh Chhabra; Andrew Daly; Zachariah DeFilipp; James Gajewski; Robert Peter Gale; Usama Gergis; Peiman Hematti; Gerhard C. Hildebrandt; William J. Hogan; Yoshihiro Inamoto; Rodrigo Martino; Navneet S. Majhail; David I. Marks; Taiga Nishihori; Richard F. Olsson; Attaphol Pawarode; Miguel Angel Diaz; Tim Prestidge; Hemalatha G. Rangarajan; Olle Ringden; Ayman Saad; Bipin N. Savani; Hélène Schoemans; Sachiko Seo; Kirk R. Schultz; Melhem Solh; Thomas Spitzer; Jan Storek; Takanori Teshima; Leo F. Verdonck; Baldeep Wirk; Jean A. Yared; Jean-Yves Cahn; Daniel J. Weisdorf
  Journal of Clinical Oncology, 38, 18, 2062, 2076, American Society of Clinical Oncology (ASCO), 2020年06月20日, ［査読有り］
  研究論文（学術雑誌）, There is no consensus on the best choice of an alternative donor (umbilical cord blood [UCB], haploidentical, one-antigen mismatched [7/8]–bone marrow [BM], or 7/8-peripheral blood [PB]) for hematopoietic cell transplantation (HCT) for patients lacking an HLA-matched related or unrelated donor.
  
  We report composite end points of graft-versus-host disease (GVHD)–free relapse-free survival (GRFS) and chronic GVHD (cGVHD)–free relapse-free survival (CRFS) in 2,198 patients who underwent UCB (n = 838), haploidentical (n = 159), 7/8-BM (n = 241), or 7/8-PB (n = 960) HCT. All groups were divided by myeloablative conditioning (MAC) intensity or reduced intensity conditioning (RIC), except haploidentical group in which most received RIC. To account for multiple testing, P < .0071 in multivariable analysis and P < .00025 in direct pairwise comparisons were considered statistically significant.
  
  In multivariable analysis, haploidentical group had the best GRFS, CRFS, and overall survival (OS). In the direct pairwise comparison of other groups, among those who received MAC, there was no difference in GRFS or CRFS among UCB, 7/8-BM, and 7/8-PB with serotherapy (alemtuzumab or antithymocyte globulin) groups. In contrast, the 7/8-PB without serotherapy group had significantly inferior GRFS, higher cGVHD, and a trend toward worse CRFS (hazard ratio [HR], 1.38; 95% CI, 1.13 to 1.69; P = .002) than the 7/8-BM group and higher cGVHD and trend toward inferior CRFS (HR, 1.36; 95% CI, 1.14 to 1.63; P = .0006) than the UCB group. Among patients with RIC, all groups had significantly inferior GRFS and CRFS compared with the haploidentical group.
  
  Recognizing the limitations of a registry retrospective analysis and the possibility of center selection bias in choosing donors, our data support the use of UCB, 7/8-BM, or 7/8-PB (with serotherapy) grafts for patients undergoing MAC HCT and haploidentical grafts for patients undergoing RIC HCT. The haploidentical group had the best GRFS, CRFS, and OS of all groups.
  
  
• High metabolic heterogeneity on baseline 18FDG-PET/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma
  Hajime Senjo; Kenji Hirata; Koh Izumiyama; Koichiro Minauchi; Eriko Tsukamoto; Kazuo Itoh; Minoru Kanaya; Akio Mori; Shuichi Ota; Daigo Hashimoto; Takanori Teshima
  Blood Advances, 4, 10, 2286, 2296, American Society of Hematology, 2020年05月26日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）,
  Metabolic heterogeneity (MH) can be measured using 18F-fluorodeoxyglucose (18FDG) positron emission tomography/computed tomography (PET/CT), and it indicates an inhomogeneous tumor microenvironment. High MH has been shown to predict a worse prognosis for primary mediastinal B-cell lymphoma, whereas its prognostic value in diffuse large B-cell lymphoma (DLBCL) remains to be determined. In the current study, we investigated the prognostic values of MH evaluated in newly diagnosed DLBCL. In the training cohort, 86 patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone–like chemotherapies were divided into low-MH and high-MH groups using receiver operating characteristic analysis. MH was not correlated with metabolic tumor volume of the corresponding lesion, indicating that MH was independent of tumor burden. At 5 years, overall survivals were 89.5% vs 61.2% (P = .0122) and event-free survivals were 73.1% vs 51.1% (P = .0327) in the low- and high-MH groups, respectively. A multivariate Cox-regression analysis showed that MH was an independent predictive factor for overall survival. The adverse prognostic impacts of high MH were confirmed in an independent validation cohort with 64 patients. In conclusion, MH on baseline 18FDG-PET/CT scan predicts treatment outcomes for patients with newly diagnosed DLBCL.
• Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
  Robert Zeiser; Nikolas von Bubnoff; Jason Butler; Mohamad Mohty; Dietger Niederwieser; Reuven Or; Jeff Szer; Eva M. Wagner; Tsila Zuckerman; Bruyère Mahuzier; Judith Xu; Celine Wilke; Kunal K. Gandhi; Gérard Socié
  New England Journal of Medicine, 382, 19, 1800, 1810, Massachusetts Medical Society, 2020年05月07日, ［査読有り］
  研究論文（学術雑誌）
• Histological and magnified endoscopic evaluation of villous atrophy in gastrointestinal graft-versus-host disease
  Kana Matsuda; Shoko Ono; Ikko Tanaka; Masaki Inoue; Sayoko Kinowaki; Marin Ishikawa; Momoko Tsuda; Keiko Yamamoto; Yuichi Shimizu; Shuichiro Takahashi; Eiko Hayase; Daigo Hashimoto; Takanori Teshima; Naoya Sakamoto
  Annals of Hematology, 99, 5, 1121, 1128, Springer Science and Business Media LLC, 2020年05月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, AIM:  To measure histological villous atrophy and to clarify the diagnostic accuracy of endoscopic villous atrophy in gastrointestinal graft-versus-host disease. METHODS:  Data for patients who underwent upper and/or lower endoscopic examinations after hematopoietic stem cell transplantation were retrospectively collected. In study 1, group A included 56 patients in whom GI-GVHD was histologically confirmed and group B included 60 patients in whom GI-GVHD was not histologically confirmed. Group C included 59 patients before HSCT. The lengths of villi and crypts in the duodenum and terminal ileum were histologically measured. In study 2, the diagnostic accuracies of villous atrophy of the duodenum and of the terminal ileum using magnifying endoscopy were evaluated. RESULTS:  In study 1, the lengths of villi and the villi/crypt (V/C) ratios of the duodenum and terminal ileum in group A were significantly smaller than those in the other groups (p < 0.05). V/C ratio was moderately correlated with clinical severity, histological grades, and endoscopic grades in the terminal ileum. In study 2, the diagnostic accuracies of magnified images for villous atrophy were 83.8% in the duodenum and 94.9% in the terminal ileum. CONCLUSION:  Magnifying endoscopy enables evaluation of villous atrophy and is useful for optical biopsy of GVHD.
• Short-term KRP203 and posttransplant cyclophosphamide for graft-versus-host disease prophylaxis.
  Emi Yokoyama; Daigo Hashimoto; Eiko Hayase; Takahide Ara; Reiki Ogasawara; Shuichiro Takahashi; Hiroyuki Ohigashi; Takahiro Tateno; Yuta Hasegawa; Xuanzhong Chen; Takanori Teshima
  Bone marrow transplantation, 55, 4, 787, 795, 2020年04月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Posttransplant high-dose cyclophosphamide (PTCY) has been increasingly used as graft-versus-host disease (GVHD) prophylaxis after HLA-haploidentical or matched hematopoietic stem cell transplantation (SCT). However, PTCY alone is insufficient and requires additional immunosuppressants such as calcineurin inhibitors. In the current study, we evaluated effects of a novel GVHD prophylaxis with PTCY in combination with short-term KRP203, a selective agonist of sphingosine-1-phosphate receptor 1 that regulates egress of lymphocytes from the secondary lymphoid organs (SLOs) in mice. Short-term oral administration of KRP203 alone induced apoptosis of donor T cells in the SLOs and ameliorated GVHD. Administration of KRP203 significantly preserved graft-versus-leukemia effects compared to cyclosporin. A combination of KRP203 on days 0 to +4 and PTCY on day +3 synergistically suppressed donor T-cell migration into the intestine and skin, and ameliorated GVHD more potently than PTCY alone. A combination of short-term KRP203 and PTCY is a promising novel calcineurin-free GVHD prophylaxis in HLA-haploidentical SCT.
• Rosai-Dorfman disease: earlier spontaneous regression of skin lesions relative to nasal, pharyngeal, and bone lesions
  Kazumasa Sato; Hideyuki Ujiie; Shinichi Nakazato; Mika Watanabe; Erika Watanabe; Teruki Yanagi; Yuji Nakamaru; Dai Takagi; Ryuta Arai; Tomohiro Onodera; Takeshi Kondo; Takanori Teshima; Hiroshi Shimizu
  European Journal of Dermatology, 30, 2, 182, 183, John Libbey Eurotext, 2020年04月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Reduced dose of MTX for GVHD prophylaxis promotes engraftment and decreases non-relapse mortality in umbilical cord blood transplantation.
  Souichi Shiratori; Hiroyuki Ohigashi; Shuichiro Takahashi; Takahide Ara; Hideki Goto; Masao Nakagawa; Junichi Sugita; Masahiro Onozawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
  Annals of hematology, 99, 3, 591, 598, Springer Science and Business Media LLC, 2020年03月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Although a combination of calcineurin inhibitor and methotrexate (MTX) is used for graft-versus-host disease (GVHD) prophylaxis in umbilical cord blood transplantation (CBT), optimal dose of MTX for CBT remains to be determined.We conducted a retrospective study to evaluate the safety and efficacy of standard-dose MTX (St-MTX, 15 mg/m2 on day 1 and 10 mg/m2 on days 3 and 6) and mini-dose MTX (Mini-MTX, 5 mg/m2 on days 1, 3 and 6) for GVHD prophylaxis in patients who underwent single unit CBT against hematological malignancies.Thirty-two and 26 patients received St-MTX and Mini-MTX, respectively. Cumulative incidence of neutrophil engraftment was significantly higher in the Mini-MTX group than in the St-MTX group (88.5% vs 65.6%, P = 0.00448). Cumulative incidences of grade II to IV and grade III to IV of acute graft-versus-host disease (GVHD) were 34.4% and 6.2% in the St-MTX group, and 34.6% and 7.7% in the Mini-MTX group with no statistical significance. One-year non-relapse mortality (NRM) was significantly lower in the Mini-MTX group compared to the St-MTX group (31.2% vs 3.8%, P = 0.00938), whereas relapse rate was not different between the groups. Multivariate analysis also indicated that Mini-MTX significantly improved engraftment (HR, 0.5359; 95% CI, 0.3082 to 0.9318; P = 0.0270) and reduced NRM (HR, 0.117; 95% CI, 0.0151 to 0.9067; P = 0.040).Our study suggests that GVHD prophylaxis using Mini-MTX in CBT is feasible and associated with improvement of engraftment and reduction in NRM.
• Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma.
  Reiki Ogasawara; Daigo Hashimoto; Junichi Sugita; Fumihiko Yamawaki; Tomoaki Naka; Tomoko Mitsuhashi; Shuichiro Takahashi; Naohiro Miyashita; Kohei Okada; Masahiro Onozawa; Yoshihiro Matsuno; Takanori Teshima
  International journal of hematology, 111, 3, 475, 479, 2020年03月, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, Nivolumab is effective in the treatment of classical Hodgkin lymphoma that relapsed after allogeneic hematopoietic stem cell transplantation (SCT) with the risk of graft-versus-host disease; however, the optimal time and dose of nivolumab administration remain to be investigated. Nivolumab binding to PD-1 masks flowcytometric detection of PD-1 by the anti-PD-1 monoclonal antibody EH12.1. Using this method, we monitored nivolumab binding on T cells after nivolumab treatment in a patient with classical Hodgkin lymphoma relapsed after allogeneic SCT. Nivolumab was effective while prolonged nivolumab binding was evident, but restoration of PD-1 staining predicted tumor relapse. Flowcytometric monitoring of nivolumab binding on T cells could be a promising biomarker for predicting tumor relapse and determining the timing of nivolumab administration.
• Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation
  Jonathan U. Peled; Antonio L.C. Gomes; Sean M. Devlin; Eric R. Littmann; Ying Taur; Anthony D. Sung; Daniela Weber; Daigo Hashimoto; Ann E. Slingerland; John B. Slingerland; Molly Maloy; Annelie G. Clurman; Christoph K. Stein-Thoeringer; Kate A. Markey; Melissa D. Docampo; Marina Burgos da Silva; Niloufer Khan; André Gessner; Julia A. Messina; Kristi Romero; Meagan V. Lew; Amy Bush; Lauren Bohannon; Daniel G. Brereton; Emily Fontana; Luigi A. Amoretti; Roberta J. Wright; Gabriel K. Armijo; Yusuke Shono; Míriam Sanchez-Escamilla; Nerea Castillo Flores; Ana Alarcon Tomas; Richard J. Lin; Lucrecia Yáñez San Segundo; Gunjan L. Shah; Christina Cho; Michael Scordo; Ioannis Politikos; Kasumi Hayasaka; Yuta Hasegawa; Boglarka Gyurkocza; Doris M. Ponce; Juliet N. Barker; Miguel-Angel Perales; Sergio A. Giralt; Robert R. Jenq; Takanori Teshima; Nelson J. Chao; Ernst Holler; Joao B. Xavier; Eric G. Pamer; Marcel R.M. van den Brink
  New England Journal of Medicine, 382, 9, 822, 834, Massachusetts Medical Society, 2020年02月27日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Relationships between microbiota composition and clinical outcomes after allogeneic hematopoietic-cell transplantation have been described in single-center studies. Geographic variations in the composition of human microbial communities and differences in clinical practices across institutions raise the question of whether these associations are generalizable. METHODS: The microbiota composition of fecal samples obtained from patients who were undergoing allogeneic hematopoietic-cell transplantation at four centers was profiled by means of 16S ribosomal RNA gene sequencing. In an observational study, we examined associations between microbiota diversity and mortality using Cox proportional-hazards analysis. For stratification of the cohorts into higher- and lower-diversity groups, the median diversity value that was observed at the study center in New York was used. In the analysis of independent cohorts, the New York center was cohort 1, and three centers in Germany, Japan, and North Carolina composed cohort 2. Cohort 1 and subgroups within it were analyzed for additional outcomes, including transplantation-related death. RESULTS: We profiled 8767 fecal samples obtained from 1362 patients undergoing allogeneic hematopoietic-cell transplantation at the four centers. We observed patterns of microbiota disruption characterized by loss of diversity and domination by single taxa. Higher diversity of intestinal microbiota was associated with a lower risk of death in independent cohorts (cohort 1: 104 deaths among 354 patients in the higher-diversity group vs. 136 deaths among 350 patients in the lower-diversity group; adjusted hazard ratio, 0.71; 95% confidence interval [CI], 0.55 to 0.92; cohort 2: 18 deaths among 87 patients in the higher-diversity group vs. 35 deaths among 92 patients in the lower-diversity group; adjusted hazard ratio, 0.49; 95% CI, 0.27 to 0.90). Subgroup analyses identified an association between lower intestinal diversity and higher risks of transplantation-related death and death attributable to graft-versus-host disease. Baseline samples obtained before transplantation already showed evidence of microbiome disruption, and lower diversity before transplantation was associated with poor survival. CONCLUSIONS: Patterns of microbiota disruption during allogeneic hematopoietic-cell transplantation were similar across transplantation centers and geographic locations; patterns were characterized by loss of diversity and domination by single taxa. Higher diversity of intestinal microbiota at the time of neutrophil engraftment was associated with lower mortality. (Funded by the National Cancer Institute and others.).
• Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma
  Richard T. Maziarz; Edmund K. Waller; Ulrich Jaeger; Isabelle Fleury; Joseph McGuirk; Harald Holte; Samantha Jaglowski; Stephen J. Schuster; Michael R. Bishop; Jason R. Westin; Stephan Mielke; Takanori Teshima; Veronika Bachanova; Stephen R. Foley; Peter Borchmann; Gilles A. Salles; Jie Zhang; Ranjan Tiwari; Lida B. Pacaud; Qiufei Ma; Constantine S. Tam
  Blood Advances, 4, 4, 629, 637, American Society of Hematology, 2020年02月25日, ［査読有り］
  研究論文（学術雑誌）, The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The objective of the current analysis was to evaluate patient-reported health-related quality of life (HRQoL) with a median follow-up of 19.3 months among patients infused with a single dose of tisagenlecleucel. Patients enrolled were ≥18 years of age with r/r DLBCL after ≥2 lines of therapy and had either undergone a failed autologous stem cell transplant or were ineligible for the procedure. Two validated HRQoL instruments, Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and Short Form-36 (SF-36) Health Survey, were used to measure HRQoL at baseline and months 3, 6, 12, and 18. At data cutoff (21 May 2018), 115 patients had received tisagenlecleucel infusion. Among the 99 patients evaluated, overall response rate was 54%, and 40% of patients achieved complete response (CR). Initially, 108 patients completed the HRQoL assessments at baseline, including 57 patients who eventually achieved CR or partial response (PR). Further, 30 and 21 patients in clinical response who completed assessments at baseline also completed assessments at months 12 and 18, respectively. Patients who achieved CR or PR sustained HRQoL improvement in all FACT scores at all time points. SF-36 instruments showed improvement above the minimal clinically important differences on 5 of 8 subscales. Long-term follow-up in the phase 2 JULIET study demonstrated that patients with r/r DLBCL who respond to tisagenlecleucel therapy had sustained, clinically meaningful improvements in HRQoL. This trial was registered at www.clinicaltrials.gov as #NCT02445248.
• Salvage Transplantation with Cord Blood for Graft Rejection of Peripheral Blood Stem Cells due to Donor Specific Antibody
  Maria Regina Pelobello de Leon; Shuichiro Takahashi; Masahiro Onozawa; Makoto Ito; Manabu Nakano; Hajime Senjo; Masahiro Chiba; Hiroyuki Ohigashi; Emi Yokoyama; Junichi Sugita; Daigo Hashimoto; Takanori Teshima
  BLOOD CELL THERAPY / The official journal of APBMT, 3, 3, 74, 77, Asia-Pacific Blood and Marrow Transplantation Group, 2020年, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for various kinds of hematological malignancies and disorders. Recently, HLA-haploidentical stem cell transplantation with post-transplantation cyclophosphamide (PTCy-haplo HSCT) has been widely performed due to its safety and favorable immune recovery. However, graft rejection remains an obstacle to PTCy-haplo HSCT. Donor specific antibody (DSA) is considered to be a major factor of graft rejection of haplo HSCT. We herein present a case of graft rejection after PTCy haplo-HSCT due to DSA induced by pretransplant platelet transfusion after donor selection. The patient was dependent on platelet transfusion and had not received cytotoxic chemotherapy because he was diagnosed as myelodysplastic syndrome/myeloproliferative neoplasm-unclassifiable. We retrospectively confirmed the level of DSA just before the first transplantation and found that it was dramatically elevated, which was enough to cause graft rejection. We successfully performed cord blood transplantation of the HLA that was not the target of DSA, as salvage transplantation without any desensitization. This case illustrates that we have to confirm the presence of DSA immediately before the haplo-HSCT, particularly in high risk patients who are dependent on platelet transfusion and have no cytotoxic chemotherapy before HSCT.
• A Novel Strategy for SARS-CoV-2 Mass-Screening Using Quantitative Antigen Testing of Saliva
  Isao Yokota; Peter Y. Shane; Kazufumi Okada; Yokota Unoki; Yichi Yang; Sumio Iwasaki; Shinichi Fujisawa; Mutsumi Nishida; Takanori Teshima
  SSRN Electronic Journal, Elsevier BV, 2020年, ［査読有り］
  研究論文（学術雑誌）
• Myeloid differentiation factor 88 signaling in donor T cells accelerates graft-versus-host disease
  Satomi Matsuoka; Daigo Hashimoto; Masanori Kadowaki; Hiroyuki Ohigashi; Eiko Hayase; Emi Yokoyama; Yuta Hasegawa; Takahiro Tateno; Xuanzhong Chen; Kazutoshi Aoyama; Hideyo Oka; Masahiro Onozawa; Kiyoshi Takeda; Koichi Akashi; Takanori Teshima
  Haematologica, 105, 1, 226, 234, Ferrata Storti Foundation (Haematologica), 2020年01月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Myeloid differentiation factor 88 (MyD88) signaling has a crucial role in activation of both innate and adoptive immunity. MyD88 transduces signals via Toll-like receptor and interleukin-1 receptor superfamily to the NFκB pathway and inflammasome by forming a molecular complex with interleukin-1 receptor-associated kinase 4. The MyD88/interleukin-1 receptor-associated kinase 4 pathway plays an important role, not only in innate immunity, but also T-cell immunity; however, its role in donor T cells on the pathophysiology of graft-versus-host disease (GvHD) remains to be elucidated. We addressed this issue by using MyD88-deficient T cells in a mouse model of allogeneic hematopoietic stem cell transplantation (allo-SCT). While MyD88-deficient and wild-type T cells proliferated equivalently after transplantation, MyD88-deficient T cells demonstrated impaired survival and differentiation toward Th1, Tc1, and Th17, and induced less severe GvHD compared to wild-type T cells. Administration of interleukin-1 receptor-associated kinase 4 inhibitor PF-06650833 significantly ameliorated GvHD after allo-SCT. These results thus demonstrate that donor T-cell MyD88/interleukin-1 receptor-associated kinase 4 pathway is a novel therapeutic target against GvHD after allo-SCT.
• Localization of BCR-ABL to Stress Granules Contributes to Its Oncogenic Function.
  Sayaka Kashiwagi; Yoichiro Fujioka; Takeshi Kondo; Aya O Satoh; Aiko Yoshida; Mari Fujioka; Hitoshi Sasajima; Maho Amano; Takanori Teshima; Yusuke Ohba
  Cell structure and function, 44, 2, 195, 204, 2019年12月26日, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）, The oncogenic tyrosine kinase BCR-ABL activates a variety of signaling pathways and plays a causative role in the pathogenesis of chronic myelogenous leukemia (CML); however, the subcellular distribution of this chimeric protein remains controversial. Here, we report that BCR-ABL is localized to stress granules and that its granular localization contributes to BCR-ABL-dependent leukemogenesis. BCR-ABL-positive granules were not colocalized with any markers for membrane-bound organelles but were colocalized with HSP90a, a component of RNA granules. The number of such granules increased with thapsigargin treatment, confirming that the granules were stress granules. Given that treatment with the ABL kinase inhibitor imatinib and elimination of the N-terminal region of BCR-ABL abolished granule formation, kinase activity and the coiled-coil domain are required for granule formation. Whereas wild-type BCR-ABL rescued the growth defect in IL-3-depleted Ba/F3 cells, mutant BCR-ABL lacking the N-terminal region failed to do so. Moreover, forced tetramerization of the N-terminus-deleted mutant could not restore the growth defect, indicating that granule formation, but not tetramerization, through its N-terminus is critical for BCR-ABL-dependent oncogenicity. Our findings together provide new insights into the pathogenesis of CML by BCR-ABL and open a window for developing novel therapeutic strategies for this disease.Key words: BCR-ABL, subcellular localization, stress granule.
• A prospective observational study of immune reconstitution following transplantation with post‐transplant reduced‐dose cyclophosphamide from HLA ‐haploidentical donors
  Hirohisa Nakamae; Kazuki Fujii; Satoru Nanno; Hiroshi Okamura; Takahiko Nakane; Hideo Koh; Yasuhiro Nakashima; Mika Nakamae; Asao Hirose; Takanori Teshima; Masayuki Hino
  Transplant International, 32, 12, 1322, 1332, Wiley, 2019年12月, ［査読有り］
  研究論文（学術雑誌）
• Ibrutinib Caused Mediastinal Emphysema and Pneumothorax in the Treatment of a Patient with Mantle Cell Lymphoma
  Yutaka Tsutsumi; Takahiro Sekine; Shinichi Ito; Satomi Matsuoka; Takanori Teshima
  Drug Safety - Case Reports, 6, 1, 3, 3, Springer Science and Business Media LLC, 2019年12月, ［査読有り］
  研究論文（学術雑誌）
• Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT
  Maddalena Noviello; Francesco Manfredi; Eliana Ruggiero; Tommaso Perini; Giacomo Oliveira; Filippo Cortesi; Pantaleo De Simone; Cristina Toffalori; Valentina Gambacorta; Raffaella Greco; Jacopo Peccatori; Monica Casucci; Giulia Casorati; Paolo Dellabona; Masahiro Onozawa; Takanori Teshima; Marieke Griffioen; Constantijn J. M. Halkes; J. H. F. Falkenburg; Friedrich Stölzel; Heidi Altmann; Martin Bornhäuser; Miguel Waterhouse; Robert Zeiser; Jürgen Finke; Nicoletta Cieri; Attilio Bondanza; Luca Vago; Fabio Ciceri; Chiara Bonini
  Nature Communications, 10, 1, 1065, 1065, Springer Science and Business Media LLC, 2019年12月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, The major cause of death after allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for acute myeloid leukemia (AML) is disease relapse. We investigated the expression of Inhibitory Receptors (IR; PD-1/CTLA-4/TIM-3/LAG-3/2B4/KLRG1/GITR) on T cells infiltrating the bone marrow (BM) of 32 AML patients relapsing (median 251 days) or maintaining complete remission (CR; median 1 year) after HSCT. A higher proportion of early-differentiated Memory Stem (TSCM) and Central Memory BM-T cells express multiple IR in relapsing patients than in CR patients. Exhausted BM-T cells at relapse display a restricted TCR repertoire, impaired effector functions and leukemia-reactive specificities. In 57 patients, early detection of severely exhausted (PD-1+Eomes+T-bet-) BM-TSCM predicts relapse. Accordingly, leukemia-specific T cells in patients prone to relapse display exhaustion markers, absent in patients maintaining long-term CR. These results highlight a wide, though reversible, immunological dysfunction in the BM of AML patients relapsing after HSCT and suggest new therapeutic opportunities for the disease.
• Lactose drives Enterococcus expansion to promote graft-versus-host disease.
  C K Stein-Thoeringer; K B Nichols; A Lazrak; M D Docampo; A E Slingerland; J B Slingerland; A G Clurman; G Armijo; A L C Gomes; Y Shono; A Staffas; M Burgos da Silva; S M Devlin; K A Markey; D Bajic; R Pinedo; A Tsakmaklis; E R Littmann; A Pastore; Y Taur; S Monette; M E Arcila; A J Pickard; M Maloy; R J Wright; L A Amoretti; E Fontana; D Pham; M A Jamal; D Weber; A D Sung; D Hashimoto; C Scheid; J B Xavier; J A Messina; K Romero; M Lew; A Bush; L Bohannon; K Hayasaka; Y Hasegawa; M J G T Vehreschild; J R Cross; D M Ponce; M A Perales; S A Giralt; R R Jenq; T Teshima; E Holler; N J Chao; E G Pamer; J U Peled; M R M van den Brink
  Science (New York, N.Y.), 366, 6469, 1143, 1149, 2019年11月29日, ［国際誌］
  英語, 研究論文（学術雑誌）, Disruption of intestinal microbial communities appears to underlie many human illnesses, but the mechanisms that promote this dysbiosis and its adverse consequences are poorly understood. In patients who received allogeneic hematopoietic cell transplantation (allo-HCT), we describe a high incidence of enterococcal expansion, which was associated with graft-versus-host disease (GVHD) and mortality. We found that Enterococcus also expands in the mouse gastrointestinal tract after allo-HCT and exacerbates disease severity in gnotobiotic models. Enterococcus growth is dependent on the disaccharide lactose, and dietary lactose depletion attenuates Enterococcus outgrowth and reduces the severity of GVHD in mice. Allo-HCT patients carrying lactose-nonabsorber genotypes showed compromised clearance of postantibiotic Enterococcus domination. We report lactose as a common nutrient that drives expansion of a commensal bacterium that exacerbates an intestinal and systemic inflammatory disease.
• Using a machine learning algorithm to predict acute graft-versus-host disease following allogeneic transplantation.
  Yasuyuki Arai; Tadakazu Kondo; Kyoko Fuse; Yasuhiko Shibasaki; Masayoshi Masuko; Junichi Sugita; Takanori Teshima; Naoyuki Uchida; Takahiro Fukuda; Kazuhiko Kakihana; Yukiyasu Ozawa; Tetsuya Eto; Masatsugu Tanaka; Kazuhiro Ikegame; Takehiko Mori; Koji Iwato; Tatsuo Ichinohe; Yoshinobu Kanda; Yoshiko Atsuta
  Blood advances, 3, 22, 3626, 3634, 2019年11月26日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Acute graft-versus-host disease (aGVHD) is 1 of the critical complications that often occurs following allogeneic hematopoietic stem cell transplantation (HSCT). Thus far, various types of prediction scores have been created using statistical calculations. The primary objective of this study was to establish and validate the machine learning-dependent index for predicting aGVHD. This was a retrospective cohort study that involved analyzing databases of adult HSCT patients in Japan. The alternating decision tree (ADTree) machine learning algorithm was applied to develop models using the training cohort (70%). The ADTree algorithm was confirmed using the hazard model on data from the validation cohort (30%). Data from 26 695 HSCT patients transplanted from allogeneic donors between 1992 and 2016 were included in this study. The cumulative incidence of aGVHD was 42.8%. Of >40 variables considered, 15 were adapted into a model for aGVHD prediction. The model was tested in the validation cohort, and the incidence of aGVHD was clearly stratified according to the categorized ADTree scores; the cumulative incidence of aGVHD was 29.0% for low risk and 58.7% for high risk (hazard ratio, 2.57). Predicting scores for aGVHD also demonstrated the link between the risk of development aGVHD and overall survival after HSCT. The machine learning algorithms produced clinically reasonable and robust risk stratification scores. The relatively high reproducibility and low impacts from the interactions among the variables indicate that the ADTree algorithm, along with the other data-mining approaches, may provide tools for establishing risk score.
• Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test.
  Takeshi Kondo; Mari Fujioka; Shinichi Fujisawa; Kaori Sato; Masumi Tsuda; Takuto Miyagishima; Akio Mori; Hiroshi Iwasaki; Yasutaka Kakinoki; Satoshi Yamamoto; Yoshihito Haseyama; Seisho Ando; Motohiro Shindo; Shuichi Ota; Mitsutoshi Kurosawa; Yusuke Ohba; Takanori Teshima
  International journal of hematology, 110, 4, 482, 489, 2019年10月, ［査読有り］, ［国内誌］
  英語, Nilotinib is widely used for primary treatment of patients with chronic myelogenous leukemia (CML). We previously reported that use of an FRET-based drug sensitivity test at diagnosis efficiently predicts the response to treatment with imatinib or dasatinib. Here, we conducted a phase-II study to evaluate the efficacy and safety of nilotinib treatment and identify useful biomarkers, including results of the FRET-based drug sensitivity test, for predicting treatment response. Data from 42 patients were used in the analysis. Major molecular response (MMR), MR4, and MR4.5 rates at 12 months were 64.3, 42.9, and 28.6%, respectively. Grade 3/4 non-hematologic adverse events occurred in 11 patients (26.2%). The dose intensity of nilotinib (> 76.44%) and halving time (HT, < 13.312 days) were identified as significant factors for MMR at 12 months. However, when we focused on patients whose dose intensity of nilotinib was > 76.44%, the FRET-based drug sensitivity test became a predictive factor of MR4 achievement at 12 months. Our study reconfirmed the efficacy and safety of nilotinib treatment in CML patients. Moreover, our results suggest that the FRET-based drug sensitivity test is an independent predictor for achievement of MR4 in patients treated with a sufficient dose intensity of nilotinib.
• Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
  Usmani SZ; Schjesvold F; Oriol A; Karlin L; Cavo M; Rifkin RM; Yimer HA; LeBlanc R; Takezako N; McCroskey RD; Lim ABM; Suzuki K; Kosugi H; Grigoriadis G; Avivi I; Facon T; Jagannath S; Lonial S; Ghori RU; Farooqui MZH; Marinello P; San-Miguel J; KEYNOTE; Investigators
  Lancet Haematol, 6, 9, e448, e458, 2019年09月, ［査読有り］
• Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation
  Ayman Saad; Lawrence Lamb; Tao Wang; Michael T. Hemmer; Stephen Spellman; Daniel Couriel; Amin Alousi; Joseph Pidala; Hisham Abdel-Azim; Vaibhav Agrawal; Mahmoud Aljurf; Amer M. Beitinjaneh; Vijaya Raj Bhatt; David Buchbinder; Michael Byrne; Jean-Yves Cahn; Mitchell Cairo; Paul Castillo; Saurabh Chhabra; Miguel Angel Diaz; Shatha Farhan; Yngvar Floisand; Hadar A. Frangoul; Shahinaz M. Gadalla; James Gajewski; Robert Peter Gale; Manish Gandhi; Usama Gergis; Betty Ky Hamilton; Peiman Hematti; Gerhard C. Hildebrandt; Rammurti T. Kamble; Abraham S. Kanate; Pooja Khandelwal; Aleksandr Lazaryan; Margaret MacMillan; David I. Marks; Rodrigo Martino; Parinda A. Mehta; Taiga Nishihori; Richard F. Olsson; Sagar S. Patel; Muna Qayed; Hemalatha G. Rangarajan; Ran Reshef; Olle Ringden; Bipin N. Savani; Harry C. Schouten; Kirk R. Schultz; Sachiko Seo; Brian C. Shaffer; Melhem Solh; Takanori Teshima; Alvaro Urbano-Ispizua; Leo F. Verdonck; Ravi Vij; Edmund K. Waller; Basem William; Baldeep Wirk; Jean A. Yared; Lolie C. Yu; Mukta Arora; Shahrukh Hashmi
  Biology of Blood and Marrow Transplantation, 25, 9, 1875, 1883, Elsevier BV, 2019年09月, ［査読有り］
  研究論文（学術雑誌）
• Resolved versus Active Chronic Graft-versus-Host Disease: Impact on Post-Transplantation Quality of Life
  Saiko Kurosawa; Takuhiro Yamaguchi; Kumi Oshima; Atsumi Yanagisawa; Takahiro Fukuda; Heiwa Kanamori; Takehiko Mori; Satoshi Takahashi; Tadakazu Kondo; Akio Kohno; Koichi Miyamura; Yukari Umemoto; Takanori Teshima; Shuichi Taniguchi; Takuya Yamashita; Yoshihiro Inamoto; Yoshinobu Kanda; Shinichiro Okamoto; Yoshiko Atsuta
  Biology of Blood and Marrow Transplantation, 25, 9, 1851, 1858, Elsevier BV, 2019年09月, ［査読有り］
  研究論文（学術雑誌）
• Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation
  Betty K. Hamilton; Ying Liu; Michael T. Hemmer; Navneet Majhail; Olle Ringden; Dennis Kim; Luciano Costa; Robert Stuart; Amin Alousi; Joseph A. Pidala; Daniel R. Couriel; Mahmoud Aljurf; Joseph H. Antin; Christopher Bredeson; Jean-Yves Cahn; Mitchell Cairo; Sung Won Choi; Christopher Dandoy; Robert Peter Gale; Usama Gergis; Peiman Hematti; Yoshihiro Inamoto; Rammurti T. Kamble; Margaret MacMillan; David I. Marks; Eneida Nemecek; Taiga Nishihori; Ayman Saad; Bipin N. Savani; Jeff Schriber; Sachiko Seo; Gérard Socié; Takanori Teshima; Leo F. Verdonck; Edmund K. Waller; Mona Wirk; Stephen R. Spellman; Mukta Arora; Saurabh Chhabra
  Biology of Blood and Marrow Transplantation, 25, 9, 1744, 1755, Elsevier BV, 2019年09月, ［査読有り］
  研究論文（学術雑誌）
• Clinical significance of end-diastolic opening of pulmonary valve in a case complicating left ventricular systolic dysfunction.
  Hisao Nishino; Hiroyuki Iwano; Sanae Kaga; Mutsumi Nishida; Koji Akizawa; Takanori Teshima; Toshihisa Anzai
  Journal of echocardiography, 19, 1, 53, 55, 2019年08月03日, ［査読有り］, ［国内誌］
  英語, 研究論文（学術雑誌）
• Anagrelide Modulates Proplatelet Formation Resulting in Decreased Number and Increased Size of Platelets.
  Naohiro Miyashita; Masahiro Onozawa; Shota Yokoyama; Daisuke Hidaka; Koji Hayasaka; Shinji Kunishima; Takanori Teshima
  HemaSphere, 3, 4, e268, 2019年08月, ［国際誌］
  英語, 研究論文（学術雑誌）, We retrospectively evaluated 48 essential thrombocythemia (ET) patients who were treated in our institute (male/female, 14/34, median age, 61.5 years). In 14 patients treated with anagrelide (ANA), the degree of platelet count reduction (median, -56.6%) was strongly correlated with increase of mean platelet volume (MPV) (median, +11.7%) (R = 0.777). This correlation was not observed in ET patients treated with hydroxycarbamide alone (R = 0.245). The change in size of platelets strongly suggested that ANA affected the final process of platelet production. Thus, we hypothesized that ANA modifies the process by which platelets are released from proplatelets. To verify the association in an in vitro setting, we compared MEG-01 cells treated with PMA ± ANA. The number of platelet-like particles (PLPs) was decreased (P < 0.05) and the size of PLPs estimated by using flow cytometry was significantly increased when MEG-01 cells were treated with PMA + ANA (P < 0.05 vs PMA alone), recapitulating the clinical findings. The cytoplasmic protrusions extending from MEG-01 cells were shorter and thicker and the number of proplatelets was decreased when MEG-01 cells were treated with PMA + ANA (P < 0.01 vs PMA alone). Western blotting analysis showed that ANA treatment resulted in increased phosphorylation of MLC2 and reduced phosphorylation of focal adhesion kinase (FAK). The morphological change of proplatelets were reversed by blebbistatin, a specific inhibitor of myosin II. These findings indicated that ANA modulates the FAK-RhoA-ROCK-MLC2-myosine IIA pathway and suppresses proplatelet maturation, leading to a decrease in platelet count and increase in MPV.
• Safety and efficacy of amnion-derived mesenchymal stem cells (AM01) in patients with steroid-refractory acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: a study protocol for a phase I/II Japanese trial.
  Kenichi Yamahara; Akiko Hamada; Toshihiro Soma; Rika Okamoto; Masaya Okada; Satoshi Yoshihara; Kyoko Yoshihara; Kazuhiro Ikegame; Hiroya Tamaki; Katsuji Kaida; Takayuki Inoue; Yuko Ohsugi; Hiroki Nishikawa; Hiroshi Hayashi; Yoichi M Ito; Hiroaki Iijima; Shunsuke Ohnishi; Daigo Hashimoto; Toshiyuki Isoe; Takanori Teshima; Hiroyasu Ogawa; Norihiro Sato; Yoshihiro Fujimori
  BMJ open, 9, 7, e026403, 2019年07月09日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, INTRODUCTION: Regenerative medicine and cell therapies have been gaining much attention among clinicians. Therapeutic infusion of mesenchymal stromal cells (MSCs) is now a leading investigational strategy for the treatment of acute graft-versus-host disease (aGVHD). Bone marrow MSCs are approved for manufacture and marketing as a cell therapy for aGVHD. Our non-clinical studies confirmed that human amnion-derived MSCs had immunomodulatory activity equal to or higher than that of human bone marrow MSCs. This study will aim to evaluate the safety and efficacy of amnion-derived MSCs (AM01) in patients with steroid-refractory aGVHD. METHODS AND ANALYSIS: This study will be a multicentre, single-arm, open-label trial (an interventional study). This clinical trial will begin with a low-dose group, and when safety has been confirmed in at least three cases in the low-dose group, treatment will begin for the high-dose group, for which the safety will also be verified. The primary endpoint is to assess the safety of intravenous infusion therapy of AM01 within 24 hours after intravenous infusion of AM01. The secondary endpoint is to explore the efficacy of intravenous infusion therapy with AM01. ETHICS AND DISSEMINATION: The institutional review boards of all participating hospitals approved this study protocol (latest V3.3.0, 3 August 2018). Final data will be publicly announced. A report releasing the study results will be submitted for publication to an appropriate peer-reviewed journal. TRIAL REGISTRATION NUMBER: UMIN000029945.
• Validation of US evaluation of ulcerative colitis activity
  Satomi Omotehara; Mutsumi Nishida; Kenji Kinoshita; Reizo Onishi; Aki Onodera; Mitsuhisa Suya; Toru Hasegawa; Daiki Mitsumori; Takehiko Katsurada; Takanori Teshima
  Ultrasound in Medicine & Biology, 45, 7, 1537, 1544, Elsevier BV, 2019年07月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, This study was aimed at validating the inter-rater grading agreement for assessing disease activity in patients with established ulcerative colitis (UC) using transabdominal ultrasonography (US) versus colonoscopy (CS). Fifty-seven patients underwent US and CS at four facilities. UC disease activity was assessed using the original US grading system and CS Matts classification. Initially, the US and CS grades were assessed at each examining facility, and still images and movie clips were re-assessed at the central facility. Grading agreement between the examining and central facilities was evaluated. Grading agreement for US and CS were 0.75 and 0.72 in all segments and 0.82 and 0.70 in the maximum grade of each patient, respectively (all p < 0.001). US grading agreement was "almost perfect" for the maximum grade and "moderate" to "substantial" for other assessments. The inter-rater US grading agreement was good and not inferior to that of CS for evaluating UC disease activity.
• Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas
  Keisuke Kataoka; Hiroaki Miyoshi; Seiji Sakata; Akito Dobashi; Lucile Couronné; Yasunori Kogure; Yasuharu Sato; Kenji Nishida; Yuka Gion; Yuichi Shiraishi; Hiroko Tanaka; Kenichi Chiba; Yosaku Watatani; Nobuyuki Kakiuchi; Yusuke Shiozawa; Tetsuichi Yoshizato; Kenichi Yoshida; Hideki Makishima; Masashi Sanada; Masahiro Onozawa; Takanori Teshima; Yumiko Yoshiki; Tadao Ishida; Kenshi Suzuki; Kazuyuki Shimada; Akihiro Tomita; Motohiro Kato; Yasunori Ota; Koji Izutsu; Ayako Demachi-Okamura; Yoshiki Akatsuka; Satoru Miyano; Tadashi Yoshino; Philippe Gaulard; Olivier Hermine; Kengo Takeuchi; Koichi Ohshima; Seishi Ogawa
  Leukemia, 33, 7, 1687, 1699, Springer Science and Business Media LLC, 2019年07月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Viral infection induces potent cellular immunity and activated intracellular signaling, which may dictate the driver events involved in immune escape and clonal selection of virus-associated cancers, including Epstein-Barr virus (EBV)-positive lymphomas. Here, we thoroughly interrogated PD-L1/PD-L2-involving somatic aberrations in 384 samples from various lymphoma subtypes using high-throughput sequencing, particularly focusing on virus-associated lymphomas. A high frequency of PD-L1/PD-L2-involving genetic aberrations was observed in EBV-positive lymphomas [33 (22%) of 148 cases], including extranodal NK/T-cell lymphoma (ENKTL, 23%), aggressive NK-cell leukemia (57%), systemic EBV-positive T-cell lymphoproliferative disorder (17%) as well as EBV-positive diffuse large B-cell lymphoma (DLBCL, 19%) and peripheral T-cell lymphoma-not otherwise specified (15%). Predominantly causing a truncation of the 3'-untranslated region, these alterations represented the most prevalent somatic lesions in ENKTL. By contrast, the frequency was much lower in EBV-negative lymphomas regardless of histology type [12 (5%) of 236 cases]. Besides PD-L1/PD-L2 alterations, EBV-positive DLBCL exhibited a genetic profile distinct from EBV-negative one, characterized by frequent TET2 and DNMT3A mutations and the paucity of CD79B, MYD88, CDKN2A, and FAS alterations. Our findings illustrate unique genetic features of EBV-associated lymphomas, also suggesting a potential role of detecting PD-L1/PD-L2-involving lesions for these lymphomas to be effectively targeted by immune checkpoint blockade.
• Myasthenia gravis after allogeneic bone marrow transplantation: A case report and literature review
  Yutaka Tsutsumi; Takashi Kamiishi; Ryo Kikuchi; Shinichi Ito; Satomi Matsuoka; Takanori Teshima
  Hematology/Oncology and Stem Cell Therapy, 12, 2, 110, 114, Elsevier BV, 2019年06月, ［査読有り］
  研究論文（学術雑誌）
• GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia
  Rohtesh S. Mehta; Shernan G. Holtan; Tao Wang; Michael T. Hemmer; Stephen R. Spellman; Mukta Arora; Daniel R. Couriel; Amin M. Alousi; Joseph Pidala; Hisham Abdel-Azim; Ibrahim Ahmed; Mahmoud Aljurf; Medhat Askar; Jeffery J. Auletta; Vijaya Bhatt; Christopher Bredeson; Saurabh Chhabra; Shahinaz Gadalla; James Gajewski; Robert Peter Gale; Usama Gergis; Peiman Hematti; Gerhard C. Hildebrandt; Yoshihiro Inamoto; Carrie Kitko; Pooja Khandelwal; Margaret L. MacMillan; Navneet Majhail; David I. Marks; Parinda Mehta; Taiga Nishihori; Richard F. Olsson; Attaphol Pawarode; Miguel Angel Diaz; Tim Prestidge; Muna Qayed; Hemalatha Rangarajan; Olle Ringden; Ayman Saad; Bipin N. Savani; Sachiko Seo; Ami Shah; Niketa Shah; Kirk R. Schultz; Melhem Solh; Thomas Spitzer; Jeffrey Szer; Takanori Teshima; Leo F. Verdonck; Kirsten M. Williams; Baldeep Wirk; John Wagner; Jean A. Yared; Daniel J. Weisdorf
  Blood Advances, 3, 9, 1441, 1449, American Society of Hematology, 2019年05月14日, ［査読有り］
  研究論文（学術雑誌）,
  We report graft-versus-host disease (GVHD)-free relapse-free survival (GRFS) (a composite end point of survival without grade III-IV acute GVHD [aGVHD], systemic therapy–requiring chronic GVHD [cGVHD], or relapse) and cGVHD-free relapse-free survival (CRFS) among pediatric patients with acute leukemia (n = 1613) who underwent transplantation with 1 antigen–mismatched (7/8) bone marrow (BM; n = 172) or umbilical cord blood (UCB; n = 1441). Multivariate analysis was performed using Cox proportional hazards models. To account for multiple testing, P &lt; .01 for the donor/graft variable was considered statistically significant. Clinical characteristics were similar between UCB and 7/8 BM recipients, because most had acute lymphoblastic leukemia (62%), 64% received total body irradiation–based conditioning, and 60% received anti-thymocyte globulin or alemtuzumab. Methotrexate-based GVHD prophylaxis was more common with 7/8 BM (79%) than with UCB (15%), in which mycophenolate mofetil was commonly used. The univariate estimates of GRFS and CRFS were 22% (95% confidence interval [CI], 16-29) and 27% (95% CI, 20-34), respectively, with 7/8 BM and 33% (95% CI, 31-36) and 38% (95% CI, 35-40), respectively, with UCB (P &lt; .001). In multivariate analysis, 7/8 BM vs UCB had similar GRFS (hazard ratio [HR], 1.12; 95% CI, 0.87-1.45; P = .39), CRFS (HR, 1.06; 95% CI, 0.82-1.38; P = .66), overall survival (HR, 1.07; 95% CI, 0.80-1.44; P = .66), and relapse (HR, 1.44; 95% CI, 1.03-2.02; P = .03). However, the 7/8 BM group had a significantly higher risk for grade III-IV aGVHD (HR, 1.70; 95% CI, 1.16-2.48; P = .006) compared with the UCB group. UCB and 7/8 BM groups had similar outcomes, as measured by GRFS and CRFS. However, given the higher risk for grade III-IV aGVHD, UCB might be preferred for patients lacking matched donors.
• Clinicopathological features of HCV-positive splenic diffuse large B cell lymphoma.
  Joji Shimono; Hiroaki Miyoshi; Fumiko Arakawa; Kyohei Yamada; Takeshi Sugio; Kohta Miyawaki; Tetsuya Eto; Takuto Miyagishima; Koji Kato; Koji Nagafuji; Koichi Akashi; Takanori Teshima; Koichi Ohshima
  Annals of hematology, 98, 5, 1197, 1207, 2019年05月, ［査読有り］, ［国際誌］
  英語, The hepatitis C virus (HCV) is a single-stranded RNA virus which is thought to be involved in the onset of B cell lymphoma. HCV-positive diffuse large B cell lymphoma (DLBCL) has been reported to clinically manifest in extranodal lesions (e.g., in the liver, spleen, and stomach). Here, we investigated HCV-positive and -negative primary splenic DLBCL (p-spDLBCL) and non-primary splenic DLBCL (ordinary DLBCL). Furthermore, to examine HCV lymphomagenesis, RNA in situ hybridization (ISH), RT-PCR (reverse-transcription polymerase chain reaction), and NS3 immunostaining of HCV viral nonstructural proteins were performed. HCV-positive p-spDLBCL patients presented fewer B symptoms (asymptomatic) and better performance status, with elevated presence of splenic macronodular lesions and more germinal center B cell (GCB) sub-group cases than HCV-negative p-spDLBCL patients. However, HCV-positive ordinary DLBCL patients were found to have more non-GCB sub-group cases than HCV-negative ordinary DLBCL patients. HCV-positive DLBCL patients showed 20.6% (7/34) NS3 positivity, 16.7% (1/6) HCV-RNA in situ positivity, and 22.2% (2/9) detection of HCV-RNA in tumor tissue by RT-PCR. Splenic samples were found to have a higher frequency of HCV detection than lymph node samples, thus suggesting that HCV may be closely related to lymphomagenesis, especially in splenic lymphoma.
• Ocular instillation of vitamin A–coupled liposomes containing HSP47 siRNA ameliorates dry eye syndrome in chronic GVHD
  Hiroyuki Ohigashi; Daigo Hashimoto; Eiko Hayase; Shuichiro Takahashi; Takahide Ara; Tomohiro Yamakawa; Junichi Sugita; Masahiro Onozawa; Masao Nakagawa; Takanori Teshima
  Blood Advances, 3, 7, 1003, 1010, American Society of Hematology, 2019年04月09日, ［査読有り］
  研究論文（学術雑誌）, Chronic graft-versus-host disease (GVHD) profoundly affects the quality of life of long-term survivors of allogeneic hematopoietic stem cell transplantation (SCT). The eyes are frequently involved, and dry eye syndrome is the most common manifestation of ocular chronic GVHD. We explored the role of heat shock protein 47 (HSP47) in ocular GVHD and developed a novel antifibrotic topical therapy using vitamin A–coupled liposomes containing HSP47 small interfering RNA (siRNA) against HSP47 (VA-lip HSP47). In a mouse model of chronic GVHD, infiltration of HSP47+ fibroblasts and massive fibrosis surrounding the lacrimal ducts were observed after allogeneic SCT, leading to impaired tear secretion. After ocular instillation, VA-lip HSP47 was distributed to the lacrimal glands, knocked down HSP47 expression in fibroblasts, reduced collagen deposition, and restored tear secretion after allogeneic SCT. Ocular instillation of VA-lip HSP47 also ameliorated established lacrimal gland fibrosis and dry eye syndrome. VA-lip HSP47 eye drops are a promising prophylactic and therapeutic option against dry eye syndrome in chronic GVHD.
• A pitfall of serum troponin assay; an estrangement of cardiac troponin T and I
  Keiichi Nakano; Naoki Mafune; Keiko Yasuda; Koji Akizawa; Junichi Sugita; Takanori Teshima
  Japanese Journal of Clinical Chemistry, 48, 2, 130, 136, Japanese Journal of Clinical Chemistry, 2019年04月01日
  日本語, 研究論文（学術雑誌）
• Gene Polymorphism of Tacrolimus-Metabolizing Enzymes Associated With Impaired Absorption of Tacrolimus Following Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
  S. Matsuoka; Y. Tsutsumi; R. Kikuchi; S. Ito; T. Teshima
  Transplantation Proceedings, 51, 3, 998, 1001, Elsevier BV, 2019年04月, ［査読有り］
  研究論文（学術雑誌）
• Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
  Cristina Toffalori; Laura Zito; Valentina Gambacorta; Michela Riba; Giacomo Oliveira; Gabriele Bucci; Matteo Barcella; Orietta Spinelli; Raffaella Greco; Lara Crucitti; Nicoletta Cieri; Maddalena Noviello; Francesco Manfredi; Elisa Montaldo; Renato Ostuni; Matteo M. Naldini; Bernhard Gentner; Miguel Waterhouse; Robert Zeiser; Jurgen Finke; Maher Hanoun; Dietrich W. Beelen; Ivana Gojo; Leo Luznik; Masahiro Onozawa; Takanori Teshima; Raynier Devillier; Didier Blaise; Constantijn J. M. Halkes; Marieke Griffioen; Matteo G. Carrabba; Massimo Bernardi; Jacopo Peccatori; Cristina Barlassina; Elia Stupka; Dejan Lazarevic; Giovanni Tonon; Alessandro Rambaldi; Davide Cittaro; Chiara Bonini; Katharina Fleischhauer; Fabio Ciceri; Luca Vago
  Nature Medicine, 25, 4, 603, 611, Springer Science and Business Media LLC, 2019年04月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Transplantation of hematopoietic cells from a healthy individual (allogeneic hematopoietic cell transplantation (allo-HCT)) demonstrates that adoptive immunotherapy can cure blood cancers: still, post-transplantation relapses remain frequent. To explain their drivers, we analyzed the genomic and gene expression profiles of acute myeloid leukemia (AML) blasts purified from patients at serial time-points during their disease history. We identified a transcriptional signature specific for post-transplantation relapses and highly enriched in immune-related processes, including T cell costimulation and antigen presentation. In two independent patient cohorts we confirmed the deregulation of multiple costimulatory ligands on AML blasts at post-transplantation relapse (PD-L1, B7-H3, CD80, PVRL2), mirrored by concomitant changes in circulating donor T cells. Likewise, we documented the frequent loss of surface expression of HLA-DR, -DQ and -DP on leukemia cells, due to downregulation of the HLA class II regulator CIITA. We show that loss of HLA class II expression and upregulation of inhibitory checkpoint molecules represent alternative modalities to abolish AML recognition from donor-derived T cells, and can be counteracted by interferon-γ or checkpoint blockade, respectively. Our results demonstrate that the deregulation of pathways involved in T cell-mediated allorecognition is a distinctive feature and driver of AML relapses after allo-HCT, which can be rapidly translated into personalized therapies.
• Quantitative detection of IKZF1 deletion by digital PCR in patients with acute lymphoblastic leukemia.
  Junichi Hashiguchi; Masahiro Onozawa; Kohei Okada; Toraji Amano; Kanako C Hatanaka; Hiroshi Nishihara; Norihiro Sato; Takanori Teshima
  International journal of laboratory hematology, 41, 2, e38-e40, e40, 2019年04月, ［査読有り］, ［国際誌］
  英語
• Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide
  Junichi Sugita; Yusuke Kagaya; Toshihiro Miyamoto; Yasuhiko Shibasaki; Koji Nagafuji; Shuichi Ota; Tatsuo Furukawa; Miho Nara; Koichi Akashi; Shuichi Taniguchi; Mine Harada; Keitaro Matsuo; Takanori Teshima
  Bone Marrow Transplantation, 54, 3, 432, 441, Springer Science and Business Media LLC, 2019年03月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, We conducted two parallel prospective, multicenter, phase II studies to evaluate the safety and efficacy of HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide (PTCy-haploPBSCT) following myeloablative conditioning (MAC, n = 50) and reduced-intensity conditioning (RIC, n = 77). Event-free survival (EFS) at 1-year as for primary endpoint was 64% and 43% in the MAC and RIC groups, respectively. Neutrophil engraftment was achieved in 98% and 94% in the MAC and RIC groups, respectively. The incidences of grades II-IV and III-IV acute graft-versus-host disease (GVHD) were 18% and 8% in the MAC group, and 14% and 5% in the RIC group, respectively. Those of all grade and moderate to severe chronic GVHD at 2-year were 36% and 20% in the MAC group, and 27% and 20% in the RIC group, respectively. Overall survival (OS), EFS, nonrelapse mortality, and relapse rate at 2-year were 68%, 54%, 10%, and 36% in the MAC group, and 44%, 35%, 20%, and 45% in the RIC group, respectively. Notably, 83% and 86% of patients who survived without relapse stopped immunosuppressant at 2-year in the MAC and RIC groups, respectively. Our results indicate that both MAC and RIC are valid options for PTCy-haploPBSCT for adults with hematological malignancies.
• Serum level of soluble interleukin‐2 receptor is positively correlated with metabolic tumor volume on 18 F‐FDG PET/CT in newly diagnosed patients with diffuse large B‐cell lymphoma
  Hajime Senjo; Minoru Kanaya; Koh Izumiyama; Koichiro Minauchi; Kenji Hirata; Akio Mori; Makoto Saito; Masanori Tanaka; Hiroaki Iijima; Eriko Tsukamoto; Kazuo Itoh; Shuichi Ota; Masanobu Morioka; Daigo Hashimoto; Takanori Teshima
  Cancer Medicine, 8, 3, 953, 962, Wiley, 2019年03月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of non-Hodgkin lymphoma. High total metabolic tumor volume (TMTV) calculated using 18 F-FDG PET/CT images at diagnosis predicts poor prognosis of patients with DLBCL. However, high cost and poor access to the imaging facilities hamper wider use of 18 F-FDG PET/CT. In order to explore a surrogate marker for TMTV, we evaluated the correlation between the serum levels of soluble interleukin-2 receptor (sIL-2R) and TMTV in 64 patients with DLBCL, and the results were verified in an independent validation cohort of 86 patients. Serum levels of sIL-2R were significantly correlated with TMTV. ROC analysis revealed that the cutoff value of TMTV ≥150 cm3 or sIL-2R ≥ 1300 U/mL could predict failure to achieve EFS24 with areas under the curve (AUC) 0.706 and 0.758, respectively. Each of TMTV ≥150 cm3 and sIL-2R ≥1300 U/mL was significantly associated with worse 5-year overall survival and event-free survival. Importantly, each of sIL-2R <1300 U/mL or TMTV <150 cm3 identified patients with favorable prognosis among NCCN-IPI high-intermediate and high-risk group. Serum level of sIL-2R represents a convenient surrogate marker to estimate metabolic tumor burden measured by 18 F-FDG PET/CT that can predict treatment outcomes of patients with DLBCL.
• A role for IL-34 in osteolytic disease of multiple myeloma
  Muhammad Baghdadi; Kozo Ishikawa; Sayaka Nakanishi; Tomoki Murata; Yui Umeyama; Takuto Kobayashi; Yosuke Kameda; Hiraku Endo; Haruka Wada; Bjarne Bogen; Satoshi Yamamoto; Keisuke Yamaguchi; Ikumi Kasahara; Hiroshi Iwasaki; Mutsumi Takahata; Makoto Ibata; Shuichiro Takahashi; Hideki Goto; Takanori Teshima; Ken-ichiro Seino
  Blood Advances, 3, 4, 541, 551, American Society of Hematology, 2019年02月26日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Multiple myeloma (MM) is a hematological malignancy that grows in multiple sites of the axial skeleton and causes debilitating osteolytic disease. Interleukin-34 (IL-34) is a newly discovered cytokine that acts as a ligand of colony-stimulating factor-1 (CSF-1) receptor and can replace CSF-1 for osteoclast differentiation. In this study, we identify IL-34 as an osteoclastogenic cytokine that accelerates osteolytic disease in MM. IL-34 was found to be expressed in the murine MM cell line MOPC315.BM, and the expression of IL-34 was enhanced by stimulation with proinflammatory cytokines or by bone marrow (BM) stromal cells. MM-cell–derived IL-34 promoted osteoclast formation from mouse BM cells in vitro. Targeting Il34 by specific small interfering RNA impaired osteoclast formation in vitro and attenuated osteolytic disease in vivo. In BM aspirates from MM patients, the expression levels of IL-34 in CD138+ populations vary among patients from high to weak to absent. MM cell–derived IL-34 promoted osteoclast formation from human CD14+ monocytes, which was reduced by a neutralizing antibody against IL-34. Taken together, this study describes for the first time the expression of IL-34 in MM cells, indicating that it may enhance osteolysis and suggesting IL-34 as a potential therapeutic target to control pathological osteoclastogenesis in MM patients.
• Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors.
  Manabu Wakamatsu; Seitaro Terakura; Kazuteru Ohashi; Takahiro Fukuda; Yukiyasu Ozawa; Heiwa Kanamori; Masashi Sawa; Naoyuki Uchida; Shuichi Ota; Akiko Matsushita; Yoshinobu Kanda; Hirohisa Nakamae; Tatsuo Ichinohe; Koji Kato; Makoto Murata; Yoshiko Atsuta; Takanori Teshima
  Blood advances, 3, 2, 105, 115, 2019年01月22日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Antithymocyte globulin (ATG) is widely used to reduce acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD). To clarify the different impacts of ATG for conditioning across different donor types, we retrospectively analyzed patients with acute leukemia (n = 6617) who underwent hematopoietic stem cell transplantation between 2008 and 2015 with ATG (n = 279) or without ATG (n = 6338). Because thymoglobulin is the only ATG drug approved for GVHD prophylaxis in Japan since September 2008, we included thymoglobulin alone in the present analysis. The survivors' median follow-up time was 1081 days. Patients were categorized into 5 groups: cord blood (CB; n = 1915), matched related donor (n = 1772), 1-antigen mismatched related donor (1-MMRD; n = 225), matched unrelated donor (MUD; n = 1742), and 1-allele mismatched unrelated donor (1-MMUD; n = 963). In multivariate analysis, ATG decreased overall survival (hazard ratio [HR], 1.403; P = .054) and GVHD-free/relapse-free survival (GRFS) (HR, 1.458; P = .053) in association with increased nonrelapse mortality (NRM) (HR, 1.608; P =03) with CB, whereas it improved GRFS (HR, 0.515; P < .01) and decreased grades II to IV aGVHD (HR, 0.576; P < .01), extensive cGVHD (HR, 0.460; P = .02), and NRM (HR, 0.545; P = .03) with 1-MMUD. ATG did not impact survival with 1-MMRD and MUD. The use of ATG in conditioning is beneficial due to the reduction in acute/chronic GVHD without increasing NRM or disease relapse only in 1-MMUD transplantation. On the other hand, ATG is not recommended for CB transplantation.
• Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
  Stephen J. Schuster; Michael R. Bishop; Constantine S. Tam; Edmund K. Waller; Peter Borchmann; Joseph P. McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R. Westin; Isabelle Fleury; Veronika Bachanova; S. Ronan Foley; P. Joy Ho; Stephan Mielke; John M. Magenau; Harald Holte; Serafino Pantano; Lida B. Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T. Maziarz
  New England Journal of Medicine, 380, 1, 45, 56, Massachusetts Medical Society, 2019年01月03日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study. METHODS: We conducted an international, phase 2, pivotal study of centrally manufactured tisagenlecleucel involving adult patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for or had disease progression after autologous hematopoietic stem-cell transplantation. The primary end point was the best overall response rate (i.e., the percentage of patients who had a complete or partial response), as judged by an independent review committee. RESULTS: A total of 93 patients received an infusion and were included in the evaluation of efficacy. The median time from infusion to data cutoff was 14 months (range, 0.1 to 26). The best overall response rate was 52% (95% confidence interval, 41 to 62); 40% of the patients had complete responses, and 12% had partial responses. Response rates were consistent across prognostic subgroups. At 12 months after the initial response, the rate of relapse-free survival was estimated to be 65% (79% among patients with a complete response). The most common grade 3 or 4 adverse events of special interest included cytokine release syndrome (22%), neurologic events (12%), cytopenias lasting more than 28 days (32%), infections (20%), and febrile neutropenia (14%). Three patients died from disease progression within 30 days after infusion. No deaths were attributed to tisagenlecleucel, cytokine release syndrome, or cerebral edema. No differences between response groups in tumor expression of CD19 or immune checkpoint-related proteins were found. CONCLUSIONS: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. (Funded by Novartis; JULIET ClinicalTrials.gov number, NCT02445248 .).
• Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
  Hirohiko Shibayama; Takanori Teshima; Ilseung Choi; Kiyohiko Hatake; Naohiro Sekiguchi; Nozomi Yoshinari
  Journal of clinical and experimental hematopathology : JCEH, 59, 4, 179, 186, 2019年, ［国内誌］
  英語, 研究論文（学術雑誌）, This phase I study evaluated the safety and efficacy of single-agent ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (aged 20-69 years and ineligible for chemotherapy using fludarabine or cyclophosphamide, or aged ≥70 years). Eight patients received oral ibrutinib 420 mg once daily until progressive disease or unacceptable toxicity. The primary endpoint was safety; secondary endpoints included the overall response rate (ORR). At the time of final analysis (August 22, 2018), eight patients (all with CLL; median age, 68.5 years) had received ibrutinib for a median of 32.2 months (range, 10.4-35.9); all patients had discontinued study treatment, with 50.0% of patients switching to marketing-approved ibrutinib as subsequent anticancer therapy. All patients had ≥1 adverse event (AE); the most common AEs included a decreased platelet count, upper respiratory tract infection, increased lymphocyte count, diarrhea, nasopharyngitis, peripheral edema and rash. Four patients (50.0%) had a total of eight grade ≥3 AEs, most commonly lung infection and decreased neutrophil count. Eight serious AEs were reported in four patients (50.0%); these included a case of muscle hemorrhage (grade 3), decreased neutrophil count (grade 4) that led to dose reduction and one case of fatal cardiac arrest. The ORR was 87.5% (7/8 patients [exact 95% confidence interval 47.3-99.7]). One patient had a complete response, six had a partial response and one had a partial response with lymphocytosis. Ibrutinib had an acceptable safety profile and high ORR in Japanese patients with treatment-naïve CLL.
• Comparative Analysis of Calcineurin Inhibitor–Based Methotrexate and Mycophenolate Mofetil–Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation
  Saurabh Chhabra; Ying Liu; Michael T. Hemmer; Luciano Costa; Joseph A. Pidala; Daniel R. Couriel; Amin M. Alousi; Navneet S. Majhail; Robert K. Stuart; Dennis Kim; Olle Ringden; Alvaro Urbano-Ispizua; Ayman Saad; Bipin N. Savani; Brenda Cooper; David I. Marks; Gerard Socie; Harry C. Schouten; Helene Schoemans; Hisham Abdel-Azim; Jean Yared; Jean-Yves Cahn; John Wagner; Joseph H. Antin; Leo F. Verdonck; Leslie Lehmann; Mahmoud D. Aljurf; Margaret L. MacMillan; Mark R. Litzow; Melhem M. Solh; Muna Qayed; Peiman Hematti; Rammurti T. Kamble; Ravi Vij; Robert J. Hayashi; Robert P. Gale; Rodrigo Martino; Sachiko Seo; Shahrukh K. Hashmi; Taiga Nishihori; Takanori Teshima; Usama Gergis; Yoshihiro Inamoto; Stephen R. Spellman; Mukta Arora; Betty K. Hamilton
  Biology of Blood and Marrow Transplantation, 25, 1, 73, 85, Elsevier BV, 2019年01月, ［査読有り］
  研究論文（学術雑誌）
• Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia.
  Motohiro Kato; Mio Kurata; Junya Kanda; Koji Kato; Daisuke Tomizawa; Kazuko Kudo; Nao Yoshida; Kenichiro Watanabe; Hiroyuki Shimada; Jiro Inagaki; Katsuyoshi Koh; Hiroaki Goto; Keisuke Kato; Yuko Cho; Yuki Yuza; Atsushi Ogawa; Keiko Okada; Masami Inoue; Yoshiko Hashii; Takanori Teshima; Makoto Murata; Yoshiko Atsuta
  Bone marrow transplantation, 54, 1, 68, 75, 2019年01月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Graft-versus-host disease (GVHD) occasionally leads to morbidity and mortality but is thought to reduce the risk of relapses in patients with a hematological malignancy. However, information on the effect of GVHD in pediatric leukemia is limited. Using a nationwide registry, we retrospectively analyzed 1526 children who underwent allogeneic stem cell transplantation for leukemia. Grades 0-I acute GVHD were associated with a higher relapse rate at three years after transplantation, at 25.4 and 24.3%, respectively, than grades II, III, or IV acute GVHD at 18.9%, 21.2%, and 2.6%, respectively. In contrast, the overall survival curve of the grades 0 and I GVHD groups (79.0% and 79.5%, respectively) approximated that of the grade II GVHD group (76.3%), and the probability of survival was worst in the severe GVHD groups (66.9% for grade III and 42.5% for grade IV). Chronic GVHD also reduced the relapse risk but conferred no survival advantage. Acute lymphoblastic leukemia was more sensitive to acute GVHD than acute myeloid leukemia (AML) while AML was more sensitive to chronic GVHD. Our study reproduced the preventive effects of GVHD against pediatric leukemia relapses but failed to demonstrate a significant survival advantage.
• Human Herpes Virus-6-Associated Encephalitis/Myelitis Mimicking Calcineurin Inhibitor-Induced Pain Syndrome in Allogeneic Stem Cell Transplantation Recipients
  Goichi Yoshimoto; Yasuo Mori; Koji Kato; Takahiro Shima; Kohta Miyawaki; Yoshikane Kikushige; Kenjiro Kamezaki; Akihiko Numata; Takahiro Maeda; Katsuto Takenaka; Hiromi Iwasaki; Takanori Teshima; Koichi Akashi; Toshihiro Miyamoto
  BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 24, 12, 2540, 2548, 2018年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Intestinal Lymphatic Endothelial Cells Produce R-Spondin3
  Reiki Ogasawara; Daigo Hashimoto; Shunsuke Kimura; Eiko Hayase; Takahide Ara; Shuichiro Takahashi; Hiroyuki Ohigashi; Kosuke Yoshioka; Takahiro Tateno; Emi Yokoyama; Ko Ebata; Takeshi Kondo; Junichi Sugita; Masahiro Onozawa; Toshihiko Iwanaga; Takanori Teshima
  Scientific Reports, 8, 1, 10719, 10719, Springer Science and Business Media LLC, 2018年12月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, The R-Spondin (R-Spo) family regulates WNT signaling and stimulates the proliferation and differentiation of intestinal stem cells (ISCs). R-Spo plays a critical role in maintaining intestinal homeostasis, but endogenous producers of R-Spo in the intestine remain to be investigated. We found that R-Spo3 was the major R-Spo family member produced in the intestine and it was predominantly produced by CD45-CD90+CD31+ lymphatic endothelial cells (LECs) in the lamina propria of the intestinal mucosa. Transcriptome analysis demonstrated that LECs highly expressed R-Spo receptor, Lgr5, suggesting an autocrine stimulatory loop in LECs. LECs were significantly reduced in number, and their R-Spo3 production was impaired in intestinal graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation. The impaired production of R-Spo3 in the intestine may be a novel mechanism of delayed tissue repair and defective mucosal defense in intestinal GVHD. We demonstrate a novel role of intestinal LECs in producing R-Spondin3 to maintain intestinal homeostasis.
• Wilms Tumor 1 Expression at Diagnosis Correlates With Genetic Abnormalities and Polymorphism But Is Not Independently Prognostic in Acute Myelogenous Leukemia: A Hokkaido Leukemia Net Study
  Daisuke Hidaka; Masahiro Onozawa; Junichi Hashiguchi; Naohiro Miyashita; Kohei Kasahara; Shinichi Fujisawa; Eiko Hayase; Kohei Okada; Souichi Shiratori; Hideki Goto; Junichi Sugita; Masao Nakagawa; Daigo Hashimoto; Kaoru Kahata; Tomoyuki Endo; Satoshi Yamamoto; Yutaka Tsutsumi; Yoshihito Haseyama; Takahiro Nagashima; Akio Mori; Shuichi Ota; Hajime Sakai; Toshimichi Ishihara; Kiyotoshi Imai; Takuto Miyagishima; Yasutaka Kakinoki; Mitsutoshi Kurosawa; Hajime Kobayashi; Hiroshi Iwasaki; Chikara Shimizu; Takeshi Kondo; Takanori Teshima
  Clinical Lymphoma Myeloma and Leukemia, 18, 11, e469, e479, Elsevier BV, 2018年11月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: The prognostic effect of Wilms tumor 1 (WT1) expression at the diagnosis of acute myelogenous leukemia (AML) has been controversial. The aim of the present study was to determine the correlations of WT1 expression at the diagnosis of AML with established prognostic alterations. PATIENTS AND METHODS: We analyzed diagnostic bone marrow samples from 252 patients. WT1 expression, single nucleotide polymorphism (SNP) in the WT1 gene (rs16754), and Fms-like tyrosine kinase receptor-3 internal tandem duplication (FLT3-ITD) mutation were analyzed for all patients. The nucleophosmin 1 (NPM1) mutation and CCAAT/enhancer-binding protein-α (CEBPA) double mutation were analyzed for cytogenetically normal (CN)-AML. The KIT mutation was analyzed for core-binding factor AML. RESULTS: Within the cytogenetically favorable prognosis group, WT1 expression in AML with inv(16) or t(15;17) was significantly greater than that in AML with t(8;21). In cases with CN-AML, FLT3-ITD and NPM1 mutations both correlated with greater expression of WT1, and the CEBPA double mutation was related to lower WT1 expression. The existence of both FLT3-ITD and NPM1 mutations showed synergistically greater expression of WT1 in CN-AML. SNP in the WT1 gene (rs16754) was significantly associated with lower expression of WT1. The WT1 levels were not prognostic factors in the total cohort or any cytogenetic group or stratified by SNP status. CONCLUSION: Because WT1 expression has correlated with known prognostic factors, the prognostic effect of WT1 levels could be misunderstood depending on the distribution of the collaborative mutations in each cohort. We have concluded that the prognostic significance of WT1 at the diagnosis of AML is weak compared with the other established prognostic factors.
• Synchronous case of follicular lymphoma and Langerhans cell sarcoma in the same lymph node
  Joji Shimono; Hiroaki Miyoshi; Fumiko Arakawa; Hideyuki Abe; Takuto Miyagishima; Jun Akiba; Takanori Teshima; Koichi Ohshima
  Pathology International, 68, 11, 614, 617, Wiley, 2018年11月, ［査読有り］
  研究論文（学術雑誌）
• Analysis of GNA13 Protein in Follicular Lymphoma and its Association With Poor Prognosis.
  Joji Shimono; Hiroaki Miyoshi; Noriaki Yoshida; Takeharu Kato; Kensaku Sato; Takeshi Sugio; Kohta Miyawaki; Daisuke Kurita; Yuya Sasaki; Keisuke Kawamoto; Yoshitaka Imaizumi; Koji Kato; Koji Nagafuji; Koichi Akashi; Masao Seto; Takanori Teshima; Koichi Ohshima
  The American journal of surgical pathology, 42, 11, 1466, 1471, 2018年11月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, GNA13 is a G protein involved in modulating tumor proliferative capacity, infiltration, metastasis, and migration. Genomic alteration of GNA13 was frequently observed in follicular lymphoma (FL). In this study, we examined 167 cases of FL by immunostaining of GNA13 using tissue microarray to evaluate the clinical significance. There were 26 GNA13-positive cases (15.6%) and 141 GNA13-negative cases (84.4%). GNA13-positive cases had a higher incidence of early progression of disease for which disease progression was recognized within 2 years compared with GNA13-negative cases (P=0.03). There were no significant differences in other clinicopathologic factors including histological grade, BCL2-IGH translocation, immunohistochemical phenotype, and Follicular Lymphoma International Prognostic Index. In addition, overall survival and progression-free survival were poorer in GNA13-positive cases than in GNA13-negative cases (P=0.009 and 0.005, respectively). In multivariate analysis, GNA13 positivity was found to be a poor prognostic factor for overall survival and progression-free survival. Thus, GNA13 protein expression was an independent prognostic factor and may affect disease progression in FL.
• Hematogones Predict Better Outcome in Allogeneic Hematopoietic Stem Cell Transplantation Irrespective of Graft Sources
  Takashi Ishio; Junichi Sugita; Takahiro Tateno; Daisuke Hidaka; Eiko Hayase; Souichi Shiratori; Kohei Okada; Hideki Goto; Masahiro Onozawa; Masao Nakagawa; Daigo Hashimoto; Kaoru Kahata; Katsuya Fujimoto; Tomoyuki Endo; Takeshi Kondo; Takanori Teshima
  Biology of Blood and Marrow Transplantation, 24, 10, 1990, 1996, Elsevier BV, 2018年10月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Benign precursors of B lymphocytes, termed hematogones, are observed in the regenerative state of hematopoiesis following chemotherapy or allogeneic hematopoietic stem cell transplantation (allo-HSCT). Previous studies have demonstrated that expansion of hematogones correlates with better clinical outcomes after allo-HSCT. We retrospectively analyzed the association between hematogones and clinical outcomes in 309 consecutive patients who underwent allo-HSCT, which is the largest population-based cohort reported so far. The incidence of hematogones was significantly higher in complete remission (CR) patients at the time of transplantation than in non-CR patients, after myeloablative conditioning than after reduced-intensity conditioning, with tacrolimus-based graft-versus-host disease (GVHD) prophylaxis than with cyclosporine-based prophylaxis, and with disease other than malignant lymphoma (all P < .05). Patients with hematogones developed less acute GVHD and infections than did those without them (P < .05). Emergence of hematogones was associated with superior GVHD-free relapse-free survival and lower nonrelapse mortality, and was an independent prognostic factor for overall survival, irrespective of donor sources.
• Essential role of IFN-γ in T cell–associated intestinal inflammation
  Yoshihiro Eriguchi; Kiminori Nakamura; Yuki Yokoi; Rina Sugimoto; Shuichiro Takahashi; Daigo Hashimoto; Takanori Teshima; Tokiyoshi Ayabe; Michael E. Selsted; André J. Ouellette
  JCI Insight, 3, 18, e121886, e121886, American Society for Clinical Investigation, 2018年09月20日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Paneth cells contribute to small intestinal homeostasis by secreting antimicrobial peptides and constituting the intestinal stem cell (ISC) niche. Certain T cell-mediated enteropathies are characterized by extensive Paneth cell depletion coincident with mucosal destruction and dysbiosis. In this study, mechanisms of intestinal crypt injury have been investigated by characterizing responses of mouse intestinal organoids (enteroids) in coculture with mouse T lymphocytes. Activated T cells induced enteroid damage, reduced Paneth cell and Lgr5+ ISC mRNA levels, and induced Paneth cell death through a caspase-3/7-dependent mechanism. IFN-γ mediated these effects, because IFN-γ receptor-null enteroids were unaffected by activated T cells. In mice, administration of IFN-γ induced enteropathy with crypt hyperplasia, villus shortening, Paneth cell depletion, and modified ISC marker expression. IFN-γ exacerbated radiation enteritis, which was ameliorated by treatment with a selective JAK1/2 inhibitor. Thus, IFN-γ induced Paneth cell death and impaired regeneration of small intestinal epithelium in vivo, suggesting that IFN-γ may be a useful target for treating defective mucosal regeneration in enteric inflammation.
• Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: Long-term follow-up on a phase II trial and treatment-related fatal cardiomyopathy
  Hiroyuki Nakamura; Toshio Odani; Shinsuke Yasuda; Atsushi Noguchi; Yuichiro Fujieda; Masaru Kato; Kenji Oku; Toshiyuki Bohgaki; Junichi Sugita; Tomoyuki Endo; Takanori Teshima; Tatsuya Atsumi
  Modern Rheumatology, 28, 5, 879, 884, Oxford University Press (OUP), 2018年09月03日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, OBJECTIVES: The objective of this study is to elucidate the efficacy and safety of autologous haematopoietic stem cell transplantation (HSCT) for Japanese patients with systemic sclerosis (SSc). METHODS: A phase II clinical trial included SSc patients diagnosed within the last three years having at least one of the following clinical features: diffuse skin sclerosis with modified Rodman total thickness skin score (mRSS) ≥ 15, refractory digital ulcer or interstitial lung disease (ILD). HSCT were performed after conditioning using cyclophosphamide. RESULTS: Fourteen patients were enrolled and underwent HSCT. Median follow-up period was 137 months. Overall survival or event-free survival rate was 93% or 40% at 10 years, respectively. Eight patients (57%) achieved more than a 50% decrease in mRSS from baseline within six months after HSCT. Six patients (43%) required additional immunosuppressive treatments due to progression of diffuse skin sclerosis and/or ILD during follow-up period. Adverse events related to HSCT occurred in six patients (43%). Severe cardiomyopathy occurred in two patients, and one of them had a fatal course. CONCLUSION: HSCT is a feasible treatment bringing favourable results to more than half of our patients with SSc. Careful selection of the patients is essential for whom benefited from HSCT, considering the risk-benefit balance of the treatment.
• The association between the incidence of intestinal graft-vs-host disease and antibiotic use after allogeneic hematopoietic stem cell transplantation
  Daisuke Hidaka; Eiko Hayase; Souichi Shiratori; Yuta Hasegawa; Takashi Ishio; Takahiro Tateno; Kohei Okada; Hideki Goto; Junichi Sugita; Masahiro Onozawa; Masao Nakagawa; Kaoru Kahata; Tomoyuki Endo; Daigo Hashimoto; Takanori Teshima
  Clinical Transplantation, 32, 9, e13361, e13361, Wiley, 2018年09月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Intestinal microbiota plays an important role in the regulation of allogeneic immune reaction after allogeneic hematopoietic stem cell transplantation (allo-SCT). Intestinal graft-vs-host disease (GVHD) is one of the major causes of mortality after allo-SCT and often complicated with intestinal dysbiosis. Recent studies suggest that antibiotic-induced dysbiosis is a risk factor for intestinal GVHD. We retrospectively evaluated the impacts of antibiotic use on the incidence of intestinal GVHD occurring before day 100 after allo-SCT. Among 213 patients who underwent allo-SCT, 200 patients achieving engraftment were analyzed. Antibiotics were classified into carbapenem, quinolone, penicillin, cephem, and glycopeptide. Among 128 patients who developed acute GVHD, intestinal GVHD developed in 36 patients. Patients with intestinal GVHD received significantly longer administration of carbapenem and glycopeptide compared to those without it in periengraftment period. In multivariate analysis, use of carbapenem for greater than 7 days was associated with an increased risk of intestinal GVHD. However, use of antibiotics for greater than 7 days was not associated with poor overall survival and high nonrelapse mortality. Long use of carbapenem in periengraftment period may be a risk for intestinal GVHD. Prospective studies are required to validate our findings.
• Disseminated fusariosis emerged from prolonged local genital infection after cord blood transplantation
  Kohei Okada; Tomoyuki Endo; Daigo Hashimoto; Tomoyuki Saga; Takahide Ara; Reiki Ogasawara; Atsushi Yasumoto; Makoto Ibata; Mutsumi Takahata; Akio Shigematsu; Takeshi Kondo; Yasunori Muraosa; Toshifumi Nomura; Hiromi Kanno-Okada; Satoshi Hashino; Shinya Tanaka; Katsuhiko Kamei; Takanori Teshima
  Journal of Infection and Chemotherapy, 24, 8, 660, 663, Elsevier B.V., 2018年08月01日, ［査読有り］
  英語, 研究論文（学術雑誌）
• Safety, tolerability and pharmacokinetics of shorter duration of infusion of obinutuzumab in Japanese patients with B-cell non-Hodgkin lymphoma: final results of the phase II GATS study
  Ken Ohmachi; Kiyoshi Ando; Tomohiro Kinoshita; Kyoya Kumagai; Kiyohiko Hatake; Takayuki Ishikawa; Takanori Teshima; Koji Kato; Koji Izutsu; Eisuke Ueda; Kiyohiko Nakai; Hiroshi Kuriki; Kensei Tobinai
  Japanese Journal of Clinical Oncology, 48, 8, 736, 742, Oxford University Press (OUP), 2018年08月01日, ［査読有り］
  研究論文（学術雑誌）
• Development of a Fluorescence in Situ Hybridization Probe for Detecting IKZF1 Deletion Mutations in Patients with Acute Lymphoblastic Leukemia
  Junichi Hashiguchi; Masahiro Onozawa; Satoshi Oguri; Shinichi Fujisawa; Masahisa Tsuji; Kohei Okada; Masao Nakagawa; Daigo Hashimoto; Kaoru Kahata; Takeshi Kondo; Chikara Shimizu; Takanori Teshima
  Journal of Molecular Diagnostics, 20, 4, 446, 454, Elsevier B.V., 2018年07月01日, ［査読有り］
  英語, 研究論文（学術雑誌）
• Pretreatment evaluation of fluorescence resonance energy transfer-based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinib.
  Takeshi Kondo; Mari Fujioka; Masumi Tsuda; Kazunori Murai; Kohei Yamaguchi; Takuto Miyagishima; Motohiro Shindo; Takahiro Nagashima; Kentaro Wakasa; Nozomu Fujimoto; Satoshi Yamamoto; Masakatsu Yonezumi; Souichi Saito; Shinji Sato; Kazuei Ogawa; Takaaki Chou; Reiko Watanabe; Yuichi Kato; Shuichiro Takahashi; Yoshiaki Okano; Joji Yamamoto; Masatsugu Ohta; Hiroaki Iijima; Koji Oba; Satoshi Kishino; Junichi Sakamoto; Yoji Ishida; Yusuke Ohba; Takanori Teshima
  Cancer science, 109, 7, 2256, 2265, 2018年07月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Tyrosine kinase inhibitors (TKI) are used for primary therapy in patients with newly diagnosed CML. However, a reliable method for optimal selection of a TKI from the viewpoint of drug sensitivity of CML cells has not been established. We have developed a FRET-based drug sensitivity test in which a CrkL-derived fluorescent biosensor efficiently quantifies the kinase activity of BCR-ABL of living cells and sensitively evaluates the inhibitory activity of a TKI against BCR-ABL. Here, we validated the utility of the FRET-based drug sensitivity test carried out at diagnosis for predicting the molecular efficacy. Sixty-two patients with newly diagnosed chronic phase CML were enrolled in this study and treated with dasatinib. Bone marrow cells at diagnosis were subjected to FRET analysis. The ΔFRET value was calculated by subtraction of FRET efficiency in the presence of dasatinib from that in the absence of dasatinib. Treatment response was evaluated every 3 months by the BCR-ABL1 International Scale. Based on the ΔFRET value and molecular response, a threshold of the ΔFRET value in the top 10% of FRET efficiency was set to 0.31. Patients with ΔFRET value ≥0.31 had significantly superior molecular responses (MMR at 6 and 9 months and both MR4 and MR4.5 at 6, 9, and 12 months) compared with the responses in patients with ΔFRET value <0.31. These results suggest that the FRET-based drug sensitivity test at diagnosis can predict early and deep molecular responses. This study is registered with UMIN Clinical Trials Registry (UMIN000006358).
• The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future
  Tessa M. Andermann; Jonathan U. Peled; Christine Ho; Pavan Reddy; Marcie Riches; Rainer Storb; Takanori Teshima; Marcel R.M. van den Brink; Amin Alousi; Sophia Balderman; Patrizia Chiusolo; William B. Clark; Ernst Holler; Alan Howard; Leslie S. Kean; Andrew Y. Koh; Philip L. McCarthy; John M. McCarty; Mohamad Mohty; Ryotaro Nakamura; Katy Rezvani; Brahm H. Segal; Bronwen E. Shaw; Elizabeth J. Shpall; Anthony D. Sung; Daniela Weber; Jennifer Whangbo; John R. Wingard; William A. Wood; Miguel-Angel Perales; Robert R. Jenq; Ami S. Bhatt
  Biology of Blood and Marrow Transplantation, 24, 7, 1322, 1340, Elsevier BV, 2018年07月, ［査読有り］
  研究論文（学術雑誌）
• Extracorporeal photopheresis with TC-V in Japanese patients with steroid-resistant chronic graft-versus-host disease
  Shinichiro Okamoto; Takanori Teshima; Mizuha Kosugi-Kanaya; Kaoru Kahata; Naomi Kawashima; Jun Kato; Takehiko Mori; Yukiyasu Ozawa; Koichi Miyamura
  International Journal of Hematology, 108, 3, 1, 8, Springer Tokyo, 2018年06月29日, ［査読有り］
  英語, 研究論文（学術雑誌）
• Re-infection of Toxoplasma gondii after HSCT presenting lymphadenopathy resembling recurrence of lymphoma
  Junichi Hashiguchi; Masahiro Onozawa; Tomoaki Naka; Kanako C. Hatanaka; Souichi Shiratori; Junichi Sugita; Katsuya Fujimoto; Yoshihiro Matsuno; Takanori Teshima
  Transplant Infectious Disease, 20, 3, e12892, Blackwell Publishing Inc., 2018年06月01日, ［査読有り］
  英語, 研究論文（学術雑誌）
• Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants
  Anita J. Kumar; Soyoung Kim; Michael T. Hemmer; Mukta Arora; Stephen R. Spellman; Joseph A. Pidala; Daniel R. Couriel; Amin M. Alousi; Mahmoud D. Aljurf; Jean-Yves Cahn; Mitchell S. Cairo; Corey S. Cutler; Shatha Farhan; Usama Gergis; Gregory A. Hale; Shahrukh K. Hashmi; Yoshihiro Inamoto; Rammurti T. Kamble; Mohamed A. Kharfan-Dabaja; Margaret L. MacMillan; David I. Marks; Hideki Nakasone; Maxim Norkin; Muna Qayed; Olle Ringden; Harry C. Schouten; Kirk R. Schultz; Melhem M. Solh; Takanori Teshima; Alvaro Urbano-Ispizua; Leo F. Verdonck; Robert Peter Gale; Betty K. Hamilton; Navneet S. Majhail; Alison W. Loren
  Blood Advances, 2, 9, 1022, 1031, American Society of Hematology, 2018年05月08日, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）,
  Compared with parous female sibling donors, male URDs confer more aGVHD in all patients and more cGVHD in females. There was no difference in survival, relapse, or transplant mortality between recipients of parous female sibling or male URD grafts.
• Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
  Shuichiro Takahashi; Daigo Hashimoto; Eiko Hayase; Reiki Ogasawara; Hiroyuki Ohigashi; Takahide Ara; Emi Yokoyama; Ko Ebata; Satomi Matsuoka; Geoffrey R. Hill; Junichi Sugita; Masahiro Onozawa; Takanori Teshima
  Blood, 131, 18, 2074, 2085, American Society of Hematology, 2018年05月03日, ［査読有り］
  英語, 研究論文（学術雑誌）
• Cecum ulcer is a reliable endoscopic finding in cytomegalovirus colitis concomitant with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
  Kana Matsuda; Shoko Ono; Marin Ishikawa; Shuichi Miyamoto; Satoshi Abiko; Momoko Tsuda; Keiko Yamamoto; Takahiko Kudo; Yuichi Shimizu; Eiko Hayase; Daigo Hashimoto; Takanori Teshima; Yoshihiro Matsuno; Naoya Sakamoto
  Annals of Hematology, 97, 5, 877, 883, Springer Verlag, 2018年05月01日, ［査読有り］
  英語, 研究論文（学術雑誌）
• Clinicopathological analysis of polyploid diffuse large B-cell lymphoma
  Joji Shimono; Hiroaki Miyoshi; Junichi Kiyasu; Tomohiko Kamimura; Tetsuya Eto; Takuto Miyagishima; Koji Nagafuji; Masao Seto; Takanori Teshima; Koichi Ohshima
  PLOS ONE, 13, 4, e0194525, e0194525, Public Library of Science (PLoS), 2018年04月11日, ［査読有り］
  研究論文（学術雑誌）
• A novel heterozygous ITGB3 p.T720del inducing spontaneous activation of integrin αIIbβ3 in autosomal dominant macrothrombocytopenia with aggregation dysfunction
  Naohiro Miyashita; Masahiro Onozawa; Koji Hayasaka; Takahiro Yamada; Ohsuke Migita; Kenichiro Hata; Kohei Okada; Hideki Goto; Masao Nakagawa; Daigo Hashimoto; Kaoru Kahata; Takeshi Kondo; Shinji Kunishima; Takanori Teshima
  Annals of Hematology, 97, 4, 629, 640, Springer Science and Business Media LLC, 2018年04月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission
  Toshihiro Miyamoto; Koji Nagafuji; Tomoaki Fujisaki; Naoyuki Uchida; Kosei Matsue; Hideho Henzan; Ryosuke Ogawa; Ken Takase; Takatoshi Aoki; Michihiro Hidaka; Takanori Teshima; Shuichi Taniguchi; Koichi Akashi; Mine Harada; For the Japan Study Group for Cell Therapy and Transplantation (JSCT)
  International Journal of Hematology, 107, 4, 468, 477, Springer Tokyo, 2018年04月01日, ［査読有り］
  英語, 研究論文（学術雑誌）
• Vitamin A–coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease
  Tomohiro Yamakawa; Hiroyuki Ohigashi; Daigo Hashimoto; Eiko Hayase; Shuichiro Takahashi; Miyono Miyazaki; Kenjiro Minomi; Masahiro Onozawa; Yoshiro Niitsu; Takanori Teshima
  Blood, 131, 13, 1476, 1485, American Society of Hematology, 2018年03月29日, ［査読有り］
  英語, 研究論文（学術雑誌）
• Overcoming HLA Barrier in Hematopoietic Stem Cell Transplantation
  Takanori Teshima
  Nihon Naika Gakkai Zasshi, 107, 3, 579, 585, Japanese Society of Internal Medicine, 2018年03月10日, ［査読有り］
  日本語, 研究論文（学術雑誌）
• Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
  Nimitha R. Mathew; Francis Baumgartner; Lukas Braun; David O'Sullivan; Simone Thomas; Miguel Waterhouse; Tony A. Müller; Kathrin Hanke; Sanaz Taromi; Petya Apostolova; Anna L. Illert; Wolfgang Melchinger; Sandra Duquesne; Annette Schmitt-Graeff; Lena Osswald; Kai-Li Yan; Arnim Weber; Sonia Tugues; Sabine Spath; Dietmar Pfeifer; Marie Follo; Rainer Claus; Michael Lübbert; Christoph Rummelt; Hartmut Bertz; Ralph Wäsch; Johanna Haag; Andrea Schmidts; Michael Schultheiss; Dominik Bettinger; Robert Thimme; Evelyn Ullrich; Yakup Tanriver; Giang Lam Vuong; Renate Arnold; Philipp Hemmati; Dominik Wolf; Markus Ditschkowski; Cordula Jilg; Konrad Wilhelm; Christian Leiber; Sabine Gerull; Jörg Halter; Claudia Lengerke; Thomas Pabst; Thomas Schroeder; Guido Kobbe; Wolf Rösler; Soroush Doostkam; Stephan Meckel; Kathleen Stabla; Stephan K. Metzelder; Sebastian Halbach; Tilman Brummer; Zehan Hu; Joern Dengjel; Björn Hackanson; Christoph Schmid; Udo Holtick; Christof Scheid; Alexandros Spyridonidis; Friedrich Stölzel; Rainer Ordemann; Lutz P. Müller; Flore Sicre-De-Fontbrune; Gabriele Ihorst; Jürgen Kuball; Jan E. Ehlert; Daniel Feger; Eva-Maria Wagner; Jean-Yves Cahn; Jacqueline Schnell; Florian Kuchenbauer; Donald Bunjes; Ronjon Chakraverty; Simon Richardson; Saar Gill; Nicolaus Kröger; Francis Ayuk; Luca Vago; Fabio Ciceri; Antonia M. Müller; Takeshi Kondo; Takanori Teshima; Susan Klaeger; Bernhard Kuster; Dennis H. Kim; Daniel Weisdorf; Walter Van Der Velden; Daniela Dörfel; Wolfgang Bethge; Inken Hilgendorf; Andreas Hochhaus; Geoffroy Andrieux; Melanie Börries; Hauke Busch; John Magenau; Pavan Reddy; Myriam Labopin; Joseph H. Antin; Andrea S. Henden; Geoffrey R. Hill; Glen A. Kennedy; Merav Bar; Anita Sarma; Donal McLornan; Ghulam Mufti; Betul Oran; Katayoun Rezvani; Omid Shah; Robert S. Negrin; Arnon Nagler; Marco Prinz; Andreas Burchert; Andreas Neubauer; Dietrich Beelen; Andreas Mackensen; Nikolas Von Bubnoff; Wolfgang Herr; Burkhard Becher; Gerard Socié; Michael A. Caligiuri; Eliana Ruggiero; Chiara Bonini; Georg Häcker; Justus Duyster; Jürgen Finke; Erika Pearce; Bruce R. Blazar; Robert Zeiser
  Nature Medicine, 24, 3, 282, 291, Nature Publishing Group, 2018年03月01日, ［査読有り］
  英語, 研究論文（学術雑誌）
• Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma
  M. Fujisawa; M. Sakata-Yanagimoto; S. Nishizawa; D. Komori; P. Gershon; M. Kiryu; S. Tanzima; K. Fukumoto; T. Enami; M. Muratani; K. Yoshida; S. Ogawa; K. Matsue; N. Nakamura; K. Takeuchi; K. Izutsu; K. Fujimoto; T. Teshima; H. Miyoshi; P. Gaulard; K. Ohshima; S. Chiba
  Leukemia, 32, 3, 694, 702, Nature Publishing Group, 2018年03月01日, ［査読有り］
  英語, 研究論文（学術雑誌）
• T-cell depletion effects of low-dose antithymocyte globulin for GVHD prophylaxis in HLA-matched allogeneic peripheral blood stem cell transplantation
  Souichi Shiratori; Mizuha Kosugi-Kanaya; Eiko Hayase; Kohei Okada; Hideki Goto; Junichi Sugita; Masahiro Onozawa; Masao Nakagawa; Kaoru Kahata; Daigo Hashimoto; Tomoyuki Endo; Takeshi Kondo; Takanori Teshima
  Transplant Immunology, 46, 21, 22, Elsevier BV, 2018年02月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Novel Ultrasonographic Scoring System of Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation
  Mutsumi Nishida; Kaoru Kahata; Eiko Hayase; Akio Shigematsu; Megumi Sato; Yusuke Kudo; Satomi Omotehara; Takahito Iwai; Junichi Sugita; Hitoshi Shibuya; Chikara Shimizu; Takanori Teshima
  Biology of Blood and Marrow Transplantation, 24, 9, 1896, 1900, Elsevier Inc., 2018年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Hepatitis C virus infection is an independent prognostic factor in follicular lymphoma
  Joji Shimono; Hiroaki Miyoshi; Takeharu Kato; Takeshi Sugio; Kohta Miyawaki; Tomohiko Kamimura; Takuto Miyagishima; Tetsuya Eto; Yoshitaka Imaizumi; Koji Kato; Koji Nagafuji; Koichi Akashi; Masao Seto; Takanori Teshima; Koichi Ohshima
  Oncotarget, 9, 2, 1717, 1725, Impact Journals LLC, 2018年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Long-Lasting Graft-Derived Donor T Cells Contribute to the pathogenesis of Chronic Graft-versus-Host Disease in Mice
  Mizuha Kosugi-Kanaya; Satoshi Ueha; Jun Abe; Shigeyuki Shichino; Francis H. W. Shand; Teppei Morikawa; Makoto Kurachi; Yusuke Shono; Naoto Sudo; Ai Yamashita; Fumiko Suenaga; Akihiro Yokoyama; Wang Yong; Masahiro Imamura; Takanori Teshima; Kouji Matsushima
  FRONTIERS IN IMMUNOLOGY, 8, 8, 1842, 2017年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• R-Spondin1 expands Paneth cells and prevents dysbiosis induced by graft-versus-host disease
  Eiko Hayase; Daigo Hashimoto; Kiminori Nakamura; Clara Noizat; Reiki Ogasawara; Shuichiro Takahashi; Hiroyuki Ohigashi; Yuki Yokoi; Rina Sugimoto; Satomi Matsuoka; Takahide Ara; Emi Yokoyama; Tomohiro Yamakawa; Ko Ebata; Takeshi Kondo; Rina Hiramine; Tomoyasu Aizawa; Yoshitoshi Ogura; Tetsuya Hayashi; Hiroshi Mori; Ken Kurokawa; Kazuma Tomizuka; Tokiyoshi Ayabe; Takanori Teshima
  JOURNAL OF EXPERIMENTAL MEDICINE, 214, 12, 3507, 3518, 2017年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Clinicopathological features of primary splenic follicular lymphoma
  Joji Shimono; Hiroaki Miyoshi; Tomohiko Kamimura; Tetsuya Eto; Takuto Miyagishima; Yuya Sasaki; Daisuke Kurita; Keisuke Kawamoto; Koji Nagafuji; Masao Seto; Takanori Teshima; Koichi Ohshima
  ANNALS OF HEMATOLOGY, 96, 12, 2063, 2070, 2017年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma
  Yutaka Tsutsumi; Chie Nakayama; Koki Kamada; Ryo Kikuchi; Daiki Kudo; Shinichi Ito; Satomi Matsuoka; Souichi Shiratori; Yoshiya Yamamoto; Hirohito Naruse; Takanori Teshima
  ANNALS OF HEMATOLOGY, 96, 12, 2057, 2061, 2017年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Effects of proton pump inhibitors and famotidine on elimination of plasma methotrexate: Evaluation of drug-drug interactions mediated by organic anion transporter 3
  Katsuya Narumi; Yu Sato; Masaki Kobayashi; Ayako Furugen; Kumiko Kasashi; Takehiro Yamada; Takanori Teshima; Ken Iseki
  BIOPHARMACEUTICS & DRUG DISPOSITION, 38, 9, 501, 508, 2017年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Transcriptome analysis reveals PDGF signaling-dependent regulation of myelofibrosis in murine chronic graft-versus-host diseases
  Shigeyuki Shichino; Satoshi Ueha; Naoto Sudo; Mizuha Kosugi-Kanaya; Francis H. W. Shand; Teppei Morikawa; Shin-ichi Hashimoto; Takanori Teshima; Kouji Matsushima
  CYTOKINE, 100, 108, 108, 2017年12月, ［査読有り］
  英語
• Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease
  Saiko Kurosawa; Kumi Oshima; Takuhiro Yamaguchi; Atsumi Yanagisawa; Takahiro Fukuda; Heiwa Kanamori; Takehiko Mori; Satoshi Takahashi; Tadakazu Kondo; Akio Kohno; Koichi Miyamura; Yukari Umemoto; Takanori Teshima; Shuichi Taniguchi; Takuya Yamashita; Yoshihiro Inamoto; Yoshinobu Kanda; Shinichiro Okamoto; Yoshiko Atsuta
  BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 23, 10, 1749, 1758, 2017年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia
  S. Terakura; Y. Kuwatsuka; S. Yamasaki; A. Wake; J. Kanda; Y. Inamoto; S. Mizuta; T. Yamaguchi; N. Uchida; Y. Kouzai; N. Aotsuka; H. Ogawa; H. Kanamori; K. Nishiwaki; S. Miyakoshi; M. Onizuka; I. Amano; T. Fukuda; T. Ichinohe; Y. Atsuta; M. Murata; T. Teshima
  BONE MARROW TRANSPLANTATION, 52, 9, 1261, 1267, 2017年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Clinicopathological analysis of primary splenic diffuse large B-cell lymphoma
  Joji Shimono; Hiroaki Miyoshi; Junichi Kiyasu; Kensaku Sato; Tomohiko Kamimura; Tetsuya Eto; Takuto Miyagishima; Koji Nagafuji; Takanori Teshima; Koichi Ohshima
  BRITISH JOURNAL OF HAEMATOLOGY, 178, 5, 719, 727, 2017年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Diffuse large B-cell lymphoma with a bulky mass in the cranial vault
  Minoru Kanaya; Tomoyuki Endo; Daigo Hashimoto; Shogo Endo; Ryo Takemura; Kohei Okada; Kanako C. Hatanaka; Yoshihiro Matsuno; Takanori Teshima
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 106, 2, 147, 148, 2017年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Disseminated toxoplasmosis after hematopoietic stem cell transplantation showing unusual magnetic resonance images
  Takahiro Tateno; Masahiro Onozawa; Junichi Hashiguchi; Takashi Ishio; Sayaka Yuzawa; Satomi Matsuoka; Mizuha Kosugi-Kanaya; Kohei Okada; Souichi Shiratori; Hideki Goto; Taichi Kimura; Junichi Sugita; Masao Nakagawa; Daigo Hashimoto; Kaoru Kahata; Katsuya Fujimoto; Tomoyuki Endo; Takeshi Kondo; Shinya Tanaka; Satoshi Hashino; Takanori Teshima
  TRANSPLANT INFECTIOUS DISEASE, 19, 4, e12720, 2017年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Inhibition of acute lethal pulmonary inflammation by the IDO-AhR pathway
  Soung-Min Lee; Ha Young Park; Young-Sill Suh; Eun Hye Yoon; Juyang Kim; Won Hee Jang; Won-Sik Lee; Sae-Gwang Park; Il-Whan Choi; Inhak Choi; Sun-Woo Kang; Hwayoung Yun; Takanori Teshima; Byungsuk Kwon; Su-Kil Seo
  PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 114, 29, E5881, E5890, 2017年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Risk factors of human herpesvirus 6 encephalitis/myelitis after allogeneic hematopoietic stem cell transplantation
  Naohiro Miyashita; Tomoyuki Endo; Masahiro Onozawa; Daigo Hashimoto; Takeshi Kondo; Katsuya Fujimoto; Kaoru Kahata; Junichi Sugita; Hideki Goto; Toshihiro Matsukawa; Satoshi Hashino; Takanori Teshima
  TRANSPLANT INFECTIOUS DISEASE, 19, 3, e12682, 2017年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• MALDI-TOF MS in post-transplant bloodstream infections: reliable identification of causative bacteria in the neutropenic phase
  M. Kanaya; Y. Hayashi; D. Hashimoto; T. Endo; J. Sugita; H. Ohigashi; J. Hashiguchi; T. Matsukawa; S. Matsuoka; M. Kosugi-Kanaya; H. Goto; M. Onozawa; K. Kahata; K. Fujimoto; T. Kondo; K. Akizawa; H. Shibuya; C. Shimizu; T. Teshima
  BONE MARROW TRANSPLANTATION, 52, 5, 778, 780, 2017年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Linear IgA Bullous Dermatosis Associated with Immunoglobulin Light-chain Amyloidosis
  Yasuyuki Yamaguchi; Hideyuki Ujiie; Hiroyuki Ohigashi; Hiroaki Iwata; Ken Muramatsu; Tomoyuki Endou; Takanori Teshima; Hiroshi Shimizu
  ACTA DERMATO-VENEREOLOGICA, 97, 4, 528, 529, 2017年04月, ［査読有り］
  英語
• Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma.
  Souichi Shiratori; Hiroyuki Ohhigashi; Shinichi Ito; Kazuhiro Kudo; Maki Adachi; Toshiyuki Minamimoto; Junji Kato; Yasue Osai; Yutaka Tsutsumi; Takanori Teshima
  Hematological oncology, 35, 1, 138, 140, 2017年03月, ［国際誌］
  英語
• Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation
  J. Kanda; Y. Morishima; S. Terakura; A. Wake; N. Uchida; S. Takahashi; Y. Ono; Y. Onishi; H. Kanamori; N. Aotsuka; Y. Ozawa; H. Ogawa; T. Sakura; K. Ohashi; T. Ichinohe; K. Kato; Y. Atsuta; T. Teshima; M. Murata
  LEUKEMIA, 31, 3, 663, 668, 2017年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes
  Y-B Chen; T. Wang; M. T. Hemmer; C. Brady; D. R. Couriel; A. Alousi; J. Pidala; A. Urbano-Ispizua; S. W. Choi; T. Nishihori; T. Teshima; Y. Inamoto; B. Wirk; D. I. Marks; H. Abdel-Azim; L. Lehmann; L. Yu; M. Bitan; M. S. Cairo; M. Qayed; R. Salit; R. P. Gale; R. Martino; S. Jaglowski; A. Bajel; B. Savani; H. Frangoul; I. D. Lewis; J. Storek; M. Askar; M. A. Kharfan-Dabaja; M. Aljurf; O. Ringden; R. Reshef; R. F. Olsson; S. Hashmi; S. Seo; T. R. Spitzer; M. L. MacMillan; A. Lazaryan; S. R. Spellman; M. Arora; C. S. Cutler
  BONE MARROW TRANSPLANTATION, 52, 3, 400, 408, 2017年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil
  S. Terakura; A. Wake; Y. Inamoto; M. Murata; R. Sakai; T. Yamaguchi; S. Takahashi; N. Uchida; Y. Onishi; K. Ohashi; Y. Ozawa; H. Kanamori; H. Yamaguchi; T. Fukuda; T. Ichinohe; M. Takanashi; Y. Atsuta; T. Teshima
  BONE MARROW TRANSPLANTATION, 52, 3, 423, 430, 2017年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Graft-versus-host disease targets ovary and causes female infertility in mice
  Sonoko Shimoji; Daigo Hashimoto; Hidetsugu Tsujigiwa; Kohta Miyawaki; Koji Kato; Shuichiro Takahashi; Reiki Ogasawara; Takashi Jiromaru; Hiromi Iwasaki; Toshihiro Miyamoto; Koichi Akashi; Takanori Teshima
  BLOOD, 129, 9, 1216, 1225, 2017年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities
  Makoto Ibata; Junko Iwasaki; Yoichiro Fujioka; Koji Nakagawa; Stephanie Darmanin; Masahiro Onozawa; Daigo Hashimoto; Yusuke Ohba; Shigetsugu Hatakeyama; Takanori Teshima; Takeshi Kondo
  CANCER SCIENCE, 108, 2, 200, 207, 2017年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Prior history of HLA-mismatched stem cell transplantation is a risk factor for graft failure in HLA-haploidentical transplantation
  J. Sugita; T. Miyamoto; N. Kawashima; N. Hatsumi; N. Anzai; H. Kaneko; M. Nara; K. Minauchi; M. Harada; T. Teshima
  BONE MARROW TRANSPLANTATION, 52, 2, 323, 325, 2017年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: an analysis of the JSHCT
  M. Murata; K. Ikegame; Y. Morishita; H. Ogawa; K. Kaida; H. Nakamae; T. Ikeda; T. Nishida; M. Inoue; T. Eto; K. Kubo; T. Sakura; T. Mori; N. Uchida; T. Ashida; Y. Matsuhashi; Y. Miyazaki; T. Ichinohe; Y. Atsuta; T. Teshima
  Bone Marrow Transplant, 52, 2, 252, 257, 2017年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Unilateral conjunctival infiltration of Adult T-cell leukemia/lymphoma. Case report and literature review
  Joji Shimono; Shigeki Kaino; Kohei Okada; Kazuo Oshimi; Yusuke Ishida; Tatsuro Takahashi; Takuto Miyagishima; Takanori Teshima
  Journal of Clinical and Experimental Hematopathology, 57, 3, 143, 146, Japanese Society for Lymphoreticular Tissue Research, 2017年, ［査読有り］
  研究論文（学術雑誌）
• Improved FRET Biosensor for the Measurement of BCR-ABL Activity in Chronic Myeloid Leukemia Cells
  Mika Horiguchi; Mari Fujioka; Takeshi Kondo; Yoichiro Fujioka; Xinxin Li; Kosui Horiuchi; Aya O. Satoh; Prabha Nepal; Shinya Nishide; Asuka Nanbo; Takanori Teshima; Yusuke Ohba
  CELL STRUCTURE AND FUNCTION, 42, 1, 15, 26, 2017年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Clinical features of diffuse large B-cell lymphoma with polyploidy
  Joji Shimono; Hiroaki Miyoshi; Masao Seto; Takanori Teshima; Koichi Ohshima
  PATHOLOGY INTERNATIONAL, 67, 1, 17, 23, 2017年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood transplantation
  Toshihiro Miyamoto; Shuichiro Takashima; Koji Kato; Ken Takase; Goichi Yoshimoto; Shuro Yoshida; Hideho Henzan; Koichi Osaki; Tomohiko Kamimura; Hiromi Iwasaki; Tetsuya Eto; Takanori Teshima; Koji Nagafuji; Koichi Akashi
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 105, 1, 92, 99, 2017年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Graft-versus-host disease in the ovary potentially causes female infertility after allogeneic hematopoietic stem cell transplantation.
  Shimoji S; Hashimoto D; Teshima T
  [Rinsho ketsueki] The Japanese journal of clinical hematology, 58, 7, 827, 834, 2017年, ［査読有り］
• Ruxolitinib treatment for GvHD in patients with myelofibrosis
  Y. Mori; K. Ikeda; T. Inomata; G. Yoshimoto; N. Fujii; H. Ago; T. Teshima
  BONE MARROW TRANSPLANTATION, 51, 12, 1584, 1587, 2016年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups
  Yoshihiro Inamoto; Fumihiko Kimura; Junya Kanda; Junichi Sugita; Kazuhiro Ikegame; Hideki Nakasone; Yasuhito Nannya; Naoyuki Uchida; Takahiro Fukuda; Kosuke Yoshioka; Yukiyasu Ozawa; Ichiro Kawano; Yoshiko Atsuta; Koji Kato; Tatsuo Ichinohe; Masami Inoue; Takanori Teshima
  HAEMATOLOGICA, 101, 12, 1592, 1602, 2016年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Successful T-cell Replete Hematopoietic Stem Cell Boost Without Conditioning for Late Graft Failure
  Y. Tsutsumi; T. Tateno; S. Ito; S. Shiratori; T. Teshima
  TRANSPLANTATION PROCEEDINGS, 48, 9, 3225, 3226, 2016年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Evaluation of Short-Term Ruxolitinib Tapering Strategy Before Allogeneic Stem Cell Transplantation for Primary Myelofibrosis Through the Transition of Serum Cytokines and Growth Factors
  Souichi Shiratori; Takahiro Tateno; Shinichi Ito; Yutaka Tsutsumi; Takanori Teshima
  Transplantation Direct, 2, 8, e95, e95, Ovid Technologies (Wolters Kluwer Health), 2016年08月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）
• Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHD
  Toshihiro Matsukawa; Daigo Hashimoto; Junichi Sugita; Seitarou Nakazawa; Takae Matsushita; Haruhiko Kashiwazaki; Hideki Goto; Masahiro Onozawa; Kaoru Kahata; Katsuya Fujimoto; Tomoyuki Endo; Takeshi Kondo; Satoshi Hashino; Yutaka Yamazaki; Takanori Teshima
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 104, 1, 117, 124, 2016年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Soluble DNAM-1, as a Predictive Biomarker for Acute Graft-Versus-Host Disease
  Minoru Kanaya; Kazuko Shibuya; Rei Hirochika; Miyoko Kanemoto; Kazuteru Ohashi; Masafumi Okada; Yukiko Wagatsuma; Yukiko Cho; Hiroshi Kojima; Takanori Teshima; Masahiro Imamura; Hisashi Sakamaki; Akira Shibuya
  PLOS ONE, 11, 6, e0154173, 2016年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation
  Toshihiro Matsukawa; Kumi Izawa; Masamichi Isobe; Mariko Takahashi; Akie Maehara; Yoshinori Yamanishi; Ayako Kaitani; Ko Okumura; Takanori Teshima; Toshio Kitamura; Jiro Kitaura
  GUT, 65, 5, 777, U777, 2016年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia
  Y. Arai; T. Kondo; H. Yamazaki; K. Takenaka; J. Sugita; T. Kobayashi; Y. Ozawa; N. Uchida; K. Iwato; N. Kobayashi; Y. Takahashi; K. Ishiyama; T. Fukuda; T. Ichinohe; Y. Atsuta; T. Mori; T. Teshima; T. Japan; Society for; Hematopoietic Cell
  Haematologica, 101, 5, 644, 652, 2016年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning for mycosis fungoides and Sezary syndrome
  Souichi Shiratori; Katsuya Fujimoto; Machiko Nishimura; Kanako C. Hatanaka; Mizuha Kosugi-Kanaya; Kohei Okada; Junichi Sugita; Akio Shigematsu; Daigo Hashimoto; Tomoyuki Endo; Takeshi Kondo; Riichiro Abe; Satoshi Hashino; Yoshihiro Matsuno; Hiroshi Shimizu; Takanori Teshima
  HEMATOLOGICAL ONCOLOGY, 34, 1, 9, 16, 2016年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Reprint of: Acute Graft-versus-Host Disease: Novel Biological Insights
  Takanori Teshima; Pavan Reddy; Robert Zeiser
  BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 22, 3, S3, S8, 2016年03月, ［査読有り］
  英語
• Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia
  Jun Aoki; Heiwa Kanamori; Masatsugu Tanaka; Satoshi Yamasaki; Takahiro Fukuda; Hiroyasu Ogawa; Koji Iwato; Kazuteru Ohashi; Hirokazu Okumura; Makoto Onizuka; Yoshitomo Maesako; Takanori Teshima; Naoki Kobayashi; Yasuo Morishima; Makoto Hirokawa; Yoshiko Atsuta; Shingo Yano; Akiyoshi Takami
  AMERICAN JOURNAL OF HEMATOLOGY, 91, 3, 302, 307, 2016年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• 5-Azacytidine partially restores CD20 expression in follicular lymphoma that lost CD20 expression after rituximab treatment: A case report
  Yutaka Tsutsumi; Hiroyuki Ohigashi; Shinichi Ito; Souichi Shiratori; Takanori Teshima
  Journal of Medical Case Reports, 10, 1, 27, BioMed Central Ltd., 2016年02月02日, ［査読有り］
  英語, 研究論文（学術雑誌）
• Cord Blood Transplantation Following Reduced-intensity Conditioning for Adult-onset Inherited Hemophagocytic Lymphohistiocytosis
  Takuro Kuriyama; Koji Kato; Keiji Sakamoto; Masayasu Hayashi; Shuichiro Takashima; Yasuo Mori; Katsuto Takenaka; Hiromi Iwasaki; Takanori Teshima; Naoki Harada; Koji Nagafuji; Toshihiro Miyamoto; Koichi Akashi
  INTERNAL MEDICINE, 55, 6, 667, 671, 2016年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Cytogenetically Unrelated Clones in Acute Myeloid Leukemia Showing Different Responses to Chemotherapy
  Kohei Kasahara; Masahiro Onozawa; Naohiro Miyashita; Emi Yokohata; Miho Yoshida; Minoru Kanaya; Mizuha Kosugi-Kanaya; Ryo Takemura; Shojiro Takahashi; Junichi Sugita; Akio Shigematsu; Mutsumi Takahata; Shinichi Fujisawa; Daigo Hashimoto; Katsuya Fujimoto; Tomoyuki Endo; Takeshi Kondo; Takanori Teshima
  Case Reports in Hematology, 2016, 1, 5, Hindawi Limited, 2016年, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, We report a case of acute myeloid leukemia (AML) with two cytogenetically unrelated clones. The patient was a 45-year-old male who was diagnosed with acute monoblastic leukemia (AMoL). Initial G-band analysis showed 51,XY,+6,+8,inv(9)(p12q13)c,+11,+13,+19[12]/52,idem,+Y[8], but G-band analysis after induction therapy showed 45,XY,-7,inv(9)(p12q13)c[19]/46,XY,inv(9)(p12q13)c[1]. Retrospective FISH analysis revealed a cryptic monosomy 7 clone in the initial AML sample. The clone with multiple trisomies was eliminated after induction therapy and never recurred, but a clone with monosomy 7 was still detected in myelodysplastic marrow with a normal blast percentage. Both clones were successfully eliminated after related peripheral blood stem cell transplantation, but the patient died of relapsed AML with monosomy 7. We concluded that one clone was de novo AMoL with chromosome 6, 8, 11, 13, and 19 trisomy and that the other was acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) with chromosome 7 monosomy showing different responses to chemotherapy. Simultaneous onset of cytogenetically unrelated hematological malignancies that each have a different disease status is a rare phenomenon but is important to diagnose for a correct understanding of the disease status and for establishing an appropriate treatment strategy.
• Determination of prognosis of Philadelphia chromosome-negative myeloproliferative neoplasms with a simple clinical examination: Retrospective analysis of 71 patients in a single institution
  SHINICHI ITO; YUTAKA TSUTSUMI; HIROYUKI OHIGASHI; SOUICHI SHIRATORI; TAKANORI TESHIMA
  Molecular and Clinical Oncology, 4, 1, 51, 57, Spandidos Publications, 2016年01月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocytosis (ET) and primary myelofibrosis (PMF), are clonal hematopoietic diseases. A single-institution retrospective analysis was performed, including 71 MPN patients diagnosed at the Hakodate Municipal Hospital between April, 2001 and April, 2014, and certain clinical characteristics were identified as effective prognostic factors. The patients were categorized by risk factor scoring based on age, number of abnormal blood cell lineages and splenomegaly at diagnosis, and the association between this categorization and prognosis was analyzed using a statistical procedure. The effect of Janus kinase 2 (JAK2) V617F mutation on prognosis was also investigated. The MPN patients were consolidated into three risk groups based on the margin of intergroup survival differences: i) Score 1-2 (n=23), ii) score 3 (n=24) and iii) score 4-5 (n=24). MPN patients with scores of 4 or 5 exhibited poorer overall survival (OS) compared with those with lower scores (P<0.001). In addition, there were significant differences in event-free survival (EFS) among scoring groups (P=0.0059). PV and ET had a better prognosis compared with PMF, although this analysis suggested that PV and ET patients with scores of 4 or 5 may have a poorer prognosis in terms of OS (P=0.0052) and EFS (P=0.022) and should be closely followed up. We observed no significant prognostic effect of the JAK2V167F mutation for OS (P=0.28) or EFS (P=0.17). Our results suggested that a simple scoring system based on age, blood cell counts and presence of splenomegaly at diagnosis may be used for the long-term prognosis of MPN patients.
• Unplanned discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia
  YUTAKA TSUTSUMI; SHINICHI ITO; HIROYUKI OHIGASHI; SOUICHI SHIRATORI; TAKANORI TESHIMA
  Molecular and Clinical Oncology, 4, 1, 89, 92, Spandidos Publications, 2016年01月, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, This study was conducted to investigate the outcomes of patients with chronic myeloid leukemia (CML) who discontinued tyrosine kinase inhibitor (TKI) treatment. A single-center retrospective analysis was performed, including 46 chronic-phase (CP) CML patients who achieved complete molecular response (CMR) with TKIs. TKI treatment was discontinued in 13 patients based on their requests. The BCR-ABL transcript levels were monitored in the peripheral blood by quantitative polymerase chain reaction analysis following treatment discontinuation. Of the 13 patients who discontinued TKI treatment, 7 remained in CMR, with a median follow-up of 26 months (range, 10-60 months). The remaining 6 patients lost CMR following TKI discontinuation; 2 of these patients achieved a second CMR following re-administration of TKIs, 2 patients spontaneously achieved CMR and 2 remained in complete hematological response (CHR) without TKI treatment with a median follow-up of 29.5 months (range, 10-52 months). In conclusion, the survival of patients who lost CMR following TKI discontinuation may not be affected, even without re-administration of TKIs. Vigilant observation is recommended for such patients. The limitations of this study included the small patient sample, retrospective design and patient heterogeneity. Therefore, the results must be interpreted with caution.
• Pharmacokinetics and dose adjustment of etoposide administered in a medium-dose etoposide, cyclophosphamide and total body irradiation regimen before allogeneic hematopoietic stem cell transplantation.
  Yuki Tazawa; Akio Shigematsu; Kumiko Kasashi; Junichi Sugita; Tomoyuki Endo; Takeshi Kondo; Takanori Teshima; Ken Iseki; Mitsuru Sugawara; Yoh Takekuma
  Journal of pharmaceutical health care and sciences, 2, 18, 18, 18, 2016年, ［査読有り］, ［国際誌］
  英語, 研究論文（学術雑誌）, BACKGROUND: We investigated the pharmacokinetics of etoposide (ETP) to reduce the inter-individual variations of ETP concentrations in patients with acute leukemia who underwent allogeneic hematopoietic stem cell transplantation. We also carried out an in vivo study using rats to verify the dose adjustment. METHODS: This study included 20 adult patients. ETP was administered intravenously at a dose of 15 mg/kg once daily for 2 days (total dose: 30 mg/kg) combined with standard conditioning of cyclophosphamide and total body irradiation. In an in vivo study using rats, ETP was administered intravenously at a dose of 15 mg/kg or an adjusted dose. The ETP plasma concentration was determined by using HPLC. The pharmacokinetic parameters were estimated by using a 1-compartment model. RESULTS: The peak concentration (Cmax) of ETP and the area under the plasma concentration-time curve (AUC) of ETP differed greatly among patients (range of Cmax, 51.8 - 116.5 μg/mL; range of AUC, 870 - 2015 μg · h/mL). A significant relationship was found between Cmax and AUC (R = 0.85, P < 0.05). Distribution volume (Vd) was suggested to be one of the factors of inter-individual variation in plasma concentration of ETP in patients (range of Vd, 0.13 - 0.27 L/kg), and correlated with Alb and body weight (R = 0.56, P < 0.05; R = 0.40, P < 0.05 respectively). We predicted Vd of rats by body weight of rats (with normal albumin levels and renal function), and the dose of ETP was adjusted using predicted Vd. In the dose adjustment group, the target plasma ETP concentration was achieved and the variation of plasma ETP concentration was decreased. CONCLUSION: The results suggested that inter-individual variation of plasma concentration of ETP could be reduced by predicting Vd. Prediction of Vd is effective for reducing individual variation of ETP concentration and might enable a good therapeutic effect to be achieved.
• Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
  Shuichiro Takashima; Toshihiro Miyamoto; Tomohiko Kamimura; Goichi Yoshimoto; Shuro Yoshida; Hideho Henzan; Ken Takase; Koji Kato; Yoshikiyo Ito; Yuju Ohno; Koji Nagafuji; Tetsuya Eto; Takanori Teshima; Koichi Akashi
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 102, 6, 689, 696, 2015年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration
  M. Takahata; S. Hashino; M. Nishio; J. Sugita; A. Shigematsu; M. Onozawa; K. Fujimoto; T. Endo; T. Kondo; J. Tanaka; M. Imamura; T. Teshima
  TRANSPLANT INFECTIOUS DISEASE, 17, 6, 810, 815, 2015年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma
  Yutaka Tsutsumi; Shinichi Ito; Hiroyuki Ohigashi; Naohiro Miyashita; Joji Shimono; Souichi Shiratori; Takanori Teshima
  LEUKEMIA & LYMPHOMA, 56, 11, 3216, 3218, 2015年11月, ［査読有り］
  英語
• Decreased secretion of Paneth cell α-defensins in graft-versus-host disease
  Y. Eriguchi; K. Nakamura; D. Hashimoto; S. Shimoda; N. Shimono; K. Akashi; T. Ayabe; T. Teshima
  Transplant Infectious Disease, 17, 5, 702, 706, 2015年10月01日
  英語, 研究論文（学術雑誌）
• Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia
  Yoshihiro Inamoto; Mary E. D. Flowers; Tao Wang; Alvaro Urbano-Ispizua; Michael T. Hemmer; Corey S. Cutler; Daniel R. Couriel; Amin M. Alousi; Joseph H. Antin; Robert Peter Gale; Vikas Gupta; Betty K. Hamilton; Mohamed A. Kharfan-Dabaja; David I. Marks; Olle T. H. Ringden; Gerard Socie; Melhem M. Solh; Goerguen Akpek; Mitchell S. Cairo; Nelson J. Chao; Robert J. Hayashi; Taiga Nishihori; Ran Reshef; Ayman Saad; Ami Shah; Takanori Teshima; Martin S. Tallman; Baldeep Wirk; Stephen R. Spellman; Mukta Arora; Paul J. Martin
  BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21, 10, 1776, 1782, 2015年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning
  Junichi Sugita; Naomi Kawashima; Tomoaki Fujisaki; Kazuhiko Kakihana; Shuichi Ota; Keitaro Matsuo; Toshihiro Miyamoto; Koichi Akashi; Shuichi Taniguchi; Mine Harada; Takanori Teshima
  BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21, 9, 1646, 1652, 2015年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Preserved in vivo reconstitution ability of PBSCs cryopreserved for a decade at -80 °C.
  Shima T; Iwasaki H; Yamauchi T; Kadowaki M; Kiyosuke M; Mochimaru T; Takenaka K; Miyamoto T; Akashi K; Teshima T
  Bone Marrow Transplant., 50, 9, 1195, 1200, 2015年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: What we do and do not know
  M. Ogata; T. Fukuda; T. Teshima
  BONE MARROW TRANSPLANTATION, 50, 8, 1030, 1036, 2015年08月
  英語
• Ultrasonographic evaluation of gastrointestinal graft-versus-host disease after hematopoietic stem cell transplantation
  Mutsumi Nishida; Akio Shigematsu; Megumi Sato; Yusuke Kudo; Satomi Omotehara; Tatsunori Horie; Takahito Iwai; Tomoyuki Endo; Akihiro Iguchi; Hitoshi Shibuya; Kanako Hatanaka; Chikara Shimizu; Takanori Teshima
  CLINICAL TRANSPLANTATION, 29, 8, 697, 704, 2015年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• PolyI:C-Induced, TLR3/RIP3-Dependent Necroptosis Backs Up Immune Effector-Mediated Tumor Elimination In Vivo
  Ryo Takemura; Hiromi Takaki; Seiji Okada; Hiroaki Shime; Takashi Akazawa; Hiroyuki Oshiumi; Misako Matsumoto; Takanori Teshima; Tsukasa Seya
  CANCER IMMUNOLOGY RESEARCH, 3, 8, 902, 914, 2015年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Key players in intestinal GVHD
  Daigo Hashimoto; Takanori Teshima
  [Rinshō ketsueki] The Japanese journal of clinical hematology, 56, 7, 807, 814, 2015年07月01日
• Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia/lymphoma.
  Shiratori S; Ohigashi H; Ito S; Kudo K; Adachi M; Minamimoto T; Kato J; Osai Y; Tsutsumi Y; Teshima T
  Hematol Oncol., 2015年07月, ［査読有り］
• Decreased secretion of Paneth cell α-defensin in graft-versus-host disease.
  Eriguchi Y; Nakamura K; Hashimoto D; Shimoda S; Shimono N; Akashi K; Ayabe T; Teshima T
  Transpl Infect Dis., 2015年07月, ［査読有り］
• Upregulation of microRNA-126-5p is associated with drug resistance to cytarabine and poor prognosis in AML patients
  YOSHIHIKO SHIBAYAMA; TAKESHI KONDO; HIROKI OHYA; SHIN-ICHI FUJISAWA; TAKANORI TESHIMA; KEN ISEKI
  Oncology Reports, 33, 5, 2176, 2182, 2015年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study.
  Youko Suehiro; Atsuhiko Hasegawa; Tadafumi Iino; Amane Sasada; Nobukazu Watanabe; Masao Matsuoka; Ayako Takamori; Ryuji Tanosaki; Atae Utsunomiya; Ilseung Choi; Tetsuya Fukuda; Osamu Miura; Shigeo Takaishi; Takanori Teshima; Koichi Akashi; Mari Kannagi; Naokuni Uike; Jun Okamura
  Br. J. Haematol., 169, 3, 356, 367, 2015年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• α-Mannan induces Th17-mediated pulmonary graft-versus-host disease in mice.
  Uryu H; Hashimoto D; Kato K; Hayase E; Matsuoka S; Ogasawara R; Takahashi S; Maeda Y; Iwasaki H; Miyamoto T; Saijo S; Iwakura Y; Hill GR; Akashi K; Teshima T
  Blood., 125, 19, 3014, 3023, 2015年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• The primacy of IL-6 in IPS?
  Takanori Teshima
  Blood, 125, 15, 2320, 2322, 2015年04月09日, ［査読有り］
  研究論文（学術雑誌）
• Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation
  H. Nakasone; T. Fukuda; J. Kanda; T. Mori; S. Yano; T. Kobayashi; K. Miyamura; T. Eto; H. Kanamori; K. Iwato; N. Uchida; S. Mori; T. Nagamura-Inoue; T. Ichinohe; Y. Atsuta; T. Teshima; M. Murata
  BONE MARROW TRANSPLANTATION, 50, 4, 559, 565, 2015年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Analysis of the influence of dabigatran on coagulation factors and inhibitors
  Y. Tsutsumi; J. Shimono; H. Ohhigashi; S. Ito; S. Shiratori; T. Teshima
  INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 37, 2, 225, 230, 2015年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• CD155 Regulates Regulatory T Cell Population and Attenuates Acute Graft-Versus-Host Disease
  Minoru Kanaya; Kazuko Shibuya; Fumie Abe; Takanori Teshima; Akira Shibuya
  Biology of Blood and Marrow Transplantation, 21, 2, S335, S335, Elsevier BV, 2015年02月, ［査読有り］
  研究論文（学術雑誌）
• Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation.
  Matsukawa T; Izawa K; Isobe M; Takahashi M; Maehara A; Yamanishi Y; Kaitani A; Okumura K; Teshima T; Kitamura T; Kitaura J
  Gut., 2015年02月, ［査読有り］
• Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
  Sally Arai; Mukta Arora; Tao Wang; Stephen R. Spellman; Wensheng He; Daniel R. Courie; Alvaro Urbano-Ispizua; Corey S. Cutler; Andrea A. Bacigalupo; Minoo Battiwallaw; Mary E. Flowers; Mark B. Juckett; Stephanie J. Lee; Alison W. Loren; Thomas R. Klumpp; Susan E. Prockup; Olle E. T. H. Ringden; Bipin N. Savani; Gerard Socie; Kirk R. Schultz; Thomas Spitzer; Takanori Teshima; Christopher N. Bredeson; David A. Jacobsohn; Robert J. Hayashi; William R. Drobyski; Haydar A. Frangoul; Gorgiin Akpek; Vincent T. Ho; Victor A. Lewis; Robert Peter Gale; John Koreth; Nelson J. Chao; Mahmoud D. Aljurf; Brenda W. Cooper; Mary J. Laughlin; Jack W. Hsu; Peiman Hematti; Leo F. Verdonck; Melhelm M. Solh; Maxim Norkin; Vijay Reddy; Jose A. Perez-Simon; Nandita Khera; Ian D. Lewis; Yoshiko Atsuta; Richard F. Olsson; Wael Saber; Edmund K. Waller; Didier Blaise; Joseph A. Pidala; Paul J. Martin; Prakash Satwani; Martin Bornhauser; Yoshihiro Inamoto; Daniel J. Weisdorf; Mary M. Horowitz; Steven Z. Pavletic
  BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 21, 2, 266, 274, 2015年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• CD4/CD8 Double-negative T-cell Lymphoma: A Variant of Primary Cutaneous CD8(+) Aggressive Epidermotropic Cytotoxic T-cell Lymphoma?
  Toshinari Miyauchi; Riichiro Abe; Yusuke Morita; Maki Adachi; Keiko Shiba; Yohei Hamade; Nan Saito; Machiko Nishimura; Makoto Ibata; Kohei Okada; Akio Shigematsu; Tomoyuki Endo; Kazuhiro Kawai; Takanori Teshima; Hiroshi Shimizu
  ACTA DERMATO-VENEREOLOGICA, 95, 8, 1024, 1025, 2015年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Human Herpesvirus-6 Pneumonitis around the Engraftment of Cord Blood Transplantation following Foscarnet Prophylaxis in a Patient with Acute Leukemia
  Takashi Ishio; Tomoyuki Endo; Kohei Okada; Akio Shigematsu; Satoshi Hashino; Takanori Teshima
  Case Reports in Hematology, 2015, 1, 5, Hindawi Limited, 2015年, ［査読有り］
  研究論文（学術雑誌）, Human herpesvirus-6 (HHV-6) reactivation is sometimes observed in immunocompromised patients, especially after allogeneic stem cell transplantation. The complications of HHV-6 reactivation in this setting are mainly recognized as HHV-6 encephalitis. We herein report the case of a patient who developed HHV-6 pneumonitis after cord blood transplantation (CBT). A 35-year-old male underwent CBT for T-cell/myeloid mixed phenotype acute leukemia and achieved neutrophil engraftment on day 31. He had received foscarnet as prophylaxis for HHV-6 reactivation. A computed tomography (CT) scan to evaluate the leukemic tumor showed bilateral interstitial pneumonitis on day 33, although he had no respiratory symptoms. The findings of the CT scan were consistent with those of HHV-6 pneumonitis that were reported previously. HHV-6 DNA, but no other pathogens, was detected in his bronchoalveolar lavage (BAL) fluid. The patient was successfully treated with a therapeutic dose of foscarnet. This case indicates that performing a CT scan around the time of neutrophil engraftment can play an important role in detecting the early phase of HHV-6 pneumonia, and BAL should be considered if features consistent with HHV-6 pneumonitis are observed in patients with a risk of HHV-6 reactivation.
• Primary Bone Lymphoma: A Clinical Analysis of 17 Patients in a Single Institution
  Eiko Hayase; Mitsutoshi Kurosawa; Hiroaki Suzuki; Kohei Kasahara; Tomohiro Yamakawa; Masakatsu Yonezumi; Sachiko Suzuki; Takanori Teshima
  ACTA HAEMATOLOGICA, 134, 2, 80, 85, 2015年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Ultra-high level of serum soluble interleukin-2 receptor at diagnosis predicts poor outcome for angioimmunoblastic T-cell lymphoma
  Souichi Shiratori; Mizuha Kosugi-Kanaya; Akio Shigematsu; Hajime Kobayashi; Satoshi Yamamoto; Naoki Kobayashi; Hiroshi Iwasaki; Akio Mori; Yasuyuki Kunieda; Yutaka Tsutsumi; Mitsutoshi Kurosawa; Yasutaka Kakinoki; Tomoyuki Endo; Takeshi Kondo; Satoshi Hashino; Takanori Teshima
  LEUKEMIA & LYMPHOMA, 56, 9, 2592, 2597, 2015年, ［査読有り］
  英語, 研究論文（学術雑誌）
• PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+T cell response to autologous survivin in HLA-A*2402 transgenic mice
  Jun Kasamatsu; Shojiro Takahashi; Masahiro Azuma; Misako Matsumoto; Akiko Morii-Sakai; Masahiro Imamura; Takanori Teshima; Akari Takahashi; Yoshihiko Hirohashi; Toshihiko Torigoe; Noriyuki Sato; Tsukasa Seya
  IMMUNOBIOLOGY, 220, 1, 74, 82, 2015年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome
  M. J. Lechowicz; H. M. Lazarus; J. Carreras; G. G. Laport; C. S. Cutler; P. H. Wiernik; G. A. Hale; D. Maharaj; R. P. Gale; P. A. Rowlings; C. O. Freytes; A. M. Miller; J. M. Vose; R. T. Maziarz; S. Montoto; D. G. Maloney; P. N. Hari
  BONE MARROW TRANSPLANTATION, 49, 11, 1360, 1365, 2014年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• [Case Report; Primary central nervous system lymphoma mimicking progressive multifocal leukoencephalopathy in a patient with acquired immune deficiency syndrome].
  Yamakawa T; Fujimoto K; Ebata K; Iwasaki J; Takahashi S; Shiratori S; Sugita J; Kondo T; Nishio M; Teshima T
  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 103, 10, 2578, 2580, 2014年10月, ［査読有り］
• Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non-responders to hepatitis B vaccine after allogeneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection
  M. Takahata; S. Hashino; M. Onozawa; A. Shigematsu; J. Sugita; K. Fujimoto; T. Endo; T. Kondo; J. Tanaka; M. Imamura; T. Teshima
  TRANSPLANT INFECTIOUS DISEASE, 16, 5, 797, 801, 2014年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• FIP1L1 presence in FIP1L1-RARA or FIP1L1-PDGFRA differentially contributes to the pathogenesis of distinct types of leukemia
  Junko Iwasaki; Takeshi Kondo; Stephanie Darmanin; Makoto Ibata; Masahiro Onozawa; Daigo Hashimoto; Naoya Sakamoto; Takanori Teshima
  ANNALS OF HEMATOLOGY, 93, 9, 1473, 1481, 2014年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Essential requirements for setting up a stem cell processing laboratory
  T. Leemhuis; D. Padley; C. Keever-Taylor; D. Niederwieser; T. Teshima; F. Lanza; C. Chabannon; P. Szabolcs; A. Bazarbachi; M. B. C. Koh
  BONE MARROW TRANSPLANTATION, 49, 8, 1098, 1105, 2014年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients
  Shuichiro Takashima; Toshihiro Miyamoto; Masanori Kadowaki; Yoshikiyo Ito; Takatoshi Aoki; Ken Takase; Takahiro Shima; Goichi Yoshimoto; Koji Kato; Tsuyoshi Muta; Motoaki Shiratsuchi; Katsuto Takenaka; Hiromi Iwasaki; Takanori Teshima; Tomohiko Kamimura; Koichi Akashi
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 100, 2, 159, 164, 2014年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• JAK inhibitors: a home run for GVHD patients?
  Takanori Teshima
  Blood, 123, 24, 3691, 3693, 2014年06月12日, ［査読有り］
  研究論文（学術雑誌）
• High Level of Serum Soluble Interleukin-2 Receptor at Transplantation Predicts Poor Outcome of Allogeneic Stem Cell Transplantation for Adult T Cell Leukemia
  Akio Shigematsu; Naoki Kobayashi; Hiroshi Yasui; Motohiro Shindo; Yasutaka Kakinoki; Kyuhei Koda; Satoshi Iyama; Hiroyuki Kuroda; Yutaka Tsutsumi; Masahiro Imamura; Takanori Teshima
  BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20, 6, 801, 805, 2014年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Stenotrophomonas maltophilia infection during allogeneic hematopoietic stem cell transplantation: a single-center experience
  Souichi Shiratori; Kentaro Wakasa; Kohei Okada; Junichi Sugita; Koji Akizawa; Akio Shigematsu; Daigo Hashimoto; Katsuya Fujimoto; Tomoyuki Endo; Takeshi Kondo; Chikara Shimizu; Satoshi Hashino; Takanori Teshima
  CLINICAL TRANSPLANTATION, 28, 6, 656, 661, 2014年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Bone Marrow Graft-versus-Host Disease: Evaluation of Its Clinical Impact on Disrupted Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation
  Yusuke Shono; Souichi Shiratori; Mizuha Kosugi-Kanaya; Satoshi Ueha; Junichi Sugita; Akio Shigematsu; Takeshi Kondo; Daigo Hashimoto; Katsuya Fujimoto; Tomoyuki Endo; Mitsufumi Nishio; Satoshi Hashino; Yoshihiro Matsuno; Kouji Matsushima; Junji Tanaka; Masahiro Imamura; Takanori Teshima
  BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20, 4, 495, 500, 2014年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Comparison of bortezomib, cyclophosphamide, and dexamethasone (VCD) induction with bortezomib and dexamethasone (BD) induction for newly diagnosed symptomatic multiple myeloma
  Takashima S; Miyamoto T; Kamimura T; Yoshimoto G; Kato K; Ito Y; Muta T; Matsushima T; Shiratsuchi M; Tanimoto K; Takenaka K; Iwasaki H; Teshima T; Akashi K
  International Journal of Myeloma, 4, 1, 7, 12, 2014年03月, ［査読有り］
• Mammalian Target of Rapamycin Inhibitors Permit Regulatory T Cell Reconstitution and Inhibit Experimental Chronic Graft-versus-Host Disease
  Haruko Sugiyama; Yoshinobu Maeda; Hisakazu Nishimori; Yoshiko Yamasuji; Ken-ichi Matsuoka; Nobuharu Fujii; Eisei Kondo; Katsuji Shinagawa; Takehiro Tanaka; Kengo Takeuchi; Takanori Teshima; Mitsune Tanimoto
  BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20, 2, 183, 191, 2014年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• “No effect of humanized CCR monoclonal antibody (Mogamulizumab) on treatment-resistant adult T-cell leukemia with meningeal infiltration.”
  Tsutsumi Y; Shimono J; Miyashita N; Teshima T
  Leuk Lymphoma (letter), 55, 2, 457, 459, 2014年02月, ［査読有り］
  英語
• Impact of Conditioning Intensity with or without Total Body Irradiation on Acute Graft-Versus-Host Disease and Clinical Outcomes
  Hideki Nakasone; Takahiro Fukuda; Junya Kanda; Takehiko Mori; Takanori Teshima; Shingo Yano; Naoyuki Uchida; Kazuhiko Kakihana; Tetsuya Eto; Shin-Ichiro Mori; Tokiko Nagamura; Tatsuo Ichinohe; Yoshiko Atsuta; Makoto Murata
  BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 20, 2, S275, S276, 2014年02月
  英語, 研究論文（学術雑誌）
• Epstein-Barr Virus-Associated Smooth Muscle Tumors After Bone Marrow Transplantation
  Eiko Hayase; Katsuya Fujimoto; Tomoko Mitsuhashi; Yutaka Hatanaka; Miho Yoshida; Ryo Takemura; Junko Iwasaki; Souichi Shiratori; Junichi Sugita; Takeshi Kondo; Junji Tanaka; Masahiro Imamura; Yoshihiro Matsuno; Takanori Teshima
  TRANSPLANTATION, 97, 1, E1, +, 2014年01月, ［査読有り］
  英語
• Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning
  M. Koyama; D. Hashimoto; K. Nagafuji; T. Eto; Y. Ohno; K. Aoyama; H. Iwasaki; T. Miyamoto; G. R. Hill; K. Akashi; T. Teshima
  BONE MARROW TRANSPLANTATION, 49, 1, 110, 115, 2014年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• The Use of Oral Beclomethasone Dipropionate in the Treatment of Gastrointestinal Graft-versus-host Disease: The Experience of the Fukuoka Blood and Marrow Transplantation (BMT) Group
  Shuichiro Takashima; Tetsuya Eto; Motoaki Shiratsuchi; Michihiro Hidaka; Yasuo Mori; Koji Kato; Kenjiro Kamezaki; Seido Oku; Hideho Henzan; Ken Takase; Takamitsu Matsushima; Katsuto Takenaka; Hiromi Iwasaki; Toshihiro Miyamoto; Koichi Akashi; Takanori Teshima
  INTERNAL MEDICINE, 53, 12, 1315, 1320, 2014年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Successful Treatment of Invasive Zygomycosis Based on a Prompt Diagnosis Using Molecular Methods in a Patient with Acute Myelogenous Leukemia
  Junichiro Yuda; Koji Kato; Yoshikane Kikushige; Kiyofumi Ohkusu; Makiko Kiyosuke; Keiji Sakamoto; Seido Oku; Noriko Miyake; Masako Kadowaki; Tadafumi Iino; Kazuki Tanimoto; Katsuto Takenaka; Hiromi Iwasaki; Toshihiro Miyamoto; Nobuyuki Shimono; Takanori Teshima; Koichi Akashi
  INTERNAL MEDICINE, 53, 10, 1087, 1091, 2014年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Hepatitis B virus reactivation with rituximab-containing regimen
  Yutaka Tsutsumi; Yoshiya Yamamoto; Joji Shimono; Hiroyuki Ohhigashi; Takanori Teshima
  World Journal of Hepatology, 5, 11, 612, 620, 2013年11月
  英語
• Reduced-intensity conditioning followed by cord blood transplantation in a patient with refractory folliculotropic mycosis fungoides
  Takashi Nakaike; Koji Kato; Seido Oku; Masayasu Hayashi; Yoshikane Kikushige; Mika Kuroiwa; Katsuto Takenaka; Hiromi Iwasaki; Toshihiro Miyamoto; Takanori Teshima; Koichi Ohshima; Koichi Akashi
  International Journal of Hematology, 98, 4, 491, 495, 2013年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: A retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group
  Yoshikiyo Ito; Toshihiro Miyamoto; Tomohiko Kamimura; Ken Takase; Hideho Henzan; Yasuo Sugio; Koji Kato; Yuju Ohno; Tetsuya Eto; Takanori Teshima; Koichi Akashi
  International Journal of Hematology, 98, 4, 463, 471, 2013年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Reciprocal Expression of Enteric Antimicrobial Proteins in Intestinal Graft-Versus-Host Disease
  Yoshihiro Eriguchi; Hidetaka Uryu; Kiminori Nakamura; Sonoko Shimoji; Shuichiro Takashima; Hiromi Iwasaki; Toshihiro Miyamoto; Nobuyuki Shimono; Daigo Hashimoto; Koichi Akashi; Tokiyoshi Ayabe; Takanori Teshima
  BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 19, 10, 1525, 1529, 2013年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration
  Kazutoshi Aoyama; Asim Saha; Jakub Tolar; Megan J. Riddle; Rachelle G. Veenstra; Patricia A. Taylor; Rune Blomhoff; Angela Panoskaltsis-Mortari; Christopher A. Klebanoff; Gerard Socie; David H. Munn; William J. Murphy; Jonathan S. Serody; LeShara M. Fulton; Takanori Teshima; Roshantha A. Chandraratna; Ethan Dmitrovsky; Yanxia Guo; Randolph J. Noelle; Bruce R. Blazar
  BLOOD, 122, 12, 2125, 2134, 2013年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
  Toshihiro Miyamoto; Goichi Yoshimoto; Tomohiko Kamimura; Tsuyoshi Muta; Shuichiro Takashima; Yoshikiyo Ito; Motoaki Shiratsuchi; Ilseung Choi; Koji Kato; Katsuto Takenaka; Hiromi Iwasaki; Yasushi Takamatsu; Takanori Teshima; Koichi Akashi
  International Journal of Hematology, 98, 3, 337, 345, 2013年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Evaluating the association between histological manifestations of cord colitis syndrome with GVHD
  S. Shimoji; K. Kato; Y. Eriguchi; K. Takenaka; H. Iwasaki; T. Miyamoto; Y. Oda; K. Akashi; T. Teshima
  BONE MARROW TRANSPLANTATION, 48, 9, 1249, 1252, 2013年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Efficacy and Safety of Aprepitant in Allogeneic Hematopoietic Stem Cell Transplantation
  Mayako Uchida; Koji Kato; Hiroaki Ikesue; Kimiko Ichinose; Hiromi Hiraiwa; Asako Sakurai; Tsuyoshi Muta; Katsuto Takenaka; Hiromi Iwasaki; Toshihiro Miyamoto; Takanori Teshima; Motoaki Shiratsuchi; Kimitaka Suetsugu; Kenichiro Nagata; Nobuaki Egashira; Koichi Akashi; Ryozo Oishi
  PHARMACOTHERAPY, 33, 9, 893, 901, 2013年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study.
  Kazuo Muroi; Koichi Miyamura; Kazuteru Ohashi; Makoto Murata; Tetsuya Eto; Naoki Kobayashi; Shuichi Taniguchi; Masahiro Imamura; Kiyoshi Ando; Shunichi Kato; Takehiko Mori; Takanori Teshima; Masaki Mori; Keiya Ozawa
  International journal of hematology, 98, 2, 206, 13, 2013年08月, ［査読有り］, ［国内誌］
  英語, We conducted a multicenter phase I/II study using mesenchymal stem cells (MSCs) manufactured from the bone marrow of healthy unrelated volunteers to treat steroid-refractory acute graft-versus-host disease (aGVHD). Fourteen patients with hematological malignancies who suffered from grade II (9 patients) or III aGVHD (5) were treated. Affected organs were gut (10 patients), skin (9 patients), and liver (3 patients). Seven patients had two involved organs. The median age was 52. No other second-line agents were given. MSCs were given at a dose of 2 × 10(6) cells/kg for each infusion twice a week for 4 weeks. If needed, patients were continuously given MSCs weekly for an additional 4 weeks. By week 4, 13 of 14 patients (92.9 %) had responded to MSC therapy with a complete response (CR; n = 8) or partial response (PR; n = 5). At 24 weeks, 11 patients (10 with CR and 1 with PR) were alive. At 96 weeks, 8 patients were alive in CR. A total of 6 patients died, attributable to the following: underlying disease relapse (2 patients), breast cancer relapse (1), veno-occlusive disease (1), ischemic cholangiopathy (1), and pneumonia (1). No clear adverse effects associated with MSC infusion were observed. Third party-derived bone marrow MSCs may be safe and effective for patients with steroid-refractory aGVHD.
• Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission
  Tetsuya Eto; Ken Takase; Toshihiro Miyamoto; Yuju Ohno; Tomohiko Kamimura; Koji Nagafuji; Yasushi Takamatsu; Takanori Teshima; Hisashi Gondo; Shuichi Taniguchi; Koichi Akashi; Mine Harada
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 98, 2, 186, 196, 2013年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• A novel filtration method for cord blood processing using a polyester fabric filter
  T. Shima; N. Forraz; N. Sato; T. Yamauchi; H. Iwasaki; K. Takenaka; K. Akashi; C. McGuckin; T. Teshima
  INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 35, 4, 436, 446, 2013年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Effectiveness and Safety of Antiemetic Aprepitant in Japanese Patients Receiving High-Dose Chemotherapy Prior to Autologous Hematopoietic Stem Cell Transplantation
  Mayako Uchida; Hiroaki Ikesue; Toshihiro Miyamoto; Koji Kato; Kimitaka Suetsugu; Kimiko Ichinose; Hiromi Hiraiwa; Asako Sakurai; Katsuto Takenaka; Tsuyoshi Muta; Hiromi Iwasaki; Takanori Teshima; Motoaki Shiratsuchi; Nobuaki Egashira; Koichi Akashi; Ryozo Oishia
  BIOLOGICAL & PHARMACEUTICAL BULLETIN, 36, 5, 819, 824, 2013年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Decrease in Venous Irritation by Adjusting the Concentration of Injected Bendamustine
  Hiroyuki Watanabe; Hiroaki Ikesue; Tomoko Tsujikawa; Kenichiro Nagata; Mayako Uchida; Kimitaka Suetsugu; Nobuaki Egashira; Tsuyoshi Muta; Koji Kato; Katsuto Takenaka; Saiji Ohga; Takamitsu Matsushima; Motoaki Shiratsuchi; Toshihiro Miyamoto; Takanori Teshima; Koichi Akashi; Ryozo Oishi
  BIOLOGICAL & PHARMACEUTICAL BULLETIN, 36, 4, 574, 578, 2013年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia/lymphoma
  Koji Kato; Toshihiro Miyamoto; Akihiko Numata; Takashi Nakaike; Hideyo Oka; Ayano Yurino; Takuro Kuriyama; Yasuo Mori; Satoshi Yamasaki; Tsuyoshi Muta; Katsuto Takenaka; Hiromi Iwasaki; Takanori Teshima; Koichi Akashi
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 97, 3, 430, 432, 2013年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Diagnosis and evaluation of intestinal graft-versus-host disease after allogeneic hematopoietic stem cell transplantation following reduced-intensity and myeloablative conditioning regimens
  Satoshi Yamasaki; Akiko Miyagi-Maeshima; Yasuo Kakugawa; Yoshihiro Matsuno; Fusako Ohara-Waki; Shigeo Fuji; Yuriko Morita-Hoshi; Masakazu Mori; Sung-Won Kim; Shin-ichiro Mori; Takahiro Fukuda; Ryuji Tanosaki; Tadakazu Shimoda; Kensei Tobinai; Daizo Saito; Yoichi Takaue; Takanori Teshima; Yuji Heike
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 97, 3, 421, 426, 2013年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy
  Mayako Uchida; Hiroaki Ikesue; Koji Kato; Kimiko Ichinose; Hiromi Hiraiwa; Asako Sakurai; Katsuto Takenaka; Hiromi Iwasaki; Toshihiro Miyamoto; Takanori Teshima; Nobuaki Egashira; Koichi Akashi; Ryozo Oishi
  American Journal of Health-System Pharmacy, 70, 4, 343, 349, 2013年02月15日, ［査読有り］
  英語, 研究論文（学術雑誌）
• Successful engraftment in hla-mismatched bone marrow transplantation despite the persistence of high-level donor-specific anti-HLA-DR antibody
  Souichi Shiratori; Makoto Ito; Maki Yoneoka; Koji Hayasaka; Eiko Hayase; Junko Iwasaki; Junichi Sugita; Akio Shigematsu; Katsuya Fujimoto; Takeshi Kondo; Chikara Shimizu; Takanori Teshima
  Transplantation, 96, 5, e34, e35, 2013年, ［査読有り］
  英語
• Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation
  Takahiro Shima; Toshihiro Miyamoto; Yoshikane Kikushige; Yasuo Mori; Kenjiro Kamezaki; Ken Takase; Hideho Henzan; Akihiko Numata; Yoshikiyo Ito; Katsuto Takenaka; Hiromi Iwasaki; Tomohiko Kamimura; Tetsuya Eto; Koji Nagafuji; Takanori Teshima; Koji Kato; Koichi Akashi
  BLOOD, 121, 5, 840, 848, 2013年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Evaluation of the Feasibility and Efficacy of Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma
  Tsuyoshi Muta; Toshihiro Miyamoto; Tomoaki Fujisaki; Yuju Ohno; Tomohiko Kamimura; Koji Kato; Katsuto Takenaka; Hiromi Iwasaki; Tetsuya Eto; Yasushi Takamatsu; Takanori Teshima; Koichi Akashi
  INTERNAL MEDICINE, 52, 1, 63, 70, 2013年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Engulfment of hematopoietic stem cells caused by down-regulation of CD47 is critical in the pathogenesis of hemophagocytic lymphohistiocytosis
  Takuro Kuriyama; Katsuto Takenaka; Kentaro Kohno; Takuji Yamauchi; Shinya Daitoku; Goichi Yoshimoto; Yoshikane Kikushige; Junji Kishimoto; Yasunobu Abe; Naoki Harada; Toshihiro Miyamoto; Hiromi Iwasaki; Takanori Teshima; Koichi Akashi
  BLOOD, 120, 19, 4058, 4067, 2012年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Low incidence of adenovirus hemorrhagic cystitis following autologous hematopoietic stem cell transplantation in the rituximab era
  Yasuo Mori; Toshihiro Miyamoto; Kenjiro Kamezaki; Koji Kato; Yoshikane Kikushige; Shuichiro Takashima; Shingo Urata; Shinji Shimoda; Nobuyuki Shimono; Katsuto Takenaka; Hiromi Iwasaki; Koji Nagafuji; Takanori Teshima; Koichi Akashi
  AMERICAN JOURNAL OF HEMATOLOGY, 87, 8, 828, 830, 2012年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Validation of pretransplantation assessment of mortality risk score in the outcome of hematopoietic SCT in non-Caucasians
  Y. Mori; T. Teshima; K. Kamezaki; K. Kato; K. Takenaka; H. Iwasaki; T. Miyamoto; K. Nagafuji; T. Eto; K. Akashi
  BONE MARROW TRANSPLANTATION, 47, 8, 1075, 1081, 2012年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of -defensins.
  Eriguchi Y; Takashima S; Oka H; Shimoji S; Nakamura K; Uryu H; Shimoda S; Iwasaki H; Shimono N; Ayabe T; Akashi K; Teshima T
  Blood, 120, 1, 223, 231, 2012年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients
  Katsuto Takenaka; Koji Nagafuji; Ken Takase; Tomohiko Kamimura; Yasuo Mori; Yoshikiyo Ito; Yukiko Nishi; Hideho Henzan; Koji Kato; Naoki Harada; Tetsuya Eto; Toshihiro Miyamoto; Takanori Teshima; Koichi Akashi
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 96, 1, 94, 100, 2012年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• GVHD-associated immunodeficiency: soil or seed?
  Takanori Teshima
  Blood, 119, 24, 5618, 5619, 2012年06月14日, ［査読有り］
  研究論文（学術雑誌）
• Successful treatment by donor lymphocyte infusion of adult T-cell leukemia/lymphoma relapse following allogeneic hematopoietic stem cell transplantation
  Tomohiko Kamimura; Toshihiro Miyamoto; Noriaki Kawano; Akihiko Numata; Yoshikiyo Ito; Yong Chong; Koji Nagafuji; Takanori Teshima; Shin Hayashi; Koichi Akashi
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 95, 6, 725, 730, 2012年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Different Risk Factors Related to Adenovirus- or BK Virus-Associated Hemorrhagic Cystitis following Allogeneic Stem Cell Transplantation
  Yasuo Mori; Toshihiro Miyamoto; Koji Kato; Kenjiro Kamezaki; Takuro Kuriyama; Seido Oku; Katsuto Takenaka; Hiromi Iwasaki; Naoki Harada; Motoaki Shiratsuchi; Yasunobu Abe; Koji Nagafuji; Takanori Teshima; Koichi Akashi
  BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 18, 3, 458, 465, 2012年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Plasma biomarkers of lower gastrointestinal and liver acute GVHD
  Andrew C. Harris; James L. M. Ferrara; Thomas M. Braun; Ernst Holler; Takanori Teshima; John E. Levine; Sung W. Choi; Karin Landfried; Koichi Akashi; Mark Vander Lugt; Daniel R. Couriel; Pavan Reddy; Sophie Paczesny
  BLOOD, 119, 12, 2960, 2963, 2012年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17
  Hisakazu Nishimori; Yoshinobu Maeda; Takanori Teshima; Haruko Sugiyama; Koichiro Kobayashi; Yoshiko Yamasuji; Sachiyo Kadohisa; Hidetaka Uryu; Kengo Takeuchi; Takehiro Tanaka; Tadashi Yoshino; Yoichiro Iwakura; Mitsune Tanimoto
  BLOOD, 119, 1, 285, 295, 2012年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease
  James L. M. Ferrara; Andrew C. Harris; Joel K. Greenson; Thomas M. Braun; Ernst Holler; Takanori Teshima; John E. Levine; Sung W. J. Choi; Elisabeth Huber; Karin Landfried; Koichi Akashi; Mark Vander Lugt; Pavan Reddy; Alice Chin; Qing Zhang; Samir Hanash; Sophie Paczesny
  BLOOD, 118, 25, 6702, 6708, 2011年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Th1 and Th17 join forces for acute GVHD
  Takanori Teshima
  Blood, 118, 18, 4765, 4767, 2011年11月03日, ［査読有り］
  研究論文（学術雑誌）
• Blood-cell banking for workers at the Fukushima Daiichi nuclear power plant – Authors' reply
  Tetsuya Tanimoto; Koichiro Yuji; Naoyuki Uchida; Miwako Hosoda; Yuko Kodama; Takanori Teshima; Shuichi Taniguchi
  The Lancet, 378, 9790, 484, 485, Elsevier BV, 2011年08月
  英語
• Successful allogeneic stem cell transplantation in two patients with acute myelogenous leukaemia and invasive aspergillosis by antifungal combination therapy
  Takatoshi Aoki; Toshihiro Miyamoto; Yasuo Mori; Goichi Yoshimoto; Takuji Yamauchi; Kenjiro Kamezaki; Katsuto Takenaka; Hiromi Iwasaki; Naoki Harada; Koji Nagafuji; Nobuyuki Shimono; Takanori Teshima; Koichi Akashi
  MYCOSES, 54, 4, E255, E259, 2011年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Regulatory T cells and IL-17-producing cells in graft-versus-host disease
  Takanori Teshima; Yoshinobu Maeda; Katsutoshi Ozaki
  IMMUNOTHERAPY, 3, 7, 833, 852, 2011年07月
  英語, 研究論文（学術雑誌）
• Role of autotransplantation in the treatment of acute promyelocytic leukemia patients in remission: Fukuoka BMT Group observations and a literature review
  T. Kamimura; T. Miyamoto; K. Nagafuji; A. Numata; H. Henzan; K. Takase; Y. Ito; Y. Ohno; T. Fujisaki; T. Eto; Y. Takamatsu; T. Teshima; H. Gondo; K. Akashi; S. Taniguchi; M. Harada
  BONE MARROW TRANSPLANTATION, 46, 6, 820, 826, 2011年06月, ［査読有り］
  英語
• Analysis of immune reconstitution after autologous CD34(+) stem/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4(+) T cells
  Hiroshi Tsukamoto; Koji Nagafuji; Takahiko Horiuchi; Hiroki Mitoma; Hiroaki Niiro; Yojiro Arinobu; Yasushi Inoue; Kentaro To; Toshihiro Miyamoto; Hiromi Iwasaki; Takanori Teshima; Mine Harada; Koichi Akashi
  RHEUMATOLOGY, 50, 5, 944, 952, 2011年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation
  Daigo Hashimoto; Andrew Chow; Melanie Greter; Yvonne Saenger; Wing-Hong Kwan; Marylene Leboeuf; Florent Ginhoux; Jordi C. Ochando; Yuya Kunisaki; Nico van Rooijen; Chen Liu; Takanori Teshima; Peter S. Heeger; E. Richard Stanley; Paul S. Frenette; Miriam Merad
  JOURNAL OF EXPERIMENTAL MEDICINE, 208, 5, 1069, 1082, 2011年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Safety of workers at the Fukushima Daiichi nuclear power plant
  Tetsuya Tanimoto; Naoyuki Uchida; Yuko Kodama; Takanori Teshima; Shuichi Taniguchi
  LANCET, 377, 9776, 1489, 1490, 2011年04月, ［査読有り］
  英語
• The Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells
  Shuichiro Takashima; Masanori Kadowaki; Kazutoshi Aoyama; Motoko Koyama; Takeshi Oshima; Kazuma Tomizuka; Koichi Akashi; Takanori Teshima
  JOURNAL OF EXPERIMENTAL MEDICINE, 208, 2, 285, 294, 2011年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Diagnostic Value of Serum Procalcitonin and C-reactive Protein for Infections after Allogeneic Hematopoietic Stem Cell Transplantation versus Nontransplant Setting
  Yasuo Mori; Kohta Miyawaki; Koji Kato; Katsuto Takenaka; Hiromi Iwasaki; Naoki Harada; Toshihiro Miyamoto; Koichi Akashi; Takanori Teshima
  INTERNAL MEDICINE, 50, 19, 2149, 2155, 2011年, ［査読有り］
  英語, 研究論文（学術雑誌）
• TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
  Yoshikane Kikushige; Takahiro Shima; Shin-ichiro Takayanagi; Shingo Urata; Toshihiro Miyamoto; Hiromi Iwasaki; Katsuto Takenaka; Takanori Teshima; Toshiyuki Tanaka; Yoshimasa Inagaki; Koichi Akashi
  CELL STEM CELL, 7, 6, 708, 717, 2010年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• High Incidence of Human Herpes Virus 6-Associated Encephalitis/Myelitis following a Second Unrelated Cord Blood Transplantation
  Yasuo Mori; Toshihiro Miyamoto; Koji Nagafuji; Kenjiro Kamezaki; Asataro Yamamoto; Noriyuki Saito; Koji Kato; Katsuto Takenaka; Hiromi Iwasaki; Naoki Harada; Yasunobu Abe; Takanori Teshima; Koichi Akashi
  BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 16, 11, 1596, 1602, 2010年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Altered Effector CD4(+) T Cell Function in IL-21R(-/-) CD4(+) T Cell-Mediated Graft-Versus-Host Disease
  Iekuni Oh; Katsutoshi Ozaki; Akiko Meguro; Keiko Hatanaka; Masanori Kadowaki; Haruko Matsu; Raine Tatara; Kazuya Sato; Yoichiro Iwakura; Susumu Nakae; Katsuko Sudo; Takanori Teshima; Warren J. Leonard; Keiya Ozawa
  JOURNAL OF IMMUNOLOGY, 185, 3, 1920, 1926, 2010年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice
  Shoji Asakura; Daigo Hashimoto; Shuichiro Takashima; Haruko Sugiyama; Yoshinobu Maeda; Koichi Akashi; Mitsune Tanimoto; Takanori Teshima
  JOURNAL OF CLINICAL INVESTIGATION, 120, 7, 2370, 2378, 2010年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Cord blood stem cell transplantation in a patient with disseminated mucormycosis and acute myelogenous leukemia
  T. Aoki; K. Kamezaki; T. Miyamoto; K. Nagafuji; Y. Mori; T. Yamauchi; K. Takenaka; H. Iwasaki; N. Harada; N. Shimono; T. Teshima; K. Akashi
  TRANSPLANT INFECTIOUS DISEASE, 12, 3, 277, 279, 2010年06月, ［査読有り］
  英語
• High incidence of false-positive Aspergillus galactomannan test in multiple myeloma
  Yasuo Mori; Yoji Nagasaki; Kenjiro Kamezaki; Katsuto Takenaka; Hiromi Iwasaki; Naoki Harada; Toshihiro Miyamoto; Yasunobu Abe; Nobuyuki Shimono; Koichi Akashi; Takanori Teshima
  AMERICAN JOURNAL OF HEMATOLOGY, 85, 6, 449, 451, 2010年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia: a propensity score-based comparison from the Japan Society for Hematopoietic Stem Cell Transplantation registry
  Koji Nagafuji; Keitaro Matsuo; Takanori Teshima; Shin-ichiro Mori; Hisashi Sakamaki; Michihiro Hidaka; Hiroyasu Ogawa; Yoshihisa Kodera; Yoshinobu Kanda; Atsuo Maruta; Takehiko Mori; Fumiaki Yoshiba; Tatsuo Ichinohe; Masanobu Kasai; Yoshifusa Takatsuka; Kohmei Kubo; Hiroshi Sao; Yoshiko Atsuta; Ritsuro Suzuki; Takashi Yoshida; Masahiro Tsuchida; Mine Harada
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 91, 5, 855, 864, 2010年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group
  A. Numata; T. Miyamoto; Y. Ohno; T. Kamimura; K. Kamezaki; T. Tanimoto; K. Takase; H. Henzan; K. Kato; K. Takenaka; T. Fukuda; N. Harada; K. Nagafuji; T. Teshima; K. Akashi; M. Harada; T. Eto
  BONE MARROW TRANSPLANTATION, 45, 2, 311, 316, 2010年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Pulmonary Nocardiosis Developed in a Hematopoietic Stem Cell Transplant Recipient with Bronchiolitis Obliterans
  Ruriko Nishida; Yasuo Mori; Hiromi Iwasaki; Takahito Tokuyama; Kenjiro Kamezaki; Yoji Nagasaki; Hideyo Oka; Kohta Miyawaki; Noriyuki Saito; Katsuto Takenaka; Naoki Harada; Toshihiro Miyamoto; Takanori Teshima; Koichi Akashi
  INTERNAL MEDICINE, 49, 14, 1441, 1444, 2010年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Successful treatment of refractory advanced nasal NK/T cell lymphoma with unrelated cord blood stem cell transplantation incorporating focal irradiation
  Yasuo Mori; Takatoshi Aoki; Katsuto Takenaka; Takuji Yamauchi; Asataro Yamamoto; Kenjiro Kamezaki; Hiromi Iwasaki; Naoki Harada; Toshihiro Miyamoto; Koji Nagafuji; Takanori Teshima; Koichi Akashi
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 91, 1, 107, 111, 2010年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Breast milk and transplantation tolerance
  Kazutoshi Aoyama; Ken-Ichi Matsuoka; Takanori Teshima
  Chimerism, 1, 1, 19, 20, Taylor and Francis Inc., 2010年
  英語, 研究論文（学術雑誌）
• Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation as Immunotherapy for Pancreatic Cancer
  Yasunobu Abe; Tetsuhide Ito; Eishi Baba; Koji Nagafuji; Ken Kawabe; Ilseung Choi; Yoshiyuki Arita; Toshihiro Miyamoto; Takanori Teshima; Shuji Nakano; Mine Harada
  PANCREAS, 38, 7, 815, 819, 2009年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Second unrelated cord blood transplantation using a reduced-intensity conditioning regimen combined with gemtuzumab ozogamicin in patients with relapsed acute myelogenous leukemia
  Takuji Yamauchi; Yasuo Mori; Toshihiro Miyamoto; Kenjiro Kamezaki; Takatoshi Aoki; Asataro Yamamoto; Katsuto Takenaka; Hiromi Iwasaki; Naoki Harada; Koji Nagafuji; Takanori Teshima; Koichi Akashi
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 90, 3, 416, 420, 2009年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Rituximab for the treatment of corticosteroid-refractory chronic graft-versus-host disease
  Takanori Teshima; Koji Nagafuji; Hideho Henzan; Koichi Miyamura; Ken Takase; Michihiro Hidaka; Toshihiro Miyamoto; Katsuto Takenaka; Koichi Akashi; Mine Harada
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 90, 2, 253, 260, 2009年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases
  K. Kohno; K. Nagafuji; H. Tsukamoto; T. Horiuchi; K. Takase; K. Aoki; H. Henzan; K. Kamezaki; K. Takenaka; T. Miyamoto; T. Teshima; M. Harada; K. Akashi
  TRANSPLANT INFECTIOUS DISEASE, 11, 4, 318, 323, 2009年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients
  Katsuto Takenaka; Tetsuya Eto; Koji Nagafuji; Kenjiro Kamezaki; Yayoi Matsuo; Goichi Yoshimoto; Naoki Harada; Maki Yoshida; Hideho Henzan; Ken Takase; Toshihiro Miyamoto; Koichi Akashi; Mine Harada; Takanori Teshima
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 89, 2, 231, 237, 2009年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Disseminated tuberculosis following second unrelated cord blood transplantation for acute myelogenous leukemia
  T. Shima; G. Yoshimoto; T. Miyamoto; S. Yoshida; K. Kamezaki; K. Takenaka; H. Iwasaki; N. Harada; K. Nagafuji; T. Teshima; N. Shimono; K. Akashi
  TRANSPLANT INFECTIOUS DISEASE, 11, 1, 75, 77, 2009年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus-host disease as antigen-presenting cells
  Motoko Koyama; Daigo Hashimoto; Kazutoshi Aoyama; Ken-ichi Matsuoka; Kennosuke Karube; Hiroaki Niiro; Mine Harada; Mitsune Tanimoto; Koichi Akashi; Takanori Teshima
  BLOOD, 113, 9, 2088, 2095, 2009年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Improved outcome of allogeneic bone marrow transplantation due to breastfeeding-induced tolerance to maternal antigens
  Kazutoshi Aoyama; Motoko Koyama; Ken-ichi Matsuoka; Daigo Hashimoto; Tatsuo Ichinohe; Mine Harada; Koichi Akashi; Mitsune Tanimoto; Takanori Teshima
  BLOOD, 113, 8, 1829, 1833, 2009年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Encephalomyelitis Mimicking Multiple Sclerosis Associated with Chronic Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation
  Yayoi Matsuo; Kenjiro Kamezaki; Shoichiro Takeishi; Katsuto Takenaka; Tetsuya Eto; Atsushi Nonami; Toshihiro Miyamoto; Hiromi Iwasaki; Naoki Harada; Koji Nagafuji; Takanori Teshima; Koichi Akashi
  INTERNAL MEDICINE, 48, 16, 1453, 1456, 2009年, ［査読有り］
  英語, 研究論文（学術雑誌）
• The engraftment of transplanted bone marrow-derived cells into the inner ear
  Yorihisa Orita; Hidetsugu Tsujigiwa; Kazunori Nishizaki; Takanori Teshima; Junko Yoshinobu; Saeko Orita; Ayako Takeuchi; Yasushi Takeda; Hitoshi Nagatsuka; Noriyuki Nagai
  EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 266, 1, 59, 63, 2009年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Allogeneic cell therapy from immunized donors with tumor antigen peptide enhances the antitumor effect after cyclophosphamide-using non-myeloablative allogeneic hematopoietic cell transplantation
  Masumitsu Hamaguchi; Masatoshi Eto; Yoriyuki Kamiryo; Ario Takeuchi; Masahiko Harano; Katsunori Tatsugami; Takanori Teshima; Mamoru Harada; Yasunobu Yoshikai; Seiji Naito
  CANCER SCIENCE, 100, 1, 138, 143, 2009年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with NUP98-HOXA9
  Takatoshi Aoki; Toshihiro Miyamoto; Shuro Yoshida; Asataro Yamamoto; Takuji Yamauchi; Goichi Yoshimoto; Yasuo Mori; Kenjiro Kamezaki; Hiromi Iwasaki; Katsuto Takenaka; Naoki Harada; Koji Nagafuji; Takanori Teshima; Koichi Akashi
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 88, 5, 571, 574, 2008年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Successful treatment of parainfluenza virus 3 pneumonia with oral ribavirin and methylprednisolone in a bone marrow transplant recipient
  Takahiro Shima; Goichi Yoshimoto; Atsushi Nonami; Shuro Yoshida; Kenjiro Kamezaki; Hiromi Iwasaki; Katsuto Takenaka; Toshihiro Miyamoto; Naoki Harada; Takanori Teshima; Koichi Akashi; Koji Nagafuji
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 88, 3, 336, 340, 2008年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Reduced-intensity unrelated donor bone marrow transplantation for hematologic malignancies
  Sung-Won Kim; Keitaro Matsuo; Takahiro Fukuda; Masamichi Hara; Kosei Matsue; Shuichi Taniguchi; Tetsuya Eto; Mitsune Tanimoto; Atsushi Wake; Kazuo Hatanaka; Shinji Nakao; Yoji Ishida; Mine Harada; Atae Utsunomiya; Masahiro Imamura; Yoshinobu Kanda; Kazutaka Sunami; Fumio Kawano; Yoichi Takaue; Takanori Teshima
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 88, 3, 324, 330, 2008年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens
  S. Yamasaki; Y. Heike; S. Mori; T. Fukuda; D. Maruyama; R. Kato; E. Usui; K. Koido; S. Kim; R. Tanosaki; K. Tobinai; T. Teshima; Y. Takaue
  TRANSPLANT INFECTIOUS DISEASE, 10, 4, 252, 259, 2008年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• An unexpected cause of a febrile patient with huge splenomegaly
  Atsushi Nonami; Hidetaka Yamamoto; Masafumi Nakamura; Koji Nagafuji; Takanori Teshima
  CLINICAL RHEUMATOLOGY, 27, 7, 941, 943, 2008年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Posttransplant administration of cyclophosphamide and donor lymphocyte infusion induces potent antitumor immunity to solid tumor
  Masatoshi Eto; Yoriyuki Kamiryo; Ario Takeuchi; Masahiko Harano; Katsunori Tatsugami; Mamoru Harada; Keijiro Kiyoshima; Masumitsu Hamaguchi; Takanori Teshima; Masazumi Tsuneyoshi; Yasunobu Yoshikai; Seiji Naito
  CLINICAL CANCER RESEARCH, 14, 9, 2833, 2840, 2008年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Preparation of functionally preserved CD4+CD25high regulatory T cells from leukapheresis products from ulcerative colitis patients, applicable to regulatory T-cell transfer therapy
  Y. Sumida; K. Nakamura; K. Kanayama; H. Akiho; T. Teshima; R. Takayanagi
  CYTOTHERAPY, 10, 7, 698, 710, 2008年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Chronic graft-versus-host disease: How can we release Prometheus?
  Takanori Teshima; Thomas A. Wynn; Robert J. Soiffer; Ken-Ichi Matsuoka; Paul J. Martin
  BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 14, 1, 142, +, 2008年01月
  英語, 研究論文（学術雑誌）
• A novel strategy for the treatment of acute graft-versus-host disease: removal of excessive inflammatory cytokines using the adsorbent
  Takami A; Teshima T; Ushizaki K; Taniguchi T; Endo T; Sakurai H; Nakao S
  BONE MARROW TRANSPLANTATION, 41, 1, S229, 2008年, ［査読有り］
  34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, Florence, ITALY, MAR 30-APR 02, 2008
• Successful treatment of primary plasma cell leukaemia by allogeneic stem cell transplantation from haploidentical sibling
  Atsushi Nonami; Toshihiro Miyamoto; Mika Kuroiwa; Yuya Kunisaki; Kenjiro Kamezaki; Katsuto Takenaka; Naoki Harada; Takanori Teshima; Mine Harada; Koji Nagafuji
  JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 37, 12, 969, 972, 2007年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• A Novel Strategy for the Treatment of Acute Graft-Versus-Host Disease Using the Adsorbent To Remove Excessive Inflammatory Cytokines.
  Akiyoshi Takami; Takanori Teshima; Koshin Ushizaki; Takumi Taniguchi; Tohru Endo; Hiroshi Sakurai; Yukio Kondo; Hirohito Yamazaki; Shigeru Shimadoi; Hirokazu Okumura; Shinji Nakao
  Blood, 110, 11, 5001, 5001, 2007年11月16日
  英語, 研究論文（学術雑誌）
• Breast-Feeding Mediates Feto-Maternal Tolerance and Improves Outcome of Allogeneic Bone Marrow Transplantation.
  Kazutoshi Aoyama; Ken-ichi Matsuoka; Daigo Hashimoto; Tatsuo Ichinohe; Mine Harada; Mitsune Tanimoto; Takanori Teshima
  Blood, 110, 11, 2165, 2165, American Society of Hematology, 2007年11月16日
  研究論文（学術雑誌）,
  The widespread application of hematopoietic stem cell transplantation (HSCT) is limited by lack of a histocompatible donor in a proportion of patients who have a rare HLA haplotype. For these patients, allogeneic HSCT from an HLA-mismatched relative donor is complicated with a high incidence of severe graft-versus-host disease (GVHD). Exposure to noninherited maternal antigens (NIMAs) during pregnancy may have an impact on transplantation later in life. We recently demonstrated in a mouse model that a “child-to-mother” BMT from a NIMA-exposed donor reduced the mortality and morbidity of GVHD, but a “mother-to-child” BMT did not reduce GVHD (Matsuoka, 2006). We therefore hypothesized that breast-feeding could play a role on the induction of the tolerogenic NIMA effect. To test this hypothesis, we generated NIMA-exposed mice by mating a B6 (H–2b) male and a B6D2F1 (H–2b/d) female to generate H–2b/b offspring. These H–2b/b offspring were then nursed by either a B6D2F1 mother (in utero and oral exposure to NIMAs) or a B6 foster mother (in utero exposure to NIMAs). Transplantation from donors exposed to NIMA in utero alone produced more severe GVHD than BMT from in utero and orally exposed donors, demonstrating that breast-feeding is required for the induction of maximum NIMA effects. Next, to examine whether breast-feeding alone could mediate NIMA effects, we generated mice exposed to NIMA orally by nursing a new born B6 mouse with a B6D2F1 foster mother. CD4+ T cells isolated from these mice were cultured with B6D2F1 stimulators. Proliferation of these cells in response to NIMAs was significantly reduced in comparison to that from the controls. Lethally irradiated B6D2F1 recipients were transplanted with 2 × 106 T cells from these mice or controls together with 5 × 106 T cell-depleted bone marrow from control donors. Five days after transplant, donor T cell expansion and production of IFN-γ were significantly reduced in recipients of orally NIMA exposed donors than controls, resulting in a significant reduction of GVHD mortality (48% vs 80%, p&lt;0.05). The tolerogenic milk effects were completely abolished when lethally irradiated B6D2F1 mice were transplanted with 1 × 106 CD25-depleted CD4+ T cells from the milk-mediated NIMA-exposed mice, thus suggesting that donor CD4+ CD25+ T cells play a role in the tolerogenic milk effects. Next, we hypothesized that generation of regulatory T cells in neonates during lactation period is essential for the induction of the tolerogenic milk effects. The anti-CD25 mAbs, PC61, is capable of depleting CD25+ cells in vivo. New born B6 mice nursed by a B6D2F1 foster mother were subcutaneously injected with anti-CD25 mAbs on days 1 and 8 of life, resulting in a decrease in numbers of Foxp3+ CD4+ CD25+ cells in spleens at 3-week-old. These mice were used as BMT donors at 8-week-old when the numbers of the regulatory T cells had recovered. After BMT from these donors, reduction of GVHD was not observed. These results suggest that development of Foxp3+ CD4+ CD25+ regulatory T cells during lactation is critical for the induction of the tolerogenic milk effects. Our findings may have immediate implications for clinical BMT to use a NIMA-mismatched donor in the absence of a HLA-identical donor in HLA mismatched HSCT.
• Toxoplasmosis encephalitis following severe graft-vs.-host disease after allogeneic hematopoietic stem cell transplantation: 17 yr experience in Fukuoka BMT group
  Yayoi Matsuo; Shoichiro Takeishi; Toshihiro Miyamoto; Atsushi Nonami; Yoshikane Kikushige; Yuya Kunisaki; Kenjiro Kamezaki; Liping Tu; Hajime Hisaeda; Katsuto Takenaka; Naoki Harada; Tomohiko Kamimura; Yuju Ohno; Tetsuya Eto; Takanori Teshima; Hisashi Gondo; Mine Harada; Koji Nagafuji
  EUROPEAN JOURNAL OF HAEMATOLOGY, 79, 4, 317, 321, 2007年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Distinctive expression of myelomonocytic markers and down-regulation of CD34 in acute myelogenous leukaemia with FLT3 tandem duplication and nucleophosmin mutation
  Yasuo Mori; Goichi Yoshimoto; Takashi Kumano; Toshihiro Miyamoto; Tadafumi Lino; Katsuto Takenaka; Hiromi Iwasaki; Naoki Harada; Naoko Kinukawa; Koji Nagafuji; Takanori Teshima; Kazuya Shimoda; Koichi Akashi; Mine Harada
  EUROPEAN JOURNAL OF HAEMATOLOGY, 79, 1, 17, 24, 2007年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Successful treatment of primary cardiac lymphoma by rituximab-CHOP and high-dose chemotherapy with autologous peripheral blood stem cell transplantation
  Atsushi Nonami; Katsuto Takenaka; Kenjiro Kamezaki; Toshihiro Miyamoto; Naoki Harada; Koji Nagafuji; Takanori Teshima; Mine Harada
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 85, 3, 264, 266, 2007年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Lymphopenia-induced proliferation of donor T cells reduces their capacity for causing acute graft-versus-host disease
  Yoshinobu Maeda; Isao Tawara; Takanori Teshima; Chen Liu; Daigo Hashimoto; Ken-ichi Matsuoka; Mitsune Tanimoto; Pavan Reddy
  EXPERIMENTAL HEMATOLOGY, 35, 2, 274, 286, 2007年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease
  Yukimi Sakoda; Daigo Hashimoto; Shoji Asakura; Kengo Takeuchi; Mine Harada; Mitsune Tanimoto; Takanori Teshima
  BLOOD, 109, 4, 1756, 1764, 2007年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Successful treatment of myelodysplastic syndrome (MDS)-related intestinal Behçet's disease by up-front cord blood transplantation
  Nonami A; Takenaka K; Sumida C; Aizawa K; Kamezaki K; Miyamoto T; Harada N; Nagafuji K; Teshima T; Harada M
  Intern Med, 46, 20, 1753, 1756, 2007年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Collection of mobilized peripheral blood stem cells from a donor with severe iron deficient anemia
  Kenjirou Kamezaki; Toshihiro Miyamoto; Tomoko Henzan; Akihiko Numata; Hiromi Iwasaki; Koji Nagafuji; Mine Harada; Takanori Teshima; Koichi Akashi
  JOURNAL OF CLINICAL APHERESIS, 22, 5, 292, 294, 2007年, ［査読有り］
  英語, 研究論文（学術雑誌）
• FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versus-host disease
  Daigo Hashimoto; Shoji Asakura; Ken-ichi Matsuoka; Yukimi Sakoda; Motoko Koyama; Kazutoshi Aoyama; Mitsune Tanimoto; Takanori Teshima
  EUROPEAN JOURNAL OF IMMUNOLOGY, 37, 1, 271, 281, 2007年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Bone marrow transplantation improves outcome in a mouse model of congenital muscular dystrophy
  Hiroki Hagiwara; Yutaka Ohsawa; Shoji Asakura; Tatsufumi Murakami; Takanori Teshima; Yoshihide Sunada
  FEBS LETTERS, 580, 18, 4463, 4468, 2006年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation
  N Fujii; K Ikeda; M Koyama; K Aoyama; T Masunari; E Kondo; T Matsuzaki; S Mizobuchi; A Hiraki; T Teshima; K Shinagawa; F Ishimaru; M Tanimoto
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 83, 5, 459, 461, 2006年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Impact of fetal-maternal tolerance in hematopoietic stem cell transplantation
  Takanori Teshima; Ken-ichi Matsuoka; Tatsuo Ichinohe
  ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 54, 3, 165, 172, 2006年05月
  英語, 研究論文（学術雑誌）
• Complete donor chimaerism of Langerhans cells in lymph node early after allogeneic bone marrow transplantation
  K Ikeda; T Shichishima; T Teshima; K Ogawa; A Nakamura-Shichishima; H Tajima; H Noji; Y Hashimoto; K Takeyama; T Ishibashi; H Ohto; M Abe; Y Maruyama
  EUROPEAN JOURNAL OF HAEMATOLOGY, 76, 3, 261, 264, 2006年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Transient respiratory disturbance by granulocyte-colony-stimulating factor administration in healthy donors of allogeneic peripheral blood progenitor cell transplantation
  Yoshida, I; K Matsuo; T Teshima; D Hashimoto; Y Tanimoto; M Harada; M Tanimoto
  TRANSFUSION, 46, 2, 186, 192, 2006年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Fetal tolerance to maternal antigens improves the outcome of allogeneic bone marrow transplantation by a CD4(+)CD25(+) T-cell-dependent mechanism
  K Matsuoka; T Ichinohe; D Hashimoto; S Asakura; M Tanimoto; T Teshima
  BLOOD, 107, 1, 404, 409, 2006年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Fetal-maternal microchimerism: impact on hematopoietic stem cell transplantation
  T Ichinohe; T Teshima; K Matsuoka; E Maruya; H Saji
  CURRENT OPINION IN IMMUNOLOGY, 17, 5, 546, 552, 2005年10月
  英語, 研究論文（学術雑誌）
• Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors
  T Teshima; K Matsuo; K Matsue; F Kawano; S Taniguchi; M Hara; K Hatanaka; M Tanimoto; M Harada; S Nakao; Y Abe; A Wake; T Eto; Y Takemoto; M Imamura; S Takahashi; Y Ishida; Y Kanda; M Kasai; Y Takaue
  BRITISH JOURNAL OF HAEMATOLOGY, 130, 4, 575, 587, 2005年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• The engraftment of transplanted bone marrow-derived cells into the olfactory epithelium
  H Tsujigiwa; K Nishizaki; T Teshima; Y Takeda; J Yoshinobu; A Takeuchi; Y Orita; Y Sugata; H Nagatsuka; N Nagai
  BRAIN RESEARCH, 1052, 1, 10, 15, 2005年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Early immune reaction after reduced-intensity cord-blood transplantation for adult patients
  Y Kishi; M Kami; S Miyakoshi; Y Kanda; N Murashige; T Teshima; E Kusumi; S Hara; T Matsumura; K Yuji; K Masuoka; A Wake; S Morinaga; M Kanemaru; T Hayashi; Y Tanaka; S Taniguchi
  TRANSPLANTATION, 80, 1, 34, 40, 2005年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Both perforin and Fas ligand are required for the regulation of alloreactive CD8(+) T cells during acute graft-versus-host disease
  Y Maeda; RB Levy; P Reddy; C Liu; SG Clouthier; T Teshima; JLM Ferrara
  BLOOD, 105, 5, 2023, 2027, 2005年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells
  D Hashimoto; S Asakura; S Miyake; T Yamamura; L Van Kaer; C Liu; M Tanimoto; T Teshima
  JOURNAL OF IMMUNOLOGY, 174, 1, 551, 556, 2005年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease
  UA Duffner; Y Maeda; KR Cooke; P Reddy; R Ordemann; C Liu; JLM Ferrara; T Teshima
  JOURNAL OF IMMUNOLOGY, 172, 12, 7393, 7398, 2004年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Peripheral blood circulating immature cell counts predict CD34+ cell yields in G-CSF-induced PBPC mobilization in healthy donors
  T Kozuka; K Ikeda; T Teshima; C Yoshida; K Shinagawa; K Kojima; K Matsuo; A Bessho; K Sunami; Y Hiramatsu; Y Maeda; T Noguchi; K Yamamoto; N Fujii; T Imai; KK Kusumoto; K Masuda; K Takenaka; F Ishimaru; K Niiya; N Koide; M Tanimoto; M Harada
  TRANSFUSION, 44, 4, 526, 532, 2004年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells
  M Niiya; K Niiya; M Shibakura; N Asaumi; C Yoshida; K Shinagawa; T Teshima; F Ishimaru; K Ikeda; M Tanimoto
  ONCOLOGY, 67, 3-4, 310, 319, 2004年, ［査読有り］
  英語, 研究論文（学術雑誌）
• [Clinical evaluation of cefozopran as treatment for febrile neutropenia].
  Takashi Saito; Masamichi Hara; Katsuji Shinagawa; Yuichiro Nawa; Koichi Nakase; Makoto Takeuchi; Akira Miyata; Shunnichi Fukuda; Kazutaka Sunami; Kenji Imajoh; Tomofumi Yano; Kensuke Kojima; Takanori Teshima; Nobuharu Fujii; Fumihiko Ishimaru; Kazuma Ikeda; Mine Harada; Mitsune Tanimoto
  Gan to kagaku ryoho. Cancer & chemotherapy, 31, 1, 61, 5, 2004年01月, ［国内誌］
  日本語, 研究論文（学術雑誌）, Clinical effects and safety of cefozopran (CZOP) were evaluated by the Okayama Bone Marrow Transplantation Group. Twenty-five patients expected to experience febrile neutropenia during induction chemotherapy or consolidation chemotherapy of acute leukemia were enrolled between July 2000 and November 2002. CZOP was administrated by drip infusion at 4g/day bid for a minimum of 3 days. The clinical effects and safety were evaluated in 20 patients with fever of 37.5 degrees C or more from a clinically suspected infection. The underlying disease was acute myeloid leukemia in 17 patients, acute lymphoid leukemia in 1 and acute promyelogeneous leukemia in 1. The complicating infections were sepsis and suspected sepsis. Clinical efficacy was excellent in 11 patients, good in 1, fair in 2 and poor in 6, with an efficacy rate of 60.0%. The efficacy rate in patients whose albumin levels before therapy were less than 3.8 g/dl was 37.5%, whereas the rate in patients whose albumin levels before therapy were between 3.8 g/dl and 5.3 g/dl was 80.0%. The efficacy rate in patients whose neutrophil counts before therapy were less than 100/microliter was 50.0%, whereas the rate in patients whose neutrophil counts after therapy were less than 100/microliter was 53.8%. The efficacy rate in patients whose neutrophil counts both before and after therapy were less than 100/microliter was 37.5%. Side effect of exanthema was observed in 1 patient. These results indicate that CZOP is an effective and safe antibiotic for the treatment of febrile neutropenia in patients with hematological malignancies.
• Role of CXCR3-induced donor T-cell migration in acute GVHD
  U Duffner; B Lu; GC Hildebrandt; T Teshima; DL Williams; P Reddy; R Ordemann; SG Clouthier; K Lowler; C Liu; C Gerard; KR Cooke; JLM Ferrara
  EXPERIMENTAL HEMATOLOGY, 31, 10, 897, 902, 2003年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect
  SG Clouthier; KR Cooke; T Teshima; KP Lowler; C Liu; K Connolly; JLM Ferrara
  BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 9, 9, 592, 603, 2003年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Impaired thymic negative selection causes autoimmune graft-versus-host disease
  T Teshima; P Reddy; C Liu; D Williams; KR Cooke; JLM Ferrara
  BLOOD, 102, 2, 429, 435, 2003年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays
  T Ichiba; T Teshima; R Kuick; DE Misek; C Liu; Y Takada; Y Maeda; P Reddy; DL Williams; SM Hanash; JLM Ferrara
  BLOOD, 102, 2, 763, 771, 2003年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Over-expression of the dominant-negative isoform of Ikaros confers resistance to dexamethasone-induced and anti-IgM-induced apoptosis
  N Sezaki; F Ishimaru; M Takata; T Tabayashi; K Nakase; T Kozuka; K Fujii; H Nakayama; T Teshima; M Harada; M Tanimoto
  BRITISH JOURNAL OF HAEMATOLOGY, 121, 1, 165, 169, 2003年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects
  P Reddy; T Teshima; G Hildebrandt; DL Williams; C Liu; KR Cooke; JLM Ferrara
  BLOOD, 101, 7, 2877, 2885, 2003年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Pulmonary infiltration with eosinophilia syndrome complicated with non-Hodgkin’s lymphoma of B cell lineage
  Fujii M; Tanimoto Y; Kiguchi T; Takehara H; Fujimori Y; Teshima T; Kanehiro A; Shinagawa K; Tada S; Kataoka M; Tanimoto M
  Allergology International, 52, 3, 161, 164, Blackwell Publishing, 2003年, ［査読有り］
  英語, 研究論文（学術雑誌）
• The pathophysiology of acute graft-versus-host disease
  International Journal of Hematology, 78, 181, 187, 2003年
  英語, 研究論文（学術雑誌）
• Predictive value of circulating immature cell counts in peripheral blood for timing of peripheral blood progenitor cell collection after G-CSF plus chemotherapy-induced mobilization
  T Kozuka; K Ikeda; T Teshima; K Kojima; K Matsuo; A Bessho; K Sunami; Y Hiramatsu; Y Maeda; T Noguchi; K Yamamoto; N Fujii; T Imai; K Takenaka; K Shinagawa; F Ishimaru; K Niiya; N Koide; M Tanimoto; M Harada
  TRANSFUSION, 42, 11, 1514, 1522, 2002年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation
  P Reddy; T Teshima; G Hildebrandt; U Duffner; Y Maeda; KR Cooke; JLM Ferrara
  BLOOD, 100, 9, 3429, 3431, 2002年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Acute graft-versus-host disease does not require alloantigen expression on host epithelium
  T Teshima; R Ordemann; P Reddy; S Gagin; C Liu; KR Cooke; JLM Ferrara
  NATURE MEDICINE, 8, 6, 575, 581, 2002年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease
  R Ordemann; R Hutchinson; J Friedman; SJ Burakoff; P Reddy; U Duffner; TM Braun; C Liu; T Teshima; JLM Ferrara
  JOURNAL OF CLINICAL INVESTIGATION, 109, 9, 1249, 1256, 2002年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Graft-versus-host disease in the absence of the spleen after allogeneic bone marrow transplantation
  SG Clouthier; JLM Ferrara; T Teshima
  TRANSPLANTATION, 73, 10, 1679, 1681, 2002年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8+ dendritic cells and reduces experimental acute graft-versus-host disease.
  Teshima T; Reddy P; Lowler KP; KuKuruga MA; Liu C; Cooke KR; Ferrara JLM
  Blood, 99, 5, 1825, 1832, 2002年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation
  T Teshima; C Liu; KP Lowler; G Dranoff; JLM Ferrara
  CANCER RESEARCH, 62, 3, 796, 800, 2002年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• New understanding of the alloresponse-new approarches to GVHD prevention
  Seminars in Hematology, 39, 15, 22, 2002年
  英語, 研究論文（学術雑誌）
• Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis
  P Reddy; T Teshima; M Kukuruga; R Ordemann; C Liu; K Lowler; JLM Ferrara
  JOURNAL OF EXPERIMENTAL MEDICINE, 194, 10, 1433, 1440, 2001年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Administration of granulocyte colony-stimulating factor induces hyporesponsiveness to lipopolysaccharide and impairs antigen-presenting function of peripheral blood monocytes
  K Sunami; T Teshima; Y Nawa; Y Hiramatsu; Y Maeda; K Takenaka; K Shinagawa; F Ishimaru; K Ikeda; K Niiya; M Harada
  EXPERIMENTAL HEMATOLOGY, 29, 9, 1117, 1124, 2001年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation
  KR Cooke; A Gerbitz; JM Crawford; T Teshima; GR Hill; A Tesolin; DP Rossignol; JLM Ferrara
  JOURNAL OF CLINICAL INVESTIGATION, 107, 12, 1581, 1589, 2001年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect
  C Schmaltz; O Alpdogan; KJ Horndasch; SJ Muriglan; BJ Kappel; T Teshima; JLM Ferrara; SJ Burakoff; MRM van den Brink
  BLOOD, 97, 9, 2886, 2895, 2001年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation
  T Teshima; N Mach; GR Hill; LY Pan; S Gillessen; G Dranoff; JLM Ferrara
  CANCER RESEARCH, 61, 1, 162, 171, 2001年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Pathogenesis and prevention of graft-versus-host disease
  Current opinion in Organ Transplantation, 6, 265, 271, 2001年
  英語, 研究論文（学術雑誌）
• Allogeneic peripheral blood stem cell transplantation in 23 adult patients with hematologic malignancies: A single-center experience
  K Takenaka; K Shinagawa; K Sunami; N Fujii; Y Hiramatsu; Y Maeda; Y Nawa; Y Katayama; T Teshima; F Ishimaru; K Kiura; K Ikeda; M Harada
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 72, 3, 362, 370, 2000年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Reactivation of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation
  Y Maeda; T Teshima; M Yamada; M Harada
  LEUKEMIA & LYMPHOMA, 39, 3-4, 229, 239, 2000年10月
  英語, 研究論文（学術雑誌）
• G-CSF reduces IFN- and IL-4 production by T cells after allogeneic stimulation by indirectly modulating monocyte function
  Nawa Y; Teshima T; Sunami K; Hiramatsu Y; Maeda Y; Yano T; Shinagawa K; Ishimaru F; Omoto E; Harada M
  Bone Marrow Transplant, 25, 10, 1035, 1040, 2000年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient
  Reddy, V; GR Hill; LY Pan; A Gerbitz; T Teshima; Y Brinson; JLM Ferrara
  TRANSPLANTATION, 69, 4, 691, 693, 2000年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• The p55 TNF-alpha receptor plays a critical role in T cell alloreactivity
  GR Hill; T Teshima; Rebel, VI; OI Krijanovski; KR Cooke; YS Brinson; JLM Ferrara
  JOURNAL OF IMMUNOLOGY, 164, 2, 656, 663, 2000年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Multiple autoimmune haemopoietic disorders and insidious clonal proliferation of large granular lymphocytes
  K Akashi; T Shibuya; S Taniguchi; S Hayashi; H Iwasaki; T Teshima; Y Takamatsu; H Gondo; T Okamura; M Harada; Y Niho
  BRITISH JOURNAL OF HAEMATOLOGY, 107, 3, 670, 673, 1999年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation
  T Teshima; GR Hill; LY Pan; YS Brinson; MRM van den Brink; KR Cooke; JLM Ferrara
  JOURNAL OF CLINICAL INVESTIGATION, 104, 3, 317, 325, 1999年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Differential roles of IL-1 and TNF- on graft-versus-host disease and graft-versus-leukemia
  Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JLM
  J Clin Invest, 104, 4, 459, 467, 1999年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease
  OI Krijanovski; GR Hill; KR Cooke; T Teshima; JM Crawford; YS Brinson; JLM Ferrara
  BLOOD, 94, 2, 825, 831, 1999年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease
  LP Pan; T Teshima; GR Hill; D Bungard; YS Brinson; VS Reddy; KR Cooke; LM Ferrara
  BLOOD, 93, 12, 4071, 4078, 1999年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Hematopoietic progenitor cells from allogeneic bone marrow transplant donors circulate in the very early post-transplant period
  Y Katayama; N Mahmut; H Takimoto; Y Maeda; T Yano; K Kojima; T Azuma; M Hara; K Imajyo; S Takahashi; T Kai; Y Ohno; T Miyamoto; K Nagafuji; K Matsue; K Takenaka; T Teshima; K Shinagawa; F Ishimaru; E Omoto; M Harada
  BONE MARROW TRANSPLANTATION, 23, 7, 659, 665, 1999年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation
  Y Maeda; T Teshima; M Yamada; K Shinagawa; S Nakao; Y Ohno; K Kojima; M Hara; K Nagafuji; S Hayashi; S Fukuda; H Sawada; K Matsue; K Takenaka; F Ishimaru; K Ikeda; K Niiya; M Harada
  BRITISH JOURNAL OF HAEMATOLOGY, 105, 1, 295, 302, 1999年04月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Nasal and nasal-type natural killer T-cell lymphoma
  S Hirakawa; H Kuyama; S Takahashi; O Yamasaki; H Kanzaki; T Teshima; M Harada; YX Ma; T Kawabata; T Yoshino; J Arata
  JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 40, 2, 268, 272, 1999年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Molecular characterization of total kininogen deficiency in Japanese patients
  F Ishimaru; H Dansako; K Nakase; N Fujii; N Sezaki; H Nakayama; N Fujii; Y Komiyama; K Iijima; K Takenaka; T Teshima; K Shinagawa; K Ikeda; K Niiya; M Harada
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 69, 2, 126, 128, 1999年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Analysis of circulating hematopoietic progenitor cells after peripheral blood stem cell transplantation
  N Mahmut; Y Katayama; K Takenaka; T Teshima; Y Ohno; K Imajyo; M Hara; K Shinagawa; F Ishimaru; K Ikeda; K Niiya; M Harada
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 69, 1, 36, 42, 1999年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Allogeneic peripheral blood stem cell transplantation for the treatment of refractory follicular lymphoma
  R Masuda; T Teshima; F Ishimaru; K Shinagawa; H Nakayama; M Shimono; S Asakura; E Ohmoto; M Harada
  INTERNAL MEDICINE, 37, 12, 1050, 1054, 1998年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Partially mismatched pediatric transplants with allogeneic CD34(+) blood cells from a related donor
  Y Kawano; Y Takaue; A Watanabe; O Takeda; K Arai; E Itoh; Y Ohno; T Teshima; M Harada; T Watanabe; Y Okamoto; T Abe; T Kajiume; T Matsushita; K Ikeda; M Endo; Y Kuroda; S Asano; R Tanosaki; K Yamaguchi; P Law; JD McMannis
  BLOOD, 92, 9, 3123, 3130, 1998年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Replating potential of colony-forming units of granulocytes/macrophages (CFU-GM) expanded ex vivo by stem cell factor, interleukin (IL)-3, IL-6, granulocyte colony-stimulating factor, erythropoietin with or without thrombopoietin
  Y Katayama; K Takenaka; N Mahmut; T Teshima; K Shinagawa; E Omoto; M Harada
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 68, 2, 157, 168, 1998年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation
  GR Hill; KR Cooke; T Teshima; JM Crawford; JC Keith; YS Brinson; D Bungard; JLM Ferrara
  JOURNAL OF CLINICAL INVESTIGATION, 102, 1, 115, 123, 1998年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Bone marrow necrosis in a patient with acute myeloblastic leukemia during administration of G-CSF and rapid hematologic recovery after allotransplantation of peripheral blood stem cells
  Y Katayama; S Deguchi; K Shinagawa; T Teshima; K Notohara; K Taguchi; E Omoto; M Harada
  AMERICAN JOURNAL OF HEMATOLOGY, 57, 3, 238, 240, 1998年03月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia
  H Gondo; M Harada; T Miyamoto; K Takenaka; K Tanimoto; S Mizuno; T Fujisaki; K Nagafuji; S Hayashi; T Eto; S Taniguchi; K Akashi; N Harada; K Yamasaki; T Shibuya; E Matsuishi; Y Ohno; S Makino; Y Takamatsu; M Murakawa; T Teshima; Y Hirota; T Okamura; N Kinukawa; S Inaba; Y Niho
  BONE MARROW TRANSPLANTATION, 20, 10, 821, 826, 1997年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Granulocyte colony-stimulating factor-combined marrow-ablative chemotherapy and autologous blood cell transplantation for the treatment of patients with acute myelogenous leukemia in first remission
  M Harada; K Akashi; S Hayashi; T Eto; Y Takamatsu; T Teshima; Y Hirota; S Taniguchi; K Nagafuji; S Mizuno; H Gondo; Y Niho
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 66, 3, 297, 301, 1997年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• G-CSF-induced mobilization of peripheral blood stem cells for allografting: comparative study of daily single versus divided dose of G-CSF
  T Yano; Y Katayama; K Sunami; S Deguchi; Y Nawa; Y Hiramatsu; H Nakayama; T Arakawa; F Ishimaru; T Teshima; K Shinagawa; E Omoto; M Harada
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 66, 2, 169, 178, 1997年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Responses of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells to alloantigen stimulation
  Y Nawa; T Teshima; K Sunami; Y Hiramatsu; T Yano; K Shinagawa; E Omoto; M Harada
  BLOOD, 90, 4, 1716, 1718, 1997年08月, ［査読有り］
  英語
• Common clonal origin of lymphocytes and plasma cells in splenic lymphoma with villous lymphocytes
  Y Katayama; K Kojima; T Yoshino; Y Matsuo; M Isokawa; T Yano; H Oka; M Yamaguchi; S Deguchi; J Tsuchiyama; K Hayashi; T Teshima; K Shinagawa; F Ishimaru; E Omoto; M Harada
  BRITISH JOURNAL OF HAEMATOLOGY, 97, 3, 626, 634, 1997年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Circulating immature cell counts on the harvest day predict the yields of CD34(+) cells collected after granulocyte colony-stimulating factor plus chemotherapy-induced mobilization of peripheral blood stem cell
  T Teshima; K Sunami; A Bessho; K Shinagawa; E Omoto; H Ueoka; M Harada; Y Ohno; T Miyoshi; T Miyamoto; M Higuchi
  BLOOD, 89, 12, 4660, 4661, 1997年06月, ［査読有り］
  英語
• Mobilization of peripheral blood progenitor cells for allogeneic transplantation
  T Teshima; M Harada
  CYTOKINES CELLULAR & MOLECULAR THERAPY, 3, 2, 101, 114, 1997年06月
  英語, 研究論文（学術雑誌）
• Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors
  K Takenaka; H Gondo; K Tanimoto; K Nagafuji; T Fujisaki; S Mizuno; T Miyamoto; T Okamura; S Hayashi; T Eto; K Osaki; K Yamasaki; T Shibuya; N Harada; T Teshima; E Matsuishi; T Minematsu; Y Minamishima; M Harada; Y Niho
  BONE MARROW TRANSPLANTATION, 19, 3, 241, 248, 1997年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Collection and transplantation of autologous peripheral blood stem cells in adults
  Miyamoto T; Inaba S; Harada M; Makino S; Teshima T; Takamatsu Y; Eto T; Nagafuji K; Mizuno S; Gondo H; Niho Y
  Jpn J Apheresis, 16, 1, 50, 55, 日本アフェレシス学会, 1997年, ［査読有り］
  英語, Autologous peripheral blood stem cell transplantation (PBSCT) is currently replacing autologous bone marrow transplantation for the therapy of malignant diseases because of rapid hematopoietic recovery after transplantation. A sufficient number of PBSCs for rapid engraftment can be effectively mobilized by administration of granulocyte colony-stimulating factor following chemotherapy. The optimal timing of collection is guided by observing trilineage hematopoietic recovery as well as measuring CD34+ cells in peripheral blood. Although the technical problems of PBSCs collection have been solved, the possible indication of PBSCT for acute leukemia is controversial. We performed autologous PBSCT on 55 acute myelogenous leukemia (AML) patients and 26 acute lymphoblastic leukemia (ALL) patients. In the AML patients, G-CSF was combined with the conditioning regimen to augment the anti-leukemic effect. The estimated three-year event-free survival (EFS) of 39 AML patients at first remission (CR) was 58%, which was comparable to that of allogeneic BMT. For the ALL patients, on the contrary, 3-year EFS was 37% at first CR. The high incidence of leukemic relapse was a major problem. From our observations, PBSCT can be used as the treatment of choice for AML. However, improvements in the therapeutic strategy is essential in PBSCT for the treatment of ALL.
• Bone-marrow transplantation for Epstein-Barr-virus-associated natural killer cell-large granular lymphocyte leukaemia
  T Teshima; R Miyaji; M Fukuda; F Ohshima
  LANCET, 347, 9008, 1124, 1124, 1996年04月, ［査読有り］
  英語
• Cyclosporine-related encephalopathy following allogeneic bone marrow transplantation
  T Teshima; T Miyoshi; M Ono
  INTERNATIONAL JOURNAL OF HEMATOLOGY, 63, 2, 161, 164, 1996年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Granulocyte colony-stimulating factor-induced mobilization of peripheral blood stem cells for autologous and allogeneic transplantation
  M Harada; T Teshima; T Fujisaki; S Mizuno; T Miyamoto; Y Takamatsu; A Kubota; Y Ohno; M Kuroiwa; K Takenaka; T Eto; K Akashi; H Gondo; T Okamura; S Inaba; Y Niho
  CANCER CHEMOTHERAPY AND PHARMACOLOGY, 38, S115, S119, 1996年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Granulocyte colony-stimulating factor-induced mobilization of peripheral blood stem cells for autologous and allogeneic transplantation
  Mine Harada; Takanori Teshima; Tomoaki Fujisaki; Shin-Ichi Mizuno; Toshihiro Miyamoto; Yasushi Takamatsu; Akira Kubota; Yuju Ohno; Mika Kuroiwa; Katsuto Takenaka; Tetsuya Eto; Koichi Akashi; Hisashi Gondo; Takashi Okamura; Shoichi Inaba; Yoshiyuki Niho
  Cancer Chemotherapy and Pharmacology, Supplement, 38, S115, S119, 1996年, ［査読有り］
  英語, 研究論文（国際会議プロシーディングス）
• RELATIONSHIP OF INFUSED CFU-GM AND CFU-MK MOBILIZED BY CHEMOTHERAPY WITH OR WITHOUT G-CSF TO PLATELET RECOVERY AFTER AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION
  Y TAKAMATSU; M HARADA; T TESHIMA; S MAKINO; S INABA; K AKASHI; T SHIBUYA; Y NIHO
  EXPERIMENTAL HEMATOLOGY, 23, 1, 8, 13, 1995年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• A randomized study of low-dose aclarubicin versus very low-dose cytosine arabinoside for myelodysplastic syndrome
  Y Niho; M Harada; T Shibuya; T Teshima; M Murakawa; T Okamura; H Gondo; S Hisano
  MYELODYSPLASTIC SYNDROMES, 1080, 383, 388, 1995年, ［査読有り］
  英語, 研究論文（国際会議プロシーディングス）
• SUCCESSFUL 2ND AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION AFTER G-CSF-COMBINED CONDITIONING FOR THE TREATMENT OF HIGH-RISK ACUTE MYELOGENOUS LEUKEMIA
  Y TAKAMATSU; T TESHIMA; K AKASHI; S INABA; M HARADA; Y NIHO
  BONE MARROW TRANSPLANTATION, 13, 3, 325, 327, 1994年03月, ［査読有り］
  英語
• EFFECTS OF MACROPHAGE-COLONY-STIMULATING FACTOR (M-CSF) ON THE MOBILIZATION OF PERIPHERAL-BLOOD STEM-CELLS
  T ETO; Y TAKAMATSU; M HARADA; N HARADA; K AKASHI; T TESHIMA; S INABA; T OKAMURA; Y NIHO
  BONE MARROW TRANSPLANTATION, 13, 2, 125, 129, 1994年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• CYTOMEGALOVIRUS (CMV) ANTIGENEMIA FOR RAPID DIAGNOSIS AND MONITORING OF CMV-ASSOCIATED DISEASE AFTER BONE-MARROW TRANSPLANTATION
  H GONDO; T MINEMATSU; M HARADA; K AKASHI; S HAYASHI; S TANIGUCHI; K YAMASAKI; T SHIBUYA; Y TAKAMATSU; T TESHIMA; T ETO; K NAGAFUJI; S MIZUNO; K HOSODA; R MORI; Y MINAMISHIMA; Y NIHO
  BRITISH JOURNAL OF HAEMATOLOGY, 86, 1, 130, 137, 1994年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• A comparative study of imipenem/cilastatin sodium bid vs qid in the treatment of infections associated with hematopoietic disorders
  Yoshiro Sawae; Yoshiyuki Niho; Takashi Okamura; Masahiro Murakawa; Takanori Teshima; Tomoaki Fujisaki; Kei Ikeda; Mitsuo Kozuru; Naokuni Uike; Makoto Katsuno; Hiroyuki Takahira; Michi Hashimoto; Sayuri Yamashita; Kousuke Obama; Junji Nishimura; Syusuke Hisano; Eiji Morioka; Morioki Ishibashi; Tomi Akiyoshi; Junji Suzumiya; Hiroaki Nakajima; Toshiki Uchida; Tetsuya Yoshida; Fumitoshi Asahara; Kouko Sakai; Naohisa Takeichi; Hideki Ishikura; Atsushi Takita; Ryokichi Asayama; Tsunefumi Shibuya; Kazuo Yamasaki; Shuichi Taniguchi; Hisashi Gondoh; Shin Hayashi; Kouichi Akashi; Seiji Motomura; Toshiyuki Ishimaru; Yusei Yamamoto; Kimiaki Ikeda; Yujiroh Yamano; Hiromi Iwasaki; Masayuki Sano; Yoshiroh Ohta; Eijo Matsuishi; Shinichi Hiramatsu; Akihiro Masumoto; Hideaki Kishikawa; Shuichi Koarada
  The Japanese Journal of Antibiotics, 47, 10, 1318, 1328, 1994年, ［査読有り］
  英語, 研究論文（学術雑誌）
• HEMATOPOIETIC PROGENITOR CELLS FROM PATIENTS WITH ADULT T-CELL LEUKEMIA-LYMPHOMA ARE NOT INFECTED WITH HUMAN T-CELL LEUKEMIA-VIRUS TYPE-1
  K NAGAFUJI; M HARADA; T TESHIMA; T ETO; Y TAKAMATSU; T OKAMURA; M MURAKAWA; K AKASHI; Y NIHO
  BLOOD, 82, 9, 2823, 2828, 1993年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• EVALUATION OF LEUKEMIC CONTAMINATION IN PERIPHERAL-BLOOD STEM-CELL HARVESTS BY REVERSE-TRANSCRIPTASE POLYMERASE CHAIN-REACTION
  K NAGAFUJI; M HARADA; Y TAKAMATSU; T ETO; T TESHIMA; T KAMURA; T OKAMURA; S HAYASHI; K AKASHI; M MURAKAWA; Y NIHO
  BRITISH JOURNAL OF HAEMATOLOGY, 85, 3, 578, 583, 1993年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• CYCLOSPORINE COMBINED WITH METHYLPREDNISOLONE OR METHOTREXATE IN PROPHYLAXIS OF MODERATE TO SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE
  H GONDO; M HARADA; S TANIGUCHI; K AKASHI; S HAYASHI; T TESHIMA; Y TAKAMATSU; T ETO; K NAGAFUJI; K YAMASAKI; T SHIBUYA; Y NIHO
  BONE MARROW TRANSPLANTATION, 12, 5, 437, 441, 1993年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF)-INDUCED MOBILIZATION OF CIRCULATING HEMATOPOIETIC STEM-CELLS
  T TESHIMA; M HARADA; Y TAKAMATSU; K MAKINO; S INABA; K AKASHI; S KONDO; T TANAKA; E ISHII; Y NIHO
  BRITISH JOURNAL OF HAEMATOLOGY, 84, 4, 570, 573, 1993年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• A RANDOMIZED PHASE-II TRIAL OF LOW-DOSE ACLARUBICIN VS VERY LOW-DOSE CYTOSINE-ARABINOSIDE FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES
  M HARADA; T SHIBUYA; T TESHIMA; M MURAKAWA; T OKAMURA; Y NIHO; H GONDO; S HAYASHI; K AKASHI; K TAMURA; S MAKINO; H NATORI; K EGAMI; S HISANO; E MORIOKA; S TANIGUCHI; K YAMAZAKI; Y YAMANO; F OMORI
  LEUKEMIA RESEARCH, 17, 8, 629, 632, 1993年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• CYTOKINE PRODUCTION BY PERIPHERAL-BLOOD MONOCYTES AND T-CELLS DURING HEMATOPOIETIC RECOVERY AFTER INTENSIVE CHEMOTHERAPY
  Y TAKAMATSU; K AKASHI; M HARADA; T TESHIMA; S INABA; K SHIMODA; T ETO; T SHIBUYA; S OKAMURA; Y NIHO
  BRITISH JOURNAL OF HAEMATOLOGY, 83, 1, 21, 27, 1993年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• BIOLOGICAL CHARACTERISTICS OF CD7 POSITIVE ACUTE MYELOGENOUS LEUKEMIA
  T ETO; K AKASHI; M HARADA; T SHIBUYA; Y TAKAMATSU; T TESHIMA; Y NIHO
  BRITISH JOURNAL OF HAEMATOLOGY, 82, 3, 508, 514, 1992年11月, ［査読有り］
  英語, 研究論文（学術雑誌）
• A FAMILIAL CASE OF HYPER-IGM IMMUNODEFICIENCY
  R IWAKIRI; T NAKANO; M HARADA; S NAGAFUCHI; T TESHIMA; N ONO; Y YAMAMOTO; Y NIHO
  ACTA HAEMATOLOGICA, 88, 1, 50, 54, 1992年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• CYTOTOXIC DRUG AND CYTOTOXIC DRUG G-CSF MOBILIZATION OF PERIPHERAL-BLOOD STEM-CELLS AND THEIR USE FOR AUTOGRAFTING
  T TESHIMA; M HARADA; Y TAKAMATSU; K MAKINO; S TANIGUCHI; S INABA; S KONDO; T TANAKA; K AKASHI; MINAMISHIMA, I; E ISHII; J NISHIMURA; Y NIHO
  BONE MARROW TRANSPLANTATION, 10, 3, 215, 220, 1992年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• CIRCULATING CD34+ HEMATOPOIETIC PROGENITORS IN THE HARVESTING PERIPHERAL-BLOOD STEM-CELLS - ENHANCEMENT BY RECOMBINANT HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR
  W IKEMATSU; T TESHIMA; S KONDO; S MAKINO; S OKAMURA; S INABA; M HARADA; Y NIHO
  BIOTHERAPY, 5, 2, 131, 136, 1992年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Deficiency of coagulation factor XIII A subunit cause by the dinucleotide deletion at the 5’ end of exon III
  Kamura T; Okamura T; Murakawa M; Tsuda H; Teshima T; Shibuya T; Harada M; Niho Y
  J Clin Invest, 90, 2, 315, 319, 1992年08月, ［査読有り］
  英語, 研究論文（学術雑誌）
• INTERSTITIAL 9Q-DELETION IN T-LYMPHOID MYELOID BIPHENOTYPIC LEUKEMIA
  K AKASHI; T SHIBUYA; M HARADA; A OOGAMI; T TESHIMA; Y TAKAMATSU; M KIKUCHI; Y NIHO
  BRITISH JOURNAL OF HAEMATOLOGY, 80, 2, 172, 177, 1992年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Folinic acid does not mobilize hemopoietic progenitors following repeated consolidation chemotherapy for acute leukemia
  Takanori Teshima; Mine Harada; Yasushi Takamatsu; Shoichi Inaba; Seiji Kondo; Koichi Akashi; Takashi Okamura; Yoshiyuki Niho
  Journal of Clinical Apheresis, 7, 4, 213, 216, 1992年, ［査読有り］
  英語, 研究論文（学術雑誌）
• Cryopreservation, cytokine mobilization, and autotransplantation of peripheral blood stem cells
  Harada M; Taniguchi S; Teshima T; Makino S; Takamatsu Y; Akashi K; Gondo H; Etoh T; Kondo S; Shibuya T; Niho Y
  Prog Clin Biol Res, 377, 297, 308, 1992年
  英語, 研究論文（学術雑誌）
• ASSESSMENT OF ABDOMINAL INVOLVEMENT OF ADULT T-CELL LEUKEMIA LYMPHOMA BY ULTRASONOGRAPHY - COMPARISON AMONG 4 CLINICAL TYPES
  R SHIMAMURA; H ISHIBASHI; E MORIOKA; T TESHIMA; J KUDO; Y HIRATA; T SHIBUYA; Y NIHO
  JOURNAL OF CLINICAL ULTRASOUND, 19, 8, 485, 492, 1991年10月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Simultaneous occurrence of myelomonocytic leukemia and multiple myeloma: involvement of common leukemic progenitors and their developmental abnormality of “lineage infidelity”
  Akashi K; Harada M; Shibuya T; Fukagawa K; Kimura N; Sagawa K; Yoshikai Y; Teshima T; Kikuchi M; Niho Y
  J Cell Physiol, 148, 3, 446, 456, 1991年09月, ［査読有り］
  英語, 研究論文（学術雑誌）
• EFFECTS OF INTERLEUKIN-4 AND INTERLEUKIN-6 ON THE PROLIFERATION OF CD34+ AND CD34- BLASTS FROM ACUTE MYELOGENOUS LEUKEMIA
  K AKASHI; M HARADA; T SHIBUYA; T ETO; Y TAKAMATSU; T TESHIMA; Y NIHO
  BLOOD, 78, 1, 197, 204, 1991年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• EFFECTS OF G-CSF, GM-CSF, AND IL-5 ON NUCLEAR SEGMENTATION OF NEUTROPHILS AND EOSINOPHILS IN CONGENITAL OR ACQUIRED PELGER-HUET ANOMALY
  T TESHIMA; T SHIBUYA; M HARADA; S TANIGUCHI; M NOZAKI; T MORI; Y MORI; H TAMAI; Y NIHO
  EXPERIMENTAL HEMATOLOGY, 19, 5, 322, 325, 1991年06月, ［査読有り］
  英語, 研究論文（学術雑誌）
• CHARACTERIZATION OF LEUKEMIC BASOPHIL PROGENITORS FROM CHRONIC MYELOGENOUS LEUKEMIA
  T TESHIMA; S KONDO; M HARADA; T SHIBUYA; T OKAMURA; Y TAMARI; N KIMURA; K AKASHI; S OKAMURA; Y NIHO
  BRITISH JOURNAL OF HAEMATOLOGY, 78, 1, 55, 59, 1991年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• FOLINIC ACID DID NOT EXPAND THE PERIPHERAL BLOOD STEM CELL POOL DURING RECOVERY FROM CONSOLIDATION CHEMOTHERAPY
  T. Teshima; S. Kondo; S. Inaba; K. Akashi; T. Shibuya; M. Harada; Y. Niho
  British Journal of Haematology, 78, 4, 583, 583, 1991年, ［査読有り］
  英語, 研究論文（学術雑誌）
• THE INHIBITORY EFFECT OF INTERLEUKIN 4 ON THE SPONTANEOUS GROWTH OF CHRONIC MYELOMONOCYTIC LEUKEMIA-CELLS
  K AKASHI; M HARADA; T SHIBUYA; K SHIMODA; Y TAKAMATSU; T TESHIMA; Y NIHO
  MYELODYSPLASTIC SYNDROME AND CYTOKINES, 956, 179, 182, 1991年, ［査読有り］
  英語, 研究論文（国際会議プロシーディングス）
• LOW-DOSE ACLARUBICIN THERAPY FOR MYELODYSPLASTIC SYNDROME
  T SHIBUYA; K AKASHI; M HARADA; T TESHIMA; M MURAKAWA; T OKAMURA; Y NIHO
  MYELODYSPLASTIC SYNDROME AND CYTOKINES, 956, 239, 248, 1991年, ［査読有り］
  英語, 研究論文（国際会議プロシーディングス）
• SPONTANEOUS REMISSION FROM ACUTE EXACERBATION OF CHRONIC ADULT T-CELL LEUKEMIA
  M MURAKAWA; T SHIBUYA; T TESHIMA; J KUDO; T OKAMURA; M HARADA; S NAGAFUCHI; Y NIHO; T MUKAE
  BLUT, 61, 6, 346, 349, 1990年12月, ［査読有り］
  英語, 研究論文（学術雑誌）
• GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR SUPPRESSES INDUCTION OF NEUTROPHIL ALKALINE-PHOSPHATASE SYNTHESIS BY GRANULOCYTE COLONY-STIMULATING FACTOR
  T TESHIMA; T SHIBUYA; M HARADA; K AKASHI; S TANIGUCHI; T OKAMURA; Y NIHO
  EXPERIMENTAL HEMATOLOGY, 18, 4, 316, 321, 1990年05月, ［査読有り］
  英語, 研究論文（学術雑誌）
• EFFECT OF N-METHIONINE-FREE, BACTERIALLY SYNTHESIZED RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR IN A PRIMATE MODEL
  K AKASHI; S TANIGUCHI; T TESHIMA; T SHIBUYA; T OKAMURA; M HARADA; Y NIHO
  EUROPEAN JOURNAL OF HAEMATOLOGY, 44, 2, 99, 104, 1990年02月, ［査読有り］
  英語, 研究論文（学術雑誌）
• CENTRAL NERVOUS-SYSTEM INVOLVEMENT IN ADULT T-CELL LEUKEMIA LYMPHOMA
  T TESHIMA; K AKASHI; T SHIBUYA; S TANIGUCHI; T OKAMURA; M HARADA; SUMIDA, I; M HANADA; Y NIHO
  CANCER, 65, 2, 327, 332, 1990年01月, ［査読有り］
  英語, 研究論文（学術雑誌）
• CLINICAL CHARACTERISTICS OF HYBRID LEUKEMIA - REPORT OF 5 CASES
  K AKASHI; M HARADA; T SHIBUYA; E MORIOKA; T OKAMURA; Y ASANO; S TANIGUCHI; T TESHIMA; M KIKUCHI; Y NIHO
  LEUKEMIA RESEARCH, 14, 2, 145, 153, 1990年, ［査読有り］
  英語, 研究論文（学術雑誌）
• TREATMENT OF MYELODYSPLASTIC SYNDROME AND ATYPICAL LEUKEMIA WITH LOW-DOSE ACLARUBICIN
  T SHIBUYA; T TESHIMA; M HARADA; S TANIGUCHI; T OKAMURA; S OKAMURA; Y NIHO
  LEUKEMIA RESEARCH, 14, 2, 161, &, 1990年, ［査読有り］
  英語, 研究論文（学術雑誌）
• A VARIANT OF MEIGS SYNDROME WITHOUT OVARIAN NEOPLASM
  T TESHIMA; K ISEKI; M NOMIYAMA; T HIRAKAWA; M FUJISHIMA
  RESPIRATORY MEDICINE, 83, 4, 363, 365, 1989年07月, ［査読有り］
  英語, 研究論文（学術雑誌）
• Remission induction of an 86-year-old patient with acute myeloblastic leukemia by aclarubicin
  Teshima T; Morioka E; Shibuya T; Ohtsuka T; Niho Y
  J Kyushu Hematological Society, 36, 13, 18, 1988年, ［査読有り］
  [症例報告]

• 血液がんに対する細胞療法
  豊嶋崇徳, 日本内科学会雑誌, 114, 2025年
• 本邦の骨髄・末梢血幹細胞移植におけるGVHD予防としてのATG使用件数の年次推移
  白鳥聡一; 大引真理恵; 土岐典子; 福田隆浩; 吉原哲; 神田善伸; 西田徹也; 淺田騰; 中前博久; 長谷川祐太; 熱田由子; 豊嶋崇徳; 豊嶋崇徳, 日本輸血細胞治療学会誌, 71, 2, 2025年
• 抗Diaによる胎児・新生児溶血性疾患の1例
  佐藤奨真; 櫻澤貴代; 増田裕弥; 畑瀬理恵; 伊藤誠; 佐々木麻記; 山下直樹; 後藤秀樹; 豊嶋崇徳, 日本輸血細胞治療学会誌, 71, 2, 2025年
• 約10か年の経験に基づく在宅赤血球輸血の安全性の検証と在宅輸血ガイド遵守上の課題
  萩野剛史; 萩野剛史; 佐藤智彦; 林武徳; 金子直也; 能登俊; 安本篤史; 後藤秀樹; 橋本大吾; 竹迫直樹; 豊嶋崇徳, 日本輸血細胞治療学会誌, 71, 2, 2025年
• 同種造血幹細胞移植後のカルシニューリン阻害剤投与時期がドナーT細胞疲弊および慢性GVHD発症に及ぼす影響の検討
  千丈創; 橋本大吾; 塚本しほり; 久保田晋平; 伊藤歩; 田中喬; 一木朝絵; 岡田怜; 齋藤祐美花; 宮島徹; 李文玉; 張紫旋; 原田晋平; 長谷川祐太; 荒隆英; 長谷川嘉則; 稲本賢弘; 村上正晃; 福田隆浩; 豊嶋崇徳, 日本輸血細胞治療学会誌, 71, 2, 2025年
• 血縁ドナーにおけるpegfilgrastimとdaily G-CSFの末梢血へのCD34+細胞動員に与える影響
  畑瀬正尚; 後藤秀樹; 清水啓明; 遠矢嵩; 杉田純一; 西田徹也; 岡田耕平; 山内拓司; 梅本由香里; 高橋秀一郎; 藤井伸治; 山下亜妃子; 日野雅之; 豊嶋崇徳; 豊嶋崇徳, 日本輸血細胞治療学会誌, 71, 2, 2025年
• 低イオン強度溶液(LISS)による自己抗体吸着法の有用性の検討
  櫻澤貴代; 伊藤誠; 佐藤奨真; 増田裕弥; 畑瀬理恵; 佐々木麻記; 山下直樹; 後藤秀樹; 豊嶋崇徳, 日本輸血細胞治療学会誌, 71, 2, 2025年
• CAR-T細胞製造時のferroptosis阻害はFoxo1の核内局在を維持し,CAR-T細胞の幹細胞性,持続性と有効性を強化する
  原田晋平; 橋本大吾; 塚本しほり; 一木朝絵; 齋藤祐美花; 宮島徹; LI Wenyu; 千丈創; ZHANG Zixuan; 菊池遼; 千葉雅尋; 大東寛幸; 荒隆英; 中川雅夫; 豊嶋崇徳, 日本輸血細胞治療学会誌, 71, 2, 2025年
• 補体結合性HLA抗体を高感度に検出する新たなリンパ球クロスマッチ「ICFA-C3d」の検討
  伊藤誠; 櫻澤貴代; 増田裕弥; 佐々木麻記; 山下直樹; 後藤秀樹; 豊嶋崇徳, 日本輸血細胞治療学会誌, 71, 2, 2025年
• 血縁ドナーにおけるpegfilgrastimとdaily G-CSFの末梢血中に動員するCD34+細胞に与える影響
  畑瀬正尚; 後藤秀樹; 清水啓明; 遠矢嵩; 杉田純一; 西田徹也; 岡田耕平; 山内拓司; 梅本由香里; 高橋秀一郎; 神澤雅美; 藤井伸治; 日野雅之; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 47th, 2025年
• 移植後シクロホスファミドによるHLA半合致移植後における心臓障害
  松川敏大; 杉田純一; 橋本大吾; 相庭昌之; 岡田耕平; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 47th, 2025年
• 末梢血幹細胞移植のGVHD予防法における低用量ATG法とPTCy法の比較研究
  白鳥聡一; 杉田純一; 石川淳; 黒羽高志; 森康雄; 衛藤徹也; 笠原千嗣; 福島健太郎; 原田実根; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 47th, 2025年
• 同種移植後FLT3変異陽性AMLに対するギルテリチニブ投与の再発抑制効果~産学共同研究による全国調査結果
  新井康之; 大引真理恵; 大引真理恵; 大引真理恵; 太田秀一; 田中正嗣; 今田和典; 福田隆浩; 片山雄太; 土岐典子; 神田善伸; 坂田(柳元)麻実子; 豊嶋崇徳; 石田隆; 内田寛樹; 馬場龍一; 宇野慧; 高見昭良; 小沼貴晶; 柳田正光; 熱田由子; 熱田由子; 矢野真吾, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 47th, 2025年
• 異なる走査法での門脈血流速度と肝動脈抵抗指数を用いた肝類洞閉塞症候群診断の検討
  岩井孝仁; 岩井孝仁; 西田睦; 豊嶋崇徳; 豊嶋崇徳; 豊嶋崇徳, 超音波医学 Supplement, 52, 2025年
• 肺高血圧症(平均肺動脈圧>20mmHg)の心電図所見の検討
  三谷麻子; 佐藤隆博; 佐藤隆博; 原田亜実; 岩井孝仁; 井上真美子; 中村順一; 今野哲; 今野哲; 辻野一三; 辻野一三; 山下直樹; 豊嶋崇徳, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 10th, 2025年
• 同種移植後血球貪食性リンパ組織球症による二次生着不全と自己造血回復を来した進行期慢性骨髄性白血病
  杉村駿介; 三木康祐; 原田晋平; 長谷川祐太; 安本篤史; 後藤秀樹; 小野澤真弘; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 47th, 2025年
• 肝転移と鑑別困難であった特異な形態を呈した柵状肉芽腫疑いの1例
  岩井孝仁; 岩井孝仁; 西田睦; 表原里実; 表原里実; 安藤風歌; 工藤悠輔; 堀江達則; 工藤悠輔; 堀江達則; 坂本圭太; 柿坂達彦; 若林健人; 豊嶋崇徳; 豊嶋崇徳, 超音波医学 Supplement, 52, 2025年
• 糖尿病患者における下大静脈から腎葉間静脈までの右房圧伝播時間とその臨床的意義
  工藤悠輔; 工藤悠輔; 武藤里奈; 村山迪史; 表原里実; 岩井孝仁; 進藤由衣香; 砂後谷華奈; 三谷麻子; 加賀早苗; 豊嶋崇徳; 表原里実; 岩井孝仁; 進藤由衣香; 砂後谷華奈; 三谷麻子; 加賀早苗; 豊嶋崇徳; 豊嶋崇徳, 超音波医学 Supplement, 52, 2025年
• ステロイド依存性/抵抗性慢性GVHDに対するベルモスジル:製造販売後臨床試験パートを含む最終成績
  白鳥聡一; 加藤光次; 河北敏郎; 大西康; 松岡賢市; 松岡賢市; 池亀和博; 平本展大; 豊崎誠子; 片山雄太; 古賀友紀; 古賀友紀; 村山竣; 笹川裕次; 進藤麻未; 畠清彦; 畠清彦; 前田嘉信; 豊嶋崇徳; 稲本賢弘; 稲本賢弘, 日本血液学会学術集会抄録(Web), 87th, 2025年
• 運動後低酸素血症遷延を示す慢性血栓塞栓性肺高血圧症患者の特徴
  大原彩友美; 村山迪史; 井上真美子; 山本雅史; 早坂光司; 山下直樹; 豊嶋崇徳; 辻野一三; 今野哲, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 10th, 2025年
• カプシド阻害剤のHIV-1薬剤耐性検査の構築と評価
  吉田繁; 佐藤かおり; 岩崎澄央; 遠藤知之; 遠藤知之; 豊嶋崇徳; 西澤雅子; 杉浦亙; 吉村和久; 菊地正, 日本染色体遺伝子検査学会雑誌, 43, 2, 2025年
• 第4群肺高血圧症のBPA前後における合成心電図V3R,V4R,V5Rの検討
  原田亜実; 佐藤隆博; 佐藤隆博; 三谷麻子; 岩井孝仁; 井上真美子; 中村順一; 今野哲; 今野哲; 辻野一三; 辻野一三; 山下直樹; 豊嶋崇徳, 日本肺高血圧・肺循環学会学術集会抄録集(Web), 10th, 2025年
• Xpert MRSA/SA BC「セフィエド」導入による,血液培養陽性患者への抗菌薬適正使用早期介入の評価
  福元達也; 菊地玲; 瀧圭介; 松山彩花; 早坂かすみ; 山下直樹; 後藤秀樹; 後藤秀樹; 豊嶋崇徳; 豊嶋崇徳, 医学検査, 74, 4, 2025年
• 大量失血を伴う手術時におけるレナカパビルの血中濃度の推移
  遠藤知之; 田澤佑基; 遠藤知之; 田澤佑基; 新井崇之; 後藤秀樹; 松川敏大; 荒隆英; 長谷川祐太; 長井惇; 森木朝子; 高橋知希; 後藤了一; 後藤秀樹; 松川敏大; 荒隆英; 長谷川祐太; 長井惇; 森木朝子; 高橋知希; 後藤了一; 嶋村剛; 原貴信; 曽山明彦; 江口晋; 豊嶋崇徳; 江口晋; 豊嶋崇徳, 日本エイズ学会誌, 27, 4, 2025年
• 2剤療法施行中のHIV陽性者におけるBlipおよびTarget Not Detected(TND)維持率の検討
  遠藤知之; 遠藤知之; 後藤秀樹; 後藤秀樹; 松川敏大; 松川敏大; 荒隆英; 荒隆英; 長谷川祐太; 長谷川祐太; 須藤啓斗; 須藤啓斗; 宮島徹; 宮島徹; 長井惇; 長井惇; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 27, 2, 2025年
• 血液がんに対する細胞療法
  豊嶋崇徳, 日本内科学会雑誌, 114, 9, 2025年
• 2024年の国内新規診断未治療HIV感染者・AIDS患者における薬剤耐性HIV-1の動向
  菊地正; 西澤雅子; 林田庸総; 潟永博之; 豊嶋崇徳; 吉田繁; 伊藤俊広; 古賀道子; 長島真美; 貞升健志; 佐野貴子; 宇野俊介; 谷口俊文; 猪狩英俊; 寒川整; 中島秀明; 吉野友祐; 堀場昌英; 茂呂寛; 渡邉珠代; 今橋真弓; 松田昌和; 重見麗; 岩谷靖雅; 横幕能行; 渡邊大; 阪野文哉; 川畑拓也; 藤井輝久; 高田清式; 末盛浩一郎; 中村麻子; 南留美; 松下修三; 仲村秀太; 小島潮子; RUNTUWENE Lucky; 椎野禎一郎; 吉村和久; 杉浦亙, 日本エイズ学会誌, 27, 4, 2025年
• HIV感染者における悪性腫瘍の発生率と予後
  松川敏大; 遠藤知之; 長谷川祐太; 高橋知希; 森木朝子; 長井惇; 後藤秀樹; 豊嶋崇徳; 松川敏大; 遠藤知之; 長谷川祐太; 高橋知希; 森木朝子; 長井惇; 後藤秀樹; 豊嶋崇徳; 遠藤知之, 日本エイズ学会誌, 27, 4, 2025年
• GVHDによる腸幹細胞の炎症記憶は腸上皮の抗原提示とアポトーシスを促進する
  宮島徹; 橋本大吾; 森木朝子; 小島圭祐; 塚本しほり; 一木朝絵; 齋藤祐美花; 李文ぎょく; 張紫せん; 原田晋平; 千丈創; 横井友樹; 長谷川祐太; 大東寛幸; 荒隆英; 中村公則; 谷口浩二; 豊嶋崇徳, 日本血液疾患免疫療法学会学術集会プログラム・抄録集, 17th, 2025年
• プロテアーゼ,逆転写酵素,インテグラーゼを対象としたHIV薬剤耐性検査試薬キット,HIV-1Genotyping Kit with Integraseの性能評価
  吉田繁; 佐藤かおり; 藤澤真一; 岩崎澄央; 遠藤知之; 豊嶋崇徳; 松田昌和; 今橋真弓; 蜂谷敦子; 岡田清美; 齊藤浩一; 奥田美那子; 加藤眞吾; 林田庸総; 椎野禎一郎; 西澤雅子; 杉浦亙; 吉村和久; 菊地正, 日本エイズ学会誌, 27, 2, 2025年
• レボレードが生化学検査に与える影響とその変動に関する解析
  中野恵一; 清宮正徳; 小島和茂; 山下直樹; 後藤秀樹; 豊嶋崇徳, 医療検査と自動化(Web), 50, 4, 2025年
• AIDS患者の髄液病原体網羅的解析を目的としたマルチプレックスPCRの有用性についての検討
  松川敏大; 松川敏大; 遠藤知之; 遠藤知之; 遠藤知之; 森木朝子; 森木朝子; 長井惇; 長井惇; 宮島徹; 宮島徹; 長谷川祐太; 長谷川祐太; 荒隆英; 荒隆英; 後藤秀樹; 後藤秀樹; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 27, 3, 2025年
• 2024年の日本の新規未治療HIV-1感染者における薬剤耐性変異の動向
  菊地正; 西澤雅子; 小島潮子; RUNTUWENE Lucky; 林田庸総; 潟永博之; 椎野禎一郎; 杉浦亙; 今橋真弓; 松田昌和; 重見麗; 岩谷靖雅; 横幕能行; 渡邊大; 南留美; 伊藤俊広; 堀場昌英; 豊嶋崇徳; 吉田繁; 古賀道子; 吉野友祐; 宇野俊介; 谷口俊文; 猪狩英俊; 寒川整; 中島秀明; 茂呂寛; 高橋雅彦; 渡邉珠代; 藤井輝久; 高田清式; 末盛浩一郎; 中田浩智; 松下修三; 山川奈津子; 仲村秀太; 中村麻子; 浜みなみ; 阪野文哉; 川畑拓也; 佐野貴子; 小泉美優; 長島真美; 貞升健志; 吉村和久, IASR (Web), 46, 10, 2025年
• 骨髄移植後のGVHD治療中にVZV髄膜炎と中枢神経リンパ増殖性疾患を合併した1例
  小宮かさね; 斎藤祐美花; 横山慶人; 原田晋平; 須藤啓斗; 長谷川祐太; 後藤秀樹; 小野澤真弘; 橋本大吾; 豊嶋崇徳, 臨床血液, 66, 11, 2025年
• Zanubrutinibが奏効したBing-Neel症候群の1例
  野島慎悟; 野津麟太郎; 堀北風花; 宮島徹; 吉田匠汰; 木村弘幸; 荒隆英; 小笠原励起; 松川敏大; 白鳥聡一; 中川雅夫; 豊嶋崇徳, 臨床血液, 66, 11, 2025年
• やむを得ない在宅輸血導入から貧血精査を進めて輸血回避に至った高齢者貧血の1例
  萩野剛史; 萩野剛史; 萩野剛史; 佐藤智彦; 林武徳; 金子直也; 能登俊; 橋本大吾; 竹迫直樹; 豊嶋崇徳, 日本輸血細胞治療学会誌, 71, 5, 2025年
• 2023年の国内新規診断未治療HIV感染者・AIDS患者における薬剤耐性HIV-1の動向
  菊地 正; 西澤 雅子; 椎野 禎一郎; 豊嶋 崇徳; 伊藤 俊広; 林田 庸総; 潟永 博之; 古賀 道子; 長島 真美; 貞升 健志; 佐野 貴子; 宇野 俊介; 谷口 俊文; 猪狩 英俊; 寒川 整; 中島 秀明; 吉野 友祐; 堀場 昌英; 茂呂 寛; 渡邉 珠代; 今橋 真弓; 蜂谷 敦子; 松田 昌和; 重見 麗; 岡崎 玲子; 岩谷 靖雅; 横幕 能行; 渡邊 大; 阪野 文哉; 川畑 拓也; 藤井 輝久; 高田 清式; 中村 麻子; 南 留美; 松下 修三; 仲村 秀太; 小島 潮子; Runtuwene Lucky; 吉村 和久; 杉浦 亙, 日本エイズ学会誌, 26, 4, 463, 463, 2024年11月
  (一社)日本エイズ学会, 日本語
• HIV感染合併血友病患者の運動機能評価およびリハビリテーションの有用性
  遠藤 知之; 渡部 恵子; 原田 裕子; 由利 真; 千田 尊子; 後藤 秀樹; 松川 敏大; 荒 隆英; 長谷川 祐太; 宮島 徹; 長井 惇; 森木 朝子; 藤谷 順子; 豊嶋 崇徳, 日本エイズ学会誌, 26, 4, 380, 380, 2024年11月
  (一社)日本エイズ学会, 日本語
• AIDS患者の髄液病原体網羅的解析を目的としたマルチプレックスPCRの有用性についての検討
  松川 敏大; 遠藤 知之; 森木 朝子; 長井 惇; 宮島 徹; 長谷川 祐太; 荒 隆英; 後藤 秀樹; 豊嶋 崇徳, 日本エイズ学会誌, 26, 4, 457, 457, 2024年11月
  (一社)日本エイズ学会, 日本語
• ART療法が奏効した難治性サイトメガロウイルス腸炎の1例
  長谷川 祐太; 遠藤 知之; 宮島 徹; 長井 惇; 森木 朝子; 松川 敏大; 荒 隆英; 後藤 秀樹; 豊嶋 崇徳, 日本エイズ学会誌, 26, 4, 459, 459, 2024年11月
  (一社)日本エイズ学会, 日本語
• 北海道ブロック「HIV/AIDS出張研修」 12年間の実践報告
  渡部 恵子; センテノ田村 恵子; 遠藤 知之; 武内 阿味; 熊谷 泰恵; 石田 陽子; 尾谷 ゆか; 山口 みなみ; 北村 末季; 松川 敏大; 長谷川 祐太; 後藤 秀樹; 豊嶋 崇徳; 三宅 亜矢, 日本エイズ学会誌, 26, 4, 514, 514, 2024年11月
  (一社)日本エイズ学会, 日本語
• 初発マントル細胞リンパ腫に対するイブルチニブ併用BR療法 SHINE試験8年追跡結果
  福原 規子; 三嶋 裕子; 一井 倫子; 内田 俊樹; 加藤 光次; 丸山 大; 尾見 歩惟; 興梠 陽介; 志賀 要; 豊嶋 崇徳, 日本血液学会学術集会, 86回, O1, 2, 2024年10月
  (一社)日本血液学会, 英語
• HLA半合致移植を施行したShwachman-Diamond症候群(SDS)を背景とした急性骨髄性白血病
  塚本 しほり; 中川 雅夫; 小野澤 真弘; 南谷 泰仁; 小島 圭祐; 原田 知弥; 荒 隆英; 松川 敏大; 白鳥 聡一; 遠藤 知之; 豊嶋 崇徳, 臨床血液, 65, 10, 1329, 1329, 2024年10月
  (一社)日本血液学会-東京事務局, 日本語
• FLT3阻害薬は投与時期に関わらずFLT3変異AMLの予後を延長する
  松川 敏大; 近藤 健; 日高 大輔; 太田 秀一; 金谷 穣; 盛 暁生; 重松 明男; 宮城島 拓人; 柿木 康孝; 橋口 淳一; 山本 聡; 山本 昌代; 若狭 健太郎; 高畑 むつみ; 石原 敏道; 長谷山 美仁; 藤見 章仁; 五十嵐 哲祥; 更科 岳大; 井山 諭; 小林 良二; 酒井 基; 藤本 勝也; 稲村 純季; 蟹澤 祐司; 平林 真介; 小野澤 真弘; 遠藤 知之; 豊嶋 崇徳, 日本血液学会学術集会, 86回, O1, 5, 2024年10月
  (一社)日本血液学会, 英語
• Ph染色体陰性BCR::ABL1陽性急性白血病の頻度と臨床的特徴
  横山 翔大; 小野澤 真弘; 木村 弘幸; 荒 隆英; 長井 惇; 吉田 匠汰; 宮下 直樹; 松川 敏大; 平林 真介; 盛 暁生; 日高 大輔; 橋口 淳一; 若狭 健太郎; 井端 淳; 武田 紫; 重松 明男; 山本 聡; 藤本 勝也; 堤 豊; 石原 敏道; 酒井 基; 柿木 康孝; 小宅 達郎; 近藤 健; 豊嶋 崇徳, 日本血液学会学術集会, 86回, O1, 1, 2024年10月
  (一社)日本血液学会, 英語
• ベネトクラクスによる治療を受けた新規診断急性骨髄性白血病の遺伝子変異と予後
  宮下 直樹; 小野澤 真弘; 長井 惇; 吉田 匠汰; 木村 弘幸; 横山 翔大; 松川 敏大; 杉田 純一; 日高 大輔; 小笠原 励起; 盛 暁生; 近藤 健; 柿木 康孝; 重松 明男; 若狭 健太郎; 笠原 郁美; 石原 敏道; 橋口 淳一; 武田 紫; 石尾 崇; 酒井 基; 堤 豊; 藤本 勝也; 井山 諭; 小宅 達郎; 豊嶋 崇徳, 日本血液学会学術集会, 86回, O2, 3, 2024年10月
  (一社)日本血液学会, 英語
• 成人B細胞性急性リンパ性白血病における複雑核型解析
  木村 弘幸; 小野澤 真弘; 長井 惇; 吉田 匠汰; 宮下 直樹; 松川 敏大; 盛 暁生; 日高 大輔; 杉田 純一; 柿木 康孝; 堤 豊; 山本 聡; 重松 明男; 橋口 淳一; 井端 淳; 横山 翔大; 若狭 健太郎; 長谷山 美仁; 藤本 勝也; 石原 敏道; 酒井 基; 平林 真介; 小宅 達郎; 近藤 健; 豊嶋 崇徳, 日本血液学会学術集会, 86回, O3, 3, 2024年10月
  (一社)日本血液学会, 英語
• HIV陽性者における性感染症の実態
  松川 敏大; 遠藤 知之; 長井 惇; 宮島 徹; 須藤 啓斗; 長谷川 祐太; 荒 隆英; 後藤 秀樹; 豊嶋 崇徳, 日本エイズ学会誌, 26, 3, 132, 138, 2024年08月
  (一社)日本エイズ学会, 日本語
• パテントブルーとインドシアニングリーンが混濁・溶血判定に与える影響
  中野 恵一; 安田 慶子; 山下 直樹; 後藤 秀樹; 豊嶋 崇徳, 医療検査と自動化, 49, 4, 390, 390, 2024年08月
  (一社)日本医療検査科学会, 日本語
• 国内HIV-1伝播クラスタの2022年の動向 薬剤耐性HIV調査ネットワークによるSPHNCS年報
  椎野 禎一郎; 潟永 博之; 今橋 真弓; 渡邊 大; 南 留美; 蜂谷 敦子; 西澤 雅子; 林田 庸総; 吉田 繁; 豊嶋 崇徳; 伊藤 俊広; 古賀 道子; 貞升 健志; 佐野 貴子; 宇野 俊介; 谷口 俊文; 猪狩 英俊; 寒川 整; 中島 秀明; 吉野 友祐; 堀場 昌英; 茂呂 寛; 渡邉 珠代; 阪野 文哉; 川畑 拓也; 藤井 輝久; 高田 清式; 中村 麻子; 仲村 秀太; 松下 修三; 吉村 和久; 杉浦 亙; 菊地 正, 日本エイズ学会誌, 26, 3, 139, 150, 2024年08月
  (一社)日本エイズ学会, 日本語
• 新型コロナウイルス感染症の患者検体からの組換えウイルスの作出
  山本紘嵩; 田村友和; 田村友和; 市川貴也; 市川貴也; 市川貴也; 鈴木紗織; 鈴木紗織; 鈴木理滋; 鈴木理滋; 豊嶋崇徳; 山本聡; 福原崇介; 福原崇介; 福原崇介, 日本ウイルス学会学術集会プログラム・予稿集(Web), 62, 7, e0004224, 2024年07月16日, ［国際誌］
  UNLABELLED: Rapid characterization of the causative agent(s) during a disease outbreak can aid in the implementation of effective control measures. However, isolation of the agent(s) from crude clinical samples can be challenging and time-consuming, hindering the establishment of countermeasures. In the present study, we used saliva specimens collected for the diagnosis of SARS-CoV-2-a good example of a practical target-and attempted to characterize the virus within the specimens without virus isolation. Thirty-four saliva samples from coronavirus disease 2019 patients were used to extract RNA and synthesize DNA amplicons by PCR. New primer sets were designed to generate DNA amplicons of the full-length spike (S) gene for subsequent use in a circular polymerase extension reaction (CPER), a simple method for deriving recombinant viral genomes. According to the S sequence, four clinical specimens were classified as BA. 1, BA.2, BA.5, and XBB.1 and were used for the de novo generation of recombinant viruses carrying the entire S gene. Additionally, chimeric viruses carrying the gene encoding GFP were generated to evaluate viral propagation using a plate reader. We successfully used the RNA purified directly from clinical saliva samples to generate chimeric viruses carrying the entire S gene by our updated CPER method. The chimeric viruses exhibited robust replication in cell cultures with similar properties. Using the recombinant GFP viruses, we also successfully characterized the efficacy of the licensed antiviral AZD7442. Our proof-of-concept demonstrates the novel utility of CPER to allow rapid characterization of viruses from clinical specimens. IMPORTANCE: Characterization of the causative agent(s) for infectious diseases helps in implementing effective control measurements, especially in outbreaks. However, the isolation of the agent(s) from clinical specimens is often challenging and time-consuming. In this study, saliva samples from coronavirus disease 2019 patients were directly subjected to purifying viral RNA, synthesizing DNA amplicons for sequencing, and generating recombinant viruses. Utilizing an updated circular polymerase extension reaction method, we successfully generated chimeric SARS-CoV-2 viruses with sufficient in vitro replication capacity and antigenicity. Thus, the recombinant viruses generated in this study were applicable for evaluating the antivirals. Collectively, our developed method facilitates rapid characterization of specimens circulating in hosts, aiding in the establishment of control measurements. Additionally, this approach offers an advanced strategy for controlling other (re-)emerging viral infectious diseases., 英語
• 術中投与色素の混濁指数への影響 パテントブルーが混濁指数に正誤差を示した一例
  中野 恵一; 清宮 正徳; 安田 慶子; 山下 直樹; 後藤 秀樹; 豊嶋 崇徳, 臨床化学, 53, Suppl.1, 162, 162, 2024年07月
  (一社)日本臨床化学会, 日本語
• イムノクロマト法によるHIT抗体測定の検討
  宇佐美 貴之; 安本 篤史; 李 明海; 畑瀬 正尚; 早坂 光司; 村上 望; 山下 亜妃子; 山下 直樹; 後藤 秀樹; 豊嶋 崇徳, 日本検査血液学会雑誌, 25, 学術集会, S205, S205, 2024年06月
  (一社)日本検査血液学会, 日本語
• プラークだけじゃない! 頭頸部エコーでみられる典型画像 巨細胞性動脈炎の診断に寄与する新たな超音波所見 生検所見との比較に基づく検討
  工藤 悠輔; 村山 迪史; 加賀 早苗; 表原 里実; 岩井 孝仁; 進藤 由衣香; 砂後谷 華奈; 西田 睦; 豊嶋 崇徳; 石津 明洋, 超音波医学, 51, Suppl., S414, S414, 2024年04月
  (公社)日本超音波医学会, 日本語
• 【血小板減少症の診かた】薬剤による血小板減少症
  安本 篤史; 豊嶋 崇徳, 日本医師会雑誌, 152, 12, 1361, 1364, 2024年03月
  (公社)日本医師会, 日本語
• 肺小細胞癌の治療中に白血球増多と線維素性心外膜炎を認めた一例
  山内 智仁; 種井 善一; 長井 淳; 小田 義崇; 菊池 遼; 小野澤 真弘; 津田 真寿美; 田中 敏; 豊島 崇徳; 田中 伸哉, 日本病理学会会誌, 113, 1, 463, 463, 2024年02月
  (一社)日本病理学会, 日本語
• ハイブリッド視察によるI&A受審を経験して
  伊藤 誠; 増田 裕弥; 南 昭子; 佐々木 麻記; 山下 直樹; 渡邊 千秋; 後藤 秀樹; 豊嶋 崇徳, 日本輸血細胞治療学会誌, 70, 1, 51, 51, 2024年02月
  (一社)日本輸血・細胞治療学会, 日本語
• 低用量ST合剤による同種造血幹細胞移植後ニューモシスチス肺炎の予防効果についての検討
  荒隆英; 遠藤知之; 長谷川祐太; 大東寛幸; 白鳥聡一; 橋本大吾; 豊嶋崇徳, 日本内科学会雑誌, 113, 2024年
• 単球の形態異常を伴うB細胞/T細胞混合系統型急性白血病の1例
  佐藤健吾; 平林真介; 長谷河昌孝; 宇佐美貴之; 小林美穂; 畑瀬正尚; 村上望; 山下亜妃子; 山下直樹; 豊嶋崇徳, 日本検査血液学会雑誌, 25, 2024年
• 巨細胞性動脈炎の診断に寄与する新たな超音波所見:生検所見との比較に基づく検討
  工藤悠輔; 工藤悠輔; 村山迪史; 加賀早苗; 加賀早苗; 表原里実; 表原里実; 岩井孝仁; 岩井孝仁; 進藤由衣香; 進藤由衣香; 砂後谷華奈; 砂後谷華奈; 西田睦; 豊嶋崇徳; 豊嶋崇徳; 豊嶋崇徳; 石津明洋, 超音波医学 Supplement, 51, 2024年
• HokUS-10による早期診断と治療介入で救命し得た,HLA半合致移植後の重症肝類洞閉塞症候群(SOS)の一例
  橋田里妙; 橋田里妙; 藤井文彰; 千丈創; 千葉雅尋; 長谷川祐太; 大東寛幸; 安本篤史; 後藤秀樹; 小野澤真弘; 表原里実; 西田睦; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th, 2024年
• 造血幹細胞の末梢血中への動員及び採取を目的としたペグフィルグラスチムの全例調査(中間報告)
  岡田耕平; 後藤秀樹; 豊崎誠子; 黒川敏郎; 日野雅之; 桑澤宏; 大庭彩; 藤田昌紀; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th, 2024年
• ステロイド依存性/抵抗性慢性移植片対宿主病に対するベルモスジルの国内第III相臨床試験
  河北敏郎; 稲本賢弘; 加藤光次; 大西康; 松岡賢市; 白鳥聡一; 池亀和博; 平本展大; 豊崎誠子; 片山雄太; 村山竣; 笹川裕次; 前田嘉信; 畠清彦; 畠清彦; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th, 2024年
• DLBCLにおいて前治療の奏効期間がCAR-T療法の治療効果に与える影響
  後藤秀樹; 荒隆英; 大東寛幸; 長谷川祐太; 千葉雅尋; 千丈創; 松川敏大; 安本篤史; 白鳥聡一; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th, 2024年
• 同種造血幹細胞移植における低分子ヘパリン投与とSOS/VOD発症との関連性
  白鳥聡一; 長谷川祐太; 大東寛幸; 荒隆英; 松川敏大; 安本篤史; 後藤秀樹; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th, 2024年
• “生きたい”を支える診断法~超音波検査による造血細胞移植後の肝類洞閉塞症候群診断
  西田睦; 岩井孝仁; 後藤秀樹; 安本篤史; 豊嶋崇徳; 岩井孝仁; 後藤秀樹; 安本篤史; 豊嶋崇徳; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th, 2024年
• 多発性骨髄腫及び悪性リンパ腫患者におけるCD34陽性細胞動員に対するpegfilgrastimの有効性と安全性
  澤正史; 後藤秀樹; 後藤秀樹; 藤原慎一郎; 李政樹; 石塚賢治; 豊崎誠子; 石田禎夫; 武内正博; 角南一貴; 塚田順一; 園木孝志; 下込愛子; 市橋裕樹; 大内喜海; 日野雅之; 前田嘉信; 宮本敏浩; 豊嶋崇徳; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 46th, 2024年
• パテントブルーとインドシアニングリーンが混濁・溶血判定に与える影響
  中野恵一; 安田慶子; 山下直樹; 後藤秀樹; 豊嶋崇徳, 医療検査と自動化(Web), 49, 4, 2024年
• 再発/難治性古典的ホジキンリンパ腫日本人患者におけるペムブロリズマブの市販後全例調査の解析
  豊嶋崇徳; 尾崎正彦; 濱田昌宏; 前川慎一郎; 中林祥子; 伊藤雄一郎, 日本リンパ網内系学会会誌, 64, 2024年
• Ruxolitinibが著効した難治性皮膚GVHD
  長井惇; 一木朝絵; 菊池遼; 長谷川祐太; 大東寛幸; 後藤秀樹; 小野澤真弘; 橋本大吾; 豊嶋崇徳, 臨床血液, 65, 10, 2024年
• 白血病治療の最前線 B細胞性急性リンパ性白血病に対するCAR-T細胞療法
  後藤秀樹; 豊嶋崇徳; 豊嶋崇徳, 月刊臨床と研究, 101, 12, 2024年
• 血液腫瘍に対するCAR-T細胞療法
  豊嶋崇徳, 日本臨床免疫学会総会プログラム・抄録集, 52nd, 2024年
• 橋中心に脳MRI T2WI高信号を呈した超高腫瘍量CD5陽性びまん性大細胞型B細胞リンパ腫
  鈴木かなん; 鈴木かなん; 原田晋平; 杉村駿介; 三木康祐; 長谷川裕太; 安本篤史; 後藤秀樹; 小野澤真弘; 橋本大吾; 豊嶋崇徳, 臨床血液, 65, 12, 2024年
• Super Wide View,Sensor3Dを用いた多発性嚢胞腎モデルの計測
  岩井孝仁; 岩井孝仁; 西田睦; 表原里実; 表原里実; 堀江達則; 堀江達則; 八反田文彦; 西尾妙織; 工藤悠輔; 工藤悠輔; 山下直樹; 後藤秀樹; 豊嶋崇徳; 豊嶋崇徳, 日本超音波検査学会学術集会講演抄録集(Web), 49th, 2024年
• 心エコー検査を契機に発見された先天性左側心膜欠損症の1症例
  柳 裕介; 加賀 早苗; 村山 迪史; 西野 久雄; 横山 しのぶ; 山下 直樹; 玉置 陽生; 青柳 裕之; 石坂 傑; 岩野 弘幸; 豊嶋 崇徳; 安斉 俊久, 超音波検査技術抄録集, 49, S198, S198, 2024年
  一般社団法人 日本超音波検査学会, 日本語
• 再発難治性びまん性大細胞型B細胞リンパ腫に対するCAR-T細胞療法後にpseudo-progressionを認めた1例
  藤井 文彰; 千葉 雅尋; 橋田 里妙; 長谷川 祐太; 大東 寛幸; 安本 篤史; 後藤 秀樹; 山口 圭介; 小野澤 真弘; 橋本 大吾; 豊嶋 崇徳, 臨床血液, 64, 12, 1523, 1524, 2023年12月
  (一社)日本血液学会-東京事務局, 日本語
• 健康成人ドナーにおける末梢血中へのCD34陽性細胞の動員に関するpegfilgrastimの有効性と安全性
  後藤秀樹; 早坂光司; 砂後谷華奈; 道又理恵; 西田睦; 神宮真希; 下込愛子; 小寺充彦; 日野雅之; 前田嘉信; 澤正史; 豊嶋崇徳; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th, 2023年11月28日, ［国際誌］
  BACKGROUND: Pegfilgrastim, a long-acting form of granulocyte-colony stimulating factor, with a convenient single-injection dosage, is being investigated for peripheral blood stem cell (PBSC) mobilization in healthy volunteers. However, data on the adequate dose of pegfilgrastim for PBSC mobilization are limited. This phase 2, single-arm study evaluated the efficacy and safety of pegfilgrastim for PBSC mobilization in healthy volunteers. METHODS: The study comprised 2 phases: pilot (steps 1-3, dose escalation, a single subcutaneous dose of 3.6, 7.2, and 10.8 mg pegfilgrastim, respectively) and evaluation (step 4, efficacy and safety assessments). The primary endpoint was the proportion of subjects who achieved mobilization of ≥20 × 106/L cluster of differentiation 34 positive (CD34+) cells. RESULTS: Thirty-five subjects (6 each in steps 1 and 2 and 23 in step 4) were included. In the pilot phase, step 3 with a 10.8 mg dose was not conducted due to favorable outcomes in step 2 (desired CD34+ cell count), at 7.2 mg pegfilgrastim, which was identified as the optimal dose for the evaluation phase. In the evaluation phase, successful CD34+ mobilization was achieved in all 23 subjects. The mean peripheral blood CD34+ cells count peaked on day 5. Back pain, thrombocytopenia, transient elevations of alkaline phosphatase, and lactate dehydrogenase were the most common adverse events. All adverse events were mild, and none led to study discontinuation. CONCLUSIONS: A single-dose pegfilgrastim successfully mobilized an optimal number of CD34+ cells and was well tolerated. Pegfilgrastim could be an alternative option for PBSC mobilization in healthy volunteers. The trial was registered at www.clinicaltrials.gov (NCT03993639)., 英語
• HIV陽性者における性感染症の実態
  松川 敏大; 遠藤 知之; 長井 惇; 宮島 徹; 須藤 啓斗; 長谷川 祐太; 荒 隆英; 後藤 秀樹; 豊嶋 崇徳, 日本エイズ学会誌, 25, 4, 441, 441, 2023年11月
  (一社)日本エイズ学会, 日本語
• 2剤療法施行中のHIV陽性者におけるBlipおよびTND(Target Not Detected)維持率の検討
  遠藤 知之; 後藤 秀樹; 松川 敏大; 荒 隆英; 長谷川 祐太; 須藤 啓斗; 宮島 徹; 長井 惇; 豊嶋 崇徳, 日本エイズ学会誌, 25, 4, 498, 498, 2023年11月
  (一社)日本エイズ学会, 日本語
• 2022年度HIV-1薬剤耐性検査外部精度評価の報告
  吉田 繁; 松田 昌和; 今橋 真弓; 岡田 清美; 齊藤 浩一; 林田 庸総; 佐藤 かおり; 藤澤 真一; 遠藤 知之; 西澤 雅子; 椎野 禎一郎; 潟永 博之; 豊嶋 崇徳; 杉浦 亙; 吉村 和久; 菊地 正, 日本エイズ学会誌, 25, 4, 443, 443, 2023年11月
  (一社)日本エイズ学会, 日本語
• Mycobacterium genavenseによる限局性の皮膚感染症を呈した1例
  黒澤 卓; 今福 恵輔; 宮澤 元; 中久保 祥; 岩崎 澄央; 後藤 秀樹; 豊嶋 崇徳; 氏家 英之, 日本臨床皮膚科医会雑誌, 40, 3, 470, 470, 2023年05月
  日本臨床皮膚科医会, 日本語
• IgG4-IgE複合体の保有頻度とIgE、IgG4濃度の比較に関する研究
  中野 恵一; 安田 慶子; 清宮 正徳; 渡邊 千秋; 後藤 秀樹; 豊嶋 崇徳, 生物試料分析, 46, 1, 51, 51, 2023年02月
  (NPO)生物試料分析科学会, 日本語
• 臨床現場での活躍が期待される医用超音波検査技術 1)超音波検査によるダイナミックな肝血流診断肝類洞閉塞症候群診断へのアプローチ
  西田睦; 岩井孝仁; 豊嶋崇徳, 超音波Techno, 35, 2, 2023年
• HLA不適合造血幹細胞移植における高感度HLA交差適合試験法の有用性の検討
  櫻澤貴代; 伊藤誠; 南昭子; 白鳥聡一; 杉田純一; 渡邊千秋; 後藤秀樹; 後藤秀樹; 豊嶋崇徳; 豊嶋崇徳, 日本輸血細胞治療学会誌, 69, 2, 2023年
• 複雑核型を有する初発急性骨髄性白血病の臨床的特徴
  吉田匠汰; 小野澤真弘; 宮下直樹; 木村弘幸; 高橋承吾; 横山翔大; 松川敏大; 近藤健; 豊嶋崇徳, 日本内科学会雑誌, 112, 2023年
• 当院におけるコンピュータクロスマッチの導入効果
  伊藤誠; 南昭子; 畑瀬理恵; 増田裕弥; 小山遥子; 櫻澤貴代; 渡邊千秋; 後藤秀樹; 豊嶋崇徳, 日本輸血細胞治療学会誌, 69, 1, 2023年
• 慢性GVHDにおける体外フォトフェレーシス(extracorporeal photopheresis)の国内臨床試験のpost-hoc解析
  杉田純一; 杉田純一; 小澤幸泰; 森毅彦; 小林智美; 豊嶋崇徳, 日本造血・免疫細胞療法学会雑誌(Web), 12, 2, 2023年
• 乳房皮下に発症した関節リウマチ治療中に発生するリンパ腫様肉芽腫症に対して造影超音波検査を施行した1例
  齊藤由衣香; 齊藤由衣香; 西田睦; 岩井孝仁; 岩井孝仁; 表原里実; 表原里実; 菊池桃佳; 坂野稜典; 坂野稜典; 工藤悠輔; 工藤悠輔; 加藤扶美; 押野智博; 高橋將人; 藤枝雄一郎; 岡崎ななせ; 松野吉宏; 渡邊千秋; 豊嶋崇徳; 豊嶋崇徳, 超音波検査技術, 48, 2, 2023年
• 適応型ノイズ除去フィルタを用いた膵臓の超音波画質向上の検討
  岩井孝仁; 岩井孝仁; 西田睦; 工藤悠輔; 工藤悠輔; 大栗拓真; 鳥井亮汰; 神山直久; 渡邊千秋; 後藤秀樹; 豊嶋崇徳, 超音波医学 Supplement, 50, 2023年
• 肝類洞閉塞症候群の診断の鍵となる超音波所見
  西田睦; 岩井孝仁; 岩井孝仁; 白鳥総一; 後藤秀樹; 後藤秀樹; 豊嶋崇徳; 豊嶋崇徳; 豊嶋崇徳, 超音波医学 Supplement, 50, 2023年
• 小児バーキットリンパ腫による腸重積の化学療法による治療効果を経過観察し得た症例
  表原里実; 表原里実; 西田睦; 工藤悠輔; 工藤悠輔; 岩井孝仁; 岩井孝仁; 砂後谷華奈; 砂後谷華奈; 渡邊千秋; 高桑恵美; 平林真介; 真部淳; 豊嶋崇徳; 豊嶋崇徳, 超音波医学 Supplement, 50, 2023年
• 理想とするタスクシフト像と当院の現状・今後の方針について
  堀江達則; 西田睦; 佐藤恵美; 坂野稜典; 青池拓哉; 工藤悠輔; 表原里実; 岩井孝仁; 砂後谷華奈; 豊嶋崇徳, 超音波医学 Supplement, 50, 2023年
• 消化器領域の描出に活きる画質設定
  工藤悠輔; 工藤悠輔; 西田睦; 表原里実; 表原里実; 岩井孝仁; 岩井孝仁; 菊池桃佳; 進藤由衣香; 進藤由衣香; 砂後谷華奈; 砂後谷華奈; 安藤風歌; 安藤風歌; 豊嶋崇徳; 豊嶋崇徳; 豊嶋崇徳, 超音波医学 Supplement, 50, 2023年
• 内科専攻医登録評価システムJ-OSLERによる症例登録の実態調査
  小野澤真弘; 石森直樹; 豊嶋崇徳, 医学教育, 54, Suppl., 2023年
• Lenalidomide長期内服中に急性赤白血病へ進展したdel(5q)単独の染色体異常を伴う骨髄異形成症候群
  長井惇; 一木朝絵; 菊池遼; 長谷川祐太; 大東寛幸; 後藤秀樹; 小野澤真弘; 橋本大吾; 豊嶋崇徳, 臨床血液, 64, 7, 2023年
• 中枢病変を有した成人T細胞性白血病/リンパ腫(ATLL)の1例
  塚本しほり; 清水亜衣; 森祐斗; 横山翔大; 荒隆英; 松川敏大; 白鳥聡一; 中川雅夫; 遠藤知之; 高桑恵美; 加留部謙之輔; 松野吉宏; 豊嶋崇徳, 臨床血液, 64, 7, 2023年
• 腸内細菌叢と好中球造血のクロストークに関する新たな知見
  橋本大吾; 豊嶋崇徳, 月刊臨床免疫・アレルギー科, 80, 3, 2023年
• 気管支喘息患者における新旧基準による気管支拡張薬反応性に影響する因子の検討
  山本雅史; 清水薫子; 木村孔一; 牧田比呂仁; 三谷麻子; 中出江美; 大沼有美; 渡邊千秋; 鈴木雅; 後藤秀樹; 豊嶋崇徳; 西村正治; 今野哲, 日本呼吸器学会誌(Web), 12, 2023年
• 当院の関節エコーレポートの書き方
  堀江達則; 堀江達則; 西田睦; 佐藤恵美; 佐藤恵美; 坂野稜典; 坂野稜典; 青池拓哉; 青池拓哉; 工藤悠輔; 工藤悠輔; 表原里実; 表原里実; 岩井孝仁; 岩井孝仁; 砂後谷華奈; 砂後谷華奈; 平野桃佳; 安藤風歌; 安藤風歌; 豊嶋崇徳; 豊嶋崇徳, 日本超音波検査学会学術集会講演抄録集(Web), 48th, 2023年
• 中枢神経感染症の診断と治療に対する髄液多項目核酸検査の効果
  岩田育子; 上床尚; 白井慎一; 松島理明; 矢口裕章; 石黒信久; 豊嶋崇徳; 矢部一郎, Neuroinfection (Web), 28, 2, 2023年
• 抗トロポニンI抗体vs.抗トロポニンT抗体の存在様式と出現頻度
  中野恵一; 中野恵一; 村上聡; 清宮正徳; 安田慶子; 山下直樹; 後藤秀樹; 豊嶋崇徳, 医療検査と自動化(Web), 48, 4, 2023年
• 新型コロナと対峙した84日間の挑戦
  豊嶋崇徳, 日本血液学会学術集会抄録(Web), 85th, 2023年
• 2022年の国内新規診断未治療HIV感染者・AIDS患者における薬剤耐性HIV-1の動向
  菊地正; 西澤雅子; 小島潮子; 大谷眞智子; RUNTWENE Lucky; 椎野禎一郎; 椎野禎一郎; 豊嶋崇徳; 伊藤俊広; 林田庸総; 潟永博之; 岡慎一; 古賀道子; 長島真美; 貞升健志; 佐野貴子; 近藤真規子; 宇野俊介; 谷口俊文; 猪狩英俊; 寒川整; 中島秀明, 日本エイズ学会誌, 25, 4, 2023年
• 臨床症状および抗核抗体パターンと矛盾した各種自己抗体陽性を認めた1症例
  菊地菜海; 山下直樹; 安田慶子; 後藤秀樹; 豊嶋崇徳, 北臨技会誌, 21, 2, 2023年
• HIV感染症の医療体制の整備に関する研究 北海道ブロックのHIV医療体制整備-北海道ブロックにおけるHIV感染症の医療体制の整備に関する研究-
  豊嶋崇徳; 遠藤知之, HIV感染症の医療体制の整備に関する研究 令和4年度 総括・分担研究報告書(Web), 2023年
• 移植医療の最前線 造血幹細胞移植
  豊嶋崇徳, Pharma Medica, 40, 3, 2023年
• 2021年度HIV-1薬剤耐性検査外部精度評価の報告
  吉田 繁; 松田 昌和; 今橋 真弓; 岡田 清美; 齊藤 浩一; 林田 庸総; 佐藤 かおり; 藤澤 真一; 遠藤 知之; 西澤 雅子; 椎野 禎一郎; 潟永 博之; 豊嶋 崇徳; 杉浦 亙; 吉村 和久; 菊地 正, 日本エイズ学会誌, 24, 4, 401, 401, 2022年11月
  (一社)日本エイズ学会, 日本語
• 国内HIV-1CRF07_BCの流行動向に関する研究
  大谷 眞智子; 椎野 禎一郎; 西澤 雅子; 林田 庸総; 潟永 博之; 豊嶋 崇徳; 渡邊 大; 今橋 真弓; 俣野 哲朗; 菊地 正, 日本エイズ学会誌, 24, 4, 438, 438, 2022年11月
  (一社)日本エイズ学会, 日本語
• 2021年の国内新規診断未治療HIV感染者・AIDS患者における薬剤耐性HIV-1の動向
  菊地 正; 西澤 雅子; 小島 潮子; 大谷 眞智子; 椎野 禎一郎; 俣野 哲朗; 佐藤 かおり; 豊嶋 崇徳; 伊藤 俊広; 林田 庸総; 潟永 博之; 岡 慎一; 古賀 道子; 長島 真美; 貞升 健志; 近藤 真規子; 宇野 俊介; 谷口 俊文; 猪狩 英俊; 寒川 整; 中島 秀明; 吉野 友祐; 堀場 昌英; 茂呂 寛; 渡邉 珠代; 蜂谷 敦子; 今橋 真弓; 松田 昌和; 重見 麗; 岡崎 玲子; 岩谷 靖雅; 横幕 能行; 渡邊 大; 阪野 文哉; 森 治代; 藤井 輝久; 高田 清式; 中村 麻子; 南 留美; 山本 政弘; 松下 修三; 饒平名 聖; 仲村 秀太; 健山 正男; 藤田 次郎; 吉村 和久; 杉浦 亙, 日本エイズ学会誌, 24, 4, 401, 401, 2022年11月
  (一社)日本エイズ学会, 日本語
• 大腿骨人工骨頭インプラント周囲に発症したALK陰性未分化大細胞型リンパ腫の1例
  森 祐斗; 荒 隆英; 中川 雅夫; 吉田 匠汰; 斎藤 祐美花; 横山 翔大; 松川 敏大; 白鳥 聡一; 遠藤 知之; 豊嶋 崇徳, 臨床血液, 63, 11, 1592, 1593, 2022年11月
  (一社)日本血液学会-東京事務局, 日本語
• 出血性膀胱炎において尿中ウイルス感染細胞が認められた同種造血幹細胞移植後の3症例
  猪股 百華; 中野 恵一; 小林 美穂; 大沼 麗子; 山下 亜妃子; 原田 晋平; 吉田 匠汰; 宮島 徹; 渡邊 千秋; 後藤 秀樹; 豊嶋 崇徳, 日本臨床検査医学会誌, 70, 補冊, 222, 222, 2022年10月
  (一社)日本臨床検査医学会, 日本語
• DLBCLにおける適切なエンドポイントはEFS36である
  泉山 康; 稲尾 翼; 後藤 秀樹; 原田 晋平; 千丈 創; 須藤 啓斗; 橋口 淳一; 小笠原 励起; 佐賀 智之; 五十嵐 哲祥; 若狭 健太郎; 笠原 郁美; 武田 紫; 山口 圭介; 重松 明男; 高畑 むつみ; 藤本 勝也; 長谷山 美仁; 永嶋 貴博; 酒井 基; 柿木 康孝; 黒澤 光俊; 横田 勲; 豊嶋 崇徳, 日本血液学会学術集会, 84回, 916, 916, 2022年10月
  (一社)日本血液学会, 英語
• IgG4-IgE複合体の存在と臨床的意義の解明に向けた解析
  中野 恵一; 杉田 純一; 清宮 正徳; 安田 慶子; 渡邊 千秋; 後藤 秀樹; 豊嶋 崇徳, 臨床化学, 51, Suppl.1, 223, 223, 2022年09月
  (一社)日本臨床化学会, 日本語
• 非アルコール性脂肪肝・脂肪肝炎例におけるオートタキシンの肝線維化進行度評価の検討
  西能 史華; 中野 恵一; 岩井 孝仁; 西田 睦; 安田 慶子; 渡邊 千秋; 後藤 秀樹; 豊嶋 崇徳, 医療検査と自動化, 47, 4, 456, 456, 2022年08月
  (一社)日本医療検査科学会, 日本語
• HIV関連悪性リンパ腫の臨床的特徴
  遠藤 知之; 後藤 秀樹; 荒 隆英; 長谷川 祐太; 横山 翔大; 高橋 承吾; 米田 和樹; 橋本 大吾; 橋野 聡; 豊嶋 崇徳, 日本エイズ学会誌, 24, 1, 13, 20, 2022年02月
  (一社)日本エイズ学会, 日本語
• CAR-T療法の現状と未来
  豊嶋崇徳, 札幌冬季がんセミナー, 36th, 2022年
• 移植後ウイルス性出血性膀胱炎の診断と予後改善への尿沈渣検査の活用
  志賀麻衣子; 眞船直樹; 杉田純一; 杉田純一; 豊嶋崇徳; 豊嶋崇徳, 日本臨床検査医学会誌, 70, 2, 2022年
• 造血幹細胞移植療法の現状と未来
  豊嶋崇徳, 日本内科学会雑誌, 111, 2022年
• 社会にリスペクトされる輸血医療とは 医療機関の立場から
  豊嶋崇徳, 日本輸血細胞治療学会誌, 68, 2, 2022年
• 血小板輸血不応患者検体を用いたHLA抗体検査試薬のカットオフ値の設定について
  中野学; 中野学; 中野学; 中野学; 中野学; 中野学; 中野学; 中野学; 高陽淑; 高橋大輔; 杉田純一; 杉田純一; 豊嶋崇徳; 豊嶋崇徳; 太田秀一; 近藤健; 大橋恒; 刀根勇一; 生田克哉; 紀野修一, 日本輸血細胞治療学会誌, 68, 2, 2022年
• 2機種の超音波装置とMRIによる肝弾性度および肝脂肪定量の比較
  岩井孝仁; 岩井孝仁; 西田睦; 畑瀬理恵; 畑瀬理恵; 工藤悠輔; 工藤悠輔; 堀江達則; 堀江達則; 小川浩司; 豊嶋崇徳; 豊嶋崇徳; 豊嶋崇徳, 超音波医学 Supplement, 49, 2022年
• ISO15189認定に向けた北海道大学病院超音波センターの精度管理に関する取り組み
  工藤悠輔; 工藤悠輔; 西田睦; 畑瀬理恵; 畑瀬理恵; 表原里実; 表原里実; 岩井孝仁; 岩井孝仁; 進藤由衣香; 進藤由衣香; 菊池桃佳; 豊嶋崇徳; 豊嶋崇徳; 豊嶋崇徳, 超音波医学 Supplement, 49, 2022年
• 急性骨髄性白血病に特化した簡易パネルシークエンスの開発
  小野澤真弘; 横山翔大; 高橋承吾; 豊嶋崇徳, 日本検査血液学会雑誌, 23, 2022年
• ABO主副不適合骨髄移植後のドナー赤血球生着後にレシピエント血液型抗原が陽性となった1例
  伊藤誠; 渡邊千秋; 南昭子; 佐藤健吾; 増田裕弥; 南静菜; 櫻澤貴代; 林泰弘; 早坂光司; 杉田純一; 豊嶋崇徳, 日本輸血細胞治療学会誌, 68, 1, 2022年
• 治療 造血幹細胞移植
  豊嶋崇徳, 日本医師会雑誌, 151, 2022年
• 肝類洞閉塞症候群診断における門脈血流速度と肝動脈末梢血管抵抗計測法の前向き検討
  菊池桃佳; 岩井孝仁; 岩井孝仁; 西田睦; 工藤悠輔; 工藤悠輔; 表原里実; 表原里実; 佐藤恵; 佐藤恵; 坂野稜典; 坂野稜典; 横田勲; 杉田純一; 豊嶋崇徳, 超音波医学 Supplement, 49, 2022年
• 血管内大細胞型B細胞性リンパ腫の初回治療中に発症したneurolymphomatosis
  宮島徹; 大東寛幸; 横山慶人; 岡田怜; 長谷川祐太; 杉田純一; 小野澤真弘; 橋本大吾; 穴田麻眞子; 矢口裕章; 豊嶋崇徳, 臨床血液, 63, 7, 2022年
• 当院における同種造血幹細胞移植後ニューモシスチス肺炎の発症状況に関する検討
  荒隆英; 長谷川祐太; 大東寛幸; 安本篤史; 白鳥聡一; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th, 2022年
• HLA一致血縁者間末梢血幹細胞移植はATGによって急性GVHDの負の影響を克服できる可能性がある
  宮尾康太郎; 鍬塚八千代; 村田誠; 長藤宏司; 豊嶋崇徳; 竹内裕貴; 白鳥聡一; 名島悠峰; 内田直之; 田中正嗣; 澤正史; 太田秀一; 福田隆浩; 小澤幸泰; 賀古真一; 河北敏弘; 荒隆英; 田中淳司; 神田善伸; 熱田由子; 諫田淳也; 寺倉精太郎, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th, 2022年
• 末梢血幹細胞移植における低用量ATGを用いたGVHD予防法-マッチドペア解析-
  白鳥聡一; 倉田美穂; 杉田純一; 太田秀一; 笠原千嗣; 石川淳; 今田和典; 大西康; 石山謙; 芦田隆司; 神田善伸; 一戸辰夫; 福田隆浩; 熱田由子; 熱田由子; 豊嶋崇徳; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th, 2022年
• 慢性移植片対宿主病患者を対象とした体外フォトフェレーシス(ECP)の国内臨床試験のpost-hoc解析
  杉田純一; 西田徹也; 小澤幸泰; 加藤淳; 森毅彦; 片岡圭亮; 岡本真一郎; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th, 2022年
• 急性GVHDに対する間葉系幹細胞治療の有効性:全国調査結果
  村田誠; 寺倉精太郎; 和氣敦; 宮尾康太郎; 池亀和博; 内田直之; 片岡圭亮; 宮本敏浩; 鬼塚真仁; 衛藤徹也; 土岐典子; 太田秀一; 佐藤真穂; 橋井佳子; 一戸辰夫; 福田隆浩; 熱田由子; 岡本真一郎; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th, 2022年
• 同種造血幹細胞移植後に発症した類洞閉塞症候群に対するDefibrotideの多施設共同研究
  白鳥聡一; 岡田耕平; 松岡里湖; 伊東慎市; 豊嶋崇徳; 豊嶋崇徳; 杉田純一, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th, 2022年
• 非古典的な移植片対宿主病
  豊嶋崇徳, 月刊血液内科, 85, 3, 2022年
• 造血幹細胞移植療法の現状と未来
  豊嶋崇徳, 日本内科学会雑誌, 111, 9, 2022年
• 尿沈渣中にヘマトイジン結晶を継続的に認めた1症例
  猪股百華; 志賀麻衣子; 小林美穂; 山下亜妃子; 渡邊千秋; 杉田純一; 豊嶋崇徳, 医学検査, 71, 4, 2022年
• クローン病に対しインフリキシマブ治療歴のある肝脾T細胞リンパ腫に対して臍帯血移植を施行した1例
  鈴木陶磨; 大東寛幸; 宮下直樹; 須藤啓斗; 日高大輔; 小笠原励起; 杉田純一; 小野澤真弘; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 44th, 2022年
• 非アルコール性脂肪肝・脂肪肝炎例におけるオートタキシンの肝線維化進行度評価の検討
  西能史華; 中野恵一; 岩井孝仁; 岩井孝仁; 西田睦; 安田慶子; 渡邊千秋; 後藤秀樹; 豊嶋崇徳; 豊嶋崇徳, 医療検査と自動化(Web), 47, 4, 2022年
• VGCV中止による免疫回復にて改善を認めたCMV感染症合併のAIDS症例
  横山翔大; 横山翔大; 遠藤知之; 遠藤知之; 宮島徹; 宮島徹; 須藤啓斗; 須藤啓斗; 高橋承吾; 高橋承吾; 長谷川祐太; 長谷川祐太; 荒隆英; 荒隆英; 松川敏大; 松川敏大; 後藤秀樹; 後藤秀樹; 橋野聡; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 24, 4, 2022年
• 当院における「いきなりエイズ」症例の患者特性の検討
  荒隆英; 荒隆英; 遠藤知之; 遠藤知之; 宮島徹; 宮島徹; 須藤啓斗; 須藤啓斗; 高橋承吾; 高橋承吾; 横山翔大; 横山翔大; 長谷川祐太; 長谷川祐太; 松川敏大; 松川敏大; 後藤秀樹; 後藤秀樹; 橋野聡; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 24, 4, 2022年
• 薬害HIV感染症患者における冠動脈スクリーニング
  遠藤知之; 遠藤知之; 後藤秀樹; 後藤秀樹; 松川敏大; 松川敏大; 荒隆英; 荒隆英; 長谷川祐太; 長谷川祐太; 横山翔大; 横山翔大; 高橋承吾; 高橋承吾; 須藤啓斗; 須藤啓斗; 宮島徹; 宮島徹; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 24, 4, 2022年
• HIV感染者に対する骨代謝異常の後方視的解析
  松川敏大; 松川敏大; 遠藤知之; 遠藤知之; 宮島徹; 宮島徹; 須藤啓斗; 須藤啓斗; 高橋承吾; 高橋承吾; 横山翔大; 横山翔大; 長谷川祐太; 長谷川祐太; 荒隆英; 荒隆英; 後藤秀樹; 後藤秀樹; 橋野聡; 橋野聡; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 24, 4, 2022年
• 移植片対宿主病(GVHD)に対する体外フォトフェレーシス(ECP)
  太田秀一; 杉田純一; 加畑馨; 豊嶋崇徳, 日本アフェレシス学会雑誌, 41, Supplement, 2022年
• HIV感染症の医療体制の整備に関する研究 北海道ブロックのHIV医療体制整備-北海道ブロックのHIV医療体制の整備に関する研究-
  豊嶋崇徳; 遠藤知之, HIV感染症の医療体制の整備に関する研究 令和3年度 総括・分担研究報告書(Web), 2022年
• 血縁ドナーの末梢血中への造血幹細胞の動員に関するペグフィルグラスチムの安全性と有効性:NJHSG-移植WG
  岡田耕平; 後藤秀樹; 杉田純一; 山崎奈美恵; 実藤菜保美; 岩松杏奈; 神澤雅美; 堀田いずみ; 小塚麻紀; 渡邊千秋; 加畑馨; 太田秀一; 豊嶋崇徳; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 45th, 2022年
• エイズ対策研究事業の企画と評価に関する研究 国内流行HIV及びその薬剤耐性株の長期的動向把握に関する研究
  菊地正; 西澤雅子; 椎野禎一郎; 増田純一; 豊嶋崇徳; 吉田繁; 古賀道子; 渡邊大; 近藤真規子; 健山正男; 中島秀明; 森治代; 吉野友祐; 茂呂寛; 南留美; 松下修三; 伊藤俊広; 藤井輝久; 高田清式; 渡邉珠代; 猪狩英俊; 上野貴将; 堀場昌英; 宇野俊介; 今橋真弓; 貞升健志, エイズ対策研究事業の企画と評価に関する研究 令和3年度 総括研究報告書(Web), 2022年
• エイズ対策研究事業の企画と評価に関する研究 HIV感染症の医療体制の整備に関する研究
  横幕能行; 田沼順子; 伊藤俊広; 南留美; 内藤俊夫; 豊嶋崇徳; 茂呂寛; 渡邉珠代; 今橋真弓; 渡邊大; 藤井輝久; 宇佐美雄司; 池田和子; 矢倉裕輝; 本田美和子; 葛田衣重, エイズ対策研究事業の企画と評価に関する研究 令和3年度 総括研究報告書(Web), 2022年
• 再発又は難治性の大細胞型B細胞リンパ腫日本人患者におけるAxi-Cel第II相試験:2年追跡データ
  諫田淳也; 加藤光次; 蒔田真一; 後藤秀樹; 藤井伸治; 島田和之; 赤司浩一; 伊豆津宏二; 豊嶋崇徳; 福田奈津子; 炭谷徳人; 角紘幸; 稲葉真一; 加倉井靖之; 吉川謙次; 飛内賢正; 薄井紀子; 畠清彦, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 45th, 2022年
• HokUS-10スコアリングシステムはSOSに対する治療反応性を予測する:NJHSG-移植WG
  白鳥聡一; 岡田耕平; 杉田純一; 西田睦; 岩井孝仁; 太田秀一; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 45th, 2022年
• 当院における成人T細胞性白血病に対する同種造血幹細胞移植の治療成績
  荒隆英; 横山翔大; 長谷川祐太; 大東寛幸; 松川敏大; 安本篤史; 白鳥聡一; 後藤秀樹; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 45th, 2022年
• 当院での造血幹細胞移植患者におけるBacillus菌血症の検討
  森祐斗; 荒隆英; 横山翔大; 松川敏大; 白鳥聡一; 中川雅夫; 遠藤知之; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 45th, 2022年
• CRPはCAR-T細胞療法時のサイトカイン放出症候群に対するトシリズマブの解熱効果の予測マーカーになる
  横山翔大; 後藤秀樹; 荒隆英; 森祐斗; 長谷川祐太; 大東寛幸; 松川敏大; 安本篤史; 白鳥聡一; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血・免疫細胞療法学会総会プログラム・抄録集, 45th, 2022年
• 新型コロナパンデミック下の造血幹細胞移植ドネーションを推進するためのシステム改革のための研究
  豊嶋崇徳; 豊嶋崇徳, 新型コロナパンデミック下の造血幹細胞移植ドネーションを推進するためのシステム改革のための研究 令和2年度 総括・分担研究報告書(Web), 2022年
• 血液内科領域における寄付講座による海外への技術移転の実例
  中川雅夫; 黒田羽衣子; しぇーん ぴーたー; 豊嶋崇徳, 国際臨床医学会学術集会プログラム抄録集, 7th, 2022年
• CAR-T療法のエビデンスと現状
  豊嶋崇徳, 日本がんサポーティブケア学会学術集会プログラム・抄録集(CD-ROM), 7th (Web), 2022年
• Tirabrutinibが奏効したBing-Neel症候群
  横山慶人; 大東寛幸; 宮島徹; 宮下直樹; 岡田怜; 長谷川祐太; 杉田純一; 小野澤真弘; 橋本大吾; 豊嶋崇徳, 臨床血液, 63, 8, 870, 875, 2022年, ［国内誌］
  Bing-Neel syndrome (BNS) is a rare disease manifestation of Waldenström's macroglobulinemia characterized by abnormal lymphoplasmacytoid cells infiltration of the central nervous system. In September 2019, a 46-year-old man presented to a previous hospital with hand tremors, nausea, and dysuria. Demyelination of cerebral white matter and the spinal cord was discovered using MRI. Steroid pulse therapy was used to treat inflammatory demyelinating disease, and it provided temporary relief, but the symptoms returned when the steroids were stopped. He was referred to our hospital in June 2020, for further evaluation with the possibility of hematological malignancy. BNS was diagnosed based on the presence of abnormal lymphoplasmacytoid cells in the bone marrow and cerebrospinal fluid (CSF), as well as the presence of the MYD88L265P mutation in the CSF specimen. In July 2020, BR (bendamustine, rituximab) therapy was administered, but it was ineffective. Oral administration of tirabrutinib, which was recently approved for WM, began in August 2020. He has achieved long-term remission and steroid withdrawal, with no notable side effects. This is the second report of successful treatment of BNS with tirabrutinib. More research is needed to confirm tirabrutinib's efficacy in the treatment of BNS., 日本語
• E157Q変異を有する未治療HIV-1感染者におけるインテグラーゼ阻害薬をキードラッグとした抗HIV薬開始後の臨床経過
  宇野 俊介; 菊地 正; 林田 庸総; 今橋 真弓; 南 留美; 古賀 道子; 寒川 整; 渡邊 大; 藤井 輝久; 健山 正男; 松下 修三; 吉野 友祐; 遠藤 知之; 堀場 昌英; 谷口 俊文; 猪狩 英俊; 吉田 繁; 豊嶋 崇徳; 中島 秀明; 横幕 能行; 岩谷 靖雅; 蜂谷 敦子; 潟永 博之; 吉村 和久; 杉浦 亙, 日本エイズ学会誌, 23, 4, 423, 423, 2021年11月
  (一社)日本エイズ学会, 日本語
• XIAP欠損症に対して非血縁者間骨髄移植を施行して移植後赤芽球癆を認めた1例
  千葉 雅尋; 杉田 純一; 宮下 直樹; 須藤 啓斗; 日高 大輔; 大東 寛幸; 安本 篤史; 小野澤 真弘; 橋本 大吾; 豊嶋 崇徳, 臨床血液, 62, 7, 848, 849, 2021年07月
  (一社)日本血液学会-東京事務局, 日本語
• 髄外腫瘤で発症したe1a3 BCR-ABL陽性慢性骨髄性白血病
  宮下 直樹; 小野澤 真弘; 須藤 啓斗; 日高 大輔; 大東 寛幸; 安本 篤史; 杉田 純一; 橋本 大吾; 豊嶋 崇徳, 臨床血液, 62, 7, 849, 849, 2021年07月
  (一社)日本血液学会-東京事務局, 日本語
• 音響特性を考慮した乳腺病変の最適な超音波画像撮像条件の検討
  岩井 孝仁; 工藤 悠輔; 西田 睦; 畑瀬 理恵; 表原 里実; 大栗 拓真; 嵯峨 早友佳; 神山 直久; 杉田 純一; 豊嶋 崇徳, 超音波医学, 48, Suppl., S790, S790, 2021年04月
  (公社)日本超音波医学会, 日本語
• 口腔とウイルス~疾患との関連から検査・感染予防対策まで~6.COVID-19における唾液検査の有用性と今後の展望
  豊嶋崇徳; 豊嶋崇徳, 季刊歯科医療, 35, 1, 2021年
• 令和時代の総合内科学 3 遺伝子治療・細胞治療の将来 2)遺伝子改変T細胞(CAR-T)療法
  豊嶋崇徳, 日本内科学会雑誌, 110, 3, 2021年
• COVID-19のサイトカインストーム
  豊嶋崇徳, 日本輸血細胞治療学会誌, 67, 2, 2021年
• FLT3-ITD変異を有する骨髄系腫瘍に対する同種造血幹細胞移植(第2報)
  皆内康一郎; 岩崎純子; 日高大輔; 小野澤真弘; 若狭健太郎; 森祐斗; 塚本しほり; 吉田匠汰; 笠原耕平; 江端浩; 高橋正二郎; 岡田耕平; 太田秀一; 豊嶋崇徳; 今村雅寛, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021年
• 難治性DLBCLに対するCAR-T療法施行後に発症した進行性多巣性白質脳症の一例
  森木朝子; 大東寛幸; 宮下直樹; 須藤啓斗; 日高大輔; 安本篤史; 後藤秀樹; 杉田純一; 小野澤真弘; 橋本大吾; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021年
• 免疫・炎症・アレルギーおよび骨・関節の病気とくすり A 免疫・炎症・アレルギー疾患 移植片対宿主病
  豊嶋崇徳; 久保田康生, 薬局, 72, 4, 2021年
• 新型コロナ感染期の造血細胞移植
  豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021年
• 同種末梢血ドナー調査2020のday30report dataを用いたPoor mobilizerの解析
  政氏伸夫; 福田隆浩; 保仙直毅; 高折晃史; 衛藤徹也; 黒川峰夫; 赤司浩一; 大橋一輝; 田中正嗣; 宮村耕一; 前田嘉信; 石黒卓朗; 日野雅之; 小川佳宏; 内山人二; 岩崎浩己; 甲田祐也; 久保恒明; 安藤潔; 益崎裕章; 奥村廣和; 中尾眞二; 末廣陽子; 宇都宮與; 堺田惠美子; 豊嶋崇徳; 烏野隆博; 塚田信弘; 矢部普正; 小寺良尚, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021年
• COVID-19に対する,北海道大学の取り組み
  氏家秀樹; 大塚慎也; 千葉龍平; 椎谷洋彦; 藤原晶; 加藤達哉; 樋田泰浩; 加賀基知三; 若狭哲; 石黒信久; 豊嶋崇徳, 日本呼吸器外科学会総会(Web), 38th, 2021年
• 同種造血幹細胞移植後の体液貯留は予後不良である
  宮下直樹; 須藤啓斗; 日高大輔; 大東寛幸; 荒隆英; 白鳥聡一; 安本篤史; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021年
• ギルテリチニブはマウスFLT3-ITD陽性白血病に対する移植片対白血病効果を促進する
  張紫せん; 長谷川祐太; 橋本大吾; 菊池遼; 陳げん仲; 米田和樹; 千丈創; 関口智子; 川瀬竜也; 續啓史; 石尾崇; 大東寛幸; 中川雅夫; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021年
• 成人急性骨髄性白血病に対する臍帯血移植後のGVHD予防におけるメソトレキサート投与量の影響
  寺倉精太郎; 鍬塚八千代; 杉田純一; 高橋聡; 小澤幸泰; 尾関和貴; 吉岡聡; 中前博久; 河北敏郎; 澤正史; 森重聡; 名島悠峰; 勝岡優奈; 堺田惠美子; 香西康司; 木村貴文; 一戸辰夫; 福田隆浩; 熱田由子; 熱田由子; 村田誠; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021年
• 類洞閉塞症候群に対するDefibrotideの安全性と有効性の検討
  木村弘幸; 白鳥聡一; 大東寛幸; 荒隆英; 安本篤史; 後藤秀樹; 中川雅夫; 杉田純一; 小野澤真弘; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021年
• 医療データベースを用いたPlerixafor投与による多発性骨髄腫の末梢血幹細胞採取の患者負担の解析
  石田禎夫; 飯田真介; 宮本敏浩; 手良向聡; 白井丙午郎; 金森里英; 田嶋雄樹; クロウフォード ブルース; イージンボ; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021年
• 非血縁者間末梢血幹細胞移植におけるAnti-thymocyte globulinの意義
  白鳥聡一; 杉田純一; 藤重夫; 青木淳; 澤正史; 小澤幸泰; 橋本大吾; 橋本大吾; 松岡賢市; 今田和典; 土岐典子; 芦田隆司; 上田恭典; 一戸辰夫; 寺倉精太郎; 森島聡子; 熱田由子; 福田隆浩; 豊嶋崇徳; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 43rd, 2021年
• がんのリハビリテーション-成果と展望 造血幹細胞移植
  荒隆英; 豊嶋崇徳, Journal of Clinical Rehabilitation, 30, 7, 2021年
• COVID-19診断における唾液検査の有用性と展望
  豊嶋崇徳; 豊嶋崇徳, 日本歯科医師会雑誌, 74, 4, 2021年
• 核分葉数別好中球分画を含む末梢血白血球画像の自動分画系の構築
  政氏伸夫; 藪田麻結; 中村伊織; 井田晴日; 小林美穂; 宇佐美貴之; 村上望; 山下亜妃子; 杉田純一; 杉田純一; 豊嶋崇徳; 豊嶋崇徳, 日本検査血液学会雑誌, 22, 2021年
• COVID-19診断における唾液検査の有用性と展望
  豊嶋崇徳; 豊嶋崇徳, 歯科薬物療法, 40, 2, 2021年
• リンパ腫診療-診断の入り口から治療まで リンパ腫に対するCAR-T療法
  後藤秀樹; 豊嶋崇徳, 内科, 128, 2, 2021年
• COVID-19の現状と将来展望 唾液によるコロナ診断法
  豊嶋崇徳; 豊嶋崇徳, 日本染色体遺伝子検査学会雑誌, 39, 1, 2021年
• 音響特性を考慮した乳腺病変の最適な超音波画像撮像条件の検討
  岩井孝仁; 岩井孝仁; 工藤悠輔; 工藤悠輔; 西田睦; 西田睦; 畑瀬理恵; 畑瀬理恵; 表原里実; 表原里実; 大栗拓真; 嵯峨早友佳; 神山直久; 杉田純一; 豊嶋崇徳; 豊嶋崇徳, 超音波医学 Supplement, 48, 2021年
• 膠原病診療における血管超音波検査の活用
  岩井孝仁; 岩井孝仁; 西田睦; 西田睦; 奥健志; 豊嶋崇徳; 豊嶋崇徳, 日本リウマチ学会総会・学術集会プログラム・抄録集, 65th, 2021年
• 唾液を用いたCOVID-19診断技術の開発
  豊嶋崇徳, 日本抗加齢医学会総会プログラム・抄録集, 21st, 2021年
• 新型コロナの唾液検査法が認められるまで
  豊嶋崇徳, 北海道医療大学歯学雑誌, 40, 1, 2021年
• 2010~2020年度に実施したHIV-1薬剤耐性検査外部精度評価の報告
  吉田繁; 松田昌和; 今橋真弓; 岡田清美; 齊藤浩一; 林田庸総; 佐藤かおり; 藤澤真一; 遠藤知之; 西澤雅子; 椎野禎一郎; 豊嶋崇徳; 杉浦亙; 吉村和久; 菊地正, 日本エイズ学会誌, 23, 4, 2021年
• 国内新規診断未治療HIV感染者・AIDS患者における薬剤耐性HIV-1の動向
  菊地正; 西澤雅子; 小島潮子; 大谷眞智子; 椎野禎一郎; 俣野哲朗; 佐藤かおり; 豊嶋崇徳; 伊藤俊広; 林田庸総; 潟永博之; 岡慎一; 古賀道子; 長島真美; 貞升健志; 近藤真規子; 宇野俊介; 谷口俊文; 猪狩英俊; 寒川整; 中島秀明; 吉野友祐; 堀場昌英; 茂呂寛; 渡邉珠代; 蜂谷敦子; 今橋真弓; 松田昌和; 重見麗; 岡崎玲子; 岩谷靖雅; 横幕能行; 渡邉大; 阪野文哉; 森治代; 藤井輝久; 高田清式; 中村麻子; 南留美; 山本政弘; 松下修三; 饒平名聖; 健山正男; 藤田次郎; 杉浦亙; 吉村和久, 日本エイズ学会誌, 23, 4, 2021年
• Multiplex PCR法を用いたAIDS患者における髄液病原体の網羅的解析
  遠藤知之; 遠藤知之; 後藤秀樹; 後藤秀樹; 荒隆英; 荒隆英; 長谷川祐太; 横山翔大; 横山翔大; 高橋承吾; 高橋承吾; 米田和樹; 米田和樹; 小野澤真弘; 中川雅夫; 橋本大吾; 橋野聡; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 23, 4, 2021年
• 急性前立腺炎後に発症したFitz-HughCurtis症候群のMSMの一例
  宮島徹; 大東寛幸; 横山慶人; 岡田怜; 長谷川祐太; 荒隆英; 荒隆英; 後藤秀樹; 後藤秀樹; 杉田純一; 小野澤真弘; 遠藤知之; 遠藤知之; 橋本大吾; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 23, 4, 2021年
• 新型コロナ唾液検査法
  豊嶋崇徳; 豊嶋崇徳, Journal of Oral Biosciences Supplement (Web), 2021, 2021年
• 全ゲノムCRISPR screeningによるATLLにおけるNK細胞免疫に関わる重要分子の探索
  千葉雅尋; 下埜城嗣; 石尾崇; 後藤秀樹; 長谷川寛雄; 前田道之; 橋野聡; 豊嶋崇徳; 中川雅夫, 日本HTLV-1学会学術集会, 7th, 2021年
• 排尿障害と視神経炎を契機に診断されtirabrutinibが奏効したBing-Neel症候群の1例
  横山慶人; 大東寛幸; 宮島徹; 岡田怜; 長谷川祐太; 杉田純一; 小野澤真弘; 橋本大吾; 豊嶋崇徳, 臨床血液, 62, 12, 2021年
• 2020年度HIV-1薬剤耐性検査外部精度評価の報告
  吉田繁; 岡田清美; 佐藤かおり; 藤澤真一; 豊嶋崇徳, 日本臨床検査医学会誌, 69, 2021年
• Loeffler心内膜炎による左室内血栓および壁運動異常を併発したPDGFRA遺伝子再構成を伴う慢性好酸球性白血病の1例
  吉田匠汰; 荒隆英; 塚本しほり; 齋藤祐美花; 伊藤謙一; 白鳥聡一; 後藤秀樹; 中川雅夫; 遠藤知之; 豊嶋崇徳, 臨床血液, 62, 12, 2021年
• 再発/難治性多発性骨髄腫の日本人患者におけるCilta-celの第二相パートの結果
  飯田真介; 黒田純也; 豊嶋崇徳; 稲垣光男; 藤川えい; JACKSON Carolyn; 鈴木憲史, 日本血液学会学術集会抄録(Web), 83rd, 2021年
• R/R大細胞型B細胞リンパ腫の日本人患者におけるAxi-Celの第二相試験:1年フォローアップ
  後藤秀樹; 加藤光次; 蒔田真一; 諫田淳也; 藤井伸治; 島田和之; 赤司浩一; 伊豆津宏二; 豊嶋崇徳; 福田奈津子; 炭谷徳人; 角紘幸; 清水伸治; 加倉井靖之; 山下知也; 飛内賢正; 薄井紀子; 畠清彦, 日本血液学会学術集会抄録(Web), 83rd, 2021年
• HIV感染症の医療体制の整備に関する研究 北海道ブロックのHIV医療体制整備-北海道ブロックのHIV医療体制の整備に関する研究-
  豊嶋崇徳; 遠藤知之, HIV感染症の医療体制の整備に関する研究 令和2年度 総括・分担研究報告書(Web), 2021年
• 再発/難治性大細胞型B細胞リンパ腫の日本人患者におけるAxi-Celへの耐性機序
  加藤光次; 藤井伸治; 蒔田真一; 後藤秀樹; 諫田淳也; 島田和之; 赤司浩一; 伊豆津宏二; 豊嶋崇徳; 中村匠汰; 小熊敏弘; 奈良原舞子; 炭谷徳人; 角紘幸; 飛内賢正; 薄井紀子; 畠清彦, 日本血液学会学術集会抄録(Web), 83rd, 2021年
• CRISPRスクリーンはPTCLにおけるNK細胞監視からの逃避における重要分子としてCD48を同定する
  千葉雅尋; 下埜城嗣; 須藤啓斗; 石尾崇; 後藤秀樹; 橋野聡; 豊嶋崇徳; 中川雅夫, 日本血液学会学術集会抄録(Web), 83rd, 2021年
• 次世代シーケンスによる高感度FLT3-ITD検出
  横山翔大; 小野澤真弘; 高橋承吾; 日高大輔; 藤澤真一; 山本聡; 長谷山美仁; 永嶋貴博; 盛暁生; 太田秀一; 宮城島拓人; 柿木康孝; 黒澤光俊; 小林一; 井端淳; 近藤健; 豊嶋崇徳; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 83rd, 2021年
• EZH2変異を伴う再発性または難治性B細胞非ホジキンリンパ腫におけるタゼメトスタットのPh2研究
  川井英嗣; 頼晋也; 高折晃史; 豊嶋崇徳; 黒田純也; 加藤光次; 今泉芳孝; 野坂生郷; 酒井リカ; 中西正; 北条誠一郎; 伊豆津宏二, 日本血液学会学術集会抄録(Web), 83rd, 2021年
• 末梢血幹細胞移植後の生活の質に対する低用量ATGの影響
  白鳥聡一; 杉田純一; 熱田由子; 原田実根; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 83rd, 2021年
• ステロイド不応性cGvHDにおけるルキソリチニブ対最良有効療法:日本人患者におけるREACH3
  福島健太郎; 白鳥聡一; 大西康; 土岐典子; 後藤辰徳; 岡田昌也; 中前博久; 前田嘉信; 加藤光次; 石川隆之; 近藤忠一; 豊崎誠子; 池田宇次; 谷口修一; 岩本章子; 島田文香; STEFANELLI Tommaso; HOLLAENDER Norbert; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 83rd, 2021年
• 北海道大学病院における新型コロナウイルス検査~唾液検体運用を中心に~
  福元達也; 岩崎澄央; 小栗聡; 菊地玲; 山下ひろ子; 市川絢子; 山下直樹; 安田慶子; 早坂かすみ; 藤澤真一; 渡邊千秋; 西田睦; 杉田純一; 豊嶋崇徳, 臨床微生物迅速診断研究会総会プログラム・抄録集, 32nd, 2021年
• 乳房皮下に発症した関節リウマチ治療中に発生するリンパ腫の1例
  齊藤由衣香; 西田睦; 岩井孝仁; 表原里実; 工藤悠輔; 坂野稜典; 加藤扶美; 押野智博; 藤枝雄一郎; 岡崎ななせ; 松野吉宏; 豊嶋崇徳, 日本超音波検査学会学術集会講演抄録集(Web), 46th, 2021年
• 新興・再興感染症のリスク評価と危機管理機能の実装のための研究 新型コロナウイルス感染症対策に関する研究
  齋藤智也; 貞升健志; 吉村和久; 羽田晋之介; 豊嶋崇徳; 大澤絵里; 奥田博子; 虎頭恭子; 柴沼晃; 竹田飛鳥; 吉松芙美; 徳本惇奈, 新興・再興感染症のリスク評価と危機管理機能の実装のための研究 令和元年度 総括・分担研究報告書(令和2年度繰越分)(Web), 2021年
• 一類感染症等の患者発生時に備えた臨床的対応に関する研究 COVID-19診断における唾液検体に関する研究
  豊嶋崇徳; 横田勲, 一類感染症等の患者発生時に備えた臨床的対応に関する研究 令和2年度 総括・分担研究年度終了報告書(Web), 2021年
• 経過中にcolony-stimulating factor 3 receptor遺伝子変異が出現した骨髄増殖性腫瘍-分類不能型
  原田晋平; 岡田耕平; 横山翔大; 日高大輔; 早瀬英子; 小野澤真弘; 後藤秀樹; 橋本大吾; 加畑馨; 遠藤知之; 豊嶋崇徳, 臨床血液, 62, 11, 1609, 1614, 2021年, ［国内誌］
  A 25-year-old male with a medical history of stress polycythemia was admitted to a previous hospital for leukocytosis, anemia, and thrombocytopenia. Bone marrow examination revealed left-shifted myeloid hyperplasia without increased blasts and normal male karyotype. No mutations of JAK2, V617F, and colony-stimulating factor 3 receptor gene (CSF3R) were detected. Fluorescence in-situ hybridization for BCR-ABL1 and FIP1L1-PDGFRA were negative. Based on these findings, a diagnosis of an unclassifiable myeloproliferative neoplasm was made, and he was started on hydroxyurea treatment. He was referred to our hospital in April 2016 for transfusion dependence. Bone marrow examination performed at our hospital revealed granulocytic dysplasia and CSF3R T618I was detected. After induction therapy, CSF3R T618I became undetectable, and he went on to undergo allogeneic stem cell transplantation in October 2016. He has been in remission for >4 years posttransplantation. CSF3R T618I is one of the genes responsible for chronic neutrophilic leukemia and atypical chronic myeloid leukemia, suggesting its involvement in the pathogenesis of this case., 日本語
• 心内圧波形に基づく拡張早期僧帽弁逆流の発生機序に関する考察
  種村 明日香; 村山 迪史; 岩野 弘幸; 西野 久雄; 横山 しのぶ; 中鉢 雅大; 本居 昂; 辻永 真吾; 岡田 一範; 加賀 早苗; 西田 睦; 豊嶋 崇徳, 超音波検査技術抄録集, 46, S132, S132, 2021年
  一般社団法人 日本超音波検査学会, 日本語
• 急性前骨髄球性白血病に対する同種造血幹細胞移植27年後に発症したドナー細胞由来未分化大細胞リンパ腫の1例
  菊池 遼; 小野澤 真弘; 今本 鉄平; 高橋 秀一郎; 杉田 純一; 橋本 大吾; 橋野 聡; 松野 吉宏; 豊嶋 崇徳, 日本内科学会雑誌, 110, 1, 92, 98, 2021年01月, ［査読有り］
  54歳男性。右鼠径リンパ節腫脹を主訴とした。27歳時に急性前骨髄球性白血病に対しHLA適合の兄から骨髄移植を受けていた。53歳時に右大腿外側部にケロイド様皮疹が出現し、皮膚生検の診断はanaplastic lymphoma kinase(ALK)陰性の未分化大細胞リンパ腫(ALCL)であった。電子線治療で皮膚病変は消失したが、7ヵ月後にFDG-PETで全身のリンパ節病変(鎖骨上窩、傍大動脈、右鼠径部)を認めた。再発病変を疑い、右鼠径リンパ節を生検したところ、右大腿皮膚生検同様の組織所見を認め、ALK陰性ALCLと診断した。末梢血をドナー細胞、頬粘膜をレシピエント細胞としてキメリズム解析を行い、ドナー由来のALCLと診断した。ALCLに対しCHOP療法(cyclophosphamide、doxorubicin、vincristine、prednisolone)を行ったが、病変の増大を認め、brentuximab vedotin(BV)単剤による治療に変更した。経過は良好で、現在まで完全奏効を維持している。, (一社)日本内科学会, 日本語
• SOS/VOD評価における超音波検査スコアHokUS-3の検者再現性に関する検討
  岩井 孝仁; 西田 睦; 工藤 悠輔; 高杉 莉佳; 横田 勲; 高木 諒; 渋谷 斉; 高橋 秀一郎; 杉田 純一; 豊嶋 崇徳, 超音波医学, 47, Suppl., S344, S344, 2020年11月
  (公社)日本超音波医学会, 日本語
• HIV薬剤耐性検査の外部精度評価での次世代シーケンサーの活用
  吉田 繁; 岡田 清美; 豊嶋 崇徳; 幸村 近; 蜂谷 敦子; 松田 昌和; 齊藤 浩一; 佐藤 かおり; 藤澤 真一; 遠藤 知之; 杉浦 亙; 吉村 和久; 椎野 禎一郎; 菊地 正, 臨床病理, 68, 補冊, 233, 233, 2020年10月
  (一社)日本臨床検査医学会, 日本語
• 多種動物に反応する異好抗体により複数の試薬で偽陽性を呈した1症例
  中野 恵一; 安田 慶子; 西田 睦; 杉田 純一; 豊嶋 崇徳, 臨床化学, 49, Suppl.1, 194, 194, 2020年10月
  (一社)日本臨床化学会, 日本語
• 臍帯血移植後のドナー由来細胞にモノソミー7を認めたAMLの一症例
  佐藤 かおり; 小栗 聡; 市川 絢子; 藤澤 真一; 西田 睦; 杉田 純一; 小野澤 真弘; 豊嶋 崇徳, 日本医学検査学会抄録集, 69回, 399, 399, 2020年09月
  (一社)日本臨床衛生検査技師会, 日本語
• MT Seminar トロポニン測定のピットフォール
  中野 恵一; 眞船 直樹; 安田 慶子; 西田 睦; 杉田 純一; 豊嶋 崇徳, Medical Technology, 48, 2, 193, 197, 2020年02月
  医歯薬出版(株), 日本語
• 不規則抗体スクリーニング試薬0.8%セルスクリーンJ-Alba-を用い不規則抗体の早期検出が可能であった2症例
  増田 裕弥; 伊藤 誠; 櫻澤 貴代; 魚住 諒; 渡邊 千秋; 西田 睦; 高橋 秀一郎; 杉田 純一; 豊嶋 崇徳, 日本輸血細胞治療学会誌, 66, 1, 57, 57, 2020年02月
  (一社)日本輸血・細胞治療学会, 日本語
• 新生児におけるcisAB型の血液型検査反応性と発育に伴う抗原量の変化に関する検討
  櫻澤 貴代; 高橋 秀一郎; 渡邊 千秋; 伊藤 誠; 魚住 諒; 増田 裕弥; 早坂 光司; 西田 睦; 杉田 純一; 豊嶋 崇徳, 日本輸血細胞治療学会誌, 66, 1, 31, 35, 2020年02月, ［査読有り］
  (一社)日本輸血・細胞治療学会, 日本語
• チサゲンレクルユーセル
  豊嶋崇徳, 日本病院薬剤師会雑誌, 56, 1, 2020年
• 少量ATGを用いたPBSCTの移植成績-R-PBSCTとUR-PBSCTの比較検討-
  白鳥聡一; 大東寛幸; 高橋秀一郎; 荒隆英; 横山絵美; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本輸血細胞治療学会誌, 66, 2, 2020年
• 血液疾患患者における患者血液管理
  豊嶋崇徳, 日本輸血細胞治療学会誌, 66, 2, 2020年
• 造血幹細胞移植と免疫細胞療法アップデート
  豊嶋崇徳, 日本輸血細胞治療学会誌, 66, 2, 2020年
• Deep Learningを用いた好中球核分葉数別判別を含む健常末梢血白血球9分画の試み
  藪田麻結; 中村伊織; 井田晴日; 小林美穂; 宇佐美貴之; 村上望; 山下亜妃子; 杉田純一; 杉田純一; 豊嶋崇徳; 豊嶋崇徳; 政氏伸夫, 日本検査血液学会雑誌, 21, 2020年
• 免疫・炎症・アレルギー疾患 移植片対宿主病
  豊嶋崇徳; 久保田康生, 薬局, 71, 4, 2020年
• 好中球減少時の反応性好中球造血における腸内細菌叢の役割
  陳げん仲; 橋本大吾; 江端浩; 高橋秀一郎; 早瀬英子; 横山絵美; 荒隆英; 大東寛幸; 長谷川裕太; 菊池遼; 張紫せん; 豊嶋崇徳, 腸内細菌学雑誌, 34, 2, 2020年
• GVHD治療-新たな時代の到来
  豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 42nd, 2020年
• VWF含有第VIII因子製剤および第IX因子製剤を併用して関節手術を施行したVWD合併血友病B保因者
  遠藤知之; 岡敏明; 小野寺智洋; 遠藤香織; 高橋承吾; 米田和樹; 荒隆英; 白鳥聡一; 後藤秀樹; 中川雅夫; 豊嶋崇徳, 日本血栓止血学会誌, 31, 2, 2020年
• 造血幹細胞移植の現状と課題
  豊嶋崇徳, 血液事業, 43, 1, 2020年
• 抗ヒト胸腺細胞グロブリンを用いたHLA適合ドナーからの同種末梢血幹細胞移植の多施設共同第II相試験-JSCT-ATG15-
  白鳥聡一; 杉田純一; 太田秀一; 笠原千嗣; 石川淳; 金森平和; 林良樹; 吉本五一; 衛藤徹也; 岩崎浩己; 松尾恵太郎; 原田実根; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 42nd, 2020年
• RICによるPTCYを用いたHLA半合致末梢血幹細胞移植における併用免疫抑制剤の減量・早期中止の検討
  杉田純一; 衛藤徹也; 上村智彦; 石川隆之; 松尾恵太郎; 赤司浩一; 谷口修一; 原田実根; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 42nd, 2020年
• 北海道白血病ネットにおける世代別AMLの移植成績
  米田和樹; 小野澤真弘; 日高大輔; 横山翔大; 宮下直洋; 荒隆英; 山本聡; 堤豊; 長谷山美仁; 永嶋貴博; 盛暁生; 太田秀一; 酒井基; 石原敏道; 宮城島拓人; 柿木康孝; 黒澤光俊; 小林一; 岩崎博; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 42nd, 2020年
• 造血幹細胞移植後のアデノウイルス関連出血性膀胱炎に対する少量シドフォビル療法の有効性に関する検討
  大東寛幸; 後藤秀樹; 藤本勝也; 荒隆英; 白鳥聡一; 杉田純一; 小野澤真弘; 森康雄; 吉本五一; 橋本大吾; 遠藤知之; 加藤光次; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 42nd, 2020年
• 造血器腫瘍の診断と治療 治療法 造血幹細胞移植
  豊嶋崇徳, 日本臨床, 78, 2020年
• ホジキンリンパ腫に対する同種移植前後の抗PD-1抗体療法に関する全国調査
  伊藤歩; 金成元; 松岡賢市; 河北敏郎; 東梅友美; 藤原慎一郎; 深谷真史; 近藤忠一; 杉田純一; 中前美佳; 鬼塚真仁; 奈良美保; 勝岡優奈; 今井洋介; 川島一郎; 中澤英之; 酒井リカ; 大和田千佳子; 寺倉精太郎; 飯田浩充; 樋口紘平; 田村志宣; 吉岡聡; 砥谷和人; 河野徳明; 伊豆津宏二; 鈴木律朗; 鈴宮淳司; 豊嶋崇徳; 福田隆浩, 日本造血細胞移植学会総会プログラム・抄録集, 42nd, 2020年
• FLT3-ITD変異を有する骨髄系腫瘍に対する同種造血幹細胞移植
  皆内康一郎; 岩崎純子; 日高大輔; 小野澤真弘; 若狭健太郎; 宮島徹; 須藤啓斗; 木村弘幸; 山川知宏; 岡田耕平; 高橋正二郎; 重松明男; 太田秀一; 豊嶋崇徳; 今村雅寛, 日本造血細胞移植学会総会プログラム・抄録集, 42nd, 2020年
• いま知っておきたい!内科最新トピックス 造血器腫瘍に対するキメラ抗原受容体(CAR)遺伝子改変T細胞療法
  豊嶋崇徳, 内科, 126, 3, 2020年
• 腸内細菌叢の変化と同種造血幹細胞移植成績との関連
  豊嶋崇徳, 無菌生物, 50, 1, 2020年
• 唾液によるコロナ診断法
  豊嶋崇徳, 日本染色体遺伝子検査学会雑誌, 38, 2, 2020年
• HSP47 siRNA含有ビタミンA結合リポソーム点眼は慢性GVHDによる涙腺線維化とドライアイを改善する
  大東寛幸; 橋本大吾; 高橋秀一郎; 荒隆英; 山川知宏; 早瀬英子; 杉田純一; 小野澤真弘; 中川雅夫; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 42nd, 2020年
• IRAK4阻害薬はドナーT細胞のMyD88シグナルを阻害して同種造血幹細胞移植後のGvHDを軽減する
  松岡里湖; 松岡里湖; 橋本大吾; 門脇賢典; 長谷川裕太; 大東寛幸; 早瀬英子; 横山絵美; 立野貴大; 青山一利; 岡英世; 小野澤真弘; 竹田潔; 赤司浩一; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 42nd, 2020年
• 造血幹細胞移植療法の進歩
  豊嶋崇徳, 日本輸血細胞治療学会誌, 66, 1, 2020年
• 白血病・リンパ腫 造血器腫瘍に対するCAR-T細胞(遺伝子改変T細胞)療法
  豊嶋崇徳, Medical Practice, 37, 9, 2020年
• 大腸杯細胞は抗菌分子Lypd8依存性に同種造血幹細胞移植後の移植片対宿主病を抑制する
  荒隆英; 橋本大吾; 早瀬英子; NOIZAT Clara; 菊池遼; 長谷川祐太; 奥村龍; 竹田潔; 豊嶋崇徳, 腸内細菌学雑誌, 34, 2, 2020年
• HIV感染血友病患者の認知機能及び心理社会的問題の現状把握に関する研究
  石田陽子; 石田陽子; 遠藤知之; 遠藤知之; 後藤秀樹; 後藤秀樹; 荒隆英; 荒隆英; 長谷川祐太; 長谷川祐太; 横山翔大; 横山翔大; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 22, 4, 2020年
• HIV関連悪性リンパ腫の臨床的特徴の検討
  遠藤知之; 遠藤知之; 後藤秀樹; 後藤秀樹; 荒隆英; 荒隆英; 長谷川祐太; 長谷川祐太; 横山翔大; 横山翔大; 橋本大吾; 橋野聡; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 22, 4, 2020年
• 国内新規HIV/AIDS診断症例における薬剤耐性HIV-1の動向
  菊地正; 蜂谷敦子; 西澤雅子; 椎野禎一郎; 俣野哲朗; 佐藤かおり; 豊嶋崇徳; 伊藤俊広; 林田庸総; 潟永博之; 岡慎一; 古賀道子; 長島真美; 貞升健志; 近藤真規子; 宇野俊介; 谷口俊文; 猪狩英俊; 寒川整; 中島秀明; 吉野友祐; 堀場昌英; 茂呂寛; 渡邉珠代; 今橋真弓; 松田昌和; 重見麗; 岡崎玲子; 岩谷靖雅; 横幕能行; 渡邉大; 小島洋子; 森治代; 藤井輝久; 高田清式; 中村麻子; 南留美; 山本政弘; 松下修三; 健山正男; 藤田次郎; 杉浦亙; 吉村和久, 日本エイズ学会誌, 22, 4, 2020年
• COVID-19診断における唾液検査
  豊嶋崇徳, 日本エイズ学会誌, 22, 4, 2020年
• リポ蛋白-Xにより異常な反応タイムコースを示した症例解析
  中野恵一; 杉田純一; 豊嶋崇徳, 臨床病理, 68, 2020年
• 尿蛋白定性検査とろう様円柱の関連
  志賀麻衣子; 杉田純一; 豊嶋崇徳, 臨床病理, 68, 2020年
• 北海道における輸血機能評価認定制度(I&A)の現状
  遠藤輝夫; 三浦邦彦; 渡邊千秋; 生田克哉; 豊嶋崇徳; 紀野修一; 幸村近, 臨床病理, 68, 2020年
• 非血縁者間末梢血幹細胞移植における末梢血幹細胞の効率的提供と至適な利用率増加に繋がる実践的支援体制の整備
  岡本真一郎; 豊嶋崇徳, 非血縁者間末梢血幹細胞移植における末梢血幹細胞の効率的提供と至適な利用率増加に繋がる実践的支援体制の整備 平成31年度/令和元年度 総括研究報告書(Web), 2020年
• SOS/VOD評価における超音波検査スコアHokUS-3の検者再現性に関する検討
  岩井孝仁; 岩井孝仁; 西田睦; 西田睦; 工藤悠輔; 工藤悠輔; 高杉莉佳; 横田勲; 高木諒; 渋谷斉; 高橋秀一郎; 高橋秀一郎; 杉田純一; 杉田純一; 豊嶋崇徳; 豊嶋崇徳, 超音波医学 Supplement, 47, 2020年
• 高度肥満例に対する肝脂肪化測定の試み
  岩井孝仁; 岩井孝仁; 西田睦; 西田睦; 畑瀬理恵; 畑瀬理恵; 吉川仁人; 高桑恵美; 小川浩司; 大栗拓真; 神山直久; 渋谷斉; 豊嶋崇徳; 豊嶋崇徳, 超音波医学 Supplement, 47, 2020年
• 同種造血幹細胞移植後早期のプロカルシトニン測定の有用性についての検討
  大東寛幸; 杉田純一; 荒隆英; 白鳥聡一; 後藤秀樹; 小野澤真弘; 中川雅夫; 橋本大吾; 遠藤知之; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 82nd, 2020年
• 再発難治性DLBCLへのtisagenlecleucelの安全性
  後藤秀樹; 杉田純一; 杉田純一; 大東寛幸; 荒隆英; 高橋秀一郎; 高橋秀一郎; 横山絵美; 白鳥聡一; 小野澤真弘; 中川雅夫; 加畑馨; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 82nd, 2020年
• 治療抵抗性又は再発の大細胞型B細胞リンパ腫日本人患者を対象としたAxi-Cel第II相試験
  伊豆津宏二; 加藤光次; 豊嶋崇徳; 諫田淳也; 藤井伸治; 島田和之; 福田奈津子; 炭谷徳人; 角紘幸; 清水伸治; 加倉井靖之; 吉川謙次; 飛内賢正; 薄井紀子; 畠清彦, 日本血液学会学術集会抄録(Web), 82nd, 2020年
• 同種造血幹細胞移植後肺合併症の診断における気管支肺胞洗浄液CD4+/CD8+比の有用性
  千丈創; 杉田純一; 岡田耕平; 鈴木雅; 千葉雅尋; 大東寛幸; 高橋秀一郎; 荒隆英; 横山絵美; 白鳥聡一; 後藤秀樹; 小野澤真弘; 中川雅夫; 加畑馨; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 82nd, 2020年
• EFS24は本邦の実臨床においても確固たるエンドポイントたりうる
  泉山康; 泉山康; 小笠原励起; 小笠原励起; 皆内康一郎; 皆内康一郎; 宮島徹; 宮島徹; 横山絵美; 横山絵美; 盛暁生; 盛暁生; 齋藤誠; 齋藤誠; 森岡正信; 森岡正信; 近藤健; 近藤健; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 82nd, 2020年
• 各種移植片対宿主病予防法におけるレテルモビル予防内服時の至適タクロリムス初回投与量に関する検討
  荒隆英; 大東寛幸; 高橋秀一郎; 白鳥聡一; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 82nd, 2020年
• 末梢性T細胞性リンパ腫の大量化学療法併用末梢血幹細胞移植の有効性の検討
  千葉雅尋; 下埜城嗣; 横田勲; 重松明男; 太田秀一; 小林一; 堤豊; 山本聡; 黒澤光俊; 柿木康孝; 近藤健; 岩崎博; 酒井基; 宮城島拓人; 長谷山美仁; 永嶋貴博; 國枝保幸; 石尾崇; 石尾崇; 後藤秀樹; 橋野聡; 松野吉宏; 中川雅夫; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 82nd, 2020年
• 少量ATGはHLA適合PBSCTにおいて重症の急性,慢性GVHDの発症を抑制する
  白鳥聡一; 杉田純一; 太田秀一; 笠原千嗣; 石川淳; 立花崇孝; 林良樹; 吉本五一; 衛藤徹也; 岩崎浩己; 松尾恵太郎; 原田実根; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 82nd, 2020年
• 正常核型急性骨髄性白血病におけるFLT3-ITD,NPM1,CEBPAの臨床的意義
  横山翔大; 小野澤真弘; 日高大輔; 藤澤真一; 山本聡; 堤豊; 長谷山美仁; 永嶋貴博; 盛暁生; 太田秀一; 酒井基; 石原敏道; 宮城島拓人; 柿木康孝; 黒澤光俊; 小林一; 岩崎博; 豊嶋崇徳, 日本血液学会学術集会抄録(Web), 82nd, 2020年
• 急性骨髄性白血病における寛解導入療法後のWT1減少度の有用性
  宮島徹; 小野澤真弘; 盛暁生; 横山絵美; 小笠原励起; 泉山康; 齋藤誠; 森岡正信; 藤澤真一; 山本聡; 堤豊; 長谷山美仁; 太田秀一; 宮城島拓人; 柿木康孝; 黒澤光俊; 岩崎博; 豊嶋崇徳; 豊嶋崇徳; 近藤健, 日本血液学会学術集会抄録(Web), 82nd, 2020年
• 融合遺伝子の寛解導入療法後の1log reduction達成とKIT変異がCBF-AMLの予後を予測する
  盛暁生; 盛暁生; 小野澤真弘; 小野澤真弘; 日高大輔; 日高大輔; 宮島徹; 宮島徹; 横山絵美; 横山絵美; 小笠原励起; 小笠原励起; 泉山康; 泉山康; 齋藤誠; 齋藤誠; 藤澤真一; 藤澤真一; 横山翔大; 横山翔大; 太田秀一; 太田秀一; 柿木康孝; 柿木康孝; 堤豊; 堤豊; 山本聡; 山本聡; 宮城島拓人; 宮城島拓人; 永嶋貴博; 永嶋貴博; 岩崎博; 岩崎博; 小林一; 小林一; 長谷山美仁; 長谷山美仁; 黒澤光俊; 黒澤光俊; 森岡正信; 森岡正信; 豊嶋崇徳; 豊嶋崇徳; 近藤健; 近藤健, 日本血液学会学術集会抄録(Web), 82nd, 2020年
• ATLLに対するCRISPRスクリーニングによるCDK6・mTORC1阻害薬併用療法の同定
  石尾崇; KUMAR Sarvesh; 下埜城嗣; LIN Yuquan; BACHY Emmanuel; PETRUS Michael; YANG Yandan; 前田道之; 後藤秀樹; 橋野聡; 豊嶋崇徳; WALDMANN Thomas; STAUDT Louis; 中川雅夫, 日本血液学会学術集会抄録(Web), 82nd, 2020年
• 免疫チェックポイント阻害薬関連胃腸炎の1例
  表原里実; 表原里実; 西田睦; 西田睦; 山梨香菜; 桜井健介; 桂田武彦; 小松嘉人; 清水亜衣; 澁谷斉; 品川尚文; 杉田純一; 豊嶋崇徳, 日本超音波検査学会学術集会講演抄録集(Web), 45th, 2020年
• コロナウイルス唾液関連データ
  豊嶋崇徳, 北海道医報, 1223, 2020年
• HIV感染症の医療体制の整備に関する研究 5 北海道ブロックのHIV医療体制整備
  豊嶋崇徳, HIV感染症の医療体制の整備に関する研究 令和元年度 総括・分担研究報告書(Web), 2020年
• Carbapenem inactivation method(CIM)を応用したESBLおよびAmpCの同時検出法の開発
  岩崎 澄央; 福元 達也; 早坂 かすみ; 西田 睦; 杉田 純一; 豊嶋 崇徳, 日本臨床微生物学会雑誌, 30, Suppl.1, 284, 284, 2019年12月
  (一社)日本臨床微生物学会, 日本語
• Simplified Carbapenem inactivation method(sCIM)を応用したESBLおよびAmpCの同時検出法の開発
  福元 達也; 岩崎 澄央; 早坂 かすみ; 西田 睦; 杉田 純一; 豊嶋 崇徳, 日本臨床微生物学会雑誌, 30, Suppl.1, 284, 284, 2019年12月
  (一社)日本臨床微生物学会, 日本語
• 妊娠後期に診断された発作性夜間ヘモグロビン尿症に対してeculizumabを導入した1例
  小島 圭祐; 荒 隆英; 遠藤 知之; 高橋 承吾; 米田 和樹; 横山 翔大; 笠原 耕平; 白鳥 聡一; 後藤 秀樹; 中川 雅夫; 森川 守; 山本 準也; 豊嶋 崇徳, 臨床血液, 60, 11, 1583, 1583, 2019年11月
  (一社)日本血液学会-東京事務局, 日本語
• ART開始後に縮小傾向を認めたEBV-associated smooth muscle tumor合併AIDSの一例
  荒 隆英; 遠藤 知之; 後藤 秀樹; 笠原 耕平; 長谷川 裕太; 横山 翔大; 高桑 恵美; 松野 吉宏; 橋野 聡; 豊嶋 崇徳, 日本エイズ学会誌, 21, 4, 426, 426, 2019年11月
  (一社)日本エイズ学会, 日本語
• 北海道大学病院における血液培養陽性検体でのDISK法による薬剤中間報告の有用性
  福元 達也; 岩崎 澄央; 早坂 かすみ; 西田 睦; 杉田 純一; 豊嶋 崇徳, 臨床病理, 67, 補冊, 144, 144, 2019年10月
  (一社)日本臨床検査医学会, 日本語
• Break Apart FISH Probeで転座判定に苦慮したKMT2A-MLLT10 mRNA陽性AMLの一症例
  小栗 聡; 佐藤 かおり; 市川 絢子; 藤澤 真一; 原 和也; 杉山 未奈子; 寺下 友佳代; 長 祐子; 井口 晶裕; 杉田 純一; 西田 睦; 豊嶋 崇徳; 真部 淳, 日本染色体遺伝子検査学会雑誌, 37, 2, 47, 47, 2019年09月
  日本染色体遺伝子検査学会, 日本語
• G-bandで非典型転座様式を示しDEK-NUP214 mRNA検出が核型決定に有用であったAMLの一症例
  佐藤 かおり; 小栗 聡; 市川 絢子; 藤澤 真一; 西田 睦; 高橋 秀一郎; 杉田 純一; 豊嶋 崇徳, 日本染色体遺伝子検査学会雑誌, 37, 2, 48, 48, 2019年09月
  日本染色体遺伝子検査学会, 日本語
• 脾臓への放射線照射が奏功した脾機能亢進症の1例
  岩崎 愛美; 安田 耕一; 遠藤 知之; 大東 寛幸; 清水 伸一; 鬼丸 力也; 豊嶋 崇徳; 白土 博樹, 日本医学放射線学会秋季臨床大会抄録集, 55回, S518, S518, 2019年09月
  (公社)日本医学放射線学会, 日本語
• IgG4による抗IgE作用の生理的意義解析 IgG4-IgE複合体がIgE測定値に与える影響
  中野 恵一; 眞船 直樹; 安田 慶子; 西田 睦; 杉田 純一; 豊嶋 崇徳, 臨床化学, 48, Suppl.1, 282, 282, 2019年08月
  (一社)日本臨床化学会, 日本語
• 新生児のcis A2B3型の判定にABO遺伝子タイピングが有用であった1例
  上床 貴代; 渡邊 千秋; 伊藤 誠; 魚住 諒; 林 泰弘; 早坂 光司; 秋沢 宏次; 早瀬 英子; 豊嶋 崇徳, 日本輸血細胞治療学会誌, 65, 3, 652, 652, 2019年06月
  (一社)日本輸血・細胞治療学会, 日本語
• 抗Dによる胎児・新生児溶血性疾患で胎児輸血が必要となった1症例
  魚住 諒; 渡邊 千秋; 伊藤 誠; 上床 貴代; 林 泰弘; 早坂 光司; 馬詰 武; 早瀬 英子; 秋沢 宏次; 豊嶋 崇徳, 日本輸血細胞治療学会誌, 65, 3, 652, 652, 2019年06月
  (一社)日本輸血・細胞治療学会, 日本語
• 新生児に対する輸血回数と曝露ドナー数の検討
  林 泰弘; 渡邊 千秋; 猪股 百華; 伊藤 誠; 上床 貴代; 魚住 諒; 秋沢 宏次; 早瀬 英子; 豊嶋 崇徳, 日本輸血細胞治療学会誌, 65, 3, 653, 654, 2019年06月
  (一社)日本輸血・細胞治療学会, 日本語
• HIV診療がカウンセラーのチーム医療への姿勢に与える影響の解析 2015・2016年度HIV医療体制班アンケート調査から
  石田 陽子; 横幕 能行; 中川 雄真; 小松 賢亮; 渡邊 愛祈; 木村 聡太; 松岡 亜由子; 豊嶋 崇徳; 小島 賢一, 日本エイズ学会誌, 21, 2, 111, 117, 2019年05月, ［査読有り］
  2015・2016年度HIV医療体制班のアンケート調査結果から、HIV診療がカウンセラーのチーム医療への姿勢に与える影響について解析した。その結果、チーム医療を重視する姿勢は、HIV臨床経験年数とは有意な相関を認めたが、他領域での経年年数とは有意な相関がみられなかった。全てのカウンセラーが患者支援と多職種連携の両方を重視していたが、HIV臨床経験年数が長い者ほどマネジメントの視点やチーム力の向上を重視する傾向がみられた。また、カウンセラーの雇用形態が患者への支援に影響する可能性が示された。, (一社)日本エイズ学会, 日本語
• 生物由来原料基準を満たす国産ウシ血小板溶解物「NeoSERA」を原材料とする羊膜由来間葉系幹細胞の細胞製剤化
  山原 研一; 浜田 彰子; 黒田 将子; 池本 純子; 吉原 享子; 吉原 哲; 岡田 昌也; 橋本 大吾; 相馬 俊裕; 豊嶋 崇徳; 藤盛 好啓, 日本輸血細胞治療学会誌, 65, 2, 476, 476, 2019年04月
  (一社)日本輸血・細胞治療学会, 日本語
• 超音波診断をググッとあげる!こんな時どう考える? できる技師のスキルアップ術
  工藤 悠輔; 西田 睦; 澁谷 斉; 豊嶋 崇徳, 超音波検査技術, 44, Suppl., S105, S105, 2019年04月
  (一社)日本超音波検査学会, 日本語
• 免疫チェックポイント阻害薬関連大腸炎3例の超音波所見
  表原 里実; 西田 睦; 長島 一哲; 桂田 武彦; 村中 徹人; 小松 嘉人; 澁谷 斉; 秋沢 宏次; 杉田 純一; 豊嶋 崇徳, 超音波医学, 46, Suppl., S650, S650, 2019年04月
  (公社)日本超音波医学会, 日本語
• 初回治療から18年後に生じた多臓器進展を伴うホジキンリンパ腫の一剖検例
  五味川 龍; 杉野 弘和; 白鳥 聡一; 石田 雄介; 王 磊; 畑中 佳奈子; 松野 吉宏; 豊嶋 崇徳; 田中 伸哉, 日本病理学会会誌, 108, 1, 453, 453, 2019年04月
  (一社)日本病理学会, 日本語
• 関節エコーで診るリウマチ性疾患の病態と治療戦略 技師による関節エコーの現状と展望
  西田 睦; 澁谷 斉; 豊嶋 崇徳, 日本リウマチ学会総会・学術集会プログラム・抄録集, 63回, 192, 192, 2019年03月
  (一社)日本リウマチ学会, 日本語
• 自己抗体保有患者の同種抗体検出におけるLISSを用いた自己抗体吸着法の有用性の検討
  上床貴代; 渡邊千秋; 伊藤誠; 魚住諒; 林泰弘; 高橋秀一郎; 高橋秀一郎; 宮下直洋; 白鳥聡一; 橋本大吾; 杉田純一; 杉田純一; 早瀬英子; 早瀬英子; 秋沢宏次; 豊嶋崇徳; 豊嶋崇徳, 日本輸血細胞治療学会誌, 65, 1, 98, 102, 2019年02月28日
  Japan Society of Transfusion Medicine and Cell Therapy
• 血液がん治療の最前線
  豊嶋崇徳, 札幌冬季がんセミナー, 33rd, 2019年
• 造血幹細胞移植療法の進歩
  豊嶋崇徳, 日本輸血細胞治療学会誌, 65, 2, 2019年
• ART時代におけるHIV感染者の死因の検討
  荒隆英; 遠藤知之; 後藤秀樹; 日高大輔; 吉岡康介; 宮下直洋; 笠原耕平; 橋野聡; 豊嶋崇徳, 日本内科学会雑誌, 108, 2019年
• 心エコーで冠動脈瘻との鑑別に苦慮した左冠動脈肺動脈起始の1例
  西野久雄; 佐々木理; 岩野弘幸; 武田充人; 横山しのぶ; 中鉢雅大; 村山迪史; 西田睦; 秋沢宏次; 杉田純一; 豊嶋崇徳; 安斉俊久, 超音波検査技術, 44, 2019年
• 国産ウシ多血小板血漿由来血清「NeoSERA」を用いた各種MSCの製剤化-ウシ胎児血清との比較
  山原研一; 山原研一; 山原研一; 山原研一; 浜田彰子; 大西俊介; 高田竜治; 須藤稔太; 岡本里香; 豊嶋崇徳; 磯江敏幸; 佐藤典宏; 藤盛好啓; 藤盛好啓; 藤盛好啓, 日本再生医療学会総会(Web), 18th, 2019年
• 10年という長期寛解後に全身再発を来した節外性NK/T cell lymphoma(鼻型)の1例
  土田直央; 荒隆英; 遠藤知之; 横山翔大; 笠原耕平; 白鳥聡一; 後藤秀樹; 中川雅夫; 豊嶋崇徳; 福井秀章; 松野吉宏, 臨床血液, 60, 7, 2019年
• 造血幹細胞移植の現状と課題
  豊嶋崇徳, 血液事業, 42, 2, 2019年
• タクロリムスと減量メソトレキセートを用いた臍帯血移植におけるGVHD予防法
  白鳥聡一; 高橋秀一郎; 宮下直洋; 後藤秀樹; 小野澤真弘; 中川雅夫; 加畑馨; 杉田純一; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 41st, 2019年
• 移植片対宿主病の病態生理の解明
  豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 41st, 2019年
• CAR-T細胞療法のシグナル伝達経路
  豊嶋崇徳, 月刊血液内科, 79, 4, 2019年
• 急性白血病に対する同種造血細胞移植で前処置ATGがドナー毎に及ぼす影響
  若松学; 寺倉精太郎; 大橋一輝; 福田隆浩; 小澤幸泰; 金森平和; 澤正史; 内田直之; 太田秀一; 松下章子; 神田善伸; 中前博久; 一戸辰夫; 加藤剛二; 村田誠; 熱田由子; 熱田由子; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 41st, 2019年
• 当院における60歳以上の高齢者に対する同種造血幹細胞移植の後方視的解析
  横山翔大; 白鳥聡一; 荒隆英; 笠原耕平; 高橋秀一郎; 宮下直洋; 後藤秀樹; 小野澤真弘; 中川雅夫; 加畑馨; 杉田純一; 遠藤知之; 橋本大吾; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 41st, 2019年
• 医療データベースを用いた多発性骨髄腫における自家造血幹細胞移植に関する患者負担の解析
  石田禎夫; 飯田真介; 堀本勝久; 風間啓敬; クロウフォード ブルース; キム レイ; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 41st, 2019年
• 国内新規HIV/AIDS診断症例における薬剤耐性HIV-1の動向
  蜂谷敦子; 佐藤かおり; 豊嶋崇徳; 伊藤俊広; 林田庸総; 岡慎一; 潟永博之; 古賀道子; 長島真美; 貞升健志; 近藤真規子; 椎野禎一郎; 須藤弘二; 加藤真吾; 谷口俊文; 猪狩英俊; 寒川整; 中島秀明; 吉野友祐; 堀場昌秀; 太田康男; 茂呂寛; 渡邉珠代; 松田昌和; 重見麗; 岡崎玲子; 岩谷靖雅; 横幕能行; 渡邉大; 小島洋子; 森治代; 藤井輝久; 高田清式; 中村麻子; 南留美; 山本政弘; 松下修三; 健山正男; 藤田次郎; 杉浦亙; 吉村和久; 吉村和久; 菊地正, 日本エイズ学会誌, 21, 4, 2019年
• 我が国の抗HIV療法の現状と今後
  横幕能行; 伊藤俊広; 山本政弘; 岡慎一; 豊嶋崇徳; 茂呂寛; 渡邉珠代; 渡邊大; 藤井輝久; 今橋真弓; 渡邉真理子, 日本エイズ学会誌, 21, 4, 2019年
• HIV感染症合併血友病患者における微小脳出血の経時的評価
  遠藤知之; 遠藤知之; 後藤秀樹; 後藤秀樹; 荒隆英; 荒隆英; 長谷川祐太; 長谷川祐太; 横山翔大; 横浜翔大; 中川雅夫; 加畑馨; 橋本大吾; 橋野聡; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 21, 4, 2019年
• 北海道白血病ネット登録症例におけるAYA世代AMLの解析
  小野澤真弘; 米田和樹; 日高大輔; 横山翔大; 山本聡; 堤豊; 長谷山美仁; 永嶋貴博; 盛暁生; 太田秀一; 酒井基; 石原敏道; 宮城島拓人; 柿木康孝; 黒澤光俊; 小林一; 岩崎博; 近藤健; 豊嶋崇徳, 臨床血液, 60, 11, 2019年
• 多中心性キャッスルマン病の経過中にlarge B cell lymphomaを合併した1例
  千葉雅尋; 杉田純一; 千丈創; 大東寛幸; 高橋秀一郎; 横山絵美; 小野澤真弘; 橋本大吾; 三橋智子; 松野吉宏; 豊嶋崇徳, 臨床血液, 60, 11, 2019年
• 『非血縁者間末梢血幹細胞移植における末梢血幹細胞の効率的提供と至適な利用率増加に繋がる実践的支援体制の整備』非血縁者間末梢血幹細胞移植における慢性GVHDの対策と治療体制の整備
  豊嶋崇徳, 非血縁者間末梢血幹細胞移植における末梢血幹細胞の効率的提供と至適な利用率増加に繋がる実践的支援体制の整備 平成30年度 総括研究報告書(Web), 2019年
• HIV感染症の医療体制の整備に関する研究 北海道ブロックのHIV医療体制整備
  豊嶋崇徳, HIV感染症の医療体制の整備に関する研究 平成30年度 総括・分担研究報告書(Web), 2019年
• 再発時に免疫グロブリン軽鎖の優位性が変化した濾胞性リンパ腫の一例
  砂後谷華奈; 早坂光司; 道又理恵; 宇佐美貴之; 山下亜妃子; 秋沢宏次; 松野吉宏; 豊嶋崇徳, 日本医学検査学会(Web), 68th, 2019年
• トロポニンT・I測定値の乖離から考えるトロポニン測定の課題
  中野恵一; 眞船直樹; 安田慶子; 秋沢宏次; 杉田純一; 豊嶋崇徳, 臨床化学, 48, 2, 2019年
• 成人T細胞性白血病/リンパ腫におけるBATF3,IRF4の検討
  下埜城嗣; 下埜城嗣; 石尾崇; 後藤秀樹; 堤豊; 盛暁生; 小林一; 黒澤光俊; 柿木康孝; 重松明男; 太田秀一; 酒井基; 宮城島拓人; 長谷山美仁; 岩崎博; 山本聡; 國枝保幸; 橋野聡; 三好寛明; 大島孝一; 畑中豊; 松野吉宏; 中川雅夫; 豊嶋崇徳, 日本リンパ網内系学会会誌, 59, 2019年
• 自己免疫性疾患患者に発生するびまん性大細胞型B細胞リンパ腫の微小環境の検討
  畑中佳奈子; 畑中佳奈子; 畑中豊; 畑中豊; 藤本勝也; 奥村麻美; 南家綾江; 津矢田明泰; 齋藤辰朗; 豊嶋崇徳; 松野吉宏; 松野吉宏, 日本病理学会会誌, 108, 1, 2019年
• サイトカインリッチな成牛多血小板血漿由来血清「NeoSERA」を用いた高品質羊膜MSCの製剤化と急性GVHD・クローン病向け医師主導治験
  山原 研一; 浜田 彰子; 黒田 将子; 岡田 昌也; 吉原 哲; 大西 俊介; 相馬 俊裕; 豊嶋 崇徳; 小川 啓恭; 藤盛 好裕, 日本内分泌学会雑誌, 94, 4, 1573, 1573, 2018年12月
  (一社)日本内分泌学会, 日本語
• 未来の造血幹細胞移植
  豊嶋 崇徳, 日本輸血細胞治療学会誌, 64, 6, 675, 680, 2018年12月, ［査読有り］
• HIV薬剤耐性検査の標準化に向けた取り組みの評価
  吉田 繁; 蜂谷 敦子; 松田 昌和; 齊藤 浩一; 岡田 清美; 椎野 禎一郎; 加藤 真吾; 佐藤 かおり; 藤澤 真一; 豊嶋 崇徳; 杉浦 亙; 吉村 和久; 菊地 正, 日本染色体遺伝子検査学会雑誌, 36, 2, 57, 57, 2018年10月
  日本染色体遺伝子検査学会, 日本語
• 骨髄バンクを介したコーディネート期間短縮に向けた開始ドナー人数増加(5人→10人)トライアル(Trial to increase the initial numbers of donor candidates for the donor coordination of JMDP)
  平川 経晃; 田島 絹子; 大橋 一輝; 豊嶋 崇徳; 大西 康; 小澤 幸泰; 加藤 剛二; 日野 雅之; 前田 嘉信; 嶋田 明; 宮本 敏浩; 白土 基明; 山口 公平; 福田 隆浩, 臨床血液, 59, 9, 1630, 1630, 2018年09月
  (一社)日本血液学会-東京事務局, 日本語
• 成人急性リンパ性白血病におけるIKZF1欠失およびCRLF2発現の解析(Analysis of IKZF1 deletion and CRLF2 expression in adult patients with acute lymphoblastic leukemia)
  橋口 淳一; 小野澤 真弘; 藤澤 真一; 高橋 秀一郎; 宮下 直洋; 早瀬 英子; 白鳥 聡一; 後藤 秀樹; 杉田 純一; 中川 雅夫; 橋本 大吾; 加畑 馨; 遠藤 知之; 山本 聡; 堤 豊; 長谷山 美仁; 永嶋 貴博; 盛 暁生; 太田 秀一; 宮城島 拓人; 柿木 康孝; 黒澤 光俊; 岩崎 博; 近藤 健; 豊嶋 崇徳, 臨床血液, 59, 9, 1648, 1648, 2018年09月
  (一社)日本血液学会-東京事務局, 英語
• 日本人未治療CLL/SLL患者を対象としたIbrutinibの第I相試験(Phase 1 study of ibrutinib in Japanese patients with treatment-naive CLL/SLL)
  豊嶋 崇徳; 柴山 浩彦; 崔 日承; 畠 清彦; 関口 直宏; 吉成 望, 臨床血液, 59, 9, 1526, 1526, 2018年09月
  (一社)日本血液学会-東京事務局, 英語
• KEYNOTE185 未治療多発性骨髄腫を対象としたLen/dex±pembrolizumab第3相試験(日本人解析含む)(KEYNOTE185: Randomized phase 3 study of Len/dex±pembrolizumab in untreated MM: including JPN subset)
  小杉 浩史; 竹迫 直樹; 松本 守生; 飯田 真介; 石川 隆之; 近藤 恭夫; 安藤 潔; 張 高明; 三木 浩和; 松村 到; 角南 一貴; 豊嶋 崇徳; 岩崎 浩己; 大西 康; 木崎 昌弘; 伊豆津 宏二; 丸山 大; 飛内 賢正; 鈴木 憲史, 臨床血液, 59, 9, 1610, 1610, 2018年09月
  (一社)日本血液学会-東京事務局, 英語
• 北海道HIV透析ネットワークの構築とその有効性の検討
  遠藤 知之; センテノ田村 恵子; 渡部 恵子; 後藤 秀樹; 宮下 直洋; 荒 隆英; 笠原 耕平; 橋野 聡; 豊嶋 崇徳, 日本エイズ学会誌, 20, 3, 199, 205, 2018年08月, ［査読有り］
  北海道透析療法学会と連携し、HIV感染者の受け入れが可能な透析施設をあらかじめ登録する「北海道HIV透析ネットワーク」を設置した。平成29年12月末までに、ネットワークには全道で42施設の登録が得られた。北海道内で維持透析を必要としたHIV感染者は、透析ネットワーク構築前後でそれぞれ4例ずつであった。維持透析施設確保までに要した期間は、ネットワーク構築前は、エイズ拠点病院でそのまま透析となった1例以外は、2ヵ月、12ヵ月と長く、透析施設が確保できず、体調が悪くなったときのみ拠点病院で緊急透析を行っていた症例もあった。自宅から透析施設までの距離も3kmから30kmとなっており、車で1時間かけて透析施設に通っていた症例もあった。透析ネットワーク構築後は、1例は、透析施設自体がない地域に居住していたため、自宅での腹膜透析となったが、他の3例はいずれも相談を行った即日維持透析受け入れの承諾が得られた。自宅から透析施設までの距離は最長で3kmで、通院に要する時間も30分以内となった。さらに、旅行者の一時透析の受け入れ相談例が1件あり、その症例に対しても即日透析受け入れの承諾が得られた。, (一社)日本エイズ学会, 日本語
• AMLにおけるWT1発現量と染色体・遺伝子異常の関連
  日高 大輔; 小野澤 真弘; 橋口 淳一; 宮下 直洋; 笠原 耕平; 藤澤 真一; 早瀬 英子; 岡田 耕平; 白鳥 聡一; 後藤 秀樹; 杉田 純一; 中川 雅夫; 加畑 馨; 橋本 大吾; 遠藤 知之; 山本 聡; 堤 豊; 長谷山 美仁; 永嶋 貴博; 盛 暁生; 太田 秀一; 酒井 基; 石原 敏道; 今井 陽俊; 宮城島 拓人; 柿木 康孝; 黒澤 光俊; 小林 一; 岩崎 博; 清水 力; 近藤 健; 豊嶋 崇徳, 臨床血液, 59, 7, 964, 964, 2018年07月
  (一社)日本血液学会-東京事務局, 日本語
• AMLにおけるWT1発現量と染色体・遺伝子異常の関連
  日高 大輔; 小野澤 真弘; 橋口 淳一; 宮下 直洋; 笠原 耕平; 藤澤 真一; 早瀬 英子; 岡田 耕平; 白鳥 聡一; 後藤 秀樹; 杉田 純一; 中川 雅夫; 加畑 馨; 橋本 大吾; 遠藤 知之; 山本 聡; 堤 豊; 長谷山 美仁; 永嶋 貴博; 盛 暁生; 太田 秀一; 酒井 基; 石原 敏道; 今井 陽俊; 宮城島 拓人; 柿木 康孝; 黒澤 光俊; 小林 一; 岩崎 博; 清水 力; 近藤 健; 豊嶋 崇徳, 臨床血液, 59, 7, 964, 964, 2018年07月
  (一社)日本血液学会-東京事務局, 日本語
• 体外診断薬開発のための慢性骨髄性白血病におけるBCR-ABL活性測定用改良型FRETバイオセンサー
  大場 雄介; 近藤 健; 豊嶋 崇徳, 臨床薬理の進歩, 39, 18, 26, 2018年06月, ［査読有り］
  アミノ酸置換および核外移行シグナル(NES)の導入により、切断抵抗性が向上した改良型Picklesバイオセンサーを開発したので報告した。フェルスター共鳴エネルギー移動(FRET)に基づくバイオセンサーPickles 2.31のために開発されたオリジナルのプロトコールでは、評価対象細胞をCFPとYFPの蛍光強度比に従って選択する。この基準に従ってPickles 2.31とPickles 2.34 NESの特性を比較したところ、薬剤処理の有無にかかわらず基準を満たす細胞の数が5%から25%増加した。さらに、実際の薬効評価指標であるFRET効率(FRET/CFP蛍光強度比)についても単一細胞レベルで評価した。以前の報告において使用した定義では、FRET効率が2.04より高い細胞は有意に高いBCR-ABL活性を示す。この基準によれば、改良型バイオセンサーはコントロールサンプル中に四つのFRET-high細胞を検出できるが、プロトタイプでは2.04以上の細胞は一つしか検出されなかった。この増加は分析対象細胞数の増加が検出能の向上に寄与した結果と考えられた。, (公財)臨床薬理研究振興財団, 日本語
• 担癌患者の精査加療中、偶発的に病理組織診断された慢性リンパ性白血病/リンパ球性リンパ腫の3例
  岡田 宏美; 清水 亜衣; 桑原 健; 大塚 拓也; 高桑 恵美; 岡田 耕平; 白鳥 聡一; 遠藤 知之; 豊嶋 崇徳; 三橋 智子; 松野 吉宏, 日本リンパ網内系学会会誌, 58, 111, 111, 2018年05月
  (一社)日本リンパ網内系学会, 日本語
• 造血幹細胞移植における組織適合性バリアの克服
  豊嶋崇徳, 日本内科学会雑誌, 107, 3, 2018年
• 免疫・炎症・アレルギーの病気とくすり 移植片対宿主病
  豊嶋崇徳; 久保田康生, 薬局, 69, 4, 2018年
• ステロイド抵抗性急性移植片対宿主病に対するヒト間葉系幹細胞療法の後方視的解析
  白鳥聡一; 早瀬英子; 岡田耕平; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 加畑馨; 橋本大吾; 遠藤知之; 近藤健; 豊嶋崇徳, 日本輸血細胞治療学会誌, 64, 2, 2018年
• 羊膜間葉系幹細胞の細胞製剤化と急性GVHDに対する第I/II相医師主導治験
  山原研一; 浜田彰子; 黒田将子; 岡田昌也; 岡田昌也; 吉原享子; 吉原哲; 相馬俊裕; 橋本大吾; 佐藤典宏; 豊嶋崇徳; 小川啓恭; 藤盛好啓, 日本輸血細胞治療学会誌, 64, 2, 2018年
• 間葉系幹細胞移植のupdate 羊膜由来間葉系幹細胞による急性GVHD治療
  山原研一; 山原研一; 濱田彰子; 濱田彰子; 大西俊介; 黒田将子; 相馬俊裕; 岡本里香; 岡田昌也; 岡田昌也; 吉原哲; 吉原享子; 橋本大吾; 磯江敏幸; 豊嶋崇徳; 佐藤典宏; 小川啓恭; 藤盛好啓; 藤盛好啓; 藤盛好啓, 月刊臨床免疫・アレルギー科, 70, 1, 2018年
• 急性GVHD・クローン病に対する羊膜由来間葉系幹細胞の医師主導治験-兵庫医科大学発・初認定ベンチャーによる開発をめざして-
  山原研一; 山原研一; 山原研一; 山原研一; 浜田彰子; 大西俊介; 相馬俊裕; 相馬俊裕; 岡本里香; 中村志郎; 岡田昌也; 吉原哲; 吉原享子; 橋本大吾; 磯江敏幸; 豊嶋崇徳; 佐藤典宏; 藤盛好啓; 藤盛好啓; 藤盛好啓, 兵庫医科大学医学会雑誌, 43, 1, 2018年
• 尿沈渣で見られたマルベリー小体からFabry病と判明した1例
  山下ひろ子; 小林美穂; 山下直樹; 秋沢宏次; 早瀬英子; 豊嶋崇徳, 北臨技会誌, 16, 2, 2018年
• HLA半合致造血幹細胞移植後のトレランスのメカニズム
  豊嶋崇徳, 日本移植学会総会プログラム抄録集, 54th, 2018年
• HLA半合致移植の進歩と今後の展望
  豊嶋崇徳, 月刊血液内科, 77, 4, 2018年
• エイズ診療の拠点病院の診療機能評価と課題の検討
  横幕能行; 今橋真弓; 伊藤俊広; 山本政弘; 岡慎一; 豊嶋崇徳; 茂呂寛; 渡邉珠代; 渡邊大; 藤井輝久, 日本エイズ学会誌, 20, 4, 2018年
• 国内新規HIV/AIDS診断症例における薬剤耐性HIV-1の動向
  岡崎玲子; 蜂谷敦子; 佐藤かおり; 豊嶋崇徳; 佐々木悟; 伊藤俊広; 林田庸総; 岡慎一; 潟永博之; 古賀道子; 長島真美; 貞升健志; 近藤真規子; 椎野禎一郎; 須藤弘二; 加藤真吾; 谷口俊文; 猪狩英俊; 寒川整; 加藤英明; 石ヶ坪良明; 中島秀明; 吉野友祐; 太田康男; 茂呂寛; 渡邉珠代; 松田昌和; 重見麗; 岩谷靖雅; 横幕能行; 渡邉大; 小島洋子; 森治代; 藤井輝久; 高田清式; 南留美; 山本政弘; 松下修三; 健山正男; 藤田次郎; 杉浦亙; 吉村和久; 菊地正, 日本エイズ学会誌, 20, 4, 2018年
• 骨髄バンクを介したコーディネート期間短縮に向けた開始ドナー人数増加(5人→10人)トライアル
  平川経晃; 田島絹子; 大橋一輝; 豊嶋崇徳; 大西康; 小澤幸泰; 加藤剛二; 日野雅之; 前田嘉信; 嶋田明; 宮本敏浩; 白土基明; 山口公平; 福田隆治, 臨床血液, 59, 9, 2018年
• 国産成牛多血小板血漿由来血清「NeoSERA」を用いた羊膜MSC製剤化と急性GVHD・クローン病向け医師主導治験
  山原研一; 山原研一; 浜田彰子; 大西俊介; 高田竜治; 須藤稔太; 岡本里香; 豊嶋崇徳; 磯江敏幸; 佐藤典宏; 藤盛好啓, 日本再生医療学会総会(Web), 17th, 2018年
• 同種造血幹細胞移植後にT細胞由来の異型リンパ球増加を伴い伝染性単核球症様症状を呈した再生不良性貧血
  江端浩; 郎朗; 長谷川祐太; 早瀬英子; 白鳥聡一; 後藤秀樹; 中川雅夫; 遠藤知之; 豊嶋崇徳, 臨床血液, 59, 7, 2018年
• 皮膚生検で血管内リンパ腫様の病理所見を呈したextranodal NK/T-cell lymphoma,nasal typeの1例
  菊池遼; 山脇文彦; 高橋秀一郎; 宮下直洋; 杉田純一; 小野澤真弘; 橋本大吾; 福井秀章; 松野吉宏; 豊嶋崇徳, 臨床血液, 59, 12, 2018年
• 『非血縁者間末梢血幹細胞移植における末梢血幹細胞の効率的提供と至適な利用率増加に繋がる実践的支援体制の整備』非血縁者間末梢血幹細胞移植における慢性GVHDの対策と治療体制の整備
  豊嶋崇徳, 非血縁者間末梢血幹細胞移植における末梢血幹細胞の効率的提供と至適な利用率増加に繋がる実践的支援体制の整備 平成29年度 総括研究報告書(Web), 2018年
• HIV感染症の医療体制の整備に関する研究 北海道ブロックのHIV医療体制の整備に関する研究
  豊嶋崇徳, HIV感染症の医療体制の整備に関する研究 平成29年度 総括・分担研究報告書(Web), 2018年
• 高感度CRPによるHIV感染者の慢性炎症の評価
  遠藤知之; 遠藤知之; 後藤秀樹; 後藤秀樹; 荒隆英; 荒隆英; 吉岡康介; 吉岡康介; 宮下直洋; 笠原耕平; 橋野聡; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 20, 4, 2018年
• 移植片対宿主病(GVHD)-病態解明と治療法の進歩-1.移植片対宿主病(GVHD)の病態解明 1)移植片対宿主病(GVHD)の病態生理
  橋本大吾; 豊嶋崇徳, 血液フロンティア, 28, 4, 2018年
• 肺拡散能力値が著明な低値を示した3群肺高血圧症の1例
  大原彩友美; 山本雅史; 三谷麻子; エラクネス江美; 井上真美子; 秋沢宏次; 早瀬英子; 豊嶋崇徳, 北臨技会誌, 16, 2, 2018年
• 末梢血幹細胞採取におけるSpectra Optia^(R) MNCモードとCMNCモードの後方視的検討
  伊藤誠; 早瀬英子; 早瀬英子; 渡邊千秋; 上床貴代; 魚住諒; 林泰弘; 早坂光司; 茂木祐子; 加畑馨; 加畑馨; 高橋秀一郎; 宮下直洋; 後藤秀樹; 小野澤真弘; 白鳥聡一; 杉田純一; 橋本大吾; 秋沢宏次; 佐藤典宏; 豊嶋崇徳; 豊嶋崇徳, 日本輸血細胞治療学会誌, 64, 6, 2018年
• AIA-パックCLインスリンを用いたインスリン製剤測定時の反応性に関する検討
  熊谷菜海; 菊地玲; 安田慶子; 秋沢宏次; 早瀬英子; 豊嶋崇徳, 日臨技北日本支部医学検査学会(Web), 7th, 2018年
• 潜伏感染III型のEBウイルスが発症に寄与したと思われる膿胸関連リンパ腫の1例
  千丈創; 盛暁生; 金谷穣; 泉山康; 岡田耕平; 竹薮公洋; 飛岡弘敏; 斉藤誠; 田中雅則; 豊嶋崇徳; 森岡正信, 日本老年医学会雑誌, 55, 1, 143, 147, 2018年, ［査読有り］
  Japan Geriatrics Society, 日本語
• 脳死肝移植時のフィブリノゲン製剤使用による術中出血量と輸血使用量に関する検討
  上床 貴代; 後藤 了一; 渡邊 千秋; 秋沢 宏次; 嶋村 剛; 清水 力; 豊嶋 崇徳; 早瀬 英子; 加畑 馨; 橋本 大吾; 伊藤 誠; 魚住 諒; 林 泰弘; 杉田 純一; 腰塚 靖之, 日本輸血細胞治療学会誌, 64, 5, 641, 648, 2018年, ［査読有り］
  <p>＜背景＞肝移植患者は，凝固障害によりしばしば大量出血をきたし，大量の輸血製剤が必要となる．肝移植時のフィブリノゲン製剤の使用で輸血使用量が減少したとの報告があり¹⁾，当院でも2012年より脳死肝移植でのフィブリノゲン製剤の使用を導入した．今回，脳死肝移植でのフィブリノゲン製剤の使用による術中出血量と輸血使用量について検討した．＜対象＞2001年2月から2016年8月の間に当院で脳死肝移植を施行した成人44例を対象とし，フィブリノゲン製剤非投与群25例，投与群19例で術中出血量，輸血使用量の比較検討を行った．また，術中出血量が循環血液量を超えた症例33例（非投与群16例，投与群17例）で同様に検討を行った．＜結果＞全症例での比較では両群で術中出血量，輸血使用量に有意差は認めなかった．循環血液量以上の出血を来した33例でサブ解析を施行したところ，投与群で術中出血量が有意に減少した．輸血使用量は投与群において濃厚血小板の使用量が有意に減少し，赤血球液，新鮮凍結血漿は減少傾向が認められた．＜結論＞脳死肝移植ではフィブリノゲン製剤の使用により大量出血を抑制し，輸血使用量を削減できると考えられた．</p>, 一般社団法人 日本輸血・細胞治療学会, 日本語
• 同種造血幹細胞移植を施行したCSF3R T613I変異陽性非定型慢性骨髄性白血病
  原田 晋平; 岡田 耕平; 日高 大輔; 早瀬 英子; 後藤 秀樹; 橋本 大吾; 加畑 馨; 遠藤 知之; 豊嶋 崇徳, 臨床血液, 58, 11, 2299, 2299, 2017年11月
  (一社)日本血液学会-東京事務局, 日本語
• JAK阻害剤を用いたGVHD治療
  豊嶋 崇徳, 日本造血細胞移植学会雑誌, 6, 4, 146, 151, 2017年10月, ［査読有り］
• IgA型ALアミロイドーシスに線状IgA皮膚症を併発した1例
  山口 泰之; 氏家 英之; 大東 寛幸; 岩田 浩明; 村松 憲; 清水 宏; 遠藤 知之; 豊嶋 崇徳, 日本皮膚科学会雑誌, 127, 9, 2111, 2111, 2017年08月
  (公社)日本皮膚科学会, 日本語
• 北海道HIV福祉サービスネットワークの構築
  富田 健一; 白坂 るみ; 遠藤 知之; 渡部 恵子; 武内 阿味; 坂本 玲子; センテノ田村 恵子; 石田 陽子; 豊嶋 崇徳, 日本エイズ学会誌, 19, 3, 180, 184, 2017年08月, ［査読有り］
  HIV陽性者に困難なく福祉サービス提供を行うために、「北海道福祉サービスネットワーク」を構築し、有効な手段を検討した。対象施設は、北海道内の福祉事業所(高齢者領域のサービス事業所、障がい領域のサービス事業所、領域を問わずサービス提供を行う保険外の事業所)とした。北海道ブロック各拠点病院HIV担当ソーシャルワーカーが、HIV陽性者に対して理解があると感じられる福祉事業所に登録依頼を行った。その結果、407件の登録が得られ、HIV陽性者へのサービス提供の経験のある福祉事業所の登録割合が92.3%と最も高かった。これは、サービス提供を行うことで、それまで未知であったHIV感染者に対する漠然とした不安や戸惑いが払拭されたものと考えられた。一方、登録を断った事業所については、施設長・責任者の賛同が得らないことを理由にあげられることから、施設長や責任者に対して、HIVに関する正しい知識を説明するなど、直接的にアプローチすることが有効と考えた。行政(北海道保健福祉部)から、ネットワークへの登録依頼文書を配布した987法人からは、2週間以内に17件の社会福祉法人、87件の福祉事業所からの登録が得られた。2週間という短期間で、多くの登録を得られたことは、行政との連携がきわめて有効と考えられた。, (一社)日本エイズ学会, 日本語
• 画像診断に苦慮したHHV8-unrelated primary effusion lymphoma-like lymphomaの1例
  中川 純一; 加藤 扶美; 三村 理恵; 藪崎 哲史; 坂本 圭太; 真鍋 徳子; 工藤 與亮; 菅野 宏美; 松野 吉宏; 豊嶋 崇徳; 金谷 穣; 渡利 英道; 櫻木 範明; 白土 博樹, Japanese Journal of Radiology, 35, Suppl., 3, 3, 2017年02月
  (公社)日本医学放射線学会, 日本語
• 同種造血幹細胞移植後のCandida感染による移植免疫反応の修飾
  豊嶋崇徳; 橋本大吾; 西城忍, 千葉大学真菌医学研究センター報告, 20, 2017年
• 本邦の同種造血幹細胞移植後長期生存成人患者のQOLに関する横断的観察研究:慢性GVHD臓器別重症度とQOL
  黒澤彩子; 大島久美; 山口拓洋; 柳澤昌実; 福田隆浩; 金森平和; 森毅彦; 高橋聡; 近藤忠一; 河野彰夫; 瀬戸愛花; 梅本由香里; 豊嶋崇徳; 谷口修一; 山下卓也; 熱田由子, 日本造血細胞移植学会総会プログラム・抄録集, 39th, 2017年
• 体外式超音波検査による造血幹細胞移植後の肝veno-occlusive diseaseの非侵襲的診断方法の確立
  西田睦; 西田睦; 加畑馨; 加畑馨; 重松明男; 重松明男; 佐藤恵美; 佐藤恵美; 工藤悠輔; 工藤悠輔; 表原里実; 表原里実; 岩井孝仁; 岩井孝仁; 渋谷斉; 渋谷斉; 井口昌裕; 長祐子; 大島淳二; 近藤健; 遠藤知之; 藤本勝也; 橋本大悟; 小野澤真弘; 杉田純一; 後藤秀樹; 清水力; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 39th, 2017年
• 同種造血幹細胞移植後のHematogonesと予後に関する検討
  石尾崇; 立野貴大; 日高大輔; 早瀬英子; 白鳥聡一; 岡田耕平; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 橋本大吾; 加畑馨; 藤本勝也; 遠藤知之; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 39th, 2017年
• 減量前処置臍帯血移植におけるMMF/CSPおよびMMF/TACによるGVHD予防法の比較:福岡BMTグループの後方向視的検討
  上村智彦; 宮本敏浩; 高嶋秀一郎; 高嶋秀一郎; 加藤光次; 高瀬謙; 高瀬謙; 吉本五一; 吉田周郎; 平安山英穂; 大崎浩一; 岩崎浩巳; 岩崎浩巳; 衛藤徹夜; 豊嶋崇徳; 長藤宏司; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 39th, 2017年
• 幹細胞システム 造血幹細胞移植後のGVHDによる腸幹細胞とそのニッチ傷害に起因する腸管免疫システムの破綻
  早瀬英子; 豊嶋崇徳, Clinical Calcium, 27, 6, 2017年
• Ph陽性急性リンパ性白血病ALLに対する同種造血幹細胞移植-Imatinibとdasatinibの比較-
  重松明男; 太田秀一; 後藤秀樹; 皆内康一郎; 杉田純一; 橋本大吾; 小原雅人; 藤本勝也; 遠藤知之; 今村雅博; 豊嶋崇徳; 小林直樹, 日本造血細胞移植学会総会プログラム・抄録集, 39th, 2017年
• 菌状息肉症/Sezary症候群に対する同種移植後における早期再発予防としてのVorinostat療法:北日本血液研究会(NJHSG)
  白鳥聡一; 岡田耕平; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 加畑馨; 藤本勝也; 橋本大吾; 遠藤知之; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 39th, 2017年
• 造血幹細胞移植アップデート
  豊嶋崇徳, 日本検査血液学会雑誌, 18, 2017年
• 高齢者慢性骨髄性白血病に対するチロシンキナーゼ阻害剤治療の後方視的検討
  太田秀一; 小林一; 伊東慎市; 松川敏大; 進藤基博; 山本聡; 幸田久平; 柿木康孝; 豊嶋崇徳; 黒澤光俊, 日本臨床腫瘍学会学術集会(CD-ROM), 15th, 2017年
• HIV薬剤耐性検査の推奨法の確立
  吉田繁; 蜂谷敦子; 松田昌和; 岡田清美; 伊部史朗; 和山行正; 椎野禎一郎; 佐藤かおり; 藤澤真一; 豊嶋崇徳; 加藤真吾; 杉浦亙; 吉村和久, 臨床化学, 46, 2017年
• 移植後シクロホスファミドを用いたHLA半合致移植
  杉田純一; 豊嶋崇徳, 医学のあゆみ, 263, 10, 2017年
• HLA半合致移植の現状 序~HLA半合致移植の現状と展望~
  豊嶋崇徳, 血液フロンティア, 27, 12, 2017年
• 造血幹細胞移植アップデート
  豊嶋崇徳, 日本検査血液学会雑誌, 18, 3, 2017年
• GVHDによる移植後不妊
  豊嶋崇徳, 月刊血液内科, 75, 5, 2017年
• 強度減弱前治療によるPTCy-HLA半合致末梢血幹細胞移植の有効性と安全性の検討(Haplo14 RIC)
  杉田純一; 加賀谷裕介; 柴崎康彦; 太田秀一; 古川達雄; 藤崎智明; 衛藤徹也; 安藤寿彦; 松尾恵太郎; 赤司浩一; 谷口修一; 原田実根; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017年
• 脳生検により診断した進行性多巣性白質脳症の長期生存例
  佐藤翔紀; 白井慎一; 高橋育子; 矢部一郎; 遠藤知之; 豊嶋崇徳; 山口秀; 桑原健; 畑中佳奈子; 松野吉宏; 今村顕史; 三浦義治; 中道一生; 西條政幸; 佐々木秀直, Neuroinfection, 22, 2, 2017年
• 北海道HIV透析ネットワークの構築とその有効性の検討
  遠藤知之; 遠藤知之; センテノ(田村)恵子; センテノ(田村)恵子; 渡部恵子; 渡部恵子; 宮下直洋; 宮下直洋; 荒隆英; 荒隆英; 後藤秀樹; 後藤秀樹; 橋野聡; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 19, 4, 2017年
• 北海道ブロック「HIV/AIDS出張研修」5年間の実践報告
  渡部恵子; 渡部恵子; センテノ(田村)恵子; センテノ(田村)恵子; 遠藤知之; 遠藤知之; 富田健一; 石田陽子; 藤田和華子; 藤田和華子; 後藤秀樹; 後藤秀樹; 宮下直洋; 宮下直洋; 大野稔子; 大野稔子; 豊嶋崇徳; 豊嶋崇徳; 本田秀子; 本田秀子, 日本エイズ学会誌, 19, 4, 2017年
• AMLの予後因子と同種造血幹細胞移植の有効性~北海道白血病ネットの症例解析を通して~
  日高大輔; 小野澤真弘; 橋口淳一; 笠原耕平; 宮下直洋; 藤澤真一; 森岡正信; 小林直樹; 山本聡; 柿木康孝; 宮城島拓人; 堤豊; 長谷山美仁; 石原敏道; 黒澤光俊; 小林一; 岩崎博; 永嶋貴博; 酒井基; 近藤健; 清水力; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017年
• 体外式超音波検査による造血幹細胞移植後の遅発性類洞閉塞症候群の非侵襲的診断
  西田睦; 西田睦; 加畑馨; 早瀬英子; 早瀬英子; 佐藤恵美; 佐藤恵美; 工藤悠輔; 工藤悠輔; 表原里美; 表原里美; 岩井孝仁; 岩井孝仁; 高杉莉佳; 樋岡拓馬; 樋岡拓馬; 坂野稜典; 坂野稜典; 秋沢宏次; 澁谷斉; 岡田耕平; 白鳥聡一; 後藤秀樹; 杉田純一; 小野沢真弘; 中川雅夫; 橋本大吾; 遠藤知之; 近藤健; 清水力; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017年
• 当院における骨髄異形成症候群に対する同種造血幹細胞移植の成績
  郎朗; 白鳥聡一; 早瀬英子; 岡田耕平; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 加畑馨; 橋本大吾; 遠藤知之; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017年
• 悪性リンパ腫患者における化学療法併用pegfilgrastim投与によるCD34陽性細胞数の末梢血中の推移
  後藤秀樹; 日高大輔; 山本聡; 早坂光司; 道又理恵; 香川郁子; 砂後谷加奈; 飯島弘章; 早瀬英子; 白鳥聡一; 岡田耕平; 杉田純一; 小野澤真弘; 橋本大吾; 加畑馨; 藤本勝也; 遠藤知之; 清水力; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017年
• 腸管GVHDにおける大腸杯細胞数と内視鏡所見の相関関係の検討
  松田可奈; 小野尚子; 加藤麻倫; 宮本秀一; 安孫子怜史; 津田桃子; 山本桂子; 工藤俊彦; 清水勇一; 荒隆英; 早瀬英子; 橋本大吾; 豊嶋崇徳; 坂本直哉, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017年
• 半夏瀉心湯による移植関連口腔粘膜炎の予防効果に関する検討
  岡田耕平; 重松明男; 中澤誠多朗; 松下貴惠; 山崎裕; 杉田純一; 笠師久美子; 池田陽子; 早瀬英子; 白鳥聡一; 後藤秀樹; 小野澤真弘; 中川雅夫; 加畑馨; 橋本大吾; 遠藤知之; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017年
• 拠点病院定期通院者の抗HIV療法によるHIV複製制御の達成度評価-我が国のHIV感染症/エイズ診療体制整備の成果-
  横幕能行; 伊藤俊広; 山本政弘; 岡慎一; 豊嶋崇徳; 田邊嘉也; 渡邉珠代; 白阪琢磨; 藤井輝久; 宇佐美雄司; 池田和子; 吉野宗宏; 本田美和子; 葛田衣重; 小島賢一; 内藤俊夫; 安藤稔, 日本エイズ学会誌, 19, 4, 2017年
• 当院における急性骨髄性白血病に対する同種造血幹細胞移植の後方視的解析
  長谷川祐太; 白鳥聡一; 早瀬英子; 岡田耕平; 後藤秀樹; 杉田純一; 小野澤真弘; 中川雅夫; 加畑馨; 橋本大吾; 遠藤知之; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017年
• 国内新規HIV/AIDS診断症例における薬剤耐性HIV-1の動向
  岡崎玲子; 蜂谷敦子; 潟永博之; 渡邊大; 長島真美; 貞升健志; 近藤真規子; 南留美; 吉田繁; 小島洋子; 森治代; 内田和江; 椎野禎一郎; 加藤真吾; 豊嶋崇徳; 佐々木悟; 伊藤俊広; 猪狩英俊; 寒川整; 石ヶ坪良明; 太田康男; 山元泰之; 古賀道子; 林田庸総; 岡慎一; 松田昌和; 重見麗; 濱野章子; 横幕能行; 渡邊珠代; 藤井輝久; 高田清式; 山本政弘; 松下修三; 藤田次郎; 健山正男; 岩谷靖雅; 岩谷靖雅; 吉村和久, 日本エイズ学会誌, 19, 4, 2017年
• 2016年度HIV薬剤耐性検査外部精度評価の報告
  吉田繁; 蜂谷敦子; 松田昌和; 岡田清美; 伊部史朗; 和山行正; 齊藤浩一; 椎野禎一郎; 加藤真吾; 佐藤かおり; 豊嶋崇徳; 杉浦亙; 杉浦亙; 吉村和久, 日本エイズ学会誌, 19, 4, 2017年
• 移植片対宿主病による不妊メカニズムの解明
  加藤光次; 下地園子; 橋本大吾; 赤司浩一; 豊嶋崇徳, 先進医薬研究振興財団研究成果報告集, 2016, 2017年
• HIV感染症の医療体制の整備に関する研究 北海道ブロックのHIV医療体制整備
  豊嶋崇徳, HIV感染症の医療体制の整備に関する研究 平成28年度 総括・分担研究報告書(Web), 2017年
• 造血幹細胞移植アップデート
  豊嶋崇徳, 日本輸血細胞治療学会誌, 63, 1, 2017年
• 当院においてドナーリンパ球輸注を施行した34症例の検討
  石尾崇; 立野貴大; 笠原耕平; 小杉瑞葉; 白鳥聡一; 岡田耕平; 後藤秀樹; 杉田純一; 小野澤真弘; 橋本大吾; 加畑馨; 藤本勝也; 遠藤知之; 近藤健; 豊嶋崇徳, 日本輸血細胞治療学会誌, 63, 2, 2017年
• 末梢血幹細胞採取におけるCD34陽性細胞採取効率不良であった血小板数高値の症例
  伊藤誠; 早瀬英子; 早瀬英子; 渡邊千秋; 上床貴代; 魚住諒; 林泰弘; 砂後谷華奈; 道又理恵; 早坂光司; 茂木祐子; 加畑馨; 加畑馨; 橋本大吾; 佐藤典宏; 豊嶋崇徳; 清水力, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017年
• ランゲルハンス組織球肉腫と濾胞性リンパ腫の合併を認めた一例
  下埜城嗣; 下埜城嗣; 三好寛明; 宮城島拓人; 大島孝一; 豊嶋崇徳, 日本リンパ網内系学会会誌, 57, 2017年
• 造血幹細胞移植後に発症したトキソプラズマ症の2症例
  立野貴大; 石尾崇; 橋口淳一; 小杉瑞葉; 白鳥聡一; 杉田純一; 小野澤真弘; 中川雅夫; 藤本勝也; 豊嶋崇徳, 臨床血液, 58, 11, 2017年
• 化学療法を施行せずに,約1年間生存を続けているRUNX1-RUNXIT1を有する急性骨髄性白血病
  金谷穣; 千丈創; 泉山康; 盛暁生; 斉藤誠; 田中雅則; 森岡正信; 橋口淳一; 宮下直洋; 小野澤真弘; 豊嶋崇徳, 臨床血液, 58, 12, 2017年
• GVHDの病態と新規治療
  豊嶋崇徳, 日本輸血細胞治療学会誌, 63, 4, 2017年
• 血液内科疾患の治療中に生じた発熱性好中球減少症に対するテイコプラニンのトラフ値と有効性の関連性
  内山数貴; 田澤佑基; 今井俊吾; 鏡圭介; 杉田純一; 鳴海克哉; 山田武宏; 笠師久美子; 小林正紀; 豊嶋崇徳; 井関健; 井関健, 日本医療薬学会年会講演要旨集(Web), 27, 2017年
• Hematogonesの鏡検とフローサイトメトリーによる計測結果の比較
  山下亜妃子; 加畑馨; 加畑馨; 石尾崇; 早坂光司; 大沼麗子; 椹わか菜; 宇佐美貴之; 増田裕弥; 道又理恵; 砂後谷華奈; 香川郁子; 渋谷斉; 豊嶋崇徳; 清水力, 日本検査血液学会雑誌, 18, 2017年
• 免疫・炎症・アレルギーおよび骨・関節の病気とくすり A 免疫・炎症・アレルギー疾患 移植片対宿主病
  豊嶋崇徳; 久保田康生, 薬局, 68, 4, 2017年
• HSP47 siRNA含有ビタミンA結合リポソームは慢性移植片対宿主病の皮膚線維化を改善する
  山川知宏; 山川知宏; 橋本大吾; 早瀬英子; 高橋秀一郎; 大東寛幸; 新津洋司郎; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 40th, 2017年
• セフェピム脳症を来した末梢性T細胞リンパ腫の1例
  長谷川祐太; 工藤彰彦; 郎朗; 江端浩; 早瀬英子; 白鳥聡一; 後藤秀樹; 中川雅夫; 加納崇裕; 遠藤知之; 豊嶋崇徳, 臨床血液, 58, 12, 2017年
• FLT-3変異の陰転化および再陽転化をきたしたFLT-3 ITD変異陽性急性骨髄性白血病
  山脇文彦; 山脇文彦; 重松明男; 小野澤真弘; 太田秀一; 今村雅寛; 豊嶋崇徳; 小林直樹, 臨床血液, 58, 11, 2017年
• 日本骨髄バンクドナーの2回骨髄提供に関する検討
  折原 勝己; 吾郷 浩厚; 奥山 美樹; 落合 亮一; 澤 正史; 田野﨑 隆二; 玉井 佳子; 豊嶋 崇徳; 中尾 康夫; 日野 雅之; 宮﨑 泰司; 神田 善伸; 金森 平和, 日本造血細胞移植学会雑誌, 6, 2, 108, 114, 2017年, ［査読有り］
  日本骨髄バンクを介して2回の骨髄提供を行ったドナー820人を解析した。骨髄穿刺部の痛みの程度は変わりなく，痛みの持続日数および日常生活への復帰日数は2回目で短かった。骨髄採取時間，骨髄採取量，総細胞数，細胞濃度，細胞数/患者体重の1回目 : 2回目の平均値は，74分 : 78分，821mL: 848mL，160×10＾8個 : 139×10＾8個，2.0×10＾7個/mL: 1.7×10＾7個/mL，3.0×10＾8個/kg: 2.7×10＾8個/kgであった。2回目提供の骨髄移植では造血回復の遅延がみられ，標準リスクの患者群では生存率の低下がみられた。, (一社)日本造血細胞移植学会, 日本語
• 少量ATGを用いたHLA一致末梢血幹細胞移植におけるGVHD予防法
  白鳥 聡一; 小杉 瑞葉; 岡田 耕平; 後藤 秀樹; 杉田 純一; 小野澤 真弘; 加畑 馨; 藤本 勝也; 橋本 大悟; 遠藤 智之; 近藤 健; 豊嶋 崇徳, MHC: Major Histocompatibility Complex, 23, 2Suppl., 94, 94, 2016年10月
  日本組織適合性学会, 日本語
• HLA半合致移植の現状と展望
  藤本勝也; 杉田純一; 豊嶋崇徳, 臨床血液, 57, 3, 288, 297, 2016年04月, ［査読有り］, ［国内誌］
  HLA-haploidentical hematopoietic stem cell transplantation from related donors has gained attention as an alternative treatment for patients who do not have HLA-identical siblings and lack the time to search for HLA-matched unrelated donors due to availability for nearly all individuals. As a key factor in the success of this approach is depletion of donor T cells, HLA-haploidentical transplantation has rapidly gained acceptance worldwide with the development of three platforms: 1) CD34-positive cell selection using CliniMACS®; 2) the conditioning regimen with anti-thymocyte globulin; and 3) a recently-developed, post-transplant cyclophosphamide regimen. Since the high efficacy of T-cell-depletion provides both sufficient suppression of GVHD and a high risk of opportunistic infection, there is an urgent need to strengthen the prevention of viral infections. On the other hand, conditioning with ATG and the post-transplant cyclophosphamide regimen are becoming the strategies mainly used in haploidentical transplantation because of high practicability and low risk of infection, though these platforms necessitate other drugs for GVHD prophylaxis due to the low efficacy of T cell depletion. Together with progress in these platforms, outcomes of haploidentical transplantation are comparable to outcomes of HLA-matched transplants. Currently, HLA-haploidentical transplantation is increasingly being recognized as a novel breakthrough in hematopoietic stem cell transplantation., 日本語
• 免疫・炎症・アレルギーおよび骨・関節の病気とくすり A 免疫・炎症・アレルギー疾患 移植片対宿主病
  豊嶋崇徳; 久保田康生, 薬局, 67, 4, 2016年
• 移植後大量シクロフォスファミドを用いたHLA半合致移植
  豊嶋崇徳, 日本輸血細胞治療学会誌, 62, 2, 2016年
• 当院における骨髄腫患者からの末梢血幹細胞動員効率の検討
  加畑馨; 加畑馨; 伊藤誠; 渡邊千秋; 上床貴代; 米岡麻記; 小杉瑞葉; 小杉瑞葉; 重松明男; 重松明男; 高橋正二郎; 高橋正二郎; 杉田純一; 橋本大吾; 山本聡; 佐藤典宏; 清水力; 豊嶋崇徳, 日本輸血細胞治療学会誌, 62, 2, 2016年
• 当院におけるSpectraとOptia 2モードの使用経験
  伊藤誠; 加畑馨; 加畑馨; 渡邊千秋; 上床貴代; 米岡麻記; 小杉瑞葉; 小杉瑞葉; 重松明男; 重松明男; 高橋正二郎; 高橋正二郎; 杉田純一; 橋本大吾; 佐藤典宏; 豊嶋崇徳; 清水力, 日本輸血細胞治療学会誌, 62, 2, 2016年
• 同種造血幹細胞移植に関する最近の展開 移植片対宿主病(GVHD)の分子病態と分子標的療法
  高橋秀一郎; 橋本大吾; 豊嶋崇徳, 月刊血液内科, 72, 3, 2016年
• 悪性リンパ腫への造血幹細胞移植におけるFludarabine-MelphalanレジメンとFludarabine-Busulfanレジメンの後方視的比較
  後藤秀樹; 後藤秀樹; 中澤誠多郎; 大東寛幸; 松川敏大; 金谷稔; 杉田純一; 小野澤真弘; 橋本大吾; 加畑馨; 藤本勝也; 遠藤知之; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 38th, 2016年
• 急性GVHD予防における短期メトトレキセート投与量の検討
  松川敏大; 杉田純一; 中澤誠多朗; 阿部貴恵; 柏崎晴彦; 大東寛幸; 金谷穣; 後藤秀樹; 小野澤真弘; 橋本大吾; 加畑馨; 藤本勝也; 遠藤知之; 近藤健; 山崎裕; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 38th, 2016年
• 造血幹細胞移植の現状と展望
  豊嶋崇徳, MHC (Web), 23, 2, 2016年
• 国内新規HIV/AIDS診断症例における薬剤耐性HIV-1の動向
  岡崎玲子; 蜂谷敦子; 潟永博之; 渡邉大; 長島真美; 貞升健志; 近藤真規子; 南留美; 吉田繁; 小島洋子; 森治代; 内田和江; 椎野禎一郎; 加藤真吾; 豊嶋崇徳; 佐々木悟; 伊藤俊広; 猪狩英俊; 上田敦久; 石ヶ坪良明; 太田康男; 山元泰之; 福武勝幸; 古賀道子; 林田庸総; 岡慎一; 松田昌和; 重見麗; 濱野章子; 横幕能行; 渡邉珠代; 田邊嘉也; 藤井輝久; 高田清式; 山本政弘; 松下修三; 藤田次郎; 健山正男; 岩谷靖雅; 岩谷靖雅; 吉村和久, 日本エイズ学会誌, 18, 4, 2016年
• HIV感染症合併血友病患者に対するMRIによる脳スクリーニングの意義
  遠藤知之; 遠藤知之; 宮下直洋; 宮下直洋; 笠原耕平; 笠原耕平; 小杉瑞葉; 岡田耕平; 白鳥聡一; 後藤秀樹; 杉田純一; 小野澤真弘; 橋本大吾; 加畑馨; 藤本勝也; 藤本勝也; 近藤健; 橋野聡; 橋野聡; 豊嶋崇徳; 豊嶋崇徳, 日本エイズ学会誌, 18, 4, 2016年
• 造血幹細胞移植の現状と展望
  豊嶋崇徳, MHC (Web), 23, 2 Suppl, 2016年
• 少量ATGを用いたHLA一致末梢血幹細胞移植におけるGVHD予防法
  白鳥聡一; 小杉瑞葉; 岡田耕平; 後藤秀樹; 杉田純一; 小野澤真弘; 加畑馨; 藤本勝也; 橋本大吾; 遠藤智之; 近藤健; 豊嶋崇徳, MHC (Web), 23, 2 Suppl, 2016年
• 白血病の治療:総論 造血幹細胞移植(理論,方法)同種造血幹細胞移植 HLA不適合血縁者移植
  白鳥聡一; 豊嶋崇徳, 日本臨床, 74, 2016年
• 白血病の基礎研究と臨床研究の動向 臨床研究の動向 移植後大量cyclophosphamide療法によるHLA半合致移植
  後藤秀樹; 杉田純一; 豊嶋崇徳, 日本臨床, 74, 2016年
• 当院における同種末梢血幹細胞採取の検討
  杉田純一; 大東寛幸; 橋口淳一; 松川敏大; 金谷穣; 小杉瑞葉; 松岡里湖; 後藤秀樹; 小野澤真弘; 橋本大吾; 加畑馨; 藤本勝也; 遠藤知之; 近藤健; 豊嶋崇徳, 日本輸血細胞治療学会誌, 62, 3, 2016年
• Spectra Optiaによる末梢血幹細胞採取の検討
  伊藤誠; 加畑馨; 加畑馨; 渡邊千秋; 上床貴代; 米岡麻記; 茂木祐子; 成田玲子; 魚住諒; 石岡聡子; 早坂光司; 渋谷斉; 小杉瑞葉; 小杉瑞葉; 重松明男; 重松明男; 高橋正二郎; 高橋正二郎; 杉田純一; 橋本大吾; 佐藤典宏; 豊嶋崇徳; 清水力, 日本輸血細胞治療学会誌, 62, 3, 2016年
• DA-EPOCH-R後に発症した治療関連AML with inv(16)の1例
  橋口淳一; 松岡里湖; 小杉瑞葉; 杉田純一; 小野澤真弘; 藤本勝也; 豊嶋崇徳, 臨床血液, 57, 11, 2016年
• 血液悪性疾患における移植ソース別GRFSの解析JSHCT Working Group研究
  稲本賢弘; 木村文彦; 諫田淳也; 杉田純一; 池亀和博; 仲宗根秀樹; 南谷泰仁; 内田直之; 福田隆浩; 吉岡康介; 河野一郎; 小澤幸泰; 熱田由子; 熱田由子; 加藤剛二; 一戸辰夫; 井上雅美; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 38th, 2016年
• 胆嚢炎症状を契機に発症したTAFRO症候群
  関根隆博; 後藤秀樹; 日高大輔; 早瀬英子; 小杉瑞葉; 岡田耕平; 白鳥総一郎; 杉田純一; 小野澤真弘; 橋本大吾; 加畑馨; 藤本勝也; 遠藤知之; 近藤健; 豊嶋崇徳, 臨床血液, 57, 12, 2016年
• GVHD組織障害の新たな概念
  豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 38th, 2016年
• 成人CMLにおける移植前チロシンキナーゼ阻害剤使用と移植成績の解析~TKI時代での検討
  近藤健; 大橋一輝; 長村登紀子; 東條有伸; 内田直之; 中前博久; 矢野真吾; 福田隆浩; 橋本尚子; 橋本尚子; 鬼塚真仁; 高梨美乃子; 一戸辰夫; 熱田由子; 熱田由子; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 38th, 2016年
• 肺胞蛋白症を合併し致死的な経過を辿った骨髄異形成症候群の1例
  大東寛幸; 松川敏大; 金谷穣; 後藤秀樹; 橋本大吾; 加畑馨; 遠藤知之; 田中伸哉; 豊嶋崇徳, 臨床血液, 57, 11, 2016年
• オーバービュー
  豊嶋 崇徳, 臨床血液, 57, 3, 270, 270, 2016年
  一般社団法人 日本血液学会, 日本語
• 組織幹細胞システム保護による次世代型造血幹細胞移植
  豊嶋 崇徳, 上原記念生命科学財団研究報告集, 29, 1, 4, 2015年12月
  マウスの同種骨髄移植のモデルにおいて、移植前処置としての全身放射線照射やGVHDと、腸幹細胞傷害、Paneth細胞傷害がどのように発生するのか検討した。腸幹細胞は移植前処置である全身放射線照射による傷害のため一時的に消失するが、GVHDを発症しない場合はニッチであるPaneth細胞が保たれるため、腸幹細胞は回復可能であった。GVHDを発症した場合は、全身放射線照射による腸幹細胞傷害後にアロ反応性T細胞によるPaneth細胞傷害が加わり、ニッチの傷害により腸幹細胞は回復できず陰窩のアポトーシスをきたした。Paneth細胞が保たれるnon-GVHD群と比較して、著明なPaneth細胞の減少をきたしたGVHD群では腸内細菌叢の異常を認めた。造血幹細胞移植においてPaneth細胞は腸幹細胞の保護と腸内細菌叢の維持の二つの点で非常に大きな役割を担っていた。, (公財)上原記念生命科学財団, 日本語
• 血縁者間HLA半合致同種造血幹細胞移植後に発症したHHV-6脊髄炎
  宮下直洋; 遠藤知之; 重松明男; 高畑むつみ; 金谷穣; 竹村龍; 横畠絵美; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 37th, 2015年
• 当院においてドナーリンパ球輸注を施行した32症例の検討
  笠原耕平; 宮下直洋; 横畠絵美; 吉田美穂; 竹村龍; 小杉瑞葉; 金谷穣; 高橋正二郎; 高畑むつみ; 杉田純一; 重松明男; 小野澤真弘; 藤本勝也; 遠藤知之; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 37th, 2015年
• 同種造血幹細胞移植における移植後女性不妊の原因
  下地園子; 加藤光次; 橋本大吾; 辻極秀次; 宮本敏浩; 竹中克斗; 岩崎浩己; 赤司浩一; 豊嶋崇徳, 日本内科学会雑誌, 104, 2015年
• 好酸球性筋膜炎を合併した末梢性T細胞性リンパ腫の1例
  野村友希子; 西江渉; 坂田真由子; 宮内俊成; 中山ちひろ; 水野修; 西村真智子; 清水宏; 重松明男; 豊嶋崇徳; 佐藤英嗣, 日本皮膚科学会雑誌, 125, 3, 2015年
• 移植後シクロホスファミドを用いた血縁者間HLA半合致末梢血幹細胞移植の安全性と有効性の検討:JSCT-Haplo13
  杉田純一; 川島直実; 藤崎智明; 垣花和彦; 内田直之; 前田嘉信; 太田秀一; 松尾恵太郎; 宮本敏浩; 長藤宏司; 衛藤徹也; 赤司浩一; 谷口修一; 原田実根; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 37th, 2015年
• 臓器別がん腫レジメンの副作用と対策 急性骨髄性白血病 Ara-C療法
  小野澤真弘; 豊嶋崇徳, 日本臨床, 73, 2015年
• 骨髄異形成症候群における遺伝子異常
  近藤健; 豊嶋崇徳, 臨床血液, 56, 1, 2015年
• 細菌性肺炎に伴い肺浸潤をきたしたSLLの1例
  横畠絵美; 宮下直洋; 竹村龍; 金谷穣; 高畑むつみ; 重松明男; 遠藤知之; 豊嶋崇徳, 臨床血液, 56, 1, 2015年
• 治療反応性の異なる二種類のクローンを認めた急性骨髄性白血病
  笠原耕平; 吉田美穂; 小杉瑞葉; 高橋正二郎; 杉田純一; 小野澤真弘; 藤本勝也; 近藤健; 豊嶋崇徳, 臨床血液, 56, 1, 2015年
• 成人T細胞白血病リンパ腫に対する非血縁間同種骨髄移植における骨髄非破壊的処置療法の安全性を検討する多施設共同臨床試験
  崔日承; 衛藤徹也; 田野崎隆二; 下川元継; 高塚祥芝; 宇都宮與; 武本重毅; 田口潤; 福島卓也; 加藤光次; 豊嶋崇徳; 中前博久; 末廣陽子; 山中竹春; 岡村純; 鵜池直邦, 日本造血細胞移植学会総会プログラム・抄録集, 37th, 2015年
• 骨髄バンクドナーの複数回骨髄提供に関する検討:ドナーの負担と移植患者の生着率への影響
  折原勝己; 吾郷浩厚; 吾郷浩厚; 奥山美樹; 奥山美樹; 落合亮一; 落合亮一; 澤正史; 澤正史; 田野崎隆二; 田野崎隆二; 玉井佳子; 玉井佳子; 豊嶋崇徳; 豊嶋崇徳; 中尾康夫; 中尾康夫; 日野雅之; 日野雅之; 宮崎泰司; 宮崎泰司; 神田善伸; 金森平和; 金森平和, 日本造血細胞移植学会総会プログラム・抄録集, 37th, 2015年
• 血縁者間HLA半合致造血幹細胞移植(ハプロ移植)の可能性
  豊嶋崇徳, 日本輸血細胞治療学会誌, 61, 2, 2015年
• 移植後シクロホスファミドを用いたHLA半合致移植の現状と課題
  杉田純一; 小杉瑞葉; 豊嶋崇徳, 日本造血細胞移植学会雑誌(Web), 4, 1, 2015年
• 腹水貯留を認めた治療抵抗性の多発性骨髄腫
  笠原耕平; 高橋秀一郎; 吉田美穂; 小杉瑞葉; 高橋正二郎; 杉田純一; 小野澤真弘; 藤本勝也; 橋本大吾; 近藤健; 豊嶋崇徳, 臨床血液, 56, 6, 2015年
• 造血幹細胞移植における腸幹細胞,ニッチシステムと腸内細菌
  豊嶋崇徳, 無菌生物, 45, 1, 2015年
• 造血幹細胞移植時の抗がん剤併用療法における投与量および薬物曝露順序の最適化
  武隈洋; 田澤佑基; 臼窪一平; 高田一輝; 柴山良彦; 重松明男; 笠師久美子; 豊嶋崇徳; 井関健; 菅原満, 臨床薬理の進歩, 36, 2015年
• リンパ組織の生物学とリンパ腫の発症機序 自己免疫疾患とリンパ腫発症
  藤本勝也; 畑中佳奈子; 豊嶋崇徳; 松野吉宏, 日本臨床, 73, 2015年
• 初回ART導入におけるRaltegravirとDolutegravirの血液毒性への関与
  後藤秀樹; 後藤秀樹; 遠藤知之; 藤本勝也; 近藤健; 加畑馨; 橋本大吾; 小野澤真弘; 杉田純一; 松川敏大; 笠原耕平; 宮下直洋; 橋野聡; 佐藤典宏; 豊嶋崇徳, 日本エイズ学会誌, 17, 4, 2015年
• 本邦の新規HIV/AIDS診断症例における薬剤耐性HIVの動向
  岡崎玲子; 蜂谷敦子; 潟永博之; 渡邊大; 長島真美; 貞升健志; 近藤真規子; 南留美; 吉田繁; 小島洋子; 森治代; 内田和江; 椎野禎一郎; 加藤真吾; 豊嶋崇徳; 伊藤俊広; 猪狩英俊; 上田敦久; 石ケ坪良明; 古賀一郎; 太田康男; 山元泰之; 福武勝幸; 古賀道子; 西澤雅子; 林田庸総; 岡慎一; 松田昌和; 服部純子; 重見麗; 保坂真澄; 横幕能行; 中谷安宏; 田邊嘉也; 白阪琢磨; 藤井輝久; 高田昇; 高田清式; 山本政弘; 松下修三, 日本エイズ学会誌, 17, 4, 2015年
• 2015年度HIV薬剤耐性検査外部精度評価の報告
  吉田繁; 蜂谷敦子; 松田昌和; 橋本修; 齊藤浩一; 岡田清美; 伊部史朗; 和山行正; 椎野禎一郎; 加藤真吾; 佐藤かおり; 豊嶋崇徳; 杉浦亙; 杉浦亙; 吉村和久, 日本エイズ学会誌, 17, 4, 2015年
• Cardio-ankle vascular index(CAVI)を用いたHIV感染者の動脈硬化の評価とリスク因子の検討
  遠藤知之; 宮下直洋; 宮下直洋; 笠原耕平; 笠原耕平; 渡部恵子; 武内阿味; 松川敏大; 金谷穣; 小杉瑞葉; 松岡里湖; 後藤秀樹; 杉田純一; 小野澤真弘; 橋本大吾; 加畑馨; 藤本勝也; 近藤健; 橋野聡; 豊嶋崇徳, 日本エイズ学会誌, 17, 4, 2015年
• 北海道におけるHIV陽性者への福祉サービスネットワーク構築
  富田健一; 白坂るみ; 遠藤知之; 渡部恵子; 渡部恵子; 武内阿味; 武内阿味; 坂本玲子; 坂本玲子; センテノ(田村)恵子; センテノ(田村)恵子; 石田陽子; 豊嶋崇徳, 日本エイズ学会誌, 17, 4, 2015年
• ヒトゲノムにおける欠失多型の解析
  小野澤真弘; 豊嶋崇徳, 日本人類遺伝学会大会プログラム・抄録集, 60th, 2015年
• 自己免疫疾患とリンパ増殖性疾患
  藤本勝也; 豊嶋崇徳, 臨床血液, 56, 12, 2015年
• HIV感染症の医療体制の整備に関する研究 北海道ブロックのHIV医療体制の整備に関する研究
  豊嶋崇徳, HIV感染症の医療体制の整備に関する研究 平成26年度 総括・分担研究報告書, 2015年
• 特発性造血障害に関する調査研究 特発性造血障害に対する造血幹細胞移植
  豊嶋崇徳, 特発性造血障害に関する調査研究 平成26年度 総括・分担研究報告書, 2015年
• 成人T細胞白血病に対する標準治療としての同種造血幹細胞移植法の確立およびゲノム解析に基づく治療法の最適化に関する研究 成人T細胞性白血病に対する同種造血幹細胞移植後の予後予測に関する研究
  豊嶋崇徳, 成人T細胞白血病に対する標準治療としての同種造血幹細胞移植法の確立およびゲノム解析に基づく治療法の最適化に関する研究 平成26年度 総括・分担研究報告書, 2015年
• 「新たな造血幹細胞移植法の開発:生着効率の向上を目指して」に関する研究
  豊嶋崇徳, 新たな造血幹細胞移植法の開発:生着効率の向上を目指して 平成26年度 総括・分担研究報告書, 2015年
• 初発の非胚中心B細胞様びまん性大細胞型B細胞性リンパ腫患者を対象としたブルトン型チロシンキナーゼ(BTK)阻害薬PCI-32765(ibrutinib)の国際共同第III相試験
  頼晋也; 豊嶋崇徳; 福原規子; 飛内賢正; 畠清彦; 下山達; 安藤潔; 内田俊樹; 永井宏和; 谷脇雅史; 柴山浩彦; 中前博久; 松村到; 石川隆之; 一戸辰夫; 加藤光次; 日高道弘, 日本リンパ網内系学会会誌, 55, 2015年
• 白血病・リンパ腫の治療:過去から未来へ
  豊嶋崇徳, 北海道医学雑誌, 90, 1, 2015年
• 非血縁者間同種末梢血幹細胞移植の今後の展開
  重松明男; 豊嶋崇徳, 医学のあゆみ, 253, 2, 2015年
• JAK阻害剤によるGVHDの制御
  豊嶋崇徳, 月刊血液内科, 70, 5, 2015年
• 抗HIV療法でコントロールされているHIV感染症患者のTリンパ球サブセットと免疫マーカー発現の検討
  藤本勝也; 小杉瑞葉; 小杉瑞葉; 金谷穣; 笠原耕平; 笠原耕平; 宮下直洋; 宮下直洋; 後藤秀樹; 後藤秀樹; 杉田純一; 小野澤真弘; 橋本大吾; 加畑馨; 加畑馨; 遠藤知之; 近藤健; 橋野聡; 豊嶋崇徳, 日本エイズ学会誌, 17, 4, 2015年
• 真菌感染によるGVHD発症のメカニズム
  橋本大吾; 瓜生英尚; 豊嶋崇徳, 月刊血液内科, 71, 6, 2015年
• 急性型成人T細胞性白血病における腹水中のモガムリズマブ濃度の検討
  小杉瑞葉; 江端浩; 橋口淳一; 松岡里湖; 杉田純一; 小野澤真弘; 藤本勝也; 豊嶋崇徳, 臨床血液, 56, 12, 2015年
• ATLに対するTax標的樹状細胞ワクチン療法:第I相臨床研究長期追跡結果
  末廣陽子; 末廣陽子; 飯野忠史; 長谷川温彦; 渡辺信和; 崔日承; 福田哲也; 田野崎隆二; 宇都宮與; 松岡雅雄; 豊嶋崇徳; 赤司浩一; 神奈木真理; 鵜池直邦; 岡村純, 日本HTLV-1学会学術集会, 2nd, 2015年
• 新薬展望2015 第III部 治療における最近の新薬の位置付け〈薬効別〉~新薬の広場~血液腫瘍治療薬
  藤本勝也; 豊嶋崇徳, 医薬ジャーナル, 51, 2015年
• 白血病・リンパ腫の治療:過去から未来へ
  豊嶋崇徳, 北海道医報, 1156, 2015年
• 腸内細菌叢がGVHDにもたらす影響
  早瀬英子; 豊嶋崇徳, Keynote R・A : rheumatic & autoimmune diseases, 3, 1, 24, 28, 2015年01月
• 当院におけるHIV 感染者のビタミンDの検討
  遠藤知之; 藤本勝也; 南昭子; 吉田美穂; 竹村龍; 渡部恵子; 坂本玲子; 武内阿味; 近藤健; 橋野聡; 清水力; 豊嶋崇徳, 日本エイズ学会誌, 17, 1, 30, 35, 2015年, ［査読有り］
  HIV感染者におけるビタミンDの充足率を把握し、骨密度低下と因果関係を評価した。方法は著者らの施設へ通院中のHIV患者118例(男性115例、女性3例、年齢24〜73歳、平均年齢43歳)を対象に、血清25水酸化ビタミンD[25(OH)D]を測定、そのうち100例でDXA法による骨塩量測定検査を行った。その結果、1)血清25(OH)Dの平均値は18.5±11.0ng/mlであり、ビタミンD不足(20〜29ng/dl)は24例(20.3%)、ビタミンD欠乏(20ng/dl以下)が79例(67.0%)にみられた。更にビタミンD高度欠乏(10ng/ml以下)は26例(22.0%)にみられ、ビタミンD正常(30ng/ml以上)は15例(12.7%)に過ぎなかった。2)100例におけるDXA法による骨塩定量測定では骨減少症は27例(27.0%)、骨粗鬆症は8例(8%)であった。3)このことからビタミンDの充足度と骨密度には有意な相関は認められなかったが、抗HIV療法を受けている症例では未治療の症例と比較して有意に骨密度が低下していた。4)多くのHIV患者でビタミンDが不足・欠乏していたが、骨密度低下の要因としてはビタミンD欠乏より抗HIV薬の影響が大きいと考えられた。以上より、HIV患者にビスホスフォネートを投与する際にはビタミンDの評価を行い、ビタミンDが低下・欠乏している症例に対するビタミンDの補充も必要と考えられた。, (一社)日本エイズ学会, 日本語

  
  ダウンロード
• チゲサイクリンとコリスチンの併用が奏功した多剤耐性アシネトバクター・バウマニによるカテーテル関連血流感染症の1例
  山田武宏; 白鳥聡一; 杉田純一; 藤本勝也; 豊嶋崇徳; 福元達也; 岩崎澄央; 秋沢宏治, 日本化学療法学会雑誌, 62, 4, 501, 505, 2014年07月, ［査読有り］
  (公社)日本化学療法学会, 日本語
• 臍帯血移植における移植片対宿主病(GVHD)
  高畑むつみ; 豊嶋崇徳, 医学のあゆみ, 249, 7, 587, 592, 2014年05月
• 造血幹細胞移植後GVHDと消化管傷害
  早瀬英子; 橋本大吾; 豊嶋崇徳, 最新医学, 69, 3, 503, 507, 2014年03月
• 移植後GVHDの分子病態と治療
  豊嶋 崇徳, 血液内科, 68, 3, 291, 297, 2014年03月
• 北海道内のHIV感染症患者におけるHBV・HCV重複感染の現状 -拠点病院・診療施設アンケート調査結果-
  藤本勝也; 遠藤知之; 吉田美穂; 竹村龍; 近藤健; 橋野聡; 須田剛生; 中馬誠; 後藤了一; センテノ田村恵子; 渡部恵子; 大野稔子; 石田禎夫; 大竹孝明; 宮城島拓人; 小林一; 堤豊; 三宅高義; 北川浩彦; 佐藤典宏; 豊嶋崇徳, 日本エイズ学会誌, 16, 1, 18, 27, 2014年02月, ［査読有り］
  北海道内のエイズ診療拠点病院と診療施設を対象として、HBVおよびHCV重複感染症に関するアンケート調査を実施し、その現状について分析した。アンケートの回収率は84%であった。HIV感染症患者総数は295名で、うちHBV重複感染例は22名(8%)、HCV重複感染例は34名(12%)で、すべて男性であった。HBV重複感染例では全例がテノフォビルまたはラミブジンを含む抗HIV療法を継続中で、86%が非活動性肝炎の状態を維持していた。HCV重複感染例では56%が抗HCV療法を施行され、うち32%が持続的ウイルス陰性化を達成していたが、41%が肝硬変に進行していた。重複感染例のうち71%は何らかの肝疾患以外の慢性合併症を有し、38%が2つ以上の合併症を認めた。HBV重複感染例に比べ、HCV重複感染例では高血圧の合併率が有意に高かった。以上の結果から、より有効で安全な抗HCV療法の導入、肝硬変例に対する肝移植を視野に入れた診療体制の整備、肝臓以外の慢性合併症の管理の重要性が示唆された。, (一社)日本エイズ学会, 日本語
• ビンクリスチンによる麻痺性イレウスに引き続きposterior reversible encephalopathy syndromeを発症したT細胞性リンパ芽球性リンパ腫
  早瀬英子; 杉田純一; 藤本勝也; 江端浩; 山川知宏; 吉田美穂; 竹村龍; 岩崎純子; 高橋正二郎; 白鳥聡一; 近藤健; 田中淳司; 豊嶋崇徳, 臨床血液, 55, 2, 249, 53, 2014年02月, ［国内誌］
  A 22-year-old woman presented with high fever, chest tightness and cough in January 20XX. Since CT scans revealed an anterior mediastinal mass, percutaneous needle biopsies of the mass were performed and she was diagnosed with T-cell lymphoblastic lymphoma (T-LBL). After the immunophenotype of lymphocytes in her pleural effusion had been identified, she received CHOP therapy because her dyspnea worsened, and induction therapy for acute lymphoblastic leukemia was subsequently performed after confirmation of her diagnosis as T-LBL. During this induction therapy, she developed paralytic ileus. One week thereafter, she suddenly exhibited visual disturbance, headache and nausea. Her cerebrospinal fluid was normal. Magnetic resonance imaging showed symmetrical high signal intensities on T2-weighted and fluid-attenuated inversion recovery images, and low signal intensities on T1-weighted images in the cortical and subcortical white matter of the posterior parietal and occipital lobes. Based on these findings, she was diagnosed as having posterior reversible encephalopathy syndrome (PRES). During chemotherapy for hematologic malignancies, some patients with PRES reportedly develop paralytic ileus or tumor lysis syndrome. PRES should be considered in patients with neurological abnormalities following such complications during chemotherapy., 日本語
• Graft-versus-host disease制御
  杉田純一; 豊嶋崇徳, 臨床血液, 55, 2, 170, 176, 2014年02月
• 造血幹細胞 6.急性GVHDの分子病態とバイオマーカー
  豊嶋崇徳, Annual Review 血液, 2014, 2014年
• Blastic Plasmacytoid Dendritic Cell Neoplasm(BPCDN)に対する造血幹細胞移植(SCT)
  西尾充史; 西尾充史; 藤本勝也; 遠藤知之; 白鳥聡一; 杉田純一; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014年
• 成人同種造血幹細胞移植後の出血性膀胱炎~単施設での後方視的解析結果~
  藤本勝也; 江端浩; 小笠原励起; 佐賀智之; 山川知宏; 岩崎純子; 高橋正二郎; 岡田耕平; 白鳥聡一; 井端淳; 杉田純一; 重松明男; 高畑むつみ; 橋本大吾; 遠藤知之; 近藤健; 橋野聡; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014年
• 移植適応初発多発性骨髄腫に対し,初回治療としてmodified CyBorDを施行した際の造血幹細胞動員不良症例の検討
  山本聡; 坂井俊哉; 山口圭介; 笠原郁美; 向井正也; 重松明男; 杉田純一; 岡田耕平; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014年
• Gemtuzumab ozogamicinを併用した強化前処置にて血縁者間末梢血幹細胞移植を施行した非寛解MLL-AF9陽性急性骨髄性白血病
  狩野皓平; 江端浩; 山川知宏; 早瀬英子; 高橋正二郎; 岩崎純子; 白鳥聡一; 杉田純一; 藤本勝也; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014年
• 造血器悪性腫瘍の移植後再発に対する再移植の成績
  小笠原励起; 遠藤知之; 重松明男; 高畑むつみ; 井端淳; 岡田耕平; 佐賀智之; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014年
• 当科におけるHCV/HIV重複感染症の現状と抗HCV療法
  荘拓也; 中馬誠; 常松聖司; 佐藤史幸; 佃曜子; 寺下勝巳; 中井正人; 堀本啓大; 須田剛生; 夏井坂光輝; 藤本勝也; 遠藤知之; 豊嶋崇徳; 坂本直哉, 肝臓, 55, Supplement 1, 2014年
• 顆粒球採取におけるSpectra Optiaの採取効率ならびにドナーへの影響
  岡田耕平; 杉田純一; 伊藤誠; 米岡麻記; 櫻澤貴代; 渡邊千秋; 橋本大吾; 重松明男; 重松明男; 佐藤典宏; 清水力; 豊嶋崇徳, 日本輸血細胞治療学会誌, 60, 2, 2014年
• 末梢血幹細胞採取におけるCOBE SpectraとSpectra Optiaの比較検討
  伊藤誠; 櫻澤貴代; 米岡麻記; 渡邊千秋; 岡田耕平; 杉田純一; 重松明男; 重松明男; 佐藤典宏; 豊嶋崇徳; 清水力, 日本輸血細胞治療学会誌, 60, 2, 2014年
• 臍帯血移植後にNeurolymphomatosisとして再発したDouble hit lymphoma
  宮下直洋; 岡田耕平; 佐賀智之; 小笠原励起; 井端淳; 高畑むつみ; 重松明男; 遠藤知之; 豊嶋崇徳, 臨床血液, 55, 7, 2014年
• 空腸原発CD30陽性末梢性T細胞リンパ腫非特定型(PTCL,NOS)の1例
  高橋正二郎; 江端浩; 山川知宏; 岩崎純子; 白鳥聡一; 杉田純一; 藤本勝也; 近藤健; 豊嶋崇徳; 畑中佳奈子; 松野吉宏, 臨床血液, 55, 7, 2014年
• 消化管GVHDに対する経口ベクロメタゾン製剤の有用性の検討
  久保田康生; 鳴海克哉; 笠師久美子; 山田武宏; 岡田耕平; 重松明男; 豊嶋崇徳; 井関健; 井関健, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014年
• 後天性免疫不全症の患者に発症し,進行性多巣性白質脳症との鑑別に苦慮した中枢神経原発悪性リンパ腫の1例
  山川知宏; 藤本勝也; 江端浩; 岩崎純子; 高橋正二郎; 白鳥聡一; 杉田純一; 近藤健; 西尾充史; 豊嶋崇徳, 日本内科学会雑誌, 103, 10, 2014年
• 菌状息肉症に対する同種造血幹細胞移植の後方視的解析-更なる移植成績の向上に向けて-
  白鳥聡一; 山川知宏; 江端浩; 小笠原励起; 佐賀智之; 高橋正二郎; 岩崎純子; 岡田耕平; 井端淳; 杉田純一; 高畑むつみ; 重松明男; 橋本大吾; 藤本勝也; 遠藤知之; 近藤健; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014年
• 造血幹細胞移植の過去から未来へ
  豊嶋崇徳, 臨床血液, 55, 7, 2014年
• 「身近な話題・世界の話題」(126)HLA半合致移植
  杉田純一; 豊嶋崇徳, 血液フロンティア, 24, 7, 2014年
• 造血幹細胞移植の最近の進歩
  豊嶋崇徳, 日本臨床腫瘍学会学術集会(CD-ROM), 12th, 2014年
• 移植後アメーバ感染症をきたした骨髄異形成症候群
  佐々木瞳; 佐賀智之; 小笠原励起; 岡田耕平; 井端淳; 高畑むつみ; 重松明男; 遠藤知之; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014年
• 同種造血幹細胞移植後の赤血球造血回復に対するABO血液型不適合の影響
  岡田耕平; 工藤明日香; 重松明男; 重松明男; 清水力; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014年
• 同種造血細胞移植後のCMV網膜炎~臨床像と治療~
  高畑むつみ; 小笠原励起; 佐賀智之; 山川知宏; 江端浩; 岩崎純子; 高橋正二郎; 岡田耕平; 白鳥聡一; 井端淳; 杉田純一; 重松明男; 藤本勝也; 遠藤知之; 近藤健; 橋野聡; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014年
• 北海道大学病院におけるHIV/AIDS電話相談の現状
  武内阿味; 武内阿味; 渡部恵子; 坂本玲子; 坂本玲子; センテノ田村恵子; センテノ田村恵子; 遠藤知之; 成田月子; 大野稔子; 富田健一; 大川満生; 江端あい; 豊嶋崇徳; 岡林靖子, 日本エイズ学会誌, 16, 4, 2014年
• ヒトゲノムにおける鋳型配列挿入多型(TSIPs)の解析
  小野澤真弘; 小野澤真弘; 豊嶋崇徳; アプラン ピーター, 日本遺伝子診療学会大会プログラム・抄録集, 21st, 2014年
• 外部精度評価をもとにしたHIV薬剤耐性検査推奨法の考案
  吉田繁; 熊谷菜海; 松田昌和; 橋本修; 岡田清美; 伊部史朗; 和山行正; 西澤雅子; 佐藤かおり; 藤澤真一; 遠藤知之; 藤本勝也; 豊嶋崇徳; 加藤真吾; 杉浦亙, 日本エイズ学会誌, 16, 4, 2014年
• 国内で流行するHIVとその薬剤耐性株の動向把握に関する研究 北海道ブロックにおける薬剤耐性HIVの動向調査研究
  豊嶋崇徳; 吉田繁; 佐藤かおり, 国内で流行するHIVとその薬剤耐性株の動向把握に関する研究 平成25年度総括・分担研究報告書, 2014年
• 「新たな造血幹細胞移植法の開発:生着効率の向上を目指して」に関する研究
  豊嶋崇徳, 新たな造血幹細胞移植法の開発:生着効率の向上を目指して 平成25年度 総括・分担研究報告書, 2014年
• 難治性造血器腫瘍に対する造血幹細胞移植の治療成績向上を目指した未承認・適応外薬のエビデンス確立に関する研究 慢性GVHDに関する基礎的研究
  豊嶋崇徳, 難治性造血器腫瘍に対する造血幹細胞移植の治療成績向上を目指した未承認・適応外薬のエビデンス確立に関する研究 平成25年度 総括・分担研究報告書, 2014年
• HIV感染症の医療体制の整備に関する研究 北海道ブロックのHIV感染症の医療体制の整備に関する研究(北海道ブロック)
  豊嶋崇徳, HIV感染症の医療体制の整備に関する研究 平成25年度 総括・分担研究報告書, 2014年
• 当院におけるHIV感染者の慢性腎臓病の有病率および腎機能の経時的変化の検討
  遠藤知之; 吉田美穂; 竹村龍; 吉田美穂; 竹村龍; 渡部恵子; 坂本玲子; 武内阿味; 杉田純一; 重松明男; 小野澤真弘; 藤本勝也; 近藤健; 橋野聡; 豊嶋崇徳, 日本エイズ学会誌, 16, 4, 2014年
• 自己免疫性疾患患者に発生した悪性リンパ腫を含むリンパ増殖性疾患に関する臨床病理学的解析
  畑中佳奈子; 藤本勝也; 辻嶐裕; 笠原郁美; 山本聡; 中田匡信; 高桑康成; 西尾充史; 小山田ゆみ子; 長谷山美仁; 鈴木宏明; 米積昌克; 野口寛子; 酒井基; 西原広史; 盛暁生; 豊嶋崇徳; 松野吉宏, 日本リンパ網内系学会会誌, 54, 2014年
• 自己免疫性疾患患者に発生した悪性リンパ腫を含むリンパ増殖性疾患に関する臨床病理学的解析
  畑中佳奈子; 藤本勝也; 辻嶐裕; 笠原郁美; 山本聡; 中田匡信; 高桑康成; 西尾充史; 小山田ゆみ子; 長谷山美仁; 鈴木宏明; 米積昌克; 野口寛子; 酒井基; 西原広史; 盛暁生; 豊嶋崇徳; 松野吉宏, 日本リンパ網内系学会会誌, 54, 2014年
• Gemtuzumab ozogamicinを使用した造血幹細胞移植症例の検討
  江端浩; 小笠原励起; 佐賀智之; 山川知宏; 高橋正二郎; 岩崎純子; 岡田耕平; 白鳥聡一; 井端淳; 杉田純一; 重松明男; 高畑むつみ; 藤本勝也; 遠藤知之; 近藤健; 橋野聡; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014年
• 造血幹細胞移植後VOD/SOSに対して遺伝子組換えトロンボモジュリンα製剤を使用した同種移植14症例の肝腺維化マーカーの検討
  安本篤史; 安本篤史; 杉田純一; 白鳥聡一; 重松明男; 橋本大吾; 藤本勝也; 遠藤知之; 近藤健; 橋野聡; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014年
• 同種造血幹細胞移植症例に対する予防的グロブリン投与の役割
  井端淳; 遠藤知之; 重松明男; 高畑むつみ; 岡田耕平; 小笠原励起; 佐賀智之; 橋野聡; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014年
• 当科における造血幹細胞移植後心不全の検討
  岩崎純子; 榊原守; 江端浩; 小笠原励起; 佐賀智之; 山川知宏; 高橋正二郎; 岡田耕平; 白鳥聡一; 井端淳; 杉田純一; 重松明男; 高畑むつみ; 橋本大吾; 藤本勝也; 遠藤知之; 近藤健; 筒井裕之; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 36th, 2014年
• 高用量メトトレキサート(MTX)投与時の血中MTX濃度に及ぼす胃酸分泌抑制剤の影響
  鳴海克哉; 樋口一世; 難波正志; 山田順子; 笠師久美子; 山田武宏; 豊嶋崇徳; 井関健; 井関健, 日本医療薬学会年会講演要旨集, 24th, 2014年
• 成人難治性造血器腫瘍に対する同種造血幹細胞移植療法の治療成績向上につながる基盤整備のための多施設共同研究
  福田隆浩; 今村雅寛; 岡本真一郎; 谷口修一; 豊嶋崇徳; 山口博樹; 明田幸宏; 神田善伸; 熱田由子; 宮村耕一; 大石和徳, 国立がん研究センター研究開発費総合研究報告書(Web), 2013, 23-A-28, 2014年
• 成人T細胞性白血病に対する樹状細胞ワクチン療法
  飯野忠史; 飯野忠史; 末廣陽子; 長谷川温彦; 渡辺信和; 田野崎隆二; 宇都宮與; 松岡雅雄; 豊嶋崇徳; 赤司浩一; 赤司浩一; 鵜池直邦; 岡村純; 神奈木真理, 日本がん免疫学会総会プログラム・抄録集, 18th, 2014年
• 消化管GVHD（graft-versus-host disease）に対する経口ベクロメタゾン製剤の有用性の検討
  久保田 康生; 鳴海 克哉; 笠師 久美子; 山田 武宏; 岡田 耕平; 重松 明男; 豊嶋 崇徳; 井関 健, 医療薬学, 40, 5, 291, 296, 2014年
  Graft-versus-host diseases (GVHD) are the main complications after stem cell transplantations. The use of systemic steroids remains the standard for first-line treatment of such complications despite the severe adverse side effects such as the risk of opportunistic infections, glucose intolerance, and bone demineralization. Many of the adverse side effects associated with systemic steroids can be avoided through the use of beclomethasone dipropionate (BDP) as BDP is promptly metabolized in the liver after absorption from the intestines. The BDP is an activated form of steroid that exerts a strong anti-inflammatory action and may be expected to have an effect on gastrointestinal GVHD (GI-GVHD).
  This retrospective study verified such an effect for 29 cases diagnosed with alimentary GI-GVHD from June 2008 to July 2013 in order to clarify an effective case. The BDP was administered to 21 patients with acute GVHD and 8 patients with chronic GVHD. The GI-GVHD improved in 20 patients and the condition worsened with 9 patients. The BDP was also effective with acute and chronic GI-GVHD. With lighter conditions of the disease at the time of the BDP internal administration, it was more effective. In 15 cases where systemic steroids were administered there were no new infections. It may be concluded that BDP is an effective medication for GI-GVHD when administered at an early stage., 一般社団法人日本医療薬学会, 日本語
• 抗癌剤治療をしている患者さんへのインフルエンザワクチン接種について教えて下さい
  藤本勝也; 豊嶋崇徳, インフルエンザ, 14, 3, 32, 2013年10月
• 基礎・臨床医学融合の最前線としての造血幹細胞移植
  豊嶋 崇徳, 細胞, 45, 11, 2, 4, 2013年10月
• 血球トラフィッキングとGVHD
  橋本大吾; 豊嶋崇徳, 血液フロンティア, 23, 10, 59, 70, 2013年10月
• BMT Tandem meetingに参加して
  豊嶋 崇徳, 血液フロンティア, 23, 6, 822, 824, 2013年06月
  日本語
• HIV感染者における梅毒血清反応と抗カルジオリピン抗体に関する検討
  遠藤知之; 藤本勝也; 吉田美穂; 竹村龍; 杉田純一; 重松明男; 近藤健; 橋野聡; 田中淳司; 佐藤典宏; 豊嶋崇徳, 日本エイズ学会誌, 15, 2, 113, 118, 2013年05月, ［査読有り］
  血清学的に梅毒と診断されたHIV感染者19例(全例男性、平均年齢41歳)を対象に、梅毒治療後の梅毒血性反応(RPR)の推移と抗カルジオリピン抗体(aCL)の有無、HIV-RNA量との関連について後方視的に検討した。その際、RPRが1.0R.U.以上、TPLAが1.0C.O.I以上の場合を血性梅毒反応陽性とし、治療開始後6ヵ月でRPR値が4分の1以下にならなかった場合を血清学的効果不十分とした。1)感染経路は同性間性行為が16例、異性間性行為が3例、AIDS発症者が4例、未発症者が15例であった。2)梅毒治療後は全症例で消失し、RPRの血清学的効果が不十分の症例は19例中10例であった。3)梅毒治療後に血清学的効果が得られた群と不十分であった群を比較したところ、梅毒の効果判定時のHIV-RNAが測定感度以上で測定されていた症例で、梅毒の血清学的効果が不十分と評価された症例と比べ有意に多かった。4)血清学的効果不十分の群では10例中6例がaCL陽性で有意差が認められた。更に梅毒治療前にaCLが陽性であった3例は治療後もRPRが持続陽性であったが、aCLが陰性であった2例は梅毒治療後にRPRが速やかに陰性化していた。5)HIV-RNA量とaCLの関連についてはHIV-RNA量が40コピー未満に十分抑制されていた症例が11例、40コピー以上が8例であった。また、HIV-RNAが測定感度以下でaCLが陰性であった10例中8例はRPRが速やかに陰性化していたが、一方、HIV-RNAの抑制が不十分でaCLが陽性であった5例は全例RPRが持続的に高値となっていた。6)梅毒治療前後のRPRの変化とaCLおよびHIV-RNA量について検討したところ、aCL陽性の群およびHIV-RNAが40copies/mL以上の群で有意にRPR低下率が低くなっていた。, (一社)日本エイズ学会, 日本語
• ～なぜ、今GVHDなのか～
  豊嶋 崇徳, 血液フロンティア, 23, 5, 17, 19, 2013年05月
  日本語
• 骨髄抑制時のエマージェンシー
  白鳥聡一; 豊嶋崇徳, 成人病と生活習慣病, 43, 4, 533, 538, 2013年04月
  日本語
• 急性および慢性GVHDの診断とマネジメント
  豊嶋 崇徳, 血液内科, 66, 3, 392, 398, 2013年03月
  日本語
• 造血幹細胞移植の話題 ASH発表演題より
  豊嶋 崇徳; 高見 昭良; 谷口 修一; 村田 誠, Therapeutic Research, 34, 3, 259, 266, 2013年03月, ［査読有り］
  ライフサイエンス出版(株), 日本語
• GVHD予防の最前線
  杉田純一; 豊嶋崇徳, 臨床血液, 54, 2, 156, 166, 2013年02月
  The Japanese Society of Hematology, 日本語
• 多発性骨髄腫患者の末梢血幹細胞採取に対するbortezomibを含む導入療法の影響
  牟田毅; 宮本敏浩; 藤崎智明; 大野裕樹; 上村智彦; 平安山知子; 加藤光次; 竹中克斗; 岩崎浩巳; 衛藤徹也; 高松泰; 豊嶋崇徳; 赤司浩一, 臨床血液, 54, 1, 109, 116, 2013年01月, ［査読有り］
  (一社)日本血液学会-東京事務局, 日本語
• GVHDの病態形成にかかわる新たなT細胞活性化機構の解明
  豊嶋崇徳, 血液医学研究年報, 5, 2013年
• 同種骨髄移植後の慢性GVHDに対する免疫抑制療法中に合併したEBV-associated smooth muscle tumorの1成人例
  早瀬英子; 吉田美穂; 竹村龍; 岩崎純子; 白鳥聡一; 杉田純一; 藤本勝也; 近藤健; 田中淳司; 豊嶋崇徳; 今村雅寛; 三橋智子, 日本造血細胞移植学会総会プログラム・抄録集, 35th, 2013年
• 同種移植後再発に対してAzacitidine併用ドナーリンパ球輸注を行い,非血縁者間同種骨髄移植を実施した急性骨髄性白血病
  高嶋秀一郎; 加藤光次; 林正康; 浦田真吾; 菊繁吉謙; 牟田毅; 竹中克斗; 岩崎浩己; 宮本敏浩; 豊嶋崇徳; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 35th, 2013年
• 献血不足とPatient Blood Management
  豊嶋崇徳, 日本輸血細胞治療学会誌, 59, 2, 2013年
• 血液型が変わる!造血幹細胞移植と輸血
  豊嶋崇徳, 日本輸血細胞治療学会誌, 59, 2, 2013年
• 急性GVHD治療の最前線
  豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 35th, 2013年
• 寒冷凝集素症を合併したリンパ形質細胞性腫瘍患者に対する血漿交換療法を安全に行う工夫
  島隆宏; 島隆宏; 岩崎浩己; 松尾弥生; 平安山知子; 宮本敏浩; 青木香苗; 山口恭子; 池松陽子; 江頭貞臣; 豊嶋崇徳; 赤司浩一; 赤司浩一, 日本輸血細胞治療学会誌, 59, 2, 2013年
• 新規薬剤が濾胞性リンパ腫の同種造血幹細胞移植に与える影響
  湯田淳一朗; 加藤光次; 高嶋秀一郎; 河野健太郎; 菊繁吉謙; 山崎聡; 牟田毅; 竹中克斗; 岩崎浩己; 宮本敏浩; 豊嶋崇徳; 赤司浩一; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 35th, 2013年
• 北海道大学病院において非血縁者間末梢血幹細胞採取を施行した3症例の検討
  重松明男; 重松明男; 渡邊千秋; 米岡麻記; 杉田純一; 伊藤誠; 櫻澤貴代; 石岡聡子; 澁谷斉; 佐藤典弘; 豊嶋崇徳; 清水力, 日本輸血細胞治療学会誌, 59, 2, 2013年
• 移植後早期再発ATLLに対する通常量抗CCR4抗体の使用経験
  陳之内文昭; 河野健太郎; 加藤光次; 瓜生英尚; 高嶋秀一郎; 山崎聡; 牟田毅; 竹中克斗; 岩崎浩己; 宮本敏浩; 豊嶋崇徳; 赤司浩一; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 35th, 2013年
• BKVサブタイプ3型が同種造血幹細胞移植後出血性膀胱炎の発症リスクである:福岡骨髄移植グループ(FBMTG)の検討
  加藤光次; 宮本敏浩; 江藤義隆; 米本孝二; 吉田周郎; 斉藤統之; 平安山英穂; 伊藤能清; 高嶋秀一郎; 菊繁吉謙; 牟田毅; 竹中克斗; 岩崎浩己; 上村智彦; 衛藤徹也; 豊嶋崇徳; 下野信行; 林純; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 35th, 2013年
• ABO不適合腎移植患者に対する術前血漿交換療法
  平安山知子; 岩崎浩己; 松尾弥生; 島隆宏; 豊嶋崇徳; 赤司浩一, 日本輸血細胞治療学会誌, 59, 2, 2013年
• 北海道における成人T細胞性白血病/リンパ腫に対する全同種造血幹細胞移植成績
  重松明男; 重松明男; 田中淳司; 小林直樹; 安井寛; 進藤基博; 柿木康孝; 幸田久平; 井山諭; 黒田裕行; 堤豊; 橋野聡; 今村雅寛; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 35th, 2013年
• Patient Blood Management
  豊嶋崇徳, 血液事業, 36, 2, 2013年
• 当院におけるHIV感染者のビタミンDの検討
  遠藤知之; 藤本勝也; 南昭子; 吉田美穂; 吉田美穂; 竹村龍; 竹村龍; 渡部恵子; 坂本玲子; 武内阿味; 杉田純一; 重松明男; 重松明男; 近藤健; 橋野聡; 清水力; 豊嶋崇徳, 日本エイズ学会誌, 15, 4, 2013年
• 北海道における「HIV/AIDS出張研修」の効果の検討-研修前後のアンケート調査結果から
  渡辺恵子; センテノ田村恵子; センテノ田村恵子; 遠藤知之; 坂本玲子; 坂本玲子; 江端あい; 藤本勝也; 富田健一; 植田孝介; 武内阿味; 武内阿味; 大川満生; 成田月子; 大野稔子; 原田幸子; 豊嶋崇徳; 岡林靖子, 日本エイズ学会誌, 15, 4, 2013年
• マイクロRNA126*の高発現は急性骨髄性白血病の予後不良因子である
  柴山良彦; 近藤健; 藤澤真一; 君家裕紀; 笠師久美子; 山田武宏; 豊嶋崇徳; 井関健; 井関健, 臨床薬理, 44, Supplement, 2013年
• 成人T細胞性白血病(ATL)の根治を目指した細胞療法の確立およびそのHTLV-1抑制メカニズムの解明に関する研究 同種造血幹細胞移植後の抗白血病効果を促進する試み
  豊嶋崇徳; 豊嶋崇徳, 成人T細胞性白血病(ATL)の根治を目指した細胞療法の確立およびそのHTLV-1抑制メカニズムの解明に関する研究 平成24年度 総括・分担研究報告書, 2013年
• 成人T細胞性白血病(ATL)の根治を目指した細胞療法の確立およびそのHTLV-1抑制メカニズムの解明に関する研究 ATLに対する同種造血幹細胞移植療法の成績向上に関する研究
  豊嶋崇徳; 田中淳司; 小林直樹; 今村雅寛; 重松明男, 成人T細胞性白血病(ATL)の根治を目指した細胞療法の確立およびそのHTLV-1抑制メカニズムの解明に関する研究 平成24年度 総括・分担研究報告書, 2013年
• EBウイルス感染症-その多様な病態 EBウイルスと血球貪食症候群
  藤本勝也; 豊嶋崇徳, 成人病と生活習慣病, 43, 9, 2013年
• 造血幹細胞移植の有効性と安全性向上のための薬剤のエビデンスの確立に関する研究 慢性GVHDに関する基礎的研究
  豊嶋崇徳, 造血幹細胞移植の有効性と安全性向上のための薬剤のエビデンスの確立に関する研究 平成24年度 総括・分担研究報告書, 2013年
• びまん性大細胞型リンパ腫(DLBCL)の初発時リンパ球減少や単球増加は初回寛解期の自家移植により予後不良因子とはならない(第二報)
  西尾充史; 西尾充史; 山本聡; 遠藤知之; 藤本勝也; 杉田純一; 重松明男; 近藤健; 坂井俊哉; 田中淳司; 橋野聡; 今村雅寛; 今村雅寛; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 35th, 2013年
• 当院における同種末梢血幹細胞採取の経験
  杉田純一; 早瀬英子; 岩崎純子; 岡田耕平; 白鳥聡一; 安本篤史; 井端淳; 重松明男; 藤本勝也; 遠藤知之; 近藤健; 橋野聡; 田中淳司; 佐藤典宏; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 35th, 2013年
• 造血幹細胞移植後の腸内フローラの解析
  豊嶋崇徳, 無菌生物, 43, 1, 2013年
• 長期凍結保存された末梢血幹細胞採取検体の細胞機能解析
  島隆宏; 島隆宏; 岩崎浩己; 松尾弥生; 平安山知子; 宮本敏浩; 豊嶋崇徳; 赤司浩一; 赤司浩一, 日本輸血細胞治療学会誌, 59, 2, 2013年
• 当院でのAML,MDS同種造血幹細胞移植症例における移植前後のWT-1推移
  井端淳; 井端淳; 井端淳; 遠藤知之; 重松明男; 高畑むつみ; 安本篤史; 岡田耕平; 大庭幸治; 佐久嶋研; 西村千佳子; 佐藤典宏; 橋野聡; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 35th, 2013年
• Maraviroc追加投与を行ったimmunological non-responder症例におけるTリンパ球の免疫学的変化の検討
  藤本勝也; 吉田美穂; 竹村龍; 白鳥聡一; 杉田純一; 重松明男; 橋本大吾; 遠藤知之; 近藤健; 橋野聡; 豊嶋崇徳, 日本エイズ学会誌, 15, 4, 2013年
• 高レベルのドナーHLA特異抗体存在下でのHLA不一致非血縁者間骨髄移植における生着不全の予防
  白鳥聡一; 早瀬英子; 岩崎純子; 杉田純一; 伊藤誠; 重松明男; 重松明男; 藤本勝也; 近藤健; 清水力; 田中淳司; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 35th, 2013年
• 成人T細胞白血病/リンパ腫細胞は正常上皮細胞との接着によってがん幹細胞様の特性を獲得する
  宮武由甲子; OLIVEIRA Andre L. A.; 外丸詩野; 豊嶋崇徳; HALL William W.; 笠原正典, ATLシンポジウム/HTLV-1国際シンポジウム/HTLV-1研究会プログラム・抄録集, 2nd-3rd-6th, 2013年
• 造血幹細胞移植後の腸内環境の変化とGVHD・感染症との関連
  豊嶋崇徳, ヤクルト・バイオサイエンス研究財団年報, 21, 2013年
• 成人T細胞白血病/リンパ腫(ATLL)の病態における正常上皮細胞の役割
  宮武由甲子; 宮武由甲子; OLIVEIRA Andre L.A.; JARBOUI Mohamed Ali; 太田秀一; 外丸詩野; 豊嶋崇徳; HALL William W.; 笠原正典, 日本病理学会会誌, 102, 1, 2013年
• 安全な血液製剤の供給のために
  豊嶋 崇徳, 血液製剤headline, 9, 3, 2013年
  日本語
• 個別化医療―臨床試験におけるバイオーマーカーと標準療法の導入
  豊嶋 崇徳, Trends in Hematological Malignancies, 5, 2, 50, 53, 2013年
  日本語
• 左副腎原発メトトレキサート関連悪性リンパ腫の一例
  亀田啓; 中垣整; 永井聡; 近藤琢磨; 三橋智子; 松野吉宏; 安部崇重; 篠原信雄; 野々村克也; 白鳥聡一; 豊嶋崇徳; 三好秀明; 清水力; 清水力; 渥美達也, 日本内分泌学会雑誌, 88, 3, 1034, 2012年12月20日
  日本語
• 同種抗原による移植片対白血病効果減弱のメカニズム
  朝倉 昇司; 橋本 大吾; 高嶋 秀一郎; 杉山 暖子; 前田 嘉信; 赤司 浩一; 谷本 光音; 豊嶋 崇徳, 岡山医学会雑誌, 124, 1, 5, 8, 2012年04月
  岡山医学会, 日本語
• 特発性血小板減少性紫斑病におけるセファランチン大量療法の有用性 -後方視的多施設共同研究-
  高畑むつみ; 橋野聡; 藤本勝也; 遠藤知之; 小林直樹; 黒澤光俊; 岩崎博; 三宅高義; 幸田久平; 前川勲; 笹川裕; 堤豊; 宮城島拓人; 田中淳司; 今村雅寛; 豊嶋崇徳, 臨床血液, 53, 12, 1983, 1990, 2012年, ［査読有り］
  (一社)日本血液学会-東京事務局, 日本語
• 当施設における同種造血幹細胞移植後の出血性膀胱炎
  宮本敏浩; 森康雄; 加藤光次; 竹中克斗; 豊嶋崇徳; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 2012年
• 急性GVHDについて
  豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 2012年
• 非血縁者間同種骨髄移植後早期に発症した伝染性単核球症様PTLDの一例
  林正康; 菊繁吉謙; 加藤光次; 湯田淳一朗; 高嶋秀一郎; 浦田真吾; 谷本一樹; 竹中克斗; 岩崎浩己; 宮本敏浩; 豊嶋崇徳; 赤司浩一; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 2012年
• 同種造血幹細胞移植におけるアプレピタントの制吐効果と安全性の検討
  加藤光次; 内田まやこ; 池末裕明; 竹中克斗; 岩崎浩己; 宮本敏浩; 豊嶋崇徳; 大石了三; 赤司浩一, 日本内科学会雑誌, 101, 2012年
• 標準治療抵抗性急性GVHD患者に対する第三者骨髄由来間葉系幹細胞投与の多施設共同臨床試験成績
  大橋一輝; 大橋一輝; 坂巻壽; 宮村耕一; 村田誠; 衛藤徹也; 小林直樹; 谷口修一; 今村雅寛; 安藤潔; 加藤俊一; 森毅彦; 豊嶋崇徳; 森政樹; 室井一男; 小澤敬也, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 2012年
• 急性骨髄性白血病の初回寛解導入療法中に粟粒結核を発症し,治療に難渋した1例
  林正康; 高嶋秀一郎; 加藤光次; 浦田真吾; 菊繁吉謙; 谷本一樹; 竹中克斗; 宮本敏浩; 赤司浩一; 岩崎浩己; 豊嶋崇徳; 門脇雅子; 江里口芳裕; 下野信行; 門脇賢典; 岡村精一, 臨床血液, 53, 2, 2012年
• 輸血部門からみた非血縁者間末梢血幹細胞移植
  豊嶋崇徳, 日本輸血細胞治療学会誌, 58, 2, 2012年
• 当院における血縁者間同種末梢血幹細胞採取の現状
  松尾弥生; 河野健太郎; 平安山知子; 岩崎浩己; 宮本敏浩; 豊嶋崇徳; 赤司浩一, 日本輸血細胞治療学会誌, 58, 2, 2012年
• Bombay型妊婦の出産を経験して
  池松陽子; 山口恭子; 青木香苗; 吉居真由; 江頭貞臣; 平安山知子; 松尾弥生; 山崎久義; 田久保智子; 渡邉聖司; 迫田岩根; 佐藤博行; 清川博之; 岩崎浩己; 豊嶋崇徳; 赤司浩一, 日本輸血細胞治療学会誌, 58, 2, 2012年
• 造血幹細胞移植の有効性と安全性向上のための薬剤のエビデンスの確立に関する研究 慢性GVHDに関する基礎的研究
  豊嶋崇徳, 造血幹細胞移植の有効性と安全性向上のための薬剤のエビデンスの確立に関する研究 平成23年度 総括・分担研究報告書, 2012年
• 造血幹細胞移植:急性および慢性GVHD対策
  豊嶋崇徳, 臨床血液, 53, 9, 2012年
• 当院における造血幹細胞移植後の血流感染症の検討
  湯田淳一朗; 竹中克斗; 林正康; 浦田真吾; 高嶋秀一郎; 菊繁吉謙; 加藤光次; 谷本一樹; 牟田毅; 岩崎浩己; 宮本敏浩; 豊嶋崇徳; 赤羽浩一; 赤羽浩一, 臨床血液, 53, 9, 2012年
• 「ABO血液型不適合移植 輸血指示書」を用いた不適合輸血防止への取り組み
  青木香苗; 池松陽子; 山口恭子; 江頭貞臣; 栢森裕三; 平安山知子; 岩崎浩巳; 豊嶋崇徳; 康東天; 赤司浩一, 日本輸血細胞治療学会誌, 58, 4, 2012年
• 多発性骨髄腫患者において化学療法併用またはG-CSF単独投与後の末梢血幹細胞採取における後方視的検討
  牟田毅; 牟田毅; 衛藤徹也; 宮本敏浩; 上村智彦; 豊嶋崇徳; 豊嶋崇徳; 赤司浩一, 日本輸血細胞治療学会誌, 58, 2, 2012年
• 同種移植後再発骨髄異形成症候群に対してAzacytidineが著効した一例
  浦田真吾; 谷本一樹; 高嶋秀一郎; 菊繁吉謙; 加藤光次; 岩崎浩己; 竹中克斗; 宮本敏弘; 豊嶋崇徳; 赤司浩一; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 2012年
• 当院におけるPOEMS症候群の長期フォローアップによる検討
  湯田淳一朗; 竹中克斗; 加藤光次; 林正康; 浦田真吾; 高嶋秀一郎; 菊繁吉謙; 谷本一樹; 岩崎浩己; 宮本敏浩; 豊嶋崇徳; 赤司浩一; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 34th, 2012年
• レナリドマイドで病勢コントロールを行い,安全に移植を行えたPOEMS症候群の1例
  湯田淳一朗; 菊繁吉謙; 加藤光次; 下地園子; 奥誠道; 谷本一樹; 竹中克斗; 宮本敏浩; 赤司浩一; 岩崎浩己; 豊嶋崇徳, 臨床血液, 53, 2, 2012年
• 成人T細胞性白血病(ATL)の根治を目指した細胞療法の確立およびそのHTLV-1抑制メカニズムの解明に関する研究 同種造血幹細胞移植後の抗白血病効果を促進する試み
  豊嶋崇徳, 成人T細胞性白血病(ATL)の根治を目指した細胞療法の確立およびそのHTLV-1抑制メカニズムの解明に関する研究 平成23年度 総括・分担研究報告書, 2012年
• GVHDのメカニズムとその克服に向けた細胞療法の展開
  豊嶋 崇徳, 医学のあゆみ, 240, 5, 460, 464, 2012年
  日本語
• Wntシグナルを標的とした腸管GVHDの制御
  豊嶋 崇徳, 血液内科, 64, 2, 197, 201, 2012年
  科学評論社, 日本語
• 移植片対宿主病(GVHD)のマネジメント
  豊嶋 崇徳, がん看護, 17, 3, 354, 356, 2012年
  日本語
• GVHDの成因と治療
  豊嶋 崇徳, 日本臨床, 70, 2, 264, 268, 2012年
  日本語
• ミニ移植における移植片対宿主病(GVHD)と移植片対白血病(GVL)効果
  重松明男; 豊嶋崇徳, 血液フロンティア, 22, 10, 23, 30, 2012年
  日本語
• 献血者不足とPatient Blood Management
  平安山知子; 豊嶋崇徳, 医学のあゆみ, 243, 4, 311, 315, 2012年
  日本語
• 血小板輸血後に不規則抗体が検出された２症例
  吉居真由; 山口恭子; 池松陽子; 江頭貞臣; 豊嶋崇徳; 赤司浩一, 日本輸血細胞治療学会誌, 57, 6, 465, 469, 2011年, ［査読有り］
  [症例報告]
• 造血幹細胞移植の新たな感染対策
  江里口芳裕; 前原依子; 下野信行; 宮本敏浩; 赤司浩一; 豊嶋崇徳, 無菌生物, 41, 1, 45, 47, 2011年, ［査読有り］
  日本無菌生物ノートバイオロジー学会, 日本語
• 血小板輸血により不規則抗体を産生した2症例
  池松陽子; 山口恭子; 吉居真由; 江頭貞臣; 豊嶋崇徳; 赤司浩一, 日本輸血細胞治療学会誌, 57, 1, 2011年
• 福岡BMTグループ(FBMTG)における再発及び治療抵抗性の濾胞性悪性リンパ腫に対する同種造血幹細胞移植の成績
  伊藤能清; 上村智彦; 宮本敏浩; 鄭湧; 亀崎健次郎; 大野裕樹; 衛藤徹也; 豊嶋崇徳; 谷口修一; 原田実根; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 33rd, 2011年
• 健常ドナーからの末梢血幹細胞採取時の血管アクセスのためのデバイスに関する全国調査
  畑中一生; 鈴木律朗; 熱田由子; 日野雅之; 豊嶋崇徳; 小寺良尚; 今村雅寛, 日本造血細胞移植学会総会プログラム・抄録集, 33rd, 2011年
• 消化管GVHDに対する経口ベクロメタゾン治療~Fukuoka BMT Groupにおける使用経験~
  奥誠道; 森康雄; 森康雄; 栗山拓郎; 加藤光次; 竹中克斗; 岩崎浩己; 原田直樹; 宮本敏浩; 衛藤徹也; 安部康信; 豊嶋崇徳; 赤司浩一; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 33rd, 2011年
• 同種骨髄移植施行当日にPRESを発症した一例
  林正康; 栗山拓郎; 奥誠道; 森康雄; 加藤光次; 竹中克斗; 宮本敏浩; 原田直樹; 豊嶋崇徳; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 33rd, 2011年
• 侵襲性肺アスペルギルス症に対しmicafunginとvoriconazole併用にて同種造血幹細胞移植を施行した7症例の検討
  徳山貴人; 宮脇恒太; 岡英世; 森康雄; 斎藤統之; 加藤光次; 竹中克斗; 岩崎浩巳; 原田直樹; 宮本敏浩; 豊嶋崇徳; 赤司浩一; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 33rd, 2011年
• GVHDの診断・治療
  豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 33rd, 2011年
• 造血幹細胞移植で長期病勢コントロールが得られた腸管症関連T細胞リンパ腫
  下地園子; 奥誠道; 河野健太郎; 竹中克斗; 栗山拓郎; 加藤光次; 宮本敏浩; 原田直樹; 岩崎浩巳; 豊嶋崇徳; 赤司浩一, 臨床血液, 52, 9, 2011年
• 依頼検査により検出されたBombay型妊婦の1症例
  山崎久義; 田久保智子; 渡邉聖司; 山口恭子; 池松陽子; 江頭貞臣; 迫田岩根; 平安山知子; 豊嶋崇徳; 赤司浩一; 佐藤博行; 清川博之, 血液事業, 34, 2, 2011年
• 同種造血幹細胞移植成績の一元化登録と国際間の共有およびドナーとレシピエントのQOLを視野に入れた成績の向上に関する研究 移植片対宿主病の診断に関するガイドラインの作成と二次治療も含めた効率的な予防および治療法の確立に関する研究
  豊嶋崇徳, 同種造血幹細胞移植成績の一元化登録と国際間の共有およびドナーとレシピエントのQOLを視野に入れた成績の向上に関する研究 平成22年度 総括・分担研究報告書, 2011年
• 成人T細胞性白血病(ATL)の根治を目指した細胞療法の確立およびそのHTLV-1抑制メカニズムの解明に関する研究 同種造血幹細胞移植後の抗白血病効果を促進する試み
  豊嶋崇徳, 成人T細胞性白血病(ATL)の根治を目指した細胞療法の確立およびそのHTLV-1抑制メカニズムの解明に関する研究 平成22年度 総括・分担研究報告書, 2011年
• 同種末梢血幹細胞移植を非血縁者間で行う場合等の医学,医療,社会的基盤に関する研究事業「非血縁者間末梢血幹細胞の利用について」の研究
  豊嶋崇徳, 同種末梢血幹細胞移植を非血縁者間で行う場合等の医学、医療、社会的基盤に関する研究事業 平成22年度 総括・分担研究報告書, 2011年
• 福岡BMTグループ(FBMTG)における悪性リンパ腫に対する自己末梢血幹細胞移植
  平安山英穂; 沼田晃彦; 衛藤徹也; 大野裕樹; 上村智彦; 高瀬謙; 伊藤能清; 加藤光次; 杉尾康浩; 竹中克斗; 宮本敏浩; 原田直樹; 長藤宏司; 豊嶋崇徳; 原田実根; 赤司浩一, 臨床血液, 52, 9, 2011年
• 造血幹細胞移植の新たな展開 6.GVHDの制御~最近の知見~
  豊嶋崇徳, 血液フロンティア, 21, 3, 2011年
• 成人難治性造血器腫瘍に対する非血縁者間の同種造血幹細胞移植法の確立に関する研究
  森島泰雄; 宮村耕一; 豊嶋崇徳; 坂巻壽; 岡本真一郎; 今村雅寛; 森慎一郎, 国立がん研究センターがん研究開発費総括研究報告書(Web), 2010, 44, 2011年
• 末梢血幹細胞移植に関するガイドラインの改訂と非血縁者間末梢血幹細胞移植の開始
  豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 33rd, 2011年
• 同種造血幹細胞移植後再発に対する再移植の成績:福岡BMTグループ(FBMTG)における検討-ドナーソースを中心に-
  加藤光次; 宮本敏浩; 衛藤徹也; 大野裕樹; 上村智彦; 長藤宏司; 高瀬謙; 平安山英穂; 伊藤能清; 杉尾康浩; 竹中克斗; 原田直樹; 岩崎浩己; 豊嶋崇徳; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 33rd, 2011年
• 非血縁者間末梢血幹細胞移植における輸血部門の役割
  豊嶋崇徳, 日本輸血細胞治療学会誌, 57, 2, 2011年
• 当院における血縁者間同種末梢血幹細胞採取の現状
  松尾弥生; 菊繁吉謙; 平安山知子; 岩崎浩己; 宮本敏浩; 豊嶋崇徳; 赤司浩一, 日本輸血細胞治療学会誌, 57, 2, 2011年
• 小児発症の全身脱毛症が初発症状と考えられた,成人診断の毛包向性菌状息肉症
  仲池隆史; 奥誠道; 加藤光次; 坂本佳治; 下地園子; 栗山拓郎; 森康雄; 竹中克斗; 黒岩三佳; 原田直樹; 岩崎浩己; 宮本敏浩; 豊嶋崇徳; 大島孝一; 赤司浩一, 日本リンパ網内系学会会誌, 51, 2011年
• 自己末梢血幹細胞移植で長期病勢コントロールが得られた腸管症関連T細胞リンパ腫
  下地園子; 奥誠道; 竹中克斗; 河野健太郎; 仲池隆史; 坂本佳治; 栗山拓郎; 加藤光次; 宮本敏浩; 岩崎浩己; 豊嶋崇徳; 赤司浩一, 日本リンパ網内系学会会誌, 51, 2011年
• 九州大学病院におけるアルブミン製剤管理システムについて
  山口恭子; 山口恭子; 吉居真由; 松本信也; 池松陽子; 棚町啓之; 江頭貞臣; 豊嶋崇徳; 赤司浩一, 日本輸血細胞治療学会誌, 57, 2, 2011年
• GVHDとGVLに関する最近の話題
  豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 33rd, 2011年
• 造血細胞移植後の感染症診断にProcalcitoninはCRPより有用でない
  宮脇恒太; 森康雄; 加藤光次; 竹中克斗; 岩崎浩己; 原田直樹; 宮本敏浩; 赤司浩一; 赤司浩一; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 33rd, 2011年
• 移植片対宿主病とToll-like receptors
  青山一利; 小山幹子; 豊嶋崇徳, 臨床免疫・アレルギー科, 55, 5, 566, 571, 2011年
  科学評論社, 日本語
• 造血幹細胞移植とウイルス感染症
  豊嶋 崇徳, 臨床とウイルス, 39, 1, 51, 61, 2011年
  日本語
• Wnt作動薬R-spondin1は腸幹細胞を保護して全身性移植片対宿主病を軽減する
  高嶋秀一郎; 豊嶋崇徳, 実験医学, 29, 13, 2139, 2142, 2011年
  日本語
• 臓器・細胞移植と輸血の現状
  豊嶋 崇徳, 血液事業, 33, 4, 439, 440, 2011年
  日本語
• 造血幹細胞移植後の感染症 ―免疫力ゼロからの闘い―
  豊嶋 崇徳, 医薬ジャーナル, 47, 11, 2790, 2794, 2011年
  日本語
• 造血細胞移植後の免疫不全とその予防治療
  豊嶋 崇徳, 日本医師会雑誌, 140, 7, 1418, 2011年
  日本語
• 日本輸血・細胞治療学会による「輸血業務に関する総合的アンケート調査」における細胞治療に用いる細胞の採取、処理、保管に関する2008年の現状
  池田和真; 長村登紀子; 田野崎隆二; 井関徹; 田中朝志; 豊嶋崇徳; 室井一男; 甲斐俊朗; 加藤俊一; 前川平; 佐川公矯; 高橋孝喜; 大戸斉, 日本輸血細胞治療学会誌, 56, 5, 639, 644, 2010年, ［査読有り］
  2008年実績に対する「輸血に関する総合的アンケート調査」の細胞治療に関する回答結果を報告する．調査は全国の7,857施設を対象とし，3,208（40.8％）から回答があった．輸血部門に専任の看護師がいる施設は53で，細胞の採取を行っている施設数は，自家末梢血幹細胞；108，同種末梢血幹細胞；75，非血縁骨髄；28，血縁骨髄；26，ドナーリンパ球；24，顆粒球；10であった．自家末梢血幹細胞については，48施設で採取が輸血部門で行われ，70施設が手順書を使用し，54施設が作業工程を記録し，59施設が規定のラベルを添付し，52施設が血液製剤に準じた照合を行い，70施設が自施設でフローサイトメトリー解析を行い，63施設が開放系処理に専用クリーン・ベンチを用いていた．処理後と解凍後の無菌検査を行っていると回答したのは7施設と1施設のみであった．成分採血の血管穿刺は82施設で担当診療科医師，成分採血装置のオペレーターは35施設で検査技師，31施設で臨床工学士，細胞の処理，凍結，保管，払出は大半の施設で検査技師により行われていた．検査技師が大きな役割を果たしていること，工程管理と品質管理には課題があることが明らかになった．
  , The Japan Society of Transfusion Medicine and Cell Therapy, 日本語
• 造血細胞移植ガイドライン 同種末梢血幹細胞移植のための健常人ドナーからの末梢血幹細胞動員・採取に関するガイドライン
  豊嶋崇徳; 日野雅之; 田中淳司; 田野崎隆二; 長藤宏司; 宮村耕一; 小寺良尚; 日本造血細胞移植学会ガイドライン委員会; 日本輸血; 細胞治療学会アフェレーシス安全委員会, 造血細胞移植モノグラフ vol.21，日本造血細胞移植学会, 2010年, ［査読有り］
• 同種造血幹細胞移植後のHHV-6脳炎~217症例の後方視的解析
  森康雄; 斎藤統之; 亀崎健次郎; 竹中克斗; 岩崎浩己; 原田直樹; 宮本敏浩; 長藤宏司; 長藤宏司; 豊嶋崇徳; 赤司浩一; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 32nd, 2010年
• R-Spondin1は移植前処置から腸管を保護し,移植片対宿主病(GVHD)を改善する
  高嶋秀一郎; 門脇賢典; 青山一利; 小山幹子; 大島毅; 富塚一磨; 赤司浩一; 赤司浩一; 豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 32nd, 2010年
• 非寛解期に播種性ムコール症を併発した急性骨髄性白血病に対して臍帯血移植を施行した一例
  青木孝友; 青木孝友; 亀崎健次郎; 宮本敏浩; 長藤宏司; 森康雄; 山内拓司; 竹中克斗; 岩崎浩己; 原田直樹; 下野信行; 豊嶋崇徳; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 32nd, 2010年
• 同種造血幹細胞移植後のHematogonesは良好な移植経過を反映する
  島隆宏; 宮本敏浩; 菊繁吉謙; 亀崎健次郎; 竹中克斗; 豊嶋崇徳; 赤司浩一, 日本造血細胞移植学会総会プログラム・抄録集, 32nd, 2010年
• 成人T細胞白血病(ATL)に対する同種幹細胞移植療法の開発とそのHTLV-1排除機構の解明に関する研究 同種造血幹細胞移植後の抗白血病効果を促進する試み
  豊嶋崇徳, 成人T細胞白血病(ATL)に対する同種幹細胞移植療法の開発とそのHTLV-1排除機構の解明に関する研究 平成21年度 総括・分担研究報告書, 2010年
• 当院で施行した小児に対する血漿交換療法
  平安山知子; 岩崎浩己; 松尾弥生; 宮本敏浩; 豊嶋崇徳; 赤司浩一, 日本輸血細胞治療学会誌, 56, 2, 2010年
• 同種造血幹細胞移植成績の一元化登録と国際間の共有およびドナーとレシピエントのQOLを視野に入れた成績の向上に関する研究「移植片対宿主病の診断に関するガイドラインの作成と二次治療も含めた効率的な予防および治療法の確立に関する研究」
  豊嶋崇徳, 同種造血幹細胞移植成績の一元化登録と国際間の共有およびドナーとレシピエントのQOLを視野に入れた成績の向上に関する研究 平成21年度 総括・分担研究報告書, 2010年
• 非血縁者間末梢血幹細胞移植の実施に向けて
  豊嶋崇徳, 日本輸血細胞治療学会誌, 56, 4, 2010年
• 重症感染症合併の同種骨髄移植後の生着不全に対し1-day conditioningにて救援移植を施行した再生不良性貧血
  宮脇恒太; 森康雄; 齋藤統之; 加藤光次; 竹中克斗; 岩崎浩巳; 原田直樹; 宮本敏浩; 豊嶋崇徳; 赤司浩一; 赤司浩一, 臨床血液, 51, 9, 2010年
• HLA半合致移植後再発に対しドナーリンパ球輸注を施行した再発難治性急性骨髄性白血病の一例
  岡英世; 齋藤統之; 宮本敏浩; 森康雄; 加藤光次; 竹中克斗; 岩崎浩己; 原田直樹; 豊嶋崇徳; 赤司浩一; 赤司浩一, 臨床血液, 51, 9, 2010年
• セバリン療法のクリティカルパス作成
  内田まやこ; 山口麻美; 池末裕明; 松江祥子; 平岩ひろみ; 馬場眞吾; 原田直樹; 宮本敏浩; 豊嶋崇徳; 江頭伸昭; 大石了三, 日本医療薬学会年会講演要旨集, 20th, 2010年
• 急性前骨髄球性白血病に対する自家移植の意義:FBMTGの経験と文献的考察
  上村智彦; 宮本敏浩; 長藤宏司; 高瀬謙; 伊藤能清; 大野裕樹; 衛藤徹也; 豊嶋崇徳; 谷口修一; 林真; 赤司浩一; 原田実根, 日本造血細胞移植学会総会プログラム・抄録集, 32nd, 2010年
• 治療関連合併症を減少させて同種造血幹細胞移植後の生存率の向上を目指す標準的治療法の開発研究 慢性GVHDに関する基礎的研究
  豊嶋崇徳, 治療関連合併症を減少させて同種造血幹細胞移植後の生存率の向上を目指す標準的治療法の開発研究 平成21年度 総括・分担研究報告書, 2010年
• リンパ球系 Th17細胞とGVHD
  豊嶋崇徳, Annual Review 血液, 2010, 2010年
• 造血細胞移植におけるドナーT細胞機能動態の新たな知見からGVHD・GVLを考える
  豊嶋崇徳, 日本造血細胞移植学会総会プログラム・抄録集, 32nd, 2010年
• 成人難治性造血器腫瘍に対する非血縁者間の同種造血幹細胞移植の確立に関する研究
  森島泰雄; 小寺良尚; 宮村耕一; 豊嶋崇徳; 坂巻壽; 高橋聡; 加藤俊一; 谷本光音; 岡本真一郎; 今村雅寛; 中尾眞二; 平岡諦; 石川淳; 森慎一郎; 磯村寛樹; 日高道広; 武本重毅, 国立がん研究センターがん研究開発費総括研究報告書(Web), 2009, 19-01, 2010年
• 最近の輸血医療の変遷-医療人として知っておかねばならないこと-
  豊嶋崇徳, 日本緩和医療薬学会年会プログラム・要旨集, 4th, 2010年
• 血液培養上清を用いた赤血球のT化について
  山口恭子; 萩尾渚; 池松陽子; 江頭貞臣; 豊嶋崇徳; 赤司浩一, 日本輸血細胞治療学会誌, 56, 2, 2010年
• マウスGVHDモデルにおける移植後長期の制御性T細胞再構築の検討
  杉山暖子; 前田嘉信; 西森久和; 小林孝一郎; 山筋好子; 竹内賢吾; 豊嶋崇徳; 谷本光音, 日本造血細胞移植学会総会プログラム・抄録集, 32nd, 2010年
• リンパ腫・骨髄腫などにおける造血細胞移植の現状と展望
  豊嶋崇徳; 角南一貴; 前田嘉信; 名和由一郎; 平松靖, 血液フロンティア, 20, 2, 234, 244, 2010年
  日本語
• 造血細胞移植における母子間免疫寛容効果
  青山一利; 松岡賢市; 豊嶋崇徳, 血液・腫瘍科, 60, 4, 465, 470, 2010年
  科学評論社, 日本語
• 骨髄増殖性腫瘍における血小板アフェレーシス
  平安山知子; 岩崎浩巳; 豊嶋崇徳; 赤司浩一, 日本アフェレーシス学会雑誌, 29, 3, 287, 289, 2010年
  日本語
• 造血幹細胞移植における慢性GVHDの発症機序
  門脇賢典; 豊嶋崇徳, 臨床免疫・アレルギー科, 53, 3, 337, 342, 2010年
  日本語
• 造血細胞移植ガイドライン インフルエンザ
  豊嶋崇徳; 下野信行; 井上雅美; 日本造血細胞移植学会ガイドライン委員会, 造血細胞移植モノグラフvol. 20，日本造血細胞移植学会．名古屋, 2009年, ［査読有り］
• 末梢血幹細胞の凍結保存における凍害防止剤CP-1の有効性と安全性に関する多施設共同研究
  牧野茂義; 水村真也; 石原樹里; 戸田麻衣子; 吉井真司; 海堀いず美; 高橋みどり; 府川正儀; 増岡和宏; 和氣敦; 谷口修一; 豊嶋崇徳; 赤司浩一; 衛藤徹也, 日本輸血細胞治療学会誌, 55, 2, 2009年
• 同種造血幹細胞移植成績の一元化登録と国際間の共有およびドナーとレシピエントのQOLを視野に入れた成績の向上に関する研究 移植片宿主病の診断に関するガイドラインの作成と二次治療も含めた効率的な予防および治療法の確立に関する研究
  豊嶋崇徳, 同種造血幹細胞移植成績の一元化登録と国際間の共有およびドナーとレシピエントのQOLを視野に入れた成績の向上に関する研究 平成20年度 総括・分担研究報告書, 2009年
• 成人難治性造血器腫瘍に対する非血縁者間の同種造血幹細胞移植の確立に関する研究
  森島泰雄; 宮村耕一; 豊嶋崇徳; 坂巻壽; 高橋聡; 加藤俊一; 谷本光音; 岡本真一郎; 今村雅寛; 中尾眞二; 平岡諦; 森慎一郎; 磯村寛樹, 厚生労働省がん研究助成金による研究報告集, 2008, 2009年
• 成人T細胞白血病(ATL)に対する同種幹細胞移植療法の開発とそのHTLV-1排除機構の解明に関する研究 同種造血幹細胞移植後の抗白血病効果を促進する試み
  豊嶋崇徳, 成人T細胞白血病(ATL)に対する同種幹細胞移植療法の開発とそのHTLV-1排除機構の解明に関する研究 平成20年度 総括・分担研究報告書, 2009年
• 同種造血幹細胞移植成績の一元化登録と国際間の共有およびドナーとレシピエントのQOLを視野に入れた成績の向上に関する研究
  一戸辰夫; 内山卓; 青山一利; 豊嶋崇徳; 島崎千尋; 丸屋悦子; 佐治博夫, 同種造血幹細胞移植成績の一元化登録と国際間の共有およびドナーとレシピエントのQOLを視野に入れた成績の向上に関する研究 平成20年度 総括・分担研究報告書, 2009年
• 治療関連合併症を減少させて同種造血幹細胞移植後の生存率の向上を目指す標準的治療法の開発研究 慢性GVHDに関する基礎的研究
  豊嶋崇徳, 治療関連合併症を減少させて同種造血幹細胞移植後の生存率の向上を目指す標準的治療法の開発研究 平成20年度 総括・分担研究報告書, 2009年
• 末梢血幹細胞移植
  豊嶋崇徳, 日本輸血細胞治療学会誌, 55, 2, 2009年
• 炎症性腸疾患の画期的治療法に関する臨床研究 潰瘍性大腸炎に対する血球成分除去・制御性T細胞分離移入療法:臨床試験実施に向けて
  中村和彦; 高柳涼一; 秋穂裕唯; 豊嶋崇徳; 赤司浩一; 谷憲三朗, 炎症性腸疾患の画期的治療法に関する臨床研究 平成20年度 総括・分担研究報告書, 2009年
• 炎症性腸疾患の画期的治療法に関する臨床研究 潰瘍性大腸炎に対する血球成分除去・制御性T細胞分離移入療法の開発
  中村和彦; 高柳涼一; 秋穂裕唯; 豊嶋崇徳; 赤司浩一; 谷憲三朗, 炎症性腸疾患の画期的治療法に関する臨床研究 平成18-20年度 総合研究報告書, 2009年
• 急性および慢性GVHDの病態と診断
  豊嶋 崇徳, 内科, 104, 2, 206, 212, 2009年
  日本語
• 同種造血幹細胞移植後のウイルス感染症
  豊嶋 崇徳, 血液フロンティア, 19, 8, 1264, 1271, 2009年
  日本語
• 慢性GVHDのマウスモデル
  豊嶋 崇徳, 分子細胞治療, 8, 4, 55, 59, 2009年
  日本語
• GVHDにおける樹状細胞の役割
  豊嶋 崇徳, 血液・腫瘍科, 59, 2, 233, 240, 2009年
  日本語
• 造血細胞移植医療の基礎的・臨床的な新たな展開
  豊嶋 崇徳, 臨床血液, 50, 8, 617, 621, 2009年
  「臨床血液」編集部, 日本語
• 同種造血幹細胞移植後の免疫再構築 造血細胞移植後の予防接種ガイドライン
  東英一; 池亀和博; 恵美宣彦; 岡村純; 加藤剛二; 坂巻壽; 豊嶋崇徳; 星順隆; 室井一男; 森慎一郎; 矢野邦夫; 矢部普正, 臨床血液, 50, 8, 642, 651, 2009年
  「臨床血液」編集部, 日本語
• GVHDとGVL
  豊嶋 崇徳, 臨床血液, 50, 10, 1407, 1419, 2009年
  「臨床血液」編集部, 日本語
• ドナーT細胞のToll-like Receptor(TLR)シグナルはGVHDの重症化に関与する
  青山 一利; 小山 幹子; 橋本 大吾; 佐古田 幸美; 竹田 潔; 赤司 浩一; 原田 実根; 谷本 光音; 豊嶋 崇徳, 臨床血液, 49, 9, 891, 891, 2008年09月
  (一社)日本血液学会-東京事務局, 日本語
• 再発・治療抵抗性多発性骨髄腫に対するbortezomib治療
  角南 一貴; 賀川 久美子; 尾崎 修治; 吾郷 浩厚; 平松 靖史; 豊嶋 崇徳; 赤司 浩一; 矢野 朋文; 朝倉 昇司; 下野 玄英; 名和 由一郎; 前田 嘉信; 多林 孝之; 牧田 雅典; 竹内 誠; 原 雅道; 宮田 明; 安倍 正博; 谷本 光音, 臨床血液, 49, 9, 905, 905, 2008年09月
  (一社)日本血液学会-東京事務局, 日本語
• 造血細胞移植ガイドライン GVHD
  豊嶋崇徳; 伊藤雅文; 井上雅美; 加藤剛二; 谷口修一; 宮村耕一; 森下剛久; 矢部普正; 日本造血細胞移植学会ガイドライン委員会, 造血細胞移植モノグラフ，日本造血細胞移植学会．名古屋, 2008年, ［査読有り］
• RhDの反応で興味を示した症例
  池松陽子; 山口恭子; 松本信也; 棚町啓之; 江頭貞臣; 豊嶋崇徳; 栢森裕三; 康東天, 日本輸血細胞治療学会誌, 54, 1, 2008年
• 造血幹細胞移植と免疫寛容
  豊嶋崇徳, MHC, 15, 2, 2008年
• 2度にわたるRA症候群を来たしたが,亜ヒ酸を用いて寛解導入療法・地固め療法を行い寛解を維持できたAPL症例
  島隆宏; 吉本五一; 竹中克斗; 吉田周郎; 野波篤; 亀崎健次郎; 岩崎浩己; 宮本敏浩; 原田直樹; 長藤宏司; 豊嶋崇徳; 赤司浩一, 臨床血液, 49, 9, 2008年
• 血小板減少症を合併した卵巣癌1例の検討
  高嶋秀一郎; 亀崎健次郎; 武石昭一郎; 原田直樹; 竹中克斗; 岩崎浩己; 宮本敏浩; 長藤宏司; 豊嶋崇徳; 赤司浩一, 臨床血液, 49, 9, 2008年
• 同種造血幹細胞移植後サイトメガロウイルス再活性化に対する経口バルガンシクロビルによる早期治療の有効性
  竹中克斗; 衛藤徹也; 豊嶋崇徳; 亀崎健次郎; 吉田周郎; 吉本五一; 原田直樹; 松尾弥生; 吉田真紀; 平安山英穂; 高瀬謙; 原田実根; 長藤宏司; 赤司浩一, 臨床血液, 49, 9, 2008年
• 同種移植後の寛容機構とGVHD
  門脇賢典; 豊嶋崇徳, 臨床血液, 49, 9, 2008年
• 骨髄,末梢血等を利用した効率的な造血細胞移植の運用・登録と臨床試験体制の確立並びにドナー及びレシピエントの安全確保とQOL向上に関する研究 細胞治療とその適正運用 5.HLA不適合造血幹細胞移植の臨床試験体制の確立と適正運用に関する研究
  一戸辰夫; 内山卓; 島崎千尋; 豊嶋崇徳; 丸屋悦子; 佐治博夫, 骨髄、末梢血等を利用した効率的な造血細胞移植の運用・登録と臨床試験体制の確立並びにドナー及びレシピエントの安全確保とQOL向上に関する研究 平成19年度 総括・分担研究報告書, 2008年
• 成人難治性造血器腫瘍に対する非血縁者間の同種造血幹細胞移植法の確立に関する研究
  森島泰雄; 小寺良尚; 豊嶋崇徳; 坂巻壽; 高橋聡; 加藤俊一; 谷本光音; 岡本真一郎; 今村雅寛; 中尾眞二; 平岡諦; 森慎一郎; 日高道広; 武本重毅; 磯村寛樹, 厚生労働省がん研究助成金による研究報告集, 2007, 2008年
• 造血幹細胞移植における免疫寛容
  豊嶋崇徳, MHC, 15, 1, 2008年
• 当院における自己末梢血幹細胞採取の現状
  平安山知子; 宮本敏浩; 岩崎浩己; 豊嶋崇徳; 赤司浩一, 日本輸血細胞治療学会誌, 54, 2, 2008年
• 骨髄異形症候群の発症および病期進展機構の解明
  宮本敏浩; 吉本五一; 豊嶋崇徳; 赤司浩一, 大和証券ヘルス財団研究業績集, 31, 2008年
• 成人T細胞白血病(ATL)に対する同種幹細胞移植療法の開発とそのHTLV-1排除機構の解明に関する研究 ATLに対する同種造血幹細胞移植後の抗白血病効果を促進する試み
  豊嶋崇徳, 成人T細胞白血病(ATL)に対する同種幹細胞移植療法の開発とそのHTLV-1排除機構の解明に関する研究 平成19年度 総括・分担研究報告書, 2008年
• I.造血管細胞 4.慢性GVHDの成因
  豊嶋崇徳, Annual Review 血液, 2008, 2008年
• ヒト正常造血幹細胞および白血病幹細胞における抗アポトーシス遺伝子Mcl-1とNOXAの発現に関する解析
  菊繁吉謙; 菊繁吉謙; 吉本五一; 吉本五一; 宮本敏浩; 岩崎浩己; 長藤宏司; 石川文彦; 豊嶋崇徳; 赤司浩一; 赤司浩一, 臨床血液, 49, 9, 2008年
• 細胞治療の臨床成績向上に向けての課題 造血幹細胞移植
  豊嶋崇徳, 日本輸血細胞治療学会誌, 54, 2, 2008年
• Jak2 V617F変異が好中球アルカリホスファターゼ(NAP)スコアを上昇させる
  奥誠道; 熊野孝; 竹中克斗; 栗山拓郎; 浦田真吾; 幣光太郎; 下田晴子; 岩崎浩己; 宮本敏浩; 豊嶋崇徳; 長藤宏司; 原田実根; 下田和哉; 赤司浩一; 赤司浩一, 臨床血液, 49, 9, 2008年
• 同種造血幹細胞移植後にFK506が原因と考えられた両下肢浮腫,低フィブリノーゲン血症を来した一例
  吉本五一; 吉本五一; 宮本敏浩; 吉田周郎; 亀崎健次郎; 竹中克斗; 原田直樹; 豊嶋崇徳; 長藤宏司; 赤司浩一; 赤司浩一, 臨床血液, 49, 9, 2008年
• 中枢神経リンパ腫の治療中に腫瘍内出血をきたした一例
  吉田周郎; 吉田周郎; 原田直樹; 島隆宏; 吉本五一; 亀崎健次郎; 竹中克斗; 宮本敏浩; 岩崎浩巳; 長藤宏司; 豊嶋崇徳; 赤司浩一, 臨床血液, 49, 9, 2008年
• Biphenotypic Acute Leukaemia8例に対する後方視的解析
  河野健太郎; 亀崎健次郎; 竹中克斗; 岩崎浩己; 宮本敏浩; 原田直樹; 長藤宏司; 豊嶋崇徳; 赤司浩一; 赤司浩一, 臨床血液, 49, 9, 2008年
• GVHD制御と移植免疫寛容誘導の展望
  豊嶋 崇徳, 日本組織適合性学会誌, 15, 1, 9, 26, 2008年
  日本語
• GVHDとGVLのメカニズムの再考察
  豊嶋 崇徳, 臨床血液, 49, 8, 592, 597, 2008年
  「臨床血液」編集部, 日本語
• 母子間免疫寛容理論に基づく同種造血幹細胞移植
  松岡 賢市; 青山 一利; 小山 幹子; 橋本 大吾; 朝倉 昇司; 一戸 辰夫; 谷本 光音; 豊嶋崇徳, 岡山医学会雑誌, 120, 1, 23, 28, 2008年
  岡山医学会, 日本語
• ドナー造血幹細胞由来細胞が慢性graft-versus-host disease(GVHD)を起こす
  佐古田 幸美; 橋本 大吾; 朝倉 昇司; 竹内 賢吾; 原田 実根; 谷本 光音; 豊嶋 崇徳, 日本内科学会雑誌, 96, Suppl., 156, 156, 2007年02月
  (一社)日本内科学会, 日本語
• 輸血前後の感染症マーカー検査についての日本輸血・細胞治療学会運用マニュアル
  熊川みどり; 長井一浩; 豊嶋崇徳; 水落利明; 佐川公矯; 高橋孝喜; 山口一成, 日本輸血細胞治療学会誌, 53, 6, 602, 606, 2007年, ［査読有り］
  日本語
• 当院における輸血前後の感染症検査の現状
  松本信也; 江頭貞臣; 棚町啓之; 山口恭子; 池松陽子; 栢森裕三; 康東天; 赤司浩一; 豊嶋崇徳, 日本輸血細胞治療学会誌, 53, 2, 2007年
• 骨髄,末梢血等を利用した効率的な造血細胞移植の運用・登録と臨床試験体制の確立並びにドナー及びレシピエントの安全確保とQOL向上に関する研究 細胞治療とその適正運用 HLA不適合造血幹細胞移植の臨床試験体制の確立と適正運用に関する研究
  一戸辰夫; 内山卓; 松岡賢市; 豊嶋崇徳; 丸屋悦子; 佐治博夫, 骨髄、末梢血等を利用した効率的な造血細胞移植の運用・登録と臨床試験体制の確立並びにドナー及びレシピエントの安全確保とQOL向上に関する研究 平成18年度 総括・分担研究報告書, 2007年
• 造血幹細胞移植
  豊嶋崇徳, 日本輸血細胞治療学会誌, 53, 2, 2007年
• 福岡BMTグループ(FBMTG)における臍帯血移植の解析
  亀崎健次郎; 亀崎健次郎; 大野裕樹; 大野裕樹; 衛藤徹也; 衛藤徹也; 長藤宏司; 長藤宏司; 豊嶋崇徳; 豊嶋崇徳; 原田実根; 原田実根, 臨床血液, 48, 9, 2007年
• 妊婦から検出された抗D+抗C+抗G抗体の1症例について
  松本信也; 山口恭子; 池松陽子; 江頭貞臣; 栢森裕三; 赤司浩一; 豊嶋崇徳; 康東天, 日本輸血細胞治療学会誌, 53, 1, 2007年
• 同種移植後の再発性急性骨髄性白血病に対してgemtuzumab ozogamicinを分割投与,再移植を行った2例の検討
  高嶋秀一郎; 河野健太郎; 武石昭一郎; 亀崎健次郎; 野波篤; 國崎祐哉; 竹中克斗; 宮本敏浩; 原田直樹; 長藤宏司; 豊嶋崇徳; 原田実根, 臨床血液, 48, 9, 2007年
• 炎症性腸疾患の画期的治療法に関する臨床研究【選択的細胞除去・移入療法の開発】潰瘍性大腸炎に対する血球成分除去・制御性T細胞移入療法の開発:CliniMACS細胞分離システムを用いた制御性T細胞の無菌的大量分離法の検討
  中村和彦; 高柳涼一; 秋穂裕唯; 豊嶋崇徳; 赤司浩一, 炎症性腸疾患の画期的治療法に関する臨床研究 平成18年度 総括・分担研究報告書, 2007年
• 母乳による非遺伝母由来抗原(NIMA)に対する免疫寛容には制御性T細胞が関与する
  青山一利; 松岡賢市; 一戸辰夫; 橋本大吾; 赤司浩一; 原田実根; 谷本光音; 豊嶋崇徳, 臨床血液, 48, 9, 2007年
• GVHDとGVLの基礎と臨床応用
  豊嶋 崇徳, 血液フロンティア, 17, 3, 357, 366, 2007年
  日本語
• GVHDとGVL
  豊嶋 崇徳, 分子細胞治療, 6, 2, 118, 123, 2007年
  日本語
• はじめに．造血幹細胞移植後のGVHD
  豊嶋 崇徳, 医学のあゆみ, 222, 3, 157, 2007年
  日本語
• 急性GVHDの病態と治療
  豊嶋 崇徳, 医学のあゆみ, 222, 3, 165, 169, 2007年
  日本語
• ドナー由来胸腺依存性Ｔ細胞によるGVHD
  佐古田幸美; 豊嶋崇徳, 血液・腫瘍科, 55, 4, 458, 463, 2007年
  科学評論社, 日本語
• FTY720によるマウス同種骨髄移植後のドナーリンパ球のアポトーシス誘導とGVHD予防
  橋本 大吾; 朝倉 昇司; 松岡 賢市; 佐古田 幸美; 小山 幹子; 青山 一利; 谷本 光音; 赤司 浩一; 豊嶋 崇徳, 臨床血液, 47, 9, 1017, 1017, 2006年09月
  (一社)日本血液学会-東京事務局, 日本語
• 血液型不適合移植でのCOBE Spectraを用いた骨髄濃縮法の検討
  平安山知子; 宮本敏浩; 和泉賢一; 沼田晃彦; 亀崎健次郎; 山崎聡; 清島久美; 宮本京子; 橋本大吾; 岩崎潤子; 岩崎浩巳; 長藤宏司; 原田実根; 稲葉頌一; 豊嶋崇徳; 赤司浩一, 日本輸血細胞治療学会誌, 52, 6, 693, 697, 2006年, ［査読有り］
  血液型不適合骨髄移植を行う際は, 輸注に伴う有害事象を避けるため, 骨髄液中の赤血球・血漿除去が必要である. 今回われわれは, 血液成分分離装置COBE Spectra により, 骨髄液から単核球を分離することで, 骨髄細胞濃縮を行った血液型不適合骨髄移植20例において, その有用性について検討した. COBE Spectra を用いた骨髄濃縮により, 赤血球量は98.4%除去され, 最終赤血球量は4.2±2.4mlであった. 有核細胞回収率は34.0±8.38%, CD34陽性細胞回収率は112.3±36.3%であった. 20症例全例で, 移植後の溶血反応および生着不全は認めず, 移植後造血回復は速やかであった. COBE Spectra を用いることで, 清潔な無菌閉鎖回路内において骨髄濃縮が可能となり, 処理時間も短縮された. 種々の細胞免疫療法の用途で広く普及しているCOBE Spectra を用いた骨髄濃縮法は, 血液型不適合骨髄移植における骨髄濃縮の標準的方法として有用であると考えられた., The Japan Society of Transfusion Medicine and Cell Therapy, 日本語
• 骨髄,末梢血等を利用した効率的な造血細胞移植の運用・登録と臨床試験体制の確立並びにドナー及びレシピエントの安全確保とQOL向上に関する研究 細胞治療とその適正運用 HLA不適合造血幹細胞移植の臨床試験体制の確立と適正運用に関する研究
  一戸辰夫; 内山卓; 松岡賢市; 豊嶋崇徳; 丸屋悦子; 佐治博夫, 骨髄、末梢血等を利用した効率的な造血細胞移植の運用・登録と臨床試験体制の確立並びにドナー及びレシピエントの安全確保とQOL向上に関する研究 平成17年度 総括・分担研究報告書, 2006年
• 血液型不適合骨髄移植でのCobe Spectraを用いた骨髄濃縮
  平安山知子; 宮本敏浩; 和泉賢一; 岩崎潤子; 清島久美; 宮本京子; 岩崎浩己; 原田実根; 赤司浩一; 稲葉頌一; 稲葉頌一; 豊嶋崇徳, 日本輸血学会雑誌, 52, 2, 2006年
• Homeostatic proliferationしたT細胞による急性移植片対宿主病誘導能の検討
  前田嘉信; 俵功; 豊嶋崇徳; 橋本大吾; 松岡賢市; 谷本光音; PAVAN Reddy, 臨床血液, 47, 9, 2006年
• 若年者骨髄性造血器腫瘍を対象とした骨髄破壊的前処置と骨髄非破壊的前処置を用いた同種末梢血幹細胞移植の比較的検討(第III相ランダム化盲検比較試験) 同種造血幹細胞移植における移植片対宿主病予防法に関する研究
  豊嶋崇徳, 若年者骨髄性造血器腫瘍を対象とした骨髄破壊的前処置と骨髄非破壊的前処置を用いた同種末梢血幹細胞移植の比較的検討(第III相ランダム化盲検比較試験) 平成17年度 総括・分担研究報告書, 2006年
• 移植片拒絶に関連するレシピエントT細胞の一過性増加
  小山幹子; 橋本大吾; 亀崎健次郎; 沼田晃彦; 佐古田幸美; 青山一利; 竹中克斗; 宮本敏浩; 原田直樹; 長藤宏司; 赤司浩一; 谷本光音; 原田実根; 豊嶋崇徳, 臨床血液, 47, 9, 2006年
• 多様化する造血幹細胞移植の適応と方法《トピックス》サイトカインとGVHD
  豊嶋崇徳, 内科, 98, 2, 2006年
• CD20陽性B細胞性リンパ腫におけるRituximab併用大量VP-16療法の末梢血幹細胞動員の検討
  亀崎健次郎; 沼田晃彦; 野波篤; 宮本敏浩; 竹中克斗; 原田直樹; 長藤宏司; 豊嶋崇徳; 稲葉頌一; 原田実根, 臨床血液, 47, 9, 2006年
• 同種骨髄移植後早期にドナー由来ランゲルハンス細胞増殖に伴うリンパ節腫脹を呈した一例
  池田和彦; 池田和彦; 小川一英; 七島勉; 七島晶子; 橋本優子; 野地秀義; 石橋敏幸; 豊嶋崇徳; 阿部正文; 大戸斉; 丸山幸夫, 日本リンパ網内系学会会誌, 46, 2006年
• 白血病幹細胞分画における表面抗原および白血病発症関連遺伝子の発現レベルの解析
  吉本五一; 宮本敏浩; 飯野忠史; 新納宏昭; 岩崎浩己; 豊嶋崇徳; 原田実根; 赤司浩一, 臨床血液, 47, 9, 2006年
• HLA-DR1座不一致非血縁者間骨髄移植後早期にCD4リンパ球増加を伴い急性GVHDを発症した2例
  武石昭一郎; 沼田晃彦; 亀崎健次郎; 竹中克斗; 宮本敏浩; 原田直樹; 長藤宏司; 豊嶋崇徳; 原田実根, 臨床血液, 47, 9, 2006年
• GVHDとGVLの病態生理
  豊嶋 崇徳, 血液・腫瘍科, 52, 3, 344, 359, 2006年
  日本語
• Maternal antigensへの免疫学的寛容とCD4+CD25+制御性T細胞
  松岡賢市; 一戸辰夫; 豊嶋崇徳, 血液・腫瘍科, 53, 4, 362, 367, 2006年
  日本語
• 造血幹細胞移植における免疫反応―移植片対宿主病―
  豊嶋 崇徳, Sysmex Journal, 29, Suppl.1, 39, 48, 2006年
  日本語
• 同種免疫反応の制御 Graft-versus-host disease (GVHD)
  豊嶋 崇徳, 今日の移植, 19, 1, 65, 72, 2006年
  日本語
• 治療法をめぐる最近の進歩 23 移植後再発・EBV感染に対するドナーリンパ球輸注
  豊嶋崇徳, 医学のあゆみ, 2005年
• 固形がんに対する同種細胞免疫療法を用いた標準的治療法の確立に関する研究 転移固形腫ようを対象としたミニ移植の安全性と有効性の検討 同種造血幹細胞移植における移植片対宿主病予防法に関する研究
  豊嶋崇徳, 固形がんに対する同種細胞免疫療法を用いた標準的治療法の確立に関する研究 平成16年度総括・分担研究報告書 転移固形腫ようを対象としたミニ移植の安全性と有効性の検討, 2005年
• 安全性向上のための院内輸血体制(患者認証輸血システム)の整備について
  栗崎宏憲; 藤原阿沙美; 松本信也; 江頭貞臣; 栢森裕三; 宮本敏浩; 豊嶋崇徳; 浜崎直孝, 日本輸血学会雑誌, 51, 1, 2005年
• 造血幹細胞および前駆細胞における転写因子および抗アポトーシス遺伝子の発現レベルの検討
  吉本五一; 宮本敏浩; 森康雄; 飯野忠史; 岩崎浩己; 長藤宏司; 豊嶋崇徳; 赤司浩一; 原田実根, 臨床血液, 46, 8, 2005年
• 筋ジストロフィーモデルマウスに対する骨髄移植法の治療効果の検討
  萩原宏毅; 大沢裕; 村上龍文; 豊嶋崇徳; 砂田芳秀, 日本神経学会総会プログラム・抄録集, 46th, 2005年
• 特発性造血障害に関する調査研究班 III. 不応性貧血(骨髄異形成症候群) 高齢者または臓器障害を有するhigh-risk骨髄異形成症候群症例に対する骨髄非破壊的移植前治療を用いた同種末梢血幹細胞移植に関する臨床第I/II相試験
  谷本光音; 池田和真; 藤井伸治; 近藤英生; 豊嶋崇徳; 品川克至; 石丸文彦; 原田実根, 特発性造血障害に関する調査研究班 平成16年度総括・分担研究報告書, 2005年
• 臨床免疫学のカッティングエッジ 同種移植と免疫寛容
  豊嶋崇徳, MHC, 12, 2, 2005年
• HLA適合度とReduced Intensity Conditioning Stem Cell Transplantation(RIST)の成績
  豊嶋崇徳; 松尾恵太郎; 末永孝生; 河野文夫; 谷口修一; 原雅道; 畑中一生; 谷本光音; 原田実根; 中尾真二; 安部康信; 和気敦; 衛藤徹也; 武元良整; 今村雅寛; 高橋聡; 石田陽治; 神田善伸; 大野裕樹; 笠井正晴; 角南一貴; 政氏伸夫; 広川誠; 安川正貴; 高上洋一, 臨床血液, 46, 8, 2005年
• GVHDとGVLの病態生理
  豊嶋崇徳, 日本リンパ網内系学会会誌, 45, 2005年
• FLT3遺伝子異常を有する急性骨髄性白血病症例の芽球形質解析
  森康雄; 吉本五一; 宮本敏浩; 宮本敏浩; 長藤宏司; 豊嶋崇徳; 赤司浩一; 原田実根, 臨床血液, 46, 8, 2005年
• 造血幹細胞移植:診断と治療の進歩 IV.最近のトピックス 2.Graft-versus-host disease(GVHD)の制御
  豊嶋崇徳, 日本内科学会雑誌, 94, 7, 2005年
• GVHDの発症メカニズム
  豊嶋 崇徳, 日本小児血液学会雑誌, 19, 4, 84, 86, 2005年
  日本語
• GVHDとGVTの病態
  豊嶋 崇徳, 綜合臨床, 54, 6, 1737, 1743, 2005年
  日本語
• 移植免疫と腫瘍免疫
  豊嶋 崇徳, Urology View, 3, 3, 48, 52, 2005年
  日本語
• 急性リンパ球性白血病に対する骨髄非破壊的移植の有効性:33例の多施設共同後方視的研究
  濱木 珠恵; 上 昌広; 神田 善伸; 和気 敦; 山根 孝久; 魚嶋 伸彦; 中井 邦久; 安部 康信; 上田 恭典; 井上 徹也; 吾郷 浩厚; 日高 道弘; 林 孝昌; 稲本 賢弘; 湯地 晃一郎; 豊嶋 崇徳; 小林 直樹; 芦田 隆司; 畑中 一生; 中尾 眞二; 宮腰 重三郎; 谷口 修一, 日本血液学会・日本臨床血液学会総会プログラム・抄録集, 66回・46回, 784, 784, 2004年09月
  日本臨床血液学会, 日本語
• NKT細胞刺激による急性GVHD予防
  橋本 大吾; 朝倉 昇司; 三宅 幸子; 山村 隆; Van Kaer Luc; Liu Chen; 谷本 光音; 豊嶋 崇徳, 日本血液学会・日本臨床血液学会総会プログラム・抄録集, 66回・46回, 747, 747, 2004年09月
  日本臨床血液学会, 日本語
• 移植骨髄由来間葉系幹細胞のきゅう上皮への移行,分化に関する研究
  竹内彩子; 辻極秀次; 折田頼尚; 武田靖志; 西崎和則; 豊嶋崇徳, 日本耳鼻咽喉科学会会報, 107, 4, 2004年
• ABO不適合造血幹細胞移植後の赤血球回復についての検討
  久保西四郎; 吉田親正; 浅野尚美; 小郷博昭; 藤井伸治; 豊嶋崇徳; 品川克至; 石丸文彦; 池田和真, 日本輸血学会雑誌, 50, 2, 2004年
• 若年者骨髄性造血器腫ようを対象とした骨髄破壊的前処置と骨髄非破壊的前処置を用いた同種末梢血幹細胞移植の比較検討に関する研究 GVHDとGVL効果の相関についての検討に関する研究
  豊嶋崇徳, 若年者骨髄性造血器腫ようを対象とした骨髄破壊的前処理と骨髄非破壊的前処理を用いた同種末梢血幹細胞移植の比較検討に関する研究 平成15年度 総括・分担研究報告書, 2004年
• 移植骨髄由来間葉系幹細胞の内耳感覚上皮への移行に関する研究
  折田頼尚; 辻極秀次; 竹内彩子; 武田靖志; 西崎和則; 豊嶋崇徳, 日本耳鼻咽喉科学会会報, 107, 4, 2004年
• Ikarosのshort isoformであるIk-6の機能解析
  多林孝之; 石丸文彦; 片岡到; 藤井伸治; 豊嶋崇徳; 品川克至; 池田和真; 谷本光音, 日本内科学会雑誌, 93, 2004年
• きゅう上皮再生過程における骨髄由来間葉系幹細胞の関与についての検討
  吉延潤子; 辻極秀次; 竹内彩子; 折田頼尚; 武田靖志; 豊嶋崇徳; 西崎和則, 日本鼻科学会会誌, 43, 3, 2004年
• 特発性造血障害に関する調査研究 不応性貧血 高齢者または臓器障害を有するhigh-risk骨髄異形成症候群症例に対する骨髄非破壊的移植前治療を用いた同種末梢血幹細胞移植に関する臨床第I/II相試験:中間解析
  谷本光音; 池田和真; 藤井伸治; 豊嶋崇徳; 品川克至; 石丸文彦; 原田実根, 特発性造血障害に関する調査研究班 平成15年度総括・分担研究報告書, 2004年
• 骨髄等を利用した効率的な造血幹細胞移植の運用・登録と臨床試験体制の確立に関する研究 同種末梢血造血幹細胞移植 同種末梢血幹細胞至適採取時期決定における末梢血circulating immature cell countの有効性に関する検討
  小寺良尚; 小塚輝彦; 原雅道; 池田和真; 久保西四郎; 吉田親正; 品川克至; 藤井伸治; 豊嶋崇徳, 骨髄等を利用した効率的な造血幹細胞移植の運用・登録と臨床試験体制の確立に関する研究 平成15年度 総括・分担研究報告書, 2004年
• Hodgkin/Reed-Sternberg様細胞を散在性に認めるLymphoplasmacytic lymphomaの一例
  小山幹子; 品川克至; 青山一利; 増成太郎; 近藤英生; 藤井伸治; 豊嶋崇徳; 石丸文彦; 池田和真, 日本リンパ網内系学会会誌, 44, 2004年
• GFPマウス骨髄由来間葉系幹細胞のきゅう上皮への移行,分化に関する定量的解析
  竹内彩子; 辻極秀次; 折田頼尚; 武田靖志; 豊嶋崇徳; 西崎和則, 日本鼻科学会会誌, 43, 3, 2004年
• GVHDとGVL
  豊嶋 崇徳, 分子細胞治療, 3, 5, 512, 517, 2004年
  日本語
• GVHDの新しい理解
  豊嶋 崇徳, 最新医学, 59, 1, 128, 134, 2004年
  最新医学社, 日本語
• 成人Ｂ細胞性急性リンパ性白血病(ALL L3)における長期予後の改善
  石丸文彦; 近藤英生; 藤井伸治; 豊嶋崇徳; 品川克至; 池田和眞; 谷本光音, 内科専門医会誌, 15, 4, 618, 621, 2003年, ［査読有り］
  [症例報告]
• マイクロアレーを用いた肝GVHD発生機構の解析
  市場保; 豊嶋崇徳; KUICK R; MISEK D; LIU C; 高田雄一郎; 前田嘉信; REDDY P; FERRARA J, 臨床血液, 44, 8, 2003年
• Fludarabineを用いた骨髄非破壊的同種造血幹細胞移植
  谷本光音; 増田浩三; 豊嶋崇徳; 品川克至; 池田和真, 特発性造血障害に関する調査研究班 平成14年度総括・分担研究報告書, 2003年
• 免疫2004 7章 病気と免疫 GVHDの新しい考え方
  豊嶋崇徳, Molecular Medicine, 40, 2003年
• Granulocyte colony-stimulating factorによる末梢血幹細胞動員におけるstromal cell-derived factor-1の動態
  小塚輝彦; 石丸文彦; 藤井敬子; 多林孝之; 豊嶋崇徳; 品川克至; 池田和真; 新谷憲治; 谷本光音, 日本内科学会雑誌, 92, 2003年
• 前処置にFludarabineを用いたRISTの成績-九州大学第一内科および岡山大学第二内科の共同研究-
  佐古田幸美; 品川克至; 増田浩三; 藤井伸治; 豊嶋崇徳; 石丸文彦; 宮本敏浩; 長藤宏司; 原田実根, 臨床血液, 44, 8, 2003年
• 同種末梢血幹細胞至適採取時期決定における末梢血circulating immature cell countの有効性に関する検討
  小塚輝彦; 池田和真; 久保西四郎; 角南一貴; 小出典男; 原田実根; 豊嶋崇徳; 品川克至; 谷本光音, 日本輸血学会雑誌, 49, 2, 2003年
• 同種末梢血幹細胞至適採取時期決定における末梢血circulating immature cell countの有効性に関する検討
  吉田親正; 池田和真; 小塚輝彦; 久保西四郎; 原田実根; 豊嶋崇徳; 品川克至; 石丸文彦; 谷本光音, 臨床血液, 44, 8, 2003年
• Doxorubicin誘導uPA及びIL-8発現とcaspase活性化へのMAP kinase関与の相違
  新谷勝美; 新谷憲治; 柴倉美砂子; 浅海昇; 吉田親正; 品川克至; 豊嶋崇徳; 石丸文彦; 池田和真, 日本血栓止血学会誌, 14, 5, 2003年
• 移植片対宿主病(GVHD)最近の理解
  豊嶋 崇徳, 最新医学, 56, 2, 192, 197, 2001年
  日本語
• 急性ＤＩＣを初発症状とした前立腺癌の1例
  小橋 賢二; 赤澤 信幸; 豊嶋 崇徳, 岡山済生会総合病院雑誌, 29, 55, 58, 1998年, ［査読有り］
  [症例報告]
• G-CSFによる末梢血幹細胞動員の現状と問題点
  豊嶋 崇徳; 品川 克至, 臨床血液, 38, 6, 479, 483, 1997年, ［査読有り］
• Annual Review 血液 造血幹細胞 同種造血幹細胞移植の現状と展望
  豊嶋崇徳; 原田実根, Annual Review 血液, 1997, 1997年
• 同種末梢血幹細胞移植における無菌管理
  品川克至; 豊嶋崇徳; 大本英次郎; 原田実根, 無菌生物, 27, 1, 1997年
• 146 気管支喘息の経過中悪性リンパ腫を発症しPIE症候群の臨床像を呈した1例
  藤井 誠; 金廣 有彦; 木口 亨; 高尾 和志; 武田 明子; 堀場 昌英; 豊嶋 崇徳; 谷本 安; 片岡 幹男; 多田 慎也; 原田 実根, アレルギー, 46, 2, 291, 291, 1997年
  一般社団法人 日本アレルギー学会, 日本語
• 末梢血幹細胞利用の進歩－末梢血幹細胞移植とは－
  豊嶋 崇徳; 原田 実根, 組織培養工学, 23, 10, 366, 371, 1997年
  日本語
• 造血サイトカイン
  豊嶋 崇徳; 原田 実根, 臨床と研究, 74, 8, 1908, 1912, 1997年
  日本語
• 同種末梢血幹細胞移植の現状と白血病治療への応用
  豊嶋 崇徳; 原田 実根, 臨床医, 23, 8, 1169, 1172, 1997年
  日本語
• 血液疾患におけるステロイド療法
  豊嶋 崇徳; 前田 嘉信; 原田 実根, 臨床と研究, 74, 5, 45, 50, 1997年
  日本語
• 成人急性白血病に対する末梢血幹細胞移植
  水野 晋一; 豊嶋 崇徳, 臨床血液, 37, 7, 584, 590, 1996年, ［査読有り］
  一般社団法人 日本血液学会, 日本語
• 自家幹細胞移植 -悪性リンパ腫における適応と方法-
  豊嶋 崇徳; 原田 実根, 最新医学, 51, 2, 226, 233, 1996年
  日本語
• 悪性リンパ腫におけるPBSCTの実際
  豊嶋 崇徳; 原田 実根, 血液腫瘍科, 33, 5, 410, 415, 1996年
  日本語
• 白血病の治療への骨髄移植療法の適応と限界
  豊嶋 崇徳; 原田 実根, 臨床成人病, 26, 7, 857, 862, 1996年
  日本語
• 悪性リンパ腫における末梢血幹細胞移植. 造血幹細胞移植
  豊嶋 崇徳, 血液腫瘍科, 31, Suppl.1, 216, 223, 1995年
  日本語
• 骨髄壊死のmagnetic resonance imaging像
  高崎智子; 大塚輝久; 権藤久司; 嘉村巧; 野本摩利; 甲斐田真弓; 下田和哉; 高松泰, 臨床血液, 35, 1349, 1354, 1994年, ［査読有り］
  [症例報告]
• Biapenemの基礎的・臨床的検討
  沢江義郎; 岡田薫; 大塚輝久; 仁保喜之; 二宮清; 熊谷幸雄; 高木宏治; 隅田いく男; 豊嶋崇徳, Chemotherapy (Tokyo), 42, Suppl 4, 1994年
• 悪性リンパ腫のPBSCT
  豊嶋 崇徳; 原田 実根, 血液腫瘍科, 29, 5, 346, 352, 1994年
  日本語
• 自己末梢血幹細胞移植術による治療を行った成人神経芽細胞腫
  樋口雅則; 豊嶋崇徳; 岡田薫; 大塚毅; 原田実根; 仁保喜之, 日本癌治療学会誌, 28, 8, 1135, 1139, 1993年, ［査読有り］
  [症例報告]
• Cytosine Arabinosideを中心とする造血器系癌化学療法に伴う悪心・おう吐に対するGranisetron経口剤の抑制効果の検討
  松石英城; 原田実根; 権藤久司; 豊嶋崇徳; 山野裕二郎; 渋谷恒文; 川崎千之; 久野修資; 仁保喜久, 癌と化学療法, 20, 10, 1993年
• 自己末梢血幹細胞移植-成人例における検討-
  谷口 修一; 原田 実根; 牧野 茂義; 赤司 浩一; 豊嶋 崇徳; 高松 泰; 近藤 誠司; 田中 毅; 村川 昌弘; 権藤 久司; 山崎 和夫; 岡村 孝; 渋谷 恒文; 仁保 喜之; 稲葉 頌一, 臨床血液, 33, 7, 945, 949, 1992年, ［査読有り］
• 進行・再発固形癌に対する自家骨髄移植併用大量化学療法
  持田和幸; 神代龍之介; 秀島輝; 前川隆文; 犬塚貞光; 神志那寿代; 浜崎直孝; 豊嶋崇徳; 原田実根, 福岡大学医学紀要, 19, 2, 1992年
• 末梢血幹細胞移植
  豊嶋 崇徳; 原田 実根, 最新医学, 47, 7, 1153, 1157, 1992年
  日本語
• 末梢血幹細胞移植に関する基礎的および臨床的研究
  原田実根; 谷口修一; 赤司浩一; 豊嶋崇徳; 岡村孝; 仁保喜之; 牧野茂美; 高松泰; 稲葉こう一, 臨床成人病, 21, 10, 1991年
• 特集□正常値・異常値 VIII. 色素 2. ヘモグロビン
  豊嶋崇徳; 前田義章; 仁保喜之, 綜合臨床, 40, 1991年
• 石灰化が著明であったすいのsolid and cystic tumorの一例
  江口克彦; 石橋大海; 道免和文; 豊嶋崇徳; 工藤二郎; 仁保喜之; 吉富聡一; 平野達也; 矢毛石陽一, 福岡医学雑誌, 81, 8, 1990年
• 重症再生不良性貧血に対するシクロスポリン療法
  岡村孝; 原田実根; 渋谷恒文; 谷口修一; 赤司浩一; 豊嶋崇徳; 仁保喜之, 免疫薬理, 8, 2, 1990年
• 妊娠・分娩を契機に結核性甲状腺炎と粟粒結核を発症した甲状腺乳頭癌の1例
  李一興; 岡村建; 佐藤薫; 黒田健郎; 吉成元孝; 池之上公; 豊嶋崇徳; 藤島正敏; 栗田幸男, ホルモンと臨床, 37, June, 1989年
• 血液浄化法がアセトアミノフェン除去に有効であった1例
  豊嶋崇徳; 平田泰彦; 冬野誠三; 隅田いく男; 花田基典, 救急医学, 13, 4, 1989年
• 超音波検査で肝ひに結節性病変を認めた成人T細胞白血病・リンパ腫(ATLL)の1例
  豊嶋崇徳; 森岡英次; 石橋大海; 池田潔; 大塚輝久; 仁保喜之, 超音波医学, 14, 6, 1987年